<SEC-DOCUMENT>0001193125-20-255106.txt : 20200928
<SEC-HEADER>0001193125-20-255106.hdr.sgml : 20200928
<ACCEPTANCE-DATETIME>20200928060727
ACCESSION NUMBER:		0001193125-20-255106
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		31
FILED AS OF DATE:		20200928
DATE AS OF CHANGE:		20200928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			C4 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001662579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475617627
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-248719
		FILM NUMBER:		201201920

	BUSINESS ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(202) 421-7994

	MAIL ADDRESS:	
		STREET 1:		675 WEST KENDALL STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d772024ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on September 28, 2020. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333&#150;248719 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>Amendment No. 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:17pt; font-family:ARIAL" ALIGN="center"><B>C4 Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Exact name of registrant
as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DELAWARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>2836</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-5617627</FONT></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL" ALIGN="center">(State or other jurisdiction of<BR>incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(Primary Standard Industrial<BR>Classification Code Number)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(I.R.S. Employer<BR>Identification No.)</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>C4 Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>490 Arsenal Way, Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Watertown, MA 02472
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">231-0700</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">of registrant&#146;s principal executive offices) </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Marc A. Cohen </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Co-Founder, Executive Chairman
and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>C4 Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>490 Arsenal Way, Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Watertown, MA 02472
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">231-0700</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Copies to: </I></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Lawrence S. Wittenberg, Esq.<BR>Edwin O&#146;Connor, Esq.<BR>Goodwin Procter LLP<BR>100 Northern Avenue<BR>Boston, MA 02210<BR>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jolie M. Siegel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Legal Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>C4 Therapeutics,
Inc.<BR>490 Arsenal Way, Suite 200</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Watertown, MA 02472<BR>(617) <FONT STYLE="white-space:nowrap">231-0700</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Brent B. Siler</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Richard Segal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>55 Hudson Yards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, NY 10001-2157</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">479-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public</B>: As soon as practicable after the effective date of this
registration statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center">Large Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Smaller reporting company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>TITLE OF EACH CLASS&nbsp;OF<BR>SECURITIES TO BE REGISTERED</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT TO BE<BR>REGISTERED&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>PROPOSED MAXIMUM<BR>AGGREGATE<BR>OFFERING PRICE PER<BR>SHARE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>PROPOSED MAXIMUM<BR>AGGREGATE<BR>OFFERING PRICE<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT OF<BR>REGISTRATION<BR>FEE<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Common stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">10,147,600</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$18.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$182,656,800.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$23,708.85</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,323,600 shares that the underwriters have the option to purchase to cover over-allotments, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes the aggregate offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(4)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule 457(a) under the Securities Act of 1933 as amended. $12,980.00 of this registration fee was previously paid by the Registrant in connection with the filing of its Registration Statement on
Form S-1 on September 10, 2020. </TD></TR></TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The registrant hereby amends this
registration statement on such date or dates as may be necessary to delay its effective date until the registrant files a further amendment which specifically states that this registration statement shall thereafter become effective in accordance
with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell
these securities until the Securities and Exchange Commission declares our registration statement effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#c21128">SUBJECT TO COMPLETION, DATED SEPTEMBER&nbsp;28, 2020 </FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>8,824,000 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g45i96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering 8,824,000 shares of common stock. This is the initial public offering of our common stock, and prior to this offering, there has been no public market for our common stock. We expect that the initial public offering price will be between
$16.00 and $18.00 per share. We expect to list our common stock on The Nasdaq Global Market under the symbol &#147;CCCC.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth
company&#148; and a &#147;smaller reporting company&#148; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to do so for
future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should read carefully the discussion of the material
risks of investing in our common stock under the heading &#147;<A HREF="#toc772024_2">Risk&nbsp;Factors</A>&#148; starting on page&nbsp;12 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities that may be offered under this
prospectus, nor have any of these organizations determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and
commissions&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to C4 Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page 171 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Delivery of the shares of common stock is expected to be made on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. We have granted the underwriters an option for a period of 30 days to purchase an additional 1,323,600 shares of our common stock. If the
underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before
expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Evercore&nbsp;ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;BMO&nbsp;Capital&nbsp;Markets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>UBS&nbsp;Investment&nbsp;Bank</B></TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020
</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_4">MARKET, INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_9">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_10a">BUSINESS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_13"><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR
COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_13a">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_14">PRINCIPAL STOCKHOLDERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_15">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_16">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_17">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_18">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_19">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_20">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_21">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc772024_22">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus, any
amendment or supplement to this prospectus and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurances as to the
reliability of, any information that others may give you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
offer or sale is not permitted. The information contained in this prospectus or in any free writing prospectus is only accurate as of its date, regardless of its time of delivery or the time of
any sale of our common stock. Our business, financial condition, results of operations and future growth prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering
of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any
restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own or have rights to various trademarks, service
marks and trade names that we use in connection with the operation of our business, including our company name, C4 Therapeutics, Inc., our logo, the name of our TORPEDO<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> technology platform
and the names of our BIDAC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> and MONODAC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> protein degrader product candidates. This prospectus may also contain trademarks, service
marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#146; trademarks, service marks, trade names or products in this prospectus is not intended to and does not imply a
relationship with, or endorsement or sponsorship by, us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, <SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (25 days after the date of this prospectus), all dealers that buy, sell or trade our common stock, whether or not participating in this
offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus. You should also
consider, among other things, the information set forth under the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations,&#148; in each case appearing elsewhere in this prospectus. Unless the context otherwise requires, we use the terms &#147;C4 Therapeutics,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and
similar designations in this prospectus to refer to C4 Therapeutics,&nbsp;Inc. and, where indicated, its wholly owned subsidiary. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a biopharmaceutical company focused on harnessing the body&#146;s natural regulation of protein levels to develop novel therapeutic candidates to target and
destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. We leverage our proprietary technology platform, TORPEDO (<U>T</U>arget <U>OR</U>iented <U>P</U>rot<U>E</U>in <U>D</U>egrader
<U>O</U>ptimizer), to synthesize a new class of small molecule protein degraders that are designed to selectively and efficiently destroy disease-causing proteins, including targets previously considered to be undruggable. Our degraders are designed
with a focus on catalytic degradation to optimize targeted protein degradation and an ability to use multiple routes of administration, which we believe offer many potential advantages over existing therapeutic modalities, including improved
potency, faster response, higher selectivity and avoidance of known toxicities. We are using our TORPEDO platform to build a robust pipeline of oral protein degradation drug candidates, with our lead product candidates focused on oncology
indications. One of our lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, or MM, peripheral <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma, or PTCL, and mantle cell lymphoma, or
MCL. We expect to submit an investigational new drug application, or IND, for this product candidate to the U.S. Food and Drug Administration, or the FDA, in the fourth quarter of 2020 and begin a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial for this product in the first half of 2021. We believe CFT7455 could eventually replace therapies based in the class of molecules known as IMiDs as the standard of care
in multiple indications, including MM. IMiD therapies have been estimated to represent worldwide sales of approximately $15&nbsp;billion in 2020 for a number of indications, including MM as well as MCL, marginal zone lymphoma, and follicular
lymphoma. We are also developing CFT8634, an orally bioavailable degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-deleted solid tumors, and we expect to submit an IND for this product candidate to the FDA in the second half
of 2021 and begin a first-in-human Phase&nbsp;1/2 clinical trial for this product candidate by the end of 2021. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We use our TORPEDO platform to synthesize a
new class of targeted small molecule protein degraders, which employ a natural protein disposal system, specifically the E3 ligases of the ubiquitin-proteasome system, to catalyze the destruction of target proteins. The E3 ligases targeted by our
degraders are a family of proteins that identify and tag proteins for degradation. Our approach is designed to optimize overall catalytic efficiency&#151;rather than specific steps in the catalytic cycle&#151;so that our degraders destroy target
proteins as quickly as possible. Our robust chemistry engine and proprietary analytic models of pharmacokinetics, or PK, and pharmacodynamics, or PD, enable us to efficiently design and synthesize degraders for a selected target that are optimized
for overall catalytic efficiency and properties such as solubility, permeability and oral bioavailability. These PK/PD models allow us to robustly predict the depth and duration of target degradation <I>in vivo</I> and select candidate degraders
with confidence. For example, our PK/PD models for CFT7455 accurately predicted the target level response as a function of time at a 1mg / kg oral dose, demonstrating the predictive capability of our TORPEDO platform. We have seen similar predictive
effectiveness in a PK/PD model for CFT7503, which is the parent compound of our lead BRD9 compound, CFT8634. As a result of data such as these, we believe our approach maximizes our potential to create effective drugs across many targets. Another
aspect of TORPEDO platform is that we have developed a rich toolkit of 14 novel, structurally distinct </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
binders targeting the E3 ligase, Cereblon. IMiDs are a class of molecules, which includes approved therapies thalidomide, lenalidomide and pomalidomide, that harness Cereblon to effect the
degradation of protein targets, resulting in anti-cancer activity. To date, Cereblon is the only E3 ligase known to be targeted by an approved drug to cause protein degradation. Notably, Cereblon is widely expressed across tissues, potentially
allowing for Cereblon-mediated targeted protein degradation in a wide variety of clinical settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have leveraged our TORPEDO<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>platform to generate a robust pipeline of orally available, potent and selective
protein degradation drug candidates that may be capable of treating diseases in a wide range of organ systems and tissues. Our pipeline focus is on establishing clear clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for targets with well-established biology and a defined regulatory pathway. As shown in the table below, we currently have four preclinical programs in
development. We anticipate our CFT7455 and CFT8634 product candidates will be in the clinic by the end of 2021 and our BRAF V600E and RET programs will be in the clinic by the end of 2022. We have also secured three strategic collaborations with
partners that provide additional pipeline optionality and an expansion of our potential targets for protein degradation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are advancing two types of protein
degraders. We refer to the first type of degrader as MonoDACs, which are <U>Mono</U>functional <U>D</U>egradation <U>A</U>ctivating <U>C</U>ompounds. MonoDACs function by binding to E3 ligases and creating a new surface on the E3 ligases that
enhances the binding of the E3 ligases to target proteins. We refer to our second type of degrader as BiDACs, which are <U>Bi</U>functional <U>D</U>egradation <U>A</U>ctivating <U>C</U>ompounds. BiDACs are designed so that one end of the molecule
binds to the disease-causing target protein and the other end binds to the E3 ligase. Each of these types of degraders is intended to result in the same end point: the specific degradation of the target proteins of interest. These two approaches
have complementary requirements for target engagement: BiDACs utilize specific binding sites where chemical binding moieties, which are portions of a molecule, can be identified, which enables a rational drug discovery approach, while MonoDACs, in
contrast, rely on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ligase-to-target</FONT></FONT> protein surface interactions to drive the ubiquitination process, which is the process by which an E3 ligase tags a target protein for
degradation using a molecular tag called ubiquitin, rather than specific compound-binding sites. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g15j64.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CFT7455 is an orally bioavailable degrader targeting IKZF1/3 for the treatment of MM and
<FONT STYLE="white-space:nowrap">non-Hodgkin</FONT> lymphomas, or NHLs, including PTCL and MCL. We have selected IKZF1/3 as our initial targets because they have a strong mechanistic rationale and well-defined biology, and targeting them with a
novel degrader may address a significant unmet need. In our preclinical studies, CFT7455 has demonstrated potent and selective protein degradation with favorable pharmacological properties. We believe that the differentiated pharmacology of CFT7455,
including its high potency, may translate into improved clinical outcomes over the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> agents in each of the indications we are pursuing. We expect
to file an IND for CFT7455 in the fourth quarter of 2020 and expect to dose the first patient in a clinical trial of this product candidate in the first half of 2021. Our planned
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 trial is designed as an open-label dose escalation study of CFT7455 in approximately 18 to 30 subjects with MM or NHL. The trial will primarily
investigate the safety and tolerability of CFT7455, and key secondary endpoints will be to characterize CFT7455&#146;s PK/PD </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
profile and anti-tumor activity. We expect the results from this clinical trial will help us better understand the disease characteristics of those patients who may derive benefit from CFT7455,
which will enable us to more effectively design future clinical trials for this product candidate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CFT8634 is an orally bioavailable degrader targeting BRD9 for
the treatment of synovial sarcoma and SMARCB1-deleted solid malignancies. BRD9 has been considered an undruggable target using currently available modalities. BRD9 is a component of the <FONT STYLE="white-space:nowrap">non-canonical</FONT> BAF
complex, or ncBAF, that regulates gene transcription. In normal cells, this complex is not required for cell survival. However, some tumors, including synovial sarcoma, encode genetic mutations that render the ncBAF complex&#151;and thus
BRD9&#151;essential for tumor growth. As a result, CFT8634 has demonstrated potent anti-tumor activity in synovial sarcoma cell lines, but does not appear to affect normal cells. Further, CFT8634 has shown excellent <I>in vivo</I> activity in
synovial sarcoma xenograft models when dosed orally. We expect to file an IND for CFT8634 with the FDA in the second half of 2021 and dose the first patient in a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial of this product candidate by the end of 2021. We expect to design our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial for this product candidate to be an open-label dose escalation/expansion study in both synovial sarcoma and solid tumors with SMARCB1 loss. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our lead product candidates, we are also developing degraders specifically targeting V600E mutant BRAF to treat melanoma,
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or NSCLC, colorectal cancer and other solid malignancies that harbor this mutation, as well as degraders targeting RET to treat lung cancer, sporadic medullary thyroid cancers and
other solid malignancies that harbor oncogenic RET lesions. We expect to have our lead product candidates, CFT7455 and CFT8634, in the clinic by the end of 2021, and product candidates from our two other lead programs, BRAF V600E and RET, in the
clinic by the end of 2022. Beyond these four initial product candidates, we are further diversifying our pipeline by developing new degraders against targets where we believe degradation offers potential advantages over existing therapeutic
modalities, such as the treatment of neurodegenerative diseases. As part of these efforts, we have engineered degraders that have successfully achieved blood-brain barrier penetration in preclinical studies, which is a key step in developing drugs
with the potential to treat neurodegenerative diseases. We also believe there are many other therapeutic areas and indications where leveraging our TORPEDO platform to develop novel degraders may be advantageous. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the programs identified above and our early-stage development collaborations with F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd., or
Roche, Biogen, Inc., or Biogen, and Calico Life Sciences LLC, or Calico, we are conducting exploratory research and development work on various other targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have been a pioneer in the field of targeted protein
degradation since our founding in 2015. Our technology originated from research at the Dana Farber Cancer Institute by Jay Bradner,&nbsp;M.D., Ken Anderson,&nbsp;M.D. and Nathanael Gray,&nbsp;Ph.D., leading researchers in the field of protein
degradation who co-founded the company along with our Executive Chairman, Marc&nbsp;A. Cohen, who serves as our interim Chief Executive Officer. We have assembled a scientific team with extensive knowledge and translational medicine expertise in the
protein degradation field. Our management team draws on experience in all phases of drug discovery and development gained at large pharmaceutical and biotechnology companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we hired our President and incoming Chief Executive Officer, Andrew Hirsch, in September 2020. Prior to joining us, Mr.&nbsp;Hirsch served as Chief
Financial Officer at Agios Pharmaceuticals, Inc., including as head of corporate development. Mr.&nbsp;Hirsch previously held various leadership positions at BIND Therapeutics, Inc. and currently serves on the board of directors of Editas Medicine,
Inc. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also entered into key strategic collaborations with each of Roche, Biogen and Calico that help us address targets across multiple therapeutic areas.
Through these collaborations we have received an aggregate of $154.8&nbsp;million in non-dilutive financing through June&nbsp;30, 2020. In addition, we have secured additional </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
funding from a strong group of investors, including Cobro Ventures, Perceptive Advisors, Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E&nbsp;Bioventures
Capital, HBM&nbsp;Healthcare Investments, Lightchain Capital, Logos Capital, Mizuho Securities Principal Investment, Nextech, RA&nbsp;Capital, RTW&nbsp;Investments, Sphera Funds Management, Taiwania Capital, Yonjin Venture and funds and accounts
managed by T.&nbsp;Rowe Price and Janus Henderson. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are committed to transforming the treatment of cancer, neurodegenerative conditions and other diseases through the discovery, development and commercialization of
novel therapies that destroy disease-causing proteins. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key elements of our strategy are to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Continue rapid progression toward clinical development of our lead programs developed with our TORPEDO<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>platform; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rapidly advance our late-stage discovery programs to generate product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Leverage our TORPEDO platform to generate discovery programs for previously undruggable or challenging targets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Strategically invest in our TORPEDO platform; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Engage with strategic partners to accelerate program development and maximize the potential of our TORPEDO<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>platform; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Maximize the potential of our product candidates with selective use of commercial partnerships. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic on Our Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is causing significant industry-wide delays in preclinical work and clinical trials. There are multiple
causes of these delays, including laboratory closures, reluctance of patients to enroll or continue in trials for fear of exposure to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> local and regional <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders and regulations that discourage, hamper or prohibit patient visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> patients and the FDA and other regulators making product candidates for the treatment of <FONT STYLE="white-space:nowrap">COVID-19</FONT> a priority over product candidates unrelated to the pandemic. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In terms of the impact on our operations, we have seen increased risk of delays in production of components used to manufacture our lead degrader candidates due to
previous delays at one of our China-based manufacturers, and one of our CROs in India was forced to temporarily shut down due to local lockdown orders. In addition, we temporarily closed the office and laboratory spaces at our corporate headquarters
in Watertown, Massachusetts, and we transitioned our employees to work from home. We are working closely with our contract research organizations, or CROs, manufacturers, investigators and preclinical and clinical trial sites to assess the full
impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the timelines and expected costs for each of our programs. While the ongoing impact of the pandemic is uncertain, we believe our CRO redundancies in China, India and Boston
and the transition of the majority of our employees to remote work arrangements have mitigated the impact of these types of disruptions on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not
aware of any of our directors or employees being infected with coronavirus, but the virus can remain asymptomatic for a significant period of time and methods and availability of testing are continuing to evolve. It is possible our directors or
employees or their family members could become infected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We note the high level of difficulty in projecting the effects of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> on our programs and our company, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental response to it. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described
more fully in the section entitled &#147;Risk Factors&#148; in this prospectus. These risks include, among others: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are an early stage biopharmaceutical company with a limited operating history and have incurred significant losses
since our inception. To date, we have not generated any revenue from product sales. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years and may never achieve or maintain
profitability. Our net loss was $22.7 million for the six months ended June&nbsp;30, 2020, $34.1&nbsp;million for the year ended December&nbsp;31, 2019 and $15.7&nbsp;million for the year ended December&nbsp;31, 2018. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We will need substantial additional funding to pursue our business objectives and continue our operations. If we are
unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our approach to the discovery and development of product candidates based on our TORPEDO platform is unproven, which makes
it difficult to predict the time, cost of development and likelihood of successfully developing any products. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All of our product candidates are still in preclinical development. Our business could be harmed if we are unable to
advance to clinical development, develop, obtain regulatory approval for and commercialize our product candidates or experience significant delays in doing so. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We cannot be certain of the timely completion or outcome of our preclinical testing and clinical trials. The results of
preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence may not be predictive of the results of later-stage clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity and efficacy of
any of our product candidates, which would prevent or delay development, regulatory approval and commercialization of our current and future product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have entered into collaboration agreements with Roche, Biogen and Calico, and may in the future seek to enter into
collaborations with third parties for the development and commercialization of certain of our product candidates. If we fail to enter into these types of new collaborations, or if our existing collaborations are not successful, we may be unable to
continue development of our product candidates, we would not receive any contemplated milestone payments or royalties, and we could fail to capitalize on the market potential of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The continuing effects of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely
impact our business, including our preclinical studies and clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical
and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates in a
timely manner, or at an acceptable cost or quality. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain required marketing approvals for, commercialize, manufacture, obtain and maintain patent
protection for or gain market acceptance of our product candidates, or if we experience significant delays in doing so, our business will be materially harmed and our ability to generate revenue from product sales will be materially impaired.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent
protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
were incorporated in October 2015 under the laws of the State of Delaware. Our principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472, and our telephone number is
<FONT STYLE="white-space:nowrap">(617)&nbsp;231-0700.</FONT> We have one wholly owned subsidiary, C4T Securities Corporation, a Massachusetts corporation. Our website address is www.c4therapeutics.com. Information contained on our website is not
incorporated by reference into this prospectus and should not be considered to be a part of this prospectus or the registration statement of which it forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging growth company, we may
take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to only provide two years of audited financial statements in addition to any required unaudited interim
financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden
parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an exemption from new or revised financial accounting standards until they would apply to private companies and from
compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may
take advantage of these exemptions until we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross
revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of 2025; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to
be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus. In addition, we have elected to use the exemption for the delayed adoption of certain accounting standards until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably
opt out of the extended transition period provided in the JOBS Act. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the
proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller
reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million
during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an
emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent
fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive
compensation. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Shares of our common stock offered by us </P></TD>
<TD>8,824,000 shares </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Shares of our common stock to be outstanding after this offering </P></TD>
<TD>40,769,194 shares (or 42,092,794 shares if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 1,323,600 additional shares of our common stock at the initial public offering price, less underwriting discounts and commissions, on the
same terms as set forth in this prospectus. </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from the sale of shares of our common stock in this offering will be approximately $135.5&nbsp;million, or $156.4&nbsp;million if the underwriters exercise their option to purchase additional shares in
full, assuming an initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. We intend to use the net proceeds of this offering, together with our existing cash resources, to: complete the Phase&nbsp;1 portion of our planned first-in-human Phase&nbsp;1/2 clinical trial of CFT7455 for patients with MM or NHL,
such as PTCL or MCL, as well as to fund a portion of the Phase&nbsp;2 expansion component of that clinical trial in these indications; complete the Phase&nbsp;1 portion of our planned first-in-human Phase&nbsp;1/2 clinical trial of CFT8634 for
patients with synovial sarcoma or solid tumors with SMARCB1 loss, as well as to fund a portion of the Phase&nbsp;2 expansion component of this trial and a portion of a Phase&nbsp;3 confirmatory clinical trial of this product candidate in synovial
sarcoma; conduct and complete IND-enabling studies with respect to BRAF V600E and RET, substantially complete the Phase&nbsp;1 portion of our planned first-in-human Phase&nbsp;1/2 clinical trials for each of these programs and fund initial portions
of our planned phase&nbsp;2 expansion component for the clinical trials for each of these product candidates; and fund continued development of our TORPEDO platform and advancement and identification of additional targets and development candidates,
hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;CCCC&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk Factors </P></TD>
<TD>Investment in our common stock involves substantial risks. You should read this prospectus carefully, including the section entitled &#147;Risk Factors&#148; and the financial statements and the related notes to those statements included in this
prospectus, before investing in our common stock. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Directed share program </P></TD>
<TD>At our request, the underwriters have reserved up to 5% of the shares of common stock being offered by this prospectus for sale, at the initial public offering price, to certain of our officers, directors, employees and other persons who do
business with us. Any reserved shares purchased by our executive officers, directors and members of their households will be subject to the 180-day lock-up described elsewhere in this prospectus. If these persons purchase reserved shares, it will
reduce the number of shares available for sale to the general public. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus. For
further information regarding our directed share program, see &#147;Underwriting.&#148; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock outstanding after
this offering is based on 31,945,194 shares of our common stock outstanding as of September&nbsp;13, 2020, after giving effect to the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 30,355,379 shares of
common stock upon the completion of this offering, and excludes as of such date: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,400,172 shares of common stock issuable upon exercise of stock options outstanding under our 2015 Stock Option and Grant
Plan, or the 2015 Plan, at a weighted-average exercise price of $4.79 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,300,043&nbsp;shares of common stock issuable upon the exercise of stock options we have agreed to grant under our 2020
Stock Option and Incentive Plan, or the 2020 Plan, to some of our executive officers immediately following the effectiveness of the registration statement of which this prospectus forms a part, assuming that we sell 8,824,000&nbsp;shares in this
offering, with an exercise price per share equal to the initial public offering price per share in this offering, as described in more detail under the caption &#147;Certain Relationships and Related Person Transactions&#151;Stock Option Grants to
Directors and Executive Officers&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">192,681 shares of common stock issuable upon the exercise of stock options we will grant under the 2020 Plan immediately
following the effectiveness of the registration statement of which this prospectus is a part to certain employees and our non-employee directors who remain on our board of directors at such time, with an exercise price per share equal to the initial
public offering price per share in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">338,784 shares of our common stock issuable upon the exercise of warrants to purchase 2,857,142&nbsp;shares of our Series
B preferred stock at an exercise price of $1.05 per share, which warrants will automatically convert into warrants to purchase shares of our common stock at an exercise price of $8.86 per share upon closing of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,074,420 shares of common stock to be reserved for future issuance under our 2020 Plan to be effective on the day
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, excluding the shares of common stock issuable upon the exercise of stock options we have agreed to grant under the 2020 Plan as described
above; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">437,809 shares of common stock to be reserved for future issuance under our 2020 Employee Stock Purchase Plan to be
effective on the day immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as
otherwise noted, all information in this prospectus: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">gives effect to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-8.4335</FONT></FONT> reverse
stock split of our common stock effected on September&nbsp;25, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">assumes no exercise of the underwriters&#146; option to purchase up to 1,323,600 additional shares of common stock in this
offering; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">assumes no exercise of the outstanding options and warrants described above; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">gives effect to the automatic conversion of all of our outstanding shares of preferred stock into an aggregate of
30,355,379 shares of common stock, which will occur upon the completion of this offering and the reclassification of the warrant liability to additional paid-in capital upon the automatic conversion of preferred stock warrants into common stock
warrants; and </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">assumes the filing and effectiveness of our amended and restated certificate of incorporation and the effectiveness of our
amended and restated bylaws, which will occur upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following summary consolidated financial data together with our audited consolidated and unaudited condensed consolidated financial statements
and the related notes appearing elsewhere in this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this
prospectus. We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2018 and 2019 from our audited consolidated financial statements appearing elsewhere in this prospectus. The summary unaudited condensed
consolidated statement of operations data for the six months ended June&nbsp;30, 2019 and 2020 and the summary unaudited condensed consolidated balance sheet data as of June&nbsp;30, 2020 have been derived from our unaudited condensed consolidated
financial statements included elsewhere in this prospectus, which have been prepared on the same basis as the audited financial statements. Our historical results are not necessarily indicative of the results that may be expected in the future, and
our results for any interim period are not necessarily indicative of results that may be expected for any full year. </I></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS&nbsp;ENDED<BR>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated statement of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive gain (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized gain (loss) on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding&#151;basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,293,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,469,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited) <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common shares outstanding&#151;basic and diluted (unaudited)&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,788,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,233,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;11 to our audited consolidated financial statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders for the
years ended December 31, 2018 and 2019 and Note 12 to our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common
stockholders for the six-month periods ended June&nbsp;30, 2019 and 2020. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JUNE&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL"><B>Consolidated balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$216,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$351,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Working capital <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">89,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">89,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">89,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:9.5pt">Warrant liability</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:9.5pt">Long-term debt</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.40em; text-indent:-1.40em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma balance sheet data give effect to: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">the issuance and sale of shares of our Series B preferred stock for gross proceeds of $4.5&nbsp;million subsequent to
June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">a one-for-8.4335 reverse stock split of our common stock effected on September&nbsp;25, 2020; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">the automatic conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 30,355,379
shares of common stock, which will occur upon the closing of this offering and the reclassification of the warrant liability to additional paid-in capital upon the automatic conversion of preferred stock warrants into common stock warrants.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted balance sheet data give further effect to our issuance and sale of 8,824,000 shares of our common stock in this offering at an assumed initial public offering price of $17.00 per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We had incurred $0.3 million of expenses related to
this offering as of June&nbsp;30, 2020, which were reflected as deferred offering costs in our consolidated financial statements. The pro forma as adjusted information discussed above is illustrative only and will depend on the actual initial public
offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents and short-term investments, working capital, total assets and total stockholders&#146; equity by $8.2 million, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares
in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents and short-term investments, working capital, total assets and
total stockholders&#146; equity by $15.8 million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this
prospectus, including our financial statements and the related notes and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; before you make an investment
decision. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. As a result, the market price of our common stock could decline, and you may lose
all or part of your investment in our common stock. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an early stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur
losses over at least the next several years and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an early stage biopharmaceutical company with limited
operating history. Our net loss was $22.7 million for the six months ended June&nbsp;30, 2020, and $34.1&nbsp;million and $15.7&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. As of June&nbsp;30, 2020, we had an
accumulated deficit of $140.2 million. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations and debt financing. We are still
in the early stages of development of our product candidates and expect to initiate our first clinical trial in the first half of 2021. As such, we expect that it will be several years, if ever, before we have a product candidate ready for
regulatory approval and commercialization. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing,
obtaining marketing approval for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including, without limitation, successfully completing preclinical studies
and clinical trials of our product candidates, discovering additional product candidates, establishing arrangements with third parties for the conduct of our clinical trials, procuring clinical- and commercial-scale manufacturing, obtaining
marketing approval for our product candidates, manufacturing, marketing and selling any products for which we may obtain marketing approval, identifying collaborators to develop product candidates we identify or additional uses of existing product
candidates and successfully completing development of product candidates for our collaboration partners. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to incur significant expenses and
increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate a planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase
1/2 clinical trial of our lead product candidate, CFT7455, in patients with MM or NHLs, such as PTCL and MCL; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate a planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase
1/2 clinical trial of our second lead product candidate, CFT8634, in patients with synovial sarcoma or SMARCB1-deleted solid tumors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">leverage our TORPEDO platform to identify and then advance additional product candidates into preclinical and clinical
development; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expand the capabilities of our TORPEDO platform; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate, conduct and successfully complete later-stage clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities
to commercialize any products for which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expand, maintain and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, regulatory and scientific personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial and management information systems and personnel, including personnel to support our ongoing
research and development and potential future commercialization efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, following the closing of this offering, we expect to incur additional costs associated with operating as a public
company, including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our expenses could
increase beyond our expectations if we are required by the FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform trials in addition to those that we currently expect, or if we experience any delays in establishing
appropriate manufacturing arrangements for, completing our clinical trials or the clinical development of any of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the numerous
risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do
achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand
our business, maintain our research and development efforts, expand our business or continue operations. A decline in the value of our company, or in the value of our common stock, could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing
those approved product candidates. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will need substantial additional funding to pursue our business objectives and continue our operations. If we are unable to raise capital when needed, we may
be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our expenses
to increase substantially in connection with our ongoing activities, particularly as we prepare for and initiate our planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trials of
CFT7455 and CFT8634, advance our TORPEDO platform and continue research and development and initiate clinical trials of, and potentially seek marketing approval for, our current and future preclinical programs. In addition, if we obtain marketing
approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Further, upon the closing of this offering, we expect to incur additional
costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be
required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had cash and cash equivalents and short term investments of $211.6&nbsp;million as of June&nbsp;30, 2020. We believe that these funds, combined with the
proceeds from the Series B Financing of $4.5 million received in July 2020, anticipated payments from collaboration partners and the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure
requirements through the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many
factors, including: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, costs and results of our planned
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trials for CFT7455 and CFT8634 and any future clinical development of CFT7455 and CFT8634; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and
development programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and development requirements of other product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of our ongoing collaborations with Biogen, Roche and Calico; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs, timing and outcomes of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval and
the timing of the receipt of any such revenue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any delays or interruptions, including due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, that we
experience in our preclinical studies, future clinical trials and/or supply chain; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to establish collaboration arrangements with other biotechnology or pharmaceutical companies on favorable
terms, if at all, for the development or commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected net proceeds of this offering will not be
sufficient for us to fund any of our product candidates through regulatory approval and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. Identifying potential product
candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. We may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years,
if at all. Adequate additional funds may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds
for our current or future operating plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring
significant costs associated with commercializing those approved product candidates. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We commenced operations in 2015 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital,
conducting discovery and research activities, filing patent applications, identifying potential product candidates, developing and advancing our TORPEDO platform, undertaking preclinical studies and establishing arrangements with third parties for
the manufacture of initial quantities of our product candidates. All of our product candidates are still in preclinical development. We have not yet demonstrated our ability to successfully initiate or complete any clinical trials, obtain marketing
approvals, manufacture a commercial scale product directly or through a third party or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future
success or viability may not be as accurate as they could be if we had a longer operating history or if we had already successfully completed some or all of these types of activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as an early-stage biopharmaceutical company, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown
challenges. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities and we may not be successful in making that transition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors,
many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The ongoing global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could continue to adversely impact our business, including our preclinical studies
and development programs, supply chain and business development activities.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which began in December 2019, has spread worldwide and caused governments worldwide to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened
border scrutiny, business shutdowns and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains
have been disrupted, facilities and production have been suspended and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
goods and services, such as travel, has fallen. The future progression of the outbreak and its effects on our business and operations remain uncertain. In addition, any delays in foreign
shipments coming into the United States could also impact our preclinical study or clinical trial plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our contract manufacturing organizations, or CMOs,
and CROs may face disruptions that could affect our ability to initiate and complete preclinical studies or clinical trials. For example, because of ongoing efforts to address the pandemic, we may face disruptions in procuring items that are
essential for our research and development activities, including, due to shortages arising in raw materials used in the manufacturing of our product candidates, laboratory supplies for our preclinical studies and clinical trials or animals that are
used for preclinical testing. We and our CROs and CMOs may face disruptions related to our planned future clinical trials arising from potential delays in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, manufacturing disruptions and/or
the ability to obtain necessary institutional review board, or IRB, or other necessary site approvals, as well as other delays at clinical trial sites, including delays related to site staffing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March 2020, due to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> we closed the office and laboratory spaces in our Watertown, Massachusetts facility
and transitioned our employees to work from home. During the spring, we also experienced closures at the locations of some of our Indian CROs due to local lockdown requirements. These shutdowns resulted in delays to our preclinical studies. Due to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have also seen the risk of delays in production of components used to manufacture our lead degrader candidates increase due to previous delays at one of our China-based manufacturers,
which we believe we have remediated by working with that manufacturer to change the location of future work to another of the manufacturer&#146;s sites. In June 2020, we reopened our office location to enable a subset of our employees&#151;those
whose work can only be performed in our laboratories&#151;to return to the office, and we have required our remaining employees to continue working from home. While the ongoing impact of this pandemic is uncertain, we believe the redundancies we
have in place between our China and India based CROs and our Watertown, Massachusetts-based laboratory staff, as well as the transition of the majority of our employees to remote work arrangements, have mitigated the impact of these disruptions on
our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in the redirection of resources with respect to regulatory
and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. For example, since March 2020, foreign and domestic inspections by FDA have largely been on
hold with FDA announcing plans in July 2020 to resume prioritized domestic inspections. As of June 23, 2020, the FDA also noted that it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line
with its user fee performance goals, including for oncology product development with its staff teleworking full-time. However, FDA may not be able to continue its current pace and review timelines could be extended. In addition, we may face
impediments to regulatory meetings and approvals due to measures intended to limit <FONT STYLE="white-space:nowrap">in-person</FONT> interactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pandemic has
already caused significant disruptions in the financial markets and may continue to cause these types of disruptions, which could impact our ability to raise additional funds through public offerings and may also contribute to volatility in our
stock price and otherwise impact trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could adversely affect our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">COVID-19&nbsp;and</FONT> actions taken to reduce its spread continue to rapidly evolve. The extent to
<FONT STYLE="white-space:nowrap">which&nbsp;COVID-19&nbsp;may</FONT> impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with
confidence. To the extent <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> adversely affects our business prospects, financial condition and results of operations, it may also have the effect of heightening many of the other
risks described in this &#147;Risk Factors&#148; section, such as those relating to the timing and results of our planned and future clinical trials and our financing needs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Credit Agreement with Perceptive Credit contains restrictions that limit our flexibility in operating our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2020, we entered into a credit agreement and guaranty, or the Credit Agreement, with Perceptive Credit Holdings III, LP, or Perceptive Credit, an affiliate of
Perceptive Advisors LLC, or Perceptive Advisors. As of June&nbsp;30, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2020, Perceptive Advisors and Perceptive Credit together beneficially own 8.07% of our common stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis before giving effect to this
offering. The Credit Agreement provides for a $20.0&nbsp;million senior secured delayed draw term loan facility, or the Delayed Draw Loan Facility. The Credit Agreement is secured by a lien on substantially all of our and our subsidiaries&#146;
assets, including, but not limited to, shares of our subsidiaries, our current and future intellectual property, insurance, trade and intercompany receivables, inventory and equipment and contract rights. The Credit Agreement requires us to meet
specified minimum cash requirements, as described below, and contains various affirmative and negative covenants that limit our ability to engage in specified types of transactions. These covenants, which are subject to customary exceptions, limit
our ability to, without Perceptive Credit&#146;s prior written consent, effect any of the following, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, lease, transfer or otherwise dispose of certain assets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire another company or business or enter into a merger or similar transaction with third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">incur additional indebtedness; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make investments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into certain inbound and outbound licenses of intellectual property, subject to certain exceptions;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">encumber or permit liens on certain assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pay dividends and make other restricted payments with respect to our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are required to deposit into controlled accounts all cash or other payments received in respect of any and all of our accounts receivable or any other
contract or right and interest and, at all times, to maintain a minimum aggregate balance of $3.0&nbsp;million in cash in one or more such controlled accounts. These accounts are required to be maintained as cash collateral accounts securing our
obligations under the Credit Agreement. Until our obligations under the Credit Agreement have been discharged, our ability to use the cash amounts held in these controlled accounts in the operation of our business will be limited. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to draw on the Delayed Draw Loan Facility is contingent on our compliance with the covenants described above and certain other covenants, as well as our
achievement of designated milestones. If we do not meet these milestones, the inability to draw on the Delayed Draw Loan Facility may adversely affect our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors or management team could believe that taking any one of these actions would be in our best interests and the best interests of our stockholders.
If that were the case and if we are unable to complete any of these actions because Perceptive Credit does not provide its consent, it could adversely impact our business, financial condition and results of operations. In the event of a default,
including, among other things, our failure to make any payment when due or our failure to comply with any provision of the Credit Agreement, subject to customary grace periods, Perceptive Credit could elect to declare all amounts outstanding to be
immediately due and payable and terminate all commitments to extend further credit. If we are unable to repay the amounts due under the Credit Agreement, Perceptive Credit could proceed against the collateral granted to it to secure this
indebtedness, which could have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Perceptive Credit&#146;s interests as a lender may
not always be aligned with our interests or with Perceptive Advisor&#146;s interests as a stockholder. If our interests come into conflict with those of Perceptive Credit, including in the event of a default under the Credit Agreement, Perceptive
Credit may choose to act in its self-interest, which could adversely affect the success of our current and future collaborative efforts with Perceptive Advisor. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to
relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until the time, if ever, when we can generate substantial revenue from product sales, we
expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our
collaborations with Biogen, Roche and Calico, we do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted and the terms of any securities we may issue in the future may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or
declaring dividends. Pursuant to the Credit Agreement, we granted Perceptive Credit a warrant to purchase 338,784 shares of our Series B preferred stock, which will be exercisable for our common stock on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis upon the completion of this offering. Covenants in the Credit Agreement impose certain limitations and obligations on us, including restrictions on our ability to incur additional debt and
to enter into certain business combinations without Perceptive Credit&#146;s prior written consent. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise additional funds through collaborations,
strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms
that may not be favorable to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Discovery and Development of Our Product Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our approach to the discovery and development of product candidates based on our TORPEDO platform for targeted protein degradation is unproven, which makes it
difficult to predict the time, cost of development and likelihood of successfully developing any products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treating diseases using targeted protein
degradation is a new treatment modality. Our future success depends on the successful development of this novel therapeutic approach. Very few small molecule product candidates using targeted protein degradation, such as those developed through our
TORPEDO platform, have been tested in humans. None have been approved in the United States or Europe, and the data underlying the feasibility of developing these types of therapeutic products is both preliminary and limited. If any adverse learnings
are made by other developers of chimeric targeting molecules, there is a risk that development of our product candidates could be materially impacted. Discovery and development of small molecules that harness the ubiquitin proteasome pathway to
degrade protein targets have been impeded largely by the complexities and limited understanding of the functions, biochemistry and structural biology of the specific components of the ubiquitin-proteasome system, including E3 ligases and their
required accessory proteins involved in target protein ubiquitination, as well as by challenges of engineering compounds that promote <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">protein-to-protein</FONT></FONT> interactions.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The scientific research that forms the basis of our efforts to develop our degrader product candidates under our TORPEDO platform is ongoing and the scientific
evidence to support the feasibility of developing TORPEDO platform-derived therapeutic treatments is both preliminary and limited. Further, certain cancer patients have shown inherent primary resistance to approved drugs that inhibit disease-causing
proteins and other patients have developed acquired secondary resistance to these inhibitors. Although we believe our products candidates may have the ability to degrade the specific mutations that confer resistance to currently marketed inhibitors
of disease-causing enzymes, any inherent primary or acquired secondary resistance to our product candidates in patients, or if the research proves to be contradicted, would prevent or diminish their clinical benefit. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not yet initiated a clinical trial of any product candidate and we have not yet assessed the safety of any of our product candidates in humans. Although some of
our product candidates have produced observable results in animal studies, there is a limited safety data set for their effects in animals. In addition, these product candidates may not demonstrate the same chemical and pharmacological properties in
humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, there could be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better-known or
extensively studied product candidates. Although other companies are also developing therapeutics based on targeted protein degradation, no regulatory authority has granted approval for any therapeutic of this nature at this time. As a result, it is
more difficult for us to predict the time and cost of developing our product candidates and we cannot predict whether the application of our TORPEDO platform, or any similar or competitive protein degradation platforms, will result in the
development of product candidates that make it through to marketing approval. Any development problems we experience in the future related to our TORPEDO platform or any of our research programs may cause significant delays or unanticipated costs or
may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate, as well as from commercializing any product candidates we may
develop on a timely or profitable basis, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an early stage biotechnology company and all of our product candidates are currently in preclinical
development. If we are unable to advance to clinical development, develop, obtain regulatory approval for and commercialize our product candidates or experience significant delays in doing so, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an early stage biotechnology company and all of our product candidates are currently in preclinical development. As a result, their risk of failure is high. We
have invested substantially all of our efforts and financial resources in building our TORPEDO platform and identifying and conducting preclinical development of our current product candidates, including CFT7455 and CFT8634. Our ability to generate
revenue from product sales, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. The success of our product candidates
will depend on several factors, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sufficiency of our financial and other resources; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful initiations and completion of preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful submission of INDs and initiation of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful patient enrollment in, and conduct and completion of, clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent or trade secret protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making arrangements with third-party manufacturers for both clinical and commercial supplies of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing product candidates that achieve the therapeutic properties desired and appropriate for their intended
indications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when
approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing a continued acceptable safety profile of the products and maintaining such that a profile following approval;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively competing with other therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not successfully achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to successfully
commercialize our product candidates, which could materially harm our business. Moreover, if we do not receive regulatory approvals, we may not be able to continue our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have no experience as a company in completing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies or commencing and conducting clinical
trials. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have no experience as a company in completing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies and then commencing and
conducting clinical trials. In part because of this lack of experience, we cannot be certain that our preclinical studies will be completed on time or if our planned clinical trials will begin or be completed on time, if at all. Large-scale clinical
trials would require significant additional financial and management resources and reliance on third-party clinical investigators and consultants. Relying on third-party clinical investigators, CROs and consultants may cause us to encounter delays
that are outside of our control. In addition, relying on third parties in the conduct of our preclinical studies or clinical trials exposes us to a risk that they may not adequately comply with good laboratory practice, or GLP, or good clinical
practice, or GCP, as required for any studies or trials we plan to submit to a regulatory authority. We may be unable to identify and contract with sufficient investigators, CROs and consultants on a timely basis or at all. For each of our lead
product candidates, CFT7455 and CFT8634, we are in the process of entering into a master services agreement with CROs to lead our planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2
clinical trial for the applicable product candidate. There can be no assurance that we will be able to negotiate and enter into additional master services agreement with this or other CROs, as necessary, on terms that are acceptable to us on a
timely basis or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, potency, purity and
efficacy of any of our product candidates, which would prevent or delay development, regulatory approval and commercialization. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining regulatory
approval for the commercial sale of any of our product candidates, including CFT7455 and CFT8634, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and
effective for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete and the outcome of these activities is inherently uncertain. Failure can occur at any time during the preclinical study
and clinical trial processes and, because our product candidates are in an early stage of development and have never been tested in humans, there is a high risk of failure. In addition, because chimeric targeting molecules are a relatively new class
of product candidates, any failures or adverse outcomes in preclinical or clinical testing seen by other developers in this class could materially impact the success of our programs. We may never succeed in developing marketable products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is also possible that the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage
clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different
conditions than testing in humans and, therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through preclinical
studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency, purity and efficacy profile despite having progressed successfully through preclinical studies and/or initial clinical
trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced
clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies and
clinical trials are never approved as products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we expect that the first clinical trials for our product candidates may be open-label studies, where
both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate
and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. In
addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the
information of the treated group more favorably given this knowledge. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any preclinical studies or clinical trials that we may conduct may not demonstrate the
safety, potency, purity and efficacy necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety, potency,
purity and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance or if there are safety concerns associated with our product candidates, we may be prevented or delayed in
obtaining marketing approval for those product candidates. In some instances, there can be significant variability in safety, potency, purity or efficacy results between different preclinical studies and clinical trials of the same product candidate
due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial
participants. While we have not yet initiated clinical trials for any of our product candidates, as is the case with all oncology drugs, it is likely that there may be side effects associated with their use. Results of our trials could reveal a high
and unacceptable severity and prevalence of these or other side effects. If that were to occur, or if other developers of similar chimeric targeting molecules were to find an unacceptable severity or prevalence of side effects with their candidates,
our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related side
effects could also affect patient recruitment or the ability of enrolled patients to complete an ongoing trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, our product candidates could cause undesirable side effects in clinical trials related to <FONT
STYLE="white-space:nowrap">on-target</FONT> toxicity. If <FONT STYLE="white-space:nowrap">on-target</FONT> toxicity is observed or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit
development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in
early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Drug development is a
lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our product candidates are in preclinical development and their risk of failure is high. We are unable to predict when or if any of our product candidates will
prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and
efficacy of our product candidates in humans. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our planned INDs in the United States or similar applications in other
jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or similar regulatory authorities outside the United States will allow us to commence our proposed clinical trials or if
the outcome of our preclinical studies ultimately will support the further development of any of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical testing is expensive, difficult
to design and implement, can take many years to complete and is uncertain as to the timing and outcome. A failure of one or more clinical trials can occur at any stage of the process. We may experience numerous unforeseen events during or as a
result of clinical trials, which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching, or the failure to reach, a consensus with regulators on clinical trial design or the inability to
produce acceptable preclinical results to enable entry into human clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be
insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of product candidates to the clinical sites by us or by third parties with whom we have contracted to perform certain of those
functions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching, or the failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
with prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the failure of regulators or IRBs to authorize us or our investigators to commence a clinical trial or conduct a clinical
trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulty in designing clinical trials and in selecting endpoints for diseases that have not been well studied and for
which the natural history and course of the disease is poorly understood; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the selection of certain clinical endpoints that may require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment
in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> or the failure
to recruit suitable patients to participate in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators or IRBs to suspend or terminate our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding
that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the third parties with whom we contract may fail to comply with regulatory requirements or meet their contractual
obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the requirement from regulators or IRBs that we or our investigators suspend or terminate clinical trials for various
reasons, including noncompliance with regulatory requirements or unacceptable safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical trials of our product candidates may produce negative or inconclusive results and we may decide, or regulators
may require us, to conduct additional clinical trials or abandon product development programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of
product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential
benefits; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disruptions caused by the evolving effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase
the likelihood that we encounter these types of difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to
successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">be delayed in obtaining marketing approval for our product candidates, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">be required to perform additional clinical trials to support marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have regulatory authorities withdraw or suspend their approval, or impose restrictions on distribution of a product
candidate in the form of a modified risk evaluation and mitigation strategy, or REMS; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">be subject to additional post-marketing testing requirements or changes in the way the product is administered; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have our product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product development costs also will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know
whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during
which we may have the exclusive right to commercialize our product candidates, or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our
business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, cancer therapies sometimes are characterized as first-line, second-line or third-line.
The FDA often approves new oncology therapies initially only for third-line or later use, meaning for use after two or more other treatments have failed. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery,
radiation therapy, immunotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second-line and third-line therapies are administered to patients when prior therapy is not effective. Our planned
clinical trials for our lead product candidates&nbsp;CFT7455 and CFT8634 and other drug candidates will be with patients who have received one or more prior treatments and we expect that we would initially seek regulatory approval of these product
candidates for second-line or third-line therapy. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if
approved for second-line or third-line therapy, may not be approved for first-line therapy and, prior to seeking and/or receiving any approvals for first-line therapy, we may have to conduct additional clinical trials. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on
proprietary products. We face, and will continue to face, competition from third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, immunotherapy, gene editing or gene therapy development platforms and from companies
focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition we face and will face is likely to come from multiple sources, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware of several biotechnology companies focused on developing product candidates based on small molecules for targeted protein degradation including Arvinas,
Inc., Cullgen Inc., Nurix Therapeutics, Inc., Vividion Therapeutics, Inc. and Kymera Therapeutics, Inc., of which Arvinas, Inc. is in clinical development and the other companies are currently in preclinical development. Further, several large
pharmaceutical companies have disclosed preclinical investments in this field, including Amgen, AstraZeneca plc, GlaxoSmithKline plc, Genentech, Inc. and Novartis International AG. In addition to competition from other protein degradation therapies,
any products that we develop may also face competition from other types of therapies, such as small molecule, antibody, T cell or gene therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our
current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining
regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among
a smaller number of our competitors, the scale of which could be difficult to compete against. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our product candidates. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are
more convenient or are less expensive than any product candidate that we may develop. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic
products. There are generic products currently on the market for certain of the indications that we are pursuing and additional products are expected to become available on a generic basis over the coming years. If our product candidates are
approved, we expect that they will be priced at a significant premium over competitive generic products. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to use our net operating loss
carryforwards and research and development tax credit carryforwards may be limited. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019, we had no federal net operating loss
carryforwards and $8.2&nbsp;million in state net operating loss carryforwards, which begin to expire in 2038. We may have federal net operating loss carryforwards in future years. Under legislation enacted in 2017, informally titled the Tax Cuts and
Jobs Act, as modified by the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, federal net operating losses generated after 2017, if any, will not expire and may be carried forward indefinitely, but the deductibility of such
federal net operating losses (particularly those generated in tax years beginning after December&nbsp;31, 2020) in tax years beginning after December&nbsp;31, 2020, is limited. It is uncertain how various states will respond to the Tax Cuts and Jobs
Act, the CARES Act or any newly enacted federal tax law. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, including a recent California franchise tax law change
limiting the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31,
2019, we also had federal and state research and development tax credit carryforwards of $0.4&nbsp;million and $0.1&nbsp;million, respectively, which begin to expire in 2039. These tax credit carryforwards could expire unused and be unavailable to
offset our future income tax liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding
provisions of state law, if a corporation undergoes an &#147;ownership change,&#148; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#146;s ability to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change
income or taxes may be limited. In 2020, the Company completed a study of ownership changes from inception through May 31, 2020, which concluded that we experienced ownership changes as defined by Section&nbsp;382 of the Code. However, there were no
net operating loss carryforwards that were limited or expired unused. We may experience ownership changes in the future as a result of subsequent changes in our stock ownership, including this offering, some of which may be outside of our control.
If we determine that an ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, that would harm our future operating results by effectively increasing our future tax
obligations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to file INDs to commence additional clinical trials on the timelines we expect and, even if we are able to, the FDA may not
permit us to proceed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to submit an IND for CFT7455 in the fourth quarter of 2020 and for CFT8634 in the second half of 2021, but we may not be able
to file these planned INDs on the timelines we expect. For example, we may experience manufacturing delays or other delays with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. Moreover, we cannot be sure that submission of an IND will
result in the FDA allowing us to commence clinical trials or that, once begun, issues will not arise that lead to the suspension or termination of our clinical trials. Additionally, even if the applicable regulatory authorities agree with the design
and implementation of the clinical trials set forth in our INDs, we cannot guarantee that those regulatory authorities will not change their requirements in the future. These considerations apply to the INDs described above and also to new clinical
trials we may submit as amendments to existing INDs or as part of new INDs in the future. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or
commercializing our products on a timely basis, if at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If serious adverse events, undesirable side effects or unexpected characteristics are identified
during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not evaluated any product candidates in human clinical trials. Moreover, we are not aware of any clinical trials using small molecules for targeted protein
degradation, such as those developed using our TORPEDO platform. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that any of the product candidates developed through
our TORPEDO platform will not cause undesirable side effects, which could arise at any time during preclinical or clinical development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A potential risk with
product candidates developed through our TORPEDO platform, or in any protein degradation product candidate, is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in and of
itself could cause adverse events, undesirable side effects or unexpected characteristics. There is also the potential risk of delayed adverse events following treatment using product candidates developed through our TORPEDO platform. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any product candidates we develop are associated with serious adverse events or undesirable side effects or have other characteristics that are unexpected, we may
need to abandon their development or limit development to certain uses or subpopulations in which the adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit
perspective. The occurrence of any of these sorts of events would have an adverse effect on our business, financial condition, results of operations and prospects. Many product candidates that initially showed promise in early-stage testing for
treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates or limited their competitiveness in the market. For example, single agent BRAF inhibitors can cause a
secondary malignancy called keratocanthoma, which is a skin cancer caused by paradoxical activation of BRAF upon inhibitor binding. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The results of
preclinical studies may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage clinical trials. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of preclinical studies may not be predictive of the results of clinical trials and the results of any early-stage clinical trials we commence in the future
may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when those trials are completed or in later stage clinical trials. In particular, the
small number of patients in our planned early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the results of the dose escalation portion of our future <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trials of CFT7455 and
CFT8634 may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and
many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our future clinical trials may not ultimately be
successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have
suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any setbacks of this nature in our clinical development could materially harm our business, financial condition, results of operations
and prospects. In addition, we may conduct some of our clinical trials in a combination Phase 1/2 design and, if the Phase 1 portion of the trial is not successful, we will not be allowed to proceed into the Phase 2 portion of the trial. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we experience delays or difficulties in the enrollment of patients in our clinical trials, our timelines for submitting for and receiving necessary marketing
approvals could be delayed or prevented. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to initiate clinical trials for our product candidates if we are unable to locate and enroll a
sufficient number of eligible patients to participate in these trials, as required by the FDA or similar regulatory authorities outside of the United States. We are preparing to advance CFT7455 into <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trials in MM and NHLs, including PTCL and MCL. In addition, we are planning to advance CFT8634 into
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trials in patients with synovial sarcoma or SMARCB1 deleted solid tumors. While we believe that we will be able to enroll a sufficient
number of patients into each of these clinical trials, we cannot predict with certainty how difficult it will be to enroll patients for trials in these rare indications generally and during the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, specifically. Our ability to identify and enroll eligible patients for CFT7455 and CFT8634 clinical trials may turn out to be limited or we may be slower in enrolling these trials than we anticipate. In addition, some of our competitors
have ongoing clinical trials for product candidates that treat the same indications as our product candidates and, as a result, patients who would otherwise be eligible for our clinical trials may instead elect to enroll in clinical trials of our
competitors&#146; product candidates. Patient enrollment in clinical trials is also affected by other factors including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the eligibility criteria for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the perceived risks and benefits of the product candidates offered in the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the burden on patients due to the scope and invasiveness of required procedures under clinical trial protocols, some of
which may be inconvenient and/or uncomfortable; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the proximity and availability of clinical trial sites for prospective patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the impact of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may affect the conduct of a
clinical trial, including by slowing potential enrollment or reducing the number of eligible patients for clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our inability to
enroll a sufficient number of patients for our planned clinical trials, or our inability to do so on a timely basis, would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our
clinical trials may also result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The conclusions and analysis drawn from announced or published interim <FONT STYLE="white-space:nowrap">top-line</FONT> and preliminary data from our clinical
trials from time to time may change as more patient data become available. Further, all interim data that we provide remains subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may publish interim <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data from our clinical trials. Interim data from clinical
trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. In addition, preliminary or
<FONT STYLE="white-space:nowrap">top-line</FONT> data also remain subject to audit and verification procedures that may result in the final data being different, potentially in material ways, from the preliminary data we previously announced or
published. As a result, interim </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and preliminary data should be viewed with caution until final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation,
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may expend our limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result,
we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial
products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the
commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more
advantageous for us to retain sole development and commercialization rights to such product candidate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may develop CFT7455 in combination with other drugs
for MM. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of these other drugs or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to
evaluate in combination with CFT7455, we may be unable to obtain approval of or market CFT7455. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a recommended dose is identified from the dose
escalation portion of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial of CFT7455 for the treatment of MM, we may conduct a portion of that clinical trial in combination with
a dexamethasone inhibitor. We did not develop or obtain marketing approval for, nor do we manufacture or sell, any of the currently approved drugs that we may study in combination with CFT7455. If the FDA or similar regulatory authorities outside of
the United States revoke their approval of the drug or drugs we intend to deliver in combination with CFT7455, we will not be able to market CFT7455 in combination with those revoked drugs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays and the FDA or similar regulatory authorities outside of
the United States may require us to redesign or terminate certain of our clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for CFT7455, the FDA or similar regulatory authorities outside of the
United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with CFT7455, we may not be able to complete clinical
development of CFT7455 on our current timeline or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if CFT7455 were to receive marketing approval or be commercialized for use in combination with other
existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with CFT7455 or that safety, efficacy, manufacturing or
supply issues could arise with these existing drugs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Combination therapies are commonly used for the treatment of cancer and we would be subject to similar risks
if we were to elect to develop any of our other product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful
commercially. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to identify or discover additional potential product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our two lead programs are focused on oncology targets, a key element of our strategy is to apply our TORPEDO platform to develop product candidates that address a
broad array of targets and new therapeutic areas, such as neurodegeneration, diseases of aging and infectious disease. The therapeutic discovery activities that we are conducting may not be successful in identifying product candidates that are
useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that
indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential product candidates may not be effective in treating their targeted diseases; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the market size for the target indications of a potential product candidate may diminish over time due to improvements in
the standard of care to the point that further development is not warranted. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research programs to identify new product candidates require
substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify suitable product candidates for
preclinical and clinical development, we will not be able to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed and, as a
result, our stock price may decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may estimate the timing of the anticipated accomplishment of various scientific, clinical,
regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings. From time to
time, we may publicly announce the expected timing of some of these milestones. Each of these milestones is and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some
cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, our revenue may be lower than expected, the commercialization of our products may be delayed or never achieved and, as a result, our stock
price may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Dependence on Third Parties </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we may develop.
If any of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate
seeking third-party collaborators for the research, development and commercialization of some of our product candidates developed using our TORPEDO platform. Previously, we entered into the following collaboration agreements: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaboration with Roche in December 2015, which we amended and restated in December 2018; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaboration with Calico in March 2017; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaboration with Biogen in December 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our likely collaborators in any other collaboration arrangements we may enter into include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical
companies and biotechnology companies. If we were to enter into any collaboration arrangements with third parties, those arrangements will likely limit our control over the amount and timing of resources that our collaborators dedicate to the
development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to
them in these arrangements. We cannot predict the success of any collaboration in which we have entered or may enter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Collaborations involving our research
programs or any product candidates we may develop, including our existing collaborations with Roche, Calico and Biogen, pose the following risks to us: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations. For example, our collaborations with Roche, Biogen and Calico are each managed by a joint governance committee, which is composed of representatives from us and the applicable collaborator. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may not pursue development and commercialization of any product candidates we may develop or may elect not
to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or market considerations or available funding or external factors such as an acquisition or business
combination that diverts resources or creates competing priorities. If this were to happen, we may need additional capital to pursue further development or commercialization of the applicable product candidates. For example, in June 2020, Roche
notified us that they will not be electing to pursue further development of our EGFR program. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Roche, Biogen and Calico have broad rights to select a limited number of targets for protein degradation development, so
long as that target is not excluded by us under the terms of each collaboration and may select targets we are considering but have not taken sufficient action (e.g., internal development of, or steps toward partnering, such target) to exclude under
the collaboration. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly
with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Subject to certain diligence obligations, Collaborators with marketing and distribution rights to one or more products may
not commit sufficient resources to the marketing and distribution of such product or products. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may
use our proprietary information in a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, Roche, Biogen and Calico have the first right to enforce and Roche also has the first right
to defend, certain intellectual property rights under the applicable collaboration arrangement with respect to particular licensed programs and, although we may have the right to assume the enforcement and defense of such intellectual property
rights if the collaborator does not, our ability to do so may be compromised by their actions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our products that
results from our collaborating with them, and in cases where that applies, we would not have the exclusive right to commercialize the collaboration intellectual property. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Disputes may arise between our collaborators and us that result in the delay or termination of the research, development
or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change
of control. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates. For example, each of Roche, Biogen and Calico can terminate its agreement with us in its entirety or with respect to a specific target for convenience upon written notice ranging
from 90 to 270 days&#146; notice or in connection with a material breach of the agreement by us that remains uncured for a specified period of time. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient
manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed,
diminished or terminated. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may be unable to maintain compliance with GLP and GCP requirements or to secure approval for clinical
development plans from the FDA or foreign regulatory authorities. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The amount of revenue we derive from our collaborations may be volatile on a quarterly basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us or
elects not to pursue a program within a collaboration, we may not receive any future research funding or milestone or royalty payments under that collaboration or in respect of that terminated program. If we do not receive the funding we expect
under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more
difficult to find a suitable replacement collaborator or attract new collaborators and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating
to product development, marketing<B><I> </I></B>approval and commercialization described in this prospectus apply to the activities of our collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future decide to collaborate with pharmaceutical and biotechnology companies for the development and
potential commercialization of any product candidates we may develop. These and other similar relationships may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near- and long-term
expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and
complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed
collaborator&#146;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of those transactions if we are unable to successfully integrate them
with our existing operations and company culture. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements
in the future and we may not realize the benefits of those collaborations, alliances or licensing arrangements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may form or seek strategic alliances,
create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future
product candidates that we may develop. For example, we may seek to enter into <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements to advance our CFT7455 product candidate in MM or other indications. Any of these relationships may
require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process for these sorts of transactions is time-consuming,
complex and expensive. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for
collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency, purity and efficacy and obtain marketing approval. Additionally, our existing partners may decide to acquire
or partner with other companies developing targeted protein degraders, which may have an adverse impact on our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, if we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the
benefit of those transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business prospects, financial condition and results of
operations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies the entry into the transaction in the first place. Any delays in entering into new
collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects,
financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to rely on third parties to conduct our future clinical trials and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such trials. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to rely on CROs to conduct our planned <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial programs for CFT7455 and CFT8634 and our other clinical trials as we currently do not plan to independently conduct clinical trials of
our other product candidates. Our agreements with these CROs might terminate for a variety of reasons, including a failure to perform by the third parties. If we were ever to need to enter into alternative arrangements, we would experience delays in
our product development activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our reliance on CROs for research and development activities will reduce our control over these activities but will not relieve
us of our responsibilities for how these activities are performed. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable
IND. Moreover, the FDA requires compliance with standards, commonly referred to as GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights,
integrity and confidentiality of trial participants are protected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, these CROs may have relationships with other entities, some of which may be our peers or competitors. If the CROs
with whom we work do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in
obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Manufacturing pharmaceutical products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture of our
product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products
or that we will not have the quantities we desire or require at an acceptable cost or quality or at the right time, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on CMOs, for both drug
substance and finished drug product. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or that we will not have the quantities we desire or require at an acceptable
cost or quality, which could delay, prevent or impair our development or commercialization efforts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be unable to establish agreements with CMOs or to do so
on acceptable terms. Even if we are able to establish agreements with CMOs, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reliance on the third party for regulatory, compliance and quality assurance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible breach of the manufacturing agreement by the third-party CMO; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the agreement by the third party at a
time that is costly or inconvenient for us. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have only limited technology transfer agreements in place with respect to our product candidates
and these existing arrangements do not extend to commercial supply. We acquire many key materials on a purchase order basis. As a result, we do not have long-term committed arrangements with respect to our product candidates and other materials. If
we receive marketing approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party
manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside of the United States. Our molecules are highly potent and, in the absence of additional safety data,
they receive a high occupational exposure band, or OEB. These assigned OEBs dictate the contaminant and other precautions that must be taken as part of the manufacture of our product candidates. Our failure, or the failure of our CMOs, to comply
with applicable regulations, including the ability of our CMOs to work with our highly potent materials and the safety protocols in connection therewith, could result in sanctions being imposed on us, including clinical holds, fines, injunctions,
civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect
supplies of our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates and any products that we may develop may compete with other product candidates and products for access to
manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any performance failure or delay in performance on the part of our existing or future manufacturers could delay clinical development or marketing approval. For
example, our contract fill/finish manufacturer had a mechanical issue arise in connection with a manufacturing step for our CFT7455 product candidate. While we do not believe this issue will have an impact on our development timelines, in the
future, we could experience a manufacturing issue that would have a material impact on development of our product candidates and the occurrence of an event of this nature would largely be outside of our control. We do not currently have arrangements
in place for redundant supply or a second source for bulk drug substance. If our current CMOs cannot perform as agreed, we may be required to replace them. Although we believe that there are several potential alternative manufacturers who could
manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
replacement manufacturers or we may not be able to reach agreement with any alternative manufacturer. While we have identified alternate vendors for CFT7455 and CFT8634, switching vendors could
result in significant additional costs of materials and significant delays to our operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current and anticipated future dependence upon others for the
manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we currently rely on single source suppliers for certain of the raw materials for our preclinical study and clinical trial supplies. If our current or
future suppliers are unable to supply us with sufficient raw materials for our preclinical studies and clinical trials, we may experience delays in our development efforts as we locate and qualify new raw material manufacturers. These third-party
manufacturers may incorporate their own proprietary processes into our product candidate manufacturing processes. We have limited control and oversight of a third party&#146;s proprietary process and a third-party manufacturer may elect to modify
its process without our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly
increase the cost of and significantly delay the manufacture of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As our product candidates progress through preclinical studies and clinical
trials towards approval and commercialization, we expect that various aspects of the manufacturing process will be altered in an effort to optimize processes and results. These types of changes may require that we make amendments to our regulatory
applications, which could further delay the timeframes under which modified manufacturing processes can be used for any of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as
we advance our product candidates into later stage clinical trials and plan for the potential commercialization of our product candidates, we may determine that it is necessary or appropriate to bring on additional suppliers of drug product and/or
drug substance, which could result in changes to the manufacturing processes for our product candidates and may require us to provide additional information to regulatory authorities. If we were to bring on additional CMOs for our product
candidates, we may also be required to conduct additional bridging studies or trials, all of which take would require additional time and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related
to the Commercialization of Our Product Candidates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if any of our product candidates receives marketing approval, it may fail to achieve the degree
of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our
product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as
chemotherapy and radiation therapy, are well-established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant
revenue from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of any side effects, in particular compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient population to try new therapies and of physicians treating these patients to
prescribe these therapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of marketing, sales and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party insurance coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of any marketing approval in relation to other product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">support from patient advocacy groups; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As a company, we currently have no marketing and sales organization and have no experience in marketing products. If
we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company, we currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We intend to develop an <FONT
STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to
recruit, hire, train and retain marketing and sales personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable or decide not to establish internal sales, marketing and distribution capabilities,
we will pursue arrangements with third-party sales, marketing and distribution collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able to establish or maintain these types
of arrangements on favorable terms or if at all, or if we are able to do so, that these third-party arrangements will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of
these third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of these third parties and our revenue from product sales may be lower than if we had commercialized our product candidates
ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There can be no
assurance that we will be able to develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or
overseas. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market opportunities for our product candidates may be relatively small as we expect that they will initially be approved only for those
patients who are ineligible for or have failed prior treatments. In addition, our estimates of the prevalence of our target patient populations may be inaccurate. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates may target cancer, but cancer therapies are sometimes characterized as first-line, second-line, third-line or subsequent line, and the FDA often
approves new therapies initially only for a particular line of use. When cancer is detected early enough, first-line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first-line therapy, usually chemotherapy,
antibody drugs, tumor-targeted small molecules, immunotherapy, hormone therapy, radiation therapy, surgery, other targeted therapies or a combination of these therapies, proves unsuccessful, second-line therapy may be administered. Second-line
therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third-line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more
invasive forms of surgery and new technologies. We expect initially to seek approval of our product candidates in most instances as a second- or third-line therapy, for use in patients with relapsed or refractory cancer. Subsequently, for those
product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second-line therapy and potentially as a first-line therapy, but there is no guarantee that any of our product candidates, even if
approved as a second or third or subsequent line of therapy, would subsequently be approved for an earlier line of therapy. Further, it is possible that, prior to getting any approvals for our product candidates in earlier lines of treatment, we
might have to conduct additional clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our projections of both the number of people who have the cancers we are targeting, who may have their tumors
genetically sequenced, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our reasonable beliefs and
estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new therapies may change the estimated
incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second or third-line of therapy, the number of patients that may be eligible for treatment with our product candidates may
turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of
approved therapies for each of those tumor types. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive marketing approval of any of our product candidates, our products may become subject to
unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The regulations that
govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs
and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain
reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical
pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay
our commercial launch of the product, possibly for lengthy time periods, which would negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to
recoup our investment in one or more of our product candidates, even if our product candidates obtain marketing approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to commercialize any product
candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers and other
organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare
industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we
commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining
adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate
reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs. In addition, coverage may be more limited than the purposes for which
the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs,
including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at
lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from
both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even
greater risk if or when we commercially sell any products that we may develop. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome,
liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased demand for any product candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of marketing approval, recall, restriction on the approval or a &#147;black box&#148; warning or
contraindication for an approved drug; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a preclinical company, we do not currently hold product liability insurance coverage. We will need to purchase product liability insurance coverage as we initiate
our clinical trials, as we expand our clinical trials and if and when we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in
an amount adequate to satisfy any liability that may arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently
broad, our competitors could develop and commercialize technology and products similar or identical to ours, our ability to successfully commercialize our technology and products may be impaired and we may not be able to compete effectively in our
market. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our intellectual property and prevent
others from exploiting our pipeline drug product candidates, any future drug product candidates we may develop and our platform technologies, as well as the use or manufacture of our current or future drug product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection in the United States and other countries with
respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. Any disclosure to or
misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent
applications we own, <FONT STYLE="white-space:nowrap">co-own</FONT> or license may fail to result in issued patents in the United States or in other foreign countries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a
reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the
right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a
manner consistent with the best interests of our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent position of the biopharmaceutical industry generally is highly uncertain, involves complex
legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the
scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with
certainty whether we were the first to make the inventions claimed in our owned, <FONT STYLE="white-space:nowrap">co-owned</FONT> or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
licensed patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability
and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or products, in whole or in part, or that effectively prevent others from
commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product
candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our owned, <FONT STYLE="white-space:nowrap">co-owned</FONT> and licensed patent estate consists principally of patent applications, many of which are
at an early stage of prosecution. Even if our owned, <FONT STYLE="white-space:nowrap">co-owned</FONT> and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned, <FONT STYLE="white-space:nowrap">co-owned</FONT> or licensed patents by developing similar or alternative
technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuance of a patent is not conclusive as to its inventorship,
scope, validity or enforceability, and our owned, <FONT STYLE="white-space:nowrap">co-owned</FONT> and licensed patents or patents obtained by our collaborators may be challenged in the courts or patent offices in the United States and abroad. These
challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or
identical technology and products or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our
drug product candidates might expire before or shortly after they are commercialized. As a result, our owned, <FONT STYLE="white-space:nowrap">co-owned</FONT> and licensed patent portfolio, or that of our collaborators, may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in patent laws or patent jurisprudence could diminish
the value of our patents in general or increase third party challenges to our patents, thereby impairing our ability to protect our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law and made a number of significant changes to United States patent law. These changes include provisions that affect the way patent
applications are prosecuted and may also affect patent litigation. The United States Patent and Trademark Office, or the USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive
changes to patent law associated with the Leahy-Smith Act, including the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> provisions, became effective on March&nbsp;16, 2013. The Leahy-Smith Act
and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business and financial
condition. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provision of the Leahy-Smith Act requires us to act promptly during the period from invention to filing of a patent application. However,
even with the intention to act promptly, circumstances could prevent us from promptly filing or prosecuting patent applications on our inventions. The Leahy-Smith Act also enlarged the scope of disclosures that qualify as prior art, which can impact
our ability to receive patent protection for an invention. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Leahy-Smith Act created, for the first time, new procedures under which third parties may challenge
issued patents in the United States, including post-grant review, <I>inter partes</I> review and derivations proceedings, all of which are adversarial proceedings conducted at the USPTO. Since the effectiveness of the Leahy-Smith Act, some third
parties have been using these types of actions to seek and achieve the cancellation of selected or all claims of issued patents of their competitors. Under the Leahy-Smith Act, for a patent with a priority date of March&nbsp;16, 2013 or later (which
is the case for all of our patent filings), a third party can file a petition for post-grant review at any time during a nine-month window commencing at the time of issuance of the patent. In addition, for a patent with a priority date of
March&nbsp;16, 2013 or later, a third party can file a petition for <I>inter partes</I> review after the nine-month period for filing a post-grant review petition has expired. Post-grant review proceedings can be brought on any ground of challenge,
whereas <I>inter partes</I> review proceedings can only be brought to raise a challenge based on published </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prior art. Under applicable law, the standard of review for these types of adversarial actions at the USPTO are conducted without the presumption of validity afforded to U.S. patents, which is
the standard that applies if a third party were to seek to invalidate a patent through a lawsuit filed in the U.S. federal courts. The USPTO issued a Final Rule on November&nbsp;11, 2018 announcing that it will now use the same claim construction
currently used in the U.S. federal courts&#151;which is the plain and ordinary meaning of words used&#151;to interpret patent claims in these USPTO proceedings. As a result of this regulatory landscape, if any of our patents are challenged by a
third party in a USPTO proceeding of this nature, there is no guarantee that we will be successful in defending the challenged patent, which could result in our losing rights under the challenged patent in part or in whole. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights, or those of our collaborators, are highly uncertain, which could
have an adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce
our patents, the patents of our licensors or other intellectual property, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors may
infringe our issued patents, the patents of our licensors or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive, time-consuming and unpredictable. Any
claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our
licensors or collaborators is invalid or unenforceable, in whole or in part, construe the patent&#146;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology
in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Even if we successfully assert our patents, a court may not award remedies
that sufficiently compensate us for our losses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may need to license intellectual property from third parties and licenses of this nature may not be
available or may not be available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A third party may hold intellectual property, including patent rights, that are
important or necessary to the development of our products. It may, therefore, be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to
obtain a license from that third party. A license to that intellectual property may not be available or may not be available on commercially reasonable terms, which could have an adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The licensing and acquisition of third-party intellectual property rights is a competitive practice. Companies that may be more established or have greater resources
than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a
competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the
intellectual property surrounding the additional product candidates that we may seek to acquire. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may initiate legal proceedings alleging that
we are infringing their intellectual property rights, the outcome of which would be uncertain and could have an adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our
proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biopharmaceutical industry, as well as administrative proceedings for challenging patents, including
interference, reexamination and <I>inter partes </I>review proceedings before the USPTO and oppositions and other comparable proceedings in foreign jurisdictions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may become party to or threatened with future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and
technology, including interference, derivation, reexamination or <I>inter</I> <I>partes </I>review proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the
future. As the <FONT STYLE="white-space:nowrap">bio-pharmaceutical</FONT> industry expands and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. There may
be third-party patents of which we are currently unaware with claims to materials, formulations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates. Because patent applications can take many years to issue, there may be currently pending
patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are found by a court of competent jurisdiction to infringe a third party&#146;s intellectual property rights, we could be required to obtain a license from the
applicable third party intellectual property holder to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to
obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing
technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a
similar negative impact on our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A number of other companies, as well as universities and other organizations, file and obtain patents in the same
areas as our products, which are targeted protein degraders, and these patent filings could be asserted against us or our collaborators in the future, which could have an adverse effect on the success of our business and, if successful, could lead
to expensive litigation that could affect the profitability of our products and/or prohibit the sale or use of our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our MonoDAC and BiDAC product
candidates are pharmaceutical small molecule targeted protein degraders. A number of companies and institutions have patent applications and issued patents in this general area, such as, for example, Arvinas, Inc.; Kymera Therapeutics, LLC.; the
Dana-Farber Cancer Institute and its Center for Protein Degradation; Foghorn Therapeutics, Inc.; Nurix Therapeutics, Inc.; Roche; Novartis AG; Amgen Inc.; AstraZeneca PLC; GlaxoSmithKline PLC and others. If any of these companies or institutions or
others not included in this list were to assert that one of its patents is infringed by any product we might develop or its use or manufacture, we or our collaborators may be drawn into expensive litigation, which could adversely affect our business
prospects, financial condition and results of operations, require extensive time from and cause the distraction of members of our management team and employees at large. Further, if litigation of this nature were successful, that could have a
material and adverse effect on the profitability of our products or prohibit their sale. We may not be aware of patent claims that are currently or may in the future be pending that could affect our business or products. Patent applications are
typical published between six and eighteen months from filing and the presentation of new claims in already pending applications can sometimes not be visible to the public, which would include us, for a period of time. In addition, even after a
patent application is publicly available, we may not yet have seen that patent application and may, therefore, not be aware of the claims or scope of filed and published patent applications. As a result, we cannot provide any assurance that a third
party practicing in the general area of our technology will not present or has not presented a patent claim that covers one or more of our products or their methods of use or manufacture. If that were to occur, we or our collaborators, as
applicable, may have to take steps to try to invalidate the applicable patent or application and, in a situation of that nature, we or our collaborators may either choose not to do so or our attempt may not be successful. If we determine that we
require a license to a third party&#146;s patent or patent application, we may discover that a license may not be available on reasonable terms, or at all. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our products are subject to The Drug Price Competition and Patent Term Restoration Act of 1984, which is also referred to as the Hatch Waxman Act, in the United
States, which can increase the risk of litigation with generic companies trying to sell our products and may cause us to lose patent protection. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because
our clinical candidates are pharmaceutical molecules that will be reviewed by the Center for Drug Evaluation and Research, CDER, of the FDA, after commercialization they will be subject in the United States to the patent litigation process of the
Hatch-Waxman Act, as amended to date, which allows a generic company to submit an Abbreviated New Drug Application, or ANDA, to the FDA to obtain approval to sell a generic version of our drug using bioequivalence data only. Under amendments made to
the Hatch-Waxman Act, we will have the opportunity to list our patents that cover our drug products or their respective methods of use in the FDA&#146;s compendium of &#147;Approved Drug Products with Therapeutic Equivalence Evaluation,&#148;
sometimes referred to as the FDA&#146;s Orange Book. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, in the United States, the FDA may grant five years of exclusivity for new chemical entities, or NCEs, which are
drugs that contain no active portion that has been approved by the FDA in any other NDA. We expect that all of our products will qualify as NCEs. A generic company can submit an ANDA to the FDA four years after approval of any of our drug products.
The submission of an ANDA by a generic company is considered a technical act of patent infringement. The generic company can certify that it will wait until the natural expiration date of our listed patents to sell a generic version of our product
or can certify that one or more of our listed patents are invalid, unenforceable or not infringed. If the generic manufacturer elects the latter, we will have 45 days to bring a patent infringement lawsuit against the generic company. If we were to
do so, that would likely initiate a challenge to one or more of our Orange Book listed patents based on arguments from the generic manufacturer that our listed patents are invalid, unenforceable or not infringed. Under amendments to the Hatch-Waxman
Act, if a lawsuit is brought, the FDA is prevented from issuing a final approval on the generic drug until 30 months after the end of the data exclusivity period (7.5 years) or a final decision of a court holding that our asserted patent claims are
invalid, unenforceable or not infringed. If we do not properly list our relevant patents in the Orange Book or if we fail to file a lawsuit in response to a certification from a generic company under an ANDA in a timely manner, or if we do not
prevail in the resulting patent litigation, we can lose our ability to benefit from a proprietary market based on patent protection covering our drug products and we may find that physicians will switch to prescribing and dispensing generic versions
of our drug products. Further, even if we were to list our relevant patents in the Orange Book correctly, bring a lawsuit in a timely manner and prevail in that lawsuit, the generic litigation may come at a significant cost to us, both in terms of
attorneys&#146; fees and employee time and distraction over a long period. Further, it is common for more than one generic company to try to sell an innovator&#146;s drug at the same time and, as a result, we may face the cost and distraction of
multiple lawsuits from generic manufacturers at the same time. We may also determine that it is necessary to settle these types of lawsuits in a manner that allows the generic company to enter our market prior to the expiration of our patent or
otherwise in a manner that adversely affects the strength, validity or enforceability of our patents. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A number of pharmaceutical companies have been the
subject of intense review by the U.S. Federal Trade Commission or a corresponding agency in another country based on how they have conducted or settled patent litigation related to pharmaceutical products. In fact, certain reviews have led to an
allegation of an anti-trust violation, sometimes resulting in a fine or loss of rights. We cannot be sure that we would not also be subject to a review of this nature or that the result of a review of this nature would be favorable to us, or that
any review of this nature would not result in a fine or penalty. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. Federal Trade Commission, or FTC, has brought a number of lawsuits in federal
court in the past few years to challenge ANDA litigation settlements reached between innovator companies and generic companies as anti-competitive. As an example, the FTC has taken an aggressive position that anything of value is a payment, whether
money is paid or not. Under their approach, if an innovator, as part of a patent settlement, agrees not to launch or delay its launch of an authorized generic during the <FONT STYLE="white-space:nowrap">180-day</FONT> period granted to the first
generic company to challenge an Orange Book listed patent covering an innovator drug, or negotiates a delay in entry without payment, the FTC may consider it an unacceptable reverse payment. Companies in the pharmaceutical industry have argued that
these types of agreements are rational business decisions entered into by drug innovators as a way to address risk and that these settlements should, therefore, be immune from antitrust attack if the terms of the settlement are within the scope of
the exclusionary potential of the patent. In 2013, the U.S. Supreme Court in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">five-to-three</FONT></FONT> decision in <I>FTC v. Actavis, Inc.</I> rejected both the pharmaceutical
industry&#146;s and FTC&#146;s arguments with regard to <FONT STYLE="white-space:nowrap">so-called</FONT> reverse payments. Instead, the Supreme Court held that whether a &#147;reverse payment&#148; settlement involving the exchange of consideration
for a delay in entry is subject to an anti-competitive analysis depends on five considerations: (a)&nbsp;the potential for genuine adverse effects on competition; (b)&nbsp;the justification of payment; (c)&nbsp;the patentee&#146;s ability to bring
about anti-competitive harm; (d)&nbsp;whether the size of the payment is a workable surrogate for the patent&#146;s weakness; and (e)&nbsp;that antitrust liability for large unjustified payments does not prevent litigating parties from settling
their lawsuits, for example, by allowing the generic drug to enter the market before the patent expires on the branded drug without the patentee paying the generic manufacturer. Further, whether a reverse payment is justified depends upon its size,
scale in relation to the patentee&#146;s anticipated future litigation costs, and independence from other services for which it might represent payment (as was the case in <I>Actavis</I>), as well as the lack of any other convincing justification.
The Supreme Court instead held that reverse payment settlements can potentially violate antitrust laws and are subject to the standard antitrust <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rule-of-reason</FONT></FONT> analysis,
with the burden of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
proving that an agreement is unlawful on the FTC. In reaching this decision, the Supreme Court left to the lower courts the structuring of this rule of reason analysis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are faced with drug patent litigation, including Hatch-Waxman litigation with a generic company, we could be faced with an FTC challenge of this nature, which
challenge could impact how or whether we settle the case and, even if we strongly disagree with the FTC&#146;s position, we could face a significant expense or penalty. Any litigation settlements we enter into with generic companies under the
Hatch-Waxman Act could also be challenged by third-party payors such as insurance companies, direct purchasers or others who consider themselves adversely affected by the settlement. These kinds of <FONT STYLE="white-space:nowrap">follow-on</FONT>
lawsuits, which may be class action suits, can be expensive and can continue over multiple years. If we were to face lawsuits of this nature, we may not be successful in defeating these claims and we may, therefore, be subject to large payment
obligations, which we may not be able to satisfy in whole or in part. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to obtain patent term extension under the Drug Price Competition and
Patent Term Restoration Act of 1984 in the United States and, as a result, our product candidates, if approved, may not have patent protection for a sufficient period. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits one patent term extension of up to five years beyond the normal
expiration of one patent per product, which if related to a method of treatment patent, is limited to the approved indication. The length of the patent term extension is typically calculated as <FONT STYLE="white-space:nowrap">one-half</FONT> of the
clinical trial period plus the entire period of time during the review of the NDA by the FDA, minus any time of delay by us during these periods. There is also a limit on the patent term extension to a term that is no greater than fourteen years
from drug approval. Therefore, if we select and are granted a patent term extension on a recently filed and issued patent, we may not receive the full benefit of a possible patent term extension, if at all. We might also not be granted a patent term
extension at all, because of, for example, our failure to apply within the applicable period, failure to apply prior to the expiration of relevant patents or other failure to satisfy any of the numerous applicable requirements. Moreover, the
applicable authorities, including the FDA and the USPTO in the United States and any equivalent regulatory authority in other countries, may not agree with our assessment of whether extensions of this nature are available and may refuse to grant
extensions to our patents or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data and
launch their product earlier than might otherwise be the case. If this were to occur, it could have an adverse effect on our ability to generate product revenue. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 1997, as part of the Food&nbsp;&amp; Drug Administration Modernization Act, or FDAMA, Congress enacted a law that provides incentives to drug manufacturers who
conduct studies of drugs in children. The law, which provides <FONT STYLE="white-space:nowrap">six-months</FONT> exclusivity in return for conducting pediatric studies, is referred to as the &#147;pediatric exclusivity provision.&#148; If we were to
conduct clinical trials that comply with the FDAMA, we could receive an additional <FONT STYLE="white-space:nowrap">six-month</FONT> term added to our regulatory data exclusivity period and on the patent term extension period, if received, on our
product. However, if we choose not to carry out pediatric studies that comply with the FDAMA, or carry out studies that are not accepted by the FDA for this purpose, we would not receive this additional
<FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity extension to our data exclusivity or our patent term extension. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In Europe, supplementary protection
certificates are available to extend a patent term up to five years to compensate for patent term lost during regulatory review, and this period can be extended to five and a half years if data from clinical trials is obtained in accordance with an
agreed Pediatric Investigation Plan. Although all countries in Europe must provide supplementary protection certificates, there is no unified legislation among European countries and, as a result, drug developers must apply for supplementary
protection certificates on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. As a result, a company may need to expend significant resources to apply for and receive these certificates in all
relevant countries and may receive them in some, but not all, countries, if at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Weakening patent laws and enforcement by courts in the United States and
foreign countries may impact our ability to protect our markets. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. Supreme Court has issued opinions in patent cases in the last few years that many
consider may weaken patent protection in the United States, either by narrowing the scope of patent protection available in certain circumstances, holding that certain kinds of innovations are not patentable or generally otherwise making it easier
to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
invalidate patents in court. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our
ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant
<FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and
patents that we might obtain in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United
States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our
intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed. For example, we could become a party to foreign opposition proceedings, such as at the European Patent Office, or patent litigation and
other proceedings in a foreign court. If so, uncertainties resulting from the initiation and continuation of such proceedings could have an adverse effect on our ability to compete in the market place. The cost of foreign adversarial proceedings can
also be substantial, and in many foreign jurisdictions, the losing party must pay the attorney fees of the winning party. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims by
third parties asserting that we, our employees, consultants or contractors have misappropriated the applicable third party&#146;s intellectual property or claiming ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We employ individuals who were previously employed at universities as well as other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. Although we try to ensure that our employees do not use the proprietary information or <FONT
STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
employee&#146;s former employer. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in
defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Even if we
are successful, litigation could result in substantial cost and reputational loss and be a distraction to our management and other employees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, while it
is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning any resulting intellectual property to us, we may be unsuccessful in executing an
agreement to that effect with each party who in fact develops intellectual property that we regard as our own. Assignment agreements of this nature may not be self-executing or may be breached and we may be forced to bring claims against third
parties or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, an employee or contractor could create an invention but not inform us of it, in which case we could lose the
benefit of the invention and the employee or contractor may leave to develop the invention elsewhere. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property litigation could cause us to
spend substantial resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if resolved in our favor, litigation or other legal
proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the
results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Litigation or
proceedings of this nature could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other
resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or proceedings of this nature more effectively than we can because of their greater financial resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, documentary, fee payment
and other requirements imposed by governmental patent offices and the protection of our patents could be reduced or eliminated if we fail to comply with these requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the
patent. The USPTO and patent offices in foreign countries require compliance with many procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of a patent or
patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have an
adverse effect on our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into
confidentiality and invention or patent assignment agreements with our employees and consultants. These agreements may not effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual
property and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary information. In
that case, we could not assert any trade secret rights against that third party. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and we may not be able to
obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome of a dispute of this nature is inherently unpredictable.
Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary rights and our failure to obtain or maintain trade secret protection could adversely affect our competitive business position. In
addition, some courts outside of the United States are less willing or unwilling to protect trade secrets. The Defend Trade Secrets Act of 2016 is a U.S. federal law that allows an owner of a trade secret to sue in federal court when its trade
secret has been misappropriated. Congress passed this law in an attempt to strengthen the rights of trade secret owners whose valuable assets are taken without authorization. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor, we would have no right to prevent them, or those to whom they communicate them, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed
by a competitor, our competitive position would be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We only have limited geographical protection with respect to certain of our patents and we may not
be able to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting and defending patents covering our product candidates in all
countries throughout the world would be prohibitively expensive. As a result, our intellectual property rights in some countries outside the United States can be less extensive than the protection we might have in the United States. <FONT
STYLE="white-space:nowrap">In-licensing</FONT> patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if these <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities are
available to us at all. Further, <FONT STYLE="white-space:nowrap">in-licensing</FONT> or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively
expensive or impractical. Competitors may use our and our licensors&#146; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing
products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the European Union. These products may compete with our product candidates, and our or our licensors&#146;
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may decide to abandon national and regional patent applications while they are still pending. The grant
proceeding of each national or regional patent is an independent proceeding that may lead to situations in which applications may be rejected by the relevant patent office, while substantively similar applications are granted by others. For example,
relative to other countries, China has a heightened detailed description requirement for patentability. Further, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#146;
patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that
depending on the country, the scope of patent protection may vary for the same product candidate or technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The laws of some jurisdictions do not protect
intellectual property rights to the same extent as the laws or regulations in the United States and the European Union, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such
jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to
prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to enforce our patent
rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business and could additionally put our or our licensors&#146; patents at risk of
being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#146; patent applications not issuing or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while
damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Further, while we intend to protect our intellectual property rights in our
expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property
rights in these countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in
protecting or are otherwise precluded from effectively protecting the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those
jurisdictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the
enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to
grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Regulatory Matters </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval processes
of the FDA and foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable and, if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain approval by the FDA and foreign regulatory authorities is unpredictable but typically takes many years following the commencement of
clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during
the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate and it is possible that none of our existing product candidates, or any product
candidates we may seek to develop in the future, will ever obtain marketing approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates could fail to receive marketing approval for many reasons, including the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its
proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of clinical trials may not meet the level of statistical significance required by the FDA for approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to
the FDA or other submission or to obtain marketing approval in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party
manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data
insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our
failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process and determining when or
whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request,
may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other
jurisdiction, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market any products in any particular jurisdiction, we must
establish and comply with numerous and varying regulatory requirements on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;country-by-country&nbsp;basis</FONT></FONT> regarding safety and efficacy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval
in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does
not guarantee regulatory approval in any other country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approval processes vary among countries and can involve additional product testing and validation and
additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory
requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and
we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international
markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage,
advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of
comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring
that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any
NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses
for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product
candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term <FONT STYLE="white-space:nowrap">patient&nbsp;follow-up,&nbsp;a</FONT> medication guide, physician
communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may also have programs similar to REMS. In
addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to
comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other
restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or
mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
revocation of license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved
indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion <FONT STYLE="white-space:nowrap">of&nbsp;off-label&nbsp;uses</FONT> and a company
that is found to have improperly <FONT STYLE="white-space:nowrap">promoted&nbsp;off-label&nbsp;uses</FONT> may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products <FONT
STYLE="white-space:nowrap">for&nbsp;off-label&nbsp;uses.</FONT> The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#146;s communications on the subject <FONT
STYLE="white-space:nowrap">of&nbsp;off-label&nbsp;use</FONT> of their products. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A Breakthrough Therapy designation
by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek Breakthrough Therapy designation for our CFT7455 and CFT8634 product candidates and some or all of our future product candidates. A
breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough
therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs
designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Designation as a
breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such
designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to candidate products considered for approval under <FONT
STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the
product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for CFT7455 and CFT8634 and some or all of our future product candidates for the treatment of various cancers, there can
be no assurance that we will receive breakthrough therapy designation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A Fast Track designation by the FDA, even if granted for CFT7455 and/or CFT8634, or
any of our other current or future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek Fast Track designation for one or more of our future product candidates. If a drug is intended for the treatment of a serious or life-threatening condition
and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for CFT7455 and/or CFT8634 and
certain of our future product candidates, but there is no assurance that the FDA will grant this status to any of our proposed product candidates. Marketing applications filed by sponsors of products in Fast Track development may qualify for
priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant Fast Track
designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster
development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track designation if it believes that
the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I></I></B><B></B><B><I>If we decide to seek Orphan Drug Designation for any of our current or future product candidates, we may be unsuccessful or may be unable to
maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek Orphan Drug
Designation for one or more of our current or future product candidates. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the
Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the
drug in the United States will be recovered from sales in the United States for that drug. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs,
tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does
not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product that has orphan drug designation subsequently
receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including
an NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug
exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product
candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan exclusivity if we are unable to manufacture
sufficient supply of our product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek orphan drug designation for CFT7455, CFT8634 and some or all of our other current or future product candidates in
additional orphan indications in which there is a medically plausible basis for the use of these product candidates. Even when we obtain Orphan Drug Designation, exclusive marketing rights in the United States may be limited if we seek approval for
an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we, through our manufacturer, are unable to assure sufficient quantities of the
product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive these designations. For example, the FDA has expressed
concerns regarding the regulatory considerations for orphan drug designation as applied to tissue agnostic therapies, and the FDA may interpret the Federal Food, Drug and Cosmetic Act, and regulations promulgated thereunder, in a way that limits or
blocks our ability to obtain orphan drug designation or orphan drug exclusivity, if our product candidates are approved, for our targeted indications. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accelerated approval by the FDA, even if granted for CFT7455 and/or CFT8634, or any other current or future product candidates, may not lead to a faster
development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to seek accelerated approval of CFT7455 and CFT8634 and may seek approval of future product candidates using the FDA&#146;s accelerated approval pathway. A
product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is
reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and <B><I></I></B>well controlled post-marketing clinical trials. These
confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the
timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process. Further, receiving accelerated approval does not provide assurance of
ultimate full FDA approval. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state
healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply or have not fully complied with these laws, we could face substantial penalties.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription
of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud
and abuse laws and other healthcare laws that may constrain the business or financial arrangements and relationships through which we research, sell, market and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
distribute our product candidates, if we obtain marketing approval. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and
services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. The applicable federal, state and foreign healthcare laws and regulations laws
that may affect our ability to operate include, but are not limited to those listed under the section titled &#147;Business&#151;Governmental Regulations&#148; in this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to
be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating
in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations <FONT
STYLE="white-space:nowrap">of&nbsp;non-compliance&nbsp;with</FONT> these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations. The shifting compliance environment and the need to build and maintain
robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to
significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us
to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses
and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws
and regulations could have an adverse effect on our ability to compete in the marketplace. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The successful commercialization of our product candidates in
the United States will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for
our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States and in
other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of reimbursement
for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid or TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is essential for most
patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an
agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Factors payors
consider in determining reimbursement are based on whether the product is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for our products and
related treatments will be available from third-party payors. Moreover, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. If coverage and adequate reimbursement is not
available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain
pricing sufficient to realize a sufficient return on our investment. A decision by a third-party payor not to cover or not to separately reimburse for our medical products or therapies using our products could reduce physician utilization of our
products once approved. We cannot be sure that coverage and reimbursement in the United States will be available for our current or future product candidates or for any procedures using our current or future product candidates, and any reimbursement
that may become available may not be adequate or may be decreased or eliminated in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, no uniform policy for coverage and
reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for our products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be
separate from the process for setting the reimbursement rate that the payor will pay for the product. One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for
the product. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. We cannot
be sure that coverage and reimbursement will be available for or accurately estimate the potential revenue from our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause payor organizations to limit both coverage
and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we
may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may
also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to
be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We
expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Lastly, in some foreign
countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, countries in the EU Member States can restrict the range of
medicinal products for which their national health insurance systems provide reimbursement and they can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the
completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the medicinal product on the market. Approaches between EU Member States are diverging. For example, in France, effective market access will be supported by agreements with
hospitals and products may be reimbursed by the Social Security Fund. The price of medicines is negotiated with the Economic Committee for Health Products. There can be no assurance that any country that has price controls or reimbursement
limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
structures of the United States and generally prices in the European Union tend to be significantly lower than prices in the United States. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and
commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and other jurisdictions, there have been, and we expect
there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at
the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Affordable Care Act, or the ACA, was enacted, which substantially changed the way healthcare is financed by
both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee payable by any entity that manufactures or imports
certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs
that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage
to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">creation of a new Patient-Centered Outcomes Research Institute to oversee and conduct comparative clinical effectiveness
research, as well as funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishment of a Center for Medicare&nbsp;&amp; Medicaid Innovation at CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There remain judicial, Congressional
and executive branch challenges to certain aspects of the ACA and we expect there will be additional challenges and amendments to the ACA in the future. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify
certain provisions of the ACA such as removing penalties, starting January&nbsp;1, 2019, for not complying with the ACA&#146;s individual mandate to carry health insurance and increasing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">the&nbsp;point-of-sale&nbsp;discount</FONT></FONT> that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Further, the 2020 federal spending package permanently eliminated, effective
January&nbsp;1, 2020, the ACA-mandated &#147;Cadillac&#148; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&nbsp;1, 2021, also eliminates the health insurer tax. On December&nbsp;14, 2018, a U.S.
District Court Judge in Texas ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December&nbsp;18, 2019, the U.S. Court of
Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&nbsp;2, 2020, the United
States Supreme Court granted the petitions for writs of certiorari to review this case and has allotted one hour for oral arguments. It is unclear when oral arguments on this case are to be held and when a decision on this case might be made. It is
also unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, other legislative changes have
been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went
into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional action is taken by Congress. However, pursuant to the CARES Act, these Medicare sequester reductions have
been suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other
things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the Bipartisan Budget Act of 2018, or BBA, among other things,
amended the ACA, effective January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount (from 50% under the ACA to 70%) that is owed by pharmaceutical manufacturers
who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; These new laws or any other similar laws introduced in the future may result in additional reductions in
Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, payment methodologies may
be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the
manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing,
reduce the cost of prescription drugs under Medicare and review the relationship between pricing and manufacturer patient programs. The Trump administration&#146;s budget proposal for fiscal year 2021 includes a $135&nbsp;billion allowance to
support legislative proposals seeking to reduce drug prices, increase competition, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lower&nbsp;out-of-pocket&nbsp;drug</FONT></FONT> costs for patients and increase patient access to
lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beneficiary&nbsp;out-of-pocket&nbsp;pharmacy</FONT></FONT> expenses, provide an option to cap Medicare Part D beneficiary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">monthly&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> and place limits on pharmaceutical price increases. On May&nbsp;11, 2018, President Trump laid out his administration&#146;s
&#147;Blueprint&#148; to lower drug prices and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reduce&nbsp;out-of-pocket&nbsp;costs</FONT></FONT> of prescription drugs that contained proposals to increase manufacturer competition,
increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of
these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January&nbsp;1, 2020. This final
rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. The Trump administration&#146;s recent budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug
prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Although such measures may require additional authorization to become effective, Congress and the
Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of
which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and
bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could adversely affect our business prospects, financial condition and results of operations. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for our product candidates or put pressure on our product pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that additional state and federal healthcare reform measures will be adopted in
the future, any of which could limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that the federal and state governments will pay for healthcare products and
services. This could result in reduced demand for any product candidate we develop or could result in additional pricing pressures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In markets outside of the
United States, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. The price control regulations outside of the United States can have a
significant impact on the profitability of a given market, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
further uncertainty is introduced if and when these laws change. For example, in Canada, price control legislation for patented medicines is currently undergoing significant change that may have
significant effects on profitability for companies selling products in Canada. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that may
arise from future legislation or administrative action in the United States or any other jurisdiction. It is possible that additional governmental action will be taken to address
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or these
third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may face potential liability under the applicable privacy laws if we obtain identifiable patient health information from clinical trials sponsored by us.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy and security
regulations promulgated under the Health Insurance Portability and Accountability Act of 1966, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH. We are not currently classified as a covered
entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#146;s criminal provisions either directly or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">under&nbsp;aiding-and-abetting&nbsp;or</FONT></FONT> conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually
identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#146;s requirements for disclosure of individually identifiable health information. In addition, in the future, we may
maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations and/or directly from individuals (or their healthcare
providers) who may enroll in patient assistance programs if we choose to implement these types of programs. As a result, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of
personal information, which is a broader class of information than the health information protected by HIPAA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The global data protection landscape is rapidly
evolving and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such
as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty
in our business, affect our or our service providers&#146; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure
or perceived failure by us to comply with federal, state or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others.
Recently, California passed the California Data Privacy Protection Act of 2018, or the CCPA, which went into effect in January 2020. The CCPA provides new data privacy rights for consumers and new operational requirements for companies, including
placing increased privacy and security obligations on entities handling certain personal data of consumers or households. These requirements could increase our compliance costs and potential liability. The CCPA gives California residents expanded
rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a
private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the
CCPA may impact certain of our business activities. The new California law may lead to similar laws in other U.S. states or at a national level, which could increase our potential liability and adversely affect our business, which exemplifies the
vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU General Data Protection
Regulation, or GDPR, also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the
GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and liability in relation to personal data that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
we process where that processing is subject to the GDPR. In addition, we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including GDPR requirements as
implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices. Despite those efforts, there is a risk that we
may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">European data protection laws also generally
prohibit the transfer of personal data from Europe, including the European Economic Area, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to
protect the transferred personal data.&nbsp;One of the primary safeguards used for transfers of personal data from the European Union to the United States, namely, the Privacy Shield framework administered by the U.S. Department of Commerce, was
recently invalidated by a decision of the European Union&#146;s highest court.&nbsp;The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission&#146;s Standard
Contractual Clauses, to lawfully transfer personal data from Europe to the United States and most other countries.&nbsp;At present, there are few if any viable alternatives to the Privacy Shield and the Standard Contractual Clauses. To the extent
that we were to rely on the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield Framework or the Standard Contractual Clauses, we may not be able to do so in the future, which could increase our costs and limit our ability to process
personal data from the European Union. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, Brexit has created uncertainty with regard to data protection regulation in the United Kingdom. In particular,
while the Data Protection Act of 2018, that &#147;implements&#148; and complements the GDPR achieved Royal Assent on May&nbsp;23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the
United Kingdom will remain lawful under the GDPR. During the period of &#147;transition&#148; (i.e., until December&nbsp;31, 2020), EU law will continue to apply in the United Kingdom, including the GDPR, after which the GDPR will be converted into
UK law. Beginning in 2021, the United Kingdom will be a &#147;third country&#148; under the GDPR. We may, however, incur liabilities, expenses, costs and other operational losses under the GDPR and applicable EU Member States and the UK privacy laws
in connection with any measures we take to comply with them. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, certain health privacy laws, data breach notification laws, consumer protection laws and
genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#146; health information. Patients about whom we or our collaborators may
obtain health information, as well as the providers who may share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and
other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive
and time-consuming to defend and could result in adverse publicity that could harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or third-party CMOs, CROs or other contractors or
consultants fail to comply with applicable federal, state/provincial or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#146; ability to develop and commercialize our
therapeutic candidates and could harm or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any
threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise
to liability, breaches of data security or reputational damage. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws
described above, among others, some of which may be broader in scope and may apply regardless of the payor. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we or our third-party manufacturers and
suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage,
treatment and disposal of hazardous materials and wastes. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these
materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage
resulting in <FONT STYLE="white-space:nowrap">costly&nbsp;clean-up&nbsp;and</FONT> liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we
believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or
eliminate the risk of accidental contamination or injury from these materials. Upon an event of this nature, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable
authorities may curtail our use of certain materials and/or interrupt our business operations. Further, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of any
changes of this nature and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and
regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of
hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and
casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.
Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and
trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the
U.S. Travel Act, the USA PATRIOT Act of 2001 and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their
employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties
for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We may also have direct or
indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents,
contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of these activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties,
imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Employee Matters, Managing Growth and Operational Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified
personnel, we may not be able to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to compete in the highly competitive biotechnology and
pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, medical personnel, sales and marketing and other personnel. We are highly dependent on our management, scientific and medical
personnel, including our President and Chief Executive Officer, our Chief Scientific Officer, our Chief Medical Officer, our Chief Financial Officer and our Chief Legal Officer. Our Chief Financial Officer is presently a consultant. While we expect
to engage in an orderly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties relating to management transition, including diversion of management
attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. In addition, the loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an
inability to find suitable replacements could result in delays in product development and harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conduct our operations at our facilities in
Watertown, Massachusetts. The Massachusetts region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire
and retain highly qualified personnel on acceptable terms or at all. Changes to U.S. immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected
by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to immigration or visa laws and regulations impair our hiring processes and goals or projects involving
personnel who are not U.S. citizens. For example, the president&#146;s Proclamation Suspending Entry of Aliens Who Present a Risk to the U.S. Labor Market Following the Coronavirus Outbreak, which was issued in June 2020, may adversely affect our
ability to hire and retain highly qualified personnel who are not U.S. citizens or permanent residents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To encourage valuable employees to remain at our company,
in addition to salary and cash incentives, we have provided stock options that vest over time. The value to our employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control
and may, at any time, be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on
short notice. Although we have employment agreements with our executive employees, these employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our executive employees could leave our
employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior managers, as well as junior, <FONT
STYLE="white-space:nowrap">mid-level</FONT> and senior scientific, medical and general and administrative personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have scientific and clinical
advisors who assist us in formulating our development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In
addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will need to grow the size of our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2020, we had 88 full-time employees, including 74 employees engaged in research and development. We also engage additional full-time equivalent
researchers through our Indian CRO. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, manufacturing, regulatory affairs and, if any of our
product candidates receives marketing approval, sales, marketing and distribution. In addition, in connection with our transition to being a publicly traded company, we expect to increase the size of our general and administrative teams to support
the growth of our business and the requirements of being a publicly traded company. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Future growth would impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for CFT7455, CFT8634
and any other product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">improving our operational, financial and management controls, reporting systems and procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future financial performance and our ability to advance into clinical development and, if approved, commercialize CFT7455, CFT8634 and any of our other product
candidates we develop will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
our management team in managing a company with this type of anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.
Further, research at our Indian CROs also exposes us to various risks, including regulatory, economic and political instability, potentially unfavorable tax, import and export policies, fluctuations in foreign exchange and inflation rates,
international and civil hostilities, terrorism, natural disasters and pandemics. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer systems, or those of any of our collaborators,
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
internal computer systems and those of any collaborators, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have
not experienced any material system failure, accidents or security breaches of this nature to date, if an event of this nature were to occur and cause interruptions in our operations, it could result in a material disruption of our development
programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in
delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications or the
inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Additionally, we
may have data security obligations with respect to the information of third parties that we store. Unauthorized access or use of any third-party data or information of this nature could result in fines or other penalties that may impact our
relationships with these third parties and our operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, vendors, principal investigators, CROs and consultants may
engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading laws. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent conduct or other
illegal activity. Misconduct by these parties could include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of
the FDA or similar foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">healthcare fraud and abuse laws and regulations in the United States and abroad; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">violations of United States federal securities laws relating to trading in our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failures to report financial information or data accurately. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other
forms of misconduct could involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm
to our reputation. We intend to adopt, prior to the completion of this offering, a code of business conduct and ethics and implement other corporate governance and compliance documents, policies and charters applicable to all of our employees.
However, it is not always possible to identify and deter misconduct by employees and other third parties. Further, the precautions we take to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other
misconduct, even if none occurred. If any actions of this nature are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the
imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our business prospects, financial condition
and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price per share of our common stock will be substantially higher than the as adjusted net tangible book value per share of our common stock.
Based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $10.62 per share, representing the difference
between our pro forma as adjusted net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price. To the extent shares are subsequently issued upon exercise of outstanding options, you will
incur further dilution. In addition, purchasers of common stock in this offering will have contributed approximately 36% of the aggregate price paid by all purchasers of shares of our common stock but will own only approximately 22% of our common
stock outstanding after this offering (assuming no exercise of the underwriters&#146; option to purchase additional shares). See the section titled &#147;Dilution&#148; for more information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. To the extent we raise
additional capital through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that sales of this nature
may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common
stock or the availability of common stock for future sales will have on the trading price of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not know whether an active, liquid and
orderly trading market will develop for our common stock or what the market price of our common stock will be and, as a result, it may be difficult for you to sell your shares of our common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there was no public trading market for shares of our common stock. Although we have applied to list our common stock on The Nasdaq Global
Market, an active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. The initial
public offering price for our common stock will be determined through negotiations with the underwriters and the negotiated price may not be indicative of the market price of the common stock after the offering. As a result of these and other
factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our
ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities or industry
analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us, our business or the
targeted protein degradation space. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our common stock
could be impacted negatively. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us were to issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock
performance, or if our preclinical studies and future clinical trials and results of operations fail to meet the expectations of any of these analysts, our stock price would likely decline. If one or more of these covering analysts were to cease
coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this
offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading price of shares of our common stock following this offering is likely to be volatile and subject to wide fluctuations in response to
various factors, some of which we cannot control. The stock market in general, and the market for smaller biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of
particular companies. As a result of this volatility, you may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
able to sell your common stock at or above the initial public offering price or at or above the price at which you acquired it. The market price for our common stock may be influenced by many
factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the degree of success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of preclinical studies and clinical trials of our product candidates or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of expenses related to any of our product candidates or clinical development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional
technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effects of public health crises, pandemics and epidemics, such as <FONT STYLE="white-space:nowrap">COVID-19;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of the foregoing matters were to occur or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock
could decline substantially. In the past, following periods of volatility in the market price of a company&#146;s securities, securities class-action litigation often has been instituted against that company. Litigation of this nature, if instituted
against us, could cause us to incur substantial costs to defend these claims and divert management&#146;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects. Further, our
director and officer liability insurance cost may increase as a result of litigation of this nature and our insurance deductible may be significant before our insurers are required to provide any coverage to us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results
of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have an adverse effect on our business, cause the price of our common stock to decline
and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>After this offering, our executive officers, directors and principal stockholders will have the ability to control or significantly influence matters submitted to
stockholders for approval. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, our executive officers and directors, combined with our stockholders who owned more than
5% of our outstanding common stock before this offering will, in the aggregate, beneficially own shares representing approximately 25.2% of our capital stock (assuming no exercise of the underwriters&#146; option to purchase additional shares, no
exercise of outstanding options and no purchases of shares in this offering by any member of this group). Certain of these stockholders may be eligible to and elect to participate in a directed share program, pursuant to which the underwriters have
reserved an aggregate of up to 5% of the common stock in this offering for sale at the initial public offering price to certain of our officers, directors, employees and other persons who do business with us. After this offering, our executive
officers and directors, combined with our stockholders who owned more than 5% of our outstanding common stock, will have the ability to control us through this ownership position even if they do not purchase any additional shares in this offering.
As a result, these stockholders, if acting together, will continue to control matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the
election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delay, defer or prevent a change in control; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">entrench our management and the board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.
</P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the
market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and
restated certificate of incorporation and amended and restated bylaws, which are to become effective upon the closing of this offering, will contain provisions that could delay or prevent a change of control of our company or changes in our board of
directors that our stockholders might consider favorable. Some of these provisions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a board of directors divided into three classes serving staggered three-year terms, the result of which is that not all
members of the board will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a prohibition on stockholder action through written consent, the result of which is that all stockholder actions will have
to be taken at a meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a
resolution approved by the affirmative vote of a majority of the directors then in office; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause
and, in addition to any other vote required by law, upon the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding shares of our voting stock then entitled to vote in the election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a requirement of approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding shares of
our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without
stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because we
are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These
antitakeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or
initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult
for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price
of our common stock to decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could
cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of a substantial number of shares of our
common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Upon completion of this offering, we will have 40,669,715
outstanding shares of common stock based on the number of shares outstanding as of June&nbsp;30, 2020 (assuming no exercise of the underwriters&#146; option to purchase additional shares). This includes the shares that we are selling in this
offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Of the remaining shares, 31,845,715&nbsp;shares are currently restricted as a result of securities laws or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements but will become eligible to be sold at various times after the offering. Moreover, after this offering securityholders holding an aggregate of 30,694,163 shares of our common stock (on an
as-converted basis) will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We
also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the
&#147;Shares Eligible For Future Sale&#148; section of this prospectus. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting
company,&#148; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an EGC until the
earlier of: (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more; (2)&nbsp;the last day of 2025; (3) the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt
during the previous three years; and (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the last day of the first year in which the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of June 30. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public
companies that are not EGCs. These exemptions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure obligations regarding executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an exemption from compliance with the requirement of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to take advantage of some, but
not all, of these available exemptions. We have taken advantage of reduced reporting requirements in this prospectus. In particular, we have not included all of the executive compensation information that would be required if we were not an EGC and
we have presented only two years of audited financial statements and correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure. We cannot predict whether investors will
find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be
more volatile. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption until the earlier of the date that we
(i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
also are a &#147;smaller reporting company,&#148; meaning that the market value of our stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;plus</FONT> the proposed aggregate amount of gross proceeds to us as a result of this
offering is less than $700&nbsp;million as of the prior June&nbsp;30 and our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if
either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million as of the prior June&nbsp;30 or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most
recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million as of the prior June 30. If we are a smaller reporting company at the time we cease to be
an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent
fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and,</FONT> similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding
executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to
devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, and particularly after we are no longer an
emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the
listing requirements of The Nasdaq Stock Market LLC and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance and insurance
costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could
make it more difficult for us to attract and retain qualified members of our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating these rules and regulations and cannot predict
or estimate the amount of additional costs we may incur or the timing of these costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in
practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, or Section&nbsp;404, we will be required to furnish a report by our management on our internal control
over financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with
Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through
testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the
prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. In the preparation of our consolidated financial statements to meet the requirements of this offering, we determined
that a material weakness in our internal control over financial reporting existed as of December 31, 2019. The material weakness identified in our internal control over financial reporting arose because we did not maintain effective segregation of
duties in the process and recording of journal entries. We are taking measures to remediate this material weakness during 2020, including implementing system controls that prevent one person from initiating and approving the same journal entry.
However, we cannot assure you that these measures will be sufficient to prevent future material weaknesses or significant deficiencies in our internal control over financial reporting from occurring. If we identify one or more material weaknesses in
the future, it could result in an adverse reaction in the financial markets and restrict our future access to the capital markets due to a loss of confidence in the reliability of our financial statements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended and restated bylaws, as will be effective upon the closing of this offering, designate specific courts as the exclusive forum for certain litigation
that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated bylaws that will become effective upon the completion of this offering, unless we consent in writing to the selection of an
alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a
fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders; (3)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation
or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. We refer to this provision in our
bylaws as the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts
shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, as our headquarters are located in Watertown, Massachusetts. We refer to this provision in our bylaws as the Federal
Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision
and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims.
Additionally, these forum selection clauses may limit our stockholders&#146; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of
lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting
to require claims under the Securities Act be brought in federal court are &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is
found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The
Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may
be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not
anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of our Credit Agreement with Perceptive
Credit also preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial
crisis caused extreme volatility and disruptions in the capital and credit markets. Similarly, the recent significant volatility associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused significant instability and
disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our product candidates, and could also impact our ability to raise additional
capital when needed on acceptable terms, if at all. Our general business strategy may be adversely affected by any economic downturn of this nature, volatile business environment or continued unpredictable and unstable market conditions. If the
current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, costly and dilutive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure
to secure any necessary financing in a timely manner and on favorable terms could have an adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition,
there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is
especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#146;s
attention and resources, which could adversely affect our business prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in
this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical
trials and IND and other regulatory submissions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain regulatory approval for any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our need to raise additional funding before we can expect to generate any revenues from product sales;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the period over which we anticipate the proceeds of this offering, together with our existing cash and cash equivalents
and short term investments, will be sufficient to fund our operating expenses and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to identify and develop product candidates for treatment of additional disease indications;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential attributes and benefits of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rate and degree of market acceptance and clinical utility for any product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effects of competition with respect to any of our current or future product candidates, as well as innovations by
current and future competitors in our industry; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the implementation of our strategic plans for our business, any product candidates we may develop and our TORPEDO
platform; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to advance programs under our existing collaboration agreements with Roche, Biogen and Calico and enter into
new collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the continuing effects of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> on our
business, including our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our belief that we are taking the appropriate measures to remediate the material weakness identified in our internal
control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for
intellectual property rights covering our product candidates and TORPEDO platform; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to use the proceeds of this offering in ways that increase the value of your investment;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our financial performance and our ability to effectively manage our anticipated growth; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our estimates regarding the market opportunities for our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148;
&#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These statements are only
predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. If one or more of these risks or
uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future
performance. You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus forms a part, completely and with the understanding that our
actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate
that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by
applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_4"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates.
Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed
in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market
research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates,
in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#147;Risk Factors&#148; and
elsewhere in this prospectus. You are cautioned not to give undue weight to any such information, projections and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds to us from the sale of 8,824,000 shares of our common stock in this offering will be $135.5&nbsp;million, or $156.4&nbsp;million if
the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering
price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $8.2 million, assuming that the number of shares offered by
us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of
shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $15.8 million, assuming no change in the assumed initial public offering price per share, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our intended uses
of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30,
2020, we had cash and cash equivalents and short-term investments of $211.6&nbsp;million. We currently intend to use the net proceeds from this offering, together with our existing cash resources, as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $40.0&nbsp;million to complete the Phase 1 portion of our planned <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial of CFT7455 for patients with MM or NHL, such as PTCL or MCL, as well as to fund a portion of the Phase 2 expansion component of that clinical trial in these
indications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $56.0&nbsp;million to complete the Phase 1 portion of our planned <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial of CFT8634 for patients with synovial sarcoma or solid tumors with SMARCB1 loss, as well as to fund a portion of the Phase 2 expansion component of this trial and
initiate a Phase 3 confirmatory clinical trial of this product candidate in synovial sarcoma; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $62.0&nbsp;million to conduct and complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with
respect to BRAF V600E and RET, substantially complete the Phase 1 portion of our planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 /2 clinical trials for each of these programs and fund
initial portions of our planned phase 2 expansion component for the clinical trials for each of these product candidates; and </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the remainder for continued development of our TORPEDO platform and advancement and identification of additional targets
and development candidates, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our current plans, we believe our existing cash and cash equivalents and short-term investments of $211.6 million as of June 30, 2020, combined with the
proceeds from the Series B Financing of $4.5 million received in July 2020, anticipated payments from collaboration partners and the net proceeds from this offering will be sufficient to fund our operations and capital expenditure requirements
through the second quarter of 2023. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and
business conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of
this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the timing
and progress of our development, the status of and results from preclinical studies or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates or strategic
opportunities that become available to us and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending our use of proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation
instruments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to fund the development and expansion of our
business and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and short-term investments and our capitalization as of June&nbsp;30, 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma basis to give effect to (i)&nbsp;the sale and issuance of shares of our Series&nbsp;B preferred stock for
gross proceeds of $4.5&nbsp;million subsequent to June&nbsp;30, 2020, (ii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 30,355,379 shares of common stock upon the closing of this offering,
(iii)&nbsp;the reclassification of the warrant liability to additional paid-in capital upon the automatic conversion of preferred stock warrants into common stock warrants upon the closing of this offering and (iv)&nbsp;the filing and effectiveness
of our amended and restated certificate of incorporation, which will occur upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma <FONT STYLE="white-space:nowrap">as-adjusted</FONT> basis to give further effect to the sale and issuance
by us of 8,824,000 shares of our common stock in this offering at an assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. We had incurred $0.3&nbsp;million of expenses related to this offering as of June&nbsp;30, 2020, which were reflected as deferred offering costs in our financial statements.
</P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read this table below with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in
this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JUNE&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">351,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock (Series Seed, Series A and Series&nbsp;B), $0.0005 par value;
264,000,000&nbsp;shares authorized and 256,003,042&nbsp;shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding, actual; 10,000,000 shares
authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value; 370,000,000 shares authorized, 1,490,336 shares issued and outstanding,
actual; 150,000,000&nbsp;shares authorized, 31,845,715 shares issued and outstanding, pro forma; 150,000,000&nbsp;shares authorized, 40,669,715 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00
increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash
and cash equivalents and short-term investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by $8.2&nbsp;million, assuming that the number of shares offered by us, as
set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares
offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents and short-term investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT>
capital, total stockholders&#146; equity and total capitalization by $15.8&nbsp;million, assuming the assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, remains
the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above excludes the
following as of June&nbsp;30, 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,052,531 shares of common stock issuable upon exercise of stock options outstanding under our 2015 Stock Option and Grant
Plan, or the 2015 Plan, and stock options outstanding outside the 2015 Plan, at a weighted-average exercise price of $4.37 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,467,424 shares of common stock issuable upon the exercise of stock options granted under the 2015 Plan subsequent to
June&nbsp;30, 2020, with an exercise price of $4.98 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,300,043 shares of common stock issuable upon the exercise of stock options we have agreed to grant under our 2020 Stock
Option and Incentive Plan, or the 2020 Plan, to some of our executive officers immediately following the effectiveness of the registration statement of which this prospectus forms a part, assuming that we sell 8,824,000 shares in this offering, with
an exercise price per share equal to the initial public offering price per share in this offering, as described in more detail under the caption &#147;Certain Relationships and Related Person Transactions&#151;Stock Option Grants to Directors and
Executive Officers&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">192,681 shares of common stock issuable upon the exercise of stock options we will grant under the 2020 Plan immediately
following the effectiveness of the registration statement of which this prospectus is a part to certain employees and our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who remain on our board of directors at such time, with an
exercise price per share equal to the initial public offering price per share in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">338,784&nbsp;shares of our common stock issuable upon the exercise of warrants to purchase 2,857,142&nbsp;shares of our
Series&nbsp;B preferred stock at an exercise price of $1.05&nbsp;per share, which warrants will automatically convert into warrants to purchase shares of our common stock at an exercise price of $8.86&nbsp;per share upon closing of this offering;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,074,420 shares of common stock to be reserved for future issuance under our 2020 Plan to be effective on the day
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, excluding the shares of common stock issuable upon the exercise of stock options we have agreed to grant under the 2020 Plan as described
above; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">437,089 shares of common stock to be reserved for future issuance under our 2020 Employee Stock Purchase Plan to be
effective on the day immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. As of June&nbsp;30, 2020, our historical net tangible book value (deficit) was
$(135.3)&nbsp;million, or $(90.82) per share of common stock. Our historical net tangible book value (deficit) is the amount of our total tangible assets less deferred offering costs, less our total liabilities and the carrying value of our
preferred stock, which is not included in stockholders&#146; deficit. Historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by 1,490,336 shares of common stock outstanding as of
June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pro forma net tangible book value as of June&nbsp;30, 2020 was $123.5&nbsp;million, or $3.88 per share of common stock, after giving effect
to the issuance and sale of shares of our Series B preferred stock for gross proceeds of $4.5&nbsp;million subsequent to June&nbsp;30, 2020 and the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 30,355,379
shares of our common stock upon the closing of this offering and the reclassification of the warrant liability to additional paid-in capital upon the automatic conversion of preferred stock warrants into common stock warrants. Pro forma net tangible
book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of June&nbsp;30, 2020, after giving effect to the pro forma adjustments described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving further effect to our issuance and sale of 8,824,000 shares of our common stock in this offering at an assumed initial public offering price of $17.00 per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible
book value as of June&nbsp;30, 2020 would have been $259.3&nbsp;million, or $6.38 per share of common stock. This represents an immediate increase in pro forma as adjusted net tangible book value of $2.50 per share to existing stockholders and an
immediate dilution of $10.62 in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible
book value per share after this offering from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(90.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase per share attributable to issuance of Series B preferred stock and conversion of all shares of our
preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share as of June&nbsp;30, 2020, before giving effect to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution in pro forma as adjusted net tangible book value per share to new investors purchasing common
stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">10.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The dilution information discussed above is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at
pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net
tangible book value by $0.20 per share and the dilution to investors purchasing common stock in this offering by $0.80 per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1,000,000 shares in the number of shares offered by us in this offering would increase the pro forma as adjusted net
tangible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
book value by $0.22 per share and would decrease the dilution per share to new investors purchasing common stock in this offering by $0.22 per share, assuming no change in the assumed initial
public offering price of $17.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the
cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value after this offering by $0.24 per share and increase the dilution to new investors purchasing common stock in this offering by $0.24 per share, assuming
no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after this offering would
be $6.67, representing an immediate increase in pro forma as adjusted net tangible book value per share of $2.79 to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of $10.33 to new investors
purchasing common stock in this offering, assuming an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, on the pro forma as adjusted basis described above as of
June&nbsp;30, 2020, the total number of shares of common stock purchased from us on an as-converted basis, the total consideration paid or to be paid and the average price per share paid or to be paid by existing stockholders and by new investors in
this offering, based on the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover of this prospectus before deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,845,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,824,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,669,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">411,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase (decrease) the total consideration paid by new investors by $8.2&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors to 38% and, in the case of a
decrease, would decrease the percentage of total consideration paid by new investors to 35%, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us in this offering would increase (decrease) the total consideration paid by new investors in
this offering by $15.8&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors to 39% percentage points and, in the case of a decrease, would decrease the percentage of total
consideration paid by new investors to 34%, assuming the assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to
purchase additional shares in this offering. If the underwriters exercise their option to purchase additional shares of our common stock in full, the number of shares of our common stock held by existing stockholders and new investors would be 76%
and 24%, respectively, of the total number of shares of our common stock outstanding after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing tables and calculations exclude as of June&nbsp;30, 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,052,531 shares of common stock issuable upon exercise of stock options outstanding under our 2015 Stock Option and Grant
Plan, or the 2015 Plan, and stock options outstanding outside the 2015 Plan, at a weighted-average exercise price of $4.37 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,467,424 shares of common stock issuable upon the exercise of stock options granted under the 2015&nbsp;Plan subsequent
to June&nbsp;30, 2020, with an exercise price of $4.98 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">2,300,043 shares of common stock issuable upon the exercise of stock options we have agreed to grant under our 2020 Stock
Option and Incentive Plan, or the 2020 Plan to some of our executive officers immediately following the effectiveness of the registration statement of which this prospectus forms a part, assuming that we sell 8,824,000 shares in this offering, with
an exercise price per share equal to the initial public offering price per share in this offering, as described in more detail under the caption &#147;Certain Relationships and Related Person Transactions&#151;Stock Option Grants to Directors and
Executive Officers&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">192,681 shares of common stock issuable upon the exercise of stock options we will grant under the 2020 Plan immediately
following the effectiveness of the registration statement of which this prospectus is a part to certain employees and our non-employee directors who remain on our board of directors at such time, with an exercise price per share equal to the initial
public offering price per share in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">338,784&nbsp;shares of our common stock issuable upon the exercise of warrants to purchase 2,857,142&nbsp;shares of our
Series&nbsp;B preferred stock at an exercise price of $1.05 per share, which warrants will automatically convert into warrants to purchase shares of our common stock at an exercise price of $8.86 per share upon closing of this offering;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">4,074,420 shares of common stock to be reserved for future issuance under our 2020 Plan to be effective on the day
immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, excluding the shares of common stock issuable upon the exercise of stock options we have agreed to grant under the 2020 Plan as described
above; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">437,809 shares of common stock to be reserved for future issuance under our 2020 Employee Stock Purchase Plan to be
effective on the day immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the
extent that outstanding stock options or warrants are exercised, new stock options are issued, or we issue additional shares of common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise
additional capital because of market conditions or strategic considerations even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt
securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following selected consolidated financial data together with our audited consolidated and unaudited condensed consolidated financial statements
and the related notes appearing elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. We have derived the consolidated statement of
operations data for the years ended December&nbsp;31, 2018 and 2019 and the consolidated balance sheet data as of December&nbsp;31, 2018 and 2019 from our audited consolidated financial statements appearing elsewhere in this prospectus. The
unaudited condensed consolidated statement of operations data for the six months ended June&nbsp;30, 2019 and 2020 and the unaudited condensed consolidated balance sheet data as of June&nbsp;30, 2020 are derived from our unaudited condensed
consolidated financial statements included elsewhere in this prospectus, which have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of
normal recurring adjustments, necessary for a fair presentation of the financial information in those statements. You should read this data together with our financial statements and related notes included elsewhere in this prospectus and the
information under the caption &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of the results that may be expected in the future, and our
results for any interim period are not necessarily indicative of results that may be expected for any full year. </I></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED<BR>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated statement of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive gain (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized gain (loss) on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (27,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding&#151;basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,293,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,469,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited) <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common shares outstanding&#151;basic and diluted (unaudited)&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,788,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,233,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;11 to our consolidated financial statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders for the years
ending December 31, 2018 and 2019 and Note 12 to our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common
stockholders for the six months ending June 30, 2019 and 2020. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATION </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the &#147;Selected
Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere
in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors
set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a biopharmaceutical company focused on transforming the treatment of cancer, serious neurodegenerative conditions and other diseases by developing novel
therapeutic candidates engineered to harness the body&#146;s natural regulation of protein levels to target and destroy disease-causing proteins. We leverage our proprietary technology platform, TORPEDO (<U>T</U>arget <U>OR</U>iented
<U>P</U>rot<U>E</U>in <U>D</U>egrader <U>O</U>ptimizer), to synthesize a new class of small molecule protein degraders that selectively and efficiently destroy disease-causing proteins. We are using our TORPEDO<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>platform to build a robust pipeline of orally administered protein degradation drug candidates, with an initial focus on oncology indications. Our approach to medicine harnesses the innate machinery
of the cell to attack disease and potentially bring deep and durable responses to patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We commenced operations in October 2015, and our operations to date
have been limited to organizing and staffing our company, business planning, raising capital, establishing development collaborations with Roche, Biogen and Calico, conducting discovery and research activities, filing patent applications,
identifying potential product candidates, undertaking preclinical studies and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product
sales and have financed our operations primarily through sales of our equity interests and proceeds from our collaborations. Through June 30, 2020, we had raised approximately $224.0&nbsp;million in gross proceeds from the sale of Series seed
redeemable convertible preferred stock, Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock and have received an aggregate of $154.8&nbsp;million in payments from collaboration partners. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization
of one or more of our product candidates. Since inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses were
$15.7&nbsp;million and $34.1&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively, and $14.0 million and $22.7 million for the six months ended June 30, 2019 and 2020, respectively. As of June 30, 2020, we had an
accumulated deficit of $140.2 million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our total operating expenses were $35.8&nbsp;million and $56.8&nbsp;million for the years ended December&nbsp;31, 2018 and
2019, respectively, and $22.8 million and $39.7 million for the six months ended June 30, 2019 and 2020, respectively. We anticipate that our expenses will increase substantially due to costs including those associated with the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our preclinical activities for our lead product candidates and the advancement of these candidates into <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trials in the United States, which we expect to initiate in the first half of 2021 for CFT755 and by the end of 2021 for CFT8634;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">development activities associated with our other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">research activities in oncology, neurological and other disease areas to expand our pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hiring additional personnel in research, clinical trials, quality and other functional areas; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">increased activities by our CMOs to supply us with product for our preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the management of our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">operating as a public company after this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will not generate any revenue from product sales unless and until we successfully complete clinical development and
obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, to the extent we decide to commercialize that product ourselves, we would expect to incur significant expenses
related to developing our internal commercialization capability to support product sales, marketing and distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, we will need substantial
additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and, if any of our product candidates are approved, proceed to commercialization.
Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, debt offerings, reimbursements and potential milestones earned under our
existing collaboration agreements and potential license and development agreements with third parties, including but not limited to our existing collaboration partners. Adequate funding may not be available to us on acceptable terms, or at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research, product development or future
commercialization efforts, relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. Although we continue to pursue these plans, there
is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2019 and June 30, 2020, we had cash and cash equivalents of $90.5&nbsp;million and $107.7&nbsp;million, respectively. In June and July 2020, we closed a Series B redeemable convertible preferred stock financing, or the Series B
Financing, for gross proceeds of $150.0 million offset by $4.5&nbsp;million in offering costs, and, in June 2020, we secured a $20.0&nbsp;million debt facility, from which we drew down $12.5&nbsp;million, or $12.0&nbsp;million net of costs. We
believe that our cash and cash equivalents and short-term investments as of June&nbsp;30,&nbsp;2020 of $107.7&nbsp;million and $103.9 million, respectively, combined with the proceeds from the Series&nbsp;B Financing of $4.5&nbsp;million received in
July 2020, anticipated payments from collaboration partners and the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through the second quarter of 2023. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus outbreak on our financial performance will depend on future developments, including the
duration and spread of the outbreak and related governmental advisories and restrictions. There are multiple causes of these delays, including laboratory closures, reluctance of patients to enroll or continue in trials for fear of exposure to <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> local and regional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and work from home orders and regulations that discourage, hamper or prohibit patient
visits, healthcare providers and health systems shifting away from clinical trials toward the acute care of <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients and the FDA and other regulators making product candidates for the treatment of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> a priority over product candidates unrelated to the pandemic. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In terms of the impact on our operations, we have seen
increased risk of delays in production of components used to manufacture our lead degrader candidates due to previous delays at one of our China-based manufacturers, and one of our CROs in India was forced to temporarily shut down due to local
lockdown orders. In addition, we temporarily closed the office and laboratory spaces at our corporate headquarters in Watertown, Massachusetts, and we transitioned our employees to work from home. We are working closely with our CROs, manufacturers,
investigators and preclinical and clinical trial sites to assess the full impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the timelines and expected costs for each of our programs. While the ongoing impact of the pandemic
is uncertain, we believe our CRO redundancies in China, India and Boston and the transition of the majority of our employees to remote work arrangements have mitigated the impact of these types of disruptions on our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not aware of any of our directors or employees being infected with coronavirus, but the virus can remain asymptomatic for a significant period of time and
methods and availability of testing are continuing to evolve. It is possible our directors or employees or their family members could become infected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We note the
high level of difficulty in projecting the effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our programs and our company, given the rapid and dramatic evolution in the course and impact of the pandemic and the societal and governmental
response to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have not generated any revenue from product
sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. We recognize revenue over our expected performance
period under each agreement. We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not
received any royalties under any of our existing collaboration agreements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Roche Collaboration and License Agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March&nbsp;2016, we entered into a collaboration and license agreement, or the&nbsp;Original Roche Agreement, with Roche, whereby Roche provided us with a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $15.0&nbsp;million, which was creditable against our target initiation fees of either $1.0&nbsp;million or $4.0&nbsp;million, depending on the compound selected. Pursuant to the
terms of the Original Roche Agreement, we collaborated on research activities to develop novel treatments in the field of targeted protein degradation using our degrader technology. We initially developed therapeutics that utilize degrader
technology for up to ten target proteins. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis, after successful completion of a defined preclinical development phase, Roche had an exclusive
option to pursue a license from us for further clinical development and commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;22, 2018, we amended and restated the Original Roche
Agreement, or the Restated Roche Agreement. Under the Restated Roche Agreement, we have a more active role in the manufacturing and commercialization of the targets included in the collaboration, whereby if we opt into certain <FONT
STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-detailing</FONT> rights, the parties will split future development costs in return for our having rights to a larger share of future earnings from
commercialization of the relevant target. The target structure was revised to six potential targets, three of which had been nominated as of the execution of the Restated Roche Agreement and represent continuations of the initial preclinical
research and development efforts begun under the Original Roche Agreement, and three additional targets that were not nominated as of the date of execution of the Restated Roche Agreement. At the time of entry into the Restated Roche Agreement,
Roche maintained its option rights to license and commercialize these six targets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Restated Roche Agreement, we received additional upfront consideration
of $40.0&nbsp;million from Roche. Roche will make annual research plan payments of $1.0&nbsp;million for each active research plan. Finally, adjustments were made to the option exercise fees, whereby targets that have progressed through GLP
toxicology studies at the time of exercise now have option exercise fees of $7.0&nbsp;million to $12.0&nbsp;million and those progressed through Phase 1 trials have option exercise fees of $20.0&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For certain targets, Roche is required to pay us fees of $2.0&nbsp;million and $3.0&nbsp;million upon the identification of a lead series and the commencement of GLP
toxicology studies, respectively. For each target option exercised by Roche, we are eligible to receive up to $275&nbsp;million in research, development and commercial milestone payments per target. Roche is also required to pay us up to
$150&nbsp;million per target in <FONT STYLE="white-space:nowrap">one-time</FONT> sales-based payments if the target achieves certain levels of net sales. Roche is also required to pay us royalties, at percentages from the <FONT
STYLE="white-space:nowrap">mid-single</FONT> digits to the low <FONT STYLE="white-space:nowrap">double-digits,</FONT> on a licensed <FONT STYLE="white-space:nowrap">product-by</FONT> licensed product basis, on worldwide net product sales. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Biogen Collaboration Research and License Agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;28, 2018, we entered into a Collaboration Research and License Agreement or the Biogen Agreement, with Biogen MA, Inc. or Biogen, whereby we agreed to
collaborate on research and development efforts for up to five targets to discover and develop potential new treatments for neurological conditions, such as Alzheimer&#146;s disease and Parkinson&#146;s disease. The Biogen Agreement also has an
option for Biogen to nominate additional targets and extend the Biogen Agreement. We granted Biogen a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research license under our intellectual property to perform research activities, select and
optimize degraders and develop products including the degraders, as well as a commercial license to manufacture and commercialize the targets once the initial research and development work is complete. The research under the Biogen Agreement will
take place over a <FONT STYLE="white-space:nowrap">54-month</FONT> research term with Biogen having an option to extend the Biogen Agreement for up to four additional years. If Biogen elects to extend the term
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of the Biogen Agreement, Biogen would be required to make an additional payment of $62.5&nbsp;million and would be entitled to nominate up to five additional targets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biogen Agreement provides for three initial targets, with Biogen having the right to initiate up to an additional two targets and to control all post-discovery
activities. Biogen paid us a nonrefundable upfront payment of $45.0&nbsp;million for access to our technology and research services through the discovery research phase. The nonrefundable upfront cash payment of $45.0&nbsp;million is not creditable
against any of the target development milestone fees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the achievement of development candidate criteria, prior to any
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> study, for any target, Biogen will bear all costs and expenses of and will have sole discretion and decision-making authority with respect to the performance of further activities with respect to
any degrader under development under the Biogen Agreement and all products that incorporate that degrader. Biogen is also required to pay us up to $35.0&nbsp;million per target in development milestones and $26.0&nbsp;million per target in <FONT
STYLE="white-space:nowrap">one-time</FONT> sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay us royalties on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, on worldwide net product sales, at percentages in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits. All milestone and sales-based payments are made after we
have met the defined criteria in the joint research plan for that target, at which time Biogen will have control of the targets for commercialization; the receipt of these payments is contingent on the further development of the targets to
commercialization by Biogen, without any additional research and development efforts from us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biogen also has the option to fund additional discovery activities,
whereby we will perform discovery-type research at Biogen&#146;s election to develop other potential targets that may be used as replacement targets for the initially nominated targets or two additional targets under the Biogen Agreement. Revenues
earned under this option, if initiated, will be recognized as services are performed and are not included in the transaction price at the outset of the arrangement. These research activities will be reimbursed on a full-time equivalent, or FTE,
basis at specified market rates. These additional discovery activities can be purchased up to a maximum amount by Biogen on an &agrave; la carte basis at an amount consistent with standalone selling price. If Biogen were to exercise these options,
we would recognize revenue as those options are exercised. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Calico License Agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March&nbsp;2017, we entered into a Collaboration and License Agreement, or the Calico Agreement, with Calico whereby we agreed to collaborate to develop and
commercialize a set number of targets for small molecule protein degraders for diseases of aging, including cancer, for a five-year period ending in March 2022, or the research term. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We provided Calico with a non-exclusive research license under our intellectual property to perform research activities and select and optimize degraders and develop
products including the degraders. We also granted Calico a commercial license for any licensed products resulting from the development candidates supplied by us. We are required to perform research and development activities for the nominated
targets over the research term, with the intent to provide a development candidate for each target to Calico once the agreed-upon research is complete. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Calico is
obligated to reimburse our research and development activities for each target at specified levels through the identification of a development candidate, after which Calico shall assume full responsibility for candidate development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the initiation of each target, the Calico Agreement does not contain any options for Calico to license the individual targets; once we complete the initial
research and development activities required, Calico controls and directs the targets with no additional work required to be performed by us. There is no exercise price or incremental fee payable to us to progress the research further, though Calico
is required to pay an initiation fee with the commencement of each research plan. Once Calico nominates a target and pays the applicable target initiation fee, we will commence research and development activities for that target. The Calico
Agreement provides for up to five initial targets. Research activities performed are reimbursed at specified levels for the five-year term of the Calico&nbsp;Agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, Calico paid us a nonrefundable upfront amount of $5.0&nbsp;million and certain annual payments of $5.0&nbsp;million through June 30, 2020. Upon
our completion of the required discovery research and development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
services on any target, Calico is entitled to pursue commercial development of that target. For each target, we are eligible to receive potential research, development and commercial milestone
payments aggregating up to $132.0&nbsp;million. Calico is also required to pay one-time sales-based payments aggregating up to $65.0&nbsp;million for the first product to achieve certain levels of net sales. In addition, Calico is required to pay us
royalties, on a licensed product-by-licensed product basis, on worldwide net product sales, at percentages in the mid-single digits. All milestone and sales-based payments are made after we have met the defined criteria in the joint research plan
for that target, at which time Calico will have control of the targets for commercialization; the receipt of these payments by us is contingent on the further development of the targets to commercialization by Calico, without any additional research
and development efforts required by us. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and
the development of our product candidates, and include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research
and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenses incurred under agreements with third parties, including contract research organizations and other third parties
that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical and potential future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of outside consultants, including their fees, unit-based compensation and related travel expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and
maintenance of facilities and other operating costs; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third-party licensing fees. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of
specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial
statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the
related goods are delivered or the services are performed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development activities are central to our business model. We expect that our research and
development expenses will continue to increase for the foreseeable future as we continue to discover and develop additional product candidates and advance&nbsp;our lead product candidates into clinical trials, including our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 trials. If any of our product candidates enter into later stages of clinical development, they will generally have higher development costs than those
in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We cannot reasonably estimate or determine with certainty the duration and costs of future clinical trials of&nbsp;CFT7455,
CFT8634 or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining
marketing approval for any product candidate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance,
business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services;
insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount
to support our growing operations. We also expect to incur increased expenses associated with being a public company, including higher costs of accounting, audit, legal, regulatory
<FONT STYLE="white-space:nowrap">and&nbsp;tax-related&nbsp;services</FONT> associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance costs and investor and public relations costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest income consists of interest income earned
on our cash and cash equivalents and short-term investments. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other (Expense) Income, Net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other (expense) income, net primarily consists of accretion of discount on short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of Years Ended December&nbsp;31,
2018 and 2019 and the Six Months Ended June 30, 2019 and 2020 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended
December&nbsp;31, 2018 and 2019 and the six months ended June 30, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED<BR>JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Revenue from our collaboration and license agreements
consisted of the following for the years ended December 31, 2018 and 2019 and the six months ended June 30, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED<BR>JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Original Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restated Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biogen License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Calico License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Revenue for the year ended December&nbsp;31, 2018 was $19.4&nbsp;million, compared with $21.4&nbsp;million for the year
ended December&nbsp;31, 2019. The increase in revenue of $2.0&nbsp;million primarily stems from the recognition of revenue for collaboration efforts conducted pursuant to the Biogen Agreement of $2.4 million and Calico Agreement of
$2.3&nbsp;million, offset by a decrease in the revenue recognized in connection with the Restated Roche Agreement as compared to the Original Roche Agreement of $2.7 million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, we recognized $9.1&nbsp;million of revenue under the Original Roche Agreement and $10.3&nbsp;million under the Calico Agreement. We executed the Restated Roche
Agreement and Biogen Agreement in December 2018 and the upfront payments of $40.0&nbsp;million and $45.0&nbsp;million, respectively, were recorded as accounts receivable and deferred revenue on our consolidated balance sheet as of December&nbsp;31,
2018, as the amounts were not received until 2019 and no research was performed under those agreements in 2018. We concluded that the Restated Roche Agreement was a modification of the Original Roche Agreement, and unrecognized revenue under the
Original Roche Agreement was added to the transaction price for the Restated Roche Agreement. The total transaction price of $61.9 million includes $40.0&nbsp;million from the upfront payment, $13.5 million of expected research plan funding payments
($1.0 million per active target per year, for a maximum of $3.0 million per target or $1.0&nbsp;million for target 1), $6.4 million remaining deferred revenue from the Original Roche Agreement and $2.0 million for a milestone achieved in April 2019
for the identification of lead series for target 2, which was achieved in April 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, we began recognizing revenue under the Restated Roche Agreement and
Biogen Agreement, in addition to the Calico Agreement. We recorded revenue of $6.4&nbsp;million under the Restated Roche Agreement, $1.9&nbsp;million under the Biogen Agreement, and $12.5&nbsp;million under the Calico Agreement in 2019. In addition,
we recorded revenue of $0.5&nbsp;million related to discovery services under the Biogen Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Revenue for the six months ended June 30, 2019 was $7.8 million,
compared with $16.5 million for the six months ended June 30, 2020. The increase in revenue of $8.7 million reflects a $3.9 million increase in the revenue related to the Restated Roche Agreement due to additional progress made on the three active
targets, a $2.2&nbsp;million increase in the Biogen revenue due to the additional progress made on the initial three targets nominated, and a $2.6 million increase in the Calico revenue primarily related to additional FTE reimbursement received in
2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
summarizes our research and development expenses for the years ended December&nbsp;31, 2018 and 2019 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE<BR>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preclinical and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Facilities and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses for the year ended December&nbsp;31, 2018 were $28.6&nbsp;million, compared with $48.1&nbsp;million for the year ended
December&nbsp;31, 2019. The increase of $19.5&nbsp;million was primarily due to&nbsp;an increase of $8.3&nbsp;million in external FTE resources for chemistry and biology, an increase of $5.7 million in external preclinical studies for our product
candidates and an increase in $4.4&nbsp;million in compensation and related personnel costs attributable to an increase in headcount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our research and development expenses for the six months ended June 30, 2019 and 2020 (in
thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE</B><br><B>(DECREASE)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preclinical and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Facilities and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses for the six months ended June 30, 2019 were $19.1 million, compared with $34.1 million for the six months ended June 30, 2020. The
increase of $15.0 million was primarily due to an increase in the use of FTE resources for chemistry and biology of $7.2 million, an increase in preclinical studies of $3.6 million for our product candidates, an increase of $2.4 million in
compensation and related personnel costs attributable to an increase in headcount and an increase in consulting costs of $1.3 million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and
Administrative Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our general and administrative expenses for the years ended December&nbsp;31, 2018 and 2019 (in
thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE<BR>(DECREASE)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Facilities and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $7.2&nbsp;million for the year ended December&nbsp;31, 2018, compared with $8.8&nbsp;million for the year ended
December&nbsp;31, 2019. The increase of $1.6&nbsp;million was primarily due to the increase in personnel expenses attributable to an increase in stock-based compensation of $0.8&nbsp;million and other increased personnel expenses of
$0.8&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our general and administrative expenses for the six months ended June 30, 2019 and 2020 (in
thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCREASE</B><br><B>(DECREASE)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Facilities and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $3.7 million for the six months ended June 30, 2019, compared with $5.6 million for the six months ended June 30, 2020. The
increase of $1.9 million was primarily due to an increase in personnel expenses of $0.7 million, primarily resulting from severance and related benefits incurred, offset by savings in salaries and related benefits and a $1.2 million increase in
legal and professional costs due to the utilization of external consultants. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income, net was $0.7&nbsp;million for the year ended December&nbsp;31, 2018, compared with $2.2&nbsp;million for the year ended December&nbsp;31, 2019. The
increase of $1.5&nbsp;million was primarily due to increased interest income resulting from a higher average cash balance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income, net was $1.2 million for
the six months ended June 30, 2019, compared with $0.2 million for the six months ended June 30, 2020. The decrease of $1.0 million was primarily due to lower interest earned on short-term investments in 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception in 2015, we have not recorded any
U.S. federal or state income tax benefits for the net losses we have incurred in any year. As of December&nbsp;31, 2019, we had no remaining federal net operating loss carryforwards and $8.2&nbsp;million in state net operating loss carryforwards,
which begin to expire in 2038. As of December&nbsp;31, 2019, we also had federal and state research and development tax credit carryforwards of $0.4&nbsp;million and $0.1&nbsp;million, respectively, which begin to expire in 2039. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is
more likely than not that the benefits will not be realized. There were no material changes in our tax position, and we were still in a valuation allowance as of June 30, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December 31, 2019, we recognized income tax expense of $0.8 million resulting from the Restated Roche Agreement and Biogen Agreement, both entered
into in December 2018. For the six months ended June 30, 2019, we recognized income tax expense of $0.3 million for the pro-rated annual tax estimated as of June 30, 2019. For the six months ended June 30, 2020, we recognized an income tax benefit
of $0.3 million resulting from the expected tax benefit to be recognized as a result of the full-year 2020 projected tax loss carryback to fiscal year 2019 allowed under the Coronavirus Aid, Relief, and Economic Security (CARES) Act signed into law
in March 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will recognize interest and/or penalties related to uncertain tax benefits in income tax expense as they arise. As of December 31, 2018 and 2019
and June 30, 2019 and 2020, we had no accrued interest or penalties related to uncertain tax benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We had cash and cash equivalents and short term
investments of $211.6 million as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have any approved products and have never generated any revenue from product sales. To
date, we have financed our operations primarily through the sale of preferred stock and through payments from collaboration partners. Through June 30, 2020, we have raised approximately $224.0&nbsp;million in gross proceeds from the sale of series
Seed redeemable convertible preferred stock, Series A redeemable convertible preferred stock, and Series B redeemable convertible preferred stock and have received an aggregate of $154.8&nbsp;million in payments from collaboration partners. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2020 and July 2020, we closed our Series B Financing with both existing and new investors. As part of the Series B Financing, we issued 142,857,142 shares of
redeemable convertible Series B preferred stock, or Series B Preferred Stock, at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0&nbsp;million or net proceeds of $145.5 million when taking into account offering costs of
$4.5 million. Every 8.4335&nbsp;shares of our preferred stock will be automatically converted into one share of common stock upon the completion of this offering. In addition, we secured a $20.0&nbsp;million credit arrangement with Perceptive Credit
Holdings III, LP, or Perceptive Credit, an affiliate of one of the Series B Financing investors, whereby we borrowed $12.5&nbsp;million at closing, bearing a variable interest rate of 11.25%, and have the opportunity to draw down another
$7.5&nbsp;million subject to the satisfaction of certain milestones relating to the filing of an IND for certain of our pipeline targets. In connection with the Credit Agreement, we issued Perceptive Credit warrants to purchase 2,857,142 shares of
Series B Preferred Stock exercisable for $1.05 per share. The loans extended under the Credit Agreement will be repaid beginning in December 2022 in monthly installments of interest plus principal equal to 2.0% of the initial principal amount
through June 2024. We paid a closing fee of $0.3&nbsp;million related to the loan and have the right to prepay the loan in its entirety prior to the maturity date by paying the applicable prepayment fee. If we do not prepay the loan, the entire
unpaid principal balance becomes due on the maturity date, June&nbsp;5, 2024. We are also subject to customary financial covenants in the Credit Agreement that dictate accelerated repayment upon the occurrence of certain events of default, none of
which are expected to occur based on our current liquidity. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our cash, cash equivalents and restricted cash totaled $38.9&nbsp;million and $93.1&nbsp;million as of December&nbsp;31, 2018 and 2019 and $96.6 million and $110.2
million as of June 30, 2019 and 2020, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our sources and uses of cash for the period presented (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Activities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating
activities for the year ended December&nbsp;31, 2018 was $17.0&nbsp;million, primarily consisting of our net loss of $15.7&nbsp;million and an increase of $84.9&nbsp;million in accounts receivable, offset by an increase of $81.0&nbsp;million in
deferred revenue. The increase in deferred revenue stemmed from $85.0&nbsp;million in <FONT STYLE="white-space:nowrap">up-front</FONT> payments due to us under the Restated Roche Agreement and the Biogen Agreement, both of which were recorded as
accounts receivable and deferred revenue as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by operating activities for the year ended December&nbsp;31, 2019 was
$55.6&nbsp;million, primarily consisting of our net loss of $34.1&nbsp;million and a decrease in deferred revenue of $3.2&nbsp;million, which were offset by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
a decrease in accounts receivable of $81.8&nbsp;million. The decrease in deferred revenue was due to the recognition of revenue under our collaboration agreements in 2019 and the $81.8 million
decrease in accounts receivable was related to the collection of <FONT STYLE="white-space:nowrap">up-front</FONT> payments from our collaboration partners, which were received in 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cash provided by operating activities for the year ended December&nbsp;31, 2019 was also impacted by changes in operating assets and liabilities, including increases in
accounts payable and accrued expenses of $8.0&nbsp;million, stemming from increased research and development efforts to advance our product candidates in 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net
cash provided by operating activities for the six months ended June 30, 2019 was $73.8 million, primarily consisting of a decrease of $83.8 million in accounts receivable, primarily from the receipt of upfront payments from Roche and Biogen of $85.0
million, partially offset by our net loss of $14.0 million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities for the six months ended June 30, 2020 was $31.3 million,
primarily consisting of our net loss of $22.7 million, an increase in accounts receivable of $3.9 million primarily related to milestones achieved and invoiced and a decrease in deferred revenue of $4.1 million, due to the recognition of revenue
under our collaboration agreements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by investing activities for the year ended December&nbsp;31, 2018 was $36.9&nbsp;million, attributable to the maturities and sales of marketable
securities of $44.6&nbsp;million, partially offset by the purchase of new marketable securities of $5.0&nbsp;million and the purchases of property and equipment of $2.7&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the year ended December&nbsp;31, 2019 was $1.6&nbsp;million, attributable to net purchases of property and equipment of
$1.3&nbsp;million and net purchases and sales of marketable securities of $0.3&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the six months ended June
30, 2019 was $16.2 million, attributable to the purchase of short-term investments of $14.9 million and net purchases of property and equipment of $1.2 million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities for the six months ended June 30, 2020 was $104.0 million, attributable to the purchase of short-term investments. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Financing Activities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing
activities for the year ended December&nbsp;31, 2018 was $2.0&nbsp;million, primarily attributable to the net proceeds received from the issuance of Series A redeemable convertible preferred stock in December 2018, offset by repurchases of common
stock issued upon the exercise of stock options of less than $0.1&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the year ended December&nbsp;31, 2019
was $0.2&nbsp;million, primarily attributable to $0.3&nbsp;million from the issuance of common stock in conjunction with the exercise of stock options, offset by repurchases of common stock issued upon the exercise of stock options of less than
$0.1&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the six months ended June 30, 2019 was less than $0.1 million, primarily attributable to the
proceeds from the issuance of common stock in conjunction with the exercise of stock options. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities for the six months
ended June 30, 2020 was $152.4 million, primarily attributable to the net proceeds received from the issuance of Series B redeemable convertible preferred stock in June 2020 of $141.0 million and the net proceeds from the issuance of long-term debt
of $12.0 million. Net cash provided by financing activities for the six months ended June 30, 2020 is also comprised of repurchases of $0.1 million related to common stock issued upon the exercise of our former Chief Executive Officer&#146;s stock
options and $0.8 million related to a settlement with our former Chief Executive Officer related to his vested stock options. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for
the foreseeable future as we advance the preclinical and clinical development of our product candidates. In addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, we anticipate that our expenses will increase substantially in the future, if and as we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2
trials of our lead product candidates, CFT7455 and CFT8634; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance additional product candidates into preclinical and clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to invest in our proprietary TORPEDO platform; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expand, maintain and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, regulatory and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial and management information systems and personnel to support our ongoing research, product
development, potential future commercialization efforts, operations as a public company and general and administrative roles; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities
to commercialize any products for which we may obtain marketing approval. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that our cash and cash equivalents and short-term
investments of $211.6&nbsp;million as of June&nbsp;30, 2020, combined with the proceeds from the Series B Financing of $4.5 million received in July 2020, anticipated payments from collaboration partners and the proceeds from this offering, will be
sufficient to fund our operating expenses and capital expenditure requirements through the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently
expect. Our future capital requirements will depend on many factors, including: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, costs and results of our planned
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 trials for&nbsp;our lead product candidates and any future clinical development of&nbsp;those lead product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and
development programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and development requirements of other product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of our collaborations with Roche, Biogen and Calico, including whether or not we receive additional research
support or milestone payments from our collaboration partners upon the achievement of milestones; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our willingness and ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical
companies on favorable terms, if at all, for the development or commercialization of current or additional future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our product candidates for which we receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval.
</P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the anticipated expenditures described above, we will need to obtain substantial additional financing in connection with our
continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt offerings, collaborations, strategic alliances and
marketing, distribution or licensing arrangements. Although we may receive potential future milestone and royalty payments under our collaborations with Roche, Biogen and Calico, we do not have any committed external source of funds, as of
June&nbsp;30, 2020, other than an additional $7.5&nbsp;million under our Credit Agreement. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we
may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that we raise additional capital through the sale of equity securities, each investor&#146;s ownership interest will be diluted, and the terms of
these securities may include liquidation or other preferences that adversely affect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
your rights as a common stockholder. Preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
making acquisitions or capital expenditures or declaring dividends. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise additional funds through collaborations, strategic alliances or marketing,
distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contractual Obligations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of our
significant contractual obligations as of June 30, 2020 (in thousands) (unaudited): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN<BR>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1 TO 3<BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>4 TO&nbsp;5<BR>YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN<BR>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease commitments <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents future minimum lease payments under our operating leases and equipment for office and lab space in Watertown, Massachusetts that expires in April 2028. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter into contracts in the normal course of business with third-party CROs for clinical trials, preclinical studies, manufacturing and other services and products
for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not
material and they are not included in the table above. We have not included milestone or royalty payments or other contractual payment obligations in the table above if the timing and amount of such obligations are unknown or uncertain. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Use of Estimates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This management&#146;s
discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of
our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues, costs and expenses and the disclosure of contingent assets and
liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different
assumptions or conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing
at the end of this prospectus, we believe that our policy for recognizing revenue associated with our collaboration agreements is the most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues from Contracts </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As discussed in Note 2 to our consolidated
audited financial statements appearing at the end of this prospectus, we account for our revenue in accordance with Accounting Standards Codification, or ASC, 606,<I>&nbsp;Revenue from Contracts with Customers</I>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our revenue is generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and
services which may include (i)&nbsp;licenses, (ii)&nbsp;research and development activities and (iii)&nbsp;participation in joint research and development steering committees. The terms of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
these agreements may <FONT STYLE="white-space:nowrap">include&nbsp;non-refundable&nbsp;upfront</FONT> license or option fees, payments for research and development activities, payments upon the
achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC&nbsp;606, we evaluate whether the license agreement, research and development services and participation in research and
development steering committees, represent separate or combined performance obligations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research collaboration and license agreements typically include
contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as
they are fully constrained under the guidance in ASC 606. We will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these
payments within the transaction price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Revenue is recognized over our expected performance period under each respective arrangement. We make our best estimate of
the period over which we expect to fulfill our performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is
required to determine the duration of and estimated costs to be incurred during the performance period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2018 and 2019 and the
six months ended June 30, 2019 and 2020, we recognized revenues under the Biogen Agreement and Calico Agreement by allocating the transaction price to a single combined performance obligation for each. For the Biogen Agreement, we recognized the
transaction price over the estimated performance period, which was determined to be the contractual term, using an input method according to costs incurred as related to the research and development activities and the costs expected to be incurred
in the future to satisfy the performance obligation. For the Calico Agreement, we amortized the upfront fee received on a straight-line basis over the period services are available to the counterparty (i.e. the contractual term). Straight-line
amortization of the upfront payment was considered the best measure of progress because the customer has access to research and development services throughout the period. Incremental fees for research and development services are paid at agreed
upon full-time equivalent employee rates and recognized in the period incurred. For the arrangement with Roche, we identified twelve performance obligations, including three research services performance obligations, six material rights for the
options to purchase a commercial license for six targets and three material rights for the option to initiate research services for the uninitiated three targets as of the outset of the arrangement. We allocated the total consideration for the
identified performance obligations utilizing an expected cost plus a margin approach based on our estimate of the expected costs to fulfill the performance obligations. We recognize revenue for six of our performance obligations, representing a
combined license and services deliverable, based on an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy the
performance obligation, as the costs under the arrangement were not expected to be incurred ratably and the agreement has no defined term. Revenue allocated to the remaining six performance obligations stemming from material rights is deferred until
Roche exercises the underlying option or the option expires. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our contracts may also call for certain sales-based milestone and royalty payments upon successful
commercialization of a target. In accordance with ASC&nbsp;606,&nbsp;we recognize revenues from sales-based milestone and royalty payments at the later of (i)&nbsp;the occurrence of the subsequent sale; or (ii)&nbsp;the performance obligation to
which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). We anticipate recognizing these milestone and royalty payments if and when subsequent sales are generated by the
licensee from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been received or recognized for any periods. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Amounts received prior to satisfying the above revenue recognition criteria are recorded as a contract liability in our accompanying consolidated balance sheets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We account for all stock-based compensation awards
granted to employees <FONT STYLE="white-space:nowrap">and&nbsp;non-employees&nbsp;as</FONT> stock-based compensation expense at fair value. Our stock-based payments include stock options and grants of common stock,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
including common stock subject to vesting. The measurement date for awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period,
which is generally the vesting period, on a straight-line basis. Stock-based compensation expense is classified in the accompanying statements of operations based on the function to which the related services are provided. We recognize stock-based
compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option pricing model includes various assumptions, including the expected life of award, the expected volatility and the expected risk-free interest rate. The fair value of the underlying common stock represents the exercise price utilized in the
Black-Scholes option pricing model. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, stock-based compensation cost could be materially impacted in future periods. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as of the
date of each stock award, with input from management, considering our most recently available third-party valuations of common stock. Valuations are updated when facts and circumstances indicate that the most recent valuation is no longer valid,
such as changes in the stage of our development efforts, various exit strategies and their timing, and other scientific developments that could be related to the valuation of our company or, at a minimum, annually. Third-party valuations were
performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </I>Our common
stock valuations in 2018 and 2019 were prepared using a market approach, specifically the guideline public company method, which &#147;back-solves&#148; to a common stock price. We allocated equity value to our common stock and shares of our
redeemable convertible preferred stock, using either an option-pricing method, or OPM, or a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method. The hybrid method estimates the probability-weighted
value across multiple scenarios. In addition to the OPM, the hybrid method considers liquidity scenarios in which the shares of our redeemable convertible preferred stock are assumed to convert into common stock. The future value of the common stock
in the applicable scenario is discounted back to the valuation date at an appropriate risk-adjusted discount rate. In the hybrid method, the present value indicated for each scenario is probability-weighted to arrive at an indication of value for
the common stock. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors determined the fair market value of our common stock to be $4.90 as of May&nbsp;31, 2018, $6.50 as of
December&nbsp;31, 2018, $6.67 as of September&nbsp;30, 2019 and $4.98 as of June&nbsp;5, 2020. The reduction in fair market value of our common stock as of June&nbsp;5, 2020 was primarily due to the dilution attributable to the Series B Financing.
Fair value estimates of our common stock will no longer be necessary to determine the fair value of new equity awards once our common stock begins trading in the public market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth, by grant date, the number of shares subject to options granted from January&nbsp;1, 2019 through June&nbsp;30, 2020, the exercise price
per share of the options, the fair value per share on each grant date and the estimated per share fair value of the options: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>GRANT DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF SHARES OF<BR>COMMON&nbsp;STOCK&nbsp;SUBJECT<BR>TO&nbsp;OPTIONS&nbsp;GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR&nbsp;VALUE<BR>PER&nbsp;SHARE&nbsp;AT<BR>GRANT DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ESTIMATED<BR><FONT STYLE="white-space:nowrap">PER-SHARE&nbsp;FAIR&nbsp;VALUE</FONT><BR>OF OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">April&nbsp;9, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July&nbsp;17, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July&nbsp;17, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">December&nbsp;4, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July 3, 2020, July 9, 2020 and July 23, 2020, we granted options to purchase an aggregate of 1,467,424 shares at an exercise price of $4.98 per share, which
represented fair value per share as of the grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>New Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For information on new accounting standards, see Note 2 to our consolidated audited financial statements appearing at the end of this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance&nbsp;Sheet</FONT> Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not entered into <FONT STYLE="white-space:nowrap">any&nbsp;off-balance&nbsp;sheet</FONT> arrangements and do not have any holdings in variable interest
entities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal control over financial reporting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the preparation
of our consolidated financial statements to meet the requirements of this offering, we determined that a material weakness in our internal control over financial reporting existed as of December&nbsp;31, 2019. The material weakness identified in our
internal control over financial reporting arose because we did not maintain effective segregation of duties in the process and recording of journal entries. We are taking measures to remediate the material weakness during 2020, including engaging
system controls that prevent one person from initiating and approving the same journal entry. However, we cannot assure you that these measures will be sufficient to prevent future material weaknesses or significant deficiencies in our internal
control over financial reporting from occurring. See &#147;Risk Factors&#151;<I></I><I>We will incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance
initiatives and corporate governance practices</I>.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of
cash and cash equivalents and short-term investments. Interest income earned on these assets was $0.6&nbsp;million and $1.8&nbsp;million for the years ended December 31, 2018 and 2019, respectively, and $0.9 million and $0.3 million for the six
months ended June 30, 2019 and 2020, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. At December&nbsp;31, 2019, our cash equivalents consisted of bank deposits and
money market funds. We did not hold any marketable securities as of December&nbsp;31, 2018 or 2019, but we made purchases and sales of marketable securities during both periods that included interest-earning securities. As of June 30, 2020, we had
marketable securities of $103.9 million which consisted entirely of government-backed securities. These interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant
for us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an &#147;emerging growth
company,&#148; the JOBS Act allows us to delay adoption of new or revised accounting standards applicable to public companies until such standards are made applicable to private companies. We have elected to avail ourselves of this extended
transition period for complying with new or revised accounting standards until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of this extended transition period.
Accordingly, the information contained herein may be different from the information you receive from other public companies that are not emerging growth companies. in which you hold stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to
public companies. These provisions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to only provide two years of audited financial statements in addition to any required unaudited interim
financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure about the compensation paid to our executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to submit to our stockholders&#146; advisory votes on executive compensation or golden parachute
arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting
pursuant to the Sarbanes-Oxley Act of 2002. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these exemptions for up to the last day of 2025 or such earlier time that we are no longer an
emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (1)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (2)&nbsp;the last day
of 2025; (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and
Exchange Commission. We may choose to take advantage of some but not all of these exemptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_10a"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a biopharmaceutical company focused on harnessing the
body&#146;s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. We leverage our proprietary
technology platform, TORPEDO (<U>T</U>arget <U>OR</U>iented <U>P</U>rot<U>E</U>in <U>D</U>egrader <U>O</U>ptimizer), to synthesize a new class of small molecule protein degraders that are designed to selectively and efficiently destroy
disease-causing proteins, including targets previously considered to be undruggable. Our degraders are designed with a focus on catalytic degradation to optimize targeted protein degradation and an ability to use multiple routes of administration,
which we believe offer many potential advantages over existing therapeutic modalities, including improved potency, faster response, higher selectivity and avoidance of known toxicities. We are using our TORPEDO platform to build a robust pipeline of
oral protein degradation drug candidates, with our lead product candidates focused on oncology indications. One of our lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, or MM, and
non-Hodgkin lymphomas, or NHLs, including peripheral <FONT STYLE="white-space:nowrap">T-cell</FONT> lymphoma, or PTCL, and mantle cell lymphoma, or MCL, and we expect to submit an investigational new drug application, or IND, for this product
candidate to the U.S. Food and Drug Administration, or the FDA, in the fourth quarter of 2020 and begin a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial for this product
candidate in the first half of 2021. We believe CFT7455 could eventually replace therapies based in the class of molecules known as IMiDs as the standard of care in multiple indications, including MM. IMiD therapies have been estimated to represent
worldwide sales of approximately $15 billion in 2020 for a number of indications, including MM as well as MCL, marginal zone lymphoma, and follicular lymphoma. We are also developing CFT8634, an orally bioavailable degrader of a protein target
called BRD9, for synovial sarcoma and SMARCB1-delete solid tumors, and we expect to submit an IND for this product candidate to the FDA in the second half of 2021 and begin a first-in-human Phase 1/2 clinical trial for this product candidate by the
end of 2021. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We use our TORPEDO platform to synthesize a new class of targeted small molecule protein degraders, which employ a natural protein disposal
system, specifically the E3 ligases of the ubiquitin-proteasome system, to catalyze the destruction of target proteins. The E3 ligases targeted by our degraders are a family of proteins that identify and tag proteins for degradation. Our approach is
designed to optimize overall catalytic efficiency&#151;rather than specific steps in the catalytic cycle&#151;so that our degraders destroy target proteins as quickly as possible. Our robust chemistry engine and proprietary analytic models of
pharmacokinetics, or PK, and pharmacodynamics, or PD, enable us to efficiently design and synthesize degraders for a selected target that are optimized for overall catalytic efficiency and properties such as solubility, permeability and oral
bioavailability. These PK/PD models allow us to predict the depth and duration of target degradation <I>in vivo</I> and select candidate degraders with confidence. For example, our PK/PD models for CFT7455 accurately predicted the target level
response as a function of time at a 1mg / kg oral dose, demonstrating the predictive capability of our TORPEDO platform. We observed similar predictive effectiveness in a PK/PD model for CFT7503, which is the parent compound of our lead BRD9
compound, CFT8634. As a result of data such as these, we believe our approach maximizes our potential to create effective drugs across many targets. Another aspect of TORPEDO platform is that we have developed a rich toolkit of 14 novel,
structurally distinct binders targeting the E3 ligase, Cereblon. The IMiD class of molecules, which includes approved therapies thalidomide, lenalidomide and pomalidomide, harness Cereblon to effect the degradation of protein targets, resulting in
anti-cancer activity. To date, Cereblon is the only E3 ligase known to be targeted by an approved drug to cause protein degradation. Notably, Cereblon is widely expressed across tissues, potentially allowing for therapeutic Cereblon-mediated
targeted protein degradation in a wide variety of clinical settings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CFT7455 is an orally bioavailable degrader targeting IKZF1/3 for the treatment of MM and NHLs,
including PTCL and MCL. We have selected IKZF1/3 as our initial targets because they have a strong mechanistic rationale and well-defined biology and targeting them with a novel degrader may address a significant unmet need. In our preclinical
studies, CFT7455 has demonstrated potent and selective protein degradation with favorable pharmacological properties. We believe that the differentiated pharmacology of CFT7455, including its high potency, may translate into improved clinical
outcomes over the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> agents in each of the indications we are pursuing. We expect to file an IND for CFT7455 in the fourth quarter of 2020 and
expect to dose the first patient in the first half of 2021. Our planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 trial is designed as an open-label dose escalation trial of CFT7455 in
approximately 18 to 30 subjects with MM and NHL. The trial will primarily investigate the safety and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tolerability of CFT7455, and key secondary endpoints will be to characterize its PK/PD profile and anti-tumor activity. We expect the results from this clinical trial will help us better
understand the disease characteristics of those patients who may derive benefit from CFT7455, which will enable us to design future clinical trials more effectively for the drug. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CFT8634 is an orally bioavailable degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted solid malignancies. BRD9 has been considered an
undruggable target using currently available modalities. BRD9 is a component of the <FONT STYLE="white-space:nowrap">non-canonical</FONT> BAF complex, or ncBAF, that plays a role in regulating gene transcription. In normal cells, this complex is not
required for cell survival. However, some tumors, including synovial sarcoma, encode genetic mutations that render the ncBAF complex&#151;and thus BRD9&#151;essential for tumor growth. CFT8634 has shown potent anti-tumor activity in synovial sarcoma
cell lines, but does not appear to affect normal cells. Further, CFT8634 has shown <I>in vivo</I> activity in synovial sarcoma xenograft models when dosed orally. We expect to file an IND for CFT8634 with the FDA in the second half of 2021 and dose
the first patient in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial of this product candidate by the end of 2021. We expect to design our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial for this product candidate to be an open-label dose escalation/expansion study in both synovial sarcoma and solid tumors with SMARCB1 loss. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our lead product candidates, we are also developing degraders specifically targeting V600E mutant BRAF to treat melanoma,
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or NSCLC, colorectal cancer and other solid malignancies that harbor this mutation, as well as degraders targeting RET to treat lung cancer, sporadic medullary thyroid cancers and
other solid malignancies that harbor oncogenic RET lesions. We expect to have our lead product candidates, CFT7455 and CFT8634, in the clinic by the end of 2021, and product candidates from our two other lead programs, BRAF V600E and RET, in the
clinic by the end of 2022. Beyond these four initial product candidates, we are further diversifying our pipeline by developing new degraders against targets where we believe degradation offers potential advantages over existing therapeutic
modalities such as the treatment of neurodegenerative diseases. As part of these efforts, we have engineered degraders that have successfully achieved blood-brain barrier penetration in preclinical studies, which is a key step in developing drugs
with the potential to treat neurodegenerative diseases. We also believe there are many other therapeutic areas and indications where leveraging our TORPEDO platform to develop novel degraders may be advantageous. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have been a pioneer in the field of targeted protein degradation since our founding in 2015. Our technology originated from research at the Dana-Farber Cancer
Institute by Jay Bradner, M.D., Ken Anderson, M.D. and Nathanael Gray, Ph.D., leading researchers in the field of protein degradation who <FONT STYLE="white-space:nowrap">co-founded</FONT> our company along with our Executive Chairman, Marc A.
Cohen. We have assembled a scientific team with extensive knowledge and translational medicine expertise in the protein degradation field. Our management team draws on experience in all phases of drug discovery and development gained at large
pharmaceutical and biotechnology companies. In addition, we have entered into key strategic collaborations with each of F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche Ltd., or Roche, Biogen, Inc., or Biogen, and Calico Life Sciences
LLC, or Calico, that help us address targets across multiple therapeutic areas. Through these collaborations we have received upfront and milestone payments in an aggregate of $154.8&nbsp;million through June&nbsp;30, 2020. In addition, we have
secured additional funding from a strong group of investors, including Cobro Ventures, Perceptive Advisors, Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments,
Lightchain Capital, Logos Capital, Mizuho Securities Principal Investment, Nextech, RA Capital, RTW Investments, Sphera Funds Management, Taiwania Capital, Yonjin Venture and funds and accounts managed by T.&nbsp;Rowe Price and Janus Henderson. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have leveraged our TORPEDO<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>platform to generate a robust pipeline of orally available, potent and selective protein degradation drug candidates that may be capable of treating diseases in a wide range of organ systems and
tissues. Our pipeline focus is on establishing clear clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for targets with well-established biology and a defined regulatory pathway. As shown in
the table below, we currently have four preclinical programs in development. We anticipate our CFT7455 and CFT8634 product candidates will be in the clinic by the end of 2021, and our BRAF V600E and RET programs will be in the clinic by the end of
2022. We have also secured three strategic collaborations with partners that provide additional pipeline optionality and an expansion of our potential targets for protein degradation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are advancing two types of protein degraders. We refer to the first type of degrader as MonoDACs, which are
<U>Mono</U>functional <U>D</U>egradation <U>A</U>ctivating <U>C</U>ompounds. MonoDACs function by binding to E3 ligases and creating a new surface on the E3 ligases that enhances the binding of the E3 ligases to target proteins. We refer to our
second type of degrader as BiDACs, which are <U>Bi</U>functional <U>D</U>egradation <U>A</U>ctivating <U>C</U>ompounds. BiDACs are designed so that one end of the molecule binds to the disease-causing target protein and the other end binds to the E3
ligase. Each of these types of degrader is intended to result in the same end point: the specific degradation of the target proteins of interest. These two approaches have complementary requirements for target engagement: BiDACs utilize specific
binding sites where chemical binding moieties, which are portions of a molecule, can be identified, which enables a rational drug discovery approach, while MonoDACs, in contrast, rely on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ligase-to-target</FONT></FONT> protein surface interactions to drive the ubiquitination process, which is the process by which an E3 ligase tags a target protein for degradation using a molecular tag called ubiquitin,
rather than specific compound-binding sites. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g15j64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the programs identified above and our early-stage development collaborations with Roche, Biogen and Calico, we are
conducting exploratory research and development work on various other targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are committed to transforming the treatment of cancer, neurodegenerative conditions and other diseases through the discovery, development and commercialization of
novel therapies that destroy disease-causing proteins. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key elements of our strategy are to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Continue rapid progression toward clinical development of our lead programs developed with our TORPEDO</B><B><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B><B>platform. </B>Our two lead product candidates are CFT7455, targeting IKZF1/3, and CFT8634, targeting BRD9. We expect to initiate a Phase 1/2 open-label trial for CFT7455 in patients with
relapsed or refractory MM or NHLs such as PTCL and MCL in the first half of 2021, and we expect to initiate a Phase 1/2 open-label trial for CFT8634 in patients with synovial sarcoma and SMARCB1-deleted solid tumors by the end of 2021. Using our
proprietary TORPEDO platform, we have generated novel product candidates for the treatment of cancer and we believe favorable trial results from our lead programs would offer important validation for both our platform and those programs themselves.
Based on the results of these planned Phase 1/2 trials, we will work with the FDA to discuss potential expedited development and accelerated approval pathways for the product candidates in these lead programs. Additionally, we will leverage the
knowledge gained from our lead programs to strengthen and improve our TORPEDO platform for our other pipeline candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Rapidly advance our late-stage discovery programs to generate product candidates.</B> In addition to our lead product
candidates, we have progressed programs targeting BRAF V600E, in collaboration with our partner Roche, and RET. We are also pursuing several other earlier-stage research programs. We believe that our platform and approach are broadly applicable to
address unmet medical needs in a variety of indications and we aim to continue expanding and advancing our pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Leverage our TORPEDO platform to generate discovery programs for previously undruggable or challenging targets.</B> We
believe that we can apply the principles and approaches used to advance our lead programs more broadly to develop novel degraders for diseases where traditional small molecule inhibitors and other
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
therapeutic approaches have been unsuccessful. We believe our degraders offer potential broad tissue distribution, oral delivery, relative ease of manufacturing and well-established development
and regulatory pathways, which are all critical characteristics across disease areas. Additionally, our targeted protein degradation approach has the potential to address many protein targets that are currently considered undruggable, as our
degraders can theoretically destroy proteins using any available conserved binding site, including <FONT STYLE="white-space:nowrap">low-affinity</FONT> binding sites or <FONT STYLE="white-space:nowrap">non-functional</FONT> binding sites, bringing
biological utility to ligands that would otherwise be inactive. We are focusing our current programs on selected oncology indications, but we believe our platform has broad applicability beyond cancer that we plan to capitalize on in the future.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Strategically invest in our TORPEDO platform. </B>To date we have invested significant time and resources into the
experimental and analytical components of our TORPEDO platform. This platform enables us to quickly develop novel protein degraders. We will continue to invest in the latest experimental tools to improve our capabilities and continue to enhance our
proprietary computational and predictive models. We believe that this investment will support our continued discovery and development of degraders against technically challenging and high-value targets. Additionally, we plan to continue expanding
our intellectual property portfolio, including through the identification and optimization of additional binders with unique and desirable drug-like properties. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Engage with strategic partners to accelerate program development and maximize the potential of our TORPEDO</B><B><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B><B>platform. </B>We have entered into strategic collaborations with Roche, Biogen and Calico, under which we are working to identify and develop novel degraders across multiple therapeutic areas.
These collaborations provide us with access to the resources of larger biopharmaceutical companies and expertise that enable us to further develop and maximize the potential of our TORPEDO platform. In the future, we may opportunistically enter into
additional strategic partnerships around certain targets, product candidates and disease areas, which could advance and accelerate our development programs, allow us to access additional capabilities and expand the utility of our TORPEDO<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>platform. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Maximize the potential of our product candidates with selective use of commercial partnerships.</B> We retain worldwide
commercial rights to CFT7455, CFT8634 and our RET program. In the future, we intend to selectively evaluate commercialization partnerships for our drug candidates with partners whose capabilities complement our own while retaining meaningful
commercial rights in key geographic territories. We evaluate potential partnerships based not solely upon their ability to generate additional revenue streams for us, but also based on how they might increase our ability to reach a broader set of
patients in our targeted disease areas or expand the breadth of indications that our product candidates are approved to treat. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of
Protein Degradation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Protein Degradation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proteins are large,
complex molecules that play many critical roles in the human body. Due to their central role in biological function, protein interactions control the mechanisms leading to healthy and diseased states. Diseases are often caused by mutations that
alter the normal function of proteins and in turn lead to protein dysfunction and then disease. Recent scientific advances continue to implicate the role of specific proteins in multiple disease states. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As proteins age or are damaged, the human body has a highly conserved homeostasis system, which maintains a stable
equilibrium, and relies on protein degradation machinery to identify and break down proteins into their component amino acids. This protein homeostasis process is mediated in part by E3 ligases. The primary role of E3 ligases is to act as a quality
control inspector by identifying proteins that are old, damaged, misfolded or otherwise deemed ready for degradation. When an E3 ligase identifies a target protein for degradation, it attaches a molecular tag called ubiquitin in a process called
ubiquitination. This ubiquitination process typically continues until the target protein is tagged with multiple ubiquitin proteins, known as poly-ubiquitination. Once the target protein is poly-ubiquitinated, it is released by the E3 ligase and is
then quickly recognized by a proteasome, which is the cell&#146;s recycling plant. The proteasome degrades poly-ubiquitinated proteins into their component amino acids, and these amino acids can then be recycled to form new proteins or can be
excreted by the cell. This process is illustrated in the following graphic. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g02d58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approximately five percent of the human genome is dedicated to the ubiquitin-proteasome system. In addition, many proteins of
therapeutic interest are often regulated by E3 ligases, which normally function to achieve rapid control of protein concentration across multiple steady states. Collectively, these factors underscore the essential role E3 ligases play in normal
cellular function and how they can be leveraged against therapeutic protein targets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our approach represents a novel modality that seeks to harness this natural degradation machinery to destroy
disease-causing target proteins. Both our MonoDACs and BiDACs follow the same catalytic process, with the first step being the formation of a complex between the native E3 ligase, degrader and target protein, which we refer to as the ternary
complex. Formation of an appropriate ternary complex that can undergo ubiquitination results in poly-ubiquitination of the target and then degradation of the target protein by the proteasome. Degraders destroy disease-causing proteins through a
catalytic process that recycles the degrader molecule so that it may degrade multiple target proteins. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g03c74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Importantly, both the natural protein degradation process and the targeted protein degradation mediated by our degraders occur
rapidly, on the order of milliseconds from initial target-ligase encounter to poly-ubiquitination and release for degradation by the proteasome. The process of targeted protein degradation mediated by our degraders is illustrated in the following
graphic. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g04f87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the targeted protein degradation process occurs for one molecule of a target protein, the degrader is released and the process
can be repeated with the same degrader molecule. This recursive process&#151;binding the target protein, ternary complex formation with the E3 ligase, ubiquitination and release for degradation&#151;can occur thousands of times with a single
degrader molecule before it is eventually cleared by the body. We refer to this process as the catalytic cycle and it is a crucial differentiator between degraders and traditional protein inhibitors, which must remain bound to the target protein to
remain effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many current targeted therapies are based on small molecules that inhibit the biological function of a protein of
interest. One of the main limitations of inhibitor-based treatments is that high doses of the inhibitor are often needed for adequate, sustained target occupancy levels that are required for efficacy. Since the pharmacological effect is driven by
the drug exposure profile, the overall timing and duration of drug action is dependent on drug absorption, distribution and elimination. These exposures can be challenging to achieve and may increase the likelihood of significant <FONT
STYLE="white-space:nowrap">off-target</FONT> side effects. A further limitation of this approach is the requirement to find compounds that bind to specific active sites on the protein that result in functional inhibition. However, there are many
sites on a target protein where small molecules can bind, but have no effect on the overall function. The following figure illustrates the use of a small molecule inhibitor to block the function of a targeted disease-causing protein. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g05l57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Advantages of Targeted Protein Degradation Over Traditional Protein Inhibitors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe targeted protein degradation is a novel modality that could offer significant potential benefits over traditional small molecule inhibitor approaches,
including improved and sustained potency, fast and recursive catalytic effect, high selectivity and an expansive target landscape. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Improved
and Sustained Potency </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Degraders offer a many-fold amplification of effect because a single degrader molecule can exert its effect recursively on a large
number of target proteins, thereby boosting the catalytic cycle, known as catalytic amplification. In contrast, traditional protein inhibitors rely on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> binding
of an inhibitor molecule with a target protein, with the protein only deactivated while the inhibitor is bound. This means that much higher concentrations of a protein inhibitor drug are needed to achieve the same level of therapeutic effect as a
protein degrader. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to requiring significantly less drug than a protein inhibitor, the catalytic amplification of degraders means that targeted protein
degradation is able to achieve a level of potency necessary for a therapeutic effect in situations that may otherwise be impossible with traditional protein inhibitors. The effect of rapidly-reversible traditional inhibitors on target protein is
transient and the target protein typically resumes its disease-causing activity as soon as the inhibitor is no longer bound to the target protein. In contrast, because targeted protein degradation leads to destruction of disease-causing proteins
into their component amino acids, the effect of a degrader can persist well after the degrader is cleared from the body because it takes a period of time for the cell to resynthesize disease-causing proteins. Additional potency amplifications can
result for target proteins that form complexes with other cellular proteins, since removal of the target protein disrupts the overall complex, not just a specific functional activity of the target protein. In these cases, cellular recovery from the
degrader effect requires not only <FONT STYLE="white-space:nowrap">re-synthesis</FONT> of the target protein, but also its incorporation into a larger molecular complex. This effect can be observed even in cases where the target protein complexes
are as small as two proteins, or dimers, as well as larger multi-protein complexes. This means that degraders may help to achieve a more durable biological effect and better clinical outcomes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Fast and Recursive Catalytic Effect </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">One degrader molecule can rapidly degrade many target proteins. Each catalytic cycle initiated by our degraders and ending with degradation of a disease-causing target
protein occurs in a matter of milliseconds. The speed of the catalytic cycle combined with the catalytic amplification of our degraders could result in clinical impact on the disease mechanism that cannot be achieved with traditional inhibitors.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>High Selectivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">One of the primary challenges
of protein inhibition is attempting to identify and develop molecules that only target cancerous cells or mutant proteins without having deleterious effects on normal cells or proteins, commonly referred to as
<FONT STYLE="white-space:nowrap">off-target</FONT> effects. We believe degraders combine the advantages of small molecule therapies with the potential of gene therapies. Degraders have drug-like properties, including oral bioavailability, and are
easier to manufacture than other therapeutic modalities involving complex macromolecules, such as antibodies and genetic material. Similar to gene therapies and gene editing strategies, degraders can eliminate the presence of a pathogenic protein.
However, treatment with degraders may be halted at any time, in contrast to the long-lasting effects of gene therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each step in the protein degradation cycle
requires specific positioning of the target protein and E3 ligase to progress through the catalytic cycle, and these positioning requirements can serve as filters to increase selectivity of a degrader molecule so that only the target protein is
ultimately degraded, even if the molecule binds to multiple proteins. For example, degraders are created with the shape, or conformation, of the target protein in mind because a degrader and its target protein must assume a conformation amenable to
forming a ternary complex with an E3 ligase. As a result, even if a degrader were to bind to a <FONT STYLE="white-space:nowrap">non-target</FONT> protein, the resulting ternary complex may not have a conformation that is appropriate to facilitate
ubiquitination and subsequent degradation. We are able to leverage these intrinsic properties of the ubiquitin-proteasome protein degradation pathway to design degraders to be highly selective for disease-causing target proteins. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Expansive Target Landscape </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since targeted protein degradation does not function by inhibiting the target protein&#146;s active site, in theory any conserved binding site on a target protein may
be used for degrader binding to facilitate formation of the ternary complex and eventual protein degradation. In contrast, inhibitors are only able to have a therapeutic effect either by binding directly to a protein&#146;s active site or by binding
to an allosteric site in such a way to cause a conformational change in the protein that inhibits the active site. This inherently limits the number of druggable targets addressable with traditional inhibitors, as many drug binding sites are
physically inaccessible or weakly bind with small molecules. Additionally, whereas an inhibitor requires high affinity and a strong bond to the binding site to remain active, degraders can bind with weak affinity for only a short amount of time and
still enable ubiquitination and destruction of the protein. Specifically, less than 15% of proteins are considered druggable with traditional small molecule inhibitors because of limitations, including lack of accessible active binding sites, while
targeted protein degradation fundamentally enables access to a high proportion of the potential target proteins that are currently considered undruggable. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g06x87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Approach </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We employ a comprehensive
approach to product candidate selection and development to maximize the potential therapeutic benefit of our protein degraders. We seek out indications with high value protein targets that may benefit the most from degraders, with catalytic
degradation turnover as the key metric by which to assess protein degradation. To that end, we have invested heavily in experimental tools, computational and predictive models and team expertise to analyze and optimize the catalytic ability of our
degraders through our TORPEDO platform. Additionally, we leverage our platform to optimize the ability of our degraders to initiate the ubiquitin-proteasome protein degradation cycle and predict their function <I>in vivo</I>. Due to the rapid
optimization allowed by our TORPEDO<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>platform and the ability of our platform to predict degrader effects <I>in vivo</I>, we are able to quickly and efficiently advance programs from target
identification to the candidate development stage. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our oral, small molecule targeted protein degraders leverage the body&#146;s natural degradation machinery and
repurpose it to recognize disease-causing proteins and tag them for destruction by the proteasome. Both our MonoDAC and BiDAC protein degrader approaches are complementary and this provides us with additional flexibility to design degraders for each
application and specific target. Since our degraders are fundamentally small molecules, we are able to deliver them through any route of administration available to traditional small molecules, including oral, intravenous and subcutaneous.
Furthermore, our approach emphasizes the value of rapid catalytic degradation to increase the rate with which degradation of disease-causing target proteins occurs. Our approach focuses on minimizing biology and toxicity risk and pursuing diseases
with significant unmet medical need and defined regulatory pathways. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our TORPEDO<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Platform </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g07z11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our proprietary platform, TORPEDO, allows for informed and efficient drug design and discovery through a robust chemistry engine and
proprietary assays, culminating in predictive models that enable us to maximize catalytic turnover and predict <I>in vivo</I> performance. Key elements of the platform include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Structural biology and ternary complex model development:</B> We have invested heavily in structure-based approaches,
such as <FONT STYLE="white-space:nowrap">x-ray</FONT> crystallography and Hydrogen-Deuterium Exchange Mass Spectrophotometry, or <FONT STYLE="white-space:nowrap">HDX-MS,</FONT> to evaluate degrader binding interactions and enable structure-based
design in both the solid-state and solution. These approaches enable, among other things, the ability to dissect the distribution of ternary complexes formed by degrader complexes, allowing us to quickly evaluate and optimize prospective compounds.
Our proprietary ternary complex model library incorporates target structure, Cereblon E3 ligase structure and chemistry data to provide insight into differences in activity between degraders and drive the medicinal chemistry optimization process.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Purpose-built chemistry engine:</B> Our TORPEDO chemistry engine is designed to facilitate development of degraders
with drug-like properties, leveraging structural insights generated by the platform and our deep drug development expertise. Traditionally, small molecule inhibitor optimization has often been guided by an emphasis on specific property enhancements,
such as the Lipinkski &#147;rule of five,&#148; which stipulates limits on the molecular weight and hydrogen bond donors and acceptors to ensure drug-like properties. Degraders often fall well outside of these traditional boundaries and therefore
require a reevaluation of these guidelines, commonly referred to as the &#147;beyond-rule-of-five&#148; space. By applying these principles in our chemistry designs, we are able to improve drug-like properties, including permeability, solubility and
oral bioavailability, while maintaining potency and <I>in vivo</I> activity. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Enabling quantitative degradation assays:</B> We have developed high-throughput cellular degradation assays that
produce quantitative data showing the relationship between degrader concentration and target protein degradation. This approach, along with similar robust cellular assay systems, allows protein degradation quantitation with greater precision and
higher throughput than traditional western-blot approaches. The application of our experimental data to our robust and proprietary models then allows us to predict protein degradation kinetics, and the high throughput of both approaches allows us to
rapidly iterate and improve on degrader candidates and design for properties that optimize catalytic degradation turnover. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Predictive pharmacology founded on an enzymology framework:</B> We have established an enzymology framework that
assesses and balances the relationship between degrader concentration, time and target protein degradation to identify the key kinetic parameters of degrader induced protein degradation. We have extended this framework to proprietary PK/PD models,
which integrate these kinetic parameters with metabolism and PK exposure profiles to predict <I>in vivo</I> degrader performance. Our predictions of degrader performance are routinely validated through <I>in vivo</I> PD experiments with measurements
of target degradation from tumor samples using standard western blot assays. We have observed that these models linking cellular assays with predicted <I>in vivo</I> performance have significantly accelerated our discovery
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
process, and we believe that this will increase the likelihood of successfully transitioning from preclinical models to the clinic. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These features help focus our platform on the creation of candidates that we believe will present minimized biology and toxicity risk and address unmet treatment needs.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Minimizing Biology and Toxicity Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We place a significant
emphasis on minimizing risk in our current and planned programs by focusing on candidates with well-established biology and toxicology profiles, which allows us to select degraders that we believe have the best chance of being successful clinically.
To reduce biology risk, we pursue targets that have been clinically validated or that have strong preclinical data suggesting that successful target degradation would result in therapeutic benefit. To reduce toxicity risk, we seek to minimize
predictable preclinical safety liabilities early in the drug development process. In furtherance of these objectives, we consider the following during program development: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Ligase selection: </B>Our lead degraders exclusively utilize Cereblon as the E3 ligase. There are over 600 E3 ligases in the human proteome, of which the biology has
been well characterized in no more than 50 of them. To our knowledge, only a limited number of E3 ligases, including Cereblon, VHL, MDM2, IAPs and &szlig;-TRCP, are currently suitable for targeted protein degradation. We have chosen to focus on
Cereblon as the E3 ligase target of our protein degradation approach for several reasons: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Extensive clinical experience with the approved drugs thalidomide, lenalidomide and pomalidomide has shown that using
Cereblon can effect target degradation. The mechanism of action of these molecules is to degrade disease targets, specifically IKZF1 and IKZF3, by bringing them into complex with Cereblon. Lenalidomide and pomalidomide are both approved drugs that
have served as part of the standard of care for the treatment of MM for the last 15 and seven years, respectively. Together, this experience clinically validates that Cereblon has been harnessed both safely and effectively by other drugs.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have developed methods to obtain high resolution structural data with Cereblon bound to novel chemical binders, which
allows us to rationally design improved binders with unique chemical features. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Cereblon is widely expressed across tissues and is present in all of the cellular compartments, including the cytoplasm
and nucleus, potentially allowing for Cereblon-mediated targeted protein degradation across a wide variety of clinical settings and potential targets. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have developed multiple distinct, proprietary Cereblon binders that we have designed for improved drug-like properties,
such as enhanced oral bioavailability, solubility, permeability and stability, and all of our product candidates and programs benefit from these properties of our proprietary Cereblon binders. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our library of Cereblon binders offers a proprietary and powerful toolkit for degrader discovery. This Cereblon binder toolkit enables a more modular approach to
identifying and optimizing degraders, as each of these binder classes encode distinct drug-like properties and, importantly, unique &#147;exit trajectories&#148; from the Cereblon surface following protein degradation, which can promote better
target degradation turnover. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Minimizing target toxicity and maximizing potential degradation</B>: We select target proteins where we believe degradation of the
target in adult humans will likely be tolerable, often by selecting target proteins that have already been targeted by traditional inhibitors with good tolerability. Three of our lead targets, IKZF1/3, BRAF V600E and RET, have been previously
targeted clinically with inhibitors, and their inhibition has been tolerated. One of our lead programs, BRAF V600E, specifically targets only the mutant disease-causing protein that is found only in cancer cells, which means that <FONT
STYLE="white-space:nowrap">on-target</FONT> protein degradation should only impact cancer cells. We also aim to limit <FONT STYLE="white-space:nowrap">on-target</FONT> toxicity risk by specifically targeting proteins that are only critical in the
setting of genetically driven cancer but not normal cells, as is the case with BRD9 and proteins that are minimally expressed in healthy adult cells, such as RET. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Degrader design: </B>We seek to optimize catalytic degradation turnover and high selectivity, while also managing safety risk, by focusing our analytical techniques
and predictive models on the relationship between degrader properties and ultimate protein degradation. Our degraders activate the E3 ligase and facilitate target protein binding and ubiquitination, resulting in rapid overall target degradation. The
ability of our degraders to repeat this process </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
recursively with many copies of the target protein with the same single degrader molecule allows us to optimize our product candidates for catalytic degradation turnover and, as a result, create
candidates that have the potential to provide a greater therapeutic effect. Our MonoDACs and BiDACs need to achieve sufficient binding affinity to initiate brief ternary complex formation, but, unlike traditional inhibitors, they do not need to
achieve prolonged stable binding to achieve desired physiological effects. In fact, in a number of our pre-clinical research activities, we have observed that even weaker binders can still result in very efficient degraders since they may allow for
higher rates of catalytic degradation turnover, which is something we prioritize to achieve potentially greater activity. We can target disease-causing proteins to which traditional inhibitors have been unable to sufficiently bind because we are not
restricted to selecting compounds that have high target binding affinity. Moreover, in some instances we are able to repurpose molecules developed for traditional inhibitor approaches as the target-protein-binding end of our degraders and improve
upon their biologic properties by incorporating them into a BiDAC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We address toxicity driven by degradation of proteins other than the intended target, or <FONT
STYLE="white-space:nowrap">off-target</FONT> toxicity, by developing degraders with high selectivity. We confirm selectivity by global protein expression studies and validate the results through standard good laboratory practice, or GLP, toxicity
studies. We also minimize the risk of toxicity driven by the chemical matter making up our MonoDAC and BiDAC molecules that is independent of the specific toxicities described above, or molecule-related toxicity, with high quality chemical matter
optimized to minimize known chemical and metabolic liabilities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Focus on High Unmet Medical Need </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently focus on indications where there is a clear and high unmet medical need. Given the broad potential applicability of our approach, we believe it is
important to prioritize treating diseases where traditional therapeutic modalities have failed or had a suboptimal therapeutic impact. In some cases of significant unmet need, there can be opportunities for expedited product development and a path
to accelerated regulatory approval. Pursuing these types of accelerated pathways is a focus of our approach and provides the potential to address patients&#146; needs expediently while also validating our platform. We believe our platform has broad
applicability beyond cancer that we plan to address in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leveraging our Differentiated Platform and Approach </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that these features differentiate our platform from other drug development approaches, including those of others in the targeted protein degradation space.
We believe these differentiating features, as exemplified in our four lead programs, will help us succeed in developing novel degraders of disease-causing proteins to address unmet medical need. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our four lead programs will be delivered orally because, in these indications, against these targets, oral delivery provides potential therapeutic and commercial
advantages. Also, oral delivery helps mitigate the risk of adverse events associated with intravenous or intramuscular administration, including pain or extravasation, or leakage into the extravascular tissue, at the infusion site. By focusing on
targets with reduced biology and toxicity risk and pursuing conditions with high unmet medical need, we have selected four preclinical programs to advance into the clinic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidates&#151;Highly Selective Protein Degraders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently
have four preclinical product candidates in development. We anticipate that our CFT7455 and CFT8634 product candidates will be in the clinic by the end of 2021, and that our BRAF V600E and RET programs will be in the clinic by the end of 2022. These
programs are directed towards targets that remain inadequately treated with available therapies or are undruggable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>CFT7455: A IKZF1/3 Degrader for Multiple
Myeloma, Peripheral <FONT STYLE="white-space:nowrap">T-Cell</FONT> Lymphoma and Mantle Cell Lymphoma </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing CFT7455, an orally bioavailable
degrader targeting IKZF1/3, for the treatment of MM and NHLs, including PTCL and MCL. We have chosen IKZF1/3 as our initial targets for degradation because of their strong mechanistic rationale and well-defined biology. In preclinical studies,
CFT7455 has shown robust activity in MM, PTCL and MCL subcutaneous xenograft mouse models, providing preclinical proof of concept. Specifically in MM, we have observed in preclinical studies that CFT7455 remains active in <I>in vivo</I> and <I>in
vitro</I> models that are relatively insensitive to standard of care agents that have a similar mechanism of action, such as pomalidomide. We believe that the differentiated pharmacology of CFT7455, including its high potency, may translate into
significantly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
improved clinical outcomes over current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> agents in each of the indications in which we are pursuing
its development. Additionally, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial is designed to capitalize on potential opportunities for expedited product development and
accelerated approval in MM, PTCL and MCL. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>IKZF1/3 Is a Well Understood Biological Target for Certain Blood Cancers </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">IKZF1 and IKZF3 are transcription factors central to the differentiation of lympho-myeloid multipotent progenitor cells through mature immune cells, including T cells
and plasma cells, such as B cells. In particular, by preventing the maturation of B cells there is an antiproliferative effect in B-cell driven blood cancers, such as MM, <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphomas and myelodysplastic
syndrome. In addition to these cell-intrinsic dependencies on IKFZ1/3 for B cell maturation, degradation of IKZF1 and IKZF3 has been shown in third-party research to lead to enhanced <FONT STYLE="white-space:nowrap">IL-2</FONT> expression in T
cells, meaning IKZF1/3 degradation also induces T cell activity and may exert anti-cancer effects. IKZF1/3 has been previously validated as a target in clinical practice. Lenalidomide and pomalidomide primarily target IKZF1/3 as their mechanism of
action. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Multiple Myeloma </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States,
MM represents nearly 1.8% of all new cancer cases. The National Cancer Institute estimates that there will be 32,270 new cases of MM in the United States and 12,830 deaths from the disease in 2020. Although overall outcomes for patients with MM have
improved substantially over the past several decades, patients with MM have a poor prognosis and the predicted median five-year relative survival rate is only 53.9%. As such, there remains a significant unmet need. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most patients with MM will have an initial response to treatment. Based on fluorescence in situ hybridization, or FISH, studies on bone marrow, patients are stratified
into high-risk or standard-risk categories. High-risk patients eligible for hematopoietic cell transplantation receive induction therapy with a combination regimen, often including an IKZF1/3 targeting drug like lenalidomide, to reduce the number of
tumor cells prior to stem cell collection. Alternatively, patients who are ineligible for hematopoietic cell transplantation immediately receive a combination regimen, often with three to four classes of drugs, including an IKZF1/3 targeting-drug
and a steroid, typically dexamethasone, until progression or unacceptable toxicity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, current therapies are not curative, and most patients will ultimately
progress. Despite the likelihood of an initial remission, there is a significant unmet need because most patients experience serial relapse and will be treated with most available agents at some point during their disease course. In our clinical
program, we will initially focus on treating patients with relapsed/refractory MM who have received at least two lines of specified prior therapy, including lenalidomide, pomalidomide, two proteasome inhibitors and/or an anti-CD38 monoclonal
antibody, or mAb. Ultimately, our intention is to seek approval in earlier lines of therapy, replacing or complementing current IKZF1/3 targeting-drugs. We believe that the high potency and activity we have seen <I>in vivo has the potential to
translate into a meaningful benefit for patients. </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Peripheral T-cell Lymphomas </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">PTCLs are a heterogeneous and typically aggressive group of NHLs. The Surveillance, Epidemiology and End Results Program or SEER Program, of the National Institutes of
Health, or NIH, estimates that there will be 77,240 new cases of NHL in the United States and 19,940 deaths from the disease in 2020. PTCLs comprise approximately 4% of all NHLs in the United States and Europe, with an incidence that increased from
0.1 cases per 100,000 in 1992 to 0.4 cases per 100,000 in 2006, potentially reflecting improved diagnostic methods. The median five-year relative survival of patients with PTCL is 50%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">PTCL is a heterogeneous malignancy with many subtypes. The outcomes in these subtypes vary, but many patients with PTCL do poorly. In patients with PTCL in whom no
subtype is defined, which is often referred to as PTCL not otherwise specified or PTCL-NOS, the five-year overall survival is approximately 20% to 32%. In other subtypes, outcomes vary greatly, though most patient with these subtypes do poorly. For
instance, patients with angioimmunoblastic, natural killer/T-cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic, enteropathy type or ALK-peripheral T-cell lymphoma all have a median five-year overall survival of less than 50%. Although
initial overall response rates for chemotherapy are approximately 40% to 75%, most patients either relapse or fail to achieve remission. Median progression free survival or PFS, following chemotherapy is 12 to 14 months with a median five-year
survival rate of approximately 20% to 30%. There is a significant unmet need for relapsed/refractory disease as there is no accepted standard of care for this population. Lenalidomide has been tested
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
clinically in PTCL in a Phase 2 trial and shown to have an overall response rate of 22% to 26%. Cereblon modulators, such as lenalidomide, also known as IMiDs, are not widely used nor approved
for treating PTCL. Based on our preclinical data, we believe CFT7455 has the potential to create a meaningful benefit for these patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Mantle Cell Lymphoma </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MCL is one of the mature B-cell
NHLs. MCL comprises approximately seven percent of adult NHLs in the United States and Europe with an incidence of approximately 0.8 cases per 100,000 persons per year according to recent SEER Program estimates. Median overall survival for patients
receiving intensive therapy is four to five years. There is no universally accepted standard of care for MCL. Outside of agents being tested in clinical trials, treatment options typically include some combination of conventional chemoimmunotherapy,
rituximab and radiation therapy. Most patients with MCL experience serial relapse and are treated with various agents, including <FONT STYLE="white-space:nowrap">IKFZ1/3-targeting</FONT> drugs, BTK inhibitors or the
<FONT STYLE="white-space:nowrap">BH-3</FONT> mimetic venetoclax. Lenalidomide is approved for use in patient with MCL whose disease has relapsed or progressed after two prior therapies, one of which included&nbsp;bortezomib, based in part on an
observed overall response rate of approximately 26%. However, lenalidomide is not widely used to treat MCL. Accordingly, we believe that CFT7455 has the potential to meaningfully improve outcomes and become an established standard of care for these
patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have
conducted a comprehensive preclinical program across multiple mouse models to study CFT7455 as a potential treatment for MM, PTCL and MCL. We are preparing to submit an IND for CFT7455 in the fourth quarter of 2020 and intend to initiate a Phase 1/2
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial in the first half of 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We performed an <I>in vitro</I>
analysis of CFT7455 at varying doses in cells lines across MM and PTCL. The figure below on the left depicts CFT7455, in a MM model, degrading up to approximately 90% of the IKZF1 target protein within 24 hours in a dose-dependent fashion. The
figure below on the right depicts CFT7455, in a PTCL model, dose dependently degrading up to approximately 90% of IKZF1 in six hours. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g08y11.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">CFT7455 is a highly selective degrader of IKZF1 and IKZF3, as demonstrated by the figure below. The figure depicts the
standard method for determining degrader selectivity is a global proteomics experiment, which utilizes mass spectrometry to quantify cellular protein levels in DL-40 xenograft tumor cells following drug treatment. Specifically, the total cellular
protein pool is extracted and processed from cells treated with a degrader, then each protein is individually identified and its level quantified. Using this process, we analyzed the effect of CFT7455 on over 8,000 proteins. These data were then
compared to control samples from cells treated with the dosing solution alone, or vehicle, to provide the relative level changes for each protein in the entire cellular protein pool. The <FONT STYLE="white-space:nowrap">x-axis</FONT> in the graph
represents the relative level of proteins in the treated cells compared to control samples, and the <FONT STYLE="white-space:nowrap">y-axis</FONT> shows the level of statistical confidence in the difference in relative levels of each protein. The
figure below depicts cells treated with CFT7455 degrading only a small subset of the cellular proteins with statistical confidence, which are the proteins highlighted in red falling outside of the shaded area. This analysis shows that CFT7455 is a
highly selective degrader of IKZF1 and IKZF3. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g09h64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, we have profiled known Cereblon targets of pomalidomide and lenalidomide, including GSPT1, GSPT2 and SALL4, using
target-specific assays. We observed that CFT7455 has no detectable activity against GSPT1 or GSPT2, but it does degrade SALL4, which is not expressed in the cell line used in the analysis reflected in the figure above, and accordingly, its
downregulation is not detected in this assay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to IKZF1 and IKZF3 degradation and selectivity, we have observed potent activity <I>in vitro</I> across a
panel of relevant cell lines. In multiple subcutaneous xenograft mouse models of MM, PTCL and other NHLs, CFT7455 treatment resulted in complete regression at doses that we believe could be clinically active, as shown in the graphs below.
Significantly, 30 &micro;g/kg of CFT7455 administered once daily, or QD, demonstrated complete regression and clear dose responsiveness in a widely used MM xenograft model, H929, as shown in the graph on the left below. Additionally, in the
RPMI-8226 MM xenograft model, a MM model that is relatively insensitive to treatment with pomalidomide, CFT7455 demonstrated tumor regression and dose responsiveness, as shown in the graph on the right below, and the combination of dexamethasone and
CFT7455 resulted in increased activity compared to either CFT7455 or dexamethasone alone. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g10m87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the RPMI-8226 MM xenograft, we observed that pomalidomide at the clinically relevant dose of 3,000 <B></B><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B></B>g/kg was indistinguishable from treatment with the vehicle as shown in the graphic below. A low dose of
CFT7455, 30 <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT>g/kg, was active in the model, even when administered to large tumors that had grown despite treatment with 3,000 <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT>g/kg of pomalidomide for 21 days and were insensitive to pomalidomide and then were switched to treatment with CFT7455. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g11w74.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As shown in the figures below, in preclinical studies evaluating various doses of CFT7455 and pomalidomide in MM H929
cells, CFT7455 was up to <FONT STYLE="white-space:nowrap">10,000-fold</FONT> more potent than pomalidomide, as measured by impact on cell viability after 96 hours. Further, CFT7455 exhibited a high catalytic turnover rate, as measured by
CFT7455&#146;s cellular degradation rate of up to 75% at 1.5 hours. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g12v69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on its pharmacological properties, we believe CFT7455 may have a favorable therapeutic index and has the potential to replace
or follow existing standard of care therapies. We have also evaluated varied dose regimens, as shown in the figure below, which suggest the possibility of intermittent dosing of CFT7455. This could further increase the therapeutic index if adverse
events are observed, by incorporating drug holidays in the dosing schedule. Preliminary data from 28-day oral toxicity studies conducted in rats and monkeys demonstrated that exposures well above the modeled efficacious exposures in humans have been
tolerated. Definitive <FONT STYLE="white-space:nowrap">GLP-toxicity</FONT> studies are ongoing. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g13y87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Our Planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Human</FONT></FONT>
Phase 1/2 Trial </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to file an IND for CFT7455 in the fourth quarter of 2020 and expect to dose the first patient in a clinical trial of this product
candidate in the first half of 2021. Our planned Phase 1/2 trial is designed as a dose escalation trial of CFT7455 in approximately 18 to 30 subjects with MM and NHL. We have designed the trial to identify a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
maximum tolerable dose and a recommended dose for expansion in patients with MM, and a discrete dose for patients with NHL. Identifying discrete doses for each indication is done for two reasons:
first, it has been observed in prior clinical experience that patients with MM may tolerate a higher dose of IKZF1/3 targeting agents than do NHL patients; second, in MM, the addition of dexamethasone to CFT7455 may increase the clinical activity or
therapeutic index of CFT7455, thus we will explore CFT7455 both as a single agent and in combination with dexamethasone in MM but only as a single agent in NHL. This trial will primarily investigate the safety and tolerability of CFT7455, and key
secondary endpoints will be to characterize its PK/PD and anti-tumor activity. We expect the Phase 1/2 results will help us better understand the disease characteristics of those patients who may derive benefit from CFT7455, which will enable us to
design future clinical trials for this product candidate more effectively. The initial cohort will enroll three to six subjects with relapsed/refractory MM or NHL and we will administer CFT7455 over a <FONT STYLE="white-space:nowrap">28-day</FONT>
cycle, evaluating the window for any potential dose-limiting toxicity. We anticipate Phase 1/2 initial topline safety and PK results approximately one year after the first patient is dosed. In the expansion stage, we expect to enroll an additional
30 patients with relapsed/refractory MM, 20 patients with MCL and 20 patients with PTCL. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>CFT8634: A Novel BRD9 Degrader for Synovial Sarcoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing CFT8634, an orally bioavailable protein degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted solid malignancies. We have
chosen BRD9 as a target for our approach because of the strong mechanistic rationale, the well-defined biology, the unique opportunity to target BRD9 with a degrader (traditional protein inhibitors are infective in this setting) and a significant
unmet need in these patient populations. We plan to initially pursue development in synovial sarcoma, which is defined by a gene translocation <FONT STYLE="white-space:nowrap">SS18-SSX</FONT> that results in dependency on BRD9 and is therefore
potentially addressable by a BRD9 degrader. There are currently no clinical stage molecules targeting BRD9, as BRD9 has been considered an undruggable target with standard modalities. There is limited benefit of existing treatments for metastatic or
locally advanced synovial sarcoma, with patients having a median survival of approximately 18 months. We believe that the ability of our degrader CFT8634 to drug BRD9 has the potential to offer a benefit over currently available therapies for
patients with synovial sarcoma. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>BRD9 Is a Well Characterized Driver of Cancer with No Currently Available Targeted Therapies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BRD9 is a component of the ncBAF, which is one of three types of BAF complexes in human cells. The BAF complexes, also known as SWI/SNF complexes, are responsible for
regulating gene transcription. Critically, BRD9 and the ncBAF complex of which it is a component, is not normally required for cell survival. Normal cells rely on another complex, cBAF, for cellular growth, and BRD9 is not a member of this complex.
However, in certain genetic settings, ncBAF drives malignancy and these tumors are dependent on BRD9. Genetic settings in which BRD9 is critical share the same feature: the function of the cBAF complex is compromised because SMARCB1, a critical
component for normal function of the cBAF complex, is removed from the complex. This situation, referred to as BAF perturbation, is seen in both cancers in which SMARCB1 is deleted, such as malignant rhabdoid tumors, or MRTs, and epithelioid
sarcoma, as well as when a pathogenic fusion protein referred to as SS18-SSX results in the ejection of SMARCB1 from the BAF complex. This SS18-SSX fusion protein is the defining genetic lesion that drives synovial sarcoma. In each of these
settings, BAF perturbation results in a central dependency on the ncBAF complex, and as a result BRD9, for tumor growth. This is an example of synthetic lethality, in which the cancer cell has a specific vulnerability to BRD9 degradation in the
setting of the underlying genetic lesion. In contrast, normal cells, which do not harbor this genetic lesion, are relatively unaffected by the degradation of BRD9. Thus, BRD9 is a critical dependency of the cancer in these genetic settings, and
depriving the cancer cell of BRD9 effectively stops tumor growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BRD9 has previously been considered undruggable because existing small molecule inhibitors of the bromodomain are inactive
against synovial sarcoma. This is because inhibition of this domain is not sufficient to block BRD9 from driving cancer cell growth, preclinically. Inhibitors of other protein functions, such as that of the critical domain of unknown function, or
DUF, have not been described. We believe that our approach to targeted protein degradation of BRD9 has the potential to offer a major benefit over currently available therapies for synovial sarcoma and SMARCB1-deleted tumors. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g14s55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Synovial Sarcoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Synovial sarcoma is an aggressive tumor that accounts for approximately 900 cases in the United States each year, or approximately 10% of all soft tissue sarcomas.
While it is prevalent in patients over a wide range of ages, it is more common in younger adult patients, with a median age of onset of 36 years. Like many sarcomas, synovial sarcoma is characterized by recurrent chromosomal arrangements and is
referred to as a fusion gene driven malignancy. Specifically, nearly all synovial sarcomas contain a fusion of the SS18 gene on chromosome 18 to the SSX1, SSX2 or SSX4 gene on the X chromosome. This type of mutation is referred to as a t(X;18)
chromosomal rearrangement, or an SS18-SSX fusion. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>SMARCB1-deleted Tumors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">SMARCB1 is a key member of the BAF chromatin-remodeling complex and assists in the control of gene transcription. The function of SMARCB1 and the BAF complex in cancer
has only recently been established. SMARCB1 is a tumor suppressor gene, meaning any decrease in function could potentially result in tumor proliferation. The inactivation of both alleles of SMARCB1 has been shown to result in several types of
tumors, including malignant rhabdoid tumors, or MRTs, as well as epithelioid sarcoma, renal medullary carcinoma, undifferentiated pediatric sarcomas, a subset of hepatoblastomas and others. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MRTs typically present in infancy or early childhood and are often aggressive. If the MRT is found in the central nervous system, MRTs are referred to as atypical
teratoid/rhabdoid tumors, or AT/RT. Whether the tumor is classified as MRT or AT/RT, the vast majority of these tumors are characterized by the loss of function of the SMARCB1 subunit of the BAF complex. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BRD9 has been shown to be an attractive target in pediatric MRTs because the loss or inactivation of the SMARCB1 subunit of the BAF complex leads to a dependency on
BRD9. Mechanistically, SMARCB1 loss results in the reprogramming of the cBAF complex and makes the ncBAF complex essential, in a similar mechanism to that which drives synovial sarcoma. As a result, SMARCB1-mutant malignant rhabdoid tumors are
dependent on the BRD9-containing ncBAF complex. Thus, we are able to target this tumor by degrading BRD9. We believe our BRD9 degrader could reduce tumor cell proliferation and improve patient outcomes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Intensive, multimodality treatment approaches have improved the clinical outcome of these young patients in a stepwise
manner. However, their prognosis remains poor even on these treatment approaches and the median duration of survival in clinical trials does not exceed nine to 17 months. New therapeutic strategies are urgently needed and we believe CFT8634 may have
a potentially meaningful clinical impact in these patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Development </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have conducted preclinical studies of CFT7503 in two mouse models. CFT7503 is the parent racemic mixture of our lead product candidate, CFT8634. In these studies, we
have observed comparability between CFT7503 and CFT8634 in terms of cellular potency, selectivity and <I>in vivo</I> activity. Further, both CFT7503 and CFT8634 are highly selective for BRD9 relative to other bromodomain containing proteins,
including BRD7 and BRD4, as shown in the dose dependency of target degradation in H293T cell lines expressing the individual proteins, as reflected in the graphs below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g15i85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also observed meaningful <I>in vitro</I> dose-dependent inhibition of cell proliferation of synovial sarcoma cell lines over
time. Cell proliferation is measured by analyzing the occupied area of cells in a sample over time and densely packed cells are considered confluent. Cell growth inhibition is evidenced in cultures that show a growth plateau below 100%. The figure
below on the left shows the effect of CFT7503 on BAF perturbed Yamato cell lines, which is a mouse xenograft model of synovial sarcoma, compared to the effect of a BRD9 inhibitor, shown as BRD9i or the vehicle, dimethylsulfoxide, or DMSO, which were
ineffective. CFT7503 had little impact on the growth of a BAF wildtype SW982 cell line, as shown in the graph on the right, showing that its effect was limited to cells with BAF perturbation. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g16p24.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The below graphic shows CFT7503 was active and tolerated when dosed orally in a mouse xenograft model of synovial sarcoma
(Yamato) and a PDX model (SA13412), with dose dependency observed between 6 mg/kg and 50 mg/kg QD for Yamato, and between 6 mg/kg and 40 mg/kg QD for PDX, with all doses being generally tolerated, indicated by limited weight loss. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g17q11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Our Planned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Human</FONT></FONT>
Phase 1/2 Clinical Trial </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to file an IND for CFT8634 with the FDA in the second half of 2021 and dose the first patient in a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial by the end of 2021. We expect to design our Phase 1/2 trial to be an open-label dose escalation trial in approximately 12 to 18
patients with synovial sarcoma or a solid tumor with SMARCB1 loss. The Phase 1 portion of the trial will primarily investigate the safety and tolerability of CFT8634. If a well-tolerated dose is identified for further development, we expect to
enroll two expansion cohorts, one which will include 30 patients who are known to have synovial sarcoma and a second with patients having solid tumors harboring SMARCB1 loss. Assuming CFT8634 has a favorable profile in these early clinical trials,
we initially intend to pursue approval in patients with synovial sarcoma after failure of first-line therapy. Depending on the results of the Phase 1/2 trials, we will work with the FDA to discuss potential accelerated approval pathways for this
product candidate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>BRAF V600E Degrader Program </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
developing orally bioavailable degraders of BRAF V600E as part of our ongoing strategic partnership with Roche. We have chosen BRAF V600E as a target for our approach due to strong mechanistic rationale, well-defined biology and unmet need. We plan
to initially pursue development in locally advanced or metastatic melanoma and NSCLC, in which approximately 50% and 2%, respectively, of cancers are driven by BRAF V600E mutation. In these patients, there remains a high unmet need for those who
relapse after, or do not respond to, approved BRAF inhibitors. BRAF V600E mutations also occur in 10% to 20% of colorectal cancer patients, so we may pursue development of our BRAF V600E programs in other indications in parallel with, or
sequentially to, development in our lead indications of relapsed/refractory BRAF V600E-positive melanoma and NSCLC. We believe that a mutant-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
specific BRAF V600E degrader could offer a significant mechanistic benefit over currently available BRAF V600E inhibitors and could have the potential to confer significant improvements in
clinical outcomes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>BRAF V600E is a Common and Well Understood Oncogenic Mutation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BRAF is one of several protein kinases involved in a signaling cascade to initiate cell proliferation, known as the mitogen-activated protein kinase, or MAPK, pathway.
The MAPK pathway conducts extracellular proliferative signals to the nucleus of cells, signaling them to proliferate. Many cancers are characterized by activating mutations in components of this MAPK pathway, including BRAF V600E mutations, which
confer constitutive activation of the MAPK pathway and promote oncogenic transformation and can cause tumor growth. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Single base substitutions for the amino acid
valine at codon 600 in the BRAF gene are known as V600 or Class I mutations, and when those V600 mutations result in substitution of glutamic acid for valine, they are referred to as V600E mutations. BRAF mutations occur in approximately 15% of all
cancers, and approximately 70% to 90% of BRAF mutations are V600E mutations. Melanomas have been shown to contain a particularly high prevalence of BRAF mutations at 50%, of which greater than 90% are driven by a V600E mutation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">BRAF V600E mutants activate the MAPK pathway constitutively, meaning that cell proliferation is activated without receiving the extracellular proliferative signals
necessary to activate the pathway normally. Constitutive activation occurs because BRAF V600E mutants are able to signal as a single protein, or monomer, while wild type BRAF proteins must form a complex of two proteins, or a dimer, before
downstream signaling can occur. This constitutive activation leads to overactivation of the MAPK cell proliferation pathway, causing oncogenic cell proliferation and tumor growth. Approved small molecule inhibitors of BRAF V600E&#151;vemurafenib,
dabrafenib and encorafenib&#151;block the constitutive activation of the MAPK pathway by the mutant BRAF monomer. However, BRAF inhibition with these molecules can lead to an alternative activation of the MAPK pathway, known as paradoxical
activation. Under these conditions, BRAF inhibitors bind and inhibit BRAF V600E, but this inhibited form can form a protein dimer with other RAF proteins, including both wild type BRAF and BRAF mutants, activating the second molecule for signaling.
This BRAF driven paradoxical activation activates, rather than inhibits, the MAPK pathway. BRAF inhibitors are frequently used in combination with MEK inhibitors, a protein downstream of BRAF in the MAPK pathway, which improves response rates and
clinical outcomes. However, patients frequently do not respond sufficiently or they develop resistance to this approach. Many known mechanisms of resistance to approved BRAF inhibitors result in the promotion of BRAF dimerization, and in these
settings the BRAF inhibitors are ineffective. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that targeted protein degradation of BRAF V600E offers the potential for a fundamental improvement over
current BRAF inhibitors due to the advantages of degraders over inhibitors in general and because degrading mutant BRAF removes the possibility of incorporation into a BRAF dimer and subsequent paradoxical activation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Melanoma </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the National Cancer Institute,
approximately 100,000 patients will be diagnosed with melanoma in 2020, and approximately 13% of those cases, or about 13,000 patients per year, will have locally advanced or metastatic disease. Moreover, approximately 50% of late stage melanoma
patients carry BRAF mutations, and approximately 90% of those are BRAF V600E mutations. Taken together, we estimate that there are over 5,000 incidents of newly diagnosed melanoma patients per year with BRAF V600E-mutated locally advanced or
metastatic disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The recommended first-line treatment for patients with BRAF V600E-mutated unresectable or metastatic melanoma is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy, such as pembrolizumab or nivolumab, or combination therapy with a BRAF inhibitor, such as dabrafenib, vemurafenib or encorafenib and a MEK
inhibitor, such as astrametinib, cobimetinib or binimetinib. However, a significant number of patients undergoing this combination therapy do not sufficiently respond or have a durable response as resistance to the therapy occurs. Specifically,
across several double-blind randomized controlled trials conducted by others evaluating BRAF and MEK inhibitor combination therapy in patients with previously untreated locally advanced or metastatic melanoma, median PFS has ranged from 9.9 to 14.9
months. After each of these lines of therapy is used, there are no approved single-agent therapies that effectively target BRAF. In preclinical models of resistance to BRAF inhibition, our degraders remained active when dosed in combination with a
MEK inhibitor, in contrast to the approved BRAF inhibitor, encorafenib, which is inactive in this setting. Thus, a BRAF V600E degrader may be active clinically in the setting of resistance to approved BRAF inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In preclinical studies, in the A375 BRAF V600E melanoma model, we have observed that one of our BRAF V600E degraders,
CFT7977, showed deeper and more sustained response in comparison to the standard of care BRAF inhibitor, dabrafenib, as shown in the figure below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g18m24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, two or our BRAF V600E degraders, CRT8442 and CFT8905, showed sustained activity in the A375 model encoding the NRAS Q61K
activating mutation, in combination with the MEK inhibitor, trametinib, which is shown in the following figure. The NRAS Q61K activating mutation is a clinically observed mechanism of resistance to BRAF inhibitors. Both BRAF V600E degraders, in
combination with trametinib, also showed improved activity compared to trametinib in combination with the BRAF V600E inhibitor, encorafenib. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g19z11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that our BRAF V600E degraders have the potential to improve upon current clinical outcomes, as our novel protein degraders
could offer a potent and selective mechanism to degrade V600E-mutant BRAF and prevent constitutive activation and oncogenic cell proliferation. Furthermore, degrading BRAF V600E may offer a fundamental improvement over inhibiting BRAF V600E because
degrading the mutant proteins with our approach may avoid the possibility of paradoxical activation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RET Degrader Program </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing orally bioavailable degrading compounds of RET for the treatment of NSCLC, sporadic medullary thyroid cancers and other solid cancer indications. We
have chosen RET because of its well-defined biology and the known drawbacks of RET protein inhibitors that we believe our degrader approach will be able to overcome. Our initial target population is relapsed/refractory patients with <FONT
STYLE="white-space:nowrap">RET-altered</FONT> cancers after treatment with RET inhibitors and we plan subsequently to pursue first-line treatment of <FONT STYLE="white-space:nowrap">RET-driven</FONT> cancers. We believe our RET degrader has the
potential to overcome resistance to standard of care RET inhibitors to effect deeper and more durable responses due to the unique advantages of protein degradation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>RET is a Well-Characterized Protein Target for Oncology with Known Resistance Mechanisms
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RET is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET typically plays a role in
normal development, but when mutated it can cause cancers, including NSCLC, medullary thyroid cancer and other solid tumors. Two <FONT STYLE="white-space:nowrap">RET-specific</FONT> inhibitors have been developed to target these malignancies. Eli
Lilly&#146;s selpercatinib and Blueprint Medicines&#146; pralsetinib were recently approved, both as <FONT STYLE="white-space:nowrap">RET-specific</FONT> kinase inhibitors to treat <FONT STYLE="white-space:nowrap">RET-altered</FONT> NSCLC and
medullary thyroid cancer. While these molecules showed in their Phase 2 trials that they are effective in the majority of the patients treated and generally well tolerated, patients are observed to relapse, at which point there are currently no
approved targeted therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The goal of our RET program is to design a degrader that covers the full landscape of observed and anticipated resistance mutants to
current and emerging RET therapies in these relapsed/refractory patients. In particular, we have identified compounds that exhibit activity against the wild-type RET fusions and fusions encoding gatekeeper mutations, as well as similar potency and
activity against a solvent front resistant mutant, or G810R, which is a mechanism of resistance to selpercatinib. We believe there may be an opportunity for our RET degrader as a viable alternative in front line therapy where we hope the RET
degrader will effect deeper and more durable responses due to the advantages of a degrader over a standard protein inhibitor. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I><FONT
STYLE="white-space:nowrap">Non-Small-Cell</FONT> Lung Cancer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Lung cancer, in particular NSCLC, is often driven by alterations in a single driver oncogene,
making these tumors well suited for precision therapies. One such example is RET translocation, which is present in one percent to two percent of NSCLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NSCLC
patients with mutated or rearranged oncogene drivers can be treated with first-line selective inhibitors and achieve fairly high response rates and longer survival than with chemotherapy. However, in some cases, resistance develops to clinical RET
inhibitors, due to mechanisms including new RET mutations that make the inhibitors inactive. Our RET degraders are designed to overcome these types of mutations. We believe that our RET degraders have the potential to improve upon current clinical
outcomes, as they could offer an alternative to RET inhibition that is less susceptible to resistance mechanisms and potentially able to achieve similar efficacy in front-line settings with an improved pharmacodynamic profile. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have conducted
preclinical experiments to characterize the activity profile of our RET degraders and have observed that they inhibit tumor growth comparably to the leading RET inhibitors, selpercatinib and pralsetinib, and retain activity in the setting of the
solvent front mutation, G810R. As shown in the figure below, one of our RET degraders, CFT2521, with daily intravenous, or IV, dosing, has comparable activity to both selpercatinib and pralsetinib dosed orally twice a day, or BID, in the KIF5B:RET
fusion murine xenograft model. We are working to identify RET degraders with similar activity using oral dosing. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g20c85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to identify a drug candidate and file an IND with the FDA in patients with
<FONT STYLE="white-space:nowrap">RET-altered</FONT> tumors by the end of 2022. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Other Discovery Programs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the programs discussed above, we are also progressing several other early stage pipeline programs. In line with our strategy, we assess on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis whether our degraders would provide a compelling and differentiated approach over standard of care or other approaches to the same disease and are
consistent with our focus on minimizing biology and toxicity risk and focusing on high unmet medical need, including rare diseases. These early stage programs include compounds that have already shown the ability to cross the blood-brain barrier in
preclinical models, and we are also evaluating degraders for additional oncology targets and rare diseases. Our discovery programs are a combination of internal programs, over which we have full control and ownership, and programs in collaboration
with our partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Collaborations and License Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Roche Amended and Restated License Agreement </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
March 2016, we entered into a license agreement with Roche, which was amended in June 2016 and amended further in March 2017. We further amended and restated that agreement (as so amended) in December 2018. We refer to this amended and restated
agreement as the Roche Agreement. Under the Roche Agreement, we agreed to collaborate with Roche in the research, development, manufacture and commercialization of target-binding small molecules using our proprietary TORPEDO platform for the
treatment of cancers and other indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the Roche Agreement, we are responsible for conducting preclinical research and development
activities for a number of targets selected by Roche in accordance with a target selection and replacement procedure set forth in the agreement. We are also responsible for conducting Phase 1 clinical trials for products directed to certain targets
and for manufacturing activities in connection with the applicable research plans, subject to Roche&#146;s right to assume manufacturing responsibilities at <FONT STYLE="white-space:nowrap">pre-defined</FONT> times. We and Roche each share in the
costs of these research activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Roche Agreement, we granted Roche an exclusive option to obtain an exclusive, worldwide license, with the right to
sublicense through multiple tiers to develop and commercialize products directed at each target that is subject to the collaboration. Upon the exercise of its option for a particular target, Roche is responsible for the manufacture, development and
commercialization of products directed to that target, at its sole expense. However, we have the option to <FONT STYLE="white-space:nowrap">co-develop</FONT> products directed to certain targets, in which case we would be responsible for a portion
of the development costs associated with such <FONT STYLE="white-space:nowrap">co-developed</FONT> products and eligible to receive increased royalties on sales of such <FONT STYLE="white-space:nowrap">co-developed</FONT> products. We also have an
option to <FONT STYLE="white-space:nowrap">co-detail</FONT> products for which have exercised our <FONT STYLE="white-space:nowrap">co-development</FONT> option. If we exercise our <FONT STYLE="white-space:nowrap">co-detail</FONT> option, we will be
responsible for a portion of the <FONT STYLE="white-space:nowrap">co-detailing</FONT> costs. We have the right to opt out of these <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-detailing</FONT>
activities.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon signing the Roche Agreement, we received upfront consideration of $40.0&nbsp;million from Roche. In addition, we receive
annual research funding from Roche for each active research plan and we are eligible to receive additional payments upon the achievement of <FONT STYLE="white-space:nowrap">pre-determined</FONT> research and development success criteria with respect
to certain targets. If Roche exercises its option right for a target, Roche is obligated to pay an exercise fee ranging from $7.0&nbsp;million to $20.0&nbsp;million, depending on the target. For each target option exercised by Roche, we are eligible
to receive milestone payments up to a range of $260&nbsp;million to $275&nbsp;million upon the achievement of certain research, development and commercial milestones with respect to corresponding products, subject to certain reductions and
exclusions based on intellectual property coverage. Roche is also required to pay us up to $150&nbsp;million per target in <FONT STYLE="white-space:nowrap">one-time</FONT> sales-based milestone payments upon the achievement of specified levels of
net sales of a product directed to such target. Finally, we are eligible to receive tiered royalties ranging from <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on net sales
of products sold by Roche pursuant to its exercise of its option rights, subject to certain reductions. For sales of products for which we exercise our <FONT STYLE="white-space:nowrap">co-development</FONT> right, the applicable royalty rates will
be increased by a <FONT STYLE="white-space:nowrap">low-single</FONT> digit percentage. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless earlier terminated, the Roche Agreement expires on the date when no
royalty or other payment obligations under the Roche Agreement are or will become due. We and Roche each may terminate the Roche Agreement in its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis and, in our case, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, for the other
party&#146;s uncured material breach of its obligations under the Roche Agreement or upon the other party&#146;s bankruptcy, insolvency or similar proceedings. Roche may terminate the Roche Agreement for convenience on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. In the event we are acquired by a competitor of Roche, Roche has the right to require us to terminate our research, development and
<FONT STYLE="white-space:nowrap">co-detailing</FONT> activities under the Roche Agreement, after which time we would not be eligible to receive payments for such terminated activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Calico License Agreement </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2017, we entered into a
Collaboration and License Agreement, or the Calico Agreement, with Calico, whereby we agreed to collaborate with Calico to discover, develop and commercialize small molecule protein degraders for diseases of aging, including cancer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Calico Agreement, we and Calico each agreed to conduct joint research activities with respect to a number of targets selected by Calico in accordance with a
target selection and replacement procedure set forth in the agreement. During the research term, which ends in March 2022, Calico is responsible for the costs of these research activities and has the right to approve targets for advancement to lead
optimization activities to be carried out by the parties under the corresponding research plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of our research activities for each target
selected by Calico for lead optimization activities, Calico is responsible for, and agrees to use commercially efforts to carry out, all further <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development, regulatory affairs, manufacturing and
commercialization for products directed against each such target. We refer to these products as Collaboration Products. We granted Calico an exclusive license to manufacture and commercialize Collaboration Products under certain of our intellectual
property rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under this agreement, Calico paid us an upfront amount of $5.0&nbsp;million and certain annual payments totaling $5.0&nbsp;million through
June&nbsp;30, 2020. Upon successful nomination of a target following a target evaluation phase and initiation of the applicable research plan, we are eligible to receive target initiation payments from Calico. For each target, we are eligible to
receive research, development and commercial milestone payments totaling up to $132.0&nbsp;million. Calico is also required to pay <FONT STYLE="white-space:nowrap">one-time</FONT> sales-based milestone payments aggregating up to $65.0&nbsp;million
upon the achievement of specified levels of net sales of a product directed to such target, subject to a reduction based on intellectual property coverage. We are also eligible to receive royalty payments on the net sales of Collaboration Products,
at percentages in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits, subject to certain reductions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless terminated earlier, the Calico Agreement
expires on the date when no royalty or other payment obligations under the Calico Agreement are or will become due. We and Calico each may terminate the Calico Agreement in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">target-by-target</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis and, in our case, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, for the other party&#146;s uncured material breach of its obligations or its bankruptcy or insolvency. Calico may terminate the Calico Agreement for convenience in its entirety or on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, subject to reimbursement of costs and
return of materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biogen Collaborative Research and License Agreement </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, we entered into a collaborative research and license agreement, or the Biogen Agreement, with Biogen, whereby we agreed to collaborate with Biogen and
use our proprietary protein degrader platform to research, develop and identify small molecule protein degraders. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Biogen Agreement, we granted
Biogen an exclusive license, with the right to sublicense through multiple tiers, under our intellectual property, (a)&nbsp;for the purpose of performing candidate development activities in accordance with research and development plans agreed upon
by the parties and (b)&nbsp;for the purpose of exploiting all degraders and products for any use in the world. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of the Biogen Agreement, we are
responsible for conducting research and development activities for a number of targets selected by Biogen in accordance with a target selection and replacement procedure set forth in the agreement. We are required to provide all resources necessary
to perform candidate development activities, perform such activities with reasonable care and skill and in accordance with applicable law and the Biogen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Agreement and to use diligent efforts to complete such activities as set forth in the applicable development plan and to deliver to Biogen a certain number of degraders directed to each target
that meet a range of <FONT STYLE="white-space:nowrap">pre-defined</FONT> criteria. We and Biogen are also responsible for research activities designed to inform Biogen&#146;s target selection process, for which Biogen will pay for its own costs and
will reimburse our costs up to a certain amount. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon Biogen&#146;s commencement of the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> study for a degrader
directed towards each target selected by Biogen, Biogen is responsible for, and agrees to use commercially reasonable efforts to carry out, all further development, regulatory affairs, manufacturing and commercialization for at least one product
directed against each such target in certain territories. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon execution of the Biogen Agreement, Biogen paid us an upfront payment of $45.0&nbsp;million as
prepayment for candidate development activities, and if Biogen elects to extend the collaboration term by a <FONT STYLE="white-space:nowrap">pre-determined</FONT> period and obtain the right to elect a certain number of additional targets, we are
eligible for an additional payment of $62.5&nbsp;million. Upon Biogen&#146;s receipt of degraders directed to each target that satisfy <FONT STYLE="white-space:nowrap">pre-defined</FONT> criteria, we are eligible to receive payments ranging from
$2.0&nbsp;million to $3.0&nbsp;million per target. Upon Biogen&#146;s commencement of the first <FONT STYLE="white-space:nowrap">IND-enabling</FONT> study for a development candidate directed towards each target, Biogen is required to pay us
$8.0&nbsp;million. For each target, Biogen is required to pay us (a)&nbsp;development and commercialization milestone payments totaling up to $35.0&nbsp;million and (b)&nbsp;sales milestone payments totaling up to $26.0&nbsp;million for the
achievement of certain amounts of net sales of all products directed to such target, each subject to certain reductions. The total development, commercialization and sales milestone payments will increase if Biogen extends the collaboration term and
elects additional targets. In addition, Biogen is required to pay us royalties on a <FONT STYLE="white-space:nowrap">product-by</FONT><B><FONT STYLE="white-space:nowrap">-</FONT></B>product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the net sales of each product, at percentages in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits, subject to certain reductions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless earlier terminated, the Biogen Agreement expires on the date of the last
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of a patent right covering the composition of matter of method of use in the approved label of the applicable product in the applicable country. We
and Biogen each may terminate the Biogen Agreement (a)&nbsp;with respect to one or more development candidates, products or collaboration targets or, only in the case of Biogen, the entire agreement, for the other party&#146;s uncured material
breach of its obligations and (b)&nbsp;in its entirety upon the other party&#146;s bankruptcy, insolvency or similar proceedings. Biogen may also terminate the Biogen Agreement in its entirety or with respect to one or more development candidates,
products or collaboration targets for convenience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. While we believe that our technology, expertise, scientific
knowledge and intellectual property estate provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic
institutions, governmental agencies and public and private research institutions that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Not only must we
compete with other companies that are focused on protein degradation, but any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Moreover,
our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our focus is on the discovery and
development of protein degradation therapies using our TORPEDO platform. Other companies researching chimeric small molecules for protein degradation include Arvinas, Inc., Cullgen Inc., Nurix Therapeutics, Inc., Vividion Therapeutics, Inc. and
Kymera Therapeutics, Inc., of which Arvinas, Inc. is in clinical development and the other companies are currently in preclinical development. Further, several large pharmaceutical companies have disclosed preclinical investments in this field,
including Amgen, AstraZeneca plc, GlaxoSmithKline plc, Genentech and Novartis International AG. In addition to competition from other protein degradation therapies, any products that we develop may also face competition from other types of
therapies, such as small molecule, antibody, T cell or gene therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates target oncologic indications. The most common methods of treating patients in oncologic
indications are surgery, radiation and drug therapy, including chemotherapy, hormone therapy, cellular therapy and targeted drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are
administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection and others are available on a generic basis. Many of these approved drugs are therapies and are widely
accepted by physicians, patients and third-party payors. In general, although there has been considerable progress over the past few decades in the treatment of cancer and the currently marketed therapies provide benefits to many patients, these
therapies are all limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating all patients. As a result, the level of morbidity and mortality from cancer remains high. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to currently marketed drugs, there are also several product candidates in preclinical development for the treatment of oncologic indications. These products
in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain market
approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our product candidates are approved for the indications for which we expect to conduct clinical trials, they will compete with the foregoing
therapies and currently marketed drugs, as well any drugs potentially in development. It is also possible that we will face competition from other biologic or pharmaceutical approaches, as well as from other types of therapies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified
scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the
pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for
ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage
the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing and additional products are expected to become available on a generic basis over the coming years. If our product
candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The key competitive factors affecting the
success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate and currently have no plans to
establish any manufacturing facilities. We rely on and expect to continue to rely on third-party CMOs for both drug substance and finished drug product </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term committed supply arrangements with respect to our product candidates and other materials. Should any of these manufacturers become unavailable
to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements. For additional information, see the section titled &#147;Risk Factors&#151;<I>Risks
Related to Dependence on Third Parties&#151;Manufacturing pharmaceutical products is complex and subject to</I> <I>product loss for a variety of reasons. We contract with third</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<I>parties for the manufacture of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third</I> <I>parties
increases the risk that we will not have sufficient quantities of our product candidates or products or that we will not have the quantities we desire or require at an acceptable cost or quality, which could delay, prevent or impair our development
or commercialization efforts.</I>&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our drug candidates are organic compounds of low molecular weight, which are often referred to in the
biopharmaceutical community as small molecules, but our BiDACS tend to be larger than traditional small molecule therapeutics. We have selected these compounds not only on the basis of their potential clinical activity and tolerability, but also for
their relative ease of synthesis and reasonable cost of goods. In particular, CFT7455 and CFT8634 are manufactured using reliable and reproducible synthetic processes from readily available starting materials. The chemistry is amenable to scale up
and does not require unusual equipment in the manufacturing process. We expect to continue to develop drug candidates that can be produced cost effectively at contract manufacturing facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercialization Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not yet established our own commercial
organization or distribution capabilities because our product candidates are still in preclinical development. We have retained full commercialization rights for all of our programs in development other than those subject to our collaboration
agreements. If any of our product candidates receive marketing approval, we will need to develop a plan to commercialize them in the United States and other key markets. We currently anticipate that we would build our own focused, specialized sales
and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. We expect to utilize a variety of types of
collaboration, <FONT STYLE="white-space:nowrap">co-promotion,</FONT> distribution and other marketing arrangements with one or more third parties to commercialize our product candidates in markets outside the United States or for situations in which
a larger sales and marketing organization is required. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As product candidates advance through our pipeline, our commercial plans may change. Some of our research
programs target potentially larger indications. Data, the size of the development programs, the size of the target market, the size of a commercial infrastructure and manufacturing needs may all influence our strategies in the United States, Europe
and the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial
success depends in part upon our ability to secure and maintain patent and other proprietary protection for our protein degradation technologies, including our TORPEDO platform, product candidates
<FONT STYLE="white-space:nowrap">and&nbsp;know-how&nbsp;related</FONT> to our business. To protect our core technology and products, we will need to successfully prosecute, defend and, if necessary, enforce our intellectual property rights,
including, in particular, our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others. For our product candidates, we generally intend to pursue
patent protection covering compositions of matter, methods of use, including combination therapies, processes of manufacture and intermediates, where relevant. We continually assess and refine our intellectual property strategies as we develop new
technologies and product candidates. We currently plan to file additional patent applications based on our intellectual property strategies, where appropriate, including where we seek to adapt to competition or to improve our business opportunities.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent positions for biopharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the
coverage claimed in a patent application can be significantly reduced before a patent is issued and its scope can be reinterpreted and challenged even after issuance. As a result, we cannot guarantee that any of our product candidates will be
protected or remain protectable by valid, enforceable patents. We also cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will
provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
exclusivity terms of our patents depend upon the laws of the countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patent application. The term of a U.S. patent may be extended to compensate for the time required to obtain regulatory approval to sell a drug (referred to as a patent term extension) or by
delays encountered during patent prosecution that are caused by the USPTO (referred to as patent term adjustment). For example, the Hatch-Waxman Act permits a patent term extension for <FONT STYLE="white-space:nowrap">FDA-approved</FONT> new
chemical entity drugs of up to five years beyond the ordinary expiration date of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review and diligence during the review process. Patent
term extensions in the United States cannot extend the term of a patent beyond a total of 14 years from the date of product approval and only one patent covering an approved drug or its method of use may be extended. A similar kind of patent
extension, referred to as a Supplementary Protection Certificate, is available in Europe. Legal frameworks may also be available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions for
our products on any of our issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however, there is no guarantee that the applicable regulatory authorities, including the FDA in the United States, will
agree with our assessment of whether extensions of this nature should be granted and, even if granted, the length of these extensions. Further, even if any of our patents are extended or adjusted, those patents, including the extended or adjusted
portion of those patents, may be held invalid or unenforceable by a court of final jurisdiction in the United States or a foreign country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30,
2020, we solely own two issued U.S. patents, 10 U.S. patent applications, seven patent applications filed under the Patent Cooperation Treaty and 22 patent applications pending in foreign countries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2020, we <FONT STYLE="white-space:nowrap">co-own</FONT> five U.S. patent applications with Roche, two patent applications filed under the Patent
Cooperation Treaty and three patent applications pending in foreign countries. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patents and Patent Applications </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our patent portfolio is generally organized into two categories: TORPEDO platform patent filings and protein target-specific product candidate filings. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>TORPEDO Platform </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We solely own our TORPEDO platform patent estate,
which, as of June&nbsp;30, 2020, includes two issued US patents, nine pending U.S. patent applications, five patent applications filed under the Patent Cooperation Treaty and <FONT STYLE="white-space:nowrap">twenty-two</FONT> pending foreign patent
applications. This patent portfolio is directed to multiple ligands of the Cereblon E3 ubiquitin ligase, or CRBN. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, this platform consists of fourteen
patent families covering the TORPEDO platform with composition of matter claims directed to various classes of CRBN ligands and degraders derived therefrom, as well as claims to associated methods of use. Patent applications for several of these
patent families have been filed in the United States, China and Europe. Patents in these families, if issued and maintained, will expire between 2037 and 2040, without taking potential patent term extensions or adjustments into account. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product Candidates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our patent applications directed to our product
candidates are focused on composition of matter claims covering novel compounds designed to degrade specific proteins. As of June&nbsp;30, 2020, we solely own one U.S. patent application and two patent applications filed under the Patent Cooperation
Treaty covering our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, as of June&nbsp;30, 2020, we solely own two patent families <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">describing&nbsp;composition-of-matter&nbsp;claims</FONT></FONT> to compounds that cause the degradation of the IKZF1/3 protein target, as well as associated methods of use to treat cancer. One of those patent families
includes claims directed to composition of matter generally and specifically covering&nbsp;CFT7455, our product candidate and associated methods of use, which if issued and maintained through the payment of all required fees, will expire in 2040,
without regard to any possible patent term extensions or adjustments. The second patent family of IKZF1/3 degraders is directed to a separate genus than the first family and, if granted and maintained through the payment of all required fees, will
expire in 2039, without regard to any possible patent term extensions or adjustments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2020, we solely own one U.S. patent application, with
claims directed to composition of matter covering&nbsp;our BRD9 degraders, including our CFT7503 and CFT8634 product candidates and associated methods of use. U.S. and foreign patents claiming priority to this patent application, if filed, granted
and maintained through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the payment of all required fees, will expire in 2041, without regard to any possible patent term extensions or adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2020, we <FONT STYLE="white-space:nowrap">co-own</FONT> five U.S. patent applications with Roche, two patent applications filed under the Patent
Cooperation Treaty and three patent applications filed in foreign countries pertaining to our product candidates. Our rights to these patent applications are governed by the Roche Agreement described below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Trade Secrets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also rely on trade secrets, <FONT
STYLE="white-space:nowrap">technical&nbsp;know-how&nbsp;and</FONT> continuing innovation to develop and maintain our competitive advantage. Under the agreements we enter into with our employees and consultants who are identified on any company-owned
patent applications assign any rights they may have in any such patent application to us. We also rely on confidentiality or other agreements with our employees, consultants and other advisors to protect our proprietary information. Our policy is to
require third parties that receive material confidential information to enter into confidentiality or other agreements with us that contain appropriate protections for our confidential and trade secret information. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Trademarks </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own various registered and unregistered trademarks in
the United States and overseas, including our company name and logo, the name of our TORPEDO platform and the names of our BIDAC degrader and MONODAC degrader products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and comparable regulatory agencies in state
and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and
development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Government Regulation of Drug Products </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States,
the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may
subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve a pending NDA, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process required by the FDA before product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">nonclinical laboratory and animal tests that must be conducted in accordance with GLPs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may
be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">adequate and well controlled human clinical trials to establish the safety and efficacy of the proposed product candidate
for its intended use, performed in accordance with good clinical practices, or GCPs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an NDA and payment of user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of manufacturing facilities and selected clinical
investigators for their compliance with cGMP and GCP; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of an NDA to permit commercial marketing for particular indications for use; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and
Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The testing and approval process requires
substantial time, effort and financial resources. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess
potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, a sponsor must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data and
any available clinical data or literature, among other required information, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the
FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the conduct of the clinical trial and imposes a clinical hold. In such a case, the IND sponsor and the FDA must
resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve the
administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements. A separate submission to the existing IND must be made for each successive clinical trial
conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its
informed consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are
being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#146;s or the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to subjects. Some studies also
include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other
grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases
that may overlap. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1&#151;Studies are initially conducted to test the product candidate for safety, dosage tolerance,
structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 clinical trials may also be used to gain an
initial indication of product effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2&#151;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide
enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expansive Phase 3
clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3&#151;These clinical trials are generally undertaken in larger subject populations to provide statistically
significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an
adequate basis for product labeling. These clinical trials may be done at trial sites outside the United States as long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA
regulations and guidance, such as compliance with GCPs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Typically, clinical trials are designed in consultation with the FDA or foreign regulatory authorities during these
development phases. The indications under development can influence the study designs employed during the conduct of clinical trials, such as for a first-line cancer treatment indication which may require <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> data demonstrating clinical superiority or <FONT STYLE="white-space:nowrap">non-inferiority</FONT> to currently available therapies. The timeline for first-line cancer indication development
programs may also be longer than for indications sought in third-line treatment or beyond due to a desire for regulatory authorities to expedite access to later-line treatments for those whose cancer has progressed despite available and earlier-line
treatments. As such, many new oncology products initially seek an indication in treatment for third-line treatment, a smaller available treatment population in any oncology indication, and any later approvals sought for those products in earlier
lines of treatment which target a larger treatment population might require the conduct of additional clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may require, or companies may
pursue, additional clinical trials after a product is approved. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 trials may be made a condition to be satisfied after approval. The results of Phase 4 trials can confirm the
effectiveness of a product candidate and can provide important safety information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must be conducted under the supervision of qualified
investigators in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial and the review and approval of the study by an IRB.
Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the
trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results,
must be submitted within specific timeframes to the NIH for public dissemination on their website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse
events occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active
pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outside of the United States is subject to
regulatory requirements of the receiving country, as well as U.S. export requirements under the FDCA. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if
serious adverse effects occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information
about the chemistry and physical characteristics of the product candidate, as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and
tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Special FDA Expedited Review and Approval Programs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA has various programs, including fast track designation, breakthrough therapy designation, orphan drug designation, accelerated approval and priority review,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical
needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the fast track program,
the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track
designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional
opportunities for interaction with the FDA&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the
FDA agrees to accept sections of the NDA and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the NDA. However, the FDA&#146;s time period goal for reviewing an
application does not begin until the last section of the NDA is submitted. The FDA may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat a
serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from the FDA on an efficient drug development program, organizational commitment to the development and review
of the product, including involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough therapy products may be eligible for accelerated approval and/or priority
review, if relevant criteria are met. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may designate a drug product as an &#147;orphan drug&#148; if it is intended to treat a
rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the
United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the
therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within
the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same
indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product
application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be
clinically superior to the approved product on the basis of greater efficacy or safety or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve
more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has
exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDA&#146;s accelerated
approval regulations, the FDA may approve a drug for a serious or life threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account
the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance requirements, including the completion of Phase 4 or
post approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post approval studies or confirm a clinical benefit during post marketing studies will allow the FDA to withdraw the drug from the market on an
expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior review by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an NDA
is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review
means that the goal for the FDA to review an application is six months, rather than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the standard review of ten months under the Prescription Drug User Fee Act, or PDUFA, guidelines. Under the current PDUFA performance goals, these six and ten month review periods are measured
from the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review from the date of submission. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that
the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or life threatening disease is required to make available, such as by posting on its website, its policy on
responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do not change the standards for approval and may not ultimately expedite the development or
approval process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>NDA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture
and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the
time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the application user fee is if the applicant
employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce and the applicant,
including its affiliates, is submitting its first marketing application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a
new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to
support dosing and administration for each pediatric subpopulation for which the product is safe and effective. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may, on its own initiative or at the
request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved
by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory
committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews applications to determine, among
other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA will
inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance
with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it
accepts the application for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has set the
review goal of 10 months from the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the application. For priority review
applications, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the FDA has set the review goal of reviewing NME NDAs within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date. Such deadlines are referred to as the PDUFA date. The
PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the
submission during the review period that amends the original application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA&#146;s review of the application is complete, the FDA will issue either a
Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in
order to secure final approval of the NDA and may require additional clinical or preclinical testing or other information or analyses in order for the FDA to reconsider the application in the future. Even with the submission of additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA may issue an approval letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may delay or refuse approval of an NDA
if applicable regulatory criteria are not satisfied, require additional testing or information, require post-marketing testing and surveillance to monitor safety or efficacy of a product and/or impose other conditions, including distribution
restrictions or other risk management mechanisms. For example, the FDA may require a REMS as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or
limit further marketing of a product or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new
indications, manufacturing changes and additional labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA
notification may be required. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may
be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a boxed warning. A boxed warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when
there is reasonable evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all labeling claims sought by an applicant. Once approved, the FDA may withdraw the product approval if compliance with <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to monitor the effect of
approved products and may limit further marketing of the product based on the results of these post-marketing studies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Post-Approval
Requirements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including periodic
reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping
and reporting requirements, including adverse experiences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After approval, most changes to the approved product, such as adding new indications or other labeling
claims are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for approved products, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their
subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance
with cGMPs and other requirements, which impose procedural and documentation requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes to the manufacturing process are strictly regulated and often
require prior FDA approval or notification before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications and impose reporting and documentation requirements upon the sponsor and
any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations,
imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions under a REMS program, among other consequences. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy that are consistent with the FDA
approved labeling. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the
FDA. However, manufacturers and third parties acting on their behalf are prohibited from marketing or promoting drugs in a manner inconsistent with the approved labeling. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to comply with any of the FDA&#146;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial
sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional
materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements,
refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also
possible that failure to comply with the FDA&#146;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer
protection laws. Any of these sanctions could result in adverse publicity, among other adverse consequences. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Marketing Exclusivity
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA provides periods of <FONT STYLE="white-space:nowrap">non-patent</FONT> regulatory exclusivity, which provides the holder of an approved NDA limited
protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#146;s approval of the NDA. Five years of exclusivity are available to new chemical
entities, or NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester,
salt, including a salt with hydrogen or coordination bonds or other noncovalent bonds not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical interaction of two compounds), chelate
(i.e., a chemical compound) or clathrate (i.e., a polymer framework that traps molecules) of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an
Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a
Paragraph IV certification is filed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulation outside the United States </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will be subject to similar foreign laws and regulations concerning the development of our product candidates outside of the United States. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Healthcare Laws </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare providers, physicians and
third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers
and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs
for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency and patient data privacy and security laws and regulations, including but not
limited to those described below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, paying, receiving or providing any remuneration (including any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
kickback, bride or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward or in return for, either the referral of an individual for, or the
purchase order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; a person or entity need not have actual knowledge of the federal
Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, which prohibit individuals
or entities from, among other things, knowingly presenting or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using or causing to be made or used a false
statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the
federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. In addition, the government
may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. The FCA also permits a private individual
acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer or
remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare
or a state health care program, unless an exception applies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for
knowingly and willfully executing a scheme or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services.
Similar to the federal Anti-Kickback Statute, a person or entity need not have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, imposes, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information including mandatory
contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in
some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#146;s Health Insurance Program, for certain payments and &#147;transfers of value&#148; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as
well as ownership and investment interests held by such physicians and their immediate family members.&nbsp;In addition, many states also require reporting of payments or other transfers of value, many of which differ from each other in significant
ways, are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT> and may have a more prohibitive effect than the Physician Payments Sunshine Act, thus further complicating compliance efforts. Effective January&nbsp;1, 2022, these reporting
obligations will extend to include transfers of value made and investment and ownership interested held in the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse
practitioners; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party-payors, including private insurers, and may be broader in scope than their federal
equivalents; state and foreign laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict
payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to drug pricing and payments and other transfers of value to physicians and other healthcare providers and
restrict marketing practices or require disclosure of marketing expenditures and pricing information; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws that govern the privacy and
security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, which may complicate compliance
efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, pharmaceutical manufacturers may also be subject to federal and state consumer protection and unfair competition laws and
regulations, which broadly regulate marketplace activities and that potentially harm consumers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of drugs and biological products is subject to
additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The full scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state
enforcement bodies have continued to increase their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It
is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our
operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment,
disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to
resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do
business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations
by government authorities, can be time- and resource-consuming and can divert a company&#146;s attention from its business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and Reimbursement
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed
services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including
government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. In the United States, no uniform
policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor
will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged,
examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary,
which might not include all of the approved products for a particular indication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to secure coverage and reimbursement for any product that might be
approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers,
private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the
product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be
approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product and the level of coverage and reimbursement can differ significantly
from payor to payor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The containment of healthcare costs has become a priority of federal, state and foreign governments and the prices of products have been a
focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage policies and
third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed
changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the
ACA, which, among other things, included changes to the coverage and payment for products under government health care programs. The ACA included provisions of importance to our potential product candidate that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for
both branded and generic drugs and revising the definition of &#147;average manufacturer price,&#148; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expanded the types of entities eligible for the 340B drug discount program; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discounts</FONT></FONT> off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the
manufacturers&#146; outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There remain numerous judicial, administrative, executive and legislative
challenges to certain aspects of the ACA. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court, and the Trump Administration has issued various Executive Orders that
eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or
biologics. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
provisions of the ACA such as removing penalties, effective as of January&nbsp;1, 2019, for not complying with the ACA&#146;s individual mandate to carry health insurance, eliminating the
implementation of certain of the ACA&#146;s mandated fees and increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in
Medicare Part D. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Cuts and Jobs Act.
Additionally, on December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the
remaining provisions of the ACA are invalid as well. On March&nbsp;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case and has allotted one hour for oral arguments, which are expected to occur
in the fall. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of
2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030
unless additional Congressional action is taken. These reductions have been suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In January 2013, the American Taxpayer
Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, payment methodologies may be subject to changes in healthcare legislation and
regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their
commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing
and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. For example, at the federal level, the Trump administration&#146;s budget proposal for fiscal year 2021 includes a
$135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients and
increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part
D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and place limits on pharmaceutical price increases. Further, the Trump administration previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of
drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs
of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using
step therapy, a type of prior authorization, for Part B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change, which was effective as of January&nbsp;1, 2019. Although a number of these and other measures may
require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from
Medicare and other government programs may result in a similar reduction in payments from private payors. In addition, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In addition, it is possible that additional governmental action is taken to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. For example, on April&nbsp;18, 2020, CMS announced that
qualified health plan issuers under the ACA&nbsp;may suspend activities related to the collection and reporting of quality data that would have otherwise been reported between May and June 2020 given the challenges healthcare providers are facing
responding to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework
for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without
enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but
the manufacturer must develop an internal policy and respond to patient requests according to that policy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outside the United States, ensuring coverage and
adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory
approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2020, we had 88 full-time employees,
including 54 employees with an M.D. and/or Ph.D. degree. Of these full-time employees, 74 employees are engaged in research and development activities and 14 are engaged in general and administrative activities. None of our employees is represented
by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We occupy approximately 45,400 square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in 2028. We believe that our facilities
are sufficient to meet our current needs for the foreseeable future and that suitable additional space will be available as and when needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of the date of this prospectus, we were not a
party to any material legal matters or claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the names and positions of our executive officers and directors, as well as their ages as of September&nbsp;13, 2020. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>AGE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>POSITION(S)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marc A. Cohen* (2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Co-Founder, Executive Chairman, Director and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Hirsch**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director, President and Chief Executive Officer-elect</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">William McKee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adam Crystal, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stewart Fisher, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jolie M. Siegel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kenneth C. Anderson, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bihua Chen***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alain J. Cohen (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce Downey (1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Elena Prokupets, Ph.D. (1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Malcolm Salter (1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of our audit committee </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of our compensation committee </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of our nominating and corporate governance committee </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Cohen will resign as our Chief Executive Officer on the day after the effectiveness of the registration statement of which this prospectus forms a part. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hirsch is our director and President and will become our Chief Executive Officer on the day after the effectiveness of the registration statement of which this prospectus forms a part. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">***</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms.&nbsp;Chen will resign from our board of directors contingent upon and effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a biographical summary of the experience of our executive officers and directors. There are no family relationships among any of our executive officers
or directors, except that Marc A. Cohen and Alain J. Cohen are siblings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Marc A. Cohen</I></B> is a <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as a member of our Board and as Executive Chairman since our
inception in October 2015. He became our Chief Executive Officer in March 2020 and will resign from such position on the day after the effectiveness of the registration statement of which this prospectus forms a part. Since December 2011,
Mr.&nbsp;Cohen has served as the Chairman and <FONT STYLE="white-space:nowrap">co-Chief</FONT> Executive Officer of Bublup, Inc., an online knowledge-sharing and organization platform, and has served as
<FONT STYLE="white-space:nowrap">co-Chief</FONT> Executive Officer of Cobro Ventures, Inc., an investment management company for technology and biotechnology companies, since October 2013. Mr.&nbsp;Cohen is also Chairman of Frequency Therapeutics,
Inc. (Nasdaq: FREQ), a regenerative medicine biotechnology company, and Executive Chairman of Mana Therapeutics, Inc., a cellular therapies biotechnology company focused on educating immune cells to target cancer, positions in which he has served
since September 2016 and January 2018, respectively. He has also served as Executive Chairman of Regenacy Pharmaceuticals, Inc., a biotechnology company, focused on diabetic and other peripheral neuropathies, since January 2016, Executive Chairman
of OncoPep, Inc., a cancer vaccine biotechnology company, since January 2010, and Executive Chairman of Raqia Therapeutics, Inc., a <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies company for cancer and other diseases, since July
2020.&nbsp;Mr.&nbsp;Cohen is also the <FONT STYLE="white-space:nowrap">co-founder</FONT> of the Dana-Farber Innovations Research Fund, a venture philanthropy fund focused on early stage research.&nbsp;Mr.&nbsp;Cohen was <FONT
STYLE="white-space:nowrap">co-founder</FONT> and served as Chief Executive Officer and Chairman of OPNET Technologies, Inc., a software company that provided performance management tools for computer networks and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applications, from 1986 through its acquisition in 2012. Mr.&nbsp;Cohen holds an M.S. in Electrical Engineering from Stanford University and an A.B. in Engineering Sciences from Harvard
University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the characteristics that qualify Mr.&nbsp;Cohen for service on our Board include his leadership experience and business judgment, his role
in leading the growth of our company since its founding and his deep knowledge of our operations and our product candidates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Andrew Hirsch</I></B> has
served as our President and a member of our Board of Directors since September&nbsp;2020 and has been elected to serve as our Chief Executive Officer effective the day after the effectiveness of the registration statement of which this prospectus
forms a part. Since May 2017, Mr.&nbsp;Hirsch has served on the board of directors of Editas Medicine, Inc. (Nasdaq: EDIT), a pharmaceutical company, and also serves as the chair of its audit committee. From September 2016 to September 2020,
Mr.&nbsp;Hirsch served as Chief Financial Officer at Agios Pharmaceuticals, Inc., a public pharmaceutical company, including as head of corporate development beginning March 2018. From March 2015 until August 2016, he served as President and Chief
Executive Officer of BIND Therapeutics, Inc., or BIND, a biotechnology company. Prior to being named President and Chief Executive Officer, Mr.&nbsp;Hirsch held several other leadership positions at BIND, including Chief Operating Officer from
February 2014 to March 2015, and Chief Financial Officer from July 2012 to March 2015. Prior to joining BIND, Mr.&nbsp;Hirsch was Chief Financial Officer at Avila Therapeutics, Inc., a biotechnology company, from June 2011 until its acquisition by
Celgene Corporation in March 2012. From 2002 to 2011, Mr.&nbsp;Hirsch held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&amp;A and program executive for the Tecfidera development team. He
holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Mr. Hirsch is qualified to
serve on our Board because of his extensive leadership and industry-specific experience in a range of strategic and operating roles in the biotech sector. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>William McKee </I></B>has served as our Chief Financial Officer since April 2020. Mr.&nbsp;McKee has also served as Chief Executive Officer of MBJC Associates,
LLC, a business consulting firm serving pharmaceutical and biotech companies, since February 2010. Mr.&nbsp;McKee served as Chief Operating Officer and Chief Financial Officer of EKR Therapeutics, Inc., from July 2010 to June 2012, when EKR was sold
to Cornerstone Therapeutics Inc., a pharmaceutical company. From January 2009 to March 2010, Mr.&nbsp;McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, Inc., a subsidiary of Teva
Pharmaceutical Industries Limited (NYSE: TEVA), or Teva. Mr.&nbsp;McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, after having served in positions of increasing responsibility at Barr
from 1995 until its acquisition. Mr.&nbsp;McKee has served as a director and chairman of the audit committee and member of the compensation committee of Assertio Therapeutics, Inc. (Nasdaq: ASRT), a specialty pharmaceutical company, since March
2017, and has served as a director and chairman of the audit committee of Aileron Therapeutics, Inc. (Nasdaq: ALRN), a biopharmaceutical company, since March 2019. Mr.&nbsp;McKee holds a B.B.A. from the University of Notre Dame. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adam Crystal, M.D., Ph.D.</I></B> has served as our Chief Medical Officer since February 2019. From May 2014 to February 2019, Dr. Crystal was a Clinical Program
Leader, Senior Director at Novartis Institutes for BioMedical Research, where he led early development trials of molecules such as Novartis AG&#146;s (NYSE:NVS) now approved CDK4/6 inhibitor ribociclib and the selective estrogen receptor degrader
LSZ102. Dr. Crystal has been an Assistant in Medicine at the Massachusetts General Hospital since 2013, where he is an oncology attending physician and was also an Instructor in Medicine at Harvard Medical School from 2013 to 2018. From 2010 to
2014, Dr. Crystal was also a laboratory-based researcher at Massachusetts General Hospital where his work on resistance mechanisms to targeted therapies was recognized with the American Society of Clinical Oncology Conquer Cancer Young Investigator
Award and was also published in <I>Science</I>. Dr. Crystal trained at Massachusetts General Hospital in internal medicine and then completed fellowship training in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana
Farber Cancer Institute in 2013. Dr. Crystal holds an M.D. and a Ph.D. in neuroscience from the University of Pennsylvania School of Medicine. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stewart
Fisher, Ph.D.</I></B> has served as our Chief Scientific Officer since May 2018 and served as our Senior Vice President, Discovery Sciences, from May 2016 to April 2018. From January 2014 to April 2016, Dr.&nbsp;Fisher was the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Director of Quantitative of Biochemistry and Enzymology at the Broad Institute, a biomedical and genomic research center, where he developed and implemented biochemical plans for therapeutic
projects. Prior to the Broad Institute, Dr.&nbsp;Fisher spent over 15 years at AstraZeneca PLC (NYSE: AZN), a research-based biopharmaceutical company, where he was the Executive Director of Infection Bioscience. Dr.&nbsp;Fisher started his
industrial career at Hoffmann LaRoche as a Research Scientist from August 1996 to August 1998 in the Department of Metabolic Diseases in Nutley, New Jersey. Dr.&nbsp;Fisher holds a B.A. in Chemistry from the University of Vermont, a Ph.D. in Organic
Chemistry from the California Institute of Technology and completed his academic training as an NIH Postdoctoral Fellow at the Harvard Medical School. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jolie M. Siegel</I></B> has served as our Chief Legal Officer since July 2020. In June 2020, Ms.&nbsp;Siegel served as our Interim Chief Legal Officer in a
consulting capacity. From August 2018 to May 2020, Ms.&nbsp;Siegel served as Vice President, General Counsel and Secretary of Neon Therapeutics, Inc. (as subsequently acquired by BioNTech SE (Nasdaq: BNTX) in May 2020), an immune oncology company,
where she was responsible for legal, intellectual property and corporate compliance matters. Ms.&nbsp;Siegel also provided consulting legal services to Neon between March and August 2018. From February 2013 to April 2017, Ms.&nbsp;Siegel served as
Senior Vice President, Deputy General Counsel and Assistant Secretary of Intralinks Holdings, Inc. (NYSE: IL, as subsequently acquired by Synchronoss Technologies, Inc. (Nasdaq: SNCR) in January 2017), a technology provider for the global financial
and capital markets communities. In this role, Ms.&nbsp;Siegel was responsible for corporate governance, compliance, public company reporting, mergers and acquisition, marketing and finance matters. From 2007 to 2013, Ms.&nbsp;Siegel was a partner
at Choate, Hall&nbsp;&amp; Stewart LLP, a law firm, where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high-growth companies. From 2005 to 2007,
Ms.&nbsp;Siegel was an associate at Choate and, from 2001 to 2005, Ms.&nbsp;Siegel was an associate at Testa, Hurwitz&nbsp;&amp; Thibeault, LLP, where she was a member of the business practice group. Ms.&nbsp;Siegel holds a J.D. from the University
of Pennsylvania Law School and a B.A. in political science from the University of Pennsylvania. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Kenneth C. Anderson, M.D. </I></B>is our co-founder and has served as our director since December 2015. Dr.&nbsp;Anderson has also served as the Kraft
Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively.
Dr.&nbsp;Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr.&nbsp;Anderson holds an M.D. from Johns Hopkins Medical School,
where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe
that Dr.&nbsp;Anderson is qualified to serve on our Board because of his experience, qualifications, attributes and skills, including his extensive experience in the life sciences industry. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Bihua Chen </I></B>has served as our director since December 2015. Ms.&nbsp;Chen is the founder of Cormorant Asset Management, LP, or Cormorant, an investment
firm focused on innovative biotechnology, medical technology and life science companies with assets under management of over $2&nbsp;billion. Ms.&nbsp;Chen manages Cormorant&#146;s hedge fund, as well as its private equity funds. Prior to founding
Cormorant, Ms.&nbsp;Chen managed a separately managed account focused on the healthcare sector as a <FONT STYLE="white-space:nowrap">sub-adviser</FONT> to a large, multi-strategy hedge fund based in New York. Previously, Ms.&nbsp;Chen was a
healthcare analyst/sector portfolio manager for American Express Asset Management, Boston. Ms.&nbsp;Chen has also served as a portfolio manager for the Asterion Life Science Fund from 2001-2002, an equity analyst/portfolio manager for Bellevue
Research from 2000-2001 and an equity analyst for Putnam Investments from 1998-2001. Ms.&nbsp;Chen holds an M.B.A. from the Wharton School of Business and an M.S. in Molecular Biology, from the Graduate School of Biomedical Science at Cornell
Medical College. Ms.&nbsp;Chen also holds a B.S. in Genetics and Genetic Engineering from Fudan University, Shanghai, China. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Ms.&nbsp;Chen is
qualified to serve on our Board because of her experience, qualifications, attributes and skills, including her global pharmaceutical industry experience and her tenure as an investment manager. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Alain J. Cohen </I></B>has served as our director since December 2015. Since October 2013, Mr.&nbsp;Cohen has been the Chief Executive Officer of Cobro Ventures,
Inc., an investment management company for technology and biotechnology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
companies. Since December 2011, Mr.&nbsp;Cohen has also been <FONT STYLE="white-space:nowrap">co-Chief</FONT> Executive Officer of Bublup, Inc., an online knowledge-sharing and organization
platform. Mr.&nbsp;Cohen also serves on the board of directors of Mana Therapeutics, Inc., a cellular therapies biotechnology company focused on educating immune cells to target cancer. In 1986, Mr.&nbsp;Cohen
<FONT STYLE="white-space:nowrap">co-founded</FONT> and served as President and Chief Technology Officer of OPNET Technologies, Inc., a software company that provided performance management tools for computer networks and applications, through its
acquisition in 2012. Mr.&nbsp;Cohen holds a B.S. in Electrical Engineering from the Massachusetts Institute of Technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Mr.&nbsp;Cohen is
qualified to serve on our Board because of his experience, qualifications, attributes and skills, including his extensive business experience and knowledge of the life sciences industry. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Bruce Downey</I></B> has served as our director since December 2015. From 1994 to 2008, Mr.&nbsp;Downey was Chairman and Chief Executive Officer of Barr
Pharmaceuticals, Inc. (until its acquisition by Teva in 2008), a global generic pharmaceutical manufacturer. Mr.&nbsp;Downey has served on a part-time basis as a Partner of NewSpring Health Capital II, L.P., a venture capital firm, since April 2009.
Prior to Barr Pharmaceuticals, Mr.&nbsp;Downey was a practicing attorney for 20 years, working in both the private sector and for the federal government, including the U.S. Department of Justice and the U.S. Department of Energy. In addition,
Mr.&nbsp;Downey has served on the boards of directors of OncoPep, Inc., a biotechnology company, Cardinal Health, Inc. (NYSE: CAH), a healthcare services company and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company, since April
2011, July 2009 and June 2009, respectively. Mr.&nbsp;Downey previously served on the board of directors of Melinta Therapeutics, Inc. (Nasdaq: MLNT), a biopharmaceutical firm, from October 2018 until April 2020. Mr.&nbsp;Downey holds a B.S. in
Economics from Miami University and a J.D. from Ohio State University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Mr.&nbsp;Downey is qualified to serve on our Board because of his
experience, qualifications, attributes and skills, including his global pharmaceutical industry experience. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Elena Prokupets, Ph.D. </I></B>has served as
our director since December 2015. Dr. Prokupets co-founded Lenel Systems International, a security software company, in 1991 and served as its President, CEO and Chairwoman of the Board until its sale to United Technology Corporation in 2005. Dr.
Prokupets also co-founded and led Edicon Systems (a division of Eastman Kodak Company) from 1985 to 1990. Dr. Prokupets was on the board of directors of Acetylon Pharmaceuticals, Inc., a pharmaceutical company, from August 2009 until its sale to
Celgene Corporation, a subsidiary of Bristol-Myers Squibb (NYSE:BMY), in December 2016, and currently serves on the boards of directors of Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, and OncoPep, Inc., a biotechnology
company that specializes in the development of targeted immunotherapeutics for the treatment of cancer. She is a Trustee of the University of Rochester and the Managing Director of the Metropolitan Opera of New York. Ms. Prokupets holds an M.S. in
Electrical Engineering and a Ph.D. in Computer Science from Saint Petersburg Electrotechnical University, Russia. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Dr.&nbsp;Prokupets is
qualified to serve on our Board because of her experience, qualifications, attributes and skills, including her extensive investment experience in the life sciences and her service as a director of other publicly traded companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Malcolm Salter </I></B>has served as our director since December 2015. Mr.&nbsp;Salter is the James J. Hill Professor, Emeritus, at the Harvard Business School.
Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. From 1986 to 2006, he served as president of Mars&nbsp;&amp; Co., a global strategy-consulting firm.
Mr.&nbsp;Salter is a Trustee of the Dana-Farber Cancer Institute. Mr.&nbsp;Salter holds an A.B., M.B.A,. and a D.B.A. from Harvard University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that
Mr.&nbsp;Salter is qualified to serve on our Board because of his business background and extensive corporate leadership experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors currently consists of seven members. After the completion of this offering, the number of directors will be fixed by our board of directors,
subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Each of our current directors will continue to serve as a director until the election and qualification of his or her successor or until
his or her earlier death, resignation or removal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of
factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is identification of persons who will further the
interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive
landscape, professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until their earlier resignation or removal. Our amended and restated
certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of
the votes that all our stockholders would be entitled to cast in an annual election of directors and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote
of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Classified Board </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
accordance with the terms of our amended and restated certificate of incorporation and our amended and restated bylaws that will become effective upon the closing of this offering, our board of directors will be divided into three classes of
directors and each director will be assigned to one of the three classes. At each annual meeting of the stockholders, one class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then
expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2021 for Class&nbsp;I directors, 2022 for Class&nbsp;II directors and 2023
for Class&nbsp;III directors. Our current directors will be divided among the three classes as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Class&nbsp;I directors will be Marc A. Cohen and Kenneth C. Anderson; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Class&nbsp;II directors will be Alain J. Cohen and Bruce Downey; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Class&nbsp;III directors will be Malcolm Salter, Elena Prokupets and Andrew Hirsch. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering will provide that the
number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The division of our board of directors into
three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director
Independence </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to list our common stock on The Nasdaq Global Market. Under the Nasdaq listing rules, independent directors must comprise a majority of
a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating
and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq
listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to be independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act and under the rule of Nasdaq, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept,
directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2)&nbsp;be an affiliated person of the listed company or any of its
subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically
relevant to determining whether a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member,
including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its
subsidiaries or affiliates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors undertook a review of the composition of our board of directors and its committees and the independence of
each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that all members of our board of
directors, except for Andrew Hirsch, Marc&nbsp;A. Cohen and Alain&nbsp;J. Cohen, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these
directors is &#147;independent&#148; as that term is defined under the rules of Nasdaq. Marc A. Cohen will resign as our interim Chief Executive Officer on the day after the effectiveness of the registration statement of which this prospectus forms
a part. Our board of directors has determined that, at that point, directors Marc&nbsp;A. Cohen and his sibling Alain&nbsp;J. Cohen shall be deemed &#147;independent&#148; as well. In making these determinations, our board of directors considered
the relationships that each director has with us and all other facts and circumstances the board of directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our capital stock by each director,
including <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that are affiliated with certain of our major stockholders. Upon the completion of this offering and after the completion of the transition periods thereunder, we expect that
the composition and functioning of our board of directors and each of our committees will comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC after the completion of the transition periods thereunder. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no family relationships among any of our directors or executive officers, other than between our <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Executive
Chairman, Director, and interim Chief Executive Officer, Marc A. Cohen, and our director Alain J. Cohen, who are siblings. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board in Risk
Oversight </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of
directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. The compensation committee is responsible for overseeing the management of
risks relating to our executive compensation plans and arrangements. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial reporting. The corporate governance and nominating committee
is responsible for overseeing the management of risks associated with the independence of our board of directors and potential conflicts of interest. Although each committee is responsible for evaluating certain risks and overseeing the management
of such risks, our entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected the board
of directors&#146; leadership structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of
directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities described below. Each committee will operate pursuant to a charter
to be adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which this prospectus forms a part. We believe that the composition and functioning of all of our committees will comply with the
applicable requirements of Nasdaq, the Sarbanes-Oxley Act of 2002 and SEC rules and regulations that will be applicable to us. Our board of directors may from time to time establish other committees. We intend to comply with future requirements to
the extent they become applicable to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, the full text of our audit committee charter, compensation committee charter and
nominating and corporate governance charter will be posted on the investor relations portion of our website at https://www.c4therapeutics.com. We do not incorporate the information contained on or accessible through our corporate website into this
prospectus, and you should not consider it a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
the effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist of Malcolm Salter, Bruce Downey and Elena Prokupets and will be chaired by&nbsp;Mr.&nbsp;Salter. The functions of the audit
committee will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing, approving the compensation of and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq listing rules.
Our board of directors has determined that Mr.&nbsp;Salter qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC regulations. In making this determination, our board of directors considered the nature and
scope of experience that Mr.&nbsp;Salter has previously had with public reporting companies, including prior consulting experience, prior service as our Audit Committee chair where he oversaw our audits, and his position as professor at Harvard
Business School since 1967 (now Emeritus). Our board of directors has determined that all of the directors that will become members of our audit committee upon the effectiveness of the registration statement of which this prospectus forms a part
satisfy the relevant independence requirements for service on the audit committee set forth in the rules of the SEC and the Nasdaq listing rules. Both our independent registered public accounting firm and management will periodically meet privately
with our audit committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the
effectiveness of the registration statement of which this prospectus forms a part, our compensation committee will consist of Marc&nbsp;A. Cohen, Alain&nbsp;J. Cohen and Bruce Downey, and will be chaired by Marc&nbsp;A. Cohen. The functions of the
compensation committee upon the completion of this offering, will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on
such evaluation (i)&nbsp;reviewing and determining the cash compensation of our Chief Executive Officer and (ii)&nbsp;reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending to the board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and when
required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each member of our compensation committee, other than Marc&nbsp;A. Cohen, will be a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Code.
Marc&nbsp;A. Cohen will resign as our interim Chief Executive Officer on the day after the effectiveness of the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the effectiveness
of the registration statement of which this prospectus forms a part, our nominating and corporate governance committee will consist of Marc&nbsp;A. Cohen, Bruce Downey and Elena Prokupets and will be chaired by Mr.&nbsp;Cohen. The functions of the
nominating and corporate governance committee will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to the board of directors criteria for board and committee membership, including a priority in
selecting board members who exhibit a record of professional accomplishment, an understanding of the competitive challenges facing our business and industry and experience that will foster growth into a clinical-stage pharmaceutical company;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate
skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except for Marc
A. Cohen, who is our interim Chief Executive Officer, director and a member of our compensation committee, none of the members of our compensation committee is, or has been at any time during the prior three years, an officer or employee of our
company. Each of Marc&nbsp;A. Cohen, who is our interim Chief Executive Officer, director and member of our compensation committee, and Alain&nbsp;J. Cohen, who is our director and member of our compensation committee, serve as co-Chief Executive
Officers and directors of Bublup, Inc. and Cobro Ventures, Inc. None of our other executive officers currently serve, or have in the past fiscal year served, as a member of the board of directors or compensation committee (or other board committee
performing equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee.
Marc&nbsp;A. Cohen will resign as our interim Chief Executive Officer on the day after the effectiveness of the registration statement of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors intends to adopt, subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a part, a Code of
Business Conduct and Ethics in connection with this offering. The Code of Business Conduct and Ethics will apply to all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal
accounting officer or controller or persons performing similar functions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to disclose future amendments to certain provisions of our Code of Business
Conduct and Ethics and our Code of Ethics on our website identified below. Upon the completion of this offering, the full text of our Code of Business Conduct and Ethics and our Code of Ethics will be posted on our website at
https://www.c4therapeutics.com. Information contained on our website is not incorporated by reference into this prospectus and should not be considered to be a part of this prospectus or the registration statement of which it forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations on Liability and Indemnification Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by
Delaware law, provisions in our amended and restated certificate of incorporation and amended and restated bylaws, both of which will become effective upon the closing of this offering, limit or eliminate the personal liability of directors for a
breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, a director exercise an informed business judgment based on all material information reasonably available to him
or her. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek <FONT STYLE="white-space:nowrap">non-monetary</FONT>
relief, such as injunctive relief or rescission. These provisions will not alter a director&#146;s liability under other laws, such as the federal securities laws or other state or federal laws. Our amended and restated certificate of incorporation
that will become effective upon the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As permitted by Delaware law, our amended and restated bylaws to be effective upon the closing of this offering will
provide that: </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted under Delaware law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we must advance expenses to our directors and officers and may advance expenses to our employees and other agents, in
connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability of our
directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other
agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our bylaws permit such indemnification. We have obtained such insurance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the indemnification that will be provided for in our amended and restated certificate of incorporation and amended and restated bylaws, we plan to enter
into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements may
require us, among other things, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in
any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary
to attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This description of the indemnification provisions of our amended and
restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of which
this prospectus forms a part. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and
controlling persons pursuant to the foregoing provisions or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or
threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This section discusses the material elements of our executive compensation policies and decisions and important factors relevant to an analysis of these policies and
decisions. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and is intended to place in perspective the information presented in the following tables
and the corresponding narrative. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officers for the year ended December&nbsp;31, 2019, which consist of our principal executive officer and the
next two most highly compensated executive officers, are: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Andrew Phillips, Ph.D., our former President and Chief Executive Officer, whose employment was terminated on March&nbsp;3,
2020; </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adam Crystal, M.D., Ph.D., our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Stewart Fisher, Ph.D., our Chief Scientific Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Elements of Executive Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Base Salaries.</I> Base salaries for
the named executive officers are determined annually by the board of directors, based on the scope of each officer&#146;s responsibilities and with due consideration of the officer&#146;s respective experience and contributions during the prior
year. When reviewing base salaries, the board of directors takes factors into account such as each officer&#146;s experience and individual performance, our performance as a whole, data from surveys of compensation paid by comparable companies and
general industry conditions, but does not assign any specific weighting to any factor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Annual Cash Bonuses.</I> Our named executive officers participate in an
annual cash bonus program, which promotes and rewards the executives for the achievement of key strategic and business goals. During fiscal year 2019, Dr.&nbsp;Phillips was eligible to receive a target bonus equal to 50% of his base salary and each
of Drs. Crystal and Fisher was eligible to receive a target bonus equal to 35% of his respective base salary, based upon achievement of corporate performance goals. For 2019, our corporate performance goals included clinical development, financing
and strategic partnership targets that would support our growth into a clinical stage company. Following the end of the fiscal year, it was determined that 100% of the corporate performance goals for 2019 had been met. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Equity Awards.</I> Our board of directors believes that equity grants provide executives with a strong link to long-term performance, create an ownership culture and
help to align the interests of executive officers and our stockholders. Accordingly, our board of directors periodically reviews the equity incentive compensation of the named executive officers and, from time to time, may grant equity incentive
awards to them. During fiscal year 2019, we granted options to purchase shares of our common stock to Drs. Phillips and Crystal, as described in more detail in the &#147;<I>Outstanding Equity Awards at Fiscal 2019</I><I></I><I><FONT
STYLE="white-space:nowrap">&nbsp;Year-End</FONT></I>&#148; table below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Benefits.</I> Our named executive officers are eligible for additional benefits,
such as participation in our 401(k) plan and basic health benefits that are generally available to all of our employees, subject to the terms of those plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table sets forth information regarding compensation awarded to, earned by or paid to each of our named executive officers for the year ended December&nbsp;31, 2019. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND PRINCIPAL POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BONUS<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-EQUITY</FONT><BR>INCENTIVE<BR>PLAN<BR>COMPENSATION<BR>($)
<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Phillips, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Former President&nbsp;&amp; Chief</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Executive Officer <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">520,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,377,316</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36,359</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,193,675</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adam Crystal, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">344,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,118,835</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">120,488</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,373</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,689,946</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stewart Fisher, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">340,313</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">119,110</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,330</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">465,753</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts represent the aggregate grant date fair value of stock options granted in 2019, computed in accordance with FASB ASC Topic 718 without including any estimates of forfeitures. The assumptions used in
calculating the grant date fair value of the stock options reported in the Option Awards column are set forth in Note 9 to our financial statements for the year ended December&nbsp;31, 2019 included elsewhere in this registration statement. Note
that the amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by the named executive officers from the options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported reflect annual bonuses paid to our named executive officers in 2019 based on achievement of corporate performance goals. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column reflect (i)&nbsp;in the case of Dr.&nbsp;Phillips, $21,019 in commuting costs and $8,838 reimbursement for taxes related to such commuting costs, $6,000 in 401(k) matching
contributions and a $502 payment reflecting the amount of payroll taxes required to be contributed by the Massachusetts Family Medical Leave Act, which we have elected to pay on behalf of each of our employees, or MFMLA Contributions; (ii) in the
case of Dr.&nbsp;Crystal, $6,000 in 401(k) matching contributions and $373 in MFMLA Contributions; and (iii)&nbsp;in the case of Dr.&nbsp;Fisher, $6,000 in 401(k) matching contributions and $330 in MFMLA Contributions. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Phillips&#146; employment terminated on March&nbsp;3, 2020. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Crystal&#146;s employment commenced on February&nbsp;14, 2019. The salary reported for Dr.&nbsp;Crystal reflects the salary earned following his start date. Dr.&nbsp;Crystal&#146;s <FONT
STYLE="white-space:nowrap">non-equity</FONT> incentive plan compensation was prorated to reflect his partial year of service in 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amount reflects an aggregate signing bonus equal to $100,000. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal <FONT
STYLE="white-space:nowrap">Year-End</FONT> 2019 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information concerning outstanding equity awards for each of the named executive
officers as of December&nbsp;31, 2019. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION AWARDS<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GRANT DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>VESTING<BR>COMMENCEMENT<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>UNEXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Phillips, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/10/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Former President &amp; Chief</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/24/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/24/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/17/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/09/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/16/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adam Crystal, M.D., Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/09/2019</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/14/19</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">172,292</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/8/2029</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stewart Fisher, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/13/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/02/16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/12/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/24/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/01/18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All options were granted pursuant to our 2015 Plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">12.5% of this option vested on the first anniversary of the vesting commencement date, subject to the named executive officer&#146;s continuous service relationship through such date, with the remainder vesting in 28
equal quarterly installments thereafter, subject to the named executive officer&#146;s continuous service relationship through each such date. In the event of a change in control, all shares subject to this option accelerate and vest in full.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,623 of the shares subject to this option vested on the first anniversary of the vesting commencement date, subject to the named executive officer&#146;s continuous service relationship through such date. Thereafter,
32,365 of the shares subject to this option vest in 28 equal quarterly installments, with the remaining shares vesting on January&nbsp;1, 2024, subject to the named executive officer&#146;s continuous service relationship through each such date. In
the event of a change in control, all shares subject to this option accelerate and vest in full. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">16,779 of the shares subject to this option vested on the first anniversary of the vesting commencement date, subject to the named executive officer&#146;s continuous service relationship through such date, with the
remainder vesting in 27 equal quarterly installments thereafter, subject to the named executive officer&#146;s continuous service relationship through each such date. In the event of a change in control, all shares subject to the option accelerate
and vest in full. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">347,790 of the shares vest in four equal quarterly installments following the vesting commencement date, subject to the named executive officers&#146; continuous service relationship through each such date. The
remaining 172,293 shares vest upon the seventh anniversary of the vesting commencement date, subject to named executive officer&#146;s continuous service relationship, provided that such options may be subject to acceleration upon achievement of
specified performance conditions. In the event of a Sale Event (as defined in the 2015 Plan), all shares subject to the option accelerate and vest in full. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% of the option vests on the first anniversary of the vesting commencement date, subject to the named executive officer&#146;s continuous service relationship through such date, with the remainder vesting in 16 equal
quarterly installments thereafter, subject to the named executive officer&#146;s continuous service relationship through such date. In the case of a Sale Event, Dr.&nbsp;Crystal&#146;s option will accelerate and vest in full. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">20% of the option vests on the first anniversary of the vesting commencement date, subject to the named executive officer&#146;s continuous service relationship through such date, with the remainder vesting in 16 equal
quarterly installments thereafter, subject to the named executive officer&#146;s continuous service relationship through such date. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment
Arrangements with our Named Executive Officers </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We initially entered into an offer letter with each of the named executive officers in connection with his
employment with us, which set forth the terms and conditions of his employment. Each named executive officer also entered into our standard confidentiality and inventions assignment agreement. We intend to enter into new employment agreements with
our named executive officers upon the completion of this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Andrew Phillips, Ph.D. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective as of March&nbsp;2020, Dr.&nbsp;Phillips&#146; employment was terminated. In connection with the termination of his employment, we entered into a separation
agreement with Dr.&nbsp;Phillips pursuant to which Dr.&nbsp;Phillips provided a general release of claims in favor of us and we agreed to provide to Dr.&nbsp;Phillips the following severance payments and benefits: (i)&nbsp;base salary continuation
at 100% of his final base salary ($546,000 annually) for 12 months, plus base salary continuation at 50% of his final base salary for an additional six months; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> annual bonus assuming
target performance in an amount equal to $52,500; and (iii)&nbsp;if Dr.&nbsp;Phillips elected continuation of health coverage under COBRA, continued health coverage at the same rate in effect for our active employees until the earlier of 12 months
following his termination, the date he becomes eligible for group health benefits with another employer or the end of Dr.&nbsp;Phillips&#146; COBRA health continuation period. In addition, we repurchased 23,714 shares of our common stock from
Dr.&nbsp;Phillips at a purchase price of $0.62 per share and, in exchange for the cancellation of all of his vested options that were outstanding and unexercised as of his date of termination, we paid Dr.&nbsp;Phillips a cash amount per vested share
equal to the excess of $0.62 over the applicable option exercise price. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adam Crystal, M.D., Ph.D. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2019, we entered into an offer letter with Dr.&nbsp;Crystal in connection with him joining us as our Chief Medical Officer on February&nbsp;14, 2019.
Dr.&nbsp;Crystal&#146;s annual base salary is $390,000, with a signing bonus of $100,000 and a target annual bonus of 35% of his annual base salary. Dr.&nbsp;Crystal&#146;s annual base salary and annual bonus were
<FONT STYLE="white-space:nowrap">pro-rated</FONT> based on his employment commencement date. Additionally, Dr.&nbsp;Crystal is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of Dr.&nbsp;Crystal&#146;s offer letter, in the event that his employment is terminated by us without &#147;cause&#148; (as defined in his offer
letter) or Dr.&nbsp;Crystal resigns for &#147;good reason&#148; (as defined in his offer letter), we have agreed to pay Dr.&nbsp;Crystal an amount equal to six months of his base salary in effect at the time of his termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Dr.&nbsp;Crystal has executed an Employee Confidentiality,
<FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and Assignment Agreement which contain certain restrictive covenants, including, among other things, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during the
term of Dr.&nbsp;Crystal&#146;s employment and for one year thereafter. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stewart Fisher, Ph.D. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2016, we entered into an offer letter with Dr.&nbsp;Fisher under which he joined us as our Senior Vice President, Discover Sciences on May&nbsp;2, 2016.
Effective as of May 2018, Dr.&nbsp;Fisher was promoted to be our Chief Scientific Officer. Dr.&nbsp;Fisher&#146;s annual base salary is $359,494 and he is eligible to receive a target annual bonus of 35% of his annual base salary. Additionally,
Dr.&nbsp;Fisher is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition,
Dr.&nbsp;Fisher has executed an Employee Confidentiality and Assignment Agreement which contain certain restrictive covenants, including, among other things, <FONT STYLE="white-space:nowrap">non-competition</FONT> and
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions that apply during the term of Dr.&nbsp;Fisher&#146;s employment and for one year thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements with Executive Officers in connection with the IPO </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Agreement with Andrew Hirsch </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into an employment agreement
with Mr.&nbsp;Hirsch in September 2020. Mr.&nbsp;Hirsch&#146;s employment agreement sets forth his annual base salary of $560,000, the terms of his discretionary annual bonus, which is based on a target of 55% of his then current base salary, the
terms of his employment, the terms of his new hire equity award, certain expense reimbursements, and his eligibility to participate in our benefit plans generally. Pursuant to the his employment agreement, in the event that Mr.&nbsp;Hirsch&#146;s
service relationship with the company is terminated without &#147;cause&#148; (as defined in his employment agreement) or upon his resignation from the company for &#147;good reason&#148; (as defined in his employment agreement), in either case
other than in connection with a &#147;change in control&#148; (as defined in his employment agreement), subject to the execution of an effective release of claims in favor of the company, he will be entitled to the following severance benefits:
(i)&nbsp;continued base salary for a period of twelve months based on his then current base salary; (ii)&nbsp;an amount equal to the pro rata portion of his annual target bonus for the then-current year based on the number of days of such fiscal
year that he provided services to us; and (iii)&nbsp;up to twelve months of COBRA premiums reimbursements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon termination of Mr.&nbsp;Hirsch&#146;s service
relationship by the company without cause or upon his resignation from the company for good reason, in either case within 18&nbsp;months after the occurrence of a change in control, subject to the execution of an effective release of claims in favor
of the company, he will be entitled to the following severance benefits: (i)&nbsp;a lump sum payment equal to one and one-half (1.5) times his then current base salary or the base salary in effect immediately prior to the change in control, if
higher; (ii)&nbsp;an amount equal to one and one-half (1.5) times his annual target bonus for the then-current year or his target bonus immediately prior to the change in control, if higher; (iii)&nbsp;up to 18&nbsp;months of COBRA premiums
reimbursements; and (iv)&nbsp;immediate and full acceleration of all stock options and other stock-based awards held by him. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, Mr.&nbsp;Hirsch has
entered into an agreement with us that contains protections of confidential information, requires the assignment of inventions and contains other restrictive covenants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Agreements with our Other Named Executive Officers </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into new
employment agreements with each of Dr.&nbsp;Crystal and Dr.&nbsp;Fisher, which replace their existing offer letters. These new employment agreements provide for Dr.&nbsp;Crystal&#146;s and Dr.&nbsp;Fisher&#146;s continued employment and set forth
their new annual base salary of $420,000 and $420,000, respectively, the terms of their discretionary annual bonuses, which are set at targets of 40% of their respective then current base salaries, the terms of their employment, certain expense
reimbursements, and their eligibility to participate in our benefit plans generally. Pursuant to the new employment agreements, in the event that such named executive officer&#146;s service relationship with the company is terminated without
&#147;cause&#148; (as defined in his employment agreement) or upon such named executive officer&#146;s resignation from the company for &#147;good reason&#148; (as defined in his employment agreement), in either case other than in connection with a
&#147;change in control&#148; (as defined in his employment agreement), subject to the execution of an effective release of claims in favor of the company, he will be entitled to the following severance benefits: (i)&nbsp;continued base salary for a
period of twelve months based on his then current </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
base salary; (ii)&nbsp;at the discretion of our board of directors and upon the recommendation of our compensation committee, an amount equal to the pro rata portion of his annual target bonus
for the then-current year based on the number of days of such fiscal year that such named executive officer provided services to the Company; and (iii)&nbsp;up to twelve months of COBRA premiums reimbursements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the termination of Dr.&nbsp;Crystal&#146;s or Dr.&nbsp;Fisher&#146;s service relationship by the company without cause or upon such named executive officer&#146;s
resignation from the company for good reason, in either case within 12&nbsp;months after the occurrence of a change in control, subject to the execution of an effective release of claims in favor of the company, such named executive officer will be
entitled to the following severance benefits: (i)&nbsp;a lump sum payment equal to 12&nbsp;months of his then current base salary or the base salary in effect immediately prior to the change in control, if higher; (ii)&nbsp;an amount equal to his
annual target bonus for the then-current year or his target bonus immediately prior to the change in control, if higher; (iii)&nbsp;up to 12&nbsp;months of COBRA premiums reimbursements; and (iv)&nbsp;immediate acceleration of all stock options and
other stock-based awards held by such named executive officer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, each of Dr.&nbsp;Crystal and Dr.&nbsp;Fisher has entered into an agreement with us that
contains protections of confidential information, requires the assignment of inventions and contains other restrictive covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employee Benefit Plans
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2015 Stock Option and Grant Plan </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2015 Plan was
approved by our board of directors and our stockholders on December&nbsp;28, 2015 and was most recently amended by our board of directors in May&nbsp;19, 2020 and approved by our stockholders in June 3, 2020. Under our 2015 Plan, we have reserved
for issuance an aggregate of 5,058,202&nbsp;shares of our common stock as of June&nbsp;30, 2020, which number is subject to adjustment in the event of a reorganization, stock split, reverse stock split, stock dividend, recapitalization,
reclassification or other similar change in capitalization or event. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares of common stock underlying any awards that are forfeited, cancelled,
reacquired by us prior to vesting, satisfied without the issuance of common stock or otherwise terminated (other than by exercise) and shares that are withheld upon exercise of an option or settlement of an award to cover the exercise price or tax
withholding under our 2015 Plan are currently added to the shares of common stock available for issuance under our 2015 Plan. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following this offering, these types
of shares will be added to the shares available under our 2020 Plan, which is described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee has acted as administrator of our 2015
Plan. The administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and to determine the specific terms and conditions of each award, subject to the provisions of our 2015
Plan. Persons eligible to participate in our 2015 Plan are our full or part-time officers, employees, directors, consultants and other key persons as selected from time to time by the administrator in its discretion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2015 Plan permits the granting of (1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and
(2)&nbsp;options that do not so qualify. The option exercise price of each option is determined by the administrator but may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option is fixed by
the administrator and may not exceed ten years from the date of grant. The administrator determines at what time or times each option may be exercised. In addition, our 2015 Plan permits the granting of restricted shares of common stock,
unrestricted shares of common stock and restricted stock units. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2015 Plan provides that upon the occurrence of a &#147;sale event,&#148; as defined in our 2015
Plan, all outstanding stock options will terminate at the effective time of such sale event, unless the parties to the sale event agree that such awards will be assumed or continued by the successor entity. In the event of a termination of our 2015
Plan and all options issued thereunder in connection with a sale event, optionees will be provided an opportunity to exercise options that are then exercisable or will become exercisable as of the effective time of the sale event prior to the
consummation of the sale event. In addition, we have the right to provide for cash payment to holders of options, in exchange for the cancellation thereof, in an amount equal to the difference between the value of the consideration payable per share
of common stock in the sale event and the per share exercise price of such options, multiplied by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the number of shares subject to such option to the extent then vested and exercisable. In the event of and subject to the consummation of a sale event, unvested restricted stock and restricted
stock units (other than those becoming vested as a result of the sale event) will be forfeited immediately prior to the effective time of a sale event unless such awards are assumed or continued by the successor entity. If shares of restricted stock
are forfeited in connection with a sale event, those shares of restricted stock shall be repurchased at a price per share equal to the original per share purchase price of such shares. We have the right to provide for cash payment to holders of
restricted stock or restricted stock units, in exchange for the cancellation thereof, in an amount per share equal to the value of the consideration payable per share of common stock in the sale event. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The board of directors may amend or discontinue the 2015 Plan at any time, subject to stockholder approval where required by applicable law. The administrator of the
2015 Plan may also amend or cancel any outstanding award, provided that no amendment to an award may adversely affect a participant&#146;s rights without his or her consent. The administrator of the 2015 Plan is specifically authorized to exercise
its discretion to reduce the exercise price of outstanding stock options or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No awards may be granted under our 2015 Plan after the date that is ten years from the date our 2015 Plan was adopted by the board of directors. Our board of directors
has determined not to make any further awards under our 2015 Plan following the completion of this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2020 Stock Option and Incentive Plan
</I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2020 Stock Option and Incentive Plan, or 2020 Plan, was adopted by our board of directors on September&nbsp;8, 2020 and approved by our
stockholders on September&nbsp;23, 2020 and will become effective on the day immediately prior to the effective date of our registration statement related to this offering. The 2020 Plan will replace the 2015 Plan, as our board of directors is
expected to determine not to make additional awards under the 2015 Plan following the completion of our initial public offering. However, the 2015 Plan will continue to govern outstanding equity awards granted thereunder. The 2020 Plan will allow
the compensation committee to make equity-based incentive awards to our officers, employees, directors and other key persons, including consultants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized
Shares.</I> A total of 6,567,144 shares of our common stock will be initially reserved for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the 2020 Plan will
automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2021, by the lesser of 5% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by
the administrator of the 2020 Plan. This number will be subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The shares we issue under the 2020 Plan will be authorized but unissued shares or
shares that we reacquire. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting,
satisfied without the issuance of stock, expire or are otherwise terminated, other than by exercise, under the 2020 Plan and the 2015 Plan will be added back to the shares of common stock available for issuance under the 2020 Plan. The maximum
number of shares of common stock that may be issued as incentive stock options in any one calendar year period may not exceed 6,567,144&nbsp;shares,&nbsp;cumulatively increased on January&nbsp;1, 2021 and on each January&nbsp;1 thereafter by the
lesser of&nbsp;5% of the number of outstanding shares of common stock as of the immediately preceding December&nbsp;31, or 6,567,144&nbsp;shares. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Limit</I>. Our 2020 Plan contains a limitation whereby the value of all awards under our 2020 Plan and all other cash compensation paid by us to any
<FONT STYLE="white-space:nowrap">non-employee</FONT> director during any one calendar year may not exceed $750,000, provided, however, that such amount shall be $1,500,000 for the calendar year in which the applicable
<FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration.</I> The 2020
Plan will be administered by our compensation committee. Our compensation committee will have full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to
participants and to determine the specific terms and conditions of each award, subject to the provisions of the 2020 Plan. The plan administrator is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock
options and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants.</FONT><B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligibility.</I> Persons eligible to participate in the 2020 Plan will be those employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and consultants selected from time to time by our compensation committee in its discretion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock
Options.</I> The 2020 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option
will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of grant unless the option is granted (i)&nbsp;pursuant to a transaction described in and in a manner consistent
with, Section&nbsp;424(a) of the Code or (ii)&nbsp;to individuals who are not subject to U.S. income tax. The term of each option will be fixed by our compensation committee and may not exceed 10&nbsp;years from the date of grant. Our compensation
committee will determine at what time or times each option may be exercised. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights.</I> Our compensation committee may award stock
appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock or cash, equal to the value of the appreciation in our stock price over the exercise
price. The exercise price may not be less than 100% of the fair market value of our common stock on the date of grant. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10&nbsp;years from the
date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock and Restricted
Stock Units.</I> Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the
achievement of certain performance goals and/or continued employment or other service relationship with us through a specified vesting period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Unrestricted
Stock Awards.</I> Our compensation committee may grant shares of common stock that are free from any restrictions under the 2020 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration
and may be issued in lieu of cash compensation due to such participant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividend Equivalent Rights.</I> Our compensation committee may grant dividend equivalent
rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cash</I>-<I>Based Awards.</I> Our compensation committee may grant cash bonuses under the 2020 Plan to participants, subject to the achievement of certain
performance goals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Sale Event.</I> The 2020 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2020 Plan, an acquirer or
successor entity may assume, continue or substitute for the outstanding awards under the 2020 Plan. To the extent that awards granted under the 2020 Plan are not assumed or continued or substituted by the successor entity, the 2020 Plan and all
awards granted under the 2020 Plan shall terminate. In such case, except as may be otherwise provided in the relevant award agreement, all options and stock appreciation rights with time-based vesting, conditions or restrictions that are not
exercisable immediately prior to the sale event will become fully exercisable as of the sale event, all other awards with time-based vesting, conditions or restrictions will become fully vested and nonforfeitable as of the sale event and all awards
with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with the sale event in the plan administrator&#146;s discretion or to the extent specified in the relevant award
agreement. In the event of such termination, individuals holding options and stock appreciation rights will be permitted to exercise any options and stock appreciation rights (to the extent exercisable) they then hold within a specified time period,
as determined by the compensation committee, prior to the sale event. In addition, in connection with the termination of the 2020 Plan upon a sale event, we may make or provide for a cash payment to participants holding vested and exercisable
options and stock appreciation rights equal to the difference between the per share cash consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights; provided, that any options or stock
appreciation rights with exercise prices equal to or greater than such per share cash consideration will be cancelled for no consideration. We may also make or provide for a payment, in cash or in kind, to the participants holding other awards in an
amount equal to the per share cash consideration payable to stockholders in the sale event multiplied by the number of vested shares of common stock under such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment.</I> Our board of directors may amend or discontinue the 2020 Plan and our compensation committee can amend
or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely and materially affect rights under an award without the holder&#146;s consent. Certain amendments to the 2020 Plan
or the terms of outstanding options or stock appreciation rights will require the approval of our stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No awards may be granted under the 2020 Plan after
the date that is 10 years from the date on which the 2020 Plan became effective. No awards under the 2020 Plan have been made prior to the date hereof. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2020
Employee Stock Purchase Plan </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2020 ESPP was adopted by our board of directors on September 8, 2020, approved by our stockholders on
September&nbsp;23, 2020 and will become effective on the day immediately before the effective date of our registration statement of which this prospectus forms a part. The 2020 ESPP is intended to qualify as an &#147;employee stock purchase
plan&#148; within the meaning of Section&nbsp;423 of the Code. The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 437,809 shares of common stock to participating employees. The 2020 ESPP provides that the number of
shares reserved and available for issuance will automatically increase on January&nbsp;1, 2021 and each January&nbsp;1 thereafter through January&nbsp;1, 2030, by the least of (i)&nbsp;656,714 shares of common stock, (ii)&nbsp;1% of the outstanding
number of shares of our common stock on the immediately preceding December&nbsp;31 or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP. The number of shares reserved under the 2020 ESPP is
subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All employees whose customary employment is for
more than 20 hours per week and who have completed at least 30&nbsp;days of employment are eligible to participate in the ESPP. However, any employee who owns 5% or more of the total combined voting power or value of all classes of stock will not be
eligible to purchase shares under the 2020 ESPP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may make one or more offerings each year to our employees to purchase shares under the ESPP. Offerings will
usually begin on each January 1 and July 1 and will continue for <FONT STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment
form at least 15 business days before the relevant offering date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each employee who is a participant in the 2020 ESPP may purchase shares by authorizing payroll
deductions of up to 15% of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of common
stock on the last business day of the offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower, provided that no more than $25,000 in
shares of common stock may be purchased by any one employee during any offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of common stock, valued at the start of the purchase period, under the
ESPP in any calendar year. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An
employee&#146;s rights under the 2020 ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
2020 ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of common stock authorized under the 2020 ESPP and certain other amendments require the approval of our stockholders. </P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Senior Executive Cash Incentive Bonus Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September 8,
2020, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan. The Bonus Plan will be administered by our compensation committee and become effective on the day the registration statement of which this
prospectus is part is declared effective by the SEC. The Bonus Plan provides for cash bonus payments based upon the attainment of performance targets established by our compensation committee. The payment targets will be related to financial and
operational measures or objectives with respect to our company or corporate performance goals, as well as individual performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee may select corporate performance goals from among the following: cash flow (including, but not
limited to, operating cash flow and free cash flow); research and development, publication, clinical, collaboration and/or regulatory milestones; revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income
(loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of our common stock; economic value added; acquisitions, licenses or strategic transactions; financing or other capital raising
transactions; operating income (loss); return on capital, assets, equity or investment; stockholder returns; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working
capital; earnings (loss) per share of our common stock; bookings, new bookings or renewals; sales or market shares; number of customers, number of new customers or customer references; operating income and/or net annual recurring revenue, any of
which may be (A)&nbsp;measured in absolute terms or compared to any incremental increase, (B)&nbsp;measured in terms of growth, (C)&nbsp;compared to another company or companies or to results of a peer group, (D)&nbsp;measured against the market as
a whole and/or as compared to applicable market indices and/or (E)&nbsp;measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis (if applicable). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be
adopted in each performance period by the compensation committee and communicated to each executive. The corporate performance goals will be calculated in accordance with our financial statements, generally accepted accounting principles or under a
methodology established by our compensation committee at the beginning of the performance period and which is consistently applied with respect to a corporate performance goal in the relevant performance period. The compensation committee will
measure the corporate performance goals after our financial reports for the applicable performance period have been published or such other appropriate time as the compensation committee determines. If the corporate performance goals and individual
performance objectives are met, payments will be made as soon as practicable following the end of each performance period. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed
by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion and provides the compensation committee with
discretion to adjust the size of the award as it deems appropriate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain a 401(k) retirement savings, or 401(k) plan, plan to eligible employees, including our named executive officers. In accordance with this plan, all eligible
employees may contribute a percentage of compensation up to a maximum of the statutory limits per year. Under our 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code and the
applicable limits under the 401(k) plan (generally, up to 90% of the employee&#146;s eligible compensation), on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) basis, through
contributions to the 401(k) plan. All of a participant&#146;s contributions into the 401(k) plan are 100% vested when contributed. We made matching contributions for each employee equal to 100% of employee contributions, up to $6,000 per employee,
during the year ended December&nbsp;31, 2019. The 401(k) plan is intended to qualify, depending on the employee&#146;s election, under Section&nbsp;401(a) and 501(a) of the Code, so that contributions by employees, and income earned on those
contributions, are not taxable to employees until withdrawn from the 401(k) plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have agreed to indemnify our directors and executive officers in certain circumstances. See<I> &#147;Management&#151;Limitations on Liability and Indemnification
Agreements.&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_13"></A><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR COMPENSATION
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following summarizes the compensation earned by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31,
2019. Directors who also serve as employees received no additional compensation for their service as directors. We reimburse <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors for reasonable travel and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation Table </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED&nbsp;OR<BR>PAID&nbsp;IN&nbsp;CASH&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marc A. Cohen <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kenneth C. Anderson, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bihua Chen <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alain J. Cohen <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce Downey <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Glenn Dubin <SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">John L. Eastman <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Elena Prokupets, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Malcolm Salter <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">William M. Scalzulli <SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miles Stuchin <SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"></P></TD>
<TD VALIGN="bottom" ALIGN="right">45,000<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">30,000</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">30,000</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"></P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"></P></TD>
<TD VALIGN="bottom" ALIGN="right">45,000<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">30,000</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="right">30,000</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Mr.&nbsp;Cohen held unexercised options to purchase an aggregate of 8,561 shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Dr.&nbsp;Anderson held unexercised options to purchase an aggregate of 4,844 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Ms.&nbsp;Chen held unexercised options to purchase an aggregate of 8,561 shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Ms.&nbsp;Cohen held unexercised options to purchase an aggregate of 8,561 shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Mr.&nbsp;Downey held unexercised options to purchase an aggregate of 8,561 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Dubin resigned from our board of directors effective August&nbsp;17, 2019. As of December&nbsp;31, 2019, Mr.&nbsp;Dubin did not hold any unexercised options to purchase our common stock. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Eastman resigned from our board of directors effective June&nbsp;5, 2020. As of December&nbsp;31, 2019, Mr.&nbsp;Eastman did not hold any unexercised options to purchase our common stock. EGC4 Managing Member,
LLC, of which Mr.&nbsp;Eastman is a member, held unexercised options to purchase 8,561 shares of our common stock. Mr.&nbsp;Eastman disclaims beneficial ownership of such options except to the extent of his pecuniary interest in such options.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Dr.&nbsp;Prokupets held unexercised options to purchase an aggregate of 8,561 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2019, Mr.&nbsp;Salter held unexercised options to purchase an aggregate of 8,561 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Scalzulli resigned from our board of directors effective June&nbsp;5, 2020. As of December&nbsp;31, 2019, Mr.&nbsp;Scalzulli did not hold any unexercised options to purchase our common stock. Kraft Group LLC,
of which Mr.&nbsp;Scalzulli is an employee, held unexercised options to purchase 8,561 shares of our common stock. Mr.&nbsp;Scalzulli disclaims beneficial ownership of such options except to the extent of his pecuniary interest in such options.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Stuchin passed away on January&nbsp;25, 2020.&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2019, Mr.&nbsp;Stuchin held unexercised options to purchase an aggregate of 8,561 shares of our common stock.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms. Chen has notified us that she will resign from our board of directors contingent upon and effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Non-Employee Director Compensation Policy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During fiscal year 2019, we provided cash compensation to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in accordance with the following policy:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ANNUAL<BR>RETAINER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, we intend to adopt a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become effective
upon the completion of this offering and will be designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not an
employee will be paid cash compensation from and after the completion of this offering, as set forth below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ANNUAL<BR>RETAINER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide that, upon initial election to our board of directors,
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an option to purchase 35,572 shares of our common stock, or the Initial Grant. Approximately 33% of the Initial Grant will vest on the first anniversary of the date
it is made, and the remainder will vest monthly for the subsequent two years thereafter, subject to continued service as a director through the applicable vesting date. Furthermore, on the date of the effectiveness of the registration statement of
which this prospectus is a part and thereafter at each annual meeting of stockholders following the completion of this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director following such meeting will be granted an option to purchase 17,786 shares of our common stock, or the Annual Grant. The Annual Grant will vest in full on the earlier of (i)&nbsp;the
first anniversary of the grant date or (ii)&nbsp;our next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. These awards are subject to full accelerated vesting upon the sale of the
company. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of the board of directors and committees thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_13a"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a description of transactions or series of transactions since January&nbsp;1, 2017, to which we were or will be a party, in which: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amount involved in the transaction exceeds or will exceed, $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in which any of our executive officers, directors or holders of 5% or more of any class of our capital stock, including
their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Compensation arrangements
for our named executive officers and our directors are described elsewhere in this prospectus under the heading &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Series A
Preferred Stock Financing </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, we sold an aggregate of 900,900 shares of our Series A preferred stock at a purchase price of $2.22 per share
for an aggregate amount of $2.0&nbsp;million to DF Investment Partners LLC, an entity affiliated with Glenn Dubin. Mr.&nbsp;Dubin joined our board of directors upon the closing of such sale and resigned from our board of directors in August 2019.
Every 8.4335 shares of Series A preferred stock will be automatically converted into one share of common stock upon the completion of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Series
B Preferred Stock Financing </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between June and July 2020, we sold an aggregate of 142,857,142 shares of our Series B preferred stock at a purchase price of
$1.05 per share for an aggregate amount of $150&nbsp;million. The following table summarizes purchases of our Series B preferred stock by related persons: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>STOCKHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR>SERIES B<BR>PREFERRED<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>PURCHASE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities and persons affiliated with Cobro Ventures
<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,952,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Perceptive Advisors
<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,047,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with RTW Investments <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,285,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce Downey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,128,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,235,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kenneth C. Anderson, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP
STYLE="font-size:85%; vertical-align:top">4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 20,952,403 shares of our Series B preferred stock purchased by Cobro Ventures Opportunity Fund, L.P. or Cobro Ventures. Each of Marc A. Cohen, who serves as a director and officer of the company, and Alain
J. Cohen, who serves as a director of the company, is a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures. Entities and persons affiliated with Cobro Ventures collectively hold more than 5% of our voting securities.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 19,047,619 shares of our Series B preferred stock held by Perceptive Life Sciences Master Fund LTD. Entities affiliated with Perceptive Advisors collectively hold more than 5% of our voting securities.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 9,061,905 shares of our Series B preferred stock purchased by RTW Master Fund, Ltd., 2,842,857 shares of our Series B preferred stock purchased by RTW Innovation Master Fund, Ltd and 2,380,953 shares of our
Series B preferred stock purchased by RTW Venture Fund Limited. Entities affiliated with RTW Investments collectively hold more than 5% of our voting securities. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 142,857 shares of our Series B preferred stock purchased by Kenneth C. Anderson 2015 Irrevocable Trust dated August&nbsp;10, 2015, of which Mr.&nbsp;Anderson, who is a director of the company, is a
beneficiary and 142,857 shares of our Series B preferred stock purchased by Cynthia E. Anderson 2015 Irrevocable Trust dated August&nbsp;10, 2015, of which Mr.&nbsp;Anderson is also a beneficiary. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Every 8.4335 shares of Series B preferred stock will be automatically converted into one share of common stock upon the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Perceptive Credit Agreement and Warrant </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2020, we entered into the
Credit Agreement with Perceptive Credit, an affiliate of Perceptive Advisors, which beneficially owns more than 5% of our common stock. The Credit Agreement provides for a $20.0&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Delayed Draw Loan Facility. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and Capital Resources&#151;Indebtedness&#148; for a
description of the terms of the Credit Agreement. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2020, the maximum amount&nbsp;of principal outstanding under the
Credit Agreement was $12.5&nbsp;million and $12.5&nbsp;million of principal was outstanding as of June&nbsp;30, 2020. The loans under the Credit Agreement accrue interest at an annual rate of one Month LIBOR plus 9.50%, provided that one Month LIBOR
shall never be less than 1.75%. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the entry into the Credit Agreement, we issued a warrant to purchase up to 2,857,142 shares of our Series B
preferred stock at an exercise price of&nbsp;$1.05 per share to Perceptive Credit. See &#147;Risk Factors&#151;Risks Related to Our Financial Condition and Capital Requirements&#151;Our Credit Agreement with Perceptive Credit contains restrictions
that limit our flexibility in operating our business.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with our Series A preferred stock financings and our Series B preferred stock
financings, we entered into investors&#146; rights, voting and right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, voting rights and rights of first refusal, among
other things, with certain holders of our preferred stock and certain holders of our common stock. These stockholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#146;
rights agreement, as more fully described in &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Option Grants to Directors and Executive
Officers </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted stock options to our directors and executive officers, as more fully described in the section titled &#147;Executive
Compensation&#148; found elsewhere in this prospectus, as of December&nbsp;31, 2019. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September 2020, we approved the issuance of stock options to
Marc&nbsp;A. Cohen, our Co-Founder, Executive Chairman and interim Chief Executive Officer, and Andrew Hirsch, our President, director and Chief Executive Officer-elect, which election will be effective upon the effectiveness of the registration
statement of which this prospectus forms a part, representing 1.5% and 3.5%, respectively, of our fully-diluted shares measured at such time (including the shares to be sold in this offering and excluding the shares reserved for future awards under
our equity incentive plans) at an exercise price per share equal to the initial public offering price, per share in this offering. These options vest quarterly over four years subject to cliff vesting after six months. Mr. Cohen&#146;s grant is
subject to full acceleration upon a sale of the company. Mr. Hirsch&#146;s option is subject to full acceleration upon a sale of the company and the termination of his employment thereafter pursuant to the terms of his employment agreement, subject
to the execution of an effective release of claims in favor of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming we sell 8,824,000 shares in this offering, as set forth on the cover page of
this prospectus, and assuming no exercise by the underwriters of their option to purchase additional shares, Mr.&nbsp;Cohen&#146;s stock options will be for 690,013 shares (710,912 shares if the underwriters exercise their option in full) and
Mr.&nbsp;Hirsch&#146;s stock options will be for 1,610,030 shares (1,658,794 shares if the underwriters exercise their option in full). The number of shares subject to each stock option will be larger or smaller if we sell more or fewer shares in
this offering. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) Mr.&nbsp;Cohen&#146;s stock options by 15,789 shares (18,157 shares if the
underwriters exercise their option in full) and Mr.&nbsp;Hirsch&#146;s stock options by 36,842 shares (42,369 shares if the underwriters exercise their option in full). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the underwriters have reserved
up to 5% of the shares of common stock being offered by this prospectus for sale, at the initial public offering price, to certain of our officers, directors, employees and other persons who do business with us. Any reserved shares purchased by our
executive officers and members of their households will be subject to the 180-day lock-up described elsewhere in this prospectus. We do not currently know the extent to which these related persons will participate in our directed share program, if
at all, or how much of our common stock they will purchase. See the section titled &#147;Underwriting&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
connection with this offering, we intend to enter into new agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including
attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or
that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies for Approval of Related Party
Transactions </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and
their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction were disclosed to our board of directors prior to their consideration of such transaction
and the transaction was not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approved the transaction. Further, when stockholders are entitled to vote on a transaction with a
related party, the material facts of the related party&#146;s relationship or interest in the transaction were disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, we expect to adopt a written related party transactions policy that will provide that such transactions must be approved by our audit
committee. This policy will become effective on the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. Pursuant to this policy, the audit committee has the primary responsibility for
reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person
has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director or greater than 5% beneficial owner of our common stock, in each case since
the beginning of the most recently completed year and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth, as of September&nbsp;13, 2020, information regarding the beneficial ownership of our common stock by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person or group of affiliated persons, who is known by us to be the beneficial owner of 5% or more of our outstanding
common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The information in the following table is calculated based on (i)&nbsp;31,945,194 shares of common stock deemed to be outstanding as of September&nbsp;13, 2020 and
(ii)&nbsp;40,769,194 shares of common stock outstanding after this offering, (assuming no exercise by the underwriters of their option to purchase additional shares of common stock). The number of shares of outstanding before this offering gives
effect to the automatic conversion of all outstanding shares of our convertible preferred stock into 30,355,379 shares of common stock upon the completion of this offering and the reclassification of the warrant liability to additional paid-in
capital upon the automatic conversion of preferred stock warrants into common stock warrants. The number of shares outstanding after this offering gives effect to the sale of 8,824,000 shares of common stock in this offering (assuming no exercise of
the underwriters&#146; option to purchase additional shares). </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have determined beneficial
ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or
shared voting power or investment power with respect to those securities as well as any shares of common stock that the person has the right to acquire within 60 days of September&nbsp;13, 2020 through the exercise of stock options or other rights.
These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the
percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each individual or entity shown on the table has furnished information with respect to beneficial ownership. Except as otherwise indicated below, the address of each
officer, director and five percent stockholder listed below is c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 200, Watertown, MA 02472. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR>COMMON<BR>STOCK<BR>BENEFICIALLY<BR>OWNED <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF&nbsp;SHARES&nbsp;OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BEFORE OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AFTER OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cobro Ventures and its affiliates <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,726,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Perceptive Advisors <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,597,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cormorant Funds <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,495,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RTW Funds <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marc A. Cohen <SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,579,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Hirsch</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Phillips, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adam Crystal, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stewart Fisher, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kenneth C. Anderson, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bihua Chen <SUP STYLE="font-size:85%; vertical-align:top">(11)**</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,495,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Alain J. Cohen <SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,451,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Bruce Downey <SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Elena Prokupets, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">716,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Malcolm Salter <SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All executive officers and directors as a group (13&nbsp;persons)&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,551,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than one percent. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All share numbers give effect to the conversion of our outstanding convertible preferred stock into shares of common stock upon the closing of this offering. The share numbers do not include any shares of common stock
that may be acquired under the directed share program in this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;2,484,425 shares of common stock held by Cobro Ventures Opportunity Fund, L.P., or Cobro Ventures; (ii)&nbsp;677,569 shares of common stock held by BC DynamoPharm Limited, or 3E Bio;
(iii)&nbsp;508,177 shares of common stock held by Yongli (Cayman) Limited, or Yongli; and (vi)&nbsp;56,464 shares of common stock held by Yonjin Venture LLC, or Yonjin. Marc Cohen and Alain Cohen are managers of Cobro Opportunity Fund GP, LLC, the
general partner of Cobro Ventures, and may be deemed to exercise shared voting and investment power over the shares held by Cobro Ventures. They disclaim beneficial ownership of the shares held by Cobro Ventures except to the extent of their
respective pecuniary interest in such shares. Each of 3E Bio, Yongli and Yonjin has granted a voting proxy over its shares of our common stock to Cobro Ventures, Inc., subject to termination upon the completion of this offering. Marc Cohen and Alain
Cohen are co-chief executive officers of Cobro Ventures, Inc. and may be deemed to have shared voting power over the shares subject to each such proxy. They disclaim beneficial ownership of the shares subject to each such proxy. For the avoidance of
doubt, the shares subject to each such proxy are included in determining the percentage of shares outstanding before this offering for Marc Cohen, Alain Cohen and Cobro Ventures, and such shares are excluded in determining the percentage of shares
outstanding after this offering owing to the termination of each such proxy upon the completion of this offering. Cobro Ventures and Cobro Ventures, Inc. may be deemed affiliated with each other due to their common control by Marc Cohen and Alain
Cohen. Marc Cohen is our director, Co-Founder, Executive Chairman and Chief Executive Officer, and Alain Cohen is our director. The address for each of Cobro Ventures and Cobro Ventures, Inc. is 1000&nbsp;Wilson Blvd. #1800, Arlington, VA 22209.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,258,566 shares of common stock held by Perceptive Life Sciences Master Fund LTD. and warrants to purchase an aggregate of 338,784 shares of common stock held by Perceptive Credit Holdings III, LP.
Perceptive Life Sciences Master Fund LTD. and Perceptive Credit Holdings III, LP are referred to collectively as Perceptive Advisors. The address for Perceptive Advisors is 51 Astor Place, 10th Floor, New York, NY 10003. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;1,867,550 shares of common stock held by Cormorant Private Healthcare Fund I, LP, or Cormorant Private Fund; (ii)&nbsp;522,040 shares of common stock held by Cormorant Global Healthcare Master Fund,
LP or Cormorant Master Fund; (iii)&nbsp;100,474 shares of common stock held by CRMA SPV, L.P. or CRMA; and (iv)&nbsp;5,083 shares of common stock exercisable within 60 days of September&nbsp;13, 2020 underlying options held by Bihua Chen. Cormorant
Private Fund, Cormorant Master Fund and CRMA are referred to collectively as the Cormorant Funds. The shares issuable upon the exercise of such options shall be transferred to the Cormorant Funds on a pro rata basis. The sole general partner of each
of the Cormorant Private Fund and the Cormorant Master Fund is Cormorant Private Healthcare GP, LLC or the GP. Ms. Chen is the sole managing member of the GP and may be deemed to have sole voting and investment power of the securities held by the
Cormorant Private Fund and the Cormorant Master Fund. She disclaims beneficial ownership of the shares held by the Cormorant Funds, except to the extent of her pecuniary interest in such shares. The sole investment manager of CRMA is Cormorant Asset
Management, LLC, or the Manager. Ms. Chen is the sole managing member of the Manager and may be deemed to have sole voting and investment power of the shares held by CRMA. The address for each of the Cormorant Funds is 200 Clarendon Street, 52nd
Floor, Boston, MA 02116. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,074,512 shares of common stock held by RTW Master Fund, Ltd. or the RTW Master Fund; (ii) 337,091 shares of common stock held by RTW Innovation Master Fund, Ltd or the RTW Innovation Fund; and (iii)
282,320 shares of common stock held by RTW Venture Fund Limited or the RTW Venture Fund. RTW Master Fund, RTW Innovation Fund and RTW Venture Fund are referred to collectively as the RTW Funds. The address for each of the RTW Funds is 412 West 15th
Street, Floor 9, New&nbsp;York, NY 10011. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,847,392 shares of common stock held by Mr.&nbsp;Cohen as trustee of Marc Andrew Cohen Revocable Trust; (ii) 5,083 shares of common stock exercisable within 60 days of September 13, 2020 underlying
options held by Mr.&nbsp;Cohen; and (iii) the shares of common stock described in note (2) above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Phillips&#146; employment terminated on March&nbsp;3, 2020. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 89,983 shares of common stock exercisable within 60 days of September 13, 2020 underlying options held by Dr.&nbsp;Crystal. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 85,372 shares of common stock held by Dr.&nbsp;Fisher and 39,805 shares of common stock exercisable within 60 days of September 13, 2020 underlying options held by Dr.&nbsp;Fisher. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 16,939 shares of common stock held by Kenneth C. Anderson 2015 Irrevocable Trust; (ii) 16,939 shares of common stock held by Cynthia E. Anderson 2015 Irrevocable Trust; (iii) 63,543 shares of common
stock held by Kenneth C. Anderson 2016 Grantor Retained Annuity Trust; (iv) 63,543 shares of common stock held by Cynthia E. Anderson 2016 Grantor Retained Annuity Trust; (v) 80,376 shares of common stock held by Dr.&nbsp;Anderson; (vi) 45,038
shares of common stock held by Cynthia Anderson; and (vii) 770 shares of common stock exercisable within 60 days of September 13, 2020 underlying options held by Dr.&nbsp;Anderson. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares described in note (4) above. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,719,332 shares of common stock held by Mr.&nbsp;Cohen as trustee of Alain J. Cohen Revocable Trust; (ii) 5,083 shares of common stock exercisable within 60 days of September 13, 2020 underlying options
held by Mr.&nbsp;Cohen; and (iii) the shares of common stock described in note (2) above. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 489,542 shares of common stock held by Mr.&nbsp;Downey and 5,083 shares of common stock exercisable within 60 days of September 13, 2020 underlying options held by Mr.&nbsp;Downey. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 592,873 shares of common stock held by ERP Business Holdings, L.P., an entity affiliated with Dr.&nbsp;Prokupets; (ii)&nbsp;118,574 shares of common stock held by her spouse Marc Grenouilleau; and 5,083
shares of common stock exercisable within 60 days of September 13, 2020 underlying options held by Dr.&nbsp;Prokupets. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 14,679 shares of common stock held by Mr.&nbsp;Salter and 5,083 shares of common stock exercisable within 60 days of September 13, 2020 underlying options held by Mr.&nbsp;Salter. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of the shares of common stock in notes (6) through (15) without double counting the shares held by Cobro Ventures and the shares subject to the voting proxy held by Cobro Ventures, Inc. included in notes (6)
and (12); and includes William McKee and Jolie M. Siegel who are executive officers but not named executive officers. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms. Chen has notified us that she will resign from our board of directors contingent upon and effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and restated bylaws, which will be
effective immediately upon the closing of this offering. The descriptions of the common stock and preferred stock give effect to changes to our capital structure that will occur immediately upon the closing of this offering. We refer in this section
to our amended and restated certificate of incorporation as our certificate of incorporation and we refer to our amended and restated bylaws as our bylaws. Copies of these documents will be filed with the SEC as exhibits to our registration
statement, of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
completion of this offering, our authorized capital stock will consist of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred
stock will be undesignated. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June 30, 2020, 1,490,336 shares of our common stock were outstanding and held of record by 28 stockholders and 4,000,000
shares of Series Seed preferred stock, 109,145,900 shares of Series A preferred stock and 142,857,142 shares of Series B preferred stock were outstanding and held of record by 116 stockholders. This amount does not take into account the conversion
of all outstanding shares of our preferred stock into common stock upon the closing of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do
not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any
outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding
preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, all outstanding
shares of our preferred stock will be converted into shares of our common stock. Upon the closing of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000&nbsp;shares of
preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change
in control of our company or other corporate action. Immediately after the closing of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June 30, 2020, options to purchase 1,052,531 shares of
common stock at a weighted-average exercise price of $4.37 per share were outstanding under our 2015 Plan and outside our 2015 Plan. For additional information regarding terms of the 2015 Plan, see the section titled &#147;Employee Benefit
Plans.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2020, we
issued a warrant to purchase 2,857,142 shares of our Series B preferred stock to our lender, Perceptive Credit Holdings III, LP, at an exercise price of $1.05 per share, which will become exercisable for our common stock on an as-converted basis
upon the closing of this offering. If unexercised as of June 5, 2030, this warrant will automatically net exercise if its exercise price per share is greater than the fair market value per share or otherwise expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering, the holders
of 30,694,163 shares of our common stock, including those issuable upon the conversion of preferred stock upon closing of this offering and those issuable upon the exercise of the warrant described above, will be entitled to rights with respect to
the registration of these securities under the Securities Act. These rights are provided under the terms of an amended and restated investors&#146; rights agreement between us, certain holders of our common stock and holders of our preferred stock.
The amended and restated investors&#146; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be
borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beginning 180 days after the
effective date of this registration statement, the holders of 30,694,163 shares of our common stock, including those issuable upon the conversion of shares of our preferred stock upon closing of this offering and those issuable upon the exercise of
the warrant described above, are entitled to demand registration rights. Under the terms of the investors&#146; rights agreement, we will be required, upon the written request of holders of at least 40% of the securities eligible for registration
then outstanding, to file a registration statement with respect to at least 25% of the securities eligible for registration then outstanding, we will be required to file a registration statement covering all securities eligible for registration that
our stockholders request to be included in such registration. We are required to effect only two registrations pursuant to this provision of the investors&#146; rights agreement in any twelve-month period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the amended and restated investors&#146; rights agreement, if we are eligible to file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of stockholders holding at least 20% of the securities eligible for registration then outstanding we will be required to file a Form <FONT STYLE="white-space:nowrap">S-3</FONT>
registration restatement with respect to outstanding securities of such stockholders having an anticipated aggregate offering, net of related fees and expenses, of at least $3.0&nbsp;million. We are required to effect only two registrations in any
twelve month period pursuant to this provision of the amended and restated investors&#146; rights agreement. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified
conditions and limitations. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the amended and restated investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, the holders of our common stock, including those issuable upon the conversion of our preferred stock, are entitled to include their shares in the registration. Subject to certain exceptions contained in the amended and restated
investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of
the offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated
investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement
attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expiration of Registration Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The demand registration rights and short form registration rights granted under the amended and restated investors&#146; rights agreement will terminate on
the fifth anniversary of the completion of this offering or at such time after this offering when the holders&#146; shares may be sold without restriction pursuant to Rule 144 within a three month period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ordinarily,
other than underwriting discounts and commissions, we are generally required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the
selling security holders and <FONT STYLE="white-space:nowrap">blue-sky</FONT> fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Delaware Law and Certain Provisions of
our Certificate of Incorporation and Amended and Restated Bylaws </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our certificate of incorporation and bylaws include a number of provisions that may have the
effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT
STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Classified Board </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected
each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of <FONT STYLE="white-space:nowrap">two-thirds&nbsp;or</FONT> more of the shares then
entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of
our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the
composition of our board of directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting and that
stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders
without holding a meeting of stockholders. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of
stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to
those matters properly brought before the meeting. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business
to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be
timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and
content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any amendment
of our certificate of incorporation must first be approved by a majority of our board of directors and, if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on
the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our
bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment and not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least two-thirds of the outstanding
shares entitled to vote on the amendment or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting
together as a single class. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our certificate of incorporation provides for 10,000,000&nbsp;authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock
may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to
determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that
might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of
authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the
rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Delaware
Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law.
In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an
interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following
conditions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors
and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or
more of the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, Section&nbsp;203 defines an interested stockholder as any entity or person
beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Choice of Forum </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our bylaws provide that, unless we consent in writing to
the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i)&nbsp;any derivative action or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our
stockholders; (iii)&nbsp;any action asserting a claim arising out of or pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; and (iv)&nbsp;any action asserting a claim
governed by the internal affairs doctrine; provided, however, that this choice of forum provision does not apply to any causes of action arising under the Securities Act or the Exchange Act. Our bylaws further provide that, unless we consent in
writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Our bylaws also provide that
any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. We recognize that the forum selection clause in our bylaws
may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum
selection clause in our bylaws may limit our stockholders&#146; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our
directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts may also reach different
judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Exchange Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to list our common stock on The Nasdaq
Global Market under the proposed trading symbol &#147;CCCC.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Transfer Agent and Registrar for our common stock will be Computershare Trust Company, N.A. The Transfer Agent and Registrar&#146;s address is 250 Royall Street,
Canton, Massachusetts 02021, and its telephone number is (800) 962-4284. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has been no public market for our shares, and although we expect that our common stock will be approved for listing on Nasdaq, we cannot
assure investors that there will be an active public market for our common stock following this offering. Future sales of our common stock in the public market or the availability of such shares for sale in the public market could adversely affect
market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of shares of our common
stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise equity capital in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, based on the number of shares outstanding as of June 30, 2020, upon the completion of this offering, 40,669,715 shares of our common
stock will be outstanding, assuming the issuance of 8,824,000 shares offered by us in this offering, no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options or warrants. Of the outstanding
shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described
below, and&nbsp;restricted shares of common stock are subject to time-based vesting terms. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be &#147;restricted
securities&#148; as such term is defined in Rule 144 under the Securities Act. These restricted securities were issued and sold by us in private transactions and are eligible for public sale only if registered under the Securities Act or if they
qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result
of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described below and the provisions of Rules 144 or 701 and no exercise of the underwriters&#146; option to
purchase additional shares, the shares of our common stock that will be deemed &#147;restricted securities&#148; will be available for sale in the public market following the completion of this offering as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">8,824,000 shares will be eligible for sale on the date of this prospectus; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">31,845,715 shares will be eligible for sale upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described below, beginning more than 180 days after the date of this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, a person who has beneficially owned restricted
stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are
subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the
90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the number of shares then outstanding, which will equal approximately 406,697 shares immediately after this
offering, assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares outstanding as of June 30, 2020; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding
the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided, in each case, that we are subject to the periodic reporting
requirements of the Exchange Act for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice
provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule&nbsp;701 under the
Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all
holders of Rule&nbsp;701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, substantially all
Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our
directors and officers and the holders of substantially all of our capital stock, options and warrants have entered into lock-up agreements with us and have entered into or will enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
with the underwriters and have agreed not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180
days thereafter, subject to certain exceptions. The representatives of the underwriters in this offering may, in their sole discretion, permit early release of shares subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. See the
section titled &#147;Underwriting,&#148; appearing elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities
Act.&nbsp;Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section titled
&#147;Description of Capital Stock&#151;Registration Rights&#148; appearing elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to file with the SEC one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our
shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC.
Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions
described above. As of the date of this prospectus, we estimate that such registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> will cover approximately 9,405,125 shares. See the section titled &#147;Executive
Compensation&#151;Employee Benefit Plans&#148; appearing elsewhere in this prospectus for a description of our equity compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_17"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax considerations applicable to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to the ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is not, for U.S. federal
income tax purposes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation or other organization taxable as a corporation for U.S. federal income tax purposes that is created or
organized in or under laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more U.S.
persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) have authority to control all substantial decisions of the trust and (2)&nbsp;has made an election to be treated as a U.S. person under applicable U.S. Treasury Regulations.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are pass-through or disregarded
entities for U.S. federal income tax purposes or persons that hold their common stock through such partnerships or other entities or arrangements. A partner in a partnership or other pass-through entity that will hold our common stock should consult
his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and
judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax
considerations to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax
considerations described herein. We have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences with respect to the matters discussed below. We assume in this discussion that a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for investment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, the
Medicare contribution tax on net investment income, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code or any other aspect of any U.S. federal tax other than income and estate taxes. This
discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that own, or are deemed to own, during the applicable testing period, more than 5% of our outstanding capital
stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who are accrual method taxpayers subject to special tax accounting rules under Section&nbsp;451(b) of the Code;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our
common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THIS SUMMARY IS NOT INTENDED TO BE TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES
TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY U.S. FEDERAL
<FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings
and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any amount distributed in excess of basis will be treated as capital gain, subject to the tax treatment described below in
&#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; Any such distributions will also be subject to the discussions below under the sections titled &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding
and Information Reporting Requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion in the following two paragraphs in this section, dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or a reduced rate if specified by an applicable income tax treaty between the United States and such holder&#146;s
country of residence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dividends that are treated as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the
United&nbsp;States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net
of specified deductions and credits, is taxed at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code), unless a specific treaty exemption applies. Any U.S. effectively connected income received by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or a reduced rate if specified by an applicable income
tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who
claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or a successor form) to the applicable withholding agent and satisfy applicable certification and other requirements.
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible
for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to
the discussions below under &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding and Information Reporting Requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be
subject to any U.S. federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
income or withholding tax on any gain realized upon such holder&#146;s sale or other taxable disposition of shares of our common stock unless: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such
lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income
tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we are, or have been, at any time during the five-year period preceding such sale of other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter), a &#147;U.S. real property holding corporation,&#148; as described below, unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on
the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. In such case, such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on its net gain
derived from the disposition at the U.S. federal income tax rates applicable to United States persons (as defined in the Code). Generally, a corporation is a U.S. real property holding corporation if the fair market value of its U.S. real property
interests, as defined in the Code and applicable Treasury Regulations, equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although
there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an
established securities market for purposes of the rules described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the dividends on our common stock paid to
such holder and the tax withheld, if any, with respect to such dividends. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not a United States person
(as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal
income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. U.S. backup withholding generally will not apply to
<FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> who provides a properly executed IRS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,&nbsp;W-8BEN-E</FONT></FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI&nbsp;or</FONT> otherwise establishes an
exemption; provided the applicable withholding agent does not have actual knowledge or reason to know that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a United States person (as defined in the Code). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain
other requirements or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction
is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office
of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of
the information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated
under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be refunded
or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding and Information Reporting Requirements&#151;FATCA </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Provisions of
the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a rate of 30% on payments of dividends on or, subject to the discussion of certain proposed U.S. Treasury
Regulations below, gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due
diligence, reporting, withholding and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any or (iii)&nbsp;the foreign
entity is otherwise exempt under FATCA. However, the U.S. Treasury released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a sale or other
disposition of our common stock. In the preamble to such proposed regulations, the U.S. Treasury stated that taxpayers may generally rely on the proposed regulations until final regulations are issued. Under certain circumstances, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in
this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our
common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF ACQUIRING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE
CONSEQUENCES OF ANY PROPOSED OR RECENT CHANGES IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, <FONT STYLE="white-space:nowrap">LOCAL,&nbsp;NON-U.S.&nbsp;OR</FONT> U.S.
<FONT STYLE="white-space:nowrap">FEDERAL&nbsp;NON-INCOME&nbsp;TAX</FONT> LAWS OR UNDER ANY APPLICABLE TAX TREATY.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement,
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, between us and Jefferies LLC and Evercore Group L.L.C., as the representatives of the underwriters in this offering named below, we have
agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name
below:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,824,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. We have agreed to
indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those
liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as
permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can
be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise
discretionary authority except sales to accounts over which they have discretionary authority to exceed 5% of the common stock being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and
Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on
the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share
of common stock. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock
to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set
forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$4,000,000. We have also agreed to reimburse the underwriters for up to $40,000 for their expenses related to clearance of this offering with the Financial Industry Regulatory Authority, Inc., or FINRA, including the related fees and expenses of
counsel for the underwriters. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination
of Offering Price </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our
common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that
we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the
offering or that an active trading market for the common stock will develop and continue after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to list our common stock on The Nasdaq Global Market under the trading symbol &#147;CCCC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the
underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 1,323,600&nbsp;shares from us at the public offering price set forth on the cover page of
this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that
underwriter&#146;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of
all or substantially all our outstanding capital stock and other securities have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell or offer to sell any shares of common stock, options, warrants or other rights to acquire shares of common stock or
any securities exchangeable or exercisable for or convertible into shares of common stock, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into shares of common stock, currently or hereafter owned
either of record or beneficially, as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act by such individual or their family member; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into any swap; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and
sale of any shares of common stock, options, warrants or other rights to acquire shares of common stock, or any securities exchangeable or exercisable for or convertible into shares of common stock, or to acquire other securities or rights
ultimately exchangeable or exercisable for or convertible into shares of common stock, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration;
or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of Jefferies LLC and Evercore Group L.L.C. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the common
stock on and including the 180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Evercore Group
L.L.C. may, in their sole discretion, and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">180-day</FONT> period, release all or any portion of the securities subject to
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the
sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that they, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in short sale
transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a
level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of our common stock in this
offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares
to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase
additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close
out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the
open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of shares of common
stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short
position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement
permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and
therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we, nor any of the underwriters make any representation or prediction as to the
direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at
any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on The Nasdaq Global Market in
accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display
its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the websites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may
be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters
on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; websites and any information contained in any other web site maintained by any of the underwriters is not part of this
prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading,
commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time,
performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. For example, Jefferies LLC acted as a
placement agent in connection with the private placement of our Series B Preferred Stock and received cash compensation in connection therewith. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary
course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective
affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into
transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could
adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have engaged Locust Walk Securities LLC, or Locust Walk, a FINRA member, to serve as our financial advisor in connection with this offering. We expect to pay Locust
Walk, upon the completion of this offering, aggregate fees of $1.0 million for its services. The services provided by Locust Walk included customary business and financial analysis, assistance in preparing information materials regarding the
offering, coordinating diligence sessions and advising us with respect to the marketing and structuring of this offering. Locust Walk is not acting as an underwriter and will not sell or offer to sell any securities and will not identify, solicit or
engage directly with potential investors. In addition, Locust Walk will not underwrite or purchase any of the offered securities or otherwise participate in any such undertaking. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the underwriters have reserved for sale, at the initial public offering price per share, up to 5% of the shares of common stock offered by this
prospectus to certain individuals, including certain of our officers, directors, employees and other persons who do business with us, through a directed share program. Any shares of our common stock purchased in the directed share program will not
be subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction, except in the case of shares purchased by any director or executive officer or member of their household. The number of shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
common stock available for sale to the general public will be reduced by the number of reserved shares sold to these individuals. Any reserved shares not purchased by these individuals will be
offered by the underwriters to the general public on the same basis as the other shares of common stock offered under this prospectus. We have agreed to indemnify the underwriters against certain liabilities and expenses, including liabilities under
the Securities Act, in connection with sales of the reserved shares. The directed share program will be arranged through Jefferies LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Disclaimers About <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdictions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area and the United Kingdom </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each Member State of the European Economic Area and the United Kingdom, each a Relevant State, no shares have been offered or will be offered pursuant to
the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State
and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of common stock may be made to the public in that Relevant State at any time under the following exemptions under
the Prospectus Regulation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; (as defined under the Prospectus Regulation);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation),
subject to obtaining the prior consent of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of common stock shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement
a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with us and each of the
underwriters and that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the case of any common stock being
offered to a financial intermediary as that term is used in Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the common stock acquired by it in the offer have not been acquired
on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer or any common stock to the public other
than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Relevant State means the communication in any form
and by any means of sufficient information on the terms of the offer and any common stock to be offered so as to enable an investor to decide to purchase or subscribe for any common stock, and the expression &#147;Prospectus Regulation&#148; means
Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is
only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of the Prospectus Regulation that are also (i)&nbsp;investment professionals falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be
communicated, each such person being referred to as a &#147;relevant person.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus and its contents are confidential and should not be distributed,
published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>(A) Resale Restrictions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of shares of common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis
exempt from the requirement that we prepare and file a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of our common stock in Canada must be made under
applicable securities laws, which may vary depending on the relevant jurisdiction and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities
regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>(B) Representations of Canadian
Purchasers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing shares of our common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the
dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the shares of our common stock without
the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> &#150; Prospectus Exemptions, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>(C) Conflicts of Interest </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of
shares of our common stock are hereby notified that each of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> &#150; Underwriting
Conflicts from having to provide certain conflict of interest disclosure in this document. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>(D) Statutory Rights of Action </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any
amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser of these shares of our common stock in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>(E) Enforcement of Legal Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers
of shares of our common stock to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible
to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>(F) Taxation and Eligibility for Investment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian
purchasers of shares of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares of our common stock in their particular circumstances and about the eligibility of the shares of
our common stock for investment by the purchaser under relevant Canadian legislation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged
with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You confirm and warrant that you are either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to the company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a person associated with the company under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of
the shares of our common stock issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under
section 708 of the Corporations Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares of our
common stock have been offered or sold, and no shares of our common stock may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or
agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or the SFO, and any rules made under that Ordinance; or in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong, or the CO, or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating
to the shares of our common stock has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be
accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of
Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the shares of our common stock may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the
shares of our common stock will be required, and is deemed by the acquisition of the shares of our common stock, to confirm that he is aware of the restriction on offers of the shares of our common stock described in this prospectus and the relevant
offering documents and that he is not acquiring, and has not been offered, any shares of our common stock in circumstances that contravene any such restrictions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the
Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of shares of our
common stock is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint
investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and
&#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for
the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under the
Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any shares of our common stock, directly or indirectly, in Japan or to, or for the benefit of, any
resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly
or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial
guidelines of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This
prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for
subscription or purchase, of the common stock may not be circulated or distributed, nor may the common stock be offered or sold or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in
Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1) or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the shares of our common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and
interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer made under Section&nbsp;275 of the SFA except:
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares may
not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or
regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, us or the securities have been or will be filed with or approved by any
Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not
be authorized under the Swiss Federal Act on Collective Investment Schemes, or the CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Cooley LLP, Boston,
Massachusetts is serving as counsel to the underwriters.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_20"></A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consolidated
financial statements as of December&nbsp;31, 2018 and 2019 and for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2019, have been included herein and in the registration statement in reliance
upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> under the Securities Act with respect to the common stock
offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information included in the registration statement. For further information pertaining to us and the common stock offered
by this prospectus, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should
refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of the offering,
we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at
the SEC&#146;s website at www.sec.gov. We also maintain a website at https://www.c4therapeutics.com and upon completion of the offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT>
quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any amendments to those reports, as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. The information contained in or that can be accessed through our website is not a part of and is not incorporated into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc772024_22"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fintoc772024_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fintoc772024_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fintoc772024_3">Consolidated Statement of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fintoc772024_4">Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fintoc772024_5">Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fintoc772024_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>



<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin772024_100">Condensed Consolidated Balance Sheets (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin772024_101">Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin772024_102">Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin772024_103">Condensed Consolidated Statement of Cash Flows (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin772024_104">Notes to Condensed Consolidated Financial Statements (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc772024_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">C4 Therapeutics, Inc.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Consolidated Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the
accompanying consolidated balance sheets of C4 Therapeutics, Inc. and its subsidiary, (the Company) as of December&nbsp;31, 2018 and 2019, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred
stock and stockholders&#146; deficit, and cash flows for each of the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material
respects, the financial position of the Company as of December&nbsp;31, 2018 and 2019, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These consolidated financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>/s/ KPMG </I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2016. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Boston, Massachusetts </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">August&nbsp;5, 2020, except for Note 13, as to which the
date is September 28, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc772024_2"></A>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">December&nbsp;31,
2018 and 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share data) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 36,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">146,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 118,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and Contingencies (see Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed redeemable convertible preferred stock, par value of $0.0005 per share; 4,000,000 shares
authorized as of December&nbsp;31, 2018 and 2019; 4,000,000 shares issued and outstanding at December&nbsp;31, 2018 and 2019; liquidation and redemption value of $1,000 as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A redeemable convertible preferred stock, par value of $0.0005 per share; 110,000,000 shares
authorized as of December&nbsp;31, 2018 and 2019; 109,145,900 shares issued and outstanding at December&nbsp;31, 2018 and 2019; liquidation and redemption value of $109,995 as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, par value of $0.0001 per share; 180,000,000 shares authorized as of December 2018 and 2019;
1,338,956 and 1,426,641 shares issued and outstanding at December&nbsp;31, 2018 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">146,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 118,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc772024_3"></A>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">December&nbsp;31, 2018 and 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands,
except per share data) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive gain:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,293,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common stock outstanding&#151;basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,788,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc772024_4"></A>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholder&#146;s Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">December&nbsp;31, 2018 and 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands,
except share data) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES SEED<BR>REDEEMABLE<BR>CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A REDEEMABLE<BR>CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT></B><br><B>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>OTHER<BR>COMPREHENSIVE</B><br><B>INCOME (LOSS)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>STOCKHOLDERS&#146;</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Balance as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Issuance of Series A redeemable convertible preferred stock, net of issuance costs of $23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">900,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,338,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,112 </TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(117,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(111,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc772024_5"></A>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statement of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">December&nbsp;31, 2018 and 2019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands) </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash flows used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to cash (used in) provided by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gain on disposal of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accretion of discount on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds received from maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from the issuance of Series A shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from the issuance of common stock, net of costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repurchase of vested stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 38,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 93,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Reconciliation of cash, cash equivalents and restricted cash:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 38,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 93,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 36,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capital expenditures in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amount due for stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock option repurchases included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:12%; text-indent:4%; font-size:9.5pt; font-family:ARIAL">See accompanying notes to consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fintoc772024_6"></A>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">December&nbsp;31, 2018 and 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(1) The Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">C4 Therapeutics, Inc., or Company, was incorporated in Delaware on October&nbsp;7, 2015. Its principal offices are in Watertown, Massachusetts. The Company is a
biopharmaceutical company focused on harnessing the body&#146;s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and
other diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks common to other life science companies in the early development stage including, but not limited to, uncertainty of
product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary
technology, ability to raise additional financing and compliance with the Food and Drug Administration (&#147;FDA&#148;) and other government regulations. If the Company does not successfully advance its programs into and through human clinical
trials and/or enter into collaborations for its programs and commercialize any of its product candidates, it may be unable to produce product revenue or achieve profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated whether there are certain
conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the financial statements are issued. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has incurred recurring losses since its inception, including net losses of $15.7&nbsp;million and $34.1&nbsp;million for the years ended December&nbsp;31,
2018 and 2019, respectively. In addition, as of December&nbsp;31, 2019, the Company had an accumulated deficit of $117.5&nbsp;million. To date, the Company has not generated any revenue from product sales as none of its product candidates have been
approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s primary activities
since inception have been focused around research and development activities, building the Company&#146;s intellectual property, recruiting personnel and raising capital to support these activities. Through December&nbsp;31, 2019, the Company has
funded its operations primarily with proceeds received from the sale of redeemable convertible preferred stock (collectively, the &#147;Preferred Stock&#148;) and through its collaboration agreements. The Company also closed a series B redeemable
convertible preferred stock financing and credit arrangement in June and July 2020 for net proceeds of $145.5&nbsp;million (see Note 13). The Company believes that its cash and cash equivalents of $90.5&nbsp;million as of December&nbsp;31, 2019,
along with the proceeds from the Series&nbsp;B redeemable convertible preferred stock financing and credit agreement, are sufficient to fund planned operations for at least twelve months from the date these consolidated financial statements are
available to be issued. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern
and contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(2) Summary of Significant
Accounting Policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has
prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#147;U.S.&nbsp;GAAP&#148;). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s consolidated
financial statements include the accounts of the Company and its wholly owned subsidiary C4T Securities Corporation, a Massachusetts securities corporation. All significant intercompany balances and transactions have been eliminated in
consolidation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Emerging Growth Company </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is an
emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for
complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&nbsp;no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably
opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective
dates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of consolidated
financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be
reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements if these results differ from historical experience or
other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, amounts
and timing of revenues recognized under the Company&#146;s research and development collaboration arrangements and accrued research and development expense. The Company assesses estimates on an ongoing basis; however, actual results could materially
differ from those estimates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Segments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are
defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment.
The Company&#146;s chief operating decision maker, its Chief Executive Officer, manages the Company&#146;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#146;s long-lived assets are held in the United
States. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company capitalizes certain
legal, professional, accounting and other third-party fees that are directly associated <FONT STYLE="white-space:nowrap">with&nbsp;in-process&nbsp;equity</FONT> financings as deferred offering costs until such financings are consummated. After
consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction of proceeds generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs would be
expensed immediately as a charge to operating expenses in the consolidated statement of operations. No deferred offering costs were capitalized as of December&nbsp;31, 2018 or 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Information </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the accompanying consolidated
statements of operations and comprehensive loss, the unaudited proforma basic and diluted net loss per share attributable to common stockholders for the year ended December 31, 2019 has been prepared to give effect to the automatic conversion of all
outstanding shares of redeemable convertible preferred stock upon the closing of the proposed initial public offering into 13,416,155 shares of common stock as if the conversion had occurred on the later of January 1, 2019 or the issuance of the
redeemable convertible preferred stock. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers all highly liquid investments with a maturity of three&nbsp;months or less when purchased to be cash equivalents. The Company&#146;s cash
equivalents are measured at fair value on a recurring basis. Cash and cash equivalents included $29.0&nbsp;million and $80.9&nbsp;million of funds held&nbsp;in money market accounts as of December&nbsp;31, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accounting Standards
Codification (&#147;ASC&#148;) Topic 820, Fair Value Measurement (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the
Company&#146;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based
on the best information available in the circumstances. ASC&nbsp;820 identifies fair value as the exchange price or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 1&#151;Quoted market prices in active markets for identical assets or liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 2&#151;Inputs other than Level&nbsp;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 3&#151;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more
judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on the lowest
level of any input that is significant to the fair value measurement. The Company had no Level&nbsp;3 investments as of December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cash, cash
equivalents and restricted cash are Level&nbsp;1 assets which are&nbsp;comprised of funds held in checking and money market accounts.&nbsp;Cash, cash equivalents and restricted cash were recorded at fair value as of December&nbsp;31, 2018 and 2019,
totaling $38.9&nbsp;million and $93.1&nbsp;million, respectively. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. Accounts receivable, which relate to the Company&#146;s
collaboration agreements, are stated at the amounts due which approximates fair value due to their short-term due dates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restricted cash consists of cash placed in separate restricted bank accounts as required under the terms of the Company&#146;s lease agreements for its Watertown,
Massachusetts facility (see Note 5 &#147;<I>Leases</I>&#148;). As&nbsp;of December&nbsp;31, 2018 and 2019, the Company had approximately $2.6&nbsp;million in restricted cash. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that potentially
subject us to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to
significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes revenue in accordance
with ASC Topic&nbsp;606, <I>Revenue from Contracts with Customers</I> (&#147;ASC&nbsp;606&#148;). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC&nbsp;606, an entity
recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for
arrangements that an entity determines are within the scope of ASC&nbsp;606, the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract;
(iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in&nbsp;the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC&nbsp;606, the&nbsp;Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company
then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of
ASC&nbsp;606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the
following: <FONT STYLE="white-space:nowrap">(1)&nbsp;non-refundable,</FONT> upfront license fees; (2)&nbsp;reimbursement of certain costs; (3)&nbsp;customer option fees for additional goods or services; (4)&nbsp;development milestone payments,
(5)&nbsp;regulatory and commercial milestone payments; and (6)&nbsp;royalties on net sales of licensed products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining the appropriate amount of revenue
to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i)&nbsp;identification of the promised goods or services in the contract; (ii)&nbsp;determination of whether the promised goods
or services are performance obligations including whether they are distinct in the context of the contract; (iii)&nbsp;measurement of the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocation of the transaction
price to the performance obligations; and (v)&nbsp;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a)&nbsp;the
number of performance obligations based on the determination under step (ii)&nbsp;above; (b)&nbsp;the transaction price under step (iii)&nbsp;above; (c)&nbsp;the stand-alone selling price for each performance obligation identified in the contract
for the allocation of transaction price in step (iv)&nbsp;above; and (d)&nbsp;the contract term and pattern of satisfaction of the performance obligations under step (v)&nbsp;above. The Company uses judgment to determine whether milestones or other
variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the
Company recognizes revenue as or when the performance obligations under the contract are satisfied. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Amounts due to the Company for satisfying the revenue
recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#146;s consolidated balance sheet. Amounts received prior to satisfying the revenue
recognition criteria are recorded as deferred revenue in the Company&#146;s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as current deferred
revenue. Amounts not expected to be recognized as revenue within the 12&nbsp;months following the balance sheet date are classified as deferred revenue, net of current portion. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:2%; font-size:9.5pt; font-family:ARIAL"><B><I>Upfront License Fees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the license to the
Company&#146;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront
fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company
considers factors such as the research, manufacturing and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the
Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that
could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation
to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress
each reporting period and, if&nbsp;necessary, adjusts the measure of performance and related revenue recognition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:2%; font-size:9.5pt; font-family:ARIAL"><B><I>Customer Options
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services
underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire
additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company
allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material
right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right
performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Services </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The promises under the Company&#146;s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the
customer. Payments or reimbursements resulting from the Company&#146;s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements
from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as <FONT STYLE="white-space:nowrap">co-development</FONT> activities, are recorded as a reduction to
research and development expense. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:2%; font-size:9.5pt; font-family:ARIAL"><B><I>Milestone Payments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being
achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction
price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the
scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant
revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction
price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For further discussion of accounting for collaboration revenues, see Note&nbsp;7, &#147;<I>Collaboration and License Agreements.&#148;</I> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company measures and recognizes
stock-based compensation expense based on the grant date fair value of the awards. The Company calculates the fair value of restricted share unit awards based on the&nbsp;grant date fair value of the underlying common stock. The Company recognizes
stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards
when the underlying performance conditions are considered probable of occurrence, using the accelerated attribution method. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company classifies stock-based
compensation expense in its consolidated statement of operations and comprehensive loss in the same manner in which the award recipients&#146; payroll costs are classified or in which the award recipients&#146; service payments are classified. The
Company also has the right and option to repurchase an individual&#146;s shares of common stock or vested stock options to acquire common stock within 18&nbsp;months of an employee termination. The Company assesses the classification of an
individual&#146;s shares of common stock or vested stock options between equity and liability when the individual&#146;s separation from the Company becomes probable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of common stock underlying share-based awards is based on an estimate at each grant date by the Company&#146;s board of directors. The Company determines
the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid,
<I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. The fair value of each share option grant was determined using assumptions discussed below. Each of these inputs is subjective and generally requires judgment and
estimation by management. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected Term</I>. The Company estimated the expected term using the simplified method, which is an average of the contractual term of
the option and the vesting period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected Volatility</I>. Since there is limited historical data for the Company&#146;s common stock and limited
company-specific historical volatility, the Company has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company
considers factors such as industry, stage of life cycle and size. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Risk-free Interest Rate</I>. The risk-free interest rate is based on the U.S.&nbsp;Treasury yield in effect at the time
of the grant for <FONT STYLE="white-space:nowrap">zero-coupon</FONT> U.S.&nbsp;Treasury notes with remaining terms similar to the expected term of the options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividend Rate</I>. The expected dividend was assumed to be zero as the Company has never paid dividends and has no current plans to do so. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment are recorded at cost.
Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the
determination of net loss. Depreciation on equipment is calculated on the straight-line method over the estimated useful lives of the assets as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ESTIMATED USEFUL LIFE</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;remaining&nbsp;lease&nbsp;term</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company evaluates its long-lived
assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to
future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the
assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were recognized for these assets in the years ended December 31, 2018 and 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for leases in accordance with ASC
Topic&nbsp;842, <I>Leases</I>, or ASC&nbsp;842. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances present, the existence of an identified asset(s), if
any, and the Company&#146;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are
recorded based on the present value of future lease payments over&nbsp;the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which
is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
elected to combine lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components as a single component for all leases. Operating leases are recognized on the balance sheet as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, operating lease liabilities, current and operating lease liabilities, net of current. Fixed rents are included in the calculation of the lease
balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are expensed
as incurred. Research and development costs include salaries, share-based compensation and other employee benefit expenses, lab related supplies and other operational costs related to the Company&#146;s research and development activities, including
allocated facility-related expenses and external costs of outside vendors engaged to conduct research and development activities. Costs associated with licenses of technology and patent costs are expensed as&nbsp;incurred and are included in
research and development expense in the consolidated statement of operations and comprehensive loss. As part of the process of preparing the consolidated financial statements, the Company is required to estimate their accrued research and
development expenses. The Company makes estimates of the accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known at that time. In addition, there may be instances in which
payments made to the Company&#146;s vendors will exceed the level of services provided and result in a prepayment of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the expense in which case such amounts are reflected as prepaid expenses and other current assets. In accruing service fees, the Company estimates the time period over which services will be
performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly.
Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed as the
related goods are delivered or the services are performed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequence of events that have been recognized in the financial statements or the Company&#146;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated
financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income
taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion
of the deferred tax assets will not be realized, a valuation allowance is established. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for uncertain tax positions recognized in the
consolidated financial statements by prescribing a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the
effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive loss is defined as the change in
equity of a business enterprise during a period from transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. For the year ended December&nbsp;31, 2018, the Company had unrealized gains, which
were a component of comprehensive loss. For the year ended December&nbsp;31, 2019, the Company did not have any unrealized gains or losses and comprehensive loss was equal to net loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Commitments and Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Liabilities for loss contingencies
arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be&nbsp;reasonably estimated. Legal costs incurred in connection with loss
contingencies are expensed as incurred. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share and diluted net loss per share are computed using the weighted-average number of shares of common stock outstanding for the period. Net loss
per share attributable to common stockholders is calculated using <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method,</FONT> which is an earnings allocation formula that determines net loss per share for the holders of shares of the
Company&#146;s common stock and participating securities. The Company&#146;s Preferred Stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. The participating securities do not include
a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Diluted net loss per share is computed using the more dilutive of <FONT STYLE="white-space:nowrap">(a)&nbsp;the&nbsp;two-class&nbsp;method</FONT> or (b)&nbsp;the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of
shares of common stock included in the computation of diluted net loss gives effect to all potentially dilutive common stock equivalent shares, including outstanding stock options and Preferred Stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports
a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have
been issued if their effect is anti-dilutive. The Company reported net losses attributable to common stockholders for the years ended December&nbsp;31, 2018 and 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Standards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2018, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;)
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation</I>&#151;<I>Stock Compensation</I> (Topic&nbsp;718): <I>Improvements to Nonemployee Share-Based Payment Accounting </I>(&#147;ASU
<FONT STYLE="white-space:nowrap">2018-07&#148;).</FONT> The amendments in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Under this ASU, an entity should apply
the requirements of Topic&nbsp;718 to&nbsp;nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of
cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#146;s own operations by issuing share-based
payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1)&nbsp;financing to the issuer or (2)&nbsp;awards granted in conjunction with selling goods or services to customers as
part of a contract accounted for under Topic 606, <I>Revenue from Contracts with Customers</I>. The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> on January&nbsp;1, 2018, and the adoption did not have a material impact on the
consolidated financial statements or financial statement disclosures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2018, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-18,</FONT> <I>Collaborative Arrangements</I> (Topic 808): <I>Clarifying the Interaction between Topic 808 and Topic 606 </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2018-18&#148;),</FONT> to clarify when
ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if
the counterparty is not a customer for that transaction. The guidance is effective for public business entities in fiscal years beginning after December&nbsp;15, 2019, and interim periods therein. Early adoption is permitted to entities that have
adopted ASC 606. The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-18</FONT> as of January&nbsp;1, 2018, and the adoption did not have a material impact on the consolidated financial statements or financial statement disclosures. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Issued Accounting Standards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2019, the FASB
issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes</I> (Topic 740): <I>Simplifying the Accounting for Income Taxes</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;),</FONT> which is intended to simplify
various aspects related to accounting for income taxes. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent
application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact that the
adoption of ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> may have on the Company&#146;s consolidated financial statements and financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(3) Fair Value Measurements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables present information about
the Company&#146;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&nbsp;31, 2018 and 2019 (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>QUOTED&nbsp;PRICES&nbsp;IN<BR>ACTIVE&nbsp;MARKETS&nbsp;FOR<BR>IDENTICAL ASSETS<BR>(LEVEL 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER<BR>OBSERVABLE&nbsp;INPUTS<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER<BR>OBSERVABLE&nbsp;INPUTS</B><br><B>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Asset</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>QUOTED&nbsp;PRICES&nbsp;IN<BR>ACTIVE&nbsp;MARKETS&nbsp;FOR<BR>IDENTICAL ASSETS<BR>(LEVEL 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER<BR>OBSERVABLE&nbsp;INPUTS<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER<BR>OBSERVABLE&nbsp;INPUTS<BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Asset</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been no transfers between fair value levels during the years ended December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(4) Property and Equipment </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consisted of the
following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total depreciation and amortization for the years ended December&nbsp;31, 2018 and 2019 was $1.3&nbsp;million and $1.6&nbsp;million, respectively. Of the
$1.3&nbsp;million for the year ended December&nbsp;31, 2018, $1.2&nbsp;million was recorded in research and development expenses and $35,000 was recorded in general and administrative expenses. Of the $1.6&nbsp;million for the year ended
December&nbsp;31, 2019, $1.5&nbsp;million was recorded in research and development expenses and $46,000 was recorded in general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(5)
Leases </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2016, the Company entered into a lease of office and laboratory space for its headquarters at 675 West Kendall Street in Cambridge,
Massachusetts (the &#147;Cambridge Lease&#148;). The Cambridge Lease commenced in January 2016 and expired in April 2018. Operating lease costs were $1.5&nbsp;million for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2017, the Company entered into a lease of office and laboratory space for its headquarters at 490 Arsenal Way in Watertown, Massachusetts (the &#147;Watertown
Lease&#148;). The Watertown Lease commenced in April 2018 with rent commencing in May 2018, and the Company recognized operating lease costs of $1.8&nbsp;million and $2.6&nbsp;million for the years ended December&nbsp;31, 2018 and December&nbsp;31,
2019, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2018, the Company incurred construction costs for the Watertown Lease of $1.0&nbsp;million through April 2018 that were recorded as
prepaid rent, resulting in a balance of $1.5&nbsp;million total construction costs funded by the Company, for which it is not deemed the accounting owner. Upon the commencement of the Watertown Lease in April 2018, the Company recorded a lease
liability of $15.1&nbsp;million, which is representative of the remaining discounted lease payments. Of the $15.1&nbsp;million lease liability, $0.8&nbsp;million was classified as an operating lease liability, current and $14.3&nbsp;million was
classified as operating lease liability, net of current, respectively. In addition, $16.7&nbsp;million was recorded as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset on the Company&#146;s
consolidated balance sheet, inclusive of the construction costs funded by the Company of $1.5&nbsp;million that was reclassified from prepaid rent to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
asset. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Watertown Lease has a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> term of ten years with an option to
extend for one additional five-year period. As the Company does not deem the exercise of this option to be reasonably certain, it is not included in the measurement of the lease liability. The fixed annual rent payable under the Watertown Lease is
$2.1&nbsp;million, with rent escalations throughout the term. The Company is responsible for paying its pro rata share of costs incurred for common area maintenance, real estate taxes and property insurance related to the leased space. Using the
relevant assumptions at the commencement date, the Company has concluded the lease classification to be operating. The total rent payments to be paid over the <FONT STYLE="white-space:nowrap">non-cancelable</FONT> term of the Watertown Lease is
$24.1&nbsp;million. The Company incurred $1.3&nbsp;million and $0.5&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively, for leasehold improvements to be paid for by the Company. The lease agreement required the Company to
provide collateral in the amount of $2.6&nbsp;million, which is recorded as restricted cash on the accompanying consolidated balance sheets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2018, assets under the Watertown Lease classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets on the Company&#146;s consolidated balance sheet were $15.6&nbsp;million.
Liabilities under the Watertown Lease were $14.5&nbsp;million, of which $0.7&nbsp;million were classified as operating lease liability, current, and $13.7&nbsp;million were classified as operating lease liability, net of current, on the
Company&#146;s consolidated balance sheet. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019, assets under the Watertown Lease classified as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets on the Company&#146;s consolidated balance sheet were $14.5&nbsp;million, net of accumulated amortization. Liabilities under the Watertown Lease were $13.7&nbsp;million, of which
$0.9&nbsp;million were classified as operating lease liability, current, and $12.9&nbsp;million were classified as operating lease liability, net of current, on the Company&#146;s consolidated balance sheet. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the Company recorded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> amortization of $2.3&nbsp;million and
$1.1&nbsp;million for the years ending December&nbsp;31, 2018 and 2019, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The elements of lease costs were as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lease cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other information:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating cash flows for operating liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities arising from obtaining <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average remaining lease term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases as of December&nbsp;31, 2019 were (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>FUTURE OPERATING LEASE PAYMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating lease liabilities at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(6) Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other current liabilities consisted of the following as of December&nbsp;31, 2018 and 2019 (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(7) Collaboration and License Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the
balance sheet and income statement impact of the collaboration and license agreements on the Company&#146;s consolidated balance sheets and consolidated statement of operations and comprehensive loss as of and for the year ended December&nbsp;31,
2018 and 2019: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial information related to the collaboration and license agreements consisted of the following as of and for the years ended December&nbsp;31,
2018 and 2019 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER 31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCOUNTS<BR>RECEIVABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COLLABORATION<BR>REVENUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED<BR>REVENUE,<BR>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED<BR>REVENUE,<BR>NET OF<BR>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED<BR>REVENUE,<BR>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Original Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restated Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biogen License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Calico License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER 31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCOUNTS<BR>RECEIVABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COLLABORATION<BR>REVENUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED<BR>REVENUE,<BR>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED<BR>REVENUE,<BR>NET OF<BR>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED<BR>REVENUE,<BR>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restated Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biogen License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Calico License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Roche Collaboration and License Agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Original Roche Agreement Structure </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2016,
the Company entered into a license agreement (the &#147;Original Roche Agreement&#148;) with <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc. (&#147;Roche&#148;).
Pursuant to the terms of the Original Roche Agreement, the Company and Roche agreed to collaborate on research activities to develop novel treatments in the field of targeted protein degradation (&#147;TPD&#148;) using the Company&#146;s degrader
technology. Under the terms of the Original Roche Agreement, the Company initially developed TPD therapeutics that utilize degrader technology for up to ten target proteins until the earlier of the exercise of the option right or termination for the
last available target. On a <FONT STYLE="white-space:nowrap">target-by</FONT> target basis, after successful completion of a defined preclinical development phase, Roche had an exclusive option to pursue further clinical development and
commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In exchange for a $15.0&nbsp;million nonrefundable upfront payment and additional fees for dedicated personnel, the
Company performed initial research and development services for drug discovery and preclinical development, provided a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and development license to its technology and participated on the
joint research committee (the &#147;Roche JRC&#148;). For each target option exercised by Roche, the Company was eligible to receive up to $277.0&nbsp;million in research, development and commercial milestone payments, with the commercial milestones
being dependent on underlying net sales. Roche was also required to pay the Company up to $150.0&nbsp;million in <FONT STYLE="white-space:nowrap">one-time</FONT> sales-based payments for the first product to achieve certain levels of net sales. In
addition, Roche was required to pay the Company royalties, at percentages from the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to the low <FONT STYLE="white-space:nowrap">double-digits,</FONT> on a licensed <FONT
STYLE="white-space:nowrap">product-by</FONT> licensed product basis, on worldwide net product sales. The research and development was to be performed by the Company over an estimated period of approximately 42 months per target according to the
research plan. Roche also reimbursed the Company for up to five full-time equivalents (&#147;FTEs&#148;) (&#147;FTE Funding&#148;) per target unless otherwise agreed upon by the Roche JRC. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Restated Roche Agreement Structure </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
December&nbsp;22, 2018, the Company and Roche executed the Amended and Restated Roche License Agreement (the &#147;Restated Roche Agreement&#148;). Under the Restated Roche Agreement, the Company has a more active role in the manufacturing and
commercialization of the targets, whereby if certain <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT STYLE="white-space:nowrap">co-detailing</FONT> rights are opted into by the Company, the parties will split future development
costs in return for the rights to a larger share of future earnings from commercialization of the target. The target structure was revised to six potential targets, three of which were nominated as of the execution of the Restated Roche Agreement
and represent continuations of the initial preclinical research and development efforts begun under the Original Roche Agreement and three additional targets that were not nominated as of the execution of the Restated Roche Agreement. Roche
maintained its option rights to license and commercialize these six targets. For certain targets, Roche is required to pay the Company fees of $2.0&nbsp;million and $3.0&nbsp;million upon the progression of targets to the lead series identification
achievement and good laboratory practice (&#147;GLP&#148;) toxicology (&#147;Tox&#148;) study phase, respectively. For each target option exercised by Roche, the Company is eligible to receive up to $275.0&nbsp;million in research and development
milestones per target and commercial milestone payments, with the commercial milestones being dependent on underlying net sales. Roche is also required to pay the Company up to $150.0&nbsp;million per target in
<FONT STYLE="white-space:nowrap">one-time</FONT> sales-based payments if the target achieves certain levels of net sales. In addition, Roche is required to pay the Company royalties, at percentages from the
<FONT STYLE="white-space:nowrap">mid-single</FONT> digits to the low <FONT STYLE="white-space:nowrap">double-digits,</FONT> on a licensed <FONT STYLE="white-space:nowrap">product-by</FONT> licensed product basis, on worldwide net product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Restated Roche Agreement: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Company received additional upfront consideration of $40.0&nbsp;million from Roche; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Company has an option for <FONT STYLE="white-space:nowrap">co-development</FONT> and
<FONT STYLE="white-space:nowrap">co-detailing</FONT> rights, whereby it would be required to provide additional financial support in return for the rights to a larger share of future earnings from commercializing one or more of the six targets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Roche will no longer provide FTE reimbursement; rather, it will make annual research plan payments of $1.0&nbsp;million
for each active research plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adjustments were made to the option exercise fees, whereby certain targets now have option exercise fees of
$7.0&nbsp;million to $12.0&nbsp;million (those progressed up to Phase 1 or through the GLP Tox studies, respectively) and others have $20.0&nbsp;million (those progressed through clinical trials). </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The collaboration is managed by a joint research committee. The Company has control over the committee and may terminate the Restated Roche Agreement on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis under several scenarios, upon at least
90&nbsp;days&#146; prior written notice. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Restated Roche Agreement Accounting </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Restated Roche Agreement is a modification of the Original Roche Agreement under ASC 606 as both the scope and price of the contract were changed under the Restated
Roche Agreement and new, distinct performance obligations were created for targets that have different standalone selling prices based on the Company&#146;s revised obligations. The Restated Roche Agreement was not determined to be a separate
contract for accounting purposes. The modification was accounted for as if it were a termination of the existing contract and the creation of a new contract, for which the unrecognized consideration from the Original Roche Agreement is added to the
new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
transaction price promised as part of the Restated Roche Agreement and will be recognized as revenue prospectively, as the new performance obligations are satisfied. The Company made this
determination after considering the performance obligations under the Restated Roche Agreement. When the amendment was signed, the contract was restructured such that the Company would pursue some of the same targets, but would have additional
material responsibility to potentially develop the targets beyond the option exercise point, to either Phase 1 completion or to a point where the Company will exercise its <FONT STYLE="white-space:nowrap">co-development</FONT> and <FONT
STYLE="white-space:nowrap">co-detailing</FONT> options and more fully share in the costs and future revenues. The $40.0&nbsp;million upfront payment, $13.5 million of expected research plan funding payments, plus $6.4&nbsp;million of remaining
deferred revenue from the Original Roche Agreement represent the transaction price as of the outset of the arrangement. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company assessed this arrangement
in accordance with ASC 606 and concluded that the contract counterparty, Roche, is a customer. The Company identified the following promises at the outset of the Restated Roche Agreement: (1)&nbsp;a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> royalty-free license to use the Company&#146;s intellectual property to conduct research and development activities; (2)&nbsp;research and development services under the research plan for the
three initial targets; (3)&nbsp;participation on the Roche JRC; (4)&nbsp;option rights to initiate a research plan for three additional targets; (5) an option to obtain a non-exclusive commercial license to intellectual property and know-how
generated from the collaboration, subject to certain exclusivity requirements; (6) option rights to develop, commercialize and manufacture products related to any of the six targets; and (7)&nbsp;rights for Roche to substitute targets prior to
completion of a research plan, limited to six exchanges in total across the arrangement and subject to approval by the Roche JRC. The Roche JRC has equal representation from both parties, but the Company holds final decision-making authority in the
event of a disagreement until the time at which Roche licenses a target and leads development efforts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The six potential targets were determined to be distinct
from one another, as Roche can derive benefit from each target independent of the others. For each target, the Company determined that the research and development license and research and development services were not distinct from one another,
because the research and development services are essential to the license. Roche would receive little to no economic benefit from the license if it did not obtain the research services. Participation on the Roche JRC to oversee the research and
development activities and the technology transfer associated with the Original Roche Agreement were determined to be quantitatively and qualitatively immaterial. The Company evaluated Roche&#146;s option rights to initiate a research plan for three
additional targets as well as the option rights to license and commercialize each target to determine whether they provide Roche with any material rights. The Company concluded that each of the options were issued with an option exercise fee that
represented a significant and incremental discount and therefore provide material rights for six of the six targets&#151;three material rights from the option to license the three initial targets at the end of their research terms and three material
rights from the option to initiate a research plan for the three additional targets along with the option to license such at the end of their research terms. The consideration allocated to the option rights to initiate the three additional targets
is deferred until the underlying option is exercised, at which point the Company will begin recognizing revenue for these targets. The non-exclusive, limited commercial license to the intellectual property and know-how generated from the
collaboration was determined to be immaterial and, as such, no consideration was allocated to it. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on these assessments, the Company identified twelve
performance obligations, including three research services performance obligations, six material rights for the options to purchase a commercial license for six targets and three material rights for the option to initiate research services for the
uninitiated three targets as of the outset of the arrangement. The first three performance obligations primarily comprise: (1)&nbsp;the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and development license and (2)&nbsp;the research
and development services for the target, including the related substitution rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company included the $40.0&nbsp;million upfront payment, $13.5 million of
expected research plan funding payments ($1.0&nbsp;million per active target per year, for a maximum of $3.0 million per target), and $6.4&nbsp;million of remaining deferred revenue from the Original Roche Agreement in the transaction price as of
the outset of the arrangement. The Company also achieved a milestone for the identification of lead series for target 2 in April 2019, resulting in a milestone payment of $2.0 million, which was added to the transaction price and recognized
cumulatively. The transaction price of $61.9 million was allocated to the performance obligations based on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
estimated stand-alone selling prices at the time of the amendment. For each performance obligation, the stand-alone selling price was determined considering the expected cost of the research and
development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#146;s estimated probability of the
options&#146; exercise as of the time of the amendment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company allocated the following amounts of the total transaction price to the performance obligations
as of the amendment date, including the $2.0 million milestone achieved in April 2019: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">$29.0&nbsp;million to the research and development performance obligations for targets&nbsp;1-3; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">$4.1&nbsp;million to the three material rights, related to the three targets initiated at the outset of the Restated Roche
Agreement, which will not begin revenue recognition until the option is exercised or expires. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">$28.8&nbsp;million to the option to nominate targets 4-6 and the three material rights related to these options.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company will recognize the portion of the transaction price allocated to each of the research and development performance obligations as the
research and development services are provided, using an input method, according to costs incurred as related to the research and development activities for each individual program and the costs expected to be incurred in the future to satisfy that
individual performance obligation. The transfer of control occurs over this time period and, in management&#146;s judgment, is the best measure of progress towards satisfying the performance obligation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are
recorded in deferred revenue on the Company&#146;s consolidated balance sheet. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biogen Collaboration Research and License Agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December&nbsp;2018, the Company entered into a collaboration research and license agreement (the&nbsp;&#147;Biogen License Agreement&#148;) with Biogen MA, Inc.
(&#147;Biogen&#148;). Pursuant to the terms of the Biogen License Agreement, the Company and Biogen agreed to collaborate on research activities to develop novel treatments in the field of TPD using the Company&#146;s degrader technology. Under the
terms of the Biogen License Agreement, the Company will initially develop TPD therapeutics that utilize degrader technology for up to five target proteins over a period of 54 months. On a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis, after successful completion of a defined target evaluation period, Biogen assumes full rights and responsibility to each degrader to meet certain criteria against a target. Biogen also
has the option to pay an additional $62.5&nbsp;million to extend the contract and select up to five additional targets for development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In exchange for the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> research license from Biogen as well as a $45.0&nbsp;million nonrefundable upfront payment, the Company will grant a license to develop, commercialize and manufacture products related to each of the
targets (which is contingent on not cancelling the contract), will perform initial research services for drug discovery, provide a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and commercial license to its intellectual property and
will participate on the joint steering committee (the &#147;Biogen JSC&#148;). The Company will also be obligated to participate in early research activities for other potential targets (&#147;Sandbox Activities&#148;) at Biogen&#146;s election up
to a maximum amount; any work performed for these services will be reimbursed by Biogen, and Biogen will reimburse the Company for certain FTE costs. Biogen is also required to pay the Company up to $35.0&nbsp;million per target in development
milestones and $26.0&nbsp;million per target in <FONT STYLE="white-space:nowrap">one-time</FONT> sales-based payments for the first product to achieve certain levels of net sales. In addition, Biogen is required to pay the Company royalties on a
licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, on worldwide net product sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
collaboration is managed by the Biogen JSC, which Biogen has control over, and Biogen may terminate the Biogen License Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis under several scenarios, upon at least 90&nbsp;days&#146; prior written notice. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The nonrefundable upfront cash payment of $45.0&nbsp;million is not creditable against any of the target development milestone fees. The research will be performed by
the Company over 54 months according to the research plan approved by the Biogen JSC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Biogen License Agreement Accounting </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company assessed this arrangement in accordance with ASC&nbsp;606 and concluded that the contract counterparty, Biogen, is a customer. The Company identified the
following promises under the arrangement: (1)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">royalty-free</FONT> license to use the Company&#146;s intellectual property to conduct research activities;
(2)&nbsp;an upfront license to develop, commercialize and manufacture products related to each of the targets (which is contingent on not cancelling the contract); (3)&nbsp;research services for preclinical activities under the research plan;
(4)&nbsp;participation on the Biogen JSC; and (5)&nbsp;substitution rights for Biogen via &#147;sandbox activities&#148; to replace targets prior to a program reaching completion of a research plan, limited to five exchanges in total. Substitution
is dependent on the original target failing to meet certain criteria; Biogen may only replace a target in this specific scenario. The Company also determined that Biogen&#146;s ability to terminate the Agreement
<FONT STYLE="white-space:nowrap">at-will</FONT> with 90 days&#146; notice is not representative of a substantive purchase option to continue to the research and does not provide a material right in the form of a continuous renewal option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company determined that the licenses and research activities were not distinct from one another, as the licenses have limited value without the performance of the
research activities by the Company. Participation on the Biogen JSC to oversee the research activities and the technology transfer associated with the Biogen License Agreement were determined to be quantitatively and qualitatively immaterial and
therefore are excluded from performance obligations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on these assessments, the Company identified one performance obligation at the outset of the Biogen
License Agreement, representing a combined performance obligation consisting of (1)&nbsp;the licenses, (2)&nbsp;the research activities for the target evaluation phase for all five targets and (3)&nbsp;the joint research plan phase for each target.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company will recognize the transaction price as the research and development services are provided, using an input method, according to costs incurred as
related to the research and development activities for the costs expected to be incurred in the future to satisfy that individual performance obligation. The transfer of control occurs over this time period and, in management&#146;s judgment, is the
best measure of progress towards satisfying the performance obligation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biogen also has the option to fund &#147;sandbox activities&#148; in exchange for
consideration, whereby the Company will perform discovery-type research at Biogen&#146;s election to develop other potential targets that may be used as replacement targets for the initially nominated targets or two additional targets under the
Biogen Agreement. Revenues earned under this option, if initiated, will be recognized as services are performed and are not included in the transaction price. Sandbox research activities will be reimbursed on an FTE basis at market rates, which is
adjusted for changes in the &#147;Consumer Price Index&#148; each year. The sandbox activities constitute additional research that can be purchased on an a la carte basis at an amount consistent with standalone selling price. The Company recognizes
revenue as the services performed for the sandbox activities are performed, and recognized $0 and $0.5&nbsp;million of revenue for the years ended December&nbsp;31, 2018 and 2019, respectively, related to the sandbox activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes FTE reimbursement related to sandbox activities as revenue as the hours are incurred each quarter. Amounts due to the Company that have not yet
been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#146;s consolidated balance sheet. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Calico Collaboration and License Agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March&nbsp;2017, the
Company entered into a collaboration and license agreement (the&nbsp;&#147;Calico License Agreement&#148;) with Calico Life Sciences LLC (&#147;Calico&#148;) whereby the Company and Calico agreed to collaborate to develop and commercialize small
molecule protein degraders for diseases of aging, including cancer for a five-year period ending in March 2022 (the &#147;research term&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of
the Calico License Agreement, the Company will initially develop and commercialize small molecule protein degraders for up to five target proteins over the research term. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis, after successful completion of a defined target evaluation period, Calico has an exclusive option to pursue further <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development and commercialization via a joint research plan for each target. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Calico License Agreement, Calico paid an upfront amount of $5.0&nbsp;million and certain annual payments
totaling $5.0&nbsp;million through June&nbsp;30, 2020, and pays target initiation fees and reimburse the Company for a number of FTEs, depending on the stage of the research, at specified market rates. Upon completion of the required discovery
research and development services on any target, Calico is entitled to pursue commercial development of that target. The Company will perform initial research services for drug discovery and preclinical development, provide a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> research and commercial license to its IP and will participate on the Calico joint research committee (the &#147;CJRC&#148;). For each target, the Company is eligible to receive up to
$132.0&nbsp;million in potential research, development and commercial milestone payments, on sales of all products resulting from the collaboration efforts. Calico is also required to pay the Company up to $65.0&nbsp;million in <FONT
STYLE="white-space:nowrap">one-time</FONT> sales-based payments for the first product to achieve certain levels of net sales. In addition, Calico is required to pay the Company royalties, at percentages in the
<FONT STYLE="white-space:nowrap">mid-single</FONT> digits, on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product basis, on worldwide net product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Calico License Agreement is managed by a joint research committee (the &#147;CJRC&#148;). Calico has control over the CJRC and may terminate the Calico License
Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis under several scenarios, upon
prior written notice. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The nonrefundable upfront and certain annual payments are not creditable against any other payments. Calico will reimburse the Company for a
contractually defined number of FTEs (&#147;Calico FTE Funding&#148;) per target depending on the phase of development, unless otherwise agreed upon by the CJRC. The research will be performed by the Company over the research term in accordance with
the research plan. For the years ended December&nbsp;31, 2018 and 2019, the Company received $0.0 and $2.0&nbsp;million in cash consideration for milestone revenue, respectively and no additional consideration in the form of cash received for target
initiation fees. The Company recorded an accounts receivable of $1.0&nbsp;million for additional target initiation fees in 2019, and received payment in 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><B><I>Calico License Agreement Accounting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
assessed this arrangement in accordance with ASC&nbsp;606 and concluded that the contract counterparty, Calico, is a customer. The Company identified the following promises under the arrangement: (1)&nbsp;the
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free research license and commercial license, which function for purposes of the arrangement as a license and are therefore analyzed together; (2)&nbsp;the target evaluation research
services for all five targets; (3)&nbsp;the joint research plan research services related to targets 1 and 2, which were nominated at the execution of the Calico License Agreement; (4)&nbsp;the target initiation rights/options associated with
targets 3, 4 and 5, subject to nomination; and (5)&nbsp;the joint research plan services associated with targets 3, 4 and 5, subject to nomination and payment of the target initiation fees from (4). The Company determined that the license and
research activities were not distinct from one another, as the license has limited value without the performance of the research activities by the Company. Participation on the CJRC to oversee the R&amp;D activities and the technology transfer
associated with the Calico License Agreement were determined to be quantitatively and qualitatively immaterial and therefore are excluded from performance obligations. The Company determined that the option rights to nominate the targets were not
distinct from one another or from the other promises in the arrangement, specifically the research license and research services. The Company evaluated the target initiation rights for targets 3, 4 and 5 and the research services associated with the
joint research plan nomination for these targets to determine whether they provide Calico with any material rights. The Company concluded that these options were not issued at a significant and incremental discount and therefore do not provide
material rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on these assessments, the Company identified one performance obligation at the outset of the Calico License Agreement, which consists of:
(1)&nbsp;the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license and (2)&nbsp;the research activities for the target evaluation phase for all five targets and the joint research plan phase for targets 1 and 2. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Calico License Agreement, the transaction price determined by the Company is the upfront amount plus the committed anniversary payments and the target
initiation fees related to the targets nominated at the execution of the Calico License Agreement. Based on the ability of Calico to cancel the arrangement for any reason, Calico effectively has an option for continued access to the Company&#146;s
research license and procurement of research services that they can cancel at any time. Under the Calico License Agreement, the Company amortized the upfront fee received on a straight-line basis over the period services are available to the
counterparty (i.e. the contractual term of five years). Straight-line amortization of the upfront payment was considered the best measure of progress because the customer has access to research and development services throughout the period.
Incremental fees for research and development services are paid at agreed upon FTE rates and recognized in the period incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that
have not yet been recognized as revenue are recorded in deferred revenue on the Company&#146;s consolidated balance sheet. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dana Farber License Agreements
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;15, 2015, the Company entered into a License Agreement (the &#147;DFCI License Agreement&#148;) with Dana-Farber Cancer Institute, Inc.
(DFCI), through which the Company obtained an exclusive, royalty-bearing license to DFCI&#146;s rights to use certain technology to develop licensed products. Pursuant to the DFCI License Agreement and subsequent First and Second Amendments, the
Company is responsible for royalty payments associated with commercialization of the products and annual maintenance fees. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Simultaneously with the entry into
the DFCI License Agreement, the Company issued 903,539 shares of the Company&#146;s common stock at the fair value of the stock of $2.11 per share, or $1.9&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;4, 2016, the Company entered into another license agreement with DFCI (the &#147;DFCI Second License Agreement&#148;), through which the Company
obtained an exclusive, royalty-bearing license to DFCI&#146;s rights to use certain technology to develop licensed product. The Company paid DFCI a license fee of $0.1&nbsp;million and reimbursed DFCI $18,000 for patent costs related to the DFCI
Second License Agreement. Pursuant to the DFCI Second License Agreement, the Company is responsible for royalty payments associated with commercialization of the products and annual maintenance fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company made payments under the DFCI Second License Agreement of less than $0.1&nbsp;million for each of the years ended December&nbsp;31, 2018 and 2019. The
Company terminated the DFCI License Agreement in February 2020 and has no additional payments due under the agreement as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(8)
Stockholder&#146;s Equity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On
November&nbsp;19, 2015, the Company issued 384,180 shares of restricted stock to certain of its founders for $0.0001 per share for net proceeds of less than $1,000. On December&nbsp;16, 2015, the Company issued 903,539 shares of restricted common
stock to DFCI in conjunction with the DFCI License Agreement (see Note&nbsp;7). The fair value of the equity instrument issued was the most reliably measurable fair value of the transaction and the Company recorded the 903,539 shares in equity at
fair value, or $1.9&nbsp;million. The founders&#146; common stock vest quarterly over three&nbsp;years (see Note&nbsp;9) and DFCI&#146;s common stock were fully vested at the time of issuance. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Features of the Common Stock </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The common stock has a par value of $0.000125,
and the holders of common stock are entitled to one vote for each share held at all meetings of stockholders and written actions in lieu of meetings provided. All dividends shall be declared and paid pro rata according to the number of shares held
by each member. In the event of a liquidation, dissolution or winding up of the Company, the common stock ranks behind the Preferred Stock in terms of distribution of assets. The holders of the common stock have no preemptive or other subscription
rights, and there are no redemption or sinking fund provisions with respect to such stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following represents the Preferred Stock transactions of the Company from January&nbsp;1, 2018 through December&nbsp;31, 2019. On December&nbsp;31, 2018, the
Company issued 900,900 shares of its Series A Preferred Stock to an investor at $2.22 per share for total gross proceeds of $2.0&nbsp;million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2018 and 2019, Preferred Stock consisted of the following (in thousands, except share data): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED<BR>STOCK<BR>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED&nbsp;STOCK<BR>ISSUED AND<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CARRYING<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LIQUIDATION<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON&nbsp;STOCK<BR>ISSUABLE<BR>UPON<BR>CONVERSION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FF Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,416,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED<BR>STOCK<BR>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED&nbsp;STOCK<BR>ISSUED AND<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CARRYING<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LIQUIDATION<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON&nbsp;STOCK<BR>ISSUABLE<BR>UPON<BR>CONVERSION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FF Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,416,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the rights and privileges of the Preferred Stockholders as of December&nbsp;31, 2018 and 2019: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conversion </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All series of Preferred Stock are convertible at any time at
the option of the holder and mandatorily convertible upon a qualified initial public offering into common stock on a 8.4335-to-one basis (see note 13). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voting </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All series of Preferred Stock have voting rights that are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> with common stock, as if they were converted into common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Redemption
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock is not redeemable except in the event of a liquidation. The Series&nbsp;Seed Preferred Stock and Series&nbsp;A Preferred Stock receive
liquidation payments at their respective issuance prices in preference to the common stock. Because the Series&nbsp;A Preferred Stock and Series&nbsp;Seed Preferred Stock are only mandatorily redeemable upon the occurrence of a liquidation event and
the preferred stockholders have control of the Company&#146;s board of directors, they are classified in the mezzanine section of the balance sheet. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series&nbsp;A Preferred Stock has dividend preference over all other common and Preferred Stock. The Series&nbsp;Seed Preferred Stock is eligible to
receive dividends on a pro rata <FONT STYLE="white-space:nowrap">as-converted</FONT> basis in&nbsp;proportion to the number of shares of common stock that would be held upon conversion to common stock. The Series A Preferred Stock accrues dividends
at a rate of $0.08 per annum, payable only if and when declared by the Company&#146;s board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(9) Stock-based Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;28, 2015, the Company&#146;s board of directors adopted the 2015 Incentive Stock Option and Grant Plan (the&nbsp;&#147;2015 Plan&#148;) and reserved
2,525,327 shares of common stock for issuance under this plan. As of December&nbsp;31, 2019, 1,182,076 shares remain available for future grant. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2015 Plan
authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options and restricted stock awards to eligible employees, outside directors and consultants of the Company. Options generally vest
over a period of five or eight&nbsp;years with a cliff vesting at one&nbsp;year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again. The contractual life of all options is ten&nbsp;years from
the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the issuance of stock options, the Company recorded stock-based compensation expense of $0.4&nbsp;million and
$1.6&nbsp;million in the years ended December&nbsp;31, 2018 and 2019, respectively. In connection with the issuance of restricted stock, the Company recorded share-based compensation expense of $0.2&nbsp;million for the year ended December&nbsp;31,
2018. As the restricted stock was fully vested as of December&nbsp;31, 2018, the Company did not record stock-based compensation expense related to restricted stock during the year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense for the year ended December&nbsp;31, 2018 and 2019 was classified in the consolidated
statement of operations and comprehensive loss as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock option activity under the 2015 Plan is summarized as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">WEIGHTED-AVERAGE</FONT><BR>EXERCISE PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">WEIGHTED-AVERAGE</FONT><BR>REMAINING<BR>CONTRACTUAL<BR>TERM (IN YEARS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,317,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 118,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(126,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,187,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,071,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93,797</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 337,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,310,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,801,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,740,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options exercisable as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,274,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019, the unrecognized compensation cost related to outstanding options was $4.2&nbsp;million, expected to be recognized over a weighted average
period of approximately three&nbsp;years. The aggregate fair value of options that vested during the years ended December&nbsp;31, 2018 and 2019 was $0.3&nbsp;million and $1.1&nbsp;million, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2018 and 2019, the weighted average grant date fair value for options granted was $2.36 and $4.13, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees during the years ended
December&nbsp;31, 2018 and 2019 were as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected option life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.35</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.75%&nbsp;-&nbsp;2.98%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.71%&nbsp;-&nbsp;2.36%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">58.9%&nbsp;-61.9%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65.5%&nbsp;-&nbsp;76.8%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.00%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$3.72&nbsp;-&nbsp;$4.90</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$6.50&nbsp;-&nbsp;$6.67</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$2.19&nbsp;-&nbsp;$2.95</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$4.05&nbsp;-&nbsp;$4.55</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All restricted stock issued <FONT STYLE="white-space:nowrap">to-date</FONT> were vested as of December&nbsp;31, 2018,
96,039 of which vested in 2018 and had a weighted-average grant date fair value of $2.11. There was $0.2&nbsp;million recognized for restricted stock for the year ending December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(10) Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income tax expense consists of the following (in
thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current tax provision:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current federal provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current state provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax provision:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred federal provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred state provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) Tax Rate Reconciliation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of income tax
expense/(benefit) computed at the statutory federal rate to income taxes as reflected in the consolidated financial statements is as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Pre-tax</FONT> book income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State tax&#151;net of federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) Significant Components of Deferred Taxes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred income taxes reflect the net tax effects of (a)&nbsp;temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes and (b)&nbsp;operating losses and tax credit carryforwards. Significant components of the Company&#146;s net deferred tax assets are as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capitalized <FONT STYLE="white-space:nowrap">start-up</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">R&amp;D and investment tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated the positive and negative evidence bearing upon the realizability of the deferred tax assets. As of December&nbsp;31, 2018, and
December&nbsp;31, 2019, based on the Company&#146;s historical operating losses, the Company has concluded that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the benefit of its deferred tax assets will not be realized.
Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December&nbsp;31, 2018 and December&nbsp;31, 2019. The valuation allowance for deferred tax assets as of December&nbsp;31, 2018 and 2019 was
$16.4&nbsp;million and $27.1&nbsp;million, respectively. The net valuation allowance increase of $10.7&nbsp;million during the year ended December&nbsp;31, 2019 was primarily due to the decrease in net operating loss and tax credits carryforward and
an increase in deferred revenue recognized during the year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the provisions of the Internal Revenue Code (&#147;IRC), the net operating loss and tax credit
carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative
changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the IRC, respectively, as well as similar state provisions. This could limit the amount of tax
attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes
may further affect the limitation in future years. The Company has completed various financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the IRC, and it may complete future financings
that could result in a change in control in the future. In 2020, the Company completed a study of ownership changes from inception through May&nbsp;31, 2020, to assess whether an ownership change has occurred or whether there have been multiple
ownership changes since its formation. The result of this study indicated that the Company experienced ownership changes as defined by IRS Section&nbsp;382 of the Code, however there are no net operating loss carryforwards that will be limited and
expire unused as a result of such ownership changes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019, the Company has no gross federal net operating loss carryforwards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019, the Company has total gross state net operating loss carryforwards of $8.2&nbsp;million which may be available to offset future income tax
liabilities that will begin to expire in 2038. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2019, the Company has research credit carryforwards of $0.4&nbsp;million and $0.1&nbsp;million
for federal and state income tax purposes, respectively, which are available to offset future federal and state income tax expense, if any, at various dates through 2039. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company will recognize interest and/or penalties related to uncertain tax benefits in income tax expense as they arise. As of December&nbsp;31, 2018 and 2019, the
Company had no accrued interest or penalties related to uncertain tax benefits. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company files income tax returns in the United States, California,
Massachusetts and Maryland. The federal and state income tax returns are generally subject to tax examinations for the tax years ended December&nbsp;31, 2015 through December&nbsp;31, 2019. To the extent that the Company has tax attribute
carryforwards, the tax years in which the attributes were generated may still be adjusted upon examination by the Internal Revenue Services or State tax authorities to the extent utilized in a future period. The Company is not currently under
examination by any tax authorities. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted on March&nbsp;27, 2020. The CARES Act is an
approximately $2 trillion emergency economic stimulus package in response to the Coronavirus outbreak, which among other things contains numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for
years ending before the date of enactment. The Company is currently evaluating the impact of the CARES Act on its consolidated financial position, results of operations and cash flow, but does not expect the impact to be material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(11) Loss Per Share </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per share is computed by
dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands, except share and per share data): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,293,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s potentially dilutive securities, which include Preferred Stock and stock options, have been
excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share
attributable to common stockholders is the same. The Company excluded the following common stock equivalents, which include the following shares of preferred stock converting into the Company&#146;s common stock at a ratio of 8.4335-to-one, from the
computation of diluted net loss per share attributable to common stockholders as of December&nbsp;31, 2018 and 2019 because including them would have had an anti-dilutive effect: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,310,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,773,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,727,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma
basic and diluted net loss per share attributable to common stockholders for the year ended December 31, 2019 has been prepared to give effect to the automatic conversion of all outstanding shares of redeemable convertible preferred stock upon the
closing of the proposed initial public offering into 13,416,155 shares of common stock as if the conversion had occurred on the later of January 1, 2019 or the issuance of the redeemable convertible preferred stock. The unaudited pro forma net loss
attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders does not include the effects of Preferred Stock dividends because the calculation gives
effect to the automatic conversion of all shares of Preferred Stock outstanding as of December 31, 2019 into shares of common stock as if the proposed IPO had occurred on the later of January&nbsp;1, 2019 or the issuance date of the preferred stock.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma basic and diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss
per share attributable to common stockholders for the year ended December 31, 2019 has been prepared to give effect, upon a qualified IPO, to the automatic conversion of all outstanding shares of convertible preferred stock into common stock as if
the proposed IPO had occurred on the later of January&nbsp;1, 2019 or the issuance date of the preferred stock. Pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>YEAR ENDED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER 31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma adjustment to reflect automatic conversion of convertible preferred stock to common stock upon
the completion of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,416,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,788,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(12) Defined Contribution Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has a 401(k) retirement plan (the&nbsp;401(k)&nbsp;Plan), whereby all full-time employees may contribute up to 90% of their
<FONT STYLE="white-space:nowrap">pre-tax</FONT> compensation, up to the maximum allowable amount set by the Internal Revenue Service. The Company matches 100% of contributions to the 401(k)&nbsp;Plan up to a maximum of $6,000 per year for each
full-time employee. During each of the years ended December&nbsp;31, 2018 and 2019, the Company contributed approximately $0.4&nbsp;million to the 401(k)&nbsp;Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(13) Subsequent Events </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated subsequent events from
the balance sheet date through the issuance date of these </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">consolidated financial statements and has not identified any requiring disclosure except as noted below.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>President and Chief Executive Officer Termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March 3,
2020 (&#147;Separation Date&#148;), the Company&#146;s president and chief executive officer (&#147;CEO&#148;) terminated employment with the Company. Pursuant to the severance agreement, the Company will pay the CEO $0.8 million in the eighteen
months following the Separation Date. The Company repurchased all of the CEO&#146;s exercised shares for total consideration of $0.1 million. The CEO also relinquished his right to purchase vested options, for total consideration paid by the Company
of $0.7 million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series B Financing and Term Loan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June and
July, 2020, the Company closed a $150.0 million series B redeemable convertible preferred stock financing (&#147;Series B Financing&#148;) with existing and new investors. As part of the Series B Financing, the Company issued 142,857,142 redeemable
convertible series B preferred stock shares (&#147;Series B Preferred Stock&#148;), at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0 million. Series B Preferred Stock shares accrue dividends of $0.084 per annum, payable
only if and when declared by the Company&#146;s board of directors, and Series B Preferred Stock is only redeemable in the event of a deemed liquidation. Shares of Series B Preferred Stock vote pro rata with common stock, and the Series B
stockholders are entitled to elect two members of the Company&#146;s board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In contemplation of the Series B Financing, the Company also entered into
a Credit Agreement and Guaranty (&#147;Credit Agreement&#148;), under which the Company may borrow up to $20.0 million from Perceptive Credit Holdings&nbsp;III, LP (&#147;Perceptive&#148;) in two tranches. Because of Perceptive&#146;s participation
in the Series B Financing, the Company&#146;s considers them to be a related party. At the closing of the Series B Financing, the Company borrowed $12.5 million, or $12.0 million net of costs, and has the opportunity to draw down another $7.5
million subject to the satisfaction of certain milestones relating to the filing of an IND for certain of the Company&#146;s pipeline targets. As part of the Credit Agreement, the Company issued Perceptive warrants to purchase 2,857,142 shares of
Series&nbsp;B preferred stock exercisable for $1.05 per share. The Company will make interest-only payments until December&nbsp;5, 2022, at which point the Company will make payments of principal equal to 2% of the loans extended under the Credit
Agreement until maturity. The Company paid a closing fee of $0.4 million related to the loan and has the right to prepay the loan plus interest in its entirety prior to the maturity date by paying the applicable prepayment fee. If the Company does
not prepay the loan, the entire unpaid principal balance becomes due on the maturity date, June&nbsp;5, 2024. The Company is also subject to customary financial covenants in the Credit Agreement that dictate accelerated repayment upon the occurrence
of certain events of default, none of which are expected to occur based on the Company&#146;s current liquidity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2020, the Company granted options to purchase 1,467,424 shares of common stock to employees and certain consultants at an exercise price of $4.98 per share,
which represents fair value as of the grant dates. In September 2020, the Company approved the issuance of stock options to Marc A. Cohen, our Co-Founder, Executive Chairman and interim Chief Executive Officer, and Andrew Hirsch, our President,
Director and Chief Executive Officer-elect, which election will be effective upon the effectiveness of the registration statement, representing 1.5% and 3.5%, respectively, of the Company&#146;s fully-diluted shares measured at such time (including
the shares to be sold in this offering and excluding the shares reserved for future awards under the Company&#146;s equity incentive plans) at an exercise price per share equal to the initial public offering price per share. These options vest
quarterly over four years subject to cliff vesting after six months. Mr. Cohen&#146;s grant is subject to full acceleration upon a sale of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Company. Mr. Hirsch&#146;s option is subject to full acceleration upon a sale of the Company and the termination of his employment thereafter pursuant to the terms of his employment agreement,
subject to the execution of an effective release of claims in favor of the Company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s board of directors approved a one-for-8.4335 reverse stock split of its issued and outstanding common stock and stock options and a proportional
adjustment to the existing conversion ratios for the Company&#146;s convertible preferred stock effective as of September 25, 2020. Accordingly, all shares of common stock, per share amounts, and additional paid in capital amounts for all periods
presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>COVID-19 Pandemic </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The impact of the COVID-19 coronavirus outbreak on
the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial
markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#146;s results may be materially adversely affected. The Company is
currently unable to determine the extent of the impact of the pandemic to its operations and financial condition, as clinical trials have not started. Once the Company begins its clinical trials, it will assess any potential delays as a result of
the pandemic and their financial impact. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin772024_100"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except share data) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA</B><br><B>JUNE&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">112,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">118,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">248,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total Liabilities, Redeemable Convertible Preferred Stock and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability, net of current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and Contingencies (see Note 5 and Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed redeemable convertible preferred stock, par value of $0.0005 per share; 4,000,000 shares
authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 4,000,000 shares issued and outstanding at December&nbsp;31, 2019 and June&nbsp;30, 2020; liquidation and redemption value of $1,000 as of December&nbsp;31, 2019 and June&nbsp;30,
2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A redeemable convertible preferred stock, par value of $0.0005 per share; 110,000,000 shares
authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 109,145,900 shares issued and outstanding at December&nbsp;31, 2019 and June&nbsp;30, 2020; liquidation and redemption value of $109,995 as of December&nbsp;31, 2019 and June&nbsp;30,
2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B redeemable convertible preferred stock, par value of $0.0005 per share; 0 and 150,000,000 shares
authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 138,571,428 shares issued and outstanding at June&nbsp;30, 2020; liquidation and redemption value of $0 and $141,026 as of December&nbsp;31, 2019 and June&nbsp;30, 2020,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, par value of $0.0001 per share; 180,000,000 and 370,000,000 shares authorized as of December
2019 and June&nbsp;30, 2020; 1,426,641 and 1,490,336 shares issued and outstanding at December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">118,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes to condensed consolidated financial statements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin772024_101"></A>Condensed Consolidated Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except per share data) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited)
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized loss on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted (Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,469,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,233,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin772024_102"></A>Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholder&#146;s Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">June&nbsp;30, 2019 and 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands, except
share data) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:5.5pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES SEED</B><br><B>REDEEMABLE</B><br><B>CONVERTIBLE</B><br><B>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A REDEEMABLE</B><br><B>CONVERTIBLE</B><br><B>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B REDEEMABLE</B><br><B>CONVERTIBLE</B><br><B>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B><FONT STYLE="white-space:nowrap">PAID-IN</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>OTHER</B><br><B>COMPREHENSIVE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>STOCK<BR>HOLDERS&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCOME (LOSS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,338,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83,389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(79,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Net unrealized gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Balance as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,354,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(97,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(93,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(117,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(111,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Issuance of Series B convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,571,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Vested stock option settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Unrealized loss on investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.55em; text-indent:-2.55em; font-size:5.5pt; font-family:ARIAL">Balance as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,571,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,490,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(140,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(135,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin772024_103"></A>Condensed Consolidated Statement of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">June&nbsp;30, 2019 and 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(In thousands) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED<BR>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash flows used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on disposal of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accretion of discount on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,923</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from the issuance of Series B convertible preferred stock, net of issuance costs of
$4,473</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from the issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested stock option settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of long-term debt, net of issuance costs of $527</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Reconciliation of cash, cash equivalents and restricted cash:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents at end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capital expenditures in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock option repurchases included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock option exercises included in prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of warrants issued in connection with debt issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:12%; text-indent:4%; font-size:9.5pt; font-family:ARIAL">See accompanying notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin772024_104"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>June&nbsp;30, 2019 and 2020 (Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(1) The Company
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">C4 Therapeutics, Inc., or Company, was incorporated in Delaware on October&nbsp;7, 2015. Its principal offices are in Watertown, Massachusetts. The Company is
a biopharmaceutical company focused on harnessing the body&#146;s natural regulation of protein levels to develop novel therapeutic candidates to target and eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions
and other diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks common to other life science companies in the early development stage including, but not limited to,
uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection
of proprietary technology, ability to raise additional financing and compliance with the Food and Drug Administration (&#147;FDA&#148;) and other government regulations. If the Company does not successfully advance its programs into and through
human clinical trials and/or enter into collaborations for its programs and commercialize any of its product candidates, it may be unable to produce product revenue or achieve profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated whether there are certain
conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the financial statements are issued. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has incurred recurring losses since its inception, including net losses of $14.0&nbsp;million and $22.7&nbsp;million for the six months ended June&nbsp;30,
2019 and 2020, respectively. In addition, as June&nbsp;30, 2020, the Company had an accumulated deficit of $140.2&nbsp;million. To date, the Company has not generated any revenue from product sales as none of its product candidates have been
approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s primary activities
since inception have been focused around research and development activities, building the Company&#146;s intellectual property, recruiting personnel and raising capital to support these activities. Through June&nbsp;30, 2020, the Company has funded
its operations primarily with proceeds received from the sale of redeemable convertible preferred stock (collectively, the &#147;Preferred Stock&#148;) and through its collaboration agreements. The Company also closed a Series&nbsp;B redeemable
convertible preferred stock financing and credit arrangement in June and July 2020 for net proceeds of $145.5&nbsp;million (see Note&nbsp;9). The Company believes that its cash and cash equivalents and short-term investments of $211.6&nbsp;million
as of June&nbsp;30, 2020 are sufficient to fund planned operations for at least twelve months from the date these condensed consolidated financial statements are available to be issued. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and contemplates
the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(2) Summary of Significant Accounting Policies
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis of Presentation and Consolidation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying interim
unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United Stated (&#147;US GAAP&#148;), and include the accounts of C4 Therapeutics, Inc. and its subsidiary.
All intercompany balances and transactions have been eliminated in consolidation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Unaudited Interim Financial Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying condensed consolidated balance sheet as of June&nbsp;30, 2020, the condensed consolidated statements of operations and comprehensive loss for the six
months ended June&nbsp;30, 2019 and 2020, the condensed consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit for the six months ended June&nbsp;30, 2019 and 2020, the condensed consolidated statements of
cash flows for the six months ended June&nbsp;30, 2019 and 2020, and the related interim disclosures are unaudited. These unaudited condensed consolidated financial statements include all adjustments necessary, consisting of only normal recurring
adjustments, to fairly state the financial position and the results of the Company&#146;s operations and cash flows for interim periods in accordance with U.S. GAAP. Interim period results are not necessarily indicative of results of operations or
cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#146;s audited consolidated financial statements included elsewhere in this
prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Significant Accounting Policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#146;s&nbsp;significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December&nbsp;31, 2019, included elsewhere in this prospectus. An update and supplement to these accounting
policies follows. The Company did not adopt any new accounting pronouncements in the six months ended June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Unaudited Pro Forma Information
</B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying unaudited pro forma condensed consolidated balance sheet as of June&nbsp;30, 2020 has been prepared to give effect, to the automatic
conversion of all outstanding redeemable convertible preferred stock into 30,355,379&nbsp;shares of common stock as if the Company&#146;s proposed initial public offering had occurred on June&nbsp;30, 2020 and the reclassification of the warrant
liability to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital upon the automatic conversion of preferred stock warrants into common stock warrants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the accompanying condensed consolidated statements of operations and comprehensive loss, the unaudited proforma basic and diluted net loss per share attributable to
common stockholders for the six months ended June&nbsp;30, 2020 has been prepared to give effect to the automatic conversion of all outstanding shares of redeemable convertible preferred stock upon the closing of the proposed initial public offering
into 30,355,379 shares of common stock as if the conversion had occurred on the later of January&nbsp;1, 2020 or the issuance of the redeemable convertible preferred stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Short-Term Investments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company classifies all short-term investments
with an original maturity when purchased of greater than three months as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive loss. The amortized cost of debt securities
in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses and declines in value judged to be other than temporary on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, are included in interest income. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The cost of securities
sold is based on the specific identification method. Interest and dividends on securities classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> are included in interest income. To determine
whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment
outweighs evidence to the contrary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s short-term investments as of June&nbsp;30, 2020 of $103.9&nbsp;million consisted entirely of
government-backed securities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Deferred Offering Costs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated.
After consummation of the equity financing, these costs are recorded in stockholders&#146; (deficit) equity as a reduction of proceeds generated as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
result of the offering. Should the <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to
operating expenses in the condensed consolidated statements of operations and comprehensive loss. The Company had $0.3&nbsp;million of deferred offering costs related to the initial public offering as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrant Liability </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the series B redeemable convertible
preferred stock (&#147;Series B&#148;) financing (&#147;Series B Financing&#148;) in June and July 2020, the Company issued warrants to purchase shares of its Series B. The Company classified the warrants as a liability on its consolidated balance
sheet. The Company remeasured this warrant liability to fair value at each reporting date and recognized changes in the fair value of the warrant liability as a component of other income (expense), net in the consolidated statement of operations.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value these warrants. The Company assessed these
assumptions and estimates on a quarterly basis. Estimates and assumptions impacting the fair value measurement include the fair value per share of the underlying redeemable convertible preferred stock or common stock issuable upon exercise of the
warrant, remaining contractual term of the warrants, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying redeemable convertible preferred stock or common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(3) Fair Value Measurements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables present information about
the Company&#146;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December&nbsp;31, 2019 and June&nbsp;30, 2020 (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>QUOTED&nbsp;PRICES&nbsp;IN<BR>ACTIVE&nbsp;MARKETS&nbsp;FOR<BR>IDENTICAL ASSETS<BR>(LEVEL 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER<BR>OBSERVABLE&nbsp;INPUTS<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER<BR>OBSERVABLE&nbsp;INPUTS</B><br><B>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Asset</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>QUOTED&nbsp;PRICES&nbsp;IN<BR>ACTIVE&nbsp;MARKETS&nbsp;FOR</B><br><B>IDENTICAL ASSETS</B><br><B>(LEVEL 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER</B><br><B>OBSERVABLE&nbsp;INPUTS</B><br><B>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT&nbsp;OTHER</B><br><B>OBSERVABLE&nbsp;INPUTS</B><br><B>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Asset</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Liability</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s warrant liability represented a level 3 investment as of June&nbsp;30, 2020 (see Note 8). There have been no transfers between fair value levels
during the six months ended June&nbsp;30, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(4) Property and Equipment </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consisted of the following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total depreciation and amortization for each of the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2019 and 2020 was $0.8&nbsp;million.
Of the $0.8&nbsp;million for the six months ended June&nbsp;30, 2019, $0.8&nbsp;million was recorded in research and development expenses and an insignificant amount was recorded in general and administrative expenses. Of the $0.8&nbsp;million for
the six months ended June&nbsp;30, 2020, $0.7&nbsp;million was recorded in research and development expenses and $0.1&nbsp;million was recorded in general and administrative expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(5) Leases </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2017, the Company entered into a lease of office and
laboratory space for its headquarters at 490 Arsenal Way in Watertown, Massachusetts (the &#147;Watertown Lease&#148;). The Watertown Lease commenced in April 2018 with rent commencing in May 2018, and the Company recognized operating lease costs of
$2.0&nbsp;million and $2.1&nbsp;million for the six months ended June&nbsp;30, 2019 and 2020, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company incurred approximately $0.5&nbsp;million in
costs for leasehold improvements for the six months ended June&nbsp;30, 2019. The Company incurred no costs for leasehold improvements for the six months ended June&nbsp;30, 2020. The lease agreement required the Company to provide collateral in the
amount of $2.6&nbsp;million, which is recorded as restricted cash on the accompanying condensed consolidated balance sheets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019, assets
under the Watertown Lease classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets on the Company&#146;s condensed consolidated balance sheet were $14.5&nbsp;million, net of accumulated
amortization. Liabilities under the Watertown Lease were $13.7&nbsp;million, of which $0.9&nbsp;million were classified as operating lease liability, current, and $12.8&nbsp;million were classified as operating lease liability, net of current, on
the Company&#146;s condensed consolidated balance sheet. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June&nbsp;30, 2020, assets under the Watertown Lease classified as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets on the Company&#146;s condensed consolidated balance sheet were $13.9&nbsp;million, net of accumulated amortization. Liabilities under the Watertown Lease were $13.3&nbsp;million, of which
$1.0&nbsp;million were classified as operating lease liability, current, and $12.3&nbsp;million were classified as operating lease liability, net of current, on the Company&#146;s condensed consolidated balance sheet. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the Company recorded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> amortization of $0.6&nbsp;million for
the six months ended June&nbsp;30, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The elements of lease costs were as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED<BR>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lease cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other information:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating cash flows for operating liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities arising from obtaining <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average remaining lease term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases as of June&nbsp;30, 2020 were (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>FUTURE OPERATING LEASE PAYMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating lease liabilities at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">For the six months ended December&nbsp;31, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(6) Accrued Expenses and Other Current Liabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses and
other current liabilities consisted of the following as of December&nbsp;31, 2019 and June&nbsp;30, 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(7) Collaboration and License Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables summarize the
impact of the collaboration and license agreements on the Company&#146;s condensed consolidated statements of operations and comprehensive loss for the six months ended June&nbsp;30, 2019 and 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and the Company&#146;s condensed consolidated balance sheet as of December&nbsp;31, 2019 and June&nbsp;30, 2020. For details on the structure and accounting treatment for the Company&#146;s
collaboration and license agreements, refer to the annual consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Revenue for the six months ended
June&nbsp;30, 2019 and 2020 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restated Roche Agreement Collaboration Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biogen License Agreement Collaboration Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Calico License Agreement Collaboration Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Revenue for the six months ended June&nbsp;30, 2019 was $7.8&nbsp;million, compared with $16.5&nbsp;million for the six months ended June&nbsp;30, 2020. Under the
Restated Roche Agreement, the Company achieved a milestone for the identification of lead series for target 2 in April 2019, resulting in a milestone payment of $2.0&nbsp;million which was originally recorded as accounts receivable and deferred
revenue on the Company&#146;s condensed consolidated balance sheet as of June&nbsp;30, 2019. The $2.0&nbsp;million was added to the transaction price and recognized cumulatively. The Company also achieved a $4.0&nbsp;million milestone under the
Biogen Agreement in the six months ended June&nbsp;30, 2020, which was also originally recorded as accounts receivable and deferred revenue on the Company&#146;s condensed consolidated balance sheet as of June&nbsp;30, 2020, added to the transaction
price and recognized cumulatively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial information related to the collaboration and license agreements consisted of the following in the Company&#146;s
condensed consolidated balance sheet as December&nbsp;31, 2019 and June&nbsp;30, 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCOUNTS</B><br><B>RECEIVABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED</B><br><B>REVENUE,</B><br><B>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED</B><br><B>REVENUE,</B><br><B>NET OF</B><br><B>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED</B><br><B>REVENUE,</B><br><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restated Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biogen License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Calico License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="17"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="16" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF JUNE&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>DESCRIPTION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCOUNTS</B><br><B>RECEIVABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED</B><br><B>REVENUE,</B><br><B>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED</B><br><B>REVENUE,</B><br><B>NET OF</B><br><B>CURRENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFERRED</B><br><B>REVENUE,</B><br><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restated Roche Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Biogen License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Calico License Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dana Farber License Agreements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company made no payments under the DFCI Second License Agreement for the six months ended June&nbsp;30, 2019 and 2020. The Company terminated the DFCI License
Agreement in May 2020 and has no additional payments due under the agreement as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(8) Debt </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;5, 2020, contemporaneously with the issuance of its Series B (see Note 9) the Company entered into the Credit Agreement with Perceptive Life Sciences
Master Fund LTD., an affiliate of Perceptive Credit Holdings III, LP (&#147;Perceptive&#148;) for an aggregate principal borrowing amount (&#147;Term Loan&#148;) of up to $20.0&nbsp;million, available in two tranches of $12.5&nbsp;million and
$7.5&nbsp;million. The Company drew down on the first tranche of $12.5&nbsp;million in June 2020, bearing interest at a variable rate of 11.25%, which was calculated based on the <FONT STYLE="white-space:nowrap">one-month</FONT> LIBOR rate, which
can never be below 1.75%, plus an applicable margin, which was initially determined to be 9.5%. The Term Loan matures on June&nbsp;5, 2024 unless accelerated. The Company will make interest-only payments until December&nbsp;5, 2022, at which point
the Company will make payments of principal equal to 2% of the Term Loan until maturity. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Credit Agreement allows for prepayment in full of the outstanding
principal at any time. Any prepayment shall be in a minimum principal amount of $0.5&nbsp;million and in multiples of $0.1&nbsp;million in excess of that amount, plus accrued interest and a prepayment fee, which would be calculated based on the
terms of the Credit Agreement. The Company paid a closing fee of $0.3&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate principal amount of debt outstanding as of June&nbsp;30, 2020 was
$12.5&nbsp;million. The entire balance of the Term Loan was recorded as long-term debt in the Company&#146;s condensed consolidated balance sheet as of June&nbsp;30, 2020, as principal repayment does not begin until December 2022. The Company
recognized interest expense under the Credit Agreement of $0.1&nbsp;million during the six months ended June&nbsp;30, 2020. As of June&nbsp;30, 2020, the unamortized debt discount was $2.8&nbsp;million. The carrying value of the long-term debt, net
of issuance costs and the debt discount related to the 2,857,142 warrants that were issued with the loan, was $9.7&nbsp;million as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
connection with the Term Loan, the Company issued 2,857,142 warrants to purchase Series B at an exercise price per share of $1.05. The warrants are exercisable anytime prior to the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the
closing date. The Company determined that the warrants were liability-classified, and will be remeasured to fair value each reporting period with changes recorded in the statement of operations. The Company determined the fair value of the warrants
to be $2.3&nbsp;million using the Black-Scholes model based on the following assumptions in June 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(9) Stockholder&#146;s Equity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Features of the Common Stock </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The common stock has a par value of $0.000125,
and the holders of common stock are entitled to one vote for each share held at all meetings of stockholders and written actions in lieu of meetings provided. All dividends shall be declared and paid pro rata according to the number of shares held
by each member. In the event of a liquidation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
dissolution or winding up of the Company, the common stock ranks behind the Preferred Stock in terms of distribution of assets. The holders of the common stock have no preemptive or other
subscription rights, and there are no redemption or sinking fund provisions with respect to such stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June and July 2020, the Company closed a $150.0&nbsp;million Series B Financing with existing and new investors. As part of the Series B Financing, the Company
issued 142,857,142 shares of &#147;Series B, at a purchase price of $1.05 per share, for aggregate gross proceeds of $150.0&nbsp;million. Of the amounts above, 138,571,428 shares were issued for gross proceeds of $145.5&nbsp;million less related
offering costs of $4.5&nbsp;million in June 2020, and 4,285,714 shares were issued for proceeds of $4.5&nbsp;million in July 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2019 and
June&nbsp;30, 2020, Preferred Stock consisted of the following (in thousands, except share data): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED</B><br><B>STOCK</B><br><B>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED</B><br><B>STOCK</B><br><B>ISSUED AND</B><br><B>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CARRYING</B><br><B>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LIQUIDATION</B><br><B>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON</B><br><B>STOCK</B><br><B>ISSUABLE</B><br><B>UPON</B><br><B>CONVERSION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FF Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">110,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,416,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="14" COLSPAN="21"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="20" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED</B><br><B>STOCK</B><br><B>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED&nbsp;STOCK</B><br><B>ISSUED AND</B><br><B>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CARRYING</B><br><B>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LIQUIDATION</B><br><B>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON&nbsp;STOCK</B><br><B>ISSUABLE</B><br><B>UPON</B><br><B>CONVERSION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,145,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,571,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,431,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,717,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">252,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">252,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,847,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the rights and privileges of the Preferred Stockholders as of December&nbsp;31, 2019 and June&nbsp;30, 2020: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conversion </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All series of Preferred Stock are convertible at any time at
the option of the holder and mandatorily convertible upon a qualified initial public offering, defined as an underwritten public offering resulting in at least $50.0&nbsp;million in gross proceeds to the Company, into common stock on a 8.4335-to-one
basis (see note 14). </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Voting </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All series of Preferred Stock have
voting rights that are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> with common stock, as if they were converted into common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Redemption </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock is not redeemable except in the event of a
liquidation. The Series&nbsp;Seed Preferred Stock, Series&nbsp;A Preferred Stock, and Series B Preferred Stock receive liquidation payments at their respective issuance prices in preference to the common stock. Because the Series&nbsp;Seed Preferred
Stock, Series&nbsp;A Preferred Stock, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Series B Preferred Stock are only mandatorily redeemable upon the occurrence of a liquidation event and the preferred stockholders have control of the Company&#146;s board of directors, they are
classified in the mezzanine section of the Company&#146;s condensed consolidated balance sheet. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series&nbsp;B Preferred Stock has dividend preference over all other common and Preferred Stock. The holders of the Series B Preferred Stock then outstanding shall
first receive, or simultaneously receive, a dividend on each outstanding share of Series B Preferred Stock in an amount at least equal to the greater of amounts accrued in Series B dividends and amounts that would be paid to Series B as common or
other shares pursuant to the dividend granted. The Series A Preferred Stock has dividend preference over the common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series&nbsp;Seed Preferred Stock is
eligible to receive dividends on a pro rata <FONT STYLE="white-space:nowrap">as-converted</FONT> basis in&nbsp;proportion to the number of shares of common stock that would be held upon conversion to common stock. Series A Preferred Stock and Series
B Preferred Stock accrue dividends at a rate of $0.08 and $0.084 per annum, respectively, and are payable only if and when declared by the Company&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(10) Stock-based Compensation </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;28, 2015, the
Company&#146;s board of directors adopted the 2015 Incentive Stock Option and Grant Plan (the&nbsp;&#147;2015 Plan&#148;) and reserved 2,525,327 shares of common stock for issuance under this plan. As of April 2019, the shares reserved increased to
3,614,753. On June&nbsp;3, 2020, the shares reserved increased to 5,058,202. As of June&nbsp;30, 2020, 3,812,039 shares remain available for future grant. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
2015 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options and restricted stock awards to eligible employees, outside directors and consultants of the Company. Options
generally vest over a period of five or eight&nbsp;years with a cliff vesting at one&nbsp;year and quarterly vesting thereafter and options that lapse or are forfeited are available to be granted again. The contractual life of all options is
ten&nbsp;years from the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the issuance of stock options, the Company recorded stock-based compensation expense of $0.3&nbsp;million
in each of the six months ended June&nbsp;30, 2019 and 2020. As the restricted stock was fully vested as of December&nbsp;31, 2019, the Company did not record stock-based compensation expense related to restricted stock during the six months ended
June&nbsp;30, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock-based compensation expense for the six months ended June&nbsp;30, 2019 and 2020 was classified in the Company&#146;s condensed
consolidated statement of operations and comprehensive loss as follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED&nbsp;JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>President and Chief Executive Officer Termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;3,
2020 (&#147;Separation Date&#148;), the Company&#146;s president and chief executive officer (&#147;CEO&#148;) terminated employment with the Company. The Company repurchased all of the CEO&#146;s exercised shares for total consideration of
$0.1&nbsp;million. The CEO also relinquished his right to purchase common shares through the exercise of vested options, for total consideration paid by the Company of $0.8&nbsp;million. The Company recorded the repurchase liability once the
termination was deemed probable on March&nbsp;3, 2020. The Company recognized the repurchase price of the common shares and the relinquishment of the vested options in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">additional-paid-in-capital</FONT></FONT> on the condensed consolidated balance sheet as of June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(11) Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the
year ended December&nbsp;31, 2019 and six months ended June&nbsp;30, 2019 and 2020, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable
position in the near future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Coronavirus Aid, Relief, and Economic Security Act
(&#147;CARES Act&#148;) was enacted on March&nbsp;27, 2020 to provide relief for taxpayers. The CARES Act contain a significant number of provisions that may impact on the Company&#146;s accounting for income taxes. The Company has considered
several key corporate provisions within the CARES Act, has evaluated its potential impact and as a result recorded a tax benefit of $335 for the six month period ending June&nbsp;30, 2020 related to an anticipated refund to be received for federal
taxes incurred for the year ending December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(12) Loss Per Share </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding (in thousands,
except share and per share data): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX MONTHS ENDED JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,469,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s potentially dilutive securities, which include Preferred Stock, warrants to purchase preferred stock and common stock options, have been excluded
from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable
to common stockholders is the same. The Company excluded the following common stock equivalents, which include the following shares of preferred stock converting into the Company&#146;s common stock at a ratio of 8.4335-to-one, from the computation
of diluted net loss per share attributable to common stockholders as of June&nbsp;30, 2019 and June&nbsp;30, 2020 because including them would have had an anti-dilutive effect: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>JUNE&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,941,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,431,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,817,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants to purchase Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,233,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,238,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Unaudited Pro Forma Net Loss Per Share </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma basic and
diluted net loss per share attributable to common stockholders for the six months ended June&nbsp;30, 2020 has been prepared to give effect to the automatic conversion of all outstanding shares of redeemable convertible preferred stock upon the
closing of the proposed initial public offering into 30,355,379 shares of common stock as if the conversion had occurred on the later of January&nbsp;1, 2020 or the issuance of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
redeemable convertible preferred stock. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share
attributable to common stockholders does not include the effects of Preferred Stock dividends because the calculation gives effect to the automatic conversion of all shares of Preferred Stock outstanding as of June&nbsp;30, 2020 into shares of
common stock as if the proposed IPO had occurred on the later of January&nbsp;1, 2020 or the issuance date of the preferred stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited pro forma basic
and diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the six months ended June&nbsp;30, 2020 has been prepared to give
effect, upon a qualified IPO, to the automatic conversion of all outstanding shares of convertible preferred stock into common stock as if the proposed IPO had occurred on the later of January&nbsp;1, 2020 or the issuance date of the preferred
stock. Pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIX&nbsp;MONTHS&nbsp;ENDED<BR>JUNE&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrual of preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,469,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma adjustment to reflect automatic conversion of convertible preferred stock to common stock upon
the completion of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,763,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,233,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(13) Defined Contribution Plan </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has a 401(k) retirement plan
(the&nbsp;401(k)&nbsp;Plan), whereby all full-time employees may contribute up to 90% of their <FONT STYLE="white-space:nowrap">pre-tax</FONT> compensation, up to the maximum allowable amount set by the Internal Revenue Service. The Company matches
100% of contributions to the 401(k)&nbsp;Plan up to a maximum of $6,000 per year for each full-time employee. During the six months ended June&nbsp;30, 2019 and 2020, the Company contributed approximately $0.3&nbsp;million and $0.4&nbsp;million to
the 401(k)&nbsp;Plan, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(14) Subsequent Events </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company has evaluated subsequent events from the balance sheet date through the issuance date of these consolidated financial statements and has not identified any requiring disclosure except as noted below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2020, the Company granted options to purchase
1,467,424 shares of common stock to employees and certain consultants at an exercise price of $4.98 per share, which represents fair value as of the grant dates. In September 2020, the Company approved the issuance of stock options to Marc A. Cohen,
our Co-Founder, Executive Chairman and interim Chief Executive Officer, and Andrew Hirsch, our President, Director and Chief Executive Officer-elect, which election will be effective upon the effectiveness of the registration statement, representing
1.5% and 3.5%, respectively, of the Company&#146;s fully-diluted shares measured at such time (including the shares to be sold in this offering and excluding the shares reserved for future awards under the Company&#146;s equity incentive plans) at
an exercise price per share equal to the initial public offering price per share. These options vest quarterly over four years subject to cliff vesting after six months. Mr. Cohen&#146;s grant is subject to full acceleration upon a sale of the
Company. Mr. Hirsch&#146;s option is subject to full acceleration upon a sale of the Company and the termination of his employment thereafter pursuant to the terms of his employment agreement, subject to the execution of an effective release of
claims in favor of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s board of directors approved a one-for-8.4335 reverse stock split of its issued and outstanding common stock and stock options and a proportional
adjustment to the existing conversion ratios for the Company&#146;s convertible preferred stock effective as of September&nbsp;25, 2020. Accordingly, all shares of common stock, per share amounts, and additional paid-in capital amounts for all
periods presented in the accompanying unaudited interim condensed consolidated financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>COVID-19 Pandemic </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The impact of the COVID-19 coronavirus outbreak on
the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial
markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#146;s results may be materially adversely affected. The Company is
currently unable to determine the extent of the impact of the pandemic to its operations and financial condition, as clinical trials have not started. Once the Company begins its clinical trials, it will assess any potential delays as a result of
the pandemic and their financial impact. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>  <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>8,824,000 Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g772024g45i96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="bottom" NOWRAP><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Evercore&nbsp;ISI</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>BMO&nbsp;Capital&nbsp;Markets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>UBS&nbsp;Investment&nbsp;Bank</B></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other
Expenses of Issuance and Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, to be paid by
us in connection with the sale of the shares of common stock being registered hereby. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or
FINRA, filing fee and the Nasdaq Global Market initial listing fee. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financial and business advisory fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145 of
the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason
of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred
by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such
action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their
capacity as a director or officer or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted provisions in our certificate of incorporation and bylaws, to be in effect upon the closing of this offering and filed as Exhibits 3.2 and 3.3,
respectively, to this registration statement, that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be
personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an
injunction or rescission. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our bylaws provide that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our
directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding judgments, fines and settlement amounts), to each
indemnified director or executive officer in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person&#146;s services as a director
or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third
parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our
obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended (the Securities Act). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement
filed as Exhibit 1.1 to this registration statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the three years
preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) Issuances
of Capital Stock and Warrant </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June and July 2020, we issued and sold 142,857,142 shares of Series B preferred stock to investors at $1.05 per share.
Jefferies LLC, one of our underwriters, acted as one of the placement agents with respect to this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2020, we issued a warrant to purchase 2,857,142
shares of Series B preferred stock to our lender Perceptive Credit Holdings III, LP at an exercise price of $1.05 per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, we issued and sold
900,900 shares of Series A preferred stock to an investor at $2.22 per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The sales of securities described above were deemed to be exempt from registration
pursuant to Section&nbsp;4(a)(2) of the Securities Act, as private placement transactions by an issuer not involving a public offering. All of the purchasers in these transactions represented to us in connection with their purchase that they were
acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of time. Such purchasers received written disclosures that the securities had not
been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the
Securities Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) Grants and Exercises of Stock Options </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted stock options to purchase an aggregate of 2,947,168 shares of our common stock, with exercise prices ranging from $3.72 to $6.67 per share, to
employees, directors and consultants pursuant to the 2015 Plan. Through the date of filing, 339,569 shares of common stock have been issued upon the exercise of stock options pursuant to the 2015 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuances of the securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act or Rule 701
promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) Exhibits. </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>EXHIBIT<BR>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>EXHIBIT TABLE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;1.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex31.htm">Fourth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex32.htm">Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.3*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex33.htm">Form of Fifth Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon the closing of this offering
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.4*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex34.htm">Amended and Restated Bylaws of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.5*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex35.htm">Form of Second Amended and Restated Bylaws of the Registrant, to be in effect upon the closing of this offering. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex41.htm">Amended and Restated Investors&#146; Rights Agreement among the Registrant, its warrant holder and certain of its stockholders, dated June&nbsp;5,
 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;4.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex42.htm">Warrant Certificate issued by the Registrant to Perceptive Credit Holdings III, LP dated June&nbsp;5, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;4.3</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex43.htm">Form of Specimen Common Stock Certificate </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex51.htm">Opinion of Goodwin Procter LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex101.htm">2015 Stock Option and Grant Plan, as amended and forms of award agreements thereunder </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex102.htm">2020 Stock Option and Incentive Plan and forms of award agreements thereunder </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex103.htm">2020 Employee Stock Purchase Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex104.htm">Senior Executive Cash Incentive Bonus Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex105.htm">Form of Director Indemnification Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex106.htm">Form of Officer Indemnification Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex107.htm">Form of Executive Employment Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.8*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex108.htm">Employment Agreement between the Registrant and Andrew Hirsch, dated September 6, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.9*#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex109.htm">Consulting Agreement between the Registrant and MBJC Associates, LLC, effective March 31, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.10*&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1010.htm">Collaboration Research and License Agreement between the Registrant and Biogen MA, Inc., dated December&nbsp;28, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.11*&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1011.htm">Amended and Restated License Agreement among the Registrant, F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT
STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc., dated December&nbsp;20, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.12*&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1012.htm">Collaboration and License Agreement between the Registrant and Calico Life Sciences LLC, dated March&nbsp;13, 2017 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.13*&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1013.htm">Credit Agreement and Guaranty among the Registrant, Perceptive Credit Holdings III, LP and the guarantors and lenders party thereto, dated
 July&nbsp;5, 2020 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.14*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex1014.htm">Lease by 480 Arsenal Group LLC to the Registrant, dated July&nbsp;5, 2017, as amended </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">21.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001662579/000119312520243234/d772024dex211.htm">Subsidiaries of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex231.htm">Consent of KPMG LLP, Independent Registered Public Accounting Firm</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d772024dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1662579/000119312520243234/d772024ds1.htm#sig">Power of Attorney (included on signature page to this registration statement) </A></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">#</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or any compensatory plan, contract or arrangement. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the Securities and Exchange Commission. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) Financial Statement Schedules. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery
to each purchaser. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(1) For purposes of determining
any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule
424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(2)
For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this amendment no. 1 to the registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on the 28th day of September, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:9.5pt"><B>C4 Therapeutics, Inc.</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc A. Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Marc A. Cohen</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer</P></TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this amendment no. 1 to the registration statement has
been signed by the following persons in the capacities indicated on the 28th day of September, 2020. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Marc&nbsp;A.&nbsp;Cohen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Marc&nbsp;A.&nbsp;Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Co-Founder, Executive Chairman, Director and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Principal Executive
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ William McKee</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">William
McKee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Laura J. Wahlberg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Laura
J. Wahlberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Vice President of Finance and Corporate Controller<BR>(Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Andrew Hirsch</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Andrew
Hirsch</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">President and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Kenneth C. Anderson,
M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Bihua Chen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Alain J. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Bruce Downey</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Elena Prokupets,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Malcolm Salter</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;28, 2020</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">*&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ William McKee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3">William McKee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3">Attorney-in-fact</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d772024dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B>&#9679;<B>]</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C4
Therapeutics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2020 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVERCORE GROUP L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o EVERCORE GROUP L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B> C4
Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of [&#9679;] shares of its common
stock, par value $0.0001 per share (the &#147;<B>Shares</B>&#148;). The [&#9679;] Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has granted to the Underwriters an option to purchase up to an
additional [&#9679;] Shares as provided in Section&nbsp;2. The additional [&#9679;] Shares to be sold by the Company pursuant to such option are collectively called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to the extent
such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; Jefferies LLC (&#147;<B>Jefferies</B>&#148;) and Evercore Group L.L.C. (&#147;<B>Evercore</B>&#148;) have agreed to act as representatives
of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on <U>Schedule A</U>, the term
&#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jefferies agrees that up to [&#9679;] of the Firm Shares to be purchased by the Underwriters (the &#147;<B>Directed Shares</B>&#148;) shall be
reserved for sale to certain eligible directors, officers and employees of the Company and persons having business relationships with the Company (collectively, the &#147;<B>Participants</B>&#148;), as part of the distribution of the Offered Shares
by the Underwriters (the &#147;<B>Directed Share Program</B>&#148;) subject to the terms of this Agreement, the applicable rules, regulations and interpretations of the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) and all
other applicable laws, rule and regulations. The Directed Share Program shall be administered by Jefferies. To the extent that the Directed Shares are not orally confirmed for purchase by the Participants by the end of the first business day after
the date of this Agreement, such Directed Shares may be offered to the public by the Underwriters as part of the public offering contemplated hereby. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-248719</FONT> which contains a form of prospectus to be used in connection with the
public offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and
the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act, is called
the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b)
Registration Statement</B>,&#148; and from and after the date and time of filing of any such Rule 462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The prospectus, in the
form first used by the Underwriters to confirm sales of the Offered Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act, is called the
&#147;<B>Prospectus</B>.&#148; The preliminary prospectus dated [&#9679;], 2020 describing the Offered Shares and the offering thereof is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other prospectus
in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus is called a &#147;<B>preliminary prospectus</B>.&#148; As used herein, &#147;<B>Applicable Time</B>&#148; is [&#9679;]
p.m. (New York City time) on [&#9679;], 2020 As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary Prospectus
together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto. As used herein, <B>&#147;</B><B>Road Show</B><B>&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the
offering of the Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). As used herein, &#147;<B>Section</B><B></B><B>&nbsp;5(d) Written Communication</B>&#148; means each
written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Section&nbsp;5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential
investors that are qualified institutional buyers (&#147;<B>QIBs</B>&#148;) and/or institutions that are accredited investors (&#147;<B>IAIs</B>&#148;), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to
determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<B>Section</B><B></B><B>&nbsp;5(d) Oral Communication</B>&#148; means each oral communication, if any, made in reliance on Section&nbsp;5(d) of the
Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Shares;
&#147;<B>Marketing Materials</B>&#148; means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor
presentations made to investors by the Company (whether in person or electronically); and &#147;<B>Permitted Section</B><B></B><B>&nbsp;5(d) Communication</B>&#148; means the Section&nbsp;5(d) Written Communication(s) and Marketing Materials listed
on Schedule C attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to (i)&nbsp;the Registration Statement, any preliminary prospectus
(including the Preliminary Prospectus), or the Prospectus, or any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval System (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic<B> </B>Prospectus&#148; provided for use in connection with the offering of the Offered Shares as contemplated by
Section&nbsp;3(o) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one subsidiary, then all references herein to
&#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
hereby confirms its agreements with the Underwriters as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B>Representations and Warranties
</B><B>of the Company</B><B>.</B><B> </B>The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as defined in Section&nbsp;2) and as of each Option Closing Date (as
defined in Section&nbsp;2), if any, as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Compliance with Registration Requirements</I></B><B>.</B> The Registration
Statement has become effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the
effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Disclosure</I></B><B>.</B> Each preliminary prospectus and the Prospectus, when filed, complied in all material respects with
the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act) to the copy thereof delivered to the
Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material
respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable
Time, the Time of Sale Prospectus (including any preliminary prospectus wrapper) did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper), as of its date, did not, and at the First Closing Date and at each
applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time
of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being
understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed
as an exhibit to the Registration Statement which have not been described or filed as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Free Writing
Prospectuses; Road Show</I></B><B>.</B> As of the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of
the Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in
accordance with the requirements of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to
by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission, retention and legending, as applicable, and each such free writing prospectus,
as of its issue date and at all subsequent times through the completion of the public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information
contained in the Registration Statement, the Prospectus or any preliminary prospectus unless such information has been superseded or modified as of such time. Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and
electronic road shows, if any, furnished to the Representatives before first use, the Company has not prepared, used or referred to, and will not, without the Representatives&#146; prior written consent, prepare, use or refer to, any free writing
prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Directed Share Program</I></B><B>.</B> (i)&nbsp;The Registration Statement,
the Prospectus, the Time of Sale Prospectus and any preliminary prospectus comply, and any further amendments or supplements thereto will comply, with any applicable laws or regulations of foreign jurisdictions<B> </B>in which the Prospectus, Time
of Sale Prospectus or any preliminary prospectus, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program, and (ii)&nbsp;no authorization, approval, consent, license, order registration or
qualification of or with any government, governmental instrumentality or court, other than such as have been obtained, is necessary under the securities laws and regulations of foreign jurisdictions<B> </B>in which the Directed Shares are offered
outside the United States. The Company has not offered, or caused the Underwriters to offer, any Offered Shares to any person pursuant to the Directed Share Program with the intent to unlawfully influence (i)&nbsp;a customer or supplier of the
Company to alter the customer&#146;s or supplier&#146;s level or type of business with the Company or (ii)&nbsp;a trade journalist or publication to write or publish favorable information about the Company or its products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Distribution of Offering Material By the Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the expiration or termination
of the option granted to the several Underwriters in Section&nbsp;2, (ii) the completion of the Underwriters&#146; distribution of the Offered Shares and (iii)&nbsp;the expiration of 25 days after the date of the Prospectus,<B> </B>the Company has
not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed
and consented to by the Representatives, the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted Section&nbsp;5(d) Communications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Authorization of the Offered Shares</I></B><B>.</B> The Offered Shares have been duly authorized for issuance and sale
pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any
preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>No
Applicable Registration or Other Similar Rights</I></B><B>.</B> There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering
contemplated by this Agreement, except for such rights as have been duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>No Material Adverse
Change</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale
Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that could be expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business,
properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the
Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii)&nbsp;the Company and its subsidiaries,
considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other
calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity,
and have not entered into any material transactions not in the ordinary course of business; (iii)&nbsp;there </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries; and (iv)&nbsp;there has been no
dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption
by the Company or any of its subsidiaries of any class of capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Independent Accountants</I></B><B>.</B> KPMG
LLP, which has expressed its opinion with respect to the financial statements (which term, as used in this Agreement, includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus
and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), and (ii)&nbsp;in compliance with the
applicable requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public
accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Financial Statements</I></B><B>.</B> The financial statements filed with the Commission as a part of the Registration
Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in
stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the
periods involved, except as may be expressly stated in the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do
not contain certain footnotes as permitted by the applicable rules of the Commission. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. The
financial data set forth in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under the captions &#147;Prospectus Summary&#151;Summary Consolidated Financial Data,&#148; &#147;Selected Consolidated Financial
Data&#148; and &#147;Capitalization&#148; present fairly in all material respects the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale
Prospectus and the Prospectus. All disclosures contained in the Registration Statement, any preliminary prospectus or the Prospectus and any free writing prospectus, that constitute <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures
(as defined by the rules and regulations under the Securities Act and the Exchange Act) comply in all material respects with Regulation G under the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Securities Act, as applicable. To the Company&#146;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300
promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of
Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Company</I></B><B><I>&#146;</I></B><B><I>s Accounting System</I></B><B>.</B> The
Company and each of its subsidiaries make and keep accurate books and records and maintain, on a consolidated basis, a system of internal accounting controls designed to provide reasonable assurance that: (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United
States and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Disclosure Controls and Procedures; Deficiencies in or Changes to Internal
Control Over Financial Reporting</I></B><B>.</B> The Company has established and maintains disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT>
under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial
officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of
the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus
and the Prospectus, (i)&nbsp;since the end of the Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company&#146;s internal control over financial reporting (whether or not
remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting, and (ii)&nbsp;the
Company is not aware of any change in its internal control over financial reporting that has occurred during its most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Incorporation and Good Standing of the Company</I></B><B>.</B> The Company has
been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business
as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good
standing in the Commonwealth of Massachusetts and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified
could not reasonably be expected to result in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Subsidiaries</I></B><B>.</B> Each of the
Company&#146;s &#147;subsidiaries&#148; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited
liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as
described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. Each of the Company&#146;s subsidiaries is
duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. All of the issued and
outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through
subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim, except to the extent that such security interest, mortgage, pledge, lien, encumbrance or adverse claim could not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change. None of the outstanding capital stock or equity interests in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary.
The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does
not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Registration Statement. Since inception, C4T Securities Corporation, a wholly owned Massachusetts
subsidiary of the Company, has not conducted, and does not currently conduct, any operations, has not had and does not have any employees and has been and is engaged exclusively in buying, selling, dealing in and holding publicly-traded securities
on its own behalf and not as a broker. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Capitalization and Other Capital Stock Matters</I></B><B>.</B> The
authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Capitalization&#148; (other than for subsequent issuances, if any,
pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Shares (including the Offered Shares) conform in
all material respects to the description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance
with all federal and state securities laws. None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no
authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its
subsidiaries other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other
rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly present in all material respects the information required to be shown with respect to such plans, arrangements,
options and rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Stock Exchange Listing</I></B><B>.</B> The Offered Shares have been approved for listing on The
Nasdaq Global Market (&#147;<B>Nasdaq</B>&#148;), subject only to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I><FONT
STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further Authorizations or Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its charter or <FONT
STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default)
(&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument
or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject
(each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company&#146;s execution, delivery and performance of this
Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Offered Shares (including the use of proceeds from the sale of the
Offered Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Use of Proceeds&#148;) (i)&nbsp;have been duly authorized by all necessary corporate action and will not result in any
violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary (ii)&nbsp;will not
conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its
subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any
of its subsidiaries, except in the case of (ii)&nbsp;and (iii) above as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. No consent, approval, authorization or other order of, or
registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus,
except (A)&nbsp;such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or <B>FINRA</B>, and (B)&nbsp;such as have
been obtained under the laws and regulations of jurisdictions outside the United States in which Directed Shares are offered. As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition which gives, or with the
giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of
such indebtedness by the Company or any of its subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Compliance with Laws</I></B><B><I>.</I></B> The Company and
its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>No Material Actions or Proceedings</I></B><B>.</B> There is no action, suit, proceeding, inquiry or investigation brought
by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could reasonably be expected, individually or in the aggregate, to result
in a Material Adverse Change. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge
of the Company, is threatened or imminent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Intellectual Property Rights</I></B><B>.</B> The Company and its subsidiaries
own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property (collectively, &#147;<B>Intellectual
Property</B>&#148;) described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as
currently proposed to be conducted (collectively, the &#147;<B>Company Intellectual</B><B> Property</B>&#148;). To the knowledge of the Company, the conduct of the Company&#146;s business does not infringe, misappropriate or otherwise conflict in
any material respect with any Intellectual Property rights of others. The Company Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any
facts which would form a reasonable basis for any such adjudication. To the Company&#146;s knowledge, (i)&nbsp;subject to ongoing inventorship determinations for recently filed patent applications, there are no third parties who have rights to any
Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company
or one or more of its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Company Intellectual Property. There is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others:
(A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity,
enforceability or scope of any Company Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its
subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any
patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and
its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Company Intellectual Property. The Company and its subsidiaries have
taken appropriate and reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments
with their employees, and to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement,
<FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such
violation relates to such employee&#146;s employment with the Company. To the Company&#146;s knowledge, the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States
patents and patent applications included in the Intellectual Property have been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with. None of the Company owned Intellectual Property or
technology (including information technology and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the
Company or its subsidiaries or, to the Company&#146;s knowledge, any of their respective officers, directors or employees or otherwise in violation of the rights of any persons. The product candidates, their method of manufacture, and/or a method of
their use described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents or patent applications owned by, or
exclusively licensed to, the Company or any subsidiary, or are otherwise described in such patents or patent applications in a manner that would support claim(s). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and its subsidiaries possess such valid and current certificates,
authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus
(&#147;<B>Permits</B>&#148;), except where the failure to possess such Permits could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries is in
violation of, or in default under, any of the Permits, except where such failure or violation could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change, or has received any notice of proceedings
relating to the revocation or material modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such certificate, authorization or permit. The Company and its subsidiaries have filed, obtained, maintained or submitted all
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Permits and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were timely, complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission), except, in each case, where the failure to do so would not reasonably be expected, individually or in
the aggregate, to result in a Material Adverse Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w) </B><B><I>Title to Properties</I></B><B>.</B> The Company and its
subsidiaries have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(k) above (or elsewhere in the Registration Statement, the Time of Sale
Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except where the failure to have such title could not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with
such exceptions as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x) </B><B><I>Tax Law Compliance</I></B><B>.</B> The Company and its subsidiaries have
timely filed all necessary U.S. federal, state and foreign income and other material tax returns or have properly requested extensions thereof and have paid all income and other material taxes due pursuant to such returns and, if due and payable,
any related or similar material assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings and for which reserves required by U.S. GAAP have been created and maintained in the
financial statements of the Company. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;1(k) above in respect of all taxes for all periods as to which the tax liability of
the Company or any of its subsidiaries has not been finally determined. No material tax deficiency has been determined adversely to the Company or its subsidiaries nor does the Company or its subsidiaries have any written notice or knowledge of any
material tax deficiency which would reasonably be expected to be determined adversely to the Company or its subsidiaries. There are no outstanding agreements or waivers extending the statutory period of limitation applicable to any federal, state,
local or foreign tax return for any period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y) </B><B><I>Insurance</I></B><B>.</B> Each of the Company and its subsidiaries are
insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to,
policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes, except where the failure to do so could not reasonably be expected, individually
or in the aggregate, to result in a Material Adverse Change. The Company has no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to
obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not reasonably be expected to result in a Material Adverse Change. Neither the Company nor any
of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z) </B><B><I>Compliance
with Environmental Laws</I></B><B>.</B> Except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal,
state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to
pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under
any applicable Environmental Laws and are each in compliance with their requirements; (iii)&nbsp;there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters,
claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv)&nbsp;to the knowledge of the Company, there are no events or circumstances
that might reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the
Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa) </B>[Reserved.]</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb) </B><B><I>ERISA Compliance</I></B><B>.</B> The Company and its subsidiaries and any
&#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by
the Company, its subsidiaries or to the extent the Company has any liability, their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the
Company or any of its subsidiaries, any member of any group of organizations described in Sections&nbsp;414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
&#147;<B>Code</B>&#148;) of which the Company or such subsidiary is a member. No &#147;reportable event&#148; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established
or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that may reasonably be expected to result in a Material Adverse Change. No &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries
or, to the extent the Company would have liability, any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any material &#147;amount of unfunded benefit liabilities&#148; (as defined under ERISA).
Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit
plan&#148; or (ii)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or, to the extent the Company has any liability, any of their ERISA Affiliates that is
intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable determination or approval letter from the IRS with respect to such qualifications, or may rely on an opinion letter issued by the IRS with respect to a prototype
plan adopted in accordance with the requirements for such reliance, or has time remaining for application to the IRS for a determination of the qualified status of such employee benefit plan for any period for which such employee benefit plan would
not otherwise be covered by an IRS determination and, to the knowledge of the Company nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc) </B><B><I>Company Not an </I></B><B><I>&#147;</I></B><B><I>Investment Company.</I></B><B><I>&#148;</I></B> The Company is not, and will
not be, either after receipt of payment for the Offered Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus or the Prospectus, required
to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the <B>&#147;</B><B>Investment Company Act</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd) </B><B><I>No Price Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>.</B> Neither the Company nor
any of its subsidiaries has taken, directly or indirectly, any action designed to stabilize or manipulate, or that would reasonably be expected to cause or result in stabilization or manipulation of, the price of any security of the Company, the
Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (<B>&#147;</B><B>Regulation M</B><B>&#148;</B>)) with respect to the Shares, whether to facilitate the sale or resale of the Offered
Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee) </B><B><I>Related-Party
Transactions</I></B><B>.</B> There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus
or the Prospectus that have not been described as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff) </B><B><I>FINRA Matters</I></B><B>.</B> All of the information
provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and to the Company&#146;s knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the
Company in connection with the offering of the Offered Shares is true, complete, correct and compliant in all material respects with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA
Rules or NASD Conduct Rules is true, complete and correct. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg) </B><B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements</I></B><B>.</B> The Company has furnished to the Underwriters a letter agreement substantially in the form attached hereto as <U>Exhibit</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;C-1</FONT></U> (the &#147;<B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from each director and officer of the Company and from all of the securityholders of the Company except as set forth in <U>Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT></U>. If any
additional persons shall become directors or officers (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company prior to the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period
(as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or officer of the Company, to execute and deliver to the Representatives a
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh) </B><B><I>Statistical and Market-Related Data</I></B><B>.</B> All
statistical, demographic and market-related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable. To the
extent required, the Company has obtained the written consent to the use of such data from such sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>Sarbanes-Oxley
Act.</I></B> There is, and has been, no failure on the part of the Company or any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the
rules and regulations promulgated in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj) </B><B><I>No Unlawful Contributions or Other Payments</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the
Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character
required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk) </B><B><I>Anti-Corruption
and Anti-Bribery Laws</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or any of its subsidiaries, nor, to the knowledge of the Company, any agent, affiliate or other person acting
on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful
expenses relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee,
including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended (the &#147;<B>FCPA</B>&#148;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any
unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll) </B><B><I>Money Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are, and have been conducted at all
times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm) </B><B><I>Sanctions</I></B><B>.</B> Neither the Company nor any of its subsidiaries,
directors, officers, or employees, nor, to the knowledge of the Company, after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury of the United
Kingdom, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions,
including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria; and the Company will not, directly or indirectly, use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any
joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any
other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its
subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn) </B><B><I>Brokers</I></B><B>.</B> Except pursuant to this Agreement, there is no broker or finder that is entitled to
receive from the Company any brokerage or finder&#146;s fee as a result of any transactions contemplated by this Agreement in connection with the issuance and sale of the Offered Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo) </B><B><I>Forward-Looking Statements.</I></B> Each financial or operational projection or other &#147;forward-looking statement&#148;
(as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with
reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause
actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B><B><I>No Outstanding Loans or Other Extensions of Credit</I></B>. The Company does not have any outstanding extension of credit, in
the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company, except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq) </B><B><I>Cybersecurity</I></B>. Except as could not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Change, the Company&#146;s and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are
adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan
horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect
their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148;
means (i)&nbsp;a natural person&#146;s name, street address, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit
card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as
defined by GDPR; (iv)&nbsp;any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and
Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an
identified person&#146;s health or sexual orientation. To the Company&#146;s knowledge, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or
liability or the duty to notify any other person, nor any material data incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or
statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems, confidential data, and
Personal Data and to the protection of such IT Systems, confidential data, and Personal Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr) </B><B><I>Compliance with Data Privacy Laws</I></B>. The Company and its subsidiaries are, and at all prior times were, in material
compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA and the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679) (collectively, the
&#147;<B>Privacy Laws</B>&#148;). The Company further certifies that neither the Company nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the
Privacy Laws, except for those that have been remedied without material cost or liability or the duty to notify any other person, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or settlement agreement that imposes any
material obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss) </B><B><I>Emerging Growth Company Status</I></B>. From the time of initial
confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section&nbsp;5(d) Written Communication or any Section&nbsp;5(d) Oral Communication) through the date hereof,
the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt) </B><B><I>Communications</I></B>. The Company (i)&nbsp;has not alone engaged in communications with potential investors in reliance on
Section&nbsp;5(d) of the Securities Act other than Permitted Section&nbsp;5(d) Communications with the consent of the Representatives with entities that are QIBs or IAIs and (ii)&nbsp;has not authorized anyone other than the Representatives to
engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section&nbsp;5(d) Oral Communications and Section&nbsp;5(d) Written Communications; as of
the Applicable Time, each Permitted Section&nbsp;5(d) Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted Section&nbsp;5(d) Communication, if any, does not, as of the date hereof, conflict with the
information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus (except where such Permitted Section&nbsp;5(d) Communication has been superseded by the information contained in the Registration Statement, the
Preliminary Prospectus and the Prospectus); and the Company has filed publicly on EDGAR at least 15 calendar days prior to any &#147;road show&#148; (as defined in Rule 433 under the Act), any confidentially submitted registration statement and
registration statement amendments relating to the offer and sale of the Offered Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu) </B><B><I>Clinical Data and Regulatory Compliance.</I></B> The preclinical tests and
clinical trials, and other studies (collectively, &#147;<B>studies</B>&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending,
are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such
studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise
call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals or authorizations as
may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility
Institutional Review Board (collectively, the &#147;<B>Regulatory Agencies</B>&#148;) to conduct its business as currently conducted; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory
Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have
each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> <B><I>Compliance with Health Care Laws</I></B>. The Company and its subsidiaries are in material compliance with all applicable
Health Care Laws, except where such failure or violation could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; means:
(i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without
limitation, the Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil
monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42
U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable
federal, state, local or foreign laws or regulatory bodies; (vi)&nbsp;and the directives and regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company
nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party
alleging that any product operation or activity is in violation of any applicable Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all
such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission).
Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended
or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be
expected to result in debarment, suspension, or exclusion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww) </B><B><I>No Contract Terminations.</I></B> Neither the Company nor any
of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the material contracts or agreements referred to or described in any preliminary prospectus, the Prospectus or any free writing
prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, and no such termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has been threatened by the Company or any of its subsidiaries or, to
the Company&#146;s knowledge, any other party to any such contract or agreement, which threat of termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has not been rescinded as of the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx) </B><B><I>Dividend Restrictions</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, or as required under applicable law, no subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such
subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any
property or assets to the Company or to any other subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy) </B><B><I>No Ratings</I></B>. There are (and prior to the Closing
Date, will be) no debt securities, convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is
defined in Section&nbsp;3(a)(62) under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of its subsidiaries
and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters
covered thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for making each of the representations set forth in this Section&nbsp;1. The Company
acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing
representations and hereby consents to such reliance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B>Purchase, Sale and Delivery of the Offered
Shares</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the
several Underwriters an aggregate of [&#9679;] Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not
jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $[&#9679;] per share.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the
Firm Shares to be purchased by the Underwriters and payment therefor shall be made at the offices of Cooley LLP, 55 Hudson Yards, New York, New York 10001 (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m.
New York City time, on [&#9679;], 2020, or such other time and date not later than 1:30&nbsp;p.m. New York City time, on [&#9679;], 2020 as the Representatives shall designate by notice to the Company (the time and date of such closing are called
the &#147;<B>First Closing Date</B>&#148;). The Company hereby acknowledges that the circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any
determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of [&#9679;] Optional Shares
from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the
Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the
time, date and place at which certificates for the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the
First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of certificates for the Firm Shares and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing
Date, is called an &#147;<B>Option Closing Date</B>,&#148; and shall be determined by the Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of exercise. If any Optional Shares are
to be purchased, (a)&nbsp;each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion
to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares and (b)&nbsp;the Company agrees to sell the number of
Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine).<B> </B>The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to
the Company.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Public Offering of the Offered Shares</I></B><B>.</B> The Representatives hereby advise the Company
that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this
Agreement has been executed and the Registration Statement has been declared effective as the Representatives, in their sole judgment, have determined is advisable and practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Payment for the Offered Shares</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Payment for the Offered Shares to be sold by the Company shall be made at the First Closing Date (and, if applicable, at each Option
Closing Date) by wire transfer of immediately available funds to the order of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives
have been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to
purchase. Each of Jefferies and Evercore, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been
received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this
Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Delivery of the Offered Shares</I></B><B>.</B> The Company shall deliver,
or cause to be delivered to the Representatives for the accounts of the several Underwriters certificates for the Firm Shares to be sold by them at the First Closing Date, against release of a wire transfer of immediately available funds for the
amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase from
them at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If Jefferies so elect, delivery of the
Offered Shares may be made by credit to the accounts designated by Jefferies through The Depository Trust Company&#146;s full fast transfer or DWAC programs. If the Representatives so elect, the certificates for the Offered Shares shall be in
definitive form and registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made
available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery
at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. </B><B>Additional Covenants </B><B>of the Company</B><B>.</B><B> </B>The Company further covenants and agrees
with each Underwriter as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Delivery of Registration Statement, Time of Sale Prospectus and
Prospectus</I></B><B><I>.</I></B><I> </I>The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus
relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of
the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed Amendments and Supplements</I></B><B><I>.</I></B><I>
</I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will
furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not
amend or supplement the Registration Statement without the Representatives&#146; prior written consent. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, the Company shall furnish to the
Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment
or supplement without the Representatives&#146; prior written consent. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such
Rule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Free Writing Prospectuses</I></B><B><I>.</I></B><I> </I>The Company shall furnish to the Representatives for
review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and
the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent. The Company shall furnish to each Underwriter, without charge, as many
copies of any free writing </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be
delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First Closing Date) there
occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement
or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the
Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing
any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus,
and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#146; prior written consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The Company shall not take any action that would result in an
Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been
required to file thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Amendments and Supplements to Time of Sale Prospectus</I></B><B><I>.</I></B><I> </I>If the
Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to
amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if,
in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and Section&nbsp;3(c) hereof) promptly
prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so
amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not
misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with
applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date of this Agreement, the Company
shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date of any filing of any post-effective amendment
to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective amendment to the
Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any
preliminary </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus
or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or
initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest moment reasonably practicable.
Additionally, the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule
424(b) or Rule 433 were received in a timely manner by the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Amendments and Supplements to the Prospectus and
Other Securities Act Matters</I></B><B><I>.</I></B> If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule) to a purchaser, not misleading, or if in the reasonable opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject
to Section&nbsp;3(b) and Section&nbsp;3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements
in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is
delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the
Representatives&#146; consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or Section&nbsp;3(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to
qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions reasonably designated by
the Representatives, shall use commercially reasonable efforts to comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall
not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign
corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or
threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as practicable.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the net proceeds from the sale of the Offered Shares sold by it
in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Earnings Statement</I></B><B>.</B> The Company will make generally
available to its security holders and to the Representatives (which may be satisfied by filing with EDGAR) as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first
fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange Act
so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement,<B> </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the
Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a
timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act. Additionally, the Company shall report the use of proceeds from the issuance of the Offered Shares as may be required under
Rule&nbsp;463 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Directed Share Program</I></B><B>.</B> In connection with the Directed Share
Program, the Company will ensure that the Directed Shares will be restricted to the extent required by FINRA or its rules from sale, transfer, assignment, pledge or hypothecation for a period of three months following the date of the effectiveness
of the Registration Statement. Jefferies will notify the Company as to which Participants will need to be so restricted. The Company will direct the transfer agent to place stop transfer restrictions upon such securities for such period of time.
Should the Company release, or seek to release, from such restrictions any of the Directed Shares, the Company agrees to reimburse the Underwriters for any reasonable expenses (including, without limitation, legal expenses) they incur in connection
with such release. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Listing</I></B><B>.</B> The Company will use its best efforts to list, subject to notice of issuance,
the Offered Shares on Nasdaq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the
Internet</I></B><B>.</B> If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<B>electronic
Prospectus</B>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of the Prospectus, and any amendment or supplement
thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and
purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material
shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format,
satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and
for <FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it
was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the
period commencing on and including the date hereof and continuing through and including the 180th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company will not, without the prior written consent of Jefferies and Evercore (which consent may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to
sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT>
under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge,
hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that
transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or
Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); (vii) submit or file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated
by this Agreement with respect to the Offered Shares); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention
to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby, (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock
option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, or issue warrants to purchase Shares in exchange for or upon conversion of outstanding warrants to
purchase preferred shares, or issue Shares upon conversion of outstanding preferred shares, in each case, described the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders of such Shares, options, warrants
or preferred shares, as applicable, agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period without the prior written
consent of the Representatives (which consent may be withheld in its sole discretion); (C) file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> with respect to any Shares or Related Securities issued or
issuable pursuant to any stock option, stock bonus, or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus or the Prospectus; (D)&nbsp;issue Shares in connection with the acquisition or license by the
Company of the securities, business, property, technology or other assets of another person or business entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition; (E)&nbsp;issue Shares or Related
Securities, or enter into an agreement to issue Shares or Related Securities, in connection with any merger, joint venture, strategic alliance, commercial or other collaborative transaction; <I>provided</I> that, in the case of immediately preceding
clauses (D)&nbsp;and (E), (x) the aggregate number of Shares issued or underlying such Related Securities issued in connection with all such acquisitions and other transactions does not exceed 5% of the number of Shares outstanding on a fully
diluted basis after giving effect to the consummation of the offering of the Offered Shares pursuant to this Agreement and (y)&nbsp;the recipients of the Shares or Related Securities provide to the Representatives a signed <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in the form set forth on <U>Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT></U> hereto; and (F)&nbsp;assist any stockholder of the Company in the establishment of a trading plan by such
stockholder pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that such plan does not provide for the transfer or any sale of shares of Common Stock
during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and the establishment of such plan does not require or otherwise result in any public filings or other public announcement of such plan during such
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and such plan is otherwise permitted to be implemented during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period pursuant to the terms of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement between such stockholder and the Underwriters in connection with the offering of the Offered Shares. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any
options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Future Reports to the
Representative</I></B><B><I>s</I></B><B><I>.</I></B><I> </I>During the period of five years hereafter, the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of
Syndicate and Evercore Group L.L.C., 55 East 52nd&nbsp;Street, New York, New York 10055, Attention: Kenneth A. Masotti,&nbsp;Esq. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(fax:&nbsp;212-857-3101):</FONT></FONT> (i) as soon
as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146;<I> </I>equity (deficit) and
cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the Company with the Commission, FINRA or any
securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this
Section&nbsp;3(q) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>Investment Limitation</I></B><B>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from
its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>No Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>.</B> The Company will not take, and
will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security with
respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I></B><B><I>s</I></B><B>.</B> During the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related
Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will direct the transfer agent to place stop transfer restrictions
upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such agreements, including, without limitation, <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers and directors and securityholders pursuant to Section&nbsp;6(l) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each applicable Option
Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any quarterly period subsequent to the period
covered by the most recent financial statements appearing in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>Amendments
and Supplements to Permitted Section</I></B><B><I></I></B><B><I>&nbsp;5(d) Communications</I></B>. If at any time following the distribution of any Permitted Section&nbsp;5(d) Communication, there occurred or occurs an event or development as a
result of which such Permitted Section&nbsp;5(d) Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d) Communication to eliminate or correct
such untrue statement or omission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w) </B><B><I>Emerging Growth Company Status</I></B>. The Company will promptly notify
the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Shares is not required by the Securities Act to be delivered (whether physically
or through compliance with Rule 172 under the Securities Act or any similar rule) and (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period (as defined herein). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x) </B><B><I>Announcement Regarding <FONT STYLE="white-space:nowrap">Lock-ups</FONT></I></B><B>.</B> The Company agrees to announce the
Representatives&#146; intention to release any director or &#147;officer&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company from any of the restrictions imposed by any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, by issuing, through a major news service, a press release in form and substance satisfactory to the Representatives or, if consented to by the Representatives, in a registration statement that is
publicly filed in connection with a secondary offering of the Company&#146;s shares promptly following the Company&#146;s receipt of any notification from the Representatives in which such intention is indicated, but in any case not later than the
close of the third business day prior to the date on which such release or waiver is to become effective; and <I>provided, further,</I> that no such announcement shall be made of any release or waiver granted solely to permit a transfer of
securities that is not for consideration and where the transferee has agreed in writing to be bound by the terms of a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in the form set forth as <U>Exhibit
<FONT STYLE="white-space:nowrap">C-1</FONT></U> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y) </B><B><I>Certification Regarding Beneficial Owners.</I></B> The Company
will deliver to the Representatives, on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the
Company undertakes to provide such additional supporting documentation as the Representatives may reasonably request in connection with the verification of the foregoing certification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B>Payment of Expenses</B><B>.</B> The Company agrees to pay all costs, fees and expenses incurred in
connection with the performance of their obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all
printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares, if any, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Shares
to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf
of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section&nbsp;5(d) Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, reasonably incurred and
documented attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares for offer
and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and
any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and
regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, (viii)&nbsp;the
costs and expenses of the Company relating to investor presentations on any &#147;road show,&#148; any Permitted Section&nbsp;5(d) Communication or any Section&nbsp;5(d) Oral Communication undertaken in connection with the offering of the Offered
Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the
Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show (with the other 50% being paid by the Underwriters), (ix)&nbsp;the fees and expenses associated with listing the Offered Shares on
Nasdaq, and (x)&nbsp;all other fees, costs and expenses of the nature referred to in Item 13 of Part&nbsp;II of the Registration Statement and (xi)&nbsp;all costs and expenses of the Underwriters, including the reasonably incurred and documented
fees and disbursements of counsel for the Underwriters, in connection with matters related to the Directed Shares which are designated by the Company for sale to Participants, provided, that, the fees and expenses of counsel with respect to clauses
(vi)&nbsp;and (viii) above shall not exceed $40,000 in the aggregate. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and
disbursements of their counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B>Covenant of the Underwriters</B><B>.</B> Each Underwriter
severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on
behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B>Conditions of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the several
Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties
on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely
performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
</B><B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and
substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72
(or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Compliance with Registration Requirements; No Stop Order; No Objection from </I></B><B><I>FINRA</I></B><B><I>. </I></B>For the
period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the Securities Act)
in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information required by such Rule 430A, and such
post-effective amendment shall have become effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or, to the knowledge of the Company, threatened by the Commission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) FINRA shall have raised no objection to the fairness and reasonableness of the
underwriting terms and arrangements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period
from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives, there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization&#148; as
that term is used in <FONT STYLE="white-space:nowrap">Rule&nbsp;15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)
</B><B><I>Opinion of Counsel for the Company</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Goodwin Procter LLP, counsel for the
Company, dated as of such date, in the form attached hereto as <U>Exhibit A</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Opinion of Intellectual Property Counsel
for the Company.</I></B><I> </I>On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Knowles Strategies, LLC, counsel for the Company with respect to intellectual property, dated as
of such date, in the form attached hereto as <U>Exhibit B</U>.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Opinion of Counsel for the
Underwriters</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Cooley LLP, counsel for the Underwriters in connection with the offer
and sale of the Offered Shares, in form and substance satisfactory to the Representatives, dated as of such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)
</B><B><I>Officers</I></B><B><I>&#146;</I></B><B><I> Certificate</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Executive Chairman and the Chief
Financial Officer of the Company, on behalf of the Company and not in their individual capacities, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the effect that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse
Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and
correct with the same force and effect as though expressly made on and as of such date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all the
agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)
</B><B><I>Bring-down Comfort Letter</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated such
date, in form and substance satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the
carrying out of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements</I></B><B><I>.</I></B> On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of <U>Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT></U> hereto from each director and officer of
the Company and all of the securityholders of the Company except for those set forth in <U>Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT></U>, and each such agreement shall be in full force and effect on each of the First Closing Date and each
Option Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Rule 462(b) Registration Statement</I></B><B>.</B> In the event that a Rule 462(b) Registration
Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon
such filing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Approval of Listing</I></B>. At the First Closing Date, the Offered Shares shall have been approved for
listing on Nasdaq, subject only to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>CFO Certificate</I></B>. On the date of this Agreement
and on the First Closing Date or the applicable Option Closing Date, as the case may be, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Representatives, of
its chief financial officer, on behalf of the Company and not in his individual capacity, with respect to certain financial data contained in the Time of Sale Prospectus and the Prospectus, providing &#147;management comfort&#148; with respect to
such information, in form and substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Additional Documents</I></B>. On
or before each of the First Closing Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them
to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all
proceedings taken by the Company in connection with the issuance and sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the
Representatives and counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required
to be satisfied, this Agreement may be terminated by the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the
applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall
survive such termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>. If this
Agreement is terminated by the Representatives pursuant to Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or
failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with
respect to themselves), severally, upon demand for all documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the Representatives and the
Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, reasonably incurred and documented fees and disbursements of counsel, printing expenses, travel expenses, postage,
facsimile and telephone charges. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. </B><B>Effectiveness of this Agreement</B>. This Agreement
shall become effective upon&nbsp;the execution and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.
</B><B>Indemnification</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold
harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or
expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the
laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as
such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (A) (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue
statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any
Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) or any prospectus wrapper material distributed in connection with the reservation and sale of Directed Shares to the
Participants, or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (iii)&nbsp;any act or failure to act or
any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action
arising out of or based upon any matter covered by clause (i)&nbsp;or (ii) above, or (B)&nbsp;the violation of any laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold; and to reimburse each Underwriter and
each such affiliate, director, officer, employee, agent and controlling person for any and all expenses (including, without limitation, the reasonably incurred fees and disbursements of counsel) as such expenses are incurred by such Underwriter or
such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the
foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made
in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any
such free writing prospectus, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information
described in Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the
Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or
other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus, that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any Section&nbsp;5(d) Written Communication
or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in
each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free
writing prospectus, such Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the
Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the
Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only
information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to
file, pursuant to Rule 433(d) of the Securities Act, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in<B> </B>the first sentence of the third paragraph,
the third sentence of the fourth paragraph, the first two sentences under the first paragraph under the section titled &#147;Commission and Expenses,&#148; the first sentence of the first paragraph under the section titled &#147;Stabilization,&#148;
and the first sentence of the first paragraph under the section titled &#147;Electronic Distribution&#148; under the caption &#147;Underwriting&#148; in the Preliminary Prospectus and the Prospectus. The indemnity agreement set forth in this
Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may otherwise have. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Notifications and
Other Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against
an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have
to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account
of this indemnity agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and,
to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense
thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably
concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are
different from or additional to those available to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action
on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election to so assume the defense of such action and approval by the indemnified party of
counsel, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the
indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate
counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for
the indemnified parties referred to in <B></B>Section&nbsp;9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel
satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified
party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or
expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such
indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and
indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such
action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Indemnification for Directed Shares</I></B><B>. </B>In connection with the offer and sale of the Directed Shares, the Company
agrees, promptly upon a request in writing, to indemnify and hold harmless the Underwriters from and against any and all losses, liabilities, claims, damages and expenses incurred by any of them as a result of the failure of the Participants to pay
for and accept delivery of Directed Shares which, by the end of the first business day following the date of this Agreement, were subject to a properly confirmed agreement to purchase. The Company agrees to indemnify and hold harmless the
Underwriters and their respective affiliates, directors, officers, employees and agents, and each person, if any, who controls any of the Underwriters within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage,
liability or expense, as incurred, to which the Underwriters or such controlling person may become subject, which is (i)&nbsp;caused by any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with
the consent of the Company for distribution to Participants in connection with the Directed Share Program (including any prospectus wrapper material distributed in connection with the reservation and sale of Directed Shares) or
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;caused by the
failure of any Participant to pay for and accept delivery of Directed Shares that such Participant agreed to purchase; or (iii)&nbsp;related to, arising out of, or in connection with the Directed Share Program. The indemnity agreement set forth in
this paragraph shall be in addition to any liabilities that the Company may otherwise have.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.
</B><B>Contribution</B>. If the indemnification provided for in Section&nbsp;9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or
expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein
(i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the
allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the
one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from
the offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page
of the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference
to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the
other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section&nbsp;9(c), any reasonably incurred and documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The
provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided, however,</I> that no additional notice shall be required
with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the
Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and
distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes
of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of
the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. </B><B>Default of One or More of the Several Underwriters</B><I>.</I> If, on the First Closing
Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Shares which such
defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for
the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of
Firm Shares set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other
proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or
refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with respect to which such
default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares are not made within 48 hours after such
default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such
termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the
required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to include any person substituted for a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting
Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.
</B><B>Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time:
(i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or the New York Stock Exchange shall have been suspended
or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York or Massachusetts authorities; (iii)&nbsp;there
shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a
prospective substantial change in United States&#146; or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the
manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or
(v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section&nbsp;12 shall be without
liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any
Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. </B><B>No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that (a)&nbsp;the
purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will
assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14. Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on
behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Offered
Shares sold hereunder and any termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15. </B><B>Notices</B>. All communications
hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the
Representatives: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">520 Madison
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">619-4437</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">857-3101</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Kenneth A. Masotti,&nbsp;Esq. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10011 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Divakar Gupta </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C4 Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">490 Arsenal Way, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Watertown, MA 02472 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Jolie M. Siegel, Chief Legal Officer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwin Procter LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">100 Northern Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (617) <FONT STYLE="white-space:nowrap">523-1231</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Lawrence Wittenberg and Edwin O&#146;Connor </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16. </B><B>Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties
hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each
case their respective successors, and personal representatives, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the
Underwriters merely by reason of such purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17. </B><B>Partial Unenforceability</B>. The invalidity or
unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Recognition of the U.S. Special Resolution Regimes. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and
shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167; 382.2(b); (C) &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#147;<B>U.S. Special
</B><B>Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
promulgated thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19. </B><B>Governing Law Provisions</B><I>.</I> This Agreement
shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the
transactions contemplated hereby (&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in
each case located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the
enforcement of a judgment of any such court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any
process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any
objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in
any such court has been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any Related Proceeding, each party irrevocably waives, to the
fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in
the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in
respect of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20. </B><B>General Provisions</B><B>.</B> This Agreement constitutes the entire agreement of the parties to this
Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or
implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities
Act and the Exchange Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Marc Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New
York, New York as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EVERCORE GROUP L.L.C.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acting individually and as Representatives of the several Underwriters named in the attached <U>Schedule A</U>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EVERCORE GROUP L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[&#9679;]</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[to be added] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Information Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Price per share to the public:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#9679;]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares being sold by the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#9679;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares potentially issuable pursuant to the option to purchase additional
shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#9679;]&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted Section&nbsp;5(d) Communications </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Opinion of Company Counsel </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Opinion of Knowles Strategies, LLC </U></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C-1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;], 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVERCORE GROUP L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the
Several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RE:&nbsp;&nbsp;&nbsp;&nbsp;C4 Therapeutics, Inc. (the &#147;Company&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an owner of
shares of common stock of the Company (&#147;<B>Shares</B>&#148;) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the &#147;<B>Offering</B>&#148;) for which
Jefferies LLC and Evercore Group L.L.C. (together, the &#147;<B>Representatives</B>&#148;) will act as the Representatives of the underwriters (collectively, the &#147;<B>Underwriters</B>&#148;). The undersigned recognizes that the Offering will
benefit each of the Company and the undersigned. The undersigned acknowledges that the Underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a
subsequent date, in entering into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company with respect to the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this letter agreement. Those
definitions are a part of this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will cause any Family Member not to), without the prior
written consent of the Representatives, which may withhold their consent in their sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration of the offer and sale of the Shares, and
the sale of the Shares to the Underwriters, in each case as contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) transactions relating to Shares or Related Securities acquired in the Offering or in open market transactions after the completion of the
Offering; <I>provided however</I>, if the undersigned is an officer or director of the Company, the foregoing exception shall not apply to any Shares or Related Securities purchased or otherwise received pursuant to a directed share program in the
Offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) transfers of Shares or Related Securities by gift, including, without limitation, to a charitable organization, or by will
or intestate succession to the legal representative, heir, beneficiary or any Family Member of the undersigned, or to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member; <I>provided however,
</I>that, such transfer is not for consideration; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) transfers or dispositions of Shares or Related Securities to a Family Member, a
trust formed for the direct or indirect benefit of the undersigned or an Immediate Family Member or any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of which, in each case, are held by
the undersigned or any Family Member; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) transfers of Shares or Related Securities by operation of law pursuant to a qualified domestic
order or other court order or in connection with a divorce settlement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) if the undersigned is a corporation, partnership, limited
liability company, trust or other business entity, distributions or transfers of Shares or Related Securities to (x)&nbsp;another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect
affiliate (as defined in Rule 405 promulgated under the Securities Act) of the undersigned, (y)&nbsp;any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of
the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (z)&nbsp;limited partners, general
partners, members, managers, managing members, stockholders or other equity holders of the undersigned or of the entities described in the preceding clauses (x)&nbsp;and (y); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) transfers or dispositions of Shares as forfeitures (x)&nbsp;to satisfy tax withholding and remittance obligations of the undersigned in
connection with the vesting or exercise of equity awards granted pursuant to the Company&#146;s equity incentive plans or (y)&nbsp;pursuant to a net exercise or cashless exercise by the stockholder of outstanding equity awards pursuant to the
Company&#146;s equity incentive plans; <I>provided however</I>, that in each case, any such equity incentive plans exist as of the date of the Underwriting Agreement and are described in the Prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) transfers of Shares or Related Securities pursuant to a change of control of the Company (meaning the consummation of any bona fide third
party tender offer, merger, consolidation or other similar transaction made to all holders of Shares the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, becomes the
beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of more than 50% of the voting capital stock of the Company) after the Offering that has been
approved by the independent members of the Company&#146;s board of directors, provided, that in the event that such change of control is not completed, the Shares or Related Securities owned by the undersigned shall remain subject to the
restrictions herein; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) transfers of Shares or Related Securities arising as a result of the termination of employment of the
undersigned to the Company pursuant to agreements that are in effect as of the date of the Underwriting Agreement for the Offering and disclosed in the Prospectus, under which the Company has the option to repurchase such Shares or Related
Securities or a right of first refusal with respect to transfers of such Shares or Related Securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, it shall be a condition to any such transfer or distribution
provided in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clauses (ii)&nbsp;through (vi), each transferee or distributee executes and delivers to the Representatives an
agreement in form and substance satisfactory to the Representatives stating that such transferee or distributee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell
or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee or distributee had been an
original signatory hereto), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clauses (i)&nbsp;through (iii), (v), (vi), and (viii), prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial
ownership of Shares in connection with such transfer (other than, in connection with a repurchase of Shares or Related Securities by the Company pursuant to clause (viii), a Form 4 or Form 5 required to be filed under the Exchange Act if the
undersigned is subject to Section&nbsp;16 reporting with respect to the Company under the Exchange Act, provided, however, that if such Form 4 or Form 5 is filed during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, such Form 4 or Form
5 shall indicate by footnote disclosure or otherwise that such Form 4 or Form 5 relates to a repurchase of Shares or Related Securities by the Company in connection with the termination of the undersigned&#146;s employment with the Company, and that
any Shares or Related Securities subject to this letter agreement that continue to be held by the undersigned remain subject to the terms of this letter agreement), and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clauses (iv)&nbsp;and (v), and, prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT>
Period, that if a Form 4, Form 5, Schedule 13D, Schedule 13G, Form 13F or Form 13H is required to be filed during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, such Form 4, Form 5, Schedule 13D, Schedule 13G, Form 13F or Form 13H shall
clearly indicate in the footnotes thereto that (A)&nbsp;the filing relates to the circumstances described in such clause, (B)&nbsp;any securities still held by the undersigned pursuant to any transfer pursuant to clause (iv), remains subject to the
terms and restrictions under this letter agreement, and (C)&nbsp;no securities were sold by the undersigned, and <I>provided further</I>, that, the undersigned does not otherwise voluntarily effect any other public filing or report regarding such
transfers during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions imposed by
this letter agreement, the undersigned may (i)&nbsp;exercise an option to purchase Shares granted under any equity incentive plan or stock purchase plan of the Company, provided that the Shares issued upon such exercise shall continue to be subject
to the restrictions on transfer set forth in this letter agreement, or (ii)&nbsp;establish a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a
&#147;<B><FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan</B>&#148;) for the transfer of Shares, provided that such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan shall not provide for or permit any transfers, sales or other dispositions of
Shares during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and the entry into such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan is not publicly disclosed, including in any filing under the Exchange Act, during the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#146;s transfer agent and registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the undersigned further agrees that the
foregoing provisions shall be equally applicable to any Company-directed Shares the undersigned may purchase or otherwise receive in the Offering (including pursuant to a directed share program). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives agree that, at least three business days before the
effective date of any release or waiver (each, a &#147;<B>Release</B>&#148;), the Representatives will notify the Company of the impending Release, and (ii)&nbsp;the Company (in accordance with the provisions of the Underwriting Agreement) will
announce the impending Release by press release through a major news service at least two business days before the effective date of the Release. Any Release granted by the Representatives hereunder to any such officer or director shall only be
effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if both (a)&nbsp;the Release is effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has
agreed in writing to be bound by the same terms described in this letter agreement that are applicable to the transferor to the extent and for the duration that such terms remain in effect at the time of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of
any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take,
directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other
factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (i)&nbsp;prior to the execution of the Underwriting Agreement, the Company, on the one hand, or the Representatives, on the other hand, notifies the other
in writing that it does not intend to proceed with the Offering, (ii)&nbsp;the Company files an application to withdraw the registration statement related to the Offering, (iii)&nbsp;the Underwriting Agreement is not executed on or before
December&nbsp;31, 2020, or (iv)&nbsp;the Underwriting Agreement (other than the provisions thereof that survive termination) terminates or is terminated prior to the closing date of the Offering, then in each case, this letter agreement shall
automatically, and without any action on the part of any other party, terminate and be of no further force and effect, and the undersigned shall automatically be released from the obligations under this letter agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter
agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed Name of Person Signing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Indicate capacity of person signing if</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>signing as custodian or trustee, or on behalf</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>of an
entity)</I></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Call Equivalent Position</B>&#148;<B> </B>shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Exchange Act</B>&#148;<B> </B>shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member
may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth
in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; shall mean the period beginning on the
date hereof and continuing through the close of trading on the date that is 180 days after the date of the Prospectus (as such term will be defined in the Underwriting Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any
securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call
Equivalent Position, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other way transfer or dispose of, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this letter agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C-2 </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d772024dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOURTH AMENDED
AND RESTATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C4 THERAPEUTICS, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C4 Therapeutics, Inc. (the &#147;<B>Corporation</B>&#148;), a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is C4 Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the
General Corporation Law on October&nbsp;7, 2015 under the name C4 Therapeutics, Inc. A Fourth Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June&nbsp;3, 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Fourth Amended and Restated
Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the
stockholders therefor, which resolutions setting forth the proposed amendments are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the following is
hereby inserted into Article FOURTH immediately before the first sentence therein: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective upon the filing of this
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#147;<U>Effective Time</U>&#148;), every 8.4335 shares of Common Stock then issued and outstanding or
held in the treasury of the Corporation immediately prior to the Effective Time shall automatically be combined into one (1)&nbsp;share of Common Stock, without any further action by the holders of such shares (the &#147;<U>Reverse Stock
Split</U>&#148;). The Reverse Stock Split will be effected on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis, and any fractional shares resulting from such combination shall be
rounded down to the nearest whole share on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis. No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu
of any fractional shares to which a holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation&#146;s Board
of Directors. The Reverse Stock Split shall occur automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the
Preferred Stock shall be appropriately adjusted to reflect the Reverse Stock Split in accordance with this Fourth Amended and Restated Certificate of Incorporation.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> That the foregoing amendment was approved by the holders of the requisite number
of shares of the Corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> That said amendment has been
duly adopted in accordance with Section&nbsp;242 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Certificate of Amendment
has been executed by a duly authorized officer of the Corporation on this 25th day of September, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc A. Cohen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc A. Cohen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>d772024dex43.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g88515dsp003.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">PO BOX 505006, Louisville, KY 40233-5006MR A SAMPLEDESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4CUSIP/IDENTIFIER XXXXXX XX XH older ID
XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456DTC 12345678 123456789012345Certificate Numbers Num/No. Denom. Total1234567890/1234567890 1 1 1 1234567890/1234567890 2 2 2 1234567890/1234567890 3 3 3 1234567890/1234567890 4 4 4
1234567890/1234567890 5 5 5 1234567890/1234567890 6 6 6 Total Transaction 7ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS#COMMON STOCKPAR VALUE $0.0001 COMMON STOCKC ertificate Number THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE
OF DELAWARE THIS CERTIFIES THAT is the owner of Shares************************ 000000SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 12529R 10 7 THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFERAGENT, AVAILABLE ONLINE AT
www.computershare.com *Shares ****000000** Shares**** 000000** Shares**** 000000** Shares**** 000000** Shares ****000000** Shares ****000000** Shares ****000000** Shares ****000000** Shares ****000000** Shares **** 000000** Shares ****000000**
Shares ****000000** Shares ****000000** Shares ****000000** Shares ****000000** Shares ****000000** SFULLY-PAID AND <FONT STYLE="white-space:nowrap">NON-ASSESSABLE</FONT> SHARES OF COMMON STOCK OFC4 Therapeutics, Inc. (hereinafter called the
&#147;Company&#148;), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject
to all of the provisions of the Certificate of Incorporation, as amended, and the <FONT STYLE="white-space:nowrap">By-Laws,</FONT> as amended, of the Company (copies of which are on file with the Company and with the Transfer Agent), to all of which
each holder, by acceptance hereof, assents. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized
officers. DATED <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">DD-MMM-YYYYPEUTA</FONT></FONT> I COUNTERSIGNED AND REGISTERED: FACSIMILE SIGNATURE TO COME R CE RPOR SH A , COMPUTER SHARE TRUST COMPANY, N.A.CO TE IT N President 4 C
TRANSFER AGENT AND REGISTRAR,C .10/7/2015DEL REFACSIMILE SIGNATURE TO COME AWA By Secretary AUTHORIZED SIGNATURE </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g88515dsp004.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">.C4 THERAPEUTICS, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS,
DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,
PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO
DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL
REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. The following abbreviations,
when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM&#151;as tenants in common UN IF GIFT MIN ACT -Custodian. (Cust) (Minor) TEN
ENT &#151;as tenants by the entireties under Uniform Gifts to Minors Act (State) JT TEN&nbsp;&nbsp;&nbsp;&nbsp;&#151;as joint tenants with right of survivorship UNIF TRF MIN ACT&nbsp;&nbsp;&nbsp;&nbsp;-Custodian (until age ) and not as tenants in
common (Cust) .under Uniform Transfers to Minors Act .(Minor) (State) Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEEF or value received, hereby sell,
assign and transfer unto (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the
said stock on the books of the within-named Company with full power of substitution in the premises. Dated: 20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks,
Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.Signature:</FONT> Signature: Notice: The signature
to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever. The IRS requires that the named transfer agent (&#147;we&#148;) report the
cost basis of certain shares or units acquired after January&nbsp;1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have
processed as you requested. If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. If you do not
keep in contact with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state. </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>d772024dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;28, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C4 Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">490 Arsenal Way, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Watertown, MA 02472 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on
Form</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;S-1</FONT></U> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-248719)</FONT> (as amended or supplemented, the &#147;Registration Statement&#148;) pursuant to the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), relating to the registration of the offering by C4 Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;Company&#148;) of up to 10,147,600 shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, $0.0001
par value per share, including Shares purchasable by the underwriters upon their exercise of an over-allotment option granted to the underwriters by the Company.&nbsp;The Shares are being sold to the several underwriters named in, and pursuant to,
an underwriting agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed such
documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions
set forth below, on certificates of officers of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation
Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against
payment therefor in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under
the caption &#147;Legal Matters&#148; in the Registration Statement.&nbsp;In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and
regulations thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>d772024dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the plan is the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the &#147;<B>Plan</B>&#148;). The purpose of the Plan
is to encourage and enable the officers, employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants of C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) and its Affiliates upon whose judgment, initiative and
efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#146;s welfare will assure a closer
identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#146;s behalf and strengthening their desire to remain with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms shall be defined as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Administrator</B>&#148; means either the Board or the compensation committee of the Board or a similar committee performing the
functions of the compensation committee and which is comprised of not less than two <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors who are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, at the time of determination, any &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such
terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Award</B>&#148; or &#147;<B>Awards</B><I>,</I>&#148; except where referring to a particular category of grant under the Plan, shall
include Incentive Stock Options, <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards and Dividend Equivalent
Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Award Certificate</B>&#148; means a written or electronic document setting forth the terms and provisions applicable to
an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148;
means the Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cash-Based Award</B>&#148; means an Award entitling the recipient to receive a
cash-denominated payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the Internal Revenue Code of 1986, as amended, and any successor Code, and
related rules, regulations and interpretations. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Consultant</B>&#148; means a consultant or adviser who provides <I>bona fide</I>
services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dividend Equivalent Right</B>&#148; means an Award entitling the grantee to receive credits based on cash dividends that would have
been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; means the date on which the Plan becomes effective as set forth in Section&nbsp;19. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fair Market Value</B>&#148; of the Stock on any given date means the fair market value of the Stock determined in good faith by the
Administrator; <I>provided</I>, <I>however</I>, that if the Stock is listed on the Nasdaq Stock Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by
reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations; <I>provided</I>, <I>further</I>,
<I>however</I>, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the &#147;Price to the Public&#148; (or equivalent) set forth on the cover page for the final prospectus relating to
the Company&#146;s initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Incentive Stock Option</B>&#148; means any Stock Option designated and qualified as
an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</B>&#148; means a member of the Board who is not also an employee of
the Company or any Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</B>&#148; means any Stock
Option that is not an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Option</B>&#148; or &#147;<B>Stock Option</B>&#148; means any option to purchase
shares of Stock granted pursuant to Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Date</B>&#148;<I> </I>means the date upon which the
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted Shares</B>&#148; means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture
or the Company&#146;s right of repurchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted Stock Award</B>&#148; means an Award of Restricted Shares subject to such
restrictions and conditions as the Administrator may determine at the time of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Restricted Stock Units</B>&#148; means an Award of stock units subject to such
restrictions and conditions as the Administrator may determine at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sale Event</B>&#148; shall mean
(i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding
voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if
applicable) immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any other transaction in which the owners of the
Company&#146;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result
of the acquisition of securities directly from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sale Price</B>&#148; means the value as determined by the
Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Section</B><B></B><B>&nbsp;409A</B>&#148; means Section&nbsp;409A of the Code and the regulations and other guidance promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Service Relationship</B>&#148;<I> </I>means any relationship as an employee, director or Consultant of the Company
or any Affiliate (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#146;s status changes from full-time employee to part-time employee or Consultant or vice versa). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Stock</B>&#148; means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to
Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Stock Appreciation Right</B>&#148; means an Award entitling the recipient to receive shares of Stock (or cash,
to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the
number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148;
means any corporation or other entity (other than the Company) in which the Company has at least a 50&nbsp;percent interest, either directly or indirectly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ten Percent Owner</B>&#148; means an employee who owns or is deemed to own (by reason of the attribution rules of Section&nbsp;424(d)
of the Code) more than 10&nbsp;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Unrestricted Stock Award</B>&#148; means an Award of shares of Stock free of any restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">SECTION&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2. <U>ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</U>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Administration of Plan</U>. The Plan shall be administered by the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers of Administrator</U>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan,
including the power and authority: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to select the individuals to whom Awards may from time to time be granted; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options,
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards and Dividend Equivalent Rights, or any combination of the
foregoing, granted to any one or more grantees; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of shares of Stock to be covered by any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan,
of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) subject to the provisions of Section&nbsp;5(c), to extend at any time the period in which Stock Options may be exercised; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and
proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes
arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All decisions and interpretations of the
Administrator shall be binding on all persons, including the Company and Plan grantees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Delegation of Authority to Grant
Awards</U>. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company, including the Chief Executive Officer, all or part of the Administrator&#146;s authority and
duties with respect to the granting of Awards to individuals who are (i)&nbsp;not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not members of the delegated committee. Any such delegation by the
Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The
Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#146;s delegate or delegates that were consistent with the terms of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Award Certificate</U>. Awards under the Plan shall be evidenced by Award Certificates
that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification</U>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any
act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#146; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#146;s
certificate of incorporation or bylaws or any directors&#146; and officers&#146; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other
countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i)&nbsp;determine which Subsidiaries shall be
covered by the Plan; (ii)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (iii)&nbsp;modify the terms and conditions of any Award granted to individuals outside the United States to comply with
applicable foreign laws; (iv)&nbsp;establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall
be attached to this Plan as appendices); <I>provided</I>, <I>however</I>, that no such subplans and/or modifications shall increase the share limitations contained in Section&nbsp;3(a) hereof; and (v)&nbsp;take any action, before or after<B> </B>an
Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions
hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Issuable</U>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 6,567,144 (the
&#147;<B>Initial Limit</B>&#148;), subject to adjustment as provided in Section&nbsp;3(c), plus on January&nbsp;1, 2021 and each January&nbsp;1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be
cumulatively increased by the lesser of (i)&nbsp;five percent (5%) of the number of shares of Stock issued and outstanding on the immediately preceding December&nbsp;31 or (ii)&nbsp;such lesser number of shares as determined by the Administrator
(the &#147;<B>Annual Increase</B>&#148;). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options under this Plan shall not exceed the Initial Limit cumulatively
increased on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January&nbsp;1, 2021 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 6,567,144 shares of Stock, subject in all cases to adjustment as provided in
Section&nbsp;3(c). For purposes of this limitation, the shares of Stock underlying any awards under the Plan and under the Company&#146;s 2015 Stock Option and Grant Plan that are forfeited, canceled, held back upon exercise of an Option or
settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock
available for issuance under the Plan and, to the extent permitted under Section&nbsp;422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. If the Company repurchases shares of
Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of
Award. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Maximum Awards to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</U>. Notwithstanding anything to the contrary in this
Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director in any calendar year shall not exceed $750,000; provided, however, that
such amount shall be $1,500,000 for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is initially elected or appointed to the Board. For the purpose of this limitation, the value of any Award
shall be its grant date fair value, as determined in accordance with ASC 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Changes in Stock</U>. Subject to Section&nbsp;3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification,
stock dividend, stock split, reverse stock split or other similar change in the Company&#146;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of
the Company, or additional shares or new or different shares or other securities of the Company or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such shares of Stock or other securities, or, if, as a
result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary
thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&nbsp;the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock
Options; (ii)&nbsp;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan; (iii)&nbsp;the repurchase price, if any, per share subject to each outstanding Restricted Stock Award; and (iv)&nbsp;the
exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock
Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards
and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and
conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Mergers and Other Transactions</U>. In the case of and subject to the consummation of
a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate
adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards,
upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with
time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards
with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become
vested and nonforfeitable in connection with a Sale Event in the Administrator&#146;s discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, (i)&nbsp;the Company shall have the option (in its sole
discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A)&nbsp;the Sale Price
multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B)&nbsp;the aggregate exercise price of all such outstanding
Options and Stock Appreciation Rights (<I>provided</I> that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or less than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no
consideration); or (ii)&nbsp;each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the
extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied
by the number of vested shares of Stock under such Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>ELIGIBILITY</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grantees under the Plan will be such employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants of the Company
and its Affiliates as are selected from time to time by the Administrator in its sole discretion; <I>provided</I> that Awards may not be granted to employees, Directors or Consultants who are providing services only to any &#147;parent&#148; of the
Company, as such term is defined in Rule 405 of the Act, unless (i)&nbsp;the stock underlying the Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A or (ii)&nbsp;the Company has determined that such Awards are exempt
from or otherwise comply with Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>STOCK OPTIONS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Award of Stock Options</U>. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be
in such form as the Administrator may from time to time approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted under the Plan may be either Incentive Stock
Options or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#147;subsidiary corporation&#148; within the meaning of
Section&nbsp;424(f) of the Code. To the extent that any Option, or any portion thereof, does not qualify as an Incentive Stock Option, it shall be deemed a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock Options granted pursuant to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional
terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee&#146;s election, subject to
such terms and conditions as the Administrator may establish. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. The exercise price per share for the Stock
covered by a Stock Option granted pursuant to this Section&nbsp;5 shall be determined by the Administrator at the time of grant but shall not be less than one hundred percent (100%) of the Fair Market Value on the date of grant. In the case of an
Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than one hundred and ten percent (110%) of the Fair Market Value on the grant date. Notwithstanding the foregoing,
Stock Options may be granted with an exercise price per share that is less than one hundred percent (100%) of the Fair Market Value on the date of grant (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with,
Section&nbsp;424(a) of the Code, (ii)&nbsp;to individuals who are not subject to U.S. income tax on the date of grant, or (iii)&nbsp;the Stock Option is otherwise compliant with Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Term</U>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than
ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercisability; Rights of a Stockholder</U>. Stock Options shall become exercisable at such time or times, whether or not in
installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only
as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Method of Exercise</U>. Stock
Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods
except to the extent otherwise provided in the Option Award Certificate: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In cash, by certified or bank check or other instrument
acceptable to the Administrator; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Through the delivery (or attestation to the ownership following such procedures as the
Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; <I>provided</I> that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply
with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) With respect to Stock Options that are not Incentive Stock Options, by a &#147;net exercise&#148; arrangement pursuant to which the
Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares
of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase
price for such shares and the fulfillment of any other requirements contained in the Option Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with
respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option
shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or
interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Annual Limit on Incentive Stock Options</U>. To the extent required for &#147;incentive stock option&#148; treatment under Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock
with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed
$100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>STOCK APPRECIATION RIGHTS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Award of Stock Appreciation Rights</U>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided
for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with
respect to which the Stock Appreciation Right shall have been exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price of Stock Appreciation Rights</U>. The exercise price of a Stock
Appreciation Right shall not be less than one hundred percent (100%) of the Fair Market Value of the Stock on the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Grant and Exercise of Stock Appreciation Rights</U>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Terms and Conditions of Stock Appreciation Rights</U>. Stock Appreciation Rights shall be subject to such terms and conditions as shall
be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ
among individual Awards and grantees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>RESTRICTED STOCK AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Awards</U>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is
any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights as a Stockholder</U>. Upon the grant of
the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; <I>provided</I> that if the lapse of restrictions
with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance
goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the
effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are
vested as provided in Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Restrictions</U>. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as
specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, if a
grantee&#146;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of
notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase price (if any) from such grantee or such grantee&#146;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall
cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such
certificates to the Company upon request without consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Vesting of Restricted Shares</U>. The Administrator at the time of
grant shall specify the date or dates and/or the attainment of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other conditions on which the <FONT STYLE="white-space:nowrap">non-transferability</FONT> of the
Restricted Shares and the Company&#146;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, objectives and other
conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#147;vested.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 8.
<U>RESTRICTED STOCK UNITS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nature of Restricted Stock Units</U>. The Administrator may grant Restricted Stock Units under the
Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant.
Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals and objectives. The terms and conditions of each such Award shall be
determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section&nbsp;409A, at the end of the
vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section&nbsp;409A and shall contain such additional terms and
conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Election to Receive Restricted Stock Units in Lieu of Compensation</U>. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an
award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section&nbsp;409A and such other rules and procedures
established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise
have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other
terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Rights as a Stockholder</U>. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon
settlement of Restricted Stock Units; <I>provided</I>, <I>however</I>, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to the provisions of
Section&nbsp;11 and such terms and conditions as the Administrator may determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in
the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#146;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#146;s termination of
employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>UNRESTRICTED STOCK AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant or Sale of Unrestricted Stock</U>. The Administrator may grant (or sell at par value or such higher purchase price determined by the
Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect
of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>CASH-BASED AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Grant of Cash-Based Awards</U>. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles
the grantee to a payment in cash upon the attainment of specified performance goals. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which
the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator.
Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 11.
<U>DIVIDEND EQUIVALENT RIGHTS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividend Equivalent Rights</U>. The Administrator may grant Dividend Equivalent Rights under the
Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such
shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall
be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional
equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash
or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only
upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination</U>. Except as may otherwise be provided by the Administrator either in
the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#146;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#146;s termination of employment (or cessation
of Service Relationship) with the Company and its Subsidiaries for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>TRANSFERABILITY OF AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferability</U>. Except as provided in Section&nbsp;12(b) below, during a grantee&#146;s lifetime, his or her Awards shall be
exercisable only by the grantee, or by the grantee&#146;s legal representative or guardian in the event of the grantee&#146;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than
by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be
null and void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Administrator Action</U>. Notwithstanding Section&nbsp;12(a), the Administrator, in its discretion, may provide
either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Options to his or her
immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, <I>provided</I> that the transferee agrees in writing with the Company to be bound by all of the terms
and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Family
Member</U>. For purposes of Section&nbsp;12(b), &#147;<B>family member</B>&#148; shall mean a grantee&#146;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, any person sharing the grantee&#146;s household (other than a tenant of the grantee), a trust in which these persons (or the
grantee) have more than 50&nbsp;percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50&nbsp;percent of
the voting interests. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Designation of Beneficiary</U>. To the extent permitted by the Company, each grantee to whom an Award has
been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#146;s death. Any such designation shall be on a form provided for that purpose by the
Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#146;s
estate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>TAX WITHHOLDING</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Payment by Grantee</U>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts
received thereunder first becomes includable in the gross income of the grantee for income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind
required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The
Company&#146;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Payment in Stock</U>. The Administrator may require the Company&#146;s tax withholding obligation to be satisfied, in whole or in part,
by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; <I>provided</I>,
<I>however</I>, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall
be determined in the same manner as the value of Stock includible in income of the grantee. The Administrator may also require the Company&#146;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain
number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>SECTION</U><U></U><U>&nbsp;409A AWARDS</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards are intended to be exempt from Section&nbsp;409A to the greatest extent possible and to otherwise comply with Section&nbsp;409A. The
Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A (a &#147;<B>409A
Award</B>&#148;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a
&#147;separation from service&#148; (within the meaning of Section&nbsp;409A) to a grantee who is then considered a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that
is the earlier of (i)&nbsp;six months and one day after the grantee&#146;s separation from service, or (ii)&nbsp;the grantee&#146;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest,
penalties and/or additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination of Service Relationship</U>. If the grantee&#146;s Service Relationship is with an Affiliate and such Affiliate ceases to be
an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For purposes of the Plan, the following events shall not be deemed a termination of a
Service Relationship: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one
Affiliate to another; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the
Company, if the employee&#146;s right to <FONT STYLE="white-space:nowrap">re-employment</FONT> is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise
so provides in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>AMENDMENTS AND TERMINATION</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the
purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#146;s consent. The Administrator is specifically authorized to
exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect the repricing of such Awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants.</FONT> To the extent required
under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under
Section&nbsp;422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section&nbsp;16 shall limit the Administrator&#146;s authority to take any action permitted pursuant to Section&nbsp;3(c) or 3(d).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>STATUS OF PLAN</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With
respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the
Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#146;s obligations to deliver Stock or
make payments with respect to Awards hereunder, <I>provided</I> that the existence of such trusts or other arrangements is consistent with the foregoing sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>GENERAL PROVISIONS</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No
Distribution</U>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Issuance of Stock</U>. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all
purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company. Uncertificated Stock shall
be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States mail, addressed to the grantee, at the grantee&#146;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic
&#147;book entry&#148; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of
any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of
governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the
Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock
certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and
representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or
other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stockholder Rights</U>. Until Stock is deemed delivered in accordance with Section&nbsp;18(b), no right to vote or receive dividends or
any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Compensation Arrangements; No Employment Rights</U>. Nothing contained in this Plan shall prevent the Board from adopting other or
additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to
continued employment with the Company or any Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Trading Policy Restrictions</U>. Option exercises and other Awards under
the Plan shall be subject to the Company&#146;s insider trading policies and procedures, as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Clawback
Policy</U>. Awards under the Plan shall be subject to the Company&#146;s clawback policy, as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>EFFECTIVE DATE
OF PLAN</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall become effective upon the date immediately preceding the Registration Date subject to prior stockholder
approval in accordance with applicable state law, the Company&#146;s bylaws and certificate of incorporation, and applicable stock exchange rules. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the
Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 20. <U>GOVERNING LAW</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of
the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by, and construed in accordance with, the internal laws of the Commonwealth of Massachusetts, applied without regard to conflict of law
principles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE APPROVED BY BOARD OF DIRECTORS:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">September&nbsp;8, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE APPROVED BY STOCKHOLDERS:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">September 23, 2020</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The share numbers in this Plan reflect the reverse stock split effected September 25, 2020.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCENTIVE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option&nbsp;Exercise&nbsp;Price&nbsp;per&nbsp;Share:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date (110% of FMV if a 10% owner)]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[up to 10 years (5 if a 10% owner)]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;<B>Plan</B>&#148;), C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants to the Optionee named above an option (the &#147;<B>Stock Option</B>&#148;) to purchase on or prior to the Expiration Date specified above all or
part of the number of shares of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and
in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become
exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the
following number of Option Shares on the dates indicated so long as the Optionee maintains a Service Relationship with the Company or a Subsidiary on each such date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="42%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Incremental Number of<BR>Option Shares Exercisable*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exercisability&nbsp;Date</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>_____________&nbsp;(___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Max. of $100,000 per yr. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration
Date, subject to the provisions hereof and of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, <I>provided</I> that in the event the Optionee
chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such
payment procedure; or (iv)&nbsp;a combination of (i), (ii) and (iii)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#146;s employment by or other Service Relationship with the
Company or a Subsidiary is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary
terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on the date of death, to the extent exercisable on such date, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a
period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary
terminates by reason of the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on the date on which the Optionee is determined to have a disability, to the extent exercisable on such date,
may thereafter be exercised by the Optionee for a period of 12 months from such date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate
immediately and be of no further force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s employment or other Service
Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;<B>Cause</B>&#148; shall
mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator<B> </B>that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any
agreement between the Optionee and the Company; (ii)&nbsp;the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT
STYLE="white-space:nowrap">non-performance</FONT> (other than by reason of disability) by the Optionee of the Optionee&#146;s duties to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary terminates for
any reason other than the Optionee&#146;s death, disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on the date on which the Optionee&#146;s employment or other Service
Relationship with the Company or a Subsidiary terminated may be exercised, to the extent exercisable on such date, for a period of three months from such date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option
that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determination of the reason for termination of the Optionee&#146;s
employment or other Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all
the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT>
and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by
the Optionee&#146;s legal representative or legatee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Status of the Stock Option</U>. This Stock Option is intended to qualify as an
&#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should
consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section&nbsp;422 of the Code, including, but not limited to, holding period
requirements. To the extent any portion of this Stock Option does not so qualify as an &#147;incentive stock option,&#148; such portion shall be deemed to be a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option. If the Optionee
intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the <FONT STYLE="white-space:nowrap">one-year</FONT> period beginning on the date after the transfer of such shares to him or her, or
within the <FONT STYLE="white-space:nowrap">two-year</FONT> period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event
for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the
withholding amount due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by
or as a result of the Plan or this Agreement to continue the Optionee in employment or other Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or
any Subsidiary to terminate the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties
with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification
number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;<B>Relevant Information</B>&#148;). By entering into this Agreement,
the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information;
(iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The
Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Optionee&#146;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Optionee&#146;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> CONSULTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[<B>FMV on Grant Date</B>]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[<B>No more than 10 years</B>]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;<B>Plan</B>&#148;), C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants to the Optionee named above, who is a Consultant of the Company, an option (the &#147;<B>Stock Option</B>&#148;) to purchase on or prior to the
Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the
terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except
as set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of
Option Shares on the dates indicated so long as the Optionee maintains a Service Relationship with the Company or a Subsidiary on each such date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Incremental Number of<BR>Option Shares
Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exercisability Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________ (___%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________ (___%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________ (___%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________ (___%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">_____________ (___%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times
prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of
this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, <I>provided</I> that in the event the Optionee
chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such
payment procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed
the aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer
agent shall have transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership
rights with respect to such shares of Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee ceases to have a Service Relationship with the Company or a
Subsidiary for any reason, any portion of this Stock Option outstanding on the date on which the Optionee&#146;s Service Relationship with the Company or a Subsidiary ceased may be exercised, to the extent exercisable on such date, for a period of
three months from such date or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee&#146;s Service Relationship with the Company or a Subsidiary ceased shall terminate immediately
and be of no further force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option
shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan,
unless a different meaning is specified herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT
STYLE="white-space:nowrap">non-assignable</FONT> and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s
lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal representative or legatee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to
Continue Service Relationship</U>. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to the continuation of Optionee&#146;s service as a Consultant or other Service Relationship with the Company or a
Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option
and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Data Privacy Consent</U>. In
order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all
personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan
and/or this Agreement (the &#147;<B>Relevant </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Information</B>&#148;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant
Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the
transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance
with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business
and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[No more than 10 years]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;<B>Plan</B>&#148;), C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the &#147;<B>Stock Option</B>&#148;)
to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;), of the Company specified above at the Option Exercise Price per Share
specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as
set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option
Shares on the dates indicated so long as the Optionee maintains a Service Relationship with the Company or a Subsidiary on each such date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Incremental Number of<BR>Option Shares Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exercisability&nbsp;Date</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times
prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, <I>provided</I> that in the event the Optionee
chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such
payment procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed
the aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer
agent shall have transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership
rights with respect to such shares of Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee ceases to maintain a Service Relationship with the Company or a
Subsidiary, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Termination Due to Death</U>. If the Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on
the date of death, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a period of 12 months from such date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not
exercisable on such date of death shall terminate immediately and be of no further force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Termination</U>. If the
Optionee&#146;s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#146;s death, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date
the Optionee ceased to maintain a Service Relationship with the Company or a Subsidiary, for a period of six months from the date the Optionee&#146;s Service Relationship with the Company or a Subsidiary ceased or until the Expiration Date, if
earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee&#146;s Service Relationship with the Company or a Subsidiary ceases shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT> and is
not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the
Optionee&#146;s legal representative or legatee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Obligation to Continue Service Relationship</U>. Neither the Plan nor this Stock
Option confers upon the Optionee any rights with respect to the continuation of the Optionee&#146;s service as a Director or any other Service Relationship with the Company or a Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all
prior agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Data Privacy Consent</U>. In order to
administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all personal
or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#147;<B>Relevant Information</B>&#148;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives
any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant
Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-QUALIFIED</FONT> STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Optionee:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Option Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Option Exercise Price per Share:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[FMV on Grant Date]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expiration Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;<B>Plan</B>&#148;), C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants to the Optionee named above an option (the &#147;<B>Stock Option</B>&#148;) to purchase on or prior to the Expiration Date specified above all or
part of the number of shares of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and
in the Plan. This Stock Option is not intended to be an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercisability Schedule</U>. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as
set forth below, and subject to the discretion of the Administrator (as defined in Section&nbsp;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option
Shares on the dates indicated so long as the Optionee maintains a Service Relationship with the Company or a Subsidiary on each such date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Incremental Number of<BR>Option Shares Exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exercisability&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U></U>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U></U>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U></U>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U></U>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U></U>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close
of business on the Expiration Date, subject to the provisions hereof and of the Plan. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Manner of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i)&nbsp;in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii)&nbsp;through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii)&nbsp;by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, <I>provided</I> that in the event the Optionee
chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such
payment procedure; (iv)&nbsp;by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed
the aggregate exercise price; or (v)&nbsp;a combination of (i), (ii), (iii) and (iv)&nbsp;above. Payment instruments will be received subject to collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i)&nbsp;the
Company&#146;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii)&nbsp;the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and
(iii)&nbsp;the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent
resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock
transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The shares of Stock
purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or
regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have
transferred the shares to the Optionee, and the Optionee&#146;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect
to such shares of Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Optionee&#146;s employment by or other Service Relationship with the
Company or a Subsidiary is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination Due to Death</U>. If the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary
terminates by reason of the Optionee&#146;s death, any portion of this Stock Option outstanding on the date of death, to the extent exercisable on such date, may thereafter be exercised by the Optionee&#146;s legal representative or legatee for a
period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Due to Disability</U>. If the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary
terminates by reason of the Optionee&#146;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on the date on which the Optionee is determined to have a disability, to the extent exercisable on such date,
may thereafter be exercised by the Optionee for a period of 12 months from such date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate
immediately and be of no further force or effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause</U>. If the Optionee&#146;s employment or other Service
Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#147;<B>Cause</B>&#148; shall
mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i)&nbsp;any material breach by the Optionee of any agreement
between the Optionee and the Company; (ii)&nbsp;the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii)&nbsp;any material misconduct or willful and deliberate <FONT
STYLE="white-space:nowrap">non-performance</FONT> (other than by reason of disability) by the Optionee of the Optionee&#146;s duties to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Termination</U>. If the Optionee&#146;s employment or other Service
Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#146;s death, disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on the date on
which the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary terminated may be exercised, to the extent exercisable on such date, for a period of three months from such date of termination or until the
Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator&#146;s determination of the reason for termination of the Optionee&#146;s employment or other Service Relationship with the
Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Incorporation of
Plan</U>. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan.
Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Transferability</U>. This Agreement is personal to the Optionee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT> and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and
distribution. This Stock Option is exercisable, during the Optionee&#146;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#146;s legal representative or legatee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event
for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the
withholding amount due. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by
or as a result of the Plan or this Agreement to continue the Optionee in employment or other Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or
any Subsidiary to terminate the Optionee&#146;s employment or other Service Relationship with the Company or a Subsidiary at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification
number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;<B>Relevant </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Information</B>&#148;). By entering into this Agreement, the Optionee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant
Information; (ii)&nbsp;waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the
transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance
with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business
and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Optionee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Optionee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Grantee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Shares:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the &#147;<B>Plan</B>&#148;) as
amended through the date hereof, C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants a Restricted Stock Award (an &#147;<B>Award</B>&#148;) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the
number of shares of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the
Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Award</U>. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company&#146;s transfer agent in book entry
form, and the Grantee&#146;s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights,
subject, however, to the restrictions and conditions specified in Paragraph&nbsp;2 below. The Grantee shall (i)&nbsp;sign and deliver to the Company a copy of this Award Agreement and (ii)&nbsp;deliver to the Company a stock power endorsed in blank.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Restrictions and Conditions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in
its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Shares of
Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the Grantee&#146;s employment with the Company and its Subsidiaries is voluntarily or involuntarily terminated for any reason (including
death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Vesting of Restricted Stock</U>. The restrictions and conditions in Paragraph&nbsp;2 of this Agreement shall lapse on the vesting date or
dates specified in the following schedule (each, a &#147;<B>Vesting Date</B>&#148; and, collectively, the &#147;<B>Vesting Dates</B>&#148;) so long as the Grantee maintains a Service Relationship on each such date. If a series of Vesting Dates is
specified, then the restrictions and conditions in Paragraph&nbsp;2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on each such date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">of Shares Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vesting&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_____________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_____________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_____________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_____________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_____________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to such Vesting Date(s), the shares of Stock on which all restrictions and conditions have lapsed
shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph&nbsp;3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Dividends</U>. Dividends on shares of Restricted Stock shall be paid currently to the Grantee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms
and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Transferability</U>. This Agreement is personal to the Grantee, is <FONT STYLE="white-space:nowrap">non-assignable</FONT> and is not
transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Tax
Withholding</U>. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any
Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required tax withholding
obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Election Under Section</U><U></U><U>&nbsp;83(b)</U>. The Grantee and the Company hereby agree that the Grantee may, within 30 days
following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section&nbsp;83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of
the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section&nbsp;83(b) election and that he or she is relying solely on such advisors and not on
any statements or representations of the Company or any of its agents with regard to such election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any
Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment or any other Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with
the right of the Company or any Subsidiary to terminate the Grantee&#146;s employment or other Service Relationship with the Company or a Subsidiary at any time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior
agreements and discussions between the parties concerning such subject matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Data Privacy Consent</U>. In order to administer the
Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all personal or
professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this
Agreement (the &#147;<B>Relevant Information</B>&#148;). By entering into this Agreement, the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any
privacy rights the Grantee may have with respect to the Relevant Information; (iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information
to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Grantee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. of Restricted Stock Units:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grant Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;<B>Plan</B>&#148;), C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;<B>Award</B>&#148;) to the Grantee named above. Each Restricted Stock Unit
shall relate to one share of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;) of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions
on Transfer of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or
otherwise encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse
on the vesting date or dates specified in the following schedule (each a &#147;<B>Vesting Date</B>&#148; and, collectively, the &#147;<B>Vesting Dates</B>&#148;) so long as the Grantee maintains a Service Relationship with the Company or a
Subsidiary on each such Vesting Date. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on each such date.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Restricted Stock Units Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Vesting&nbsp;Date</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>_____________ (___%)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service
Relationship</U>. If the Grantee&#146;s Service Relationship with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any
Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have
any further rights or interests in such unvested Restricted Stock Units. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date
(but in no event later than two and <FONT STYLE="white-space:nowrap">one-half</FONT> months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate
number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Section</U><U></U><U>&nbsp;409A of the Code.</U> This Agreement shall be interpreted in such a manner that all provisions relating
to the settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Obligation to Continue Service Relationship</U>. Neither the Plan nor this Award confers upon the Grantee any rights with respect to
the continuation of the Grantee&#146;s service as a Director or any other Service Relationship with the Company or a Subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Integration</U>. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification
number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;<B>Relevant Information</B>&#148;). By entering into this Agreement,
the Grantee (i)&nbsp;authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information;
(iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The
Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>C4 THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#146;s Signature</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grantee&#146;s name and address:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR COMPANY EMPLOYEES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK OPTION AND INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Grantee:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. of Restricted Stock Units:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan as amended through the date hereof
(the &#147;<B>Plan</B>&#148;), C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) hereby grants an award of the number of Restricted Stock Units listed above (an &#147;<B>Award</B>&#148;) to the Grantee named above. Each Restricted Stock Unit
shall relate to one share of Common Stock, par value $0.0001 per share (the &#147;<B>Stock</B>&#148;) of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Restrictions
on Transfer of Award</U>. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or
otherwise encumbered or disposed of until (i)&nbsp;the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii)&nbsp;shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting of Restricted Stock Units</U>. The restrictions and conditions of Paragraph&nbsp;1 of this Agreement shall lapse
on the vesting date or dates specified in the following schedule (each a &#147;<B>Vesting Date</B>&#148; and, collectively, the &#147;<B>Vesting Dates</B>&#148;) so long as the Grantee maintains a Service Relationship with the Company or a
Subsidiary on each such Vesting Date. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&nbsp;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on each such date.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Incremental Number of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Restricted Stock Units Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vesting&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">_____________ (___%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_________</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination of Service Relationship</U>. If the Grantee&#146;s employment or other Service Relationship with the Company and its
Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and
without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Issuance of Shares of Stock</U>. As soon as practicable following each Vesting Date
(but in no event later than two and <FONT STYLE="white-space:nowrap">one-half</FONT> months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate
number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Incorporation of Plan</U>. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section&nbsp;2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Withholding</U>. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for
Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the
authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the
withholding amount due. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Section</U><U></U><U>&nbsp;409A of the Code.</U> This Agreement shall be interpreted in such a manner that
all provisions relating to the settlement of the Award are exempt from the requirements of Section&nbsp;409A of the Code as &#147;short-term deferrals&#148; as described in Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>No Obligation to Continue Service Relationship</U>. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Grantee in employment or other Service Relationship with the Company or a Subsidiary, and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the
employment or other Service Relationship with the Company or a Subsidiary of the Grantee at any time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Integration</U>. This
Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Data Privacy Consent</U>. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the
Company, its subsidiaries and affiliates and certain agents thereof (together, the &#147;<B>Relevant Companies</B>&#148;) may process any and all personal or professional data, including but not limited to Social Security or other identification
number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#147;<B>Relevant Information</B>&#148;). By entering into this Agreement,
the Grantee (i)&nbsp;authorizes the Company to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii)&nbsp;waives any privacy rights the Grantee may have with respect to the Relevant Information;
(iii)&nbsp;authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv)&nbsp;authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The
Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C4 THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company&#146;s instructions to the Grantee (including through an online acceptance process) is acceptable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Grantee&#146;s name and address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>d772024dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C4 THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the C4 Therapeutics, Inc. 2020 Employee Stock Purchase Plan (&#147;the <B>Plan</B>&#148;) is to provide eligible employees of
C4 Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) and each Designated Subsidiary (as defined in Section&nbsp;11) with opportunities to purchase shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<B>Common
Stock</B>&#148;). 437,809 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January&nbsp;1, 2021, and each January&nbsp;1 thereafter through January&nbsp;1, 2030, the number of shares of Common Stock
reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i)&nbsp;one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, (ii) 656,714
shares of Common Stock, or (iii)&nbsp;such lesser number of shares of Common Stock as determined by the Administrator. The Plan is intended to constitute an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the
Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;), and shall be interpreted in accordance with that intent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Administration</U>. The Plan will be administered by the person or persons (the &#147;<B>Administrator</B>&#148;) appointed by the Company&#146;s Board of Directors (the &#147;<B>Board</B>&#148;) for such purpose. The Administrator has authority
at any time to: (i)&nbsp;adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii)&nbsp;interpret the terms and provisions of the Plan;
(iii)&nbsp;make all determinations it deems advisable for the administration of the Plan; (iv)&nbsp;decide all disputes arising in connection with the Plan; and (v)&nbsp;otherwise supervise the administration of the Plan. All interpretations and
decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or
determination made in good faith with respect to the Plan or any option granted hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Offerings</U>. The Company will make one
or more offerings to eligible employees to purchase Common Stock under the Plan (&#147;<B>Offerings</B>&#148;). Unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each
January&nbsp;1 and July&nbsp;1 and will end on the last business day occurring on or before the following June&nbsp;30 and December&nbsp;31, respectively. The Administrator may, in its discretion, designate a different period for any Offering,
<I>provided</I> that no Offering shall exceed twenty-seven months in duration or overlap any other Offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Eligibility</U>. All
individuals classified as employees on the payroll records of the Company and each Designated Subsidiary are eligible to participate in any one or more of the Offerings under the Plan, <I>provided</I> that, as of the first day of the applicable
Offering (the &#147;<B>Offering Date</B>&#148;), such individual is customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and has completed at least 30 days of employment. Notwithstanding any other provision
herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Subsidiary for purposes of the Company&#146;s or applicable Designated Subsidiary&#146;s payroll system are not considered to be eligible
employees of the Company or any Designated Subsidiary and shall not be eligible to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a
Designated Subsidiary for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or
administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees
of the Company or a Designated Subsidiary on the Company&#146;s or Designated Subsidiary&#146;s payroll system to become eligible to participate in this Plan is through an amendment to this Plan, duly executed by the Company, which specifically
renders such individuals eligible to participate herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Participation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Participants</U>. An eligible employee who is not a Participant in any prior Offering may participate in an Offering by submitting an
enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Enrollment</U>. The enrollment form will (a)&nbsp;state a whole percentage or the amount to be deducted from an eligible
employee&#146;s Compensation (as defined in Section&nbsp;11) per pay period, (b)&nbsp;authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c)&nbsp;specify the exact name or names in which shares of
Common Stock purchased for such individual are to be issued pursuant to Section&nbsp;10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new
enrollment form (which may effect a change in enrollment percentage or amount) or withdraws from the Plan, such Participant&#146;s deductions and purchases will continue at the same percentage or amount of Compensation for future Offerings,
<I>provided</I> he or she remains eligible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Compliance with Code Requirements</U>. Notwithstanding the foregoing, participation in
the Plan will neither be permitted nor be denied contrary to the requirements of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Employee Contributions</U>. Each
eligible employee may authorize payroll deductions at a minimum of 1&nbsp;percent up to a maximum of 15&nbsp;percent of such employee&#146;s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll
deductions made by each Participant for each Offering. No interest will accrue or be paid on payroll deductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Deduction
Changes</U>. Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction during any Offering, but may increase or decrease his or her payroll deduction with
respect to the next Offering (subject to the limitations of Section&nbsp;5) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the
Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction during an Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Withdrawal</U>. A Participant may withdraw from participation in the Plan by
delivering a written notice of withdrawal to his or her appropriate payroll location. The Participant&#146;s withdrawal will be effective as of the next business day. Following a Participant&#146;s withdrawal, the Company will promptly refund such
individual&#146;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again
during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Grant of
Options</U>. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (&#147;<B>Option</B>&#148;) to purchase on the last day of such Offering (the &#147;<B>Exercise Date</B>&#148;), at
the Option Price hereinafter provided for, the lowest of (a)&nbsp;a number of shares of Common Stock determined by dividing such Participant&#146;s accumulated payroll deductions on such Exercise Date by the lower of (i)&nbsp;85% of the Fair Market
Value of the Common Stock on the Offering Date, or (ii)&nbsp;85% of the Fair Market Value of the Common Stock on the Exercise Date; (b)&nbsp;a number of shares of Common Stock determined by dividing $25,000 by the Fair Market Value of the Common
Stock on the Offering Date of such Offering; or (c)&nbsp;such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering; <I>provided</I>, <I>however</I>, that such Option shall be subject to
the limitations set forth below. Each Participant&#146;s Option shall be exercisable only to the extent of such Participant&#146;s accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option
(the &#147;<B>Option Price</B>&#148;) will be 85% of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was
granted, would be treated as owning stock possessing 5%&nbsp;or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section&nbsp;11). For purposes of the preceding
sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock that the Participant has a contractual right to purchase shall be treated as stock owned by the
Participant. In addition, no Participant may be granted an Option that permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which
exceeds $25,000 of the fair market value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with
Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Exercise of Option and Purchase of Shares</U>. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of
whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a
Participant&#146;s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant&#146;s account at the end of an Offering
will be refunded to the Participant promptly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Issuance of Certificates</U>. Certificates representing shares of Common Stock
purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her
or their, nominee for such purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Definitions</U>. For purposes of this Plan, the following terms shall have the meanings set
forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Compensation</B>&#148; means the amount of base pay, prior to salary reduction pursuant to
Sections&nbsp;125, 132(f) or 401(k) of the Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise of Company
stock options, and similar items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Designated Subsidiary</B>&#148; means any present or future Subsidiary (as defined
below) that has been designated by the Board to participate in the Plan. The Board may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Fair Market Value of the Common Stock</B>&#148; on any given date means the fair market value of the Common Stock
determined in good faith by the Administrator; <I>provided</I>, <I>however</I>, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#147;<B>NASDAQ</B>&#148;), NASDAQ Global
Market or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such
date for which there is a closing price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Parent</B>&#148; means a &#147;parent corporation&#148; with respect to the
Company, as defined in Section&nbsp;424(e) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Participant</B>&#148; means an individual who is eligible to
participate in this Plan as determined in Section&nbsp;3 and who has complied with the provisions of Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term
&#147;<B>Subsidiary</B>&#148; means a &#147;subsidiary corporation&#148; with respect to the Company, as defined in Section&nbsp;424(f) of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Rights on Termination of Employment</U>. If a Participant&#146;s employment terminates for any reason before the Exercise Date for any
Offering, no further payroll deduction will be taken from any pay due and owing to the Participant and the balance in the Participant&#146;s account will be paid to such Participant or, in the case of such Participant&#146;s death, to his or her
designated beneficiary as if such Participant had withdrawn from the Plan under Section&nbsp;7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated
Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated Subsidiary. An employee will not be deemed to have terminated employment for purposes of this Section&nbsp;12 if the
employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee&#146;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant
to which the leave of absence was granted or if the Administrator otherwise provides in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Special Rules</U>. Notwithstanding anything herein to the contrary, the Administrator
may adopt special rules applicable to the employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated
Subsidiary has employees; <I>provided</I> that such rules are consistent with the requirements of Section&nbsp;423(b) of the Code. Any special rules established pursuant to this Section&nbsp;13 shall, to the extent possible, result in the employees
subject to such rules having substantially the same rights as other Participants in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Optionees Not Stockholders</U>.
Neither the granting of an Option to a Participant nor the deductions from his or her pay shall constitute such Participant a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and
issued to him or her. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Rights Not Transferable</U>. Rights under the Plan are not transferable by a Participant other than by will
or the laws of descent and distribution, and are exercisable during the Participant&#146;s lifetime only by the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.
<U>Application of Funds</U>. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Adjustment in Case of Changes Affecting Common Stock</U>. In the event of a subdivision of outstanding shares of Common Stock, the
payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section&nbsp;8 shall be equitably or proportionately adjusted to give proper
effect to such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Amendment of the Plan</U>. The Board may, at any time and from time to time, amend the Plan in any respect,
except that, without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order
for the Plan, as amended, to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423(b) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.
<U>Insufficient Shares</U>. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date, plus the number of shares purchased under previous Offerings under the Plan, exceeds the maximum number of shares
issuable under the Plan, the shares then available shall be apportioned among Participants in an Offering in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common
Stock on such Exercise Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Termination of the Plan</U>. The Plan may be terminated at any time by the Board.
Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Governmental Regulations</U>.
The Company&#146;s obligation to sell and deliver Common Stock under the Plan is subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Governing Law</U>. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the
General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by, and construed in accordance with, the internal laws of the Commonwealth of Massachusetts, applied without
regard to conflict of law principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Issuance of Shares</U>. Shares may be issued upon exercise of an Option from authorized but
unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Tax Withholding</U>.
Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to
deduct any such taxes from any payment of any kind otherwise due to the Participant, including shares issuable under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.
<U>Notification Upon Sale of Shares</U>. Each Participant agrees, by entering the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of
the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Effective
Date and Approval of Shareholders</U>. The Plan shall take effect on the date immediately preceding the date upon which the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that is filed by the Company with respect to its
initial public offering of Common Stock under the Securities Act of 1933, as amended, is declared effective by the Securities and Exchange Commission, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at
which a quorum is present or by written consent of the stockholders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE APPROVED BY BOARD OF DIRECTORS:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">September 8, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE APPROVED BY STOCKHOLDERS:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">September 23, 2020</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The share numbers in this Plan reflect the reverse stock split effected September 25, 2020.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>d772024dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C4 Therapeutics, Inc.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report dated August&nbsp;5, 2020, except as to Note 13, which is as of September&nbsp;28, 2020, included herein and to the
reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ KPMG LLP </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;28, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g772024g02d58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g02d58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[28*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )>Z^EQ X0DE-! 0      #T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   F:T' (% !E0<F]T96EN($=R87!H:6-?,#<R.3(P7W8Q #A"24T$)0
M    $(MLVD3=+?3JW%@1^)N[K10X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +>   '8P         !
M                  $             !V,   +>
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +>     %)G:'1L;VYG   '
M8P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "W@    !29VAT;&]N9P  !V,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     &UH
M   !    H    #X   '@  !T0   &SX &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( .L"70,!$0 "$0$#$0'_Q  ?  $  0,% 0$
M        " 8'"0(#! 4* 0O_Q !@$  !! $# @,#!@D'" 8%" L$ 0(#!08
M!Q$($A,A,11!40D5%R)A<189,E>!D9;4U2-8EZ&QP? 8)#-"4H;1X0HE5L33
M\393@H?#)C5(5&)R=Z(G*#A$17-V@X2RQ?_$ !X! 0  !P$! 0
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M5J.KJ8YEG5%!EUN\6'-0L0H=U<08%1D;?Q2AYKCNY'7'O7MYF]I;V=U1%9#
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MK-S0[6^V>V+?=RGVF[VXTK'VF?68^ZV:WP.7XENW)AN\.,5;\=K"<7QW:?(
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M'4^)^-J>T>6MWGE. X=G8<WL<Z5I(;.3RB(5:>I!/6@IEU6Q9>PDM1-D\*<
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M=(:T2= 0H.L:L>)O&,DA>ADH^'U!(C'#=.I@YXD](QD:$466F4>C6\A8D/\
M6D.MC(,(V'P9F,AE;6;:A-RS*:S#J<4?!L5'C(MK2 TN*)&-JVL5&!UII+F\
M<N; YK?K*FO='P[@(E*18+#QH=R5CQE)%._<E5@ ._KN.NK7+QUQM,_F3<8\
M52R=_,EXAR\C[_'F>X6_7KJL_P!N.F?;O%KW/<QP[;_;W'Z$5I=WE]-4P84<
M%!-/")"GSWB$55>NF*+('#$%$(D*,,(@%%AF(GCC?YFX2X:;<QX/'57(.\U"
MLF.L==R=K- 5IQU).XD&QZCKUUZX_$?CQ J2\69S(0(1RU,Q>FSE'<=!O0S!
MO4FV_P"] >GU#5A,8+VSSN[QJHZ>M[2[RPR[;ZSW4I*+)T)R_'H\.J,BJ<6)
M4NS+6LS^@M2KVTDJV1Y!:7Y->357,1M"TD!P\MKL<)2P!GP^4GA(/NU,GOD*
MI7?<HM@M'DHV;MYLMJXL?1O9W/0Y!3\2*MLK%Q-P[2L*5*ODN'PN%R 9NTDE
M%5GP4\<?TC6JX[%/-]$WHALR\?(,KWIHLF!PJY"I]J1SGL@@SDU[\T@R6962
M.FK=N^!JS'H;-(D\<0G-I6W;%%+E?M;:U35LF6M,C<QEB.KEZST9I7\N"3S/
M/HVVVZBI="HK.0"RUYXZ]UE1W]E\I?,-^EP>-SM.;)<,Y"/+U*\8EN1>3[+E
M\6C'EYLGBWDDDBA0\JO>I37\2K210_.0L/Y.KN8-MOMV/:U>47PIFXF;UDKR
M*_.=R35S#)*@N9JL))Q=I\246!L*:[M* V]I<4J9N$5U<CO-<LJY%90!S#KZ
MCM]^W7OV[>O0=M:YR.&:%F'*3MOL3]_0]STWV&^Y^).VQE**4R9K>%YY]%\O
MU>7_ !^S[[PCAAN".PW^L=>OQ_4/V;8O+$T3$$?C\?CX\SGG^W575+333333
M3335I<MV/VVR^XGRHBA=CV=S"L#7<;!K _!MPE$AY4<(K,,7(J[FWJ8)5;-^
M#]Z3:8Z3(QGMM25&BQJTU1Y9F]>TPQ)U@0-OM@5<.DY9<B8]A.\5* .CG&G%
M.[J':_/HQXE4HCP8]J"P*X6;P(,JLY(H)GX_'Z].OW?C\;?KU9WHLZ^=I^MH
MC>,;;QD]=/M;G$M.")8R/CL,IP(R-&XON) !/ ,37@Y"8'<C_-9$;C:KV(9+
M'P9CH8M1((.Q^&^FIV:AIIIIIIIIIIIIIJ&O61US;+]$&-X5D.[4>36LV>Y(
M['Z#'<+"J[+(91PQVE7>0/#M;BD'2EHHI0XSIF%O)>795PHPTSR'NBJ0PS6)
M!%!&9'Y6?;F50%78=6=E4%F954$@DG?HH8C/. _#K/\ B'<O5,(:D(Q]83V+
M-^2:*L'D8I7K!X(+#^?8*R,@,818XI79ARJK[NUGR@/1OO%3K<8AU!;=C>&(
MXTNHS&[@P+( 88HEE(<129FM)8/8*QKUG)#A*#1&.?&3)%VO6:>O/5.UF&6
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M65G?9]:3'U>/7]8_%;"^G#PC\)PJ5;\U61&C'G5*#D"DYKF-.T6^?L[A?@_
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M6N(7%+9UN45E_$-/1'X^8'-!;AW,!B*'-5$ /GBL(BT4:01TK"$6)7IJ(!)
M ))(  ZDD]@ .I)/;;36!I_RGWR)G2!N9;P[15N&@YBT8K$\CR[IXV6>^G^;
M7GB%F5C\MJZ^DJ,EJ?;ZP$MTF.%W]?+,(/*/+*^%.W.Z/AMQA?KK93&B"-U#
MQK<L0UY74C<'R7?S4)WW E2,_G&_D:[74[<Y;XE5) ^_H#]V^NJZE/\ I'71
MUM?2T+NG^BRCJ6R>]K$M)PX8[;:K&L78^66!E?DMSEV,DWJ7;GQ+*@%-B5J$
M@RMEGN!G2CQS7;#^$_$5^:9<DT.'BA?D+RE+<LW0'F@B@EY&CZ[>8\R L"%#
M%6VDDOPJ!R R$^G5 /M)&_ZM66Z:/^DM8%N;N)CV![V]-.3[<A9/;#4X&6[;
MY85NM[ 2=*V(:6TPY,.QO(9@(G.Y,GQV2_M4C19!:$I46-+GE_!W(5*TEC&9
M2#(/$A<UIX/8I)-NZQ2&>:(N?ZJR-$I/3GWVW\<^<ITH);>0DBI5($,D]J>9
M4AAC&V[R._*%&YV[]20 "2-9HS>OW9,>S]B!J-P[D#Q.Q+\&BI ZQS.[M69
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MTD(=G3$F0O-]5)*LL[I:E$2)6FG7<LJN\?*51RFSE.7G8K&R.W+MS ;@] >
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MCI8+H$LDB)II8Q*8D#J->.K7J3+*_LU5@+4X#*D; LQ4. 6YV5RZ\LF_)S,
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M\R0#\?7_ ,O7?4;=S\RCI*TPU[""71K%".$&Q9C;$\R>(.MJJ^%5:I-A:6!
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M*&AG(H_-=Z\*=(:&4A87Z"*L44,@R&.@5H\9YCRDH;%"(8U[NY41/MY1?/\
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M7CA^59%WXJ]]A"=W\TM[C(MKAZ8K ,X#%$Q-H6,VV3V$]-E6.LQFMKT#>XZ
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M>9^+,AQ V6ER"1W<#7NAH:MJ2N:?M$#V56&C)5KUTFR,LJS,BQO4DD:+^DL
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MC6CS6%D10?ZD<LW#DDP4=@9'E?XL=9BGBIQ"J[-5Q+OM_G#7LJQ^LA;84G[
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M2.[D#<[N6Y>VP"<H&W0#5Z<!ZE<GI"APLY3\(J5[DCDLX8(8+L%'.3B7B!L
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M3"78*%#,%S*+564A!90+LWX!Q:97+SURB!X*K78W811,'1Q7YHK:$W*TB&P
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M( FQV=/:5"F0Z \,Z:J,%L)>>LMBK>(O3XZZACGKR*=U)Y)$#!XY8GV!:*4
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MU<JIKP)8.Z5[6N[45$7CESE^_P"'E]W*_#6Y.&\+B;--FGDC1@C$;CH2!N
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M0U[7E^Y'DL=*&I9&$!1Y\7M$ >E9J3S6UZN=R=Q-K=ELAR3;/&CKN_=V@SW
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MD]2=5#JEJ73333333333333333333333333335C-Z]WAMN:IH%6^ C+K6+D
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MHB4$YB.[>?5KFO:J>2HK5]R^J(YO+'<<*K'.;SPY=:,5RG-MV961@=]B&'J
M1ORG9UWZ!U5MMP-9(0#]W4'X:U:EU'33333365'9=['[680L<3(4;2Q1JUB<
M(Z2*::*694_VR)6/(D7WR2N7RYXU^B'Y-<L4W@+X4/#7CJH.#,3&8HP54R0Q
M&&:?8]2]J:-[,C$^]),S>NN4^,%9>)\V&<N?G"9N8^@8AE7[$4A!\ H&NYW&
MP&@W2PC(\ RCV_YARBO=76#JLZ:N/9'XD<\4HQ4*_5?"1#%+X,\<X9+6*,<*
M4'+./+MS,XBGGL7>Q%\2FG?@:"?R)7@E"DA@4D0@@JRJW*P:-P"DJ/&S(V&Y
M+'U\K1LX^WYGL]J/RY/*D:*0 ,&5E=?5656Y7#QN!R2I)&S(V ?>;I0W!V%R
MT2L<*5EF)W]A'7XAD]6%+(MF65(K Z*P @\:0+(WJK61@M\6"S\Y:N4CM)@$
MX"\3_"?B3A2_#%4K6,SC<C:CJXF]3A9Y)+,\G)!3M1(&]GN,Q 38^5.?>B?<
M-''J*7A^UP_:6";>>K(_)4M(A*S[[\D+Q@,5M$=/('-YO>$R#G5,S_3IM%:X
M!AU%:;@O$NMSY*1M47>$#!$75'C3I("J_!WW\;'&VP=-)$USY22RXV$JX,&=
M]2#6M9V3X;<)Y/AWA[%-Q1:BR_%B8Y:=O*R0P/<KT><3087YP5!8NUZ)V433
MR2-)(&*L8UCVVAA\::L26+,:>VO&8PQ"O+7JGD*4S,-V=4*!B.=TC8^3"Q@B
MBU(_6Q]7O33333333349=^-Z5P^+\$\7+8F3EQHZQ/B[)5Q\.5O+6M1>YB6Q
M3%1\#)&N]D&5"I&(^817<-_*X^5&OA31/ O UR"7Q#RU<-<NIR3KPCC9U/)9
M="&B.:N*=Z%:8,*L!]OL1D/32?9' O!AS<AR>1C88N!MHHCNIOS*>J@]#[-&
M01*RD&1QY2'<2%8>5^0.C4F<R20HLMSY"2R7/())ED\W33D2N=+-,Y?RY)7O
M>[GERJOEKY98WCZS/)>OYJY8RV5R#/+=R&2L27;UJ9_IRV+5EY)II&.YYV<L
M.PV&MPSXQ (HX$2&&( 1Q1*(HT5>@5$5>4+MV  '?IUZ=9#EEUCIDEEC]Q8T
M<ZJDCWUQ<PJ2MCY5/:H8G)$7'QYK"3%-$]4X5CN$35OPWBEQSP?F3DN!N*LW
MPW.\RLZXN_/!4M,6YE6Y1+&C=CW #17*\T1'="-M>B7"X[(0>3D:5>X@!ZS1
M*SIS=S%*=I(F] T;JPW.Q^.O,=P\MW (#+RBQ]I<$/'"*(.Q!@1W-8C92&"1
M.\#VTI4[S"FM197JK(6P"1CBPW/Q;\=/$3QGNT+'&>8$]3%U8*]'%8^)Z&&2
M>*$16,I\W+*\1R60?GFLV7W9!)[-7$%2.*ND,%PUB>'XI5Q]?E>=V>2:8B6<
MJ6)2'S2H;RHALJ)V!!9B[LSM12L1SF/7E',5W"IY<HYJM5KO>K57M?V\\*]C
M'+SVIK3X<JKJ-B' !!Z[%6!##T##JH/<*S@?2.K_ +#<'U'XV^S6K4NHZ:::
M+YHJ<\<IZ_#[=1!V(.V^Q!V/8_4?MU _#X]OJZ?'KZ^OV:S"XT^.3',?DBA8
M/%)253XAXT[8X(W 0.9"Q%\T9$U48U/<UJ)K].'"DL4W"_#<T-=*D,N P\L5
M6->6.M%)CJSQUXUZ<J0J1&J[#95 UQU>#+=N*SF1EM6 SGJ783."Y/J6.Y/U
MG7=ZO^O+IIIKXY$<BHOHJ?\ EJ!'V?C?X?;_ ,M]].VJ0O:AI<3T[45>%3R3
MU3S5./M^//V^J\IJW6J_F*05V![?5W&V_P /A]W;H=7O'7FA=?>V*D'U[_7Z
M['T';K^:,F1T&0XKD8V<83- )DU?"H9 QBR,ILJH_%?--C60^!'+.P597R%5
M%L-%+88Y:.2P$A. )NZ*\PFW5N8^XF3QA1+D2^6Z2;BO>K$EVIVPBLX3<EZ\
MR*9:<Y$J++$]FM8VOC,CC<SBY<!GDDFQ5EQ-'+ %:]A\@$")E,8)&1#-R*L-
MVG*Z5LG3'L\SP6(J&0Q\A=OMR\=W'KR5!;-6WE:V&')<1MTACO: @ACNV,T>
M.2: RO)5LJ5]U73&4UJR*5039G0D1PYAB<U3S,+F+FALPA5N8^QRBU4=P=EE
M1699(GV;R;,+25YPK&*1BKA=9\3<*9+ABQ&EKRK>.N>8V,S%/GDQV3AC8!FA
M=U22&Q&&3VJA:CAO5"Z"Q BR1-)%K).@G:JXW5J<[JU6AQ5Y<MCEFWH0R,J+
M<V/B49E1-%-"M#6F$^=S701302CH^"J^:EF62+4F:\!.#LOQ;0XB\OV:A',U
MG*</Q1J,?D;"#F@*<I0U(&E]^Y716BL*/+C$ =RVK'X1I"^MBL_LU-V+V:2*
M0K$=0E=U9?9X9#N)8PK!4)6N8=U,<YH((1H81AHHAQQXHX(((8VQ0PPQ,2.*
M**)B-9'%&QK61QL:C6-:C6HB(B:WBJJBJB*J(BA410%554;*JJ  JJ
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M<483%\18&]#DL-FJ-?(XV] 28[-2S&)(I &"NC;'EDBD598I%>*5$D1E'/\
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MEJY#D,3!NXZL(*,17?E$C;!CM'&>'6%F0BS;R%B0 AI(6AK1@CN4C:&=AUW
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M9G6,1(>2.*.*)69A''%$J1HO,S,2%YF))8D]=26;4]R3S;#\[\H4=%4!1N0
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MDOZ7) I;&@M K<""UOJ*8L"=A,$=QB]Y8XSD5:^2-5:TRER"HM*>Q@5>\:P
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MFS:*%W=EJUU>9SR>CA[$9#BJZ88F:"G"0;ET@L(P>T2 D!YY #RH2 H!=B
M#CUR7)KC*;Z?);TI232'M;(Y$6,<43R2(8*!5<T807AC6,1R\,6:>:24B266
M3X>>(7B/Q5XJ<5Y+BWBZ[[9ELAY:P0P*8J..JUBXJXO&UF>0UZ4$<DOE0\SR
MRV':>>2:S/--)O['8RIAZ,5"A%Y<$?,79B&EFD?;GEG?8>9*[ <QV "@(JJB
MHHJ6FM&CHUJJC5:GU57GA6KZ_#]*>J*GIY^7NX7XD%10K-L0!OL>Q7H"!UZ;
M?#[^@Z>"]4,A8[;@]@/O^._IT]/M&VQW;FU0ACD:YKWN141.51JJB+PBN1%5
M$Y7S7A?+S1%7RUZ.)N(H[L1',3S=_4DGUVW!.W?N-STZ>E.E4,9 V( /[3^;
M[/OWVU<SIFRA,?W!FIS).V#+PW!*]>8V?.P7)5:Y4<O"1NA8:! Q.7OG+'17
M.57N=TQ\@KQ'BX9\6K_!UV4PXWQ Q)HTE9AR+GL*9\CC3(QY5WLTY,Q6&R\T
MENQ6C3E4A=8OXEXAKF!BOQCFEQ4_F2;=3[+8Y8I@ .ONR>SR'T5$<D#TR*:^
MT&N?=---8U_E0<!O\FV)ILSH!IC4VTRQEUD<$*.?)!B=K6EU=C:,A9R^5*NT
M=23F.1O8)4.M+"=\0P<STVGX196KC^*&JVW6-,M2DHP2.0JK:$L4\*%CT7SA
M%)$G^E*\2#Z6N>OE*\-W\[X?+>QT;S2\.92'+V8(U+N^/]FLT[<BH.K&M[3'
M9D ^C!%,YZ+L?/E->13CJV>* KPT<^*,B)LK/%:WEJHV1%1%Y1J>7"^[X)KJ
M@UNY&_KVVW^SIZ=_3UU\\H+TT3#RY7CW 5FC=D8KN-Q[A VZ="=^W75B=T^F
M[:S>T2KL[+VW'LG&K Q(LHH?9VDGBPCQL'CNPR8I!K9D,:?R4[E&LD;VPI8H
M,QL"3U9[%-=HMGB/O>6_5=SU)4KU4GN>NQ]0QZZVAPAXL<0\'F6G'Y.1QC32
MN:%\R;02,Y,C5)XV$M8NVY:,^;7+EG$'F.SZL_B/0#MQ3V<1V79Q>Y@"/,DS
M*8.M&Q@4EK%Y2"Q)BL;DZ:"1/JRM GK)U1/J$Q\Z],F4LN.6.-(MQL7W,C G
MU7H OP!*MU([>N;Y7Y0N6L57BQ.%I8J9U*FU-:?)/'N-B\$1K4X4D7NIG2Q&
M/ZT;=M76MNE[IQL<C),EV[$&:P8"=0JV[R.LKGSR3V+95]@ N!QXFNCA&181
MF01)V]R,YD=W48[-X<R>>Y  (+!&;WBW<\A/8#;F)('V:P>+QEX_JU5A7.M(
M"\JB6Q1QUBPJJ(RI$TM1GD/,[>](9&]-QRZDGMGM3995-3;.[%8$--:61+2*
MK&,=CK:J)R5SH[.TM##; D&OA>."#(23:7%A&\F6& =Q,YI L,UFS&4HX.I)
ME<S;\BM%)"'FD625W=Y%"QHB!I'9NI$<:'959B%16U8<;7XP\2^(A0J>UY[-
MW*UIMY[$8"5XH9&9FFG>.O4JQ,X4)O%$K2+'$A=T5L\70YT'6&Q=PW=C=HNM
ML=ROF\D'&L?JYFV%9A ]H.H]D=/9K$R,_*"P92*=\E<CJRMKBK088ZW;9^T"
M\X^(?B0.*(UQ.)BEK8>.599I)@$GR$L9/E<\:DB*M&?Z1(V9G>0)(X0HJ#M3
MP5\#O^CZ:3B+B&Q6O<33UWKUXJN\E/$5Y@//$4TBJT]V=08I;"HD<<)DABYU
MEDD?*!K4NNC=------------------------------------------------
M------------------08ZM:TEE]B5QV.40FH,K4D1.6,)",4IS'+_JNDB/:Y
MB+^6D4G;SV.X^47^4>P5Y,YX:\3B-SC9L5F,"TP^A%>KW(<A'&Y'T7L06I&C
M!^F*TI'T#K=_A):B-;+T^8"99X+(4GWFC>,Q$@>H1HP&^!==_I#41VKPJ+\%
M37S-!Z@D_?\ ;^[KU^_6X"-P1]7X^KKJJJDR(>5'O1%:[A>?)4^Y>?7X>[U7
MX^69<,Y."A.C3*I"L20Q !!Z]>NQ(^_?5GNP/(I"[[]?CUWW_9O^<:J"VN12
M(D;&UB.[>U$9[_O\O\?UZS7B/BBA=JA(HXU(502%VWY1WV[DGX[@'X>FK;4I
M2QONS-MS;]3V'7MWV_Y_'I;XIZ.<B(O*^:KQZ)YKY:T].X=W( ',Q('P!Z]O
M3T[]>_IK)85('7?X=?Q]GWG7 C^LZ23XN6-OV,B56JBIZ<^+XB\IQRU6HOY*
M:ED]U8X^HV42-\"T@# CZO+\L;'L0VW<ZJ =68_8.W0#OL>_4]2/JUNZI:FU
MR@@C+(L<"O$)..+D2$8,2&0@DB5454CA@A:^21W:CG*C&JJ-:YR\-:JI=<)@
MLSQ+E*>$X?Q=_,Y?(2B&EC<;5EN7+,A!)6*"%7D8*H9W;;EC16=V5%9A0LV:
M]."2S:FCKP1+S233.J1HO;=F8@#<D #N20 "2!J<VQ^PD^-%#9AFL47SW"GB
M4]&CXYV5,CD5$//DC5\,MDUJJ@H\3Y8 >Y2'22&^$@'UW^2C\D*7PXMU?$;Q
M+BK3\9I&6P'#\<D=JKPQYR<KWKL\?-!:SIC9XX17>6ICD=Y(Y9[CI)3T3QOQ
MX,LDF)PY=<>6VLVR&1[H7_\ "C4[,E;?8L7"R3$!2JQ@B6ONI?;C(=W]@]UM
ML<4-$K<DS?#K.@IK Z=HP@1YC6-A*FG=76[(T@5JRL=+5V$7B-8DHD\:OC=]
M!-:LU$S>7I#W%(EOK#;C++[/LAS^HW*)N\GS[/(,$M\4WLR'%MJ<*VGWT AV
MQPW',>FEVBQ7;:>HK@:7'JV^@^=YS )S3;J^+5IJVF4=,^^MME]_MABVX-UC
M-?E6']5FX>4&UA&;5F'A9AF&ZG4*;TX1PY('7A5L5K;-ZB"\SW K:&<NZJK/
M8G"VSCDULM098/P/Q^K[SIK>W'Z8>I?<O(,USLZAQD#(<I#WGK-N1Y]Y<C99
M;&W.X&W'2-C&!Y]66=3C,0\Y&$YKL?GN;%T]!+#(.5=5IE00?:VEF\1^/^?X
M_9IZ_F_?^/NU4&2;%[]8UGM-E=B*7G(IV]N%%4F1TFX&6RVVV.'V_6MN-N!D
M@*8HRN8/8TF2;29]@53EDC"8:VLJ<'-K[9\U+AN)O/::I"WZ1NJ3</:Z' LW
MNL?&]DZ?*G9BQ%,W1RK(*_+LGQ[IWWMVRESJR1F/"K[)DVY&9X1E;XSV&6\E
M94-MKF/Y\ AJ&O7_ (?N[?=IJK[CI)WTR#(,KR2*Z H!?#9=;2XY+N1ELZ;;
MY#"G3.M-X; A)*J(S'P]MMT*B*R"]O;[-DD\ [GA9?D+&M-5GU/5TX>YCC)&
MN\"VHZLH>147L7V=)J^:-J^G=&\1'O;ZHV:-5_+3GXK?Y0+!W<?XV4LQ*C^P
MY_@[$24YMCY;2XVQ>H6ZZMV,D)C@F=>ZK:B8CWP3T/X6V8Y>'9(%8>95OSAU
MW]X"58Y48C_1;=E!]2C#TU'F-R->UR^2(J+KAI>_7KN-OV;=R/A\?LULAAN#
MJLJ4^$5Z+(C53GN15\T5/7A?+W_>OFU%5/+6?\*YFMCY%,RJW*-MCMUZ^G;K
MZ;#X=/75BO5GE!Y=^VQV_:/CV^KN=<Z[M1RVJD;6(JMX1&_D^7*^?N]_Z%3W
M:O7%7$=+(1GRHXT.Q]U5  )&VP'?;Z_7?\_FHTY(B"S,>IZD]=^G3U_'V=:#
M(<CI/+W>2ZU1(=R2.QZCOVZD?M^)[:R*(;+^;]^_ZSKAP_69XG//BKXB+Y_D
M+_HTX55XXC[>43A.[N=QRY56,WNMY?;RAR$?]\?YP[[#?>3FV)Z\O*.P $ZC
MH3ZL2?N]!OL.@';?6[JEJ;7:4U);Y#8055'7%VEB2J^$('"Z:56HJ(Z1_:G;
M#!'W(LI$SHX(6JCI9&-\]9/PAP7Q5Q[FJ_#O!^"R'$&8L]8Z>/A,C1Q!E5[%
MF4E8*E6,LOFVK4L->+<>9*NXUX[^0I8RN]N_9BJUTZ&25M@6.Y"(HW9W.QY4
M16=MN@.L@>R6R4>W\?X0Y L!F6EP+%''&K91:$:9J>*.-+PJ36$R<QFFQ_R;
M8^X,-70.((-^T'R6?DLT_!2F_%'%+U,KXC96J:\LM<^=0X:H3<K2XS&3,H,]
MR<J!D<DJHLB@4Z@%8337>>^->-9.(I!2I!X<3 _, VZRW)%Z++,H^C$O>&$]
M03YDGO\ (L4B==DZU_IIIIIIIIIIIIIIIK1)+'"QTLTC(HV)R^21[8V-3XN>
MY4:U/M5435.66*&-I9I(XHD&[R2NL<:#XL[D*H^LD#40"Q"J"S$[  $DGX #
MJ3]FJ7FSO"!RD"GS#&(2W+VH-)?5;)NY>.&K&XI'-<[E.UKD17<_51=8;9\2
M_#JG?3%6^/>#*V3=@BX^QQ/A8;A=OHI[/)=64.YZ(I0,YZ*"=7!,/EI(C-'B
M\@\(&YE6E9:/8=SSB,J0-NI!V'KMJJ6N:]K7L<U['M1S'M5'-<UR(K7-<BJC
MFN145%15145%1>-9HK)(BNC*Z.H9&4AD=6 *LK#<,K @@@D$$$';5O(()!!!
M!(((V((Z$$'J"#W&BL:O'*)Y>FHD [CX]]0ULN&C=[N/N]/Z_P#C\=2% >X!
M^OM\/3;L2.W7;N-3B1Q_6.P]-:/8XE]4_J1?[OT_\M/+'IT'H-NWX_Y[^LXG
MD VYNVOK18DX7CCX(GE_=^M.-/+7?MO\3Z_=T]"!MN3^S4IE<_UCO]_[SKCV
M1H5+6V%L:Y(@JP(JP+E7S\,8."0B=_'HJMBC<J)Y<KY)YZM^8RE' XC*9O)S
M+6QN'Q]W*7YSU$%.A7DM693OW\N&)W/;?8#MTU/!#+:GAK1 O+8EC@B0?UI)
M75$'WLP&L3.:9999QDEEDEJYWCG3+[..KU?%7@1JJ!UX_/DD(L2HWEK6^-,Z
M8E[?&GE<[\Y_B]XGYSQ>X]S?&N;DD'MUAX<3CS(SPX;"02.,=BZP)Y52")N>
M=T"^T7);-IQYD[ZZQP.&K8'&5L=6 VB4--)L T]E@/.G?;J2[= "3R1JD8]U
M% I?U]=:S[=M7C[=:H7O@;VM<KF(OU6O7E&M\N&HODO">B<\JB>7*\:J^<_-
MS \I.W-R[CF8?UB-^Y[G;8$]=M4VC0CKZ;]=^V_[OO\ J]!MVU>OM94<4G",
M<J(O'/*IYJO*JOV<>[UU=,1&+V1KP6')1W .YZ=>G4G?X[_MZ:\MH"&%F3N!
M^SX?#OJJ;09V/$5]Q73>$77SBV DL;E:L1(DC28)$5%Y16RQ-551WG]Z)QLR
M_4FX%SG#7%&"G\G)8?*XO+4I86]Y+5*W!9AV*[$GS$4$;CF',AWWU98)%R4%
MNE:7FAL13UY58 @I*I1N^W]5NG3IMW[C65J"19H(9E:K%EBCD5B^K5D8CNU?
MM;SPOVIK]$U>4SP0S%"AFBCE*-])#(BOR'H.J[['H.H[:Y98<K,NX/*Q&X['
M8[;CZCK=U5U+K:G@@*@F&)AB(&(BD@('GC9-!/!,Q8Y89HI$='+%+&YS)(WM
M<Q['*UR*U53402I#*2&!!!!(((.X((Z@@]01U!U!E5E964,K JRL 592-BK
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M8S709&2=D-()!AX;K'+)2+0*)N,@,KG6[C+]73)\T#)5,?9),>D$:@M4M'+
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M<LS'8<SR2,\LLA:65WD=F.G[5F>[8FMVI6FL6)&EFE?Z3NYW).P  ] J@*H
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MY;-FQ*Q>6>Q/(TLTTKL2SR2R.SNS$EF8DG<ZZ^C18T2-%"I&JHBJ-E55 "@
M=    !K;<]C$17N1O*\)RJ)ROKPU/557CR1.57W)JDJ.YV12Q W.P[ >I/8
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M)ZDDG7)UZ]4]------1AZA:G= Z]VEL< P#;?,:['LG)M\BM,YJJFRL<42%
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M82Q+P/E_F[+5[45RY5BD6(0T$66)ZZ6"&>">>40VB\57:?RY(VVC>5CNW/\
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M1A,FCE$NCL?M,>M+D*P8V%LN81V>04I)^(!QS!EFBD!-!RE%JU*&9AI9&M+
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M?'OK7J0#<@?$[:FU5%0"TJ1L7DK>&^7Q5RI_4J^_S\OLUEW#.*3(V0C;'<[
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M_>6/_3*_^)I])6W/_;_"OVJHOW_4?GC$_P!Z8[]-K?XNHC*XP]LE0/V7*_\
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MV/LE8:D/B3Q\>_%V=_\ D)OYM:5^3PZ&5]>E+8[]@J3]WU'Y]S/]Y7/]\_\
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MOZ.,>Y_7[)J/Y8<5?ZP9;]-F_FU(9';N['[6/\=?/Q;70+_-"V"_1MSCZ?\
M=-1_++BK_6#*_IDO\VJ9 /< _:-]??Q;G0.G_P!$/8+^CG'_ -TU#\L>*O\
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MR5L#?&P3VKEJ4*-V7=I)II" "3W9CU/37.'$F/VXDRF.QE0[+?L0U:E6(ML
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g772024g03c74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g03c74.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %B2^5F@X0DE-! 0      #T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   F:T' (% !E0<F]T96EN($=R87!H:6-?,#<R.3(P7W8Q #A"24T$)0
M    $(MLVD3=+?3JW%@1^)N[K10X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +;   '9          !
M                  $             !V0   +;
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +;     %)G:'1L;VYG   '
M9     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "VP    !29VAT;&]N9P  !V0    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     "Y
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M5?/]3P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ Z@)= P$1  (1 0,1 ?_$ !X  0  !P$! 0
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M<SXG9N3(VKMJAAKE:_AZ.$R.(LU9Y,;>J8[9J231FT9VVH7DR,FBGCY7DEK
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MUA$PE* )%$3B(F   O(B ><(HC8I2-VY"'!4A$4BD4 0$%"E(4"G 0$0$#@
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M<Z @8#%$%2E%,0,4P#W<" AXPBBM#D5:ME4TP234;HG(D   )$.F4Q4P
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M(*GLJ2Z4PB81,(F$3")A%3)M=LUAI=T];_%LVT8_7=M1 H@Y;(M55%VX@?[
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MD,;(H^D<4;8XVCT:QH8T:[= !V'9>B88R-K(HV\L<;6LC8-:8Q@#6M !(&@
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M2-+X;7W*XZMDJ\,\9;)$;E*LY['-<&:(7EKQ1X%>*_#EN2E8X*S62:)#Y-[
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M.#=RK'.!30D60J 4ZD=*M1;R<:L8I17CWC9?@/4 ,V.JW8LC2K7H?_+LQ,E
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MME,3:MVFM>-3V&BP*^1;9EYWOO6*5Q\<<MV5SW2ML1PB29M83R[7@
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M+NAM49HV'L>>-\<^@?8LC>2/706;_ B]%!Q3D*4A =D,/*(#TVZ:K9KSF,?
MP>?(?_[0[]%^7%HF'V0X_L]P#VXXX]_[\R^\[.O3M\/7?Z@:_,=]+;%7.U2
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M1N.)3#PEP1Q5Q"X-#GOQ."R-V*-I'1TMB&NZ")IZ<KI96@G0!)T%U6LCB,8
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M-]:X?RE[$9:E;H.D,PGBC,+"2+4<CVL?6>P?SB4'E:""6O+7MT]K2.0Y0.<
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M(V*-C)V<G)!25LB$,_=)M%Y5HW:_!0\6Y8$6!Z=%R,^W,F@=+O/Z@&+K9_\
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MZV.N_CUT-]-*V,@Z8.(;LZ'X0>V_7TZD>@/?9.NFQ&G4V12&](0'@ $H_,?
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M02FQW%":R;*"E+PHF_,DTEY=>==L5HAFFQ@GL<E*NG;B/:R<;('8@Z<)IN#
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M)%6]6:.TY1ZMVA/J1[1!Q#REL<2<;MTZG@I#ZMER&M:].2JUS1KIWG<.@/\
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MJ-:]%N9CHHH<?1A@ $,5.M'$!V$;(6-9K_Z@*1:!R)S"(?:5/S^'8(IE\?\
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M,NA4?O3 ;DR2!U2LVG<8C)JV2'TPH_#_  O@^%ZGW/"T(JC':,TO62S8</\
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MJ3T]'0<C'R4E8)B:.O2Z'28^B1%D7DY&28&NKB<3?H.G1FDBYCKZ[D._KO\
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MPB81,(F$3")A%J'OO>[6,9NZ729$CB8=%.VFIIBJ4Z40W'N378,G*9A*:56
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M2./HQC20T N>[3&-<YP![J]>:U/#6KQNEGGD;%%&P;<^1Y#6M'S)ZDZ &R2
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M8B?,D>&MY6L+I&].TTTT4TT4B%322(5-),A0*1-,A0*0A"@  4I"@!2E
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M="2%I/-TUWZ*<QT+;.0HUWC;)[E:%X]VRSLC<.G7LX]ER/;29VR8%35.4>T
M,(F[C&$ _:$QA$1,/N(F'D3<B(\B.?-'6XCNP>;(;$DD]A\DLTTDCGS2RS.+
MY9))"[F?)(]SGO<YQ<YSG%Q))6VTE-CR/\-H:WHT#30&CH  !H  :UV^'HI!
MP[4<&$1$1$1]Q'R(_F/G_+\? A1;E^6Y(7/D+GN]3UZG]OU^?53<-=L8!(
MWH :]O3\NGL>WIKT@S,K^//L <^?R_GY\>^<JN.DLN(:TN)V?@/S]/TVH2V
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MA(40\?8,;SXR4B_ 'R^L>@SH#_B/WRD@_P#*UKW@_P#.U@[$J8=UTWT/4_\
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6&R=#X*/G>N*81,(F$3")A$PB81?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g772024g04f87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g04f87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2AL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *%"^$#(#A"24T$!       /1P!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP"   "9K0< @4 &5!R;W1E:6X@1W)A<&AI8U\P-S(Y,C!?=C$ .$))300E
M     0BVS:1-TM].K<6!'XF[NM%#A"24T$.@      Y0   !     !
M +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M!);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G
M1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $
M)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M    (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $
M-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V
M]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M!%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %
M)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M        !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M       $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M          "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M   %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4F
MQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H96
MY0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W
M)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M  "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  (!+
M    $  CA"24T$)@      #@             _@   .$))300-       $
M  'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32
M<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M   0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0
M M    !@       3A"24T#^       <   __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M X0DE-! @      !     !   "0    D      .$))300>       $     #
MA"24T$&@     #-0    8              Y$   <"          $
M                   0             ' @   Y$
M   0                         0     0       &YU;&P    "    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P   Y$     4F=H=&QO;F<
M<"    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6
MYE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&
M5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M      0G1O;6QO;F<   .1     %)G:'1L;VYG   ' @    -U<FQ415A4
M   0       &YU;&Q415A4     0       $US9V5415A4     0      !F
M%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96
MQL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W
M)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC95
M9E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4V
MQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M  "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M    MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M   #A"24T$$0       0$ .$))3004       $     SA"24T$#      =O
M    $   "@    40   >   )?@   =H  8  '_V/_B#%A)0T-?4%)/1DE,10
M ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T
M94     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                          $6
M-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M  %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
M)4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6
MD   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&
M=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2
M Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D
M="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M    !865H@        \U$  0    $6S%A96B                      6%
ME:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M     DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F
M-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                               &1E<V,
M  +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U
M)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W
M5R('-P86-E("T@<U)'0@                            !D97-C
M   "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,B
MXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($
ME%0S8Q.38V+3(N,0                                  =FEE=P
M  $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M!7'^=M96%S          $                        "CP    )S:6<@
M   $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P
M!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *
MX L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!$P$9 1\!)0
M$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I ;$!N0'! <
MD!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"<0)Z H0"C@
M*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-: V8#<@-^ X
MH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J
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M6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4J&QP? E-#9"=[C1X4-B<I?7\8(F)RA'5O_$ !T! 0 !! ,!
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M7&?;<,9=@WBMXW)M0J-*C>0VRZ#/YC1ARYCO]Q;G6<H$\.Y<;7%0G3 CMO\
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M76+1!IWPEDU-I#&X*>RAY^T' O0Q6(B=,8ZL-*= ?G$U6*"%F!T2MB*4, R
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MR79M I_DBW!;KWCJWL.9>/CJ//9B@U.AMA=QE<T'!%)G!=$ !?5EA5A%B6Y
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MY?/D3\K+9Y.Z'T#JHX;4:'4:9E?/Z_A\_P O^/;);=N_"$RMY/S!UE70\?\
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M)([/([DL[NY+,S,=EF9B22?))).;?CC2&-(HD6.*-%CCC10J)&@ 1$50 JJ
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MVCN?O$$-?M"RS%HT422"-Y 65W("/&(XHY'<G>UA[PT>("TQEWL=OK=C>B:
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M@]!L9-A3U/'5=9/I<_A]+!FF7UP;8#DY&L*G.$.'>E%?32CXH0QS*#*K=FK
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MU5,L<B@^&(7;1_BL@4@^Q(T34 ^6>/#BFACZ4?U7N\B/G#LPQ4=[_P \XL*
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M+4&0 B5D4K9(7J^%_E5)8I43LBM:CD1>JO)/]FMUH9GA6W T$O8==RD'M#$
MG08[U['6B"/&6-SCJEUH);$$<L]0RR4Y9%[C6FDC:(RQ[V X5B%8J2ONNCYS
M$WA?@/28S2#W%M-+00Y6S:6-&%7TT .D*,R?W)U#!& W-F9'16[<WE-B,3:M
M%/;:G602U(KAT+6 \-T0.*L<9</),;''RF5XZ]=8H)O5X:OQ%F$]\DCB&Q]C
MJ6V&]+/74HJ[VN*XS@):<U>5KQD>.3O>-(.R-N^E%5F12\LC!99((K'D$*P8
M*J]P9)UV=PHT$ZHKW^5CG*R/W>]4:J^1C5<U%<Y?9J=T3NK454ZE]PGM(W^
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MU\;VJCFO:CD7NB=9J[#-TYR-/D.*NO!;IV(;=*W6D*2U[-=UEAFB=2"K(X#
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M3X?\76#662P)!T%AIN41; O:V]K)6D4L3(EU;#PU5E@KQRCE6=7L*T[3/4@
ME/9RDK][6><N/(MGD C)#08+35"Z2Z@=21I5+A0D/M%VCM1@-#<(\:KH!VQ,
M1N1?]0?=*D[.K>ZIL^$^SOK:LI*Z.2&&2PMCA:X*.4B1L(\;RC)88&R3S/9%
M$QTB.DD<UC$5RHG4() !)(  )))T !Y))/@ #R2?;+HD $D@  DDG0 'DDD^
M  /))]LQ>KO$S'!K-K2Z&LKVATEQJ?EHX%@&-="9K(S4]>6=9BV-BV0FSMI;
M--""+(+0BQYAR$C%VKAB9DPU/GJ=V]%0BCM+-.>12!I8EC26;B[:U;<"@R&7
MU?\ 4ALP*T0$].9)T.NX"P7DZIE$3,T6ULLLDO;'&WV-PMA=E]J41EG'<JAH
M&$H.@P7)(6[JM#3C75#8AVU4? ^4.P (C)$(8V1\+UCFB<YJNBF9)#*SNCXI
MHY(I$:]CVIGI8I()'BF1HY$/:Z..UE.MC8/X$$?(@@@Z(.7M"S7NI!:JS1V:
MTP#1S1,'C=>[M)##?LP*L/#*P*MH@C, /&@_45/'&JV&9V ]'89?-7-G7YVS
M8^6GV)M7%\ZGS)8\=K6.-^\=-56="H_IG%0--0^K08@2=IG0JU7LUX[OJ"K)
M*L<K1.D<B+(0OJ@R*R,(F/>Z,NW0,J-&Q[QL/C0XA,D+J'1"ZQL-K*5&^T]I
M!\C8!'D>/!&QF1O@^TY&V\-?$VR+%%!(UE 5HY0@6/C"#6YN[2P8((DJ)(X8
M6,A@\$C^[I8HV2JYWG\R]5>JE'[53C8LE7D^6KAV&F?T>4N1^H1Y[2Y7N[=_
M=WV_+(]U/9EN<O):F01RST>&D>-2"L9;AJ!$8()5@@TO<ITVNX>#F2G5QF Q
MTQFJG[2O:["HBX_R,+[ 3 WXMN?:N#66(:\OJXD1@U5:31N8V4:O#E^805TJ
MK"21.TQ\,TE;"\?3WQ9Y#FZU;CJG'3S5*=HS&W8A=XVD=  M9I$TP0JQ<IW
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M^>_D?H?Q/X9[T\1'#R:1Q"C\F_./D;85)_D2YO5GRWX]\B0(*F#\_F0I5?\
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MBD5LGF>UOE[N1%>HFF/>FE/:Q[AI6\?=8[\'R/!\^1@R1@,3(@"MVL2RZ5O
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MZ4;$[?1$5?I_SV_=V]OIU+XD"*-?@ #Y\_Q\$?,Z]O.LUO;E]20^=_H_U/\
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M3E5OEQ'8CGKD'@5W+Y^ O,AL\G?8VHQU#D1+T\J736N:DSNRH] ;M<#; /*
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M(\;-H> 7+-K0WX&8YZ/AC;TITH]=7NOJY7J@AX,@Z/?$J_LVE"S3LF&G1O\
MI55KQ47W82Y%[)XSZU_PK_$K@.9GAZ<XO_ZKX26=O\OY"G:HU["PNW^G%R-2
MU8KO!/$I[998?5J,5[EE79C78W%]<<+;K(;D_P!ALJ@$L,L<KH6 ^\T4D:.K
M(3^R&[7\Z*^-Y>5#X?R2:U)]%>OJ;.9%6, 2& U@:>_E0LCXA(R9'(J*^(5[
M(XU3LTJ;S=V[4Z0_P:BWP2V>M>I+7$\[97N7CN'AIW*W&@G2QV[,K.+T^AN5
M:CPPHVUCGG ]0X:_\0&2T8^,HI8JH=&:PTL3S?\ W1H%!B7_ ,3(&=O<HA)
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MA"R1CM8HO;V(2J@G*_K.Y)<=,9CMS?PK4;N@E6HSU9+:%:FMO=+&-65#[?3
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M 5 A>N^\)@U_:O.G@&)<6V#M3)!$CVRB#15#8QDA\C%<Z<N6?05C_%=\6O\
M.;?*P<GQD%2SVK%P1XNM/Q56.,MZ8@]4'D!)HL9IFO\ ?.==Y[$B2/J-AB=
M(!YT-;/T_:V"3\C\A[CSGLQ_@X\/?'EG#<@94C1V8CTE"(V%E)>0"R-5%;+'
M6+&+3R2L<B.BF)KYYH9$:^%[)&HY(EUE_B;^+75?'3\78Z@BX>A81H[,73U.
M/BIK$9!#QR7E:7D5B8;$D<-N*.5"4E5T)&6[VY-'M(3\5]Q[^Q).OGH_S)UD
MX%S-4]']_*UPLWJ*JHC?*-+$L:KW[(U(T)G[JJ]NSOT3NOF6>0S!B/(61 @
M_P#-7V-#WWV*!X^66@))\@[[B?GL[!/M\_(W]2?/OF:_@1J,S;\FWER>9_\
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M^E&ORD:V?WZ/Z_1UO/?$%'']$:G;\D3^WW5/;V_<OY?IUVK&!KQ_'QXUX/\
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MD?L,WPWZEL2+(%,O'54Y.BX)(#)R/'RV:(1AY[FL+V@[;L/MCX^6XU@)1<@
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MM+DM):P+V(!I;&<9?T):+(@RK^Y)UC55]^R=U[+].HA\0.:DZ<Z&ZOYZ#_\
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M>Q>MN=:#E!O?IC6J?B1/*W(4*Q)$$=1IE'R,LLKHY_-5B0#>R-GV#9AYX8O
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M"&0#S\O'XYL&Z^PF:!QTQCIC'3&.F,=,8Z8QTQCIC'3&.F,=,8Z8QTQE#')
M?I+8.,166<%+0$F'>5G8D$HW1QUXJ.1RR*H<XEE*K7,:QOQJ*QSE<]&5^7[S
M_;_K&5SJF,=,8Z8QTQFMK1>,_6YKD_E<2+-NN,-%8,PO#:7.?UF0SFAWN(UN
M4R&]@3D^?,6%!?E75QJMDT*ES;[T^CJ.#M#:$!)\VE9 QGJMO&)R-4-E'T_'
MF<IB8;C015\V0WA5RVR;QMSR_A38"6S-'QN$@%?>GQ1V]3\N0BR;4$3AR6%9
M8PPGO#S_  W_  V?[8RGWGC:T=0.<[6\4<>0WF*9:Z]\$_))CA;<*OXVX4W
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MS[;/R_@=?]Y8DN^\2G/G.&NX<?JM1R59\=\R978\@8(23BXSCGC\CC7[0WB
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M7:'5\?@WU?=:VKEX^J-!I[S-1.TZV30"#"P:W!&,KKW]_&]^/H?/\O/G,O\
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M\=!:,]66E7[*\[V.ZUPL=5V:5IZWKN)YQ+")##6FDK7$GB+Y3XRY:M\-XO\
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M;G05#C[O.6ARU:56J]/VH8:L_8DI2!/3D@CN35HJ?J3):DF:NOW8UTT2QYY
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M0QP9^NU_%'AVXI?85@T,D(R2U8'AYJK4()D(X;2-)8!,;"( &CF5[C^'OO\
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MKR58:/GR001[@N:4<'U!R%*OZT0X^])'6D=M3B-'W#*701@L\920,JJ"&!
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MH3I&_P!(<C34R7:U.TJA9:-R2."53K[W8TACCL1^^FBV='[Z1MM1Y5YWX?\
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MF;NP'$#+L\WGY(F#^>\]8>T\6%QR--Q/+R'LR^51J6F(UH><7A$#,T6;AKN
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M'W_#^>/O/XF/Z&>&?[P^P_PW],IX_0_[Q]Y_$Q_0SPS_ 'A]A_AOZ8\?H?\
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MR>UFS%UIUKK^^R]GX1MAS1;Q:6ZJ..91A37ZFB8RGM,UEJ6N,,#+#D%#KQB
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$IC/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g772024g05l57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g05l57.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )NJ^F6(X0DE-! 0      #T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   F:T' (% !E0<F]T96EN($=R87!H:6-?,#<R.3(P7W8Q #A"24T$)0
M    $(MLVD3=+?3JW%@1^)N[K10X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +A   '8P         !
M                  $             !V,   +A
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +A     %)G:'1L;VYG   '
M8P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "X0    !29VAT;&]N9P  !V,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     '%8
M   !    H    #X   '@  !T0   '#H &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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MDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)$*AP1@E.-'A\3-28G>W@I(F4U5RHLC8_\0 '0$!   ' 0$
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M .K8' 0Z7Q&CG)4VMJ;Z5K,'#75O=0#GEC+:S)L '):0$QJHY9F ')P<"]J
MN#T'U&UJ&,L=I#,P4$GP(+VVFNFX[*MLDKL>VQ6SQFN<;A/E.U&Y8IIJG>YK
M!&1063TN-1J \,*8(@KEL<_5;NQSVBK<-H;^N4NKI-6<($-4&D,>ZS%DDB9-
MF-E[.V@L_>$L[J=@ ,6ELUS.A<;?%$*,LLJQYW.D1:5AG:#R1Q;TKK$\>OVS
M6VJ66DR(DW]YOKY-,22/PV\>SM]5FM+R'2[R[@$D%K?RI&D$C!C,AP&N#NLY
MESU_W#;*UR6GI-)4E!XY'V6=/AMZO\4&QF?$N0V:,;P)KR0;6 L6PUPS(A](
M=&3:0Q0QD-C;4-[.+B?3EGNK*6"9S+E+B%HY2BR.L<CQ,-\)>-5?PG!=,A6^
M+D5G7^OV5WU=J-Q87MM>P21:=NFM)%N(1<)IMI'<QB]4[-0DBG61)=00!;R9
M7G15WX$NG;;:8*N[.>VZPYFSVLTDNAYAVJ\0Y[+5][87Y6HN ^8O8= #2DB.
MF%*Q3>1+5C[&7\+0,J F-%-2M<W"K^S&G3)8=VM((87YS@[=Z+Y_X<3QQ8\B
MF/+%==^R07/_ ( T)[D,&F6\FA5@01;2W]R\!Y_A=")$/8HZXXK/%)3]CFDH
MBM(Z_P S00&<.Z3!WM;MMW=X324/%M-#%P=KP-3E];=TM]ETSYV;7!7=S;5P
M)U7I*^8>2R9;2.EEHJV15(/PW819[+3"D<@9<2YRF2I>3>0*Z+FR_JLL7QWR
M5R'+R+36>WB_:P?)7N,TFY#&N4$L9"@_PZPJ:LN.'([0:NT"E5";CCLMJFFC
MDZFKP(V?)XZSU%?%\Q$Y>#\4SH[^1,+?X:^)US)9K2,+G,RJGM0YTDT5#LR,
ME<0W&8M!PBU*SE2=K7$&>VV;Y K@=>[09:Z%U59^)<D<@7-61M!>*S.$OVYO
M*FWTAP.EV97%IK\D?I=!%9V9PL0YQ,\EO&M@Y2KFV7 _&V[?K"+RLLV6&SL.
M-;>XMJG17U-9QW'$-\S3\=6M6576$"U1N<O8HSV.!;#%9*Q!KB*P#<\=ZE8C
MN^SKC\#!39;BA\F%T,-]D]+2["^N.1]G:U-QDKG0VHEE%:0<D9?8_BA4.PUM
M:=90[(>:UK]#8UVB9?TQ1E26I7KXS[*.)^/L9ELJ49L+\BKXXK./-B7'M-I0
M4O)<0.5N,C/=;'*5FE6JMK(BGT%N'&3:/M+!HJ426%E:G9++V%2I6U&;H0\M
MGJ/-5\]@2!GZFOI@B+8\BTLYA*T6(,>0^R,?(4>6Z&%BD%DR/G(E]4LKG/<J
MJI5:Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI
M3I2G2E.E*C [^/AS57=BZ'?8'15^!YDKJV.ME,M1B9,IMP VR)7!:=:]DI]9
M8@(_Y</3 AVA+:YK*P^JLAQ:IU5L7H3KL=*7'A:A8G4M*=RQB1U2ZM68_$]L
MS@HZMRS0.44N2ZR1LSE]/>T[V2V/7PBU"UN5TS7K:(0K=-&7MKV!"QCM[U4^
M-3&S'PKF,/)&I*-'*@0)"U2?!K[Y[#2QUEK'Q)04J$M9/IBMY.=7(,C_ !).
M(#5T)=]/(D?ET$!-6"DK_2R64='.>S>4_MLZ'2W9XK'4KB0H=MK[G%%)N(X5
MY6G\)1G +*\FT9*JQX.AX/[.G5\DZPS7.D6\6[#W7O<LJ!<\LD20"5R1RJLL
M?/!9<Y'1%V:]G6)[/N/2,S264VLV>BE%-W.\-"97DWI0<<C 0*^O;.8M1GJE
M)R5K:QQILR3EFFEF$$E.5G./5O5-SU5J;WLD"65JA9;.QB8NENC$9+R%5,T[
MX7Q)2B [55$1%"UT_P! ]!:5T#I!TZP=[J[N&674=2F4)->3*"J ("PAMX06
M$$"LP3<[L[R.[G+W(G&%EM-OQQL*Z^$II,%7\DB)$55-MOFB=UE69X(IL$I$
M(LD520QIQ 93)(K")/E7.A1[G]8M6=5'ODOAR7U'GMY!H-?GGE:/CODW.5@^
M&H56QSNGVO!^$X=@V&,DNS\Y145^/%B)+:G!JALA29\6W!Q]:2#3T26YJE65
M5=CW)'-(G(&DVF(Q?#(>IWVP&'XCC&@J,N3C]=P#P#Q-8ZT<?%6=U-37M5:\
M5Z&&E"A*J;6PSU_<!P7^:;8!WQ#T_7ZXI6ZCNU8@SAG6\,DW=?4U5WW.#<WB
M766(T.=N)LRO<]0=QAE-+8Y\ZBO,]K(A@['"5>DS]ZA0#!*33B%ADHZI 4JS
M^0>P_'7MA<FXN:FIFG<>DYUJ[470<E6M]IS.5,AR3=F[W4:S0V&MV&=W=?D!
MN/MZ!9WTUE<X@N2B2P;6"! PJ5C?4=@>FU$=R<W48+.66O Y+6YI:7/G+ELS
M+L.7N(.6Z[)9J)6#3V6)M9^+[3/\C0&#4SM-+R+M=,/6!.M9\[(I5>QO8-'4
M;/CO4W]GD#J7+ZJBV-[A2*JPU52=9U\'>J0? -8Z!T$)'O7W=?67,!3L_5AP
MG8VR(KZ*GBN*X&F4JL]NW9CJN#=YQWHYM1A;8#(\78?&Z:T%S)LVHV=WD>#^
M.^'?Q!LVE(OR<?-*[ C6\UOC-#15]Y1+69?18<^WKB=S9J5(=TI3I2G2E.E*
MHMJ^Z:=FTJXHI 9+F=FC=(L2/@IDS][)!+#[DL;UE70,HX52!LTOLS2JZ-($
MFEBB,<Y]./KD=_NS]]/T:K74*5IGWG]F>+[P<('2V5I)C]YF7%$8C>" LL9:
MMQJ1?/U%Q7+.(ZVSUHHX\A0D9H98I8PQP)<3F$CFY5TGU3<=+Z@MTMNE[:2%
M1=V4CF,2JN</%(%?PID!(5]CJ02KHPP5P'V@^S_2O:!I2V5[(UG?6K/)IVIP
MH'EM9' #HZ%D\:VFVKXL.]"2B.CHZ USS7/P;.^@;2/JZV+B2VJ'3N9%J(-\
M0-5+!Z_$<Y(A^?&T,3E8J.EB@IBEC<CF1OG1&N=T;![:NAA;*QLM3AD"@M:M
M9122!@.565+CPF&> QDCSP2%[#F1_P"SIUA'.T*7&CSQ;L+=B[EC0KG[31/!
MXR'!Y54?!& S#!,V/8-\.RE[1H2MMM-"%ON9KFL=5S6U<,1!F,=5%+!+85&6
M8>C3CR3IAXFV&F/&KS"@XHP0ZNI&ELF66C>O>O6ZNN%BLK+]F:3"^]("XDN+
MF09"S7+J J@ Y2W0LD;$LTDK!"F_/9C[)]/]GZ37L]PNIZ]=Q^#+>",I!:6Y
M*LUM9(Y+X=U!EN'VR3!54)$@*-D;5]G6CV.@Y0;9\IU(^ W_ "OH.9PLX!@2
MV:0#8VO!%?PG5A6^K(V\X-IF*-P7[9H!69:@M;*UBKJV>[AJA[""VUU6W:MS
MDGLAN]DLE4#R.#4X4FHSS[BEJ\=-#LR+K,]OW(/ 4$>5TO[9 4><",J-D!>B
MM.H+.:MM::07YUX=DR>K4K)?:)@N5<JSF73<LY:EQMOO]UD3J:BIZG/4/IHL
M=PWQMQW&<92Y;D+E*EJW&6.4L4!"'VUK)%50 >]$#ZF"1J5N-TI3I2G2E.E*
M=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*51;5]TPO/)511R"273V:!TBP
MHZ&E_!+E[)8?=DC<LBW;*:)4@;--[4LBK&D*2RQOU^OT*?K]?HU]EI65UW6V
M%-< BV=3; EUEI6G01E!6%>?!(*:$8-,U\1 I0TLD!$$K71RQ2/8]JM<J=>D
M=XG22-F22-E='4E61T(964CD,K $$<@@$5XDCCFCDAE19(I4>.6-U#))&ZE7
M1U((974E64@@@D$8-<W/=%\&+EN'3V-]VQ:?,Z3'V!4Q0V(W5T91Z;--E>Y[
M*NOO)A3ZO35XZ*K!S[8VEM(H$AA+;;$QSV9'1/1WM@T2SLDM>HM,G2\B4*+^
MRCCFMYP,?'+;;HG@D.!N$0FC8Y95BR%')_5O]G2Z?49KSI.^MC8SR-(-+OWD
MAELRQ),5O<A94GA!/P"812(N%9I2-YH_;3\%SFRPU-=<=R^JRV.Q0!,))N6P
M]T1H=CH8XI&NDJI+2((2CS893?+9;<0^]L&,22(>N%FEBL!JGJOVSZ'/82VO
M3VES3WLJLB7M[$EO;6V>/$6!7>2YD7NJ.L$8;#,T@!1I/2_]G.]-_#==57]M
M#80R+(]AI\CRW-YM.?"DN-J1VT3\!WB,LI7*IX;$2+/#REVWY/D>DX/R TTF
M1Q7"W(%1KP<]FY;FB>92T?&V\X]J\M4769O,_<9B(5FQ$/;85YDSWBT\E1*+
M(/9S30\WS2R3RR33.TDLSO)+(YRSR.Q9V8^99B2?F:ZT@@AM8(;:VB2"WMXH
MX((8E"1Q0Q*$CCC1<!41%"JH&   *Q[H>T&FAMSKOC2QS>*<&_@4W)YXS)37
M&9%LN$MQR9MY5U,$%_5V&E@UUAR98V,A3S1+6HV8(F[E-O+A'0.EU-K#]AV!
M7<XK6B<L""$K%QW>D0U>?UN1K%VV$YKYOYA?#5KB^1Z+0T& GDYXT%+EL[6:
M-MQB9<IA[5FAT$=895'*5[*/X=U529W89P;;5$%?I^-N2L$ !!D;RPK\S-R+
MP'PUPC)8UC];R!J= 2)3-XK.N!0;/0F'3UNG7./N8XZQUA8J5(^".X,(,1TB
MS.%%''=,J*U9701,C616JYZM5ZM]2HKG*GGPKE^ZJ5]72E.E*=*4Z4ITI3I2
MG2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4
MZ4ITI3I2G2E.E*=*5C\C:RP<J5''*5\;H+/C_1;5UJI+DEAEH]'EZ)E>T3V5
M8^,EFA>2XE2&NB<*R)(7I*KXU//]??\ TQ]]9 Z4ITI3I2G2E.E*=*4Z4ITI
M5$M0K$H_-3A'J&-6W4YMN.DDK/Q2O?GKZOB 5L?[DJ1VIU99>B;Q&BUZ2I_7
M1Q(L1CGCN./D<@Y_ $??4.<CGZCUJM]0J-.E*=*4Z4ITI3I2G2E.E*=*4Z4I
MTI5JW^WR>6ML?1:"\"JK??79.<QX!+I/?O+H.DM-$2$,D<;VQK%44QY#B"G0
M"K.T4!L[K"QKA2E*MFRYLXCJK=* SD;(K>^W-.^F#N@[*T'&$U5-B+$TL"MD
M+*"KZ;4W]547U@7%"%03$23W,X(@9I ZE7O'H\]-:MHHKZEENWQ&SLIH[0%]
MJ^"N>''83-KVSJ6Z("2P 8;(D*L%><&V=T;B84>I59Z4ITI3I2G2E.E*=*4Z
M4ITI3I2G2E46V"L2S,[,">H<%?=O-M8?<E9^)URT=T$T!6QIZ94;8FUY_MS>
M(D^1]SS[L<:*I5:Z4ITI3I2G2E.E*=*4Z4ITI7CRGZI_BG2E>>E*=*4Z4ITI
M3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4K2WN:[S*;MEU6-I]!QQL+S*6A&:+W
MW)8CA!,7QQG-7I9<11D'EHAQUGJ+;8S5-72Y-H5?)<B&6%D':+!0VZ"WK2M%
MEU9;@6\\(N(H;B6&SSFXN/=K=KJ4@$HD4"01RN]P[[$*;6&67-\L=+T^?2]2
MU._U[3]--G'(MI82;YK_ %"\"QO!!' FWPX+A3+&MWND5+B-87C!E0F_\IW)
M8^WWLF'OKC,TA^@WN@X\XS!'LS[*UV%[E*[97EY$](JME: UV<Q5O=USICXU
M+6NO:V!L\U/&59446G7TUM<WD5M*]M9Q)-<S;<)'$\\-JKY8@NOO%Q#$WAAM
MC2)NP&!JP&2-65&8!W)55)Y)"L^/_A5F&<9 -;)]45>ZIUQ9QTM39W$PIYL5
M77F6,@=4'-8V9; AY"'C5P Z.G-.G;&L0HL*+(1.YD3/WG)TI6OEYW?]MV5S
M&<UVMY>PV7I]-=1YX2:VTU&K0;=\5M*^"W*K[$^MK@XTH[)C;J4Y:$R6,6*N
MM#7VE4AM7;V-Y=RR06]O)+/$C.\*J?%"HRHX$9P[,K,-R*I8#<Q 56(N6EZ1
MJ6M2S6^E6DM]/#;-=M!;@/,T"2PPLT,0/B3L))XAX<*R2;6,A7PTD==BPS!+
M$06P )@,!.&@,",&E9.,4(3$V8<D>:-71S03PO9+%*QSF21N:]JJU47JE(*D
MJP(92001@@@X((\B#P15O='B=XY%9)(V9'1P5='0E65E."K*P(8$ @@@\U]/
M4*\TZ4ITI3I2G2E.E*=*4Z4ITI3I2G2E8'/_ /$[E/\ [#\@?_D'C3J/D?J.
M?Q_G_2H>8^AX_#^7]:SQU"HTZ4ITI3I2G2E.E*=*4Z4JV[T.M*M,;,<<HA5=
MHRC*8?RQ/Q2R?DM0!*"J/:YSO;J3K2R],2L?YK_4KEC;(UT03@X\Q@_(9!_F
M /OJ!QD>O./]OU_3%R=0J-.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI47_/O(?$FJ
MY.UY7(5SR)BKS@*XKJ#%V%;)JA<PR:GM>!>7M1O@DH:>>JVUC66^BXE -X^U
M3+"G)'I?(I,'XIH)*A2L":,G@#C^@S4 5KL-?%A  Z#0TMYQ5!B(:/&<;'Y3
MDS'U_*EO6X,RQ,MKP3L^GI";.QK[J[T-/<6Y@5570PY7//4J]\)!VK\4\@Y?
MDAF_YFT5YPYG-'^+"WF-VYQ-R'G[KG+/7G,18=>,)5/H0[K><EY6RTD],:UT
MT%%#3%UE4:Z;2J5,)TI3I2G2E.E*=*4Z4ITI3I2G2E.E*MN^#K2K#(RGG?)D
M :20RHA\L3\2LES.C#<#X>U5=Z:PRR/\1JU_^X^?5Z$>URE7)TI3I2G2E.E*
M=*5Z)B(X6JKW(GA%_/[>/U_3KTJENWZ^GK7AY%3N?K],9SVJV#],,-ZD]QJ>
M//G]Y$^G^O'W_P OO5QVCOY>8[Y[_=Y<?/YU;)]2CCS\0_WYQ]/7G'(')%6Q
M/NAVN5/=9X3^*?1/"?Q1?/Y_PZK%TUCSR/3X1^1_G5M?6X@?M@?>.<]_/[QG
MGSXS7RIO!_*?UK?_ -Z+_BGG_+SU[_9S8X[_ $/^O'YU*_;L7^?Y\L/ZG_OZ
M56@=B/.Y$25OW_)?IX7_ #^O\OY_I3R6#J#Q^(P?R^G?-5<.K1R$88=\9'K^
MB.WKY<"KV#.B*8CFN1?/V7_S\?3_ "_P\*MO>,H3P1CN/,?[?R\_.KW#,L@X
M/S_ECR_/UXK[^I=3Z=*4Z4KPKD3[JB?S7I@GL,U D#N1^O\ O1'-7[*B_P E
M1>F".XQ0$'L17GI4:=*4Z4ITI3I2G2E.E*I5[6/NJ2XIX[*QIY+6L/K66]1.
M@UK5O-%E&;85I*M>@YX:RH0)/Z'>U/'&_P *K>E*YD.>+GE;D7O-"[2\GRS!
MJ,1!R/E.2N,^:;UU$?4Y'3\C843&4EMR5K&N/K]MH>. J;D6C[=\A,+5WVBY
M%TV5L"K4:#+T9=YN[I&VT*RZ1NNIEMI);M4FL-6TZ.8RSWUMIDD-]<):)S);
MVFHBYTT:W*<K9Z;:7AA4K>$P8KJ4UY)J0T\RI;V[QQM;797!6ZO&E@C4GA?$
MMQ#*;4,<3W-Q A(:+;)CKLZSV_I>8./8-#.FECXL[B^WCC2M+H:O.+:9S0<;
M3[SBP$+1R9?U/@H=1Q;R[S049I='-$>;H>+(ZFV$#M[@09*N_P!3L+G1]7\5
MX+.XU#3=>O62:0P0WBZLMMJC"R2;8LEU!K&E:>JVUK& T&J220@PV\C#9WM/
MZ3T_IK4.CI^FM/N;?0]0TC3!$N[4+LK=V,TD$TMQ=WI9Y1<:3J$4DDR8M1+:
MQE&D:ZC>3K)ZT-6-U&I\13:]T>&Q!9/;'H98])<8W5/M15SM;8!<?9/)4=YH
M]5R(XU\I]R9IKJ=F9P&$J0,S?*W36XA+ GCK:O;EG1MCHE[K-O\ ^(+N.WT^
M*:VW6[2"%[^6>XC@C@,[O'%;6T9<W-]<221B.TAE5'262-UMVJRW4-E.UFCF
M<12LKI&9GC5(V=FCA 8S3$+M@B"G?*R@@J"#!5L;'F3M\FXY[0^Y+D.R=QUG
M,_F/Q7'YKN SI7'F?S])+)H9,_KJ? ]I-+R'>Z+D>*(:LS&9N[:[U=Q=VT1=
MV6:R]'LH]LR2:%KIU+6.GK"$:I>2W+6IFT&Z-S/=S.P>=;V_ZJFM+:VM4+RS
MSVEJ([*&(R1H/"*+==&Z7ZZT[1#U;!<FTTG1FA9]5FUA=*OFC$B6SMI,-II<
M;7DL4\D4)'O43R32>#'+),-AZ1^TKE<OE?/:,E;K/-&R)%!D['CFLJ3Z^[XA
MT4>?!O)<#IG&00*+<U69N\M#<9HR:TOLK?1V]7H+$2U^8S.=T=JFE7VE31K>
MJ"+E'GMKA'$D-[ L\L'O=O)PTMO++%(89RH6XC FB+Q.CM(2Y%TTDID:20N3
M,TA+2^*X$C>*6);Q3O#2;B6#$A_B!%;<]6NO=.E*=*4Z4ITI3I2G2E.E*IEW
M<UF<I[6_NBV U%)7&6MH:]DLK10 !Y"BYUB@CEGE]J")[TB@BEFE5$9%')(Y
MK%=Z5#9WH=VFEH--Q1R7PQW! 5^)%VL^:"X\]BGKZ#76V*K++4\X[+D32/+_
M &@J,%Q9QNYX)67M:1UC9<I&9FJ'KH99@ISLXZ5T(:LFHV\^FREA:(\-V=XF
M>XOV2VT:RLK=U6-[G4-1:)8YR^T6@NI,,L1S<4ZAT?2-&U"VN-%M+S4+U9HT
MU:ZNY-NFV<21S7$\-JJ%$N+4PL_O(D5BDC6[QE7R:WV]=_5;N.5L+5YVOL+Z
M@YUY7IP+RZN]LM\F#H^4N'>5^9>'*6HJ*_07%;36XZX*SR&QJI:^KEK[&4>G
M=.8_/P1"S)^A[FSTW6+N[N4]YTV"\FBA@5FBF_9NMV6DWS"9T420&.^@O+66
M/_$A969%5U+62XFN;.XL;>^T^]TZ2^CMIHX=1MI;.Y\&\M9KFVD,$ZI(H?W>
M6(_"1XJ.@8F-\2)G_P#B=RG_ -A^0/\ \@\:=8)Y'ZC^OZ_7%3YCZ'^GZ_7-
MT<H<E9#!9;8EW?(N+X_L*3%7.I=;ZZP!C!SU:-%*+!I[:NG.#F(I1+-8HY$2
M2)IDS%!@D<0]&=3;>WFNIX;:VB>:XN)8X((8U+22S2N$CC11RSNY"J!R2<5!
MW2-'DD8(B*SN[$!51069F)X 4 DD\ #-136?Q9Z).(.(];A+3M^W7)FT,RLQ
MO"9O/%&+S!8TFGA-K:^L,S&9SUT)C-^MX=EIK6KL7D@@C/N R1J<[VQJ[-U]
MG^NP7FH6^HZ?J=M9V)N4_:R:?.;!FM9,-.KW"6YFM'CCF*/"6+G88_$'#5W3
M-UTMJUR(=7UU=,MKBV_NU];QK?K;W9E@95O+>!_%:(VQN%*Q,)A/X VD%E,Q
MU#=CW@$9#5@@L(8Q([JIC-%-*H+:< 4^>FLE%>]L)XD9D*R12(Q[HY(IVL]J
M:-SL#8 ,P5MR@D!@" P!P&P<$9'.",C.#S5-(J))(L<@E1794E"L@D0,0L@5
MP&4. &"L PSA@"#5;ZA7BG2E.E*=*4Z4JV[V6FCM,:RS'FF-FT94>=DB5Z,%
MN$R6HFFG(1DT370NH8KL5J21D,^8(@<D+9$C(@B,X./3GZ9']<5 XR/7G'X<
MU<G4*C3I2G2E.E*=*53+JZJ,Y5'WM_9@T]-5#2&65I9$Q!@A"Q)YDG))G<R*
M*-OT3RYR>IRM8U%<YJ+-AAFN)8X((I)II7"111(SR2.QPJHB@LS$]@!5->7E
MII]K<7U_<P6=G:Q/-<W5S*D,$$2#+R2RR%41%'<L0/+N142G.??MJ+XTJ@X5
M<_,YZ)[X5V!@,,FCNF_5CI:X"Q@F'H )4]2PN)&EO)&+%.Y:4AL@B;MZ;]F5
MK#$EWU'^_G8!ET^*1E@AXR!/-$RO-)_F2)UB7!&Z8'CC'VB?VD-4O;B;2_9\
M/<+!&,;:_<VZ27UY@E2UC:W,;Q65N?X);B*2[<%6"6;C:=)S.4.5[*9Y!_)O
M(Q<KW.<KB=SJI4:JJJJD;7VKF1-^_AL:-8U/HB)]NMBQ:'T]" D>B:2H48&=
M/M"Q],L8BS$]\MD_,5H&?K+KR[<R7'5_5,C.V3NU[5MHW<_ @NPB+GLJ*JCR
M'/-.DY Y">BI-O-O*GU14FUN@E:J+^2MDL7)X7]%3QU/71]$[KI&EY[Y6PM
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M=5=3/%=26,(9-.=:A!I9#*15'0.ECC8UZQ-(&^8#FA)DN6I:'J6D16LNH0"
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M:+97-]?W<5K9VR%Y9Y7"JHSA5 &6=W8B...-7DDD9(XT:1E%11\I=V>ZV)A
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MLIZ(%\<"0AC_ #<PS+.PL99\(ZDNM4U/4);J\M+NWB7]W;0S02QB&!2=H^)
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MSC/..#QYG.,TITQ]WF?3'IZ=N.W;&/LTK<[L)M8ZSN'KAI)/0Z_Q^JHX6_\
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MTEK,DJI-M5]C[22CJC*^Q@&&]&X\[Z <WRU55/"(GU_U_/Z_W]>),C. >_\
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M+9VMU-!92*" 1&;6.*./.=Z1B124=:WMA\^TSS^GY_S7K7C?:/Z^OYUOR/[
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M6G97U?*UWJ<S_P#Q^G^/GSY_-?I^:_IU6PVTBD'DY'H<>OECMY<8 _*V7%[
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ME';11QQQK&D:*B1HH5$C10J(B*-JJH 1%7 4 !1@<Y*1/"(B?DGCJT]ZR,#
M ]*@D^(FWBC%\T.YIDYKG#YJJ#^URIR&!3DX? D6F"K>X0*GY@Q&=9E!ZN^N
MA79S5SZ+71VT^I.JX2$*0-M;70C [#Z)AO-5][TA=,%SISZ=K9GN19RW"6^H
M2:1=O83S3$2):R^-;I!;O%X#DR%029'+56L=42VW3%KH)-M:6$&L1:K,R-(+
MB]NY'CM!+,9IWB46]LYC5;>*%3&&,@=F=FC*P7'O.E;4<!\C\D7UDO'?= -Q
MOF,EL\QGJ4JM77T!CLCQG>[*N;/EW3<LTD$(!-1R\+L..^5B\U7B34')1($.
M@SE?L"^UG3-,U/6--L;.!H=&FOG6RDFFB>WM+G^\7EE93%;E1ITCS>"^D7-I
M>Z89#(TEAOV3'(M'Z.Z<ZSZ LY+/4)-&ZTT+29;K6I;R22Y@USW0NXOI;=/C
M\<[+86DVD^Z7=O))*ERTD8@9NIKA32<BJ$G'?*U%H5VV*HJQEGR"4'5)F^16
M./MJL70U)U"_\,98V E4-97-6\*@/$-.EE?F*.NGK8IM"74D4UQ/-! MK#++
M(\5LCO(ENC,66%'E)D9(P=B-(S.54;G=LL<1C5D1%=S(RJJM(P56=@ "[*@5
M06/)"@*"> !Q6=^J>O=:Z\G=U7"_$/)F!XAW.AL*[<\CRUZY\"#/W1E?#6V1
MEC617US>0AK35-(-;U\=58FDG(M:59U4QL, !+S8:^WTV[NK6YO(D0V]HKM,
M[2Q(1L57*JC,'9BA+(%4[PD@4ED(J_:?TWJNIZ9J&KVL=O[AID<TEU--=VT#
M PI%(T4<4LJRR3/'+OAC5,SB*9(B\B%#F.CV>:TEG?T])9M.L<P4@5W P4V%
MH92D&B+$T@@:$8M6%UIXLKP9B8X21)X)7,E8K.J"K#5S]*5H7W^[KD/AKA;6
M<V9K0T%IE^/Q,O>:OAK0@-$&Y*R])JXK'D.H@UPQ?XC436&*>3-*CZBYJ8@\
M^3%<ART%I>MZOW3.F6FM:W8Z1=S2VRZG+[E;W,05A!>W \.SDFC8?O;;W@QI
M.B-'((W9T<L@1Z._N6LK.YNUC,WNL3SO"OVY8XE+R)'Y>*4!\/((+X4X!W#F
M]U'_ &B=EQO/W$)8U-=F.YW8<F86YU!06AK[R\Y3V0])766W>!7VX=AE<IQ2
M)7OX>X;#V3*?\*PV2TNALZJEFW"CV^[;MM TS4[+1VM!<3Z"^GWL.Y(2;;1K
M2.98=/CD9)4NKC5!=W.L:D;??'+=W5K%'*_[/\6LB]G722=9P=42W5W-'J,'
M3MXVC6=M=+%:S:T_B--<7@,,L\XL9[:SL+6TAC2X:)[UV,8D(3HB^&S=$6_&
M'-*SU=E0^ON7Y.T;\W9C$#$Y.YY(K\IRCNL;(DZ>F0G&<E[7;96SD'DF'=;T
MY_M2O;X7K6/M!@2#4M(5)HKC'3VG0^\0NKI<Q6,MWIMG=@J<A;S3K.SNXPP5
MA#/&"H[5A^ASO/!=L\<D6+^;$<BE6C,D<$\T1! R8+B::W<J64R1/AC4BG6!
M5>JQ+SJW)3\3;8#<TT^BR]O5)2V5(/\ ,-?9+<%#UH8KI!;"JGBCD/)%21\5
MD'+Z?+()7$/BBDF0RR02QS0MLEC8.C@ [6'8X8%>/F"*J;2[N+"YAO+23P;F
MW<20R[4?8X! .R161NYX92#YBN5W;4?&G)G=]8<+SF[GM9S9YHE[>A;C VG'
M]WAZ8+M%H>*[D>^B#)"@.XVTVNX[XSJFPUML-2W%?J9YP;*,E[%#Z$LK?4H>
MB%OD2RUNZ6U6R5K.\M=0:2[M^H/VK#(DB/*\5[;66J:DQ1HUEB:-I&C:.0-)
M:=%ZK31>O8.H+V+WF:SFN;NY&I1E5NEUFPN[&:4O-#)"94NH8;J&9UEC%S%"
M75@"AD2^'QP+R=DK7<E5 E=G.4> +JSP]4\@S;R<*\LXO;5US9'$9>*L*?AJ
M>AAT4>?MJ6#CZ8( F;-M7<X&DU9HFL@UMU9U+<:K9VL*7,=S9WC+=NTT%JU^
MD]L'@C2YN@OOL\D4;N/'NWEE82/'#<O:MX2YQUCHG1MM?Z?KO1Z26UIK-G<R
M2Z<+DM;Z9*ER(Y+2&RDFDFLV)B66X3:MG+,?&LF>$J(YVZJ4^>LK9[46,&TF
M #EL@H96D0AGR#QO,%BG:YS9HQR%DB9*USFR-8CT<J.1>L K%*T/[A^]OB;"
M\B6W;<1=[.BWEK2Y6%-OF*.2]S6=O]V7?19?%W5U0'RVN/TVI%R]K (>>)5I
M3"G@WHUC'(V"1E\M.GM3O["74+6))8XEN)'A,@2X,%L(C-<112;?'B1IHXSX
M+22;R?W>U79;S<:)<VG3UKU'<S6\-I>ZH^EVEO(TJ7EP\<!FDNXHVB$4EE&1
MX#SQS-LG_=NB]ZTMXN^)W;NYK'BT^BS^GXDN\MAU-QU=/2&[;*UEEEZVVK>:
M^-C*CW[/DK.6[3"8.8^%;8NWYMXCM*PW0UPFCQT3W/S?_P !>-H2[89K77+:
M2=9Y)5FCMFNXIGBGT75(YF*Z9=PN@_9NI_!I6H[_ '626*[&:Q&YO;BS_9][
M/;SC2]8MQ<Z9<M$RQWUH O\ ?]+E**FHVZE@+F.W:2:W!64(T9&9PZRSK;NM
MK[FFL K:HMP1+.JM*TJ ZNLJT\>,H&P -&?*,8$8++$2*4/)) 1!)'+$]\;V
MN75\D<D,DD,T;Q2Q.\<L4B,DD<B,5>.1& 9'1@5=& 96!! ((JYJRNJNC*Z.
MH9'4AE96&596!(96!!!!((.0<5]W7BO5.E*]!,4DXQ$$1,P4LT$L49@S1WD"
M221N8PF!A<!0CIH'*DL32AB!W/8U)H)HU=&Y2K-XZX_I.,LI79*BE-+%!<5+
M-9VBA/M[0HTP@T@RS( "KQB"%D(=%&Y@D+8AHX!V,2.%J=*53.2MZ-EJ*\ I
M;FB3D<FCG7$9HY4LCK316?OUN6:_."6-=:GU15\V.$V:(NN$A#'L"2[:M#!-
M/$]Q^&)$\4.8MZ^((R%<Q[AO"%@RARN0I8$ X)!'%3K<VXN(#=K,]J)HS<I;
MLB3M '7QEA>17C64Q[A&SJR!R"RD BH;LI\0#DJJI>1\ES;OXCKC \H:.WL.
M3N'LK!)47O$^&>/GN8OV$!FSYA<^4XIY:T%3QCG-C<5KC-O;T=K/--:! :(
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M%K;J>3Q!&&.<<EMNXXX')YQR<"LI]@_->MX)[P.$>1<H55I=R:UN-<NDE(_
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M0&&<I#>174@QW!CM6F<'OP5!SP,DXJMCTK49>5LY\>K(4&?J^/E^?UK=[!_
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MZH,EF*C$97,XS/QE14.1S]-F*2(ZP.MC8JB@KAJJMC,M;0@NRLRF!B0M(L+
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M+POB3*KLQSM 1$<9/_7@#))XJGMM8O+^ZCM;33PK/DF6XF(2)%R6=E2)C@#
MQNY8A5R2 =[^RCX#';CHZJ36<[8'G(4J&QKR<S7:7DX*G6WKW0_,_B$]=A\Y
MD=+03P$-C:P8VP%-1521B?NH_K'Y.N]8FC<FWM[$'A%"^-(RD=V,A(7/F#&/
MNJIN+FX,ZPVUU!<)@B5H[=D57SM**9))1("/XPQ7GU''6#G:.(."%J^5]#&M
M17N=(]WI:B*Y[WJKGN7Q^\YRN<YWU<JKY<[7=U.9&(!X\\=ON_I\NWEBYV-H
MJ*N1@\^GW #.?U]]7MZHX8_IX143_2?S_EY^OW^B=4!!9N1@#\_^_P#*KL2J
M#R&/4]S6N7<3SWEN N,]%R5JUEG!IV0C@50LD49]]='2_+U=* LJHWWBIU62
M>;TR-!KX#K.:-T <W54JK&AD?L.P'&3VV@X\^<D>A]*H7=YI1%&>6/)/90!D
M\CT[X/)/&.:T(!YZ^(E/7"\C+V[<;V.,LAF6@_'@M\;7<D"5$S&D#O)(/O5C
M6QD'<USPF9Y]HDCO:DSPI*.&;- NMH?P(RAR0F!NQSC@DGMSP,GTR:DDV ?P
M_>I X^$N5S&3SD A0<9\]Q'SP<UL+P!WP\=<P7K\#;@WO%/+@*K'8<9<@#OJ
MKAY<4:2D0TA),0C+A\47F?Y*0:MO5%9*:^EC#B<0GD&*;X=OAR_Y&R">">,^
M?GCT\CS7MEF@ D#"6$CB6,AE !P#QG;]<E1VW$UOI763)VI]45%3S]_/W_U_
M?]O[7WI98BI/&#_/]>1['^5=;W < 9SY8\_EQZX^?/GS7ZOL]1ZFL?3Z.I N
MZF4NL.EKK(:,L*8JGLP[FLFF&F:Z*50[, ,V)DC7,]X>/UM<U%:M/5;4<O)'
M8I6W/'?)O&_&UP[B*?;7=T39;8:0G3&Z3,ZCG@CGPNE0DVVAM\^;0:6\V8E1
M_N]C7",T;Y(%+#E-JFY1%U)J$]U937[^]P6:H(;0)%' )(=,ATJ*4QA-I;W>
MUM1-P#,(0#@D%:SIS4K3IG7;;6Q91W,D"W0:-]I$WBPW@B2;Q%</#%/=O*8B
M,.#(BLA?=5?X2X.QG!'+NPFS=3?_ "M9QKAL=GM39EGDMLZ86JH:JPCNB9HQ
M:>TULZX:@'(,H AX@\_1T%?9"@HRK0N;<ZKJFIV4=A=2(;..YDNXH4MX8Q'*
M[W$A6-U42^%OO+F18W=E22:5E&YF-8QK.K)J&N:EKTT4,5]J;M+<&V5H;8LX
MC5Q';[S'&?[O$"R+O*QKO<GD[/&[L87R^8J*%BN]*/EF;$U7?FWRY43RG^*_
MGU31Z:S\"-G(&< $G&>^%!Q\QCS'/G5AGUZ&(9EFCC7. SNJ*3Z D@9Y'P_*
MO<%MH9T;(R=DD;_/I>QZ/:Y/IY\.\JU43S]T\_EUYET\KD;67'..<CS],^OI
M\^.:]P:W'(JLDBNA[,K!E//D0<-W\JOFMT4<_I_?:OG]%_DGCPOE4\?7Z+Y^
M_P!OSZMTUJR^60,_4?4^O('?MWJ]VU^L@'Q?+S]?,_[XJLVVFH<]3FW^DN:K
M/T=9"A%E<W5@+5U0 ZO9$DYM@;+ (+$LDC&))/*QBO>UJ.]2HBT8AD=UCC1Y
M'8E51%+,Q R0%4$D@9/'D">U7RU26\D2"WBDGGD.V.&%&EED8 DA$0,S$ $D
M*#P">P.,$Y#NOX>Y)Q>+W_%]N;R%F=WK(,;3&T@D=9)#;26J5,WX@+K"<X2.
MP:5)BU@CBGL"ZT4NSKPBP RB89MY97.GW#6MW$89T5&9"5;"R*'0Y0L.58<9
MRI^%@""!<=7TC4-#OI--U2 6U["D$DD/BPRE%N88[B'<T,DB!FAE1RA;>N[#
MJK BL_T=[2::I!OLW<U6@H[.'YBMN:.Q$MJFP'];H_?!L0)B RX?<8]GNP32
M,];'-]7J:J))EAE@D>&>*2&6,X>*5&CD0X!PZ.%93@@X(!P0:M@(8 J0P/8@
M@@_0C@U5>I=1ITI3I2K,Y!P6>Y-R%QB-5"1/1W<,41;!2%&(:X<B(H>:*3TR
M1J^ F"*5(B(2!9O1[1(\\#GQ.4JG4_$O'&<N);S-Y&IS1A-J??GCYMDV?I+;
M1VCIWV&GN\W3S!9V\U)3B)G2Z>WJS;Y5<BI8IZ&>F=/<W%RR-<SS7#1Q)!&T
M\KRM'#$,1PH9&8I%&.$C4A4&0H ->515&%55!)8A0 "QY)(&,DGDD\D\]ZR)
MU)KU5D\A6]U29<DW/8I_(%J\^E!'R[31:Z,M+&X!!E+).,&,'%#JXR'619$@
MTK((!9)I/:BCDGB4KD1 [8=:!V_=P_(//6GT& J<R+8U&&R58#I*EFASU?W+
M:7BZ?C&YV-]"^PSW'F V=+:Z\7AO'8\+*FE7N+Y)UY^OGI1*>BZ,U'JJUMKG
M0K314M)=0F@A:^N?%ADEM[VXT*RN;K5[:V@>..6\OX+CW8:O<77CVR075I:1
MV09II7LVZ;AUSK'3K#6K=M1L9M0GN/<[I ]E=V]H;^XM=/N(WFMUEM+1[..:
MXL'DBM[P.HNI98G>-)*?A>8772<^?MIN$MK6^$XGY,V1>Q.K"F1:Q>Y%W:UO
MJ^ZFNUK:\.SM&RY;2YHM&I(3$W*HWW2A4@+FQ'K.^LVZ6M+:TE@!DO-*MWLX
MYHS+:G0AU+9/&UNLLDD,;+<VMS&3B-UN@5YX6/45K[K[0NJ;6&T%K9V6I:M%
M:I%!X5MX,\NG20B%DEGB(3;/"52>0J8CG:"%$_?6H:A3I2K5IL7G:&'Y4$)[
MPX[!;*O"L"BK02D(20B6-E!!8RDLI!!7E$("%6H,+7P2(&!$,%".-%$$C."1
MD$'!(R#W!]0?,&O2LR[MK,NY2K;6(W*>ZG!Y4\9!X.!GL*^FJRF?I+C37]76
MQBW&Q-KS]&>DQ,TMD3550M+7^6D32QB0"UX<3(PP6#!_,2&'N@=86!Y1,*\U
M</2E.E*I4%%2#6UA?#4]6/>6PH(-K<P5XD5K9A5BDK6AV%C'$TLT6O4PM08"
M9I(A%*)6!D?OR^I2ON&%%"@C%#&@$%A:K81AH8X((FJJN5L<,361L:KG*Y4:
MU$555?NJ]*5[^E*HMK)=1G9MM7!%*#-<SQZ-\GM^L:G3/WLT$\'KFB=[JW\5
M&.J0L(D]DB55A;$DL\,1CG/IQ\SD?TS4.>/S_7Z_TK74*C46'Q9S.2R^!LCA
M>/\ +Z?1@;KD*N#UZ9BJL;@F2OIQ9[6GI"!JP4LEC+>_C ,@E2/P\FDB%1'N
M)2)ZE8SXO^';O>;<M0:KNXY2WU,]::N%R'"7'YX>>S?&.="#@$HJ)HA@=S4U
MY(%9$.,165=5"2.^%JV][=6:ES(I5?,[<N[[LU-_:;M9Y NN?>+8T<^[X,Y+
M.85<!AQ?OK)EY_?"#D)]I)5]>:;GK*2=!HIJ#4)XBB4K43C_ +X!N%>\;ECF
M+D[ASDKCC.<S96E VF&,K$_:+.[/+UE>,&?51W<.62ZKC9:XYTSC(*<QDFB(
M(]N6*N:M@I4>7Q:_BE7W/H%!Q+QI1'YG/&NEMZ:AN#89#9YH)2@/]HFZ;5OE
M#@#J6R3U^8RT1=D(3<_/&3EV;QFC ;.]F/1^J=1:W!>6Y-O8Z?,KSW1CC</(
MI5O 3Q4=!P099-I*(0B8EE0BQ]0:C8V&GSF].Y)4,?@JS+)+N!^!-C(VXX\F
M4*N78A%)J*KM\I=%RIRCQGPU/O<U56>UO:JB(UVX*H\_2U0D\KG6N@LR725
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M=K>W$\+),S-<6[&*0LQ9VQPK9R221E2V?B(+>=3=3TNUAO4N82/=;Y?>8?\
M*-X!=!G( 4D$*!A%9$QQD2%B!UL3$54C^B?HWRGG_7U^B^.I3R2L>Y)/<9(\
MO3(J=##;*!D*.!V ./UG\>PJWM3ML'CDIVZC3YO-NT5Q#G<\E]<UE,M[H"!#
M3QZ*F2P)&_%+B<"ML3H:L'Y@V4, TED"PB3OC]QQ7$N=J.VT;CM#$*H(&YN^
M!D@9/&2!G)J+O" P5<E%+L%&=J@@$G&<#+*">P)&:CX^(*97K3=OIEBUDF9
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M\<Y1$TTB_5[W+]>K+)J%],<R7<Y&<A!*R1K\DB0K'&H\E154>0%97;Z'H]J
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M)=(LI,L,$C3=?LM:N]9MK)A(NB7XTR>96#))=K!%/<)'_P L#RB!R6.9HY0
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M>TLJD D,ZJ2,\9&<X\\8R*X*?B,]^&S[^.?[+DBRCL:#C;-QSYSB# F3Q/\
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M.<?Y40,S'Y &J"',[K'$-SL<  @CZEL\  $EFP  23Q6@.,Q&^^(-JJ_D;E
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ME-S<LHFO;N5Y))KJ\G+2SS2.WPIL1<"MH6@B5'E::0G=)(1M#.0,[(P2L48
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M(U$3RJJJ=MB>$1$\JJ_1$_/QU2"&9AQ'D?7O],@?=\_G5Q]YMX\+XA^0V?\
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MZNU2#Q5C=TT2"087Q4;9+J1!#!C$P>&U!4@2B2<;7C@>JUSW\'_B7']H^WY
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M[PKJ%ZI%HIS!$P/]X8=G8'O"I^6)&!'V00>U0<> 2" 46"$88:&,<88>-D,
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MD<Z4B>>5[GR2/<^665SG.5SG*J[!X \@ /H !^0 K<X 10 %55    554#
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MT\1[7C;BY%D8[0VD$B2Y.FG2N$].DLGDYG8?2O3PDVW]W&/!4Y@B< ^*X/\
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MOM7.6%8'KNJ)H^DZAJ<A!]VMW= Q'QSM\$"$G_U)G13W[DX-?SS J>_V6C%
M"AL-'J=5=0!B#1),=;7N@O3V0#P1-\.E,L;2R*9&QO[TI!4[43R]_P!?H;(;
M:PM'E=HK:SLK=G<DA(K>VMX\LQX"I'%$A/D%5?E7*J33WMRD<>Z>ZNYU1%4D
MO+//(  !W+.[>O)-?T!.P[M1I.SGMMP_$@D0<VL>.FGY.O!$]27_ "'=CC/O
M2&D+X>0!4LA%SE(]S8U6EIP))(FD23J_Y^]==53]8=1WVKR%UM2WNVFP.?\
MR^GPLPMTQV5Y,M<3@<>/-)@D8KJ7I_1XM#TJVL$VM(B^)<R@8\:Y< RR$GD@
M'"1Y.1&B+Y587Q'.^;.]CO!9FJA^0M^6MHIF>XBR1;D?&;?) UQFFN!F/80N
M7R,$T5A:>A8_Q Z6IH&$ARW+#1JWV>=$7/6^N1V8WQ:7:;+C5KM>#%;[L+!$
MQ!7WFZ8&.($'8HDG*NL)1I/4FO0:!I[7+[7N928K. G'B38SN;S$40^.1O\
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M-A9'33FG%22$%3RRO<Y:>YN9[R>2YN9&EFE8L[MCD^0  "JJC 5% 55 50
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MM4&/.!&*YCZV]B#ZSUOHG5&DF"&"35+&?J6TD.P216LJ2O?6O!5YIXHEMYX
MJB24I<;B6N&J5NDR<<34]<:?9//EOGS]U7S^?Z?7SX7Q]/OXZP*>])/PGMY^
M0Y[9[?\ <<>==#6FEJH&5!)^6//^ISSW'%5PW)#R1*B1M_\ V^?KX\)Y^WT^
MOV\*OT3[^.J=+Y@>3GZ<'D^6<<_Z_=5;-I<;#[([>G?\O]>_IG.MG(G:3P]R
M78LM];@:0R]@DCE@TH44U)IXGPM],/G04DP%M/#%^0A99 3T7T2C21N<QV06
M'4VHZ<5-G>S0X.[P]V^$G.?BAD#1-D=R4)QD9'E@'4/LRZ7ZD+'6-%LKN5E*
M"[$?@7R<8&R]MVBN1M'*KXI0$'*D5F3,<?TV3J@JFGK1:RKK!FCA!"QMB@'A
MC\JC6-155SG+ZI9))'.EFF<^:61\DCWNMEUJ4UW+)-+*\LTC%Y))"69V8\DG
M)R3P#Y=AP *RG2] LM)M(+.RM8;6TM8UAM[>% D<4: !451W&226.69BS,2S
M$UJQWT=SV)[..V[E/N"W'JGJ./\ //*KJ:%_H+T^IL98JO)98)4:]T<]]H#*
M^OD+]+HJT28FT+](014C+AH]I)?74$"_:E8?$<811RS'/DJ\CS8X .2*A=0O
M<2I;18!<[2><*N2&)\P N6]3Y"OY<;'<M=X7<6B*^?9\T]Q'*CGO=X<Q+39<
M@:%7RR*UOK97U0Q=@YZHU&AU%0-X:D08:(S=H,-C: #"06T.!Z[8UX.,]SCD
M$=SZG%9$S0:?9EC\%O:PY/F=D:_BS-CZLQ]37]#+C#ECLW^&YQGQMVC:WF+%
M\<E\5\$1[WT:TR*BGTV>!MBJ_5[.+W$0>PT6IVKKJV_9JL>5?6991B4U69 )
M-[.M9X+W4YI;I(9)?&N-F44G:Q4%$.!@!4P"QPHQR036L4.H:E)-?I;RR^/<
MF,[ 6"NPRD?DP2- JAB H &XC.3Q]?%)^)?R+\2KF>DX_P",:K4#<%9;1MJ^
M'^-0@BR])R!JCY9*D;<7U'7,().U-VPIU;EL]"TU^=JBY 0_7:V]V0;F^CZ3
M#I%NTTS)[PZ9GE8@+$@^(QJQ[*",NW&X^04 5GNE::NFPM-<,IN77,TA("Q)
MP?"1B>%3'Q.<;VYSM KH%^#I\"X#@IV8[E.[>AKM#SGZ1KG!<7%H-:9SA]\C
M$D$N+]&.GK]#R3"U[9!_2I--BR/$]<\_10"V]3BG4/4_CA[6R<I;\B27.'FP
M>0.Q6+/EG<_\6%R#0WE[+J#FVM=R6OV9) "&G]0.Q6$<]N7SS@9%=7V?S40L
M;%<Q$5$1?[/Y?Q^R)^GCQ_!?/U\ZTNKLOG!//S[^GY 9/^V+GI^GK$J_" <
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MI2G2E.E*=*4Z4ITI5O79L AV5AEJVV+[#0R!#DN8URTL[<YH#EM&*Z&56.=
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43I2G2E.E*=*4Z4ITI3I2G2E?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g772024g06x87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g06x87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )=2^EH0X0DE-! 0      #T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   F:T' (% !E0<F]T96EN($=R87!H:6-?,#<R.3(P7W8Q #A"24T$)0
M    $(MLVD3=+?3JW%@1^)N[K10X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              .&   ')0         !
M                  $             !R4   .&
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   .&     %)G:'1L;VYG   '
M)0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #A@    !29VAT;&]N9P  !R4    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     &T
M   !    H    $\   '@  "4(   &R0 &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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MS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8GX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  #_X5A":'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L
M(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO
M9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E
M9F%U;'0B/E!R;W1E:6X@1W)A<&AI8U\P-S(Y,C!?=C$\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-RTS,50Q-#HT,SHQ-RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#<M,S%4,30Z-#,Z
M,3<K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C R,"TP-RTS,%0Q-#HU-3HQ-RTP-#HP,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W1-9G,](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]-
M86YI9F5S=$ET96TC(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HQ0S-#1C0S03!$1#-%03$Q04%&04$R-3@Q034U-#4P.#PO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#IB8C5F.&(X-"UF,C)F+30W-30M.&4U,BTS9F$X,F8S.#1D.&4\+WAM<$U-
M.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^<')O;V8Z<&1F/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @
M(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HQ
M0C-#1C0S03!$1#-%03$Q04%&04$R-3@Q034U-#4P.#PO<W12968Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#IB
M8C5F.&(X-"UF,C)F+30W-30M.&4U,BTS9F$X,F8S.#1D.&4\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N
M9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4X
M-V,V,V)A+3(P8F8M-#<Y9BTX,F4W+3EF-&%C,#$Y.#1F9#PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP
M-BTR-U0Q.3HR-#HR-RTP-#HP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@
M,C0N,B H36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1C4V-C<T.#DP
M-D0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,S%4,3,Z-3$Z
M,C@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!I;6%G
M92]J<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.D8V-C8W-#@Y,#9$,T5!,3%!049!03(U.#%!-34T-3 X/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(P+3 W+3,Q5#$S.C4Q.C(X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,4(S0T8T,T$P
M1$0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,S%4,30Z-#,Z
M,3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C%#,T-&-#-!,$1$,T5!,3%!049!03(U.#%!-34T-3 X/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(P+3 W+3,Q5#$T.C0S.C$W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ
M36%N:69E<W0^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T369S.FQI;FM&;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T
M369S.FQI;FM&;W)M/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z<F5F97)E
M;F-E(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @/'-T4F5F.F9I;&50871H/B]5<V5R<R]M:6-H96QL979A:7)A+T1R
M;W!B;W@@*$U"22!#<F5A=&EV92DO0S0@5&AE<F%P975T:6-S+T-U<W1O;2!!
M<G1W;W)K+S<R,2]);6%G92!F;W(@;&%S="!S;&ED93$N<&YG/"]S=%)E9CIF
M:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^,#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^,#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI;FM&
M;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @
M(" @(" @(" @(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H
M/B]5<V5R<R]M:6-H96QL979A:7)A+T1R;W!B;W@@*$U"22!#<F5A=&EV92DO
M0S0@5&AE<F%P975T:6-S+T-U<W1O;2!!<G1W;W)K+S<R,2]);6%G92!F;W(@
M;&%S="!S;&ED93,N<&YG/"]S=%)E9CIF:6QE4&%T:#X*(" @(" @(" @(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^,#PO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^,#PO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/"]S=$UF<SIR
M969E<F5N8V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T369S.FQI;FM&;W)M/D5M8F5D0GE2969E<F5N8V4\
M+W-T369S.FQI;FM&;W)M/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z<F5F
M97)E;F-E(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @/'-T4F5F.F9I;&50871H/B]5<V5R<R]M:6-H96QL979A:7)A
M+T1R;W!B;W@@*$U"22!#<F5A=&EV92DO0S0@5&AE<F%P975T:6-S+T-U<W1O
M;2!!<G1W;W)K+S<R,2]);6%G92!F;W(@;&%S="!S;&ED930N<&YG/"]S=%)E
M9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^,#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @(" @(" @
M(" @/'-T4F5F.FEN<W1A;F-E240^,#PO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI
M;FM&;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @
M(" @(" @(" @(" @(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50
M871H/B]5<V5R<R]M:6-H96QL979A:7)A+T1R;W!B;W@@*$U"22!#<F5A=&EV
M92DO0S0@5&AE<F%P975T:6-S+T-U<W1O;2!!<G1W;W)K+S<R,2]);6%G92!F
M;W(@;&%S="!S;&ED93(N<&YG/"]S=%)E9CIF:6QE4&%T:#X*(" @(" @(" @
M(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^,#PO<W12968Z9&]C=6UE
M;G1)1#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M,#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/"]S=$UF
M<SIR969E<F5N8V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T369S.FQI;FM&;W)M/D5M8F5D0GE2969E<F5N
M8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z
M<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]5<V5R<R]M:6-H96QL979A
M:7)A+T1R;W!B;W@@*$U"22!#<F5A=&EV92DO0S0@5&AE<F%P975T:6-S+T-U
M<W1O;2!!<G1W;W)K+S<R,2]);6%G92!F;W(@;&%S="!S;&ED934N<&YG/"]S
M=%)E9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^,#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^,#PO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ36%N:69E<W0^"B @(" @(" @(#QX;7!-33I);F=R961I
M96YT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W12968Z9FEL95!A=&@^+U5S97)S+VUI8VAE;&QE=F%I<F$O1')O
M<&)O>" H34))($-R96%T:79E*2]#-"!4:&5R87!E=71I8W,O0W5S=&]M($%R
M='=O<FLO-S(Q+TEM86=E(&9O<B!L87-T('-L:61E,2YP;F<\+W-T4F5F.F9I
M;&50871H/@H@(" @(" @(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#XP
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#XP/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=%)E9CIF:6QE
M4&%T:#XO57-E<G,O;6EC:&5L;&5V86ER82]$<F]P8F]X("A-0DD@0W)E871I
M=F4I+T,T(%1H97)A<&5U=&EC<R]#=7-T;VT@07)T=V]R:R\W,C$O26UA9V4@
M9F]R(&QA<W0@<VQI9&4S+G!N9SPO<W12968Z9FEL95!A=&@^"B @(" @(" @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/C \+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/C \+W-T
M4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]5<V5R<R]M:6-H
M96QL979A:7)A+T1R;W!B;W@@*$U"22!#<F5A=&EV92DO0S0@5&AE<F%P975T
M:6-S+T-U<W1O;2!!<G1W;W)K+S<R,2]);6%G92!F;W(@;&%S="!S;&ED930N
M<&YG/"]S=%)E9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^,#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^,#PO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W12968Z9FEL95!A=&@^+U5S97)S+VUI8VAE;&QE=F%I<F$O1')O<&)O
M>" H34))($-R96%T:79E*2]#-"!4:&5R87!E=71I8W,O0W5S=&]M($%R='=O
M<FLO-S(Q+TEM86=E(&9O<B!L87-T('-L:61E,BYP;F<\+W-T4F5F.F9I;&50
M871H/@H@(" @(" @(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#XP/"]S
M=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#XP/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=%)E9CIF:6QE4&%T
M:#XO57-E<G,O;6EC:&5L;&5V86ER82]$<F]P8F]X("A-0DD@0W)E871I=F4I
M+T,T(%1H97)A<&5U=&EC<R]#=7-T;VT@07)T=V]R:R\W,C$O26UA9V4@9F]R
M(&QA<W0@<VQI9&4U+G!N9SPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/C \+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/C \+W-T4F5F
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP34TZ26YG<F5D:65N=',^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O
M<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @
M(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU
M<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @(" @/&EL;'5S=')A=&]R
M.D-R96%T;W)3=6)4;V]L/D%)4F]B:6X\+VEL;'5S=')A=&]R.D-R96%T;W)3
M=6)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D
M9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q-2XP,#PO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S
M:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @
M(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R
M36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $A DD# 1$  A$! Q$!_\0
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M+8ZFNM,L;:92A B#;:U!-6I@^MJL%H>U=17'#EVD)#@!\$'4&#FQ 1P#6!,
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M,((2%Y!199$SF1#C#01R33SRO;'%$Q\CW-:U520"Q"J"68@  9)).  .Y)V
MKTJL[*B*6=V"JJ@EF9CA54#<DD@ #<DX%1PZX\R/&/M6,9V/[CR#R"_8@U;H
M"Y<A:D.D]/8P6NU<%,68YWJBM4*,AKT5%:YR*B\K[C2=2M1S3V<Z)@-SA#)'
M@C()>/F0;'H2".X!K)]1X)XJTL%KO1+[PU 9I;:,7L2*1G,DEFTZQ;=1*48'
M8@':I-(J*GJB^J+^45/V5/[^6^L6JW]7J:'$9F^V&IL8:C.9FI.O+NRG21T8
M5;6CR%%SK'$R2:9[8HW?+@@CD((E5D,$4DTC&.4J&Z=G^3G:M*;O,?783QQZ
M>%KC+P/6]PUA^H[ N,Z&/(8[2D8RNLZ>FR-/(%'*8D-W;E6'TL;"VM48F-[9
M.WU^/U^(\E>GB1W%Y =J65_-V!F1;+JC[1%98'N!V0+ZT-VD\Q8S($&Q%CI-
M";/2V%=(19U]\UE9"L$,#)!Y)#6-@BE3DXI3BE.*4XI3BE.*4XI3BE.*4XI6
M+NR.ONN.P)<Z'V%$*:T=-8#2U1EO)716+M7CKK'Z.&,:(D:4\B3)7EX&U87.
M(!'-**A=$]$E8!Q2H_V'4/BQUUEM=O[BZFGI[*"@(UVH,VUWK;30S8/2 ]AA
M,DEB,M;2\M7$4M/ 965L1!5CFJ:IH6!+5AP#I.2=OCY ;C?TZ?AN:5^ZKPV\
M7[Z,2BTX1"D UM1!".5N;(2P^W(=K 0)9H7'QOE^Y7G8.A8XV6%TY]Q;N&;.
MY\\@TP$CIZ]AZ9_:E5HSQT\<SB[.W6V)'LG&_J&"XK^R[,"QS!-KN-UHI;"@
ML1+B(FBBM]3V'LZ^62&9L)C;-].WU^D&B@9/U\O[#X4KZL!UEXOXJ\L:7%V&
M:AL*S'6] ;GDUZ&CU^.[*BK]$0)]'/82-8':4N KI )?>^:#,YR)89&5\+I7
M"2>OUC_OO^=*]LGUUX^=,W^/L:6R,ET9ET5US0%':G0;:S*O-?F,M]-56,LY
M=N1#*)A^I: .G(L7#"5&<IB',EC^Y'$&-S\AZ?74_,TKX/\ HY>-+'&Q&R"&
MP17$L=D!:;LHH>,LB7M^;[$<R>T^>R%I7;?9!,-=-*TAI;X2$<L]&,\=D_7R
M_L/G2OHI^I_&?'9G$=2UEG45]<_<F;C*5D>R?]RNM9BX'3W4\D\)R/M8:FI'
M>!> D)()$!'\LR)I36S(R3D_B<>?Z9_.E65F/''Q(Q\EAD*&)U9 7D:N.20C
M2W;:4[+:[04UG7 5NE.F^S6LUD3T_51%@@VAES)4U?U=Q&YF@DL+.<MU[CO@
M;?6?G\J5\^\\6_$RJTM,=LH;$33;4V_R59!^J=#-871O9+NP&W_^HB33S0P6
M#=_LE,LUA&JZR(I\\Q BL?+)&3^G8=L8_;Z-*RIFNL>K:?1=R;+0:+'WMCY$
MN'BM)H9@Z80GKZDS86*J,U7N2\.FL8!@?G.N;P(H5+*VM'/8'710UX@[/3T_
M7.<TJU3?&GQQN1'-L[Z\N& 9E@EL99=PZ>SD,S]=8VY.?-T#R])/ 0%C+NPM
M3<A,3&RNSMPWZ@*-A0,"P,GZ !_'K2L<Z?J7Q>TF3CW=1V'#B,[2Z5VEO=%+
MH+&ND92YOL7 #V[*YIQ]671P%ZWH_"4M)IQ8)QVCT4,=(TV"U26>=QMZ=/B#
M_<_O2KFK/&'Q'N@0OIZQRQ9S57EJ)->:+0BFOL,779_#:@EK](1&7=4"_H:I
M*M[E/KJVVL82KYEH0EP:09&3YYS\_K]J5(;I[J_K[JZBN ^MYS2JC3Z$K3VI
MA>E.U3K+3RA5]+>W#[,\LZ5]C;$4K3;]S2/0O026=C/&TXPMSQ)/6E9:Y%*<
M4JWQPAF:JVL6V3)#"<_G0IJA'1K(&,#8ZB<6R<Q)5E:RREL"Q6.?"R-SJF1(
MY97,D9#/;IW._P"&WR_>E7!R*4XI6'.Y.JNN>TJNC@[(-L@*ZCLCWUI%?KK+
M'*IFFH;3%V <EA6'5\TZ7.>T%S0*-\]'RCVQ+!O82^*6-G'U\_VI6%-#X_\
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MR\"\L,I16-5)Z?ZP(<',Q?;*U5WK[1I[;B7V:#6K7WX@=,U2(=6C+S+:SHV
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MFI1M"4.SK@/25#;0BY$I@[C,[[?LH+0H\X3,HVO)MHM#)]NOHZ=@]OW^/EW
MR,9I5]'=_P#6H8>0L/H+HRCVF8RNI^\C4HOV[/YS=6=9G<H5J6%&#&A,O+@L
M.I'%$"LIF*(627#!5U1IHK'U]>74^7X4JU+SRDQ-;F+"_P#T+MII&TAA0M78
M5E!726&@_1#.P@\03/+>$1A:"SZ^0'5JR>.0$:G(%KBBFZA&9KC&^,CKVW^O
MW[4KYB/+WJ@,F[KP(K&4[-WI=/?UXT-<26TRJJ-V?="!#4IUG)+;@%=<:&D'
M LV53K<V.O*J)CJ*TJ[<M@[>OGMW _<?6:5(K&:T';4,=^ %9UL:VFAI2JZX
MA&AL@+;*Z&URUV$4T(RP">\2YICX&SA'%B$QQL(&(EAD8]8I5T\4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*Y#OC1>,'6G5G?]7V'UJXD"_P"WQKC<]B9URL2GK-#.5.T:XJG0Q1*&[:$U
MM^>4')]0]+L \UI#(;2,<7I?V0<73:I:7'#6H%9I=-M%DT\D#FFT]7$,L$A<
M\KM;M+"L><<T+A2,1%CA7$T(LFAOTYEBEG2&<ID^%+(RB.<<OO!-F\3'3 91
MS$*T9/&GIU?)_P D>KNK^P]I65;=256!:"Z-(JZ$RTSV.I1!GTF=@C:+ 3IK
M.FJ0Z&FC&AG-F,G;;EQ'.@/EDV'Q)=P<"<(WDVCZ>%2TCD6RMK6)W@MYKN9V
M^T2@<WAVL,LK2N6PF.6)2G,H&!:))-Q9KWBW,F(24DN.=@&,<**J6Z;#FEE5
M/>" 842R@Y49FK\7WXA5%9A+X1^-QP0/6V,BKL_VE?9F2.*ILY,XV(:NZKSL
M@G]3^F<TX,1-#.+)\HZT#AH8U:#5V4=GK7V6\#S+*.+M>C=[VY+SZ;#< F53
M.29-2G##)FFYV, 8$JC&=L.\93:&K7BE#90G"@!92NPP-O"&.@&W-TV]WXY"
M^"M\/RP--I_,CN2DD'K TDFZ'S-J.K9+(M[%A=VB6-+Z?^CQ(WSC8EI$2_5F
M.DU(S(XP<\>51^UKCM627A329N8D@:S<QL,  Y_AR,N<DL UV0<  0'FYIE7
MQHVEB-A>3*.;!\!2/N@]9#G^KJ%[@$GKC$WOB-V6C\<.].B?,?,86BWH0E9:
M]3Z^IT(LSJZ!2V6A5).P\=)7T]G:UEWJ*T.XF$.&%^C8-.$8A<8S]4\/JNI6
M=[HLEP\'B.EY!X9',\J<L93E)'.H(C;DYE)8!@1RDUT#P%X7$.A:OP5+>36,
MMQ<Q:G:31%?>1!$+B)T8J9(HI8+:X>-65BO.X9>1LZMNQ/,#M'L34V6@S9%;
MTQ4$SD*#1=3!AX><4"1[D:/;ZK.B5&DTD[XD9];-9GJ#/.CYA*NOB>T9F:6O
M#UC9P*MSS7TH +27C-+$&&-HX)"T**,X4E2WFYQMN'1^"M$TRVBAFM_XQ<*
M)+G5A]N+L-RT-K<F>UM0&!Y1#&)%7 DEE/OF27C!U^SSCP'>7CKVKN+Z^-ES
MU+V-U?I-#;V.G.P>ZH2RZ66_K7V1TY'T)T.@KJO1UD,\4=K3S3Q-<.8T8R"E
M?5WX/U?2]<TJ")(Q)+;7]O J117EH_([02>&O*'PKO%)CF21$?HI4ZO]N/"N
MERZ-I4\.GVUD7N;BSEEM;6*V/-)")[1BL2(KM$\%R5+#/*\B'*L16"?AU]S:
M[P:\L-+T'W/'+F<SLKR#KW>A'%(VMRVV#G5F.VD1$B(-)3&_6(!/:L<.$9F=
M"%I)B9 JD5KMI>T31K/CGA*UXDT0BXN;&!KVV9%S+/8N,WEFRCWA/ RF01$,
MRS0R0JH:4FN0.'[^70];FT:__EI<R")2QPBW/_(D0G&8[A"$#8!+-%G&#B4W
MGGGJSI/XF_B_WD/\BLK=[<]9V&J,5S86J7FM:)B]18SRN<R..-,,7GX)9'N:
MWT'E?*JHYZKC' <\FM>S'B[0VS))I\-\UJF"2$GMFO8$48.6^VPSL -\N ,'
M>KAQ HL>+>'K\'E%W(EK(?\ JY_LY)Z=8KI02>R#RQ70U#-"1#$0/+'.//&R
M:">&1LL,T,K4?%+%*Q7,DCD8YKV2,<K7M5'-545%YSZ05)5@0P)!!!!!!P00
M=P0=B#N#6PNO2O3D4J!6[O>T<MY/_87]_;X;K47HOL/OVQR$E/T!654<N%W>
M*KHL?^K+_JR*SJ\:727ED)8V=QJ8KH1J0V$FOKT&F)52K)QWGELML=0Y&HZ=
MR\F_TG;&(ZZK(9NQ=U4X5:G<].=K]N":A-+INC,_I3TK(NHM#1S0U&#/S]RX
MFMM:#6'C3SPBJG&V>W?\L_KZ5_%_\0.[RE$-NKWI<1W7^TR/9FIZE,I-_9W&
MQTSL1VUUET]G*O6X^'K>-N4GW%_VGG[6%U#=;HRCJ$)A*K#;B+[<]457>M_+
M+NKLOM_J?'Q]1YS'Y*^L.WZ;<G:*U[.J;&R?@:7KZ_K-+UD+MNG,);W.<>#N
M@0IY-!0YR0W2#Z:E8\,;+B6^G5.-L_#]^N^W2JBSR'[4QO=W=]=>9NJU73-1
MY,=)=-!7KM>M9KL&5V]U+T8+2"TF+BQ,X.ES_P#25O1#[VQL]S7VP0^KL2@*
MXT2A8$0Q_?\ #_M3'3X9_,_L/K-6%U=YP[BXPO5NB+ZZ@T.5*ROB&1V#M])V
M+7A[M+'RKTP.&HRJS)9/J2FR%^3G;T\2PTKX2>OZXBMFGDHJMA$3:WBF-R/+
M/Y59&D\S.W+DK"]F#T2X+J7>]$;#L7 5^:V=)>ZW25Y/D)XRX;)Z+7!:CJLZ
MEQE[%DM_9DRT-=/M@D!UEC7/M [VJ!MAE,;'IL1^AVV^&/WQO65;;SRT>9&N
M[_2=,5L>3);Y'UO74U)V7-9Z;4:CQZ[>KNGW5>EI3<#3U&/K-Q<VD!M;<"Z7
M4NI!(9EM:]4<U[51]?7U\*E#TCVUL.Q;CM_);W$9_$ZSI[;T>,MHLKM3]UGK
MEU]UQB^QA+2LMK3&82QBB8#LQJZ<0RBCD86"1(R62&2)RJ5G[BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*5;HXU6W67!D1;WW4^=S@QP"JWY8]6+9:J6J
M+:GRD=[S"S+B%ZK,]JM!9[8HE1SYE*N+BE.*5:>LPV2W0X NLI!;J"K-^X Q
MDNGC^20\:<(ACG#30/G".!)) M*TATM=:UY$X-D*4)+)"Y2L2]D=?>/V2QRW
M>_SE6!E: 2BH?J7/NUDC ?.=GZ:E5:XI; X,DG6'C2 2J0.:19O*.BFFC9/%
M._KUS\_/XTK$FLJO%SMC+RRR[BEPX(VJ+R=V2->9FNNC91;;L@>>C),M_NQ=
M:+HOU1V'9M*KIZ^PL*:\N?N4GTK3@A6_Q^7PV/P.-NF:5E$2Z\>9,[J-*'+1
M,RF\T&QQNN-)LW55(0=F8=8;MVO&N+*O$#!;#0:>]O)J =BW$2&Z<F,Z.4NS
M1OMUVQCYXQ^WY"E?!#MO&E;6[R@UAD)4VO79<U@0VYKTJ]7E$T':9-K2C'3V
MT:F&"W4/:%A<Q0I&\&1UG)8%POBC9"P>N_Q_#^XQ2J#/J_&"XH+DJS^TCIF[
M?25EZ"5HX8-7G"H]5H]1H+CW@Z9]P%)/?8W1Z)+.I,=<FP414P#9Q1/DL8(_
M7/;ZW'[TJJNK_&K?6MUMB[W.Z.*DZPS$5A0R7*M"RF(I1M/=5]F=G!2("!YV
M![ F;Y]L-,32S#5D]:VLLHDFE;C&W?;;OM_:E4\/5>)^]*V-N45D828\_0QW
MTUY8K0S3T&ARF /JKL*NFL12 "YZC48/-2W\ 5=I/JQZ+-2%.97TH[6#ML=_
MV]/2E9<"ZIZ?OQHK\#/4EU77UF/MP3Q; NQJ##3UGLX+JG2,^:MB$L9;0^U5
MM6R*ML"KJVLI(9R;FQG+9/[?X-*R54T]91!N J X@0WG6MD^")7JUQ]W:&75
ML4Y9'/>Z8^UL#3B'*Y?=.1(Y$1%1$BE5+BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6@CXU/6_V?*S]W6P
MCK#'V--@\H:6+'.19X[2X3:6&W@M6BQ1R?4TVDQ!&VS=@C7P- EF:?-*Y/E#
MD9_[,;W[#QGI4K2I# XN8;F21@BB*2WDY$R2,O-<""&)!EI)I(XT!=EJR<1V
M\UWHFHVUM&);F>V>*V0D ">3$<<A)V"PLWC,W55C9@#C%<YG8W:?7TO6^2J\
MUE=91=W5>UO+F[[$CU,C,XF,>%5+F:?/4<(L,@M^#:PF&E:&(B D5\2_+(/;
M8!B93K)H=5?5KQKFZM9M!EL88(-.-J#*+DNYN999V)$D3IRIR<K(X( 2,QEI
M]=</Z5IUGIT!CCD.HI<M)/<F3!DY<B)?"4GPXT.&2,GF# LSR*^*D-\,_P >
M.A^V_)#/U'E-H7YG.BRPEY?#W@TM;6=FZQA+?HLIHKR>>!*,"=_MF96DQQ2:
MV5&T0Y@\I<(]CBGM"U;7M-X:EN^&[83\X*7-[;N))-.M.4AKF*!01)T*^,N1
M;#^:RD#F3)M-NM.DU0V%S.%N@ R0R JLDAPPBYVP&EP0_A]6!&,L"H[FPPQ*
MX06OKQ1@0 1H P@@X(A1 Q!HFPC"BC0-9".,/"QD4$$+&111,;'&UK6HB<=L
MS.S.[,[NQ9W8EF9F)+,S$DLS$DDDDDDDG-9UTZ5$'X@>8L-;X=]YU=9"Z<L3
M-5VD6-C/F/\ HLAIJ/5VKVM1%<JQU-,<_P#A3W>C5]/7\HMXX=F2#6].DD(5
M/M 0DG 'BJT2DGR#."<[>9'6LR]GUS':\9:%)*<*]Q-:@DXS)>VEQ9PC_P!4
MT\8'J:Y^B?#_ ,?S.E\!VW?^;&7K9M13A$'X'-89-_>UE_*-&78YZ,"IW%59
M16-*TF *UFOJNI&$,]&S&0PDB))G?\<U&?4+BVBT22;PG81223> B0ABJ2,T
MD31J' +Y5BS9*C(4 ;R/%?$EYK6HZ/8<*3RV]E</&+RXNVT^W>)3RK<322VL
MB,LY4R01PM(YA(*0EA(QE3X/]T>'WC!I8*K)97MG3:[>&UF4T';VQ!RE6X&J
M-LA6L%J,M4Z"V6ES+3FBV5I#'865T9])'.22:@-;7CVS7=-UO48VGG>RCBMT
M:5+2!I&)(7+%I&B4/)C(&6"Y&% R35CXMX0XRXALY)[O4=(BM[&*6[M]&LI+
MUTDEBB9B7GFMH5ENRA>*)V18U+%%\,.[MG3XN_B"SL+(5_DAA*9Q&YP[*Z@W
ME?7"OF,U&*--:'66311HI)CK;*VAT43O:SYLV<L#7D3.AH !^93['N,!I>HO
MP]J,P73=1+RVLDKA8K2^1.9PS.RI'#=11E6R0JSK&0,RR$\=\=:&]_8'4;*-
MVU"Q4>[$K-+<6_-DHBH"S2PLWBQ8!) D0 EEQKW[DP%IY!^-7C[WWN1C<YV[
M!<'='6UG;N26?N'!XP Y]5V$\:.;[@-H,G,,N,T15U&(3=D_+.E+^3%60.M?
M&/MAT7V,IQ0-%>UX@T_40;G0+6UE/V>PUNY?EN;66X0$2:?$H>YQ;-)@B"W0
MQR3RR)B7% GN.'M%U76;::TUJ&=+,VDN%.HQJ&D\1D#$VV502RO(B-'S2IR'
M,(.>V^7_ ),"D"$ =ID4PE=".)64--F<B+FZRO$C9"+6B5$U$3%*$+!'&/ I
M[C"TA8U)"I'^KU_/J?VL\8W%T]V+Y$\21I#%]GMVC)9^9N8/$SDL<\Q+LQR3
MS;XK')..>+3,9?XI%$N<BVAL+7[,@Z\B^+&\[+C;F:7G]16U3PX\M9N_1;3'
M[00"N[)S0#+.6:K8^"KU-$DT DMP('(^5]<> 62*-;@)+,,JF!G R1Q%3U]9
MNW@/CB/BRVEAN(TM]4M$5YXD/\N>(D(+B$'WE <A)$)8(S*0Q#@#:W!W%R\2
M0RP7"1P:G:*K3QQ$^%/"2%%Q$K$L@YR%DC8MR$H0Q#@+*K0=78#5WI>DTF8K
M[JWL,%H>KSYK%22!3L#K# #]%F#*Q\ZU90%L55@O*=.'(2L<*P,G8/--%)L&
MLVK&F-\5.B\%:5=_19:YFO:2_I=2!?ZKL3LK=7<5[FLGN,-0GD7.XU^AL3?L
M^.[&V&; &/))#&J+(<2,=L=-1I6J>G;Z-8'S/@IB8^UMOM-W?4&TQ>LH.V\G
M4]5A5.RJ\_7 ]L[K-;O52R"WO:NSSU7;!662JYH).J,EU0)+>RV>PMZX[2S
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MT8N9+E8U#@<C1Q >%B,&1W978D(2%&-$L)B_1ZN]C'?M&Q?1$_N]7?A7*O\
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M?(+N'#T77&@ZZ>'G2K#-55AA,)@])I3Z:JLC8!B>_9RHFL")K"S51]=_K?\
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MJK*VU<X=M(P>5GT!Z?EC/XX_7S-*KMOXZ:2PZUZSP@VEJX)<?JK#3611@\1
MP\MI:V=A\FEKZJEH*"42E$M["II@Q<UEBJWWUMQEKC&'TL#"HSU[9\OS]=_/
M\>M/KZ^O\V/I?$;3WXILS-;1U][>W=-;:JXKZT>(K1#_ &;:CVE78RVE'>PE
M#46IV,NRRDA0,TS# *L89V:LZ*CTP,@X[=CW[YZ[8[8!QC]J5.T>'Z>""!))
M94@ACA^;.]9)I?EL:SYDTB_E\K_;[I'K^7/57+^5YYI7MQ2G%*<4IQ2G%*<4
MIQ2J9<75/G:PRZO[:MHZ>OB6<^VN#A:VM"@1419BSC9811HD5419)I6,]51/
M7U5..I &Y)  [DG8 >I.PJ"0 22  "23L  ,DD]   22=@!DU#'?>=O6= I(
M77]/==FV4+EB8<*OZ8QGS45%57:6W&E/L!'QK[X+'+YO2UQ"JUK"T17O9E>F
M<&:_J85UM19P-C$U\Q@!!WRL7*]PPQT81<A.!S#<C6O$/M:X)X>9X9-3_BEX
MF0UIHRK>LK#;EDN?$CL48,"'0W7BI@DQ] 8HZCS3[\T,SDIC<CU]7N159!GZ
M!N@O8'+Z^C'Z#6RGTQC&IZ?QMPX#G+ZJK6HOM3-K+V9VB8;4-1N)SC)CM(X[
M=0?+Q)?M#.!YA(R?(5I_5O\ :'U*3F31.'[*T&<+/J=S/?.5_P!0@MOL*1L?
M)IIU'F:PQ<=Q=T:!ZR77<?9D\GY_BJ-25BFIZKZJGT_7[,F)_P#Z_P"$_">B
M>OK?X>!.&8@.:QDF8?U37EV2?BL<T<?_ ,,>E8/=>VKVB7!/)K,%HA.?#M=*
MTO QT >XM+B;'_Y<GN35L_J_L-'>[^EON[W(OKZ_TX]N^OK_ /WK_P /VY5_
M[G<-8Q_"8,?_ -RXS_[O&YOSJW?_ %8]H/-S_P"\EUG<X^SV')N<G^7]EY/E
MRX[=*NFG[F[KSSD?2=R=E#O]?576^DDVS5_/K_U/84&N'3_9#^WX_DGI23<"
M<,R@\MC) Q_JAO+O(^"RS2Q__#%7*U]M7M#MR/$U>WO$!SX=UI6F@$=P7M;6
MVF(__+D=B*S/EO-;OK/2M;=S8[L.O8C56"[I'9B^G<BHCD_466?%2BM5/5?5
M,(6Y'?LBI^$Q^]]F=JW,VGZE/">JQW<23J3_ *?%A^SL@_ZO"D(\CVSG2?\
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M!AC@1G; YG\.) SMEY&!DD9I&9CY5510J *HS@#8#)).!V&2< ;#H !M4W3
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M%&UK(XV-8U$:B)S=ZJJ*J* JJ JJH 5548  &P    &P&U;L "@*H"JH 50
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M #U)ZDDDDDDUQM>WUYJ5U/?7]S->7ES(TL]S<2-+-+(W5G=B2>P4=%4!5 4
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M]%]6R,9+%(QS)8)HXYX7QRQL>U2O3-YK/XZBJ\QE::MSV>I16!5--4"0@UP
ML:JK81AH&LC8BO<^21WHKY97R32N?+(][E*K?%*<4IQ2J5>WE/F*2WTF@L1*
M>BH*PZYN;4^9@X5;5UHTAAYQ<\BHR$<4:&6::1RHC6,<J_MSTB-(ZQHI9W8(
MBJ,EF8X50.Y)( KZ1123RQPPHTDLKK''&@+.\CL%1%4;EF8@ #J346NM/.SQ
M7[4C&^P]L4E.82V)T=;MXR\26YTR(L<44ND@ KC)7(YOI'7GEKZK[5_B142Y
MW.B:I:#FELYBF WB1 3)RG<$F(MR@_\ 6%/F*R_4O9_Q=I89IM&N+B)<YET\
MI?J .I9+5I)HP.YEB0=^E2Y:YKVM>QS7L<U'-<U4<US7)ZM<UR>J*U45%145
M45%]4_'+56&$$$@C!&Q!Z@^1JT=]N<WUGB]+OM>:ZOS63J2KBW*9"\B9HPS?
M5(AAHD60DPJ5T8H8T:?,(*FA@9_%(G%*AN9L_*?L#+W':1^CQ_B+U)4TQNF%
M;I,?'V9VG-G 193Y+G65QUC6YO,,GKF,+91#Q6-V%,LH12RRLC=-/ZY],?CG
M_'K2JKXA;_R7WLM_9]KUOU_5)M4'9]9[[0Y.DZ[W>H4HAJLE.PV?T^D$!IBJ
MY5."**96DO8H<T/U\)[TKQ^OK]L?'I2IQ<BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI5OCA#LU5O8MLF2%$Y_.A35".9\P(<*QU$XUDYJ2K(C+.2P*
M%8YT$;'.J9$9+*YLC(9[=.YW_#;Y?O2K@Y%*<4IQ2G%*<4IQ2L<]N_\ LTV?
M_P"2S_\ ZX^*5D;BE.*4XI3BE.*4XI5D[?L++=?5\9VC/6.8M9(ZNH#9]7=W
M4\?RT?!5UK')+.D2RQ*89(L-=60R(7:F@AMD(8I6J7R:\B=QO)EP !LN8K+0
M9I=K24Y;EDJLY+(0/%+H;>%C?O.@OUBG%KJ:#Z?/TT4=G:$1W)]+G["TRWA/
MAM]>O>:8,NGVI#7<@RO.3O';1,/^9+@L[ _RH@S9#M$&UG[3N/HN"=&'V9HY
M-=U)7BTNW8*XA &)M0N(R?\ @6_,!$K#$]R4C"O$EP8HH#"CA#PB"01#"C1,
MA@@A8C(HHHVHUC&-3\(UJ(B?WK^ZJJJJ\W_%%'!%'##&D442+''&BA41$ 55
M51@!5   %<-7-S<7MQ/=W<\MS=7,KSW%Q,[22S32,6DDD=B69W8DL2<DFO?G
MTKX4XI3BE.*4XI3BE.*4XI3BE.*5M:\%<RVNZWT.FDB]I.ETSQHI?9Z++64(
MD4 _HY4]7-99&7#/POM1S53]T7TTC[1[OQM9M[0-E+.S4E?],UR[2/\ C$MO
M^%=?_P"S_I8M>%=1U1DQ)JNK.B/C'/::?#'#'@]PMW+?+D=\CJ*F-H*"FU5+
M99W05\%I36XKP[ $E'?+GA?Z*BH]CF2P3Q2-9.,5!)$2(3'$2--$1%'(W7M;
MYK&^"OKFDO3.J-H<19WM57R7.,U)C4;-OL-"1 &I9TC(H1W[/)%%!TVVB%;\
M@Q#,]K88J^/5K1TJGU]?7QK,'%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2K>UN
M4SVZS%[CM76#W.;TM673W565[OE& '1.AGC]\;F30RHUWS("8)(B19V1D#2Q
M3Q1R-4J(]-U3Y<]5UP^+ZL[<ZLV^"KVM"S<_=V6U)&YRE)$BQ!5+KK&VX06O
M96#HR(8NU#JR)&,9 KH1X8HT4K,O5V0[ZI+HVU[9[ES6[JRJR4<7*9KJ\7'!
MU=I(4'-'91W[]'<VI\0XT1@3021XF2H6PF2;YH[6/4K.G%*<4IQ2G%*<4IQ2
MG%*B+YD^2QWBW@L+N1*(*^%O^V,MC;\<SZKW"9@ZNO[F_/KOI)H7+<1 4,D5
M8DR3BH1.CYQIV,^6Z[:/IG\6N)[82>&\=G/<1[ \\D?((XSGHK.X#$;@9-9A
MP7PQ'Q5J%_8/<26[V^DW-Y;M'R>_=)-;00)+SJ?Y!>X#2\O*Y5<*RD\PU'_%
M2\]:?9@2>-?2FC&MLY,X0SM;8T9;" +=\3HS ,'5'0HZ(H$:9!K'4EAS.CE,
MA%SRS>T;0!2Y7PIH3(PU.\C*$9%I$ZD,#T-PP."-LK$"-]WZ<A.P/9SP7-;S
M?QW5[=H9(F=-.M9T*R)("4>[D0[J5]Y(%89SF8#:)JU$XJUG+ #"BBED+9-'
M6P1L:J_42.5C1H8U5/:KW))''[%7U]?1?PCD7F<D(JR!BH$2M(?,1^\>;'7"
M@,FQS[H)&X WQ'*I0-SA2JCQ,_T<H(#GOAE4L"1@D.,DJ:Z_L_NY^J+'QL\;
M6UA&RVEKU_!#J;&*S^2W)Y? 90.N/V=M[A#)"X+?21"457 ^0)##2Y5^M;(.
MV C14\@EGFE50JR2R2!1@!0[E@HZ= <;>5<3ZO=QW^JZG?1((XKW4+R[CC Y
M1''<7$DR( -ARJX&!TQ69>T>NZ'MKKS7];:;ZAM)L:0RE-F$<UA@:SM1PM@&
M][7QM,KC(QSQ%D8^+Z@>+YL;X_<Q?E5OK7YK=IM]AX2^4G7N^(C/[-Z,!U/7
M6NMQ&+$S65F>#K+ZFU[!$3WC-T^/G@G+B?ZI(9&=.C8HIFPQ/G_CTH?K^WRK
M9!DRA#LKFC:]&( 9GZ8H)(T:D:"$5PTPR1HS^%&)"]B-1O\ "C?3T_'IQ2J'
M9]I]8TE@VIN>Q\'4VKC65K:RSU^> L'6,LR#Q5[0BK&(E39"') P5(UG?,J1
M-C5ZHWE6EA?R)XD=E=R1\AD\1+:9DY .8OS*A7D W+9P!OG%>>= <%E!SC',
M,Y\NO7TJ_.4E>J<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4JW1TJ/U9<+"^
M9;]<[FTL&*DGR&U"66J6F?&JM2'YSS5O4F1CW2(R.#YK6-6)7NWIO^V?VI5Q
M<4IQ2G%*<4IQ2G%*QSV[_P"S39__ )+/_P#KCXI61N*4XI3BE.*4541%55]$
M3\JJ_LB?WKQ2HZ[?O**-9ZGKM@=R6U9("=86CYLM6RM:J/96-@DAEUA\4JMB
MD97DBT8LC3(RKUUI7344\X.,GI^?UTW]<[U&1G'XGL,>9Z5##L32QYNKT&YT
M1=A?VC!V?4''S,FMK@N8AH]12"O9#$(#";:F0AUE8 *#2@%'.D'"%CEG<M5;
M6\EU-%;6\9>:>1(8T&Y9Y"%49[;MN3L!EC@9-45]?6VG6ESJ%[*(+2RMYKJY
MF.PCA@#/(V"06/*N%0'F=B%4%B 8,Q?632F6-I.PJYN#)+2Z+C1[8R+"=D<;
MFCMD=)*P$$:$:LJH)9)'BU(((CI)/D>]>D-%TJ'1=.M["'#&->:>4#!GN' ,
MLI[X8CE0$DI$J1@X05^??&'$]YQ=K]]K5V659G,=G;%N9;.PB9A;6J=%]Q27
ME9542W$DTQ4-*U>_+K6,TXI3BE.*4XI3BE.*4XI3BE.*4XI6]/QZHDSW2G6]
M?\M(GS9D*XF9Z>U6D:!9+Z=KD7\^]LEBYCO7\HK?3T3T]$YLXGN?M?$&K39Y
M@+V6%3G(*6Q%LA'H4B!';RS7Z ^S?3_X9P)PO;<O(SZ3;WLBXP1+J(;4)00=
M\J]TRG.^VX'2LR\L59O6.>S,<;JJ44S/3"@;K(V#=-@K<M'?3AZ$0<@9U?8/
MC:^;[!IZPH_+Z2.%KIEI+<R8-([$<$B!2J_C-4%M<Q3Z<$<L&.T&<I-78,CC
MLZ2T$GE!NL_;PQ22QCW.?MQ3J6X&9+(T:S *@21_R_<JE7/Q2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K%W</3> [VPY_7W9%,
MEQ0&3P'0.BF<)95%J(V5H5S3'QHL@-D(V>>-DS6OBG&(*!,@) +*%FJ;2\N+
M&=+FUD,4J9 (W#*?O(ZG9D;NI]",$ BZZ+K6HZ!?QZCID_@W"*T;!E#Q3PN5
M+P3QG:2)RJDKD,KJDD;)*B.O.M3_  JKGNOL/L$WI[LND Z>RO9MA@VZO8@F
MS7EPE(&,NEMLW64(B5&@BK+J:2GBF?;9ZON)H"#!R048\&+-;;C;DA9;FR+2
MA?Y9A<"-FVV8."T:DY.QE*_='ND<FXH_;#:R6KO=Z+-'J*H JVMPC65Q)C[[
MM-B>U&<94+>,>I?FR3-3SAZ4\:/#?X>%Y4P5*Q7>2M*TWK#2OE#AVVD[UN71
MB@7AIR#>P^.<04H[15#8$!AQM%.+60!S5-20'ZX075>)^+K6(2,4N XU!1S"
M&/2T&9XL!AR@@B.%L\PN)$<DL3G6DGM#UVQU2[X@,R/+<026K64@9K(P.&$%
MNL/.,+!(WBQMS!S(',C,LLROJ/\ A)^37D/HO,?*";/M77ZO):4#]%:T[6A.
M["N212H[RTQN/J]'>,/O,E6D:9"+LIM4>+7,K*FUF($<P6.839OM7T'A+1]$
MCNX-*M[75[NXBM;%K,M;*0N9;B>>WB98952%0A=HRXEFA!<@FM9Z5/=S3,KR
ML\2)S-S@$[X"@-UR<YQD[ GL<].'F1K]%E.CK(7%75C1;[;:_K[K_#&U!4H=
MJN@U.SI17Q $0*DS)OLD5Q-)\I?>X:&=$_"KSG*L@K$W6E-6[<GXA!=X3 #6
M:?L30]?6B3*U8@:K)]04.?FM)T=ZM1I YTQCU5B)Z0K^7(U/3W&C2.D: L\C
MJB*.I9R%4#U)(%1T&_0#.3Y?X^LU=GP].[,]WSX@=);"DM0[ VJQM5BM0' 5
M&092:7'"0T1M9;1(OSA39!Q [2%A4<,I5;8@6#&*.9"]UXXAT*\X<U:ZTN]5
MN>!R89BI5+FV8DP7$>205D3', S>'('B)+(U?.&9)XUD0@AAN,YY6&S*?4';
MMD8.!FN2OXM'7)75GQ!.Z9@8WU\&OL\WVI0%P>L,JOU-)6GV1T$C/1S)6; 7
M0-;*QR.2:!7HJ.3G4_LQNTU3@C3$D ?[*EQILZ, 05@ED5$.V"&MY(L@]L Y
MS6*ZOF"[=@2.8+(IZ#/<CX$;CSQYX'91XJ]N?T\>.'2O;LCHW';KKS.6UVV)
M46*'2L!8#J1HU3T3V":,.T&:GHBHD7HJ(J*G.5^(]+.BZ[JVEG/+97UQ#&3U
M,'.6@;_U0-&WSK*;:43P0S#_ )D:M\R-Q\CD?M6?^66OM3BE:\?B&^:1_B7@
M<Y6X*JJK_N7L\NSK\0%>.E?0YVKIH()=#M]",*^,DP&H4VN" K(YAEL[:Q'9
M\YT A<$F/\0:W'HUJ'V,TF0@V) ! R%)',[$X0$A=GD8E8F5L6XLXC3AVP65
M$66[N&:.VC;[HY0"\K@%2RIS* H8%F89(4,1SY_].'S@@T*ZV3RBV\MPDRSK
M7)28YN*]$57*/^BW43Z;Z5$3V>B,9.K/XD(9)_&FM!Q=JIF\03.!S9Y#*Y\A
M]P8@ZX'+X'+N=CC;2;>T#B87'CB_.,Y\)HX?"(S]WD$0C'4#/)GOS;;;\/AS
M^>L/F+E=3F]B#3T?='6,@L6M#HI)?L&II2WO& V>>'(DF(!@F,@F!N*=Y)OV
MDU1)6EJ/:B#P;-T/6!JD.)%Y+E$5V7'+S(V!SX/1@<!P/=R5*X#<J[HX2XG7
MB*S8RQK!?6X0SQ#(5T<>[-&&RP4L&5URW(P!YBKK6RKE^K+:<4IQ2G%*<4IQ
M2G%*<4JWAS 'ZRWKXP&QV8V>SAA5G[8_<4 ;9:F  !7(GS5;7D 61#6O58VK
M9.6-$<Z7U?7U^-*N'BE.*4XI3BE.*5Y/FCC_ +3D_P!Z?^/) )Z"O#.J]>WT
M?KO6->V2XI.M]BQKD5RTI"(B.15_MQ_RYZ\-L9Q]8S_C_&]>1,A. 0?+# G\
M!Z;]ZR:U[7_V51?^_P#G_P#3GC!'48KV&4]_Q^O\U_7%>J<4JV=1KZ''A1F7
M9BQO*>Z"NKAHGF6UN4UJ.<+55L"/*.F8Q?G$.BC^0$*V4T^84&"<F)2HSZ_4
MZ3<,E&MT=0YF1?:S)ADME(L(E>Y4376HSEC.;+#\IL^<JG_88GJ:)86&M"E&
MG'^@7!SW&3^F-C@GKZ;^5><^F-LG.?7R]0/B,[5CPIC(VMCC8UC(VLC8QC48
MR-C$]C&,8B(UC6-1&M:U$:UJ(U$1$X/W3Y[^9.S;YS\!UW %&./AGT\C]#/4
M^F*A3WY?NM=939&%SE!S0K--;*R3^J(N[1IE?0A2(S]WU-9';69@9/JWWW69
MLH6I*-%(W97L[TKQ[RXU:5<QV2^!;D][J9!XC9&Q:&#W3G_^2I&Z@CGSV]\3
M&QT>QX9MI"L^LL;R_"[$:;:2_P B-@=^2[O5Y@1C:PD1LJY!P]S<5<F4XI3B
ME.*4XI3BE.*4XI3BE.*4XI7I%#(1+&/"GK+.]L4:)^ZR2.1C$3_%7*B)_CSR
M[A$=VV5%9V/D%!)_(5Z2-IG2) 2\K+&@&Y+.0J@#S)(KHEJ@(:NLKJP=J-@K
M@ P(&HGM1L(8\8\;43\^B(R-J(GK^$3TYRK+(TLLDK;M+(\C=_>=BQW[[DU^
ME]K;I:VUO:Q +';00V\:@8"I#&L:  ; !5  '0;5]_/G7WIQ2L,T2+C.VM#E
MT8V*@[+K2>Q,^U'K[!==225=)V%71Q+[8A8+40[(Z@$:!'2GW!&[M2$]ZR2/
MGL/3Z'[_ )4^OKZ\_EF;D4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*ACV;VUV9V9K-KT)XYU$0UQ0- H^R^\+PN*'+=7S7P?U4
MU?G:R%ZV6OW8M1(LT @JBU]'93@_="4]I#1I^NW]]J5)#JWKC.=1=?93K?*1
M21T>3J8*P62?V*6=.BOG/M3WQL9')8V]A,59V$K&,9(87,YC&,5K&Q3K7)9\
M<ORK7MSR$KN@<Q9.GP_044L%XV"1'"6G:=U!')?2N5BJV?\ 2U2X'.0_,_K0
M;9^I'3T;,[W=1>Q[AK^':++KES'RW>L$> 2,-'IT3?R\'?'VB4-.>@:-;<G=
M<C&=8N?$D$"GW8MWZ;R$=.N=E\QUSCSK9-\/_P +>MNK/AZP]@=WW176.EWU
MC7>0Y/9@AR9W2]6@TX,L'6)E?:R,>^.87/FE7"U\X[Y)RMK853!E.:+*S5WM
M)UBXXIXO_AFG))=1Z>_\*L8(1XAGNS)_XIXU P2TP$/-]WP[=6)"YQ<["*.S
MLS-,5B!4S3.Y"K'&!S>\QP J*"23MN3G%1UI_/GM3N#R2Z-QL4P/>&?Z][$T
M,O5TIM"'U59]G[FVQMYFL#I=Z EQ84]2-07M@RQJPPTK"5@D>791PVI$(=3>
M]4]F/^[/ 6K:UJS)+KA.G<D49YX=.AFU&TCDB5@2LMRZR8FG "HI,,/,K/++
MB=EQDNK<3VVE6*8TX1W1:X<%7NYHX&D4QHP#) @5N7F'/(Q#D(J@'9?WWB.P
M_';P1\J]+$^[[/[][7S6INMK9XVD/-CCTFTKA\H:3GJL 1T]?D>N,O,19(>9
M% C :0RR*^B9/#7"ZZX-M[6ZXIT..]F@M[5;^":9YY$BC(@;QDBYG8 M/(B0
M(HRS-(  =S6<73,MO,8U+/R,%4 DY(Q^0W)V'EV%:/?@*V?84_E-K,OGNS"L
MOBV=;6VSV>!FK6W%3V%'4W%!G@8HHYSQ(\_<TY>F&LX-*%"6?]$*32R025]F
M2L>^O;3#8KP_9W4VGK/>&_CM+:^#F*2S#PRSN&Y4/C12K R?9Y"BAV$RD,@S
MC^BR.;B2)9,1K'SM&1D,V0N1O[I'<CKT(%9X_P!((ZI>-V1X_P#<HP_J/HLC
MHNM[:=C%](R\E;MTE*DSD3T^86-KKE(?<ON5E<]$16QKZ6OV&:B&M=;TIF/-
M#/!?Q+G^F=/L\I'?9H(<XVRPSU%>>)$Y5MYN@RT1/KCG7/;LQ^7H,WU\-GXD
MG2'C?X;5G7W;=GJK?7Y7L3:5^/PF(SA&CU-AC[1*O5_=T;+/74U?5QZ+17X,
M9-O= -EE&EA%;+]-*D>L_;G>Z9HG&#S23(TE[IUE<SPPO$9(I0)+8>,'D18F
MDBMXI%5RKNC"159<M5OMN*=*TC38EU"X*RK)*L<$:<\K1\W.K8)554EBJEW4
M,58+GE.-G'0WQ3?%COC7U>!@-VO5NPOR6A9NJ[;SX.<%T=@__JJRHT-1=Z+-
M/M"5_@"JSK<&QL)E0< 4HAS8EU!8<1Z9J#^'%(T;DX E\/!).!O'(_*#T#.$
M4L0H)8@&NTKC/0=7F%M;W+0W#G$<5RHC,AVP$97="3D!5+*S$X4$U//;;K%]
M;9JSV78&JH,9E::!2+30:6U#IZD*-/V^<8=+##\R1WHR"!KG3$2JV*".25[6
M+>99HH$,DTB1H.K.0!GL!W+'LH!).P!-9--/#;1/-<2QP0H,O+*ZQHH\RS$
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M,&D'L2\VTN8069PS9"21%*^KP1%81X]5.W)7YVA[4V?8_8VM/=^9K#076XO
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MRW:3GOOF:)SG?]/*O)D_Z_P],^7?\<X&W2NMGP$[-[DM?#/QT,H.OX^U:?\
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MFVR0VX-]'.\DUUXC-)-)DB,N@.$"@YBBW\-@65F:1V:7/PPNC/'J\\F:H'S
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M0JB:10XX.]S6AH*8.J(;N-EI*-,8)FM]GLQ28^4G4V %)AZS*]L;NMR]!E7
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M_OD5L&PN%M+ZTNGC,JVUS#.T8;E+B*17Y0PZ,>78],XSM7$A2_;^NLL()H]
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MPS=:4NHI_P"D5L"Z3H3QEZ1^H7)K+]&OCKMMGL%TJQ?J2/ZA-?\ J[[>E/\
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MX8E"1PPPQJL<4<:@*B(JJJ@   56# & , = .@^M_GN<[Y^'GWI7ZO[K_/\
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M1@BEBJ(I9W( .%1069CLH!)(%5-K9W=Z\D=G;3W4D4,MQ(D$;RLD$"\\LS!
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MX!OY?CZ.YMP_3\?CT3Y'HG[?A/V3]N:4]H"\G&?$(\]09O\ WQQO_P#]5>;
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MQ)(&Q)+=<FB0-(P9^@    55 ']*J HZG91C)SFLOC!QP-1$:B>B)^/Y^O\
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M-QGU"S1$K6$67S)F*(/,WY'*72[%]2U*PT^,$O>WEM:KCMX\R1DY[!0Q8GH
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MHV2$=FNH>;_V\_,?PVKY\I\O3Z_OTJ7^+^"9\339M@GA\:;'.!3(W_6]GO\
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MK&_E@8]@,CDR7V1<.G5^(_XG-&6LM#5;DDKE'O9.9;--Q@F,K)<;;JT*9QS
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M_6V#N-]<T^'HLV %34=' 'E"R\]&' -25^F)S;0EOAZ^LA@@"A+7Y,H_R2+
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M=-?B//HK:LN@8C[6JD-J3Q;$2.TH;0RCO*UY(<LT+3Z:ZKSZBU#<]"*^S!,
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M"J+A%JP;*LTM"X99[;+FL/LE0=AGU _/'[YJK0>:6FDOJOKJ?HV87N#8W77
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M::CA!L6?;)[!:8-3IU]/SZ?7K4MQ.RM5V]UCV1>=52BXHRFWVLP>2V=Q5/W
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MO09O/VUU,0%$[-RW6-OU3G<'RQ^53'V?3G7O8!Q5EJZ6:R,-ZQW?3Q,K+:W
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,<4IQ2G%*<4IQ2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g772024g07z11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g07z11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[24:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )/Z^E' X0DE-! 0      #T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   F:T' (% !E0<F]T96EN($=R87!H:6-?,#<R.3(P7W8Q #A"24T$)0
M    $(MLVD3=+?3JW%@1^)N[K10X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              +(   &(0         !
M                  $             !B$   +(
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   +(     %)G:'1L;VYG   &
M(0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "R     !29VAT;&]N9P  !B$    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     &FD
M   !    H    $D   '@  "(X   &DT &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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M[&E#:9II\6I(:I]J]VM/
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRLG[DI?CW$MX&7D7VO*L9\Y)]&%^E*L^CSYQC'G/$3W^(E%MV=?RXNR7+?\
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MQO>B)"- ?19G#&AD*?&1((&?/X]!_P ?"!H#1Z>HUU ^('W^^=B>L.K]AU$
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MJ>4M:VD2==,L%9G9 +$* 22=  $DD]  !U))T-#J9!( ))  !)).@ .I))Z
M =23VFGZ+[-:\[!R%SCZ(F3PNBMUU$VN12#A&9"=:E,D!@O1YL@'(L1),40
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M"NK;Y6#:[Z(.OP^!DE676P1O>MC6^WM^(_&2IK#'BS7#_' TS/\ A_>0N_\
M7^O_ $_?]^:CB'^<O_\ &/\ W,/;[N^O=LZZ9V+_ );?]Y_19M=E\8NE&RK/
MIQ\*Y^5>XMKTX^V@><^ZWY6UXQ^?<1CUH_ND_G&.8$R9K="(3B8M+.,I7A^7
M$,0\W/RLRTYEN##%=\2APS!I>4X0.G*GVD>UG_:[>,M-(4JVI_J./0\I'W*-
M_JLRK5!Q<9M@E38I'8A;'L*:UWZI9U[@;Z]9([><>I'Y3X]L'QX,*Q^WN_\
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M".MB(ZG:NBV+[U8 @].G8CILS,2GI^V27\V?_HV8_P#MA6?SZ5?CQE&/W_\
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MTW?-+KT!6[O 63L/N;<D;NVRV*BOU(&N;+L%PV1#'A5\F1=V(-N>H3%D$UO
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M0FX9\ YIJ6CW''8^72VVB4PI:U*QE*4(QY\J4K.<8]./SE6<)\8SG',@,"=
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M6W=RHJT:Y12*+&3.O('KK$]A-@P=BU_)5&$K<I*@-5O1C5)G(R[.6%Z0G;M
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M_6%0_/FUUC^N?[X(C.?_ .Y^_G&,_P!<>,Y\\>?1_P"-5_\ V)_,>79_T/\
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MH$@D2S=D4T &UPN^PZEC\%4%C\=:E,W/JA]<WYZ/@(*-V-/O2<H%%#'#5V.
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MBJK)./FT)=R4M4S7JK;=TGV">;V*U\!&N*;1,MVJ+FDLJQA!,,FGSDRH=_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g772024g08y11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g08y11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[21 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )"2^DE(X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             ":@  !?T
M 0                         !              7]   ":@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   ":@    !29VAT
M;&]N9P  !?T    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
M     !H&     0   *    !!   !X   >>   !GJ !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM;?6%R(S<[+8(R1!45?5"BAA<8&1\"4F)S0V592QT__$ !L! 0$!  ,! 0
M           ! @,%!@0'_\0 /1$  @$" P8% P,"!00!!0    $" Q$$(3$%
M$D%18?!Q@9&AL1/!T08BX13Q(R0R0E(5)5-B-%1R@L+B_]H # ,!  (1 Q$
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MQ=%0QE%).,93K4U+_#LI')N+N[9IO-N+TN^:T?%VO;,N+SSIH8 P!@# & ,
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M46A)DX@F%'!$04()Q = (-ULL.]&$@T,S0"AZ_K%AT89H(-ZUH8O3VMTA[X
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MKHZO^FE.3$Z!V"V#CDC:I&6G:9,0D7#2(G@;4%F?THDAQ;I'U[HUF: !9LP
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M"/8 C%2;TS-#/WDUX-B]7U]=#_TO 6NKK5=)8S5Y,E!<AVV2MT@JTINER-L
M6R&+=F,2X\I,M$H2D%Z-,#HH9FO7>A+-Z*YY^1)Z:Y)XT^T9$QK2G%E?N,[V
M>F=P(T/1"]K=*?DBYO6DZ," S12I(>2>7HP !^P9KV@A%ZZU):/P?P"75:?>
MXK_\R8I^XD&4&;8 P!@# & , I1\L-//CA/N5NFH.NM$V5\\3(Y^D4:K.'RE
MQ='FL$:U#+I<J1S*/L;HWQ]Z3)8P<RMS5)!&-3[N2B*/*3)"UYBK]#_1&T*<
M,-MK8^)C@_H;5PZITJN,KT8PAC)*5"A&6'JU(2JTY2K*I.=*TZ?T;IMN.[Q5
M%?=DK_M=\E>ZRO\ &7/PN7'Q24,$WC$>F45=$KW&96RMDBC[PA,T:C<V9Y1D
MN#:N3&:^H1*I(H*.!Z^F]:'Z"UH6MZUX&O1JX:M5P]>#IUJ%2=*K3DK2A4IR
M<)Q?5231RIW5UH\T??SB P!@# & , 8 P!@# & , YS?)S(R)OU%/.:SJ@X>
M86R<<XU3)9A<'9UZV%2([.:8[9,W4Q%AJEW@3BQGE/E1R4;DO6/:%V*E3=J8
M 2^\2L2X!3A'GEZ9\OBSMI<J\6EFLL]>EUK]NF5T?'[&WQCE^BHZU(*?:VUC
MK>.-2%OH%_<)7325*@1A3$E5Y)W<]2ZR&/: 7K9#TYJE3BY'[/6+52E2<:>9
M2%2Q/.7E+5W'UCT[!NF+':+$AG1\X;:4Y1M@] Y<D77S*W)F!Q@#,TIDB\((
M))I R+%C0IGS:0C>FV6M!Y+[[GY@Z/HGAWWVF7OEG[Y=Y%B?C@2W<FY"KXSH
MJ.32'V\ZR^\)%)8G83X;))9&D,FOBRY#$F)>]G*5>UZ5JAKG'T+,,HT*4IE(
M;B$9"5(42F)BOQ5NFH=KY<E\$TWEG:Y"T.K ^($KJROC:N9WAK7%!/1.36YI
M343@@6$#UL!R58D/.3J"AZV$PHP8!:WH6\I#EO;.4^=%_%7DHZ1B##&^6J]O
MV?/G/D)?JNIAVEC=7_*=,7,PUT]OKC64$6,[L\'V9*HU.Y;/9(H< &M$46L:
MQ2O2QR)EIP3KI_#\OQXHJU7'H^_[DK/'?_3XNYOMR+<1D\9Q"&PGK"P6.*W(
M?0$XC%1]'UXG@\.!JRHI!JYLF/$E24A^#J&.$O;GYUBC^AB)9;>F"L3*3],\
M[-/-\/'+R?'^XE;.Z=K9YYZ:WMQ7N6%^-'V_M<G$_M$!5F?8I4I[2;7L! J'
M_1RQ^I&O?B]V$)PO]'KWPO8UH7^D%[.M[S4=5=VS5VKY=<L\M>9",_B\L:Q(
MR3+>?;@J\VF-/KK8-V<]1%6[-3M[BLEEANK'-H"C7LQ1#:9NL9>-(<VHBR2#
MTL+F<8(*3C0-Y:LWW?ZSPF$K2H;3P&,6T/I4\+L_:M>-.I#>QD<)3JX?%.-2
M\DL;0WM^3DT\10K7>]*QQTV\TU;.3BNF\TUE_P 7Y6:L7!YX,Y!@# & , 8
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M8G85]1B2-'#LH6VC1T-240.F7Z:1B@SR;#:Q*%U-N4ZTP361H'@]Z$S3=M.
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M(@Z=?#5:E&K!Y.,Z<G&7BFU>+64HM--IIE335UFF9AGSE& , 8 P!@# & ,
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MK>L\].$J<YTYQ<)PE*$XR5I1E%N,HM<&FFFN#1H_NS(& , 8 P!@# & , 8
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MC]*I4_T5:F'^I%_XJ,1NFXV:6L;YY97L]=7Y7M?1%C8))'3'XZ+%O[*9)TZ
M#JHC@'1")^(;##-%%N)S0$_;@4@,-%HL"P:<*<1F] "9L6]:SRCHU525=TJB
MHRDX*LX25)S2NX*I;<<DDVXIWLKV-GVLXP, 8 P!@# & , 8 P!@# & , 8
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MJ;G)IN-VG_I:R3<LLS3:35[7=[?>QOS.L*, 8 P!@# & , 8 P!@# & , 8
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M<FQ<3HP(!Z*5HE)"@O0P!'[!FO:"'?KK1Z/P?P"7]:?>XK_\R8I^XD&4&;8
MP!@# & , 8 P"&O5?"U"]<)].MD1P_=BL40?(U7-AH'A]0.]?KW("E2W/[2D
M;W1&W*ES,]FIWE-I>F4A&H2%%CW[O6M:[_8OZDVGL-[F$K+^DJ5Z=;%864*<
MJ>*C"RG2G*4)3C&I33IRW)+]LGQ,RA&6JSMD^*ZHS;DFVWFY**B<AF"3Y994
M;.>:UMMF&/VCFBU*W=54/FY)@/<I]E$N3LU&2!K!LH.ALKPV'@$:6< T?S;<
MP-/ ;2KTL/+?PE54\7@:G">#Q<(U\/I*5W"$_I3>\_\ $IS3LTTK%W2OKFGX
MIV?NB2F=248 P!@# & , 8 P!@'(#R75<SN:8HFSD_RVP"//G'=B=.RFO:AF
M_%[$FLB$HK<DTOU93N2VRBRPJ;-CCEIW<4Z.0IQ/;8TF*$Q.PL#CLM 1FS;R
M=L^7S=^EK>]S62UBWIJVO#AW8Z7>*;0775R=0-KN<\5V>XSZM8_(UU@KH*W5
MDKEJI<0(1[RH@#0Z/;9%#%)@1>K.A=EZ=-H.O=J!Z%]6C)4#T'Y,N\Z)Z"LZ
MO+&KSE3FNH6ZPGQBIBX^DHOU&=7UE0P#F:1%7U3;%0LDSK=@>79JT2X.;/)U
MD3/:#!G$*4X/<[%L6W+/IY^_D75\U32=6)24&FMDR2C9?+Y"E=%J^2\VR-ZE
ME*O"/YZYDLJN$2&0:TZN2?;*4WENIJC8@%OQ;H0E$)*43O!#;DB*7'1]]):R
MC3G,UG<RFXDA<2V''+C$1X4A1+DH1N!#>:8HV6 M<>@7$I![TH,1J0%B)&!R
M:I.1^MEW.UO4Q1](==1GGZ'4WS:[F41U--HE+IBZ=%U7U%#[-GC30;F!>W,[
ME%C:E8WDL]4PI(I IK*36K3:UI'D:@ 9W;C\_P >6M\?7[Z?SD^.99YR3RS>
M4ZKWIZ;NUD])\5 Z [FNCI&#QB)HJI9K,#6\IC<2BK*CL6/V)!K:;8TMD*^.
M+I0J84Q"%[1"VUF+5A6U"EO"2M?J[Y]\B2>3XV7]^?&_>1,'QD:V'QV</AV+
M8]AY8H_6Q"]/:%O5>L.MB%Z:UKUW]W?IK6O7?U:UKZLH)RX P"+_ %C4,DM"
MN6]\K4Q,BN^G),W6W2;DJ,$G3&3>,DJ@'1)U4 &6,,:L>.+'N 24L1FB--<B
M,6C (Y"GV#N-B8ZC@\7*GC%*6SL?1G@MH0CFUAZUK5X1T=;"553Q5%VOOTMU
M939F2;6636:\?P]&?'@DXJSHLGFV]DD%TY.QZ"8*X^Z.<$7/;W54B.;AQV;Q
M9?)M,)X(0]-3\@<8H]@5KF;Y@M:E!!>E "]:UR8G#8[9,MK;->)<*:E0C6A'
M$PI4\;14OJX:M&C]5/$4ZE.<*]/=C4W(U$W:X34E&5L^&5VGHU>V7)Z$N,Z,
MT, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7CY8&F#OOCOZE:K(F[E7$*
M5P-!I\FS1#3K!<F LJ7QH]&I2PTAZCIK\(]Q*1HAI /;?L!2D:G9V]$;+&*M
M5E?/3GT*C.>QWK&S5'=\-\MU:776=[WIRS!+P;8-Q=#TLDDKJ=+H51$.@;VS
MN=A)WBH743<_(V)[4#9&QX:DB@V4":W522F^*RKNW[ESTX/S\OY*[9K=STUO
MW\'01U/+6R \R]#3EZE,Q@[1#:1M.4NDSKPMN-GT30,$'?'17(X24[D*FDR6
M,Q"4;A'0.:<YO$[)TFEA8D_O-9HR4!])<ER]/X^)#TE?'?\ Y#)Q3SW5, L.
MQ:36RJCG-Q40V8KXHL6M*Q5]$DK"[*V!$\ENBI,D<RRG,QK,1-RD9YZ?8I;J
MWZ?A%OT2]?NW\'36A.3J$2-0D,V:E/2ISDQN]"#LQ.:4 9)FPB" 6MC+$$7H
M( 1:]?380[]=:I")G:=*3"\:PB[)"*]YRM9XB%HQ"PCJZZAC;@_5O+6R.D/"
M=>U(G%N;I 9"YB:4Z:''9FJB$T0-1@%25;&E9+B)6B/N_?/Q&7'O\^&7B4VF
M^'CI^(5\E*K&<4 GG-C\_=A\Q6E%71=8+95E/5CU=:V[*:4] ;11AS='-NI\
M"IS:&J,R5GC:5^TM,/ N: >Y3I\V\-+67"^MOY7#JS5_'6Z?'I?/PTMYY$DO
M(+XZN1V'@OH^>.E0QZ36O3O$<M8(O9SF<]ER(*BEZ&4QJ#O R"7G3=I8UHXR
MU#*"8F/!L:<.C]J-^V(=>2;XV>9+OFRX>M/O<5_^9,4_<2#*0S; & , 8 P!
M@# & , @FS!'0W;#^PBT%+6W9+ 9-600M^PD:^BZK9&]HE[40$/H24=8]4HV
M62%!'H)JIQKJ0G@V88I,]/25/^Y?IVE5NY8O8%58:HM7/96.J3J4*CRO;"8Z
M52DW>RABZ2R45?.DNDL__P DK/U5O1\R=F>;-# & , 8 P!@# & , Y3;'>O
M'*PT4GYCZ$IKJJL^RJ*G]AIZ(C$/8CE/:T@?K)LJP+)9I)S7:U;Q=NB\\KMY
M7/;M\*N5D"B+$G 2@EK:8^Z0.#M';-+3-K@[7ULFVK]&^5V:DEO/<<I0WFHR
MG%1;BLHN45*<8MQ2<HJ<TG=;TM7?MP)6#O2_%_--6/\ $9# GJ#U+%F-RADL
MD##*I-&E9"3WAK2^O\7;FJ/N+HE$;["LQJ;TZ0DWVDP=&")$<93)S[]FA\AM
MN]%WK#+<^06AR^WSZ4QZNJ5K#R.T'QU%WZLBW$].V-%TLX(X^W!*7EQ:@I]R
M5O>)=&R4KF-<D1MQ3>$@.YX]7R[L6ZY>?>GEYWN7]>/R/-<4Y%J&/LM)P#G9
ML:TDH3)*@K&UVR\(;% !FTDV(;?:C0 **7K'X>Q2-Z6Z$>I2O3NX-JY0>N1*
M#!7P(^^_@F5@# /,[^R-_NQ_X=X)+1^#^"$'C+_!W<0_HM4A_#UAP4G'@# &
M 0$(WKE;J<Y,89M%0O8TD&J0>H#OEM?]5A0E?%-Y>P;^%;6>^8ZV'NA>S  "
M99<=7ZV<)9,2"M^F?_>MBJ22EM/8-%*>F_BMB[W[9O+>G/9E6<:;S=L'4ADH
MT&S'^F7_ *R]I>'*2X\UGJ3-FC^[1MI1N#.TMSRH42*,,AJ5R>5+&241)) W
M1_2TM4E8W\9QJ-0YIU&T8DA(%!(#M?&$C" )G08>E"M.49SE32I5JF]"FJC;
MHTIU=W==2FDI*#6]O.SM^UJ]MF79P 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8!#'R&5ONV^,+]K[Z"V%9A;[$D1BF"5.\QUALJ2HF62L3^N0PEPEC._L
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MA*-*4E0G"C+$R^I"'T(*K9O=.*\HU-W_ &RSX>>O7/FV\B]K/S8Y1@# & ,
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MMZWO>];RD/? & 0C\EWX.WNG]$?H;^%,JR/1^#!*:M/O<5_^9,4_<2#*#-L
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MRY,W:R?)6=KK73@KV6G#C9G< F, :F3FE*-*RS""C"U81%""I ,L(@* B("
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MU6H$-0J-3MR%,48H/&,X\8-FFB$,0M[/1^#)J31K3[W%?_F3%/W$@R@S; &
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MO+[W+S>5$E9-_-]*M],0:45G52"O(ZA@<!F[ \1>816.(T0$R!HE#%(##GQ
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MITJU.=*I%\I0FHR7FD<J:>:=US0<)4Q-;ZR1I<L-*>I$!:8SHPH'%0%66W
M8N'M6G2&HDP4P#2MF;5J2-:]Z7K7KLP&A(T*LZ52M&-Z=%Q526]%;KFVH?M<
ME)[S32LF#Z+B[-3044>[.;>UDGG@2D'.*Q,B*.5&!&(M,48I,* 8>8$L8@$@
MWLP80#V$.]!WZ9A3J56U3ISJ-1<FH1E-J*LG)J*;44VDV\E=<P?0S & , 8
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MFY429[OWHBQQFUD,.?-C #VMC]VA&$.P&:]K^H/T\96_3.WJ,=];,Q.(I_\
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M1A-"[0Y]?RG]C.]1CC[=C;I_47YSW:P8[]+A5OJ.UQN;AB^U&DNI *,:0_.
MM&U&]%!7"1Z3B%Z[T/8=;WH#/OZ Z+_X+5-^KF'_ /)L _@<Z8YW94)[F\U1
M2[2VIO=_$N#G!8.@0I_?&@(*]^K5-11!7O3S2R2_>&!]LTP!8?48PZV!H=SY
M"YH*ZGBMQ+6BK6^1?T&RRH&FGSXA $[:_IWN<1>=J)RF:#4@%RY\9@0\YG*.
M3-YP"FM>X[&H+T 0!.^_0<+>'M?\FWFRO.6'J4RB#L\!H5UF4(21Y?,HJWQ&
M +)!%44M ZF1=3(6E.VF+F<F0E,;P:S#7DD:<2FU::E]Z6G,$$#*?Z!*+_X+
M5-^KF'_\FP#Y[A37.S3\%\UJFEFSYDX)FEN^80:#(_CW5;L>D;8B^):R_BG!
M7L ])D1'O%)^P#T46/V=^@&O*@H6IZ;O[H&:0=]CC;(;O:*D5/-5LB.-,9,2
M0U8QOL?1O"%E:!$+AD2'<D$I<%JI 42%460 HTS9N][#[=]^+-Q5U<M26^&1
M#JFS8'9 (B[B8)0*#RMDE 8^\Z (S3:\;9EJS3>K&  QE%*?=[. 68(KVPEC
MV$#96 , 8 P!@# & , 8 P!@$=+WY)YKZ;5PUPOVG8;:"ROUBA;%%,F1GFF-
MH%IR%2XM:@212D^;QMU4-;:>\Q5[^8QEY-;T0W1I5B2D[ !@E^63R!:/)UE%
M6A?M81OFFW(S.Z,?[026=#([&-Z?B9!74F88[-7!4HCA4G;5:5^:24H KC43
MJTK"C4!NT"DD)]>.7J#=SI8E:593R6P5LDTJJ^-Q:/G-\BCZ1SG9KPRJ2VYJ
MC9D?00IO?'>7K7\U6V)61'%VQS6ORU>D(:4:DU426(#(ZXL6%VY!(I9E=OJ>
M30>;LB*11A]3$+$I;BU.!6C2#1HG%,C<F]2#^L2L;G)&C<FY64>B<$B98G.(
M+ ^^_/S)%F-XDTE=VR/QR/-:]\?GYZ7)FQG969J2FKG-V=7)882D0-S>B(.5
MK5JHXI.E3$F''& + (6@(M=!V5R7**RK-'<U^5G"8%;,QIRP:GD#E:$-B::Q
MG:OY_!+IK\V&.KXLVCDK2Z/,<BRA9\I"I"X,3EHDA4D&XI%80-L7A?M5\Y0D
M-AV[('"/Q4;D6TE*VB(S*<N)ZT;:YO1NB(] 8_)Y$>F0LC(\OCLO*:AH&=E:
MG%V=%*-O1J%!8&TFAW;) TM;\R+TKJS/;<B=VAS0G 4(G%L<DQ2Q O1GE[V6
M>E6)#BE"<X&]@,*, ,.]Z%K> 8_/K#@=51-VGEF3*,P"%,04PWJ63![;H['F
MH*U8G;T>U[NZJ$J%+M6O5)42;1IP=GJE!*<K0C30!V!'6^S^7)5<G,D)MZXX
M=$;E@UHE711E;J[&B<:ETUE">'SBMROAXD[&C?)2S&M<WD))*1G3D'*7=,1L
MA69M"I2F ;GL>[JIJ-VK=@L6;L\7?K>FS=7=:,BP2E0\3&7N8@!3M;.V($ZM
M::41LTC;FZFD%,[,!2D&[N"(*M-LT#:F 8A/; @U61!\L"RI?&X#!HPDTOD4
MOE[TWQZ.,:(1Q2<*IT>'0]*@0DC4'DD ,4'EA&<<44'>S# !V!'>QUO+T>ZL
MHN9V-<D-AO0@Z\L6K*<KV06+%(^XSF/6E(Z_=9#\GACH:2_R9U&]5O'43(H:
M3?=A,&Y(0I5JI27I,!L2+=)TI-;FG'/T:FY3C;=<H1.,KB^V.2HB4R8@B,J'
M/33)'!F2164*H^7-8>&5(8N^/*Z)G2F/II(G:E#LA*. WG@&'S"PH)7P8V*=
M3&,P\,QEC) XEN2O3>S?2:;24X:>/1)BTX*"-NLB>CRC"FQG1:.7K1EF:3D#
M]@7H!'B.J>7XQV-9QC;<,/WU/;58U@R2JGE-BQ4V5EP:I3IV\15X:J[":7*4
M>S"K&?U;JO."J(6-X6Y422E3IC3U &Y*TNVJ;C7V2W5?-V6;GU%/3ZPL,U@,
M/5M\>GJ2.QZ4KXR)UT2%L<U[:T2EEVZB9U;@F:W(]6Q.!Z9\:G5N1 ;3P##G
MZPX'%I+"X9)9E&&&76.L=V^OXP[O;<WO\U71]J.?7U+%VE4H*7/A[,S)SG1S
M+;B%&T*$L2E3[LKT%L"/U13#EF-6AU$PUQ=L!DEG/%AF73T!"$MCQ.02.O'Q
MLK.MZG5G.<::U&GB)L:*,U7& KD[R0::D?#7(Q0K*VM(0IP-+J?+?XYVTWX2
M1=2PF%NP2R#SH[8#-.*^E:1,L(+6-JM?$YK%F&2-Z1X;5"-Y9%2UK3IWMA<&
MQ]:C%C0YH%J@"QK & , 8 P#'Y:PF2F*R:,$OS_%3I''WEA*E$45IV^41LQW
M;E+>6_1M>K2."5$_LXE&G!G5J4"U.F<4Z<XY(I+ (D8'*P&HD=4\P7["7IIG
MTJYSK[SX-#QT8*8ZD5AN4MYM9$-2"E4JM(2]*YN]BQ15+@1F0V"J4HW-,[)T
MSDM5IC4Q!Y0)[\],^&9?'EEKET_'E?B6->-FFIM+N)$1<2G$UIV'I[ZZUDO.
ML<,CB Z O=)2^SYR&H&Z>UM*VHA^>JG E6!D;+#FQ\@"UTCJI*4G>4C<N2J-
M%EZOW=R/U+#^1Z(DG.]3+()+)4R2Q[>++M2RUJF-M#TTL+4IM*>/D\7,;6*4
MR.7R]Y)0N+ZM,/D$MD[P_/"Y2J5J#TR<25O1T&T[AK)-<=<R6M5TQL"!()22
MA2.$FJV4'0N<I6],Z(7!<A992E3J%S*!\2I#6-U6-VB'/3.XN!;:N;UIA"Y.
M!R8,D7C3#P9XAE71L-5.G)T30=X-MJ,,CB#Y*HVUV>^LUPMU +9A&"6AW4FG
MF.QCXBAK@J0B5(Y2XMAR%2G5JB33)RUY^WKQY>^1I<;6SR\;M::_.G,N'H;F
MGJNP/'!S QEWG-:6Z"2\MUC#%37/F)NED3BSH4H97E)-)'#G1O*F6KJB<93)
M6J./7TT:]0^4)T;TH8C75F"GW?;OS)E?FK^%U\EFG/\ 66Z8I*K*F$1&$^Z[
MA#!$=EPQ"^-L9W\D0%(O>M*23/LHD0"5'NO?FFODB>W94I,/5+W)6I.,.$(1
M)\KE2!MW@?II .4V0PZA]+6[/B62N9&KCOT^<8W5DT,9H9- MR8USD4*5O)Z
M!U<XHD4H2G]<TMB%S,6- U[4O/OOOT'>???B4$^06)*5;73P)["7Z0F2#PY5
M7 N,P)X9(Y(X-G:>[5KQ<J05X8UM+GN+VZ=%@Q50F<THV9W^CK:O*$M&C3*-
M)X^-M;67GRX<+\\BI^B:;[M]^)T(W;QDX="UPO;9Y8[TYRYX'1<E9V>9-T:E
M5=U'/:O<HVMD<JJ]J*86V4LDCF+<BD[(Z/*J8.ANBI.XA2 2MZA0@-I"?6 0
M-\F=1DW'Q#T:R*938\>(CE/6Q./E=<259&5$Z51JK9H>UPB6FMJ<US>H2ZNI
MR%8]QA"I0?2$UM0MJ]0H:3G!M7@<[/;T4*.J_FPNU82\R-H?/"<QU[R2DW"I
M%*U+7W$JD%6J$J*%IVIF=#HS;:Z, BX8\Z$_+'32!L=R0J])TZ@ 9R]OCPZ+
MQ?6]MD_'T23X]Z97X7R5GQ'/4?3D%ZCG%E(SS@,$'FLQ@WR)P-D KM:>;#N<
M7G14K,DJIKU #XZ[N\B.9 ,(G0<T G</G9J3:@L^]]_S<=]]2S3!"F;SETSN
MQ^)I/-2Y'9VEE72"M5[/7D/D3@WPJ9.TDO&HFG3O/XNU)MJIH=#VD#N?%4*Y
M9MD:%CLX/BEK6N:)F7-(=]]_<KF[>B<D5^1ZXB5,8=%_2DJZ%\7;OP=)]Q60
MN2]GJ.(+W@SHLZ*2M(V+TD;@C*YES!;;R MU9T:HE:4L=TB@I20-3,\\M+6Z
M\7IGT_.AK*R\V_%Y+7IGE=ZZ:G1%77/#-6_1?0%YL(8^VI;WAM*LKLP,L?(:
M5@I55[Q=#D]S%^<TPP@?G.5)[1:D0E*A*%>G+C(0*%BLDY*4CIGAZ_;OS)(8
M!3;Y0J43OUQ^.F[ O5CNKM%>^N5(<WPA+(7(RL&)L5RF:/4AGIT*0DA1&S%:
M4%M8U<M>#E>FV/MZ9N;"VW2UU.<1?3S[OWGD5XUU%S->4QI2M\+DB7K-'Y/.
MG; LB9'0][)7#X4=N9P,]?C?YOIK^7*:K<1;BK!!VA0YC:RYBF4E(TJ=[.VJ
M/GEWS\[+M"V6NB][Z<-+W>OCF7A<=\V6?0SK>,EMR757.I9;TN8WTI^K:OWZ
MOMM4<CC>O8XK #&EQE\D9$L1@4=$VL\*;(ZWLGN!CD;W(#7Z0R1P=1TG?Y)O
M8 P!@# & , 8 P!@# & 8#:5:16XZ_E%83DIV4P^9MVF>2(V20/D6<'%G,4D
M'K6K3Y&U[6]HT3J20)N=2T*],-<U*EK><9M.J. (#F1KFGYU37*'C(FDXH:U
M7>FN;>QNSG:XZ=8*<ETQE;)%IZ^]&QFI)B94S>QKI0ZQUK4O;84@-3,"M$%N
MEK:Z;,+;S250H^\K^VO=]"VORYZI?QY%F_$'(-DI/'ARK + E=G4M<</H8R)
M.,;.>E[Q$FM/)GE4\&,%FTRYN.X+,S?HRI)BKJVR!$6_QQL7.C7'WJ,/:9(Y
MMQ9)7S8>KY9EAO.],H>>J2KBE6R0NLJ05W'BF!(^.Y*9*H4D 4J58$R-N1^J
M5G8FO2KY5&F%,,\E@CJ)J92U*H"'2DVD-.]_T9&.@>2;LA4G8)#+0ME>3N81
MR(Q]TDJ/<GFL=@DH-AS6Z,T96)3YHWAD"A"X)H:YDN;.[OJ!F-5-*XY$E+T!
MS_\ 6=,6PCHKEPQWY_M^RDTU\)<CY"A$:BM.22?NU>=93)CI53&T4O:4#4M<
MJS7+DK0K0F2F0I&9(RJ8VN2*G!.I+-)!FV2OQ5LN%]=/OED5YMV?%OEI=KSY
M%V%E\13.X:3B$(5] V=7,E=*^JB%W,W%R"43FNIPPPN/H$\KA@J^4S-CCC.W
M3YW2%IYZ^QW:![F$:TZ1AT7GLLA=R5-:[]/#KK?7ED$[>18(P-FV1B96;8D@
M]M#2W-FQM[<0SH![0(R4NQ(FE*,:9K2"]UZIFY.,9"(G8$Q0Q%E!WND*HO-A
MSPFO?A:QUS9!IA8]D5R;%'NKHK$P2IZ4?2)WLFOVIW?"8-&QG$RAY:8E\^+;
M5;@TNAL<;7!_6M^D0E"I4&.]G;7T[?+J5:KQ\2 ?=='7#(>V;VCT=J&R7F8]
M'V5XR91S3<L?KIZET,KEJYUG;JNNM_?;$1(5+!60H02,]]6,,A>& Z2IG0@]
MM)<1. M"/\<^?-?'KD%SRX\OB]_/@7B6#R=%9X]1N0'S*?!<H]T' ^@"MR*4
M/DY1(G"#K-K?H5#V^3.BM)7T->S0)!N#-$BD#;I0A2*OEYIY)8P7OGW]B$J\
M J;\U7/:2_> +L+1PB6V//H''!R6K8A$]2EW5*IHJ<VAG YE0F-&&!E[NULR
MQV&RE.#6[?)C5"IU;B$ZXHM62"*\?(Q25O2CJB_8U&Z9LJ53;IR.^.MJY;MJ
M-UZ^2V*5J\41>C_)K?<'^PF]"I::C#$FY>DEZU/(7./HW]&+XI.:K4>T#3OC
M]N_*Y5]G?KKS[3YO(NDK?C=FKOJ&=])E3]]>/I.EL@,=@"AH:DC;$W"Y%%,N
M%G+C'XC8W20%NSK1D/6QY&J*1 C8%TC2"-=R5K=\H$[?74F=@%1WDWY[(GUC
M>/\ N2/PB8S.?USW=S0VF*V/4K?FN$5@;*GM_G,F61EL,4Q]D2;4MS$&1SI>
MV$J$C:A;VY0\)F\0DYP$"!4E;^_(,9"]TM96["%Y9"NSR;Z^@;SNNTW'H>9D
M$&/;=7/\'N.FGK7D@VOQUIM[T\IEOI[+)M'K1VI^?MTMX9W^Y>#\,O&_XOZE
M_554BSU1..@YHT.ARO=_VC';/<&?;>E0H8NKCU)U-2Q;0V;3"WM6D5(*I1OY
MIYY9)H%SRL2A+$2G*-,I#=V 5"=0<X(P^37QX]%16$3602%=,[O9[/G !R^3
M1V$0]HYTD+/$&K8##ET8K:/ND@<%)VRT9#&1*)6XFJEQCDZC(]W'JGX_'#O2
MY>?7\]^Q7GP50]ZLO4?/\--K6RJOLKFIJ\FZ?I:ZI54SNCA<W=>B+G02"A'E
MFG;JF;HW;X7@DQ'/$;7'Y \EH4#&H3K3V\)QXRG3S?G?G?\ @.WXYJUM;=/G
M5M,L 8?%0M;FTLB36_4]J20]4Y.4@L6W>2H58=CS!Z>')6[.CW*I?()ZI<7-
M<J7+3_<D@VF:VA %(RL+<U,3<W-B1GS7I_(N^;]2X?*08 P!@# & /N_=P!@
M# & /_7_ )?<P!@# & /37U?5]SZ]?\ 9OTWKUU_X;WK_NWO & , 8 ]-;^[
MK[GUZ_[-_P"_ & , 8 _]?\ K_RU@# & , >FO7U]/K^YZ_[?37KZ:_\/7?_
M )[P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8!HOIV[D'-?.UVW^YM!T@1T[6,RL(;
MG/TD.?#HPR+'-(S@5[*/"C^9JR"$(E@B3@) 'B4C+&$K8=@5-/\ T7Y-:9X8
MM/N.W9MRG($RGF4%S0ZHHK5,[;%%93-]-B+K$6)9*3K)<"K!CH(NZNY,JT>!
MB<")'M#\D=ES42:,^9Y^UUIT=G\#OQ]C5C[WMU\Y\)6]VA1_7W%MWI*+:%CO
M/(ZP<J6XR)P.PF2'N9$!VXN_1NC6]Y:?GBE0N?0H'1O<$ZQ$6F0IC$9XU!NV
M?+7XY\_BVI;9VXMJV?/RS\4;LZ=O+R/<V<=.?5;UT%QJI;XA -SN0-BSFRTV
M]5(U\G(CY->P&*HB>@G$!;VZ2!T!'AN:UP&0L5.R)0%N0D(5&U+/A;TU\,_R
M3CR^?M]C479WDQ[(YWHFFTL9A]3'=)0ZI*.N;N QS8GQR@55)+CGD/JJ*5NQ
M-264)U*:;3.9R9]<D*1;(7$YIB->OSB,I24\,SAC/OAX99ELN?.V63MVO7,V
MC/O(!=,4\D<XYIEMV4!0E+L-JT##*Z0VCS_=#U(KL16#6,&FDQ8HQ>+3+VBH
MHU*3']X?(O&]2-, 1:XQ$5IL=SV]44J7S:[>G'06ROZ],_7SZGTZ2[VN&9=]
MSCGJT[MH2M8NU7W<];5Y1S]S_=#':UIPZ#MKD**/<0O-VEA5/.CJM4:3.BUL
M0M:QT7-K4N(1M)!CHWJ2KV^_3R#6F=^^];7)#W'T;/&?R)UW2+1(79FJFH^+
M;FZ\N)@9&YH5*;'']+&^L8!%U:YS*&<WIF4]-+).F*;UC08O=T[66N7C;RCD
MXHW;T;]-1POY=^AH,OS*06QZNMITK.G+HKB=).'+3[*H)WO>$LK9 K6CD C:
M@T\UM)C<Z<) <C:94).B5EN2>-D2-H2JGF,NRMG7,SHX+\/E/O+CXI:BUM?E
M?R1ZB7ERZ#6<6RA7(HQ5P.]BK]K&B81$TS#(D=:OB6\(DQW77-I.$<,E"M^1
MQ,NB%DH?G HN4#-.=88IWLQ(4Y)TVEWIJ[VOPYWUX+U8MZ:]=;:7^YM#E#O.
M^[2M[Q@RBSGQE^B/?_)U[EO5=QAD"W1>,WA13LFGQ<Y81JQ/$B1E2* +72-K
MVQRDJUK]MN;U"8DE8 0E)9I/GWU#6N6CS??"_3S+X\I!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8!35R-T=W1V[*'KHNMI9SQ7O(C)T+)ZMCE3R
MBOY=(K0L*K*^DZ:-3*P%=DMDS1((G-7,U,^*8='@Q!>R%&$HT;Z,:<7S=0+E
MUZ^/AP[\".?!G?/6/=R>6Q^+=;<:0R[&XFPUFZ*/Y=MF1R:"L,(MI'#4LJD;
M_KH5@99(W/4=&E/ A:P-2M&OE;2H,,-):EB59._P^^HRXI^MOLS<G)ER>3;J
M7D=AZ21WMQC"%<L=9E\*U23G2S0,D48:TL"PX%*%CR])NA3!.!CJ.)H'Q$=I
M$TIF1&-<E6"<!>[5@9]/1\O'GX<@U9VXV7KK_'OT-3U1Y+NN9)PPU6L[,U0S
M/HWI&][(KSC5/&(7+(G#7^FZ]+&&2]#6!"GB8OLH1PN(M45GLV=2T[R0:I;S
MX0Q%^BZ0)3E1/+NS_CK_  +:9\.TN;[=L[:UD/E8ZE)H+Q_VLZSNBZ09NB:#
MMBS;KMR9\YW?;]?QF4PB61=DC;,B9*JEI;M$4+TV.CRN5.+\L6MI(FHPTQ6C
M)UH.S??7^>^ Y]]_/3EM;HWR/WG5W0M;P$'1W+M343)>:Z LY-T1/.=+OL6L
MK1G5EO\ *&>0[BLT@D^1Q.OXDJ0M#,_L1TW>C$3:WO1.G"1+-:V?JBW]GJOC
MSY<;$]?(3=EC5_'N5:^IJ5F1&6=1=?TE21L[:2F1P<(W7CD8\SRQ'E@*>RE[
M4<XKX="U[$@/.0.!16GS9Y)?Q6D@\!<?#G;OP-5HO,#1JNYMU,.FNCDC(EZ^
M<^'7FZ5$*BW]$#+T 4^*F".QI2^E3<Q[6DRQ2DVM0G,\><3F9J6-:R4)F03B
M21J77O;S%G[7U\/ROL12H#R_V&@L[L]LZR;:Y9JRJB.=26)0+["VQUCSI(F'
ME.[II54XKR0B>Y(]$2&?N" %>O3.8RIFA.H^<+2_@A#& I*OJ^"^S=_@6TSS
M>O)7M;YS[OK.'^1[M5WY3!T?=ZN$5S+.>/)#1M/WI"Z[C&VR.NU$6/#JD3S.
M'2-/+GJ6.WTDBSY=85 'J/.C>;MVBZ#T(VW:7&'7O+OAVN ROS77OT]SIAP0
M8 P!@# & , 8 P!@# & , 8 P!@# ->6Y5L-N^KK#IVQ&XQV@MH0V1026MY*
M@:12I8).U*FAR"D6%?Z5$M F5#-1+2?],C5@)4E;T84'> 5;$>+*U%_.=E\I
MSOONX[%I*0TJZ4=6$5D=:UH0;74=5.#&>RO$F?F@A!([2?XHT1]''F ]R=XZ
MB3-JMT]XB,,4)-H!6[]O/QNR;/0W*#%??(%@<C"E"F',\\K%%6ILS0,B-Q<&
M\E"E;$Q;T)FVJ;4JY49IL+$<G$M3!%[P00G@T$.\C5TUS"=FGR=S$NA^)F'H
MUHY6A<MG;HFK+G"T(/:<@@0&1,M07*YUHQC00AFEBDQQ3E(F%N>!Z?W)N^7N
MZ9W.+)2F$I]$E*0TFG??>9IKM_Q)<J]M)9]()#'-06Z["55T-WNME/D3B^"0
MUX[1L:9 ?&!RELBB_2^*1\<."J4M_OVY&X#<DVQN"8H0EER+=\V?T73XY7J^
MY3!XS/\ IF9G\D5U8-86-$^6VVOH.C"B<*D:VM)%(PKN8P"B>ND(TY-HW9P;
M' I0_JA+E*7Z4 "4C.3!S[_O_!]Q?P9.I_T=5EV7UU;-[AA- V1+K5HNGQ5M
M7<%2125R-.Y-K29+)O%TA;[/$,,9750V1].<D8S#@DHU#TH=# K0KYG?7R_/
M\6\QE;3/F:DZ9@X6;R?\TR82T8$'7O(73'%CR%.(8U<>41(H%^1^6!0C]RB7
MIBTI$L:% #57Q):M6UZ)3B3F*U":]^ON.%O/OM]-6>OVI6)"BE714VZ)&(JL
M_';9'CZ*6 B#8 ;PQV(SM;0=9HR1/1@4+LU%MYQQ<:"8J1JQ*"@"=TX4P]JA
M.^WD?3:/$C3K;T=672)LS?%,BKKE5BYU-CY3*C2LLFF,9KMQJ%@O=T+VX*"_
MIFTUB^/<00-YJ586C1*40TCL1\"86M67+O3XR+?VT(Z4ERPWU#WMX^^5TDK5
M2EA\=?"%PVFTRUP;BF=SG,CZ%GIE)DZ&THU*Y.WI6AGC<E7'D&.*G0#%K463
MM8/:E0FEM.B:^/Q_/-=V?5Y^6?WX=<B^_*08 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & 5=5)XY)AS[;3Z[T5V';=<\VRRZ%=[2?EY/#J[?6<Z7/
M#XFD<GCD<LI\:E<NB5;RER1D$O42:$^E!C6>Z(TKXE/<3%I4MU?AWG[EOT7C
M_:W\DDN*N3V'C&A6&C624*IR4R2:R))N6.;*B9'):*Q;#DL_.0F(T:E<$LAJ
M-D.FLD7QANU0$(%8@$".^')I#2;-X^CHKX[G_@&'WI)8VGD+)8\957(BBJ#<
MD3Q^U+/DL\F*!)'?G9:,HQ<PRQZA!:O3O[9*13\W"#XD.DFA6[N_?PC,K+\;
M7']N55451SJJ43TPT'6ZRL*=6_.9&T.4)8%S&P,:LU,.-/+$0Y*UH(LP+G#;
MH2J*6KF_1QI>MJ%.C7V(1GCOBOFM;<H0GCNE>QIG5M3%5M,*WN=*FJ* RQ;;
M),^6K1RZ3M*V5K')QK*2.K*Z.4?+$S.+RRHDAB5:G9PNB8U8KELDD[67>M_D
MM\]+]Y=/;@9);OC#>K(J",<HQ_J^Q*^XO;:VJ^K)/0[=75:/4BD47K0IO)&%
MLN%>UDR2,K)GIG;%<H/"T/&AN):Q0UEMR9>8B+O?;U%^/&]^^!Y^5=@*KVB^
M:K[8@EE(N,.N>;+9,8=B$8I?X1N1:IJ11=L4'@-]EV4,%CB/;CUJ@A-M0W!V
MK4:$((].^^_34+[/V5S^G?BOB.VMT;0V_)-!=/*,B\G@C11=K$(F4I71M<A5
M,$&G0.AQ\W:#9.I/O>G$OWVC-M1GNMEFRW+G?\]_V(\W?HEY*_Y-<V%X5Z9M
M*,UY&YG8\A7A@_9%S=3+UJ:.($1LNA]ZV ;/[ Y_>0 =C!:AKTJ31Q O>-''
M'JRV M3MF*,5^[3+</'W=RWSOX6\LD^^/H:I[4Y5;(&@BM$(Y2?(FWR.>6VK
M;;FX75H3-S?$8Q'8LPV!+(4F^'/<3GGXU!S^F3-"XPAOT:N?/<KBTR-$,U50
1N+Y9_;[E_&"# & , 8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g772024g09h64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g09h64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2PT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +!B^$2B#A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   F:T #
MA"24T$)0      $/=@K4H0T#=N&%EU]=/2>JDX0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M   0 " 2P    !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              1H   #%P
M !                          $              Q<   1H
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   1H     %)G:'
M1L;VYG   #%P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   $:     !29VAT;&]N9P   Q<    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-!
MP     (?H    !    <    *    %0  #2    (=X &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
MP,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( *  < ,!(@
M "$0$#$0'_W0 $  ?_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@
ML!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% P
MPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M')L4?5+5.UT&?(J/2Z^62ID38D.>&/+/5>QBBS]==/;?<A)L8>6C%"GLMOI
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MPQY5<=%N0Q4[[L@T5@1IZ::]':FU^3E[\'2KOOW-]^; X X X X X X X X
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MOB)88"^84*\BIIJ4O;+_ +J^<NX+I2;8*%K/ZA8W#K[9*O6%$RJX4!+9]DD
M!,K=P$$VG&/=)6CTX5AK"W,841D?#BLL\E&^N\ITVG#B:;;@K5*LJ[A4X&SN
M0TG7W)N/;-7#3#669$#*U+1[1"%)1G*5^CWAW<MMY?%<9>RTUES+:4PXW;C-
M%?:K<S=IWF9!='+*JN*ISC]S?(/"'"QDQLW1SLCJDO9SD)M)N;C)$4NNBIU/
M)L4.]!-;5+1/S<,\8+$CGDUE0=>:FY]3ML9(%A7Q1C"@RWWY4X2KP[9]&"1[
ME X X X X X X X X X!!)X@OBI;$Z;]HX_4SBM-T_7A&JYV<A5['JVS+!>M
MGWJ4T]ONT4HNAN5:4A:^15(?;6N-;:LLM;#Q-W68FMD@CB?9YHR)D2 [[W)L
MZ/,R]CI5/L,_"NUN=GJO7YF:KI'K]^!EY2)$.DH5[W,)<]V+,?>!<]Q*5^MA
M7JQA7GC@%T< UPW!USB=O;@ZN;?/LTC#2'5_8%ZO\+#" C%!VLJ\ZGN&J28Z
M4)>=;?CQP ;>_+L/"(=<>+"9&<2EEU:T@:I=7/#PMF@MK[YV-L+LS)=C(CLJ
M]9CMPU#8ND=5,/W$V=0-'Q4=+7A DG<2J#3ZT@^J5?5JY+&OXJ"E"QA8%G+C
MJG@(U/'%ZS]<--:NZ06;3_7[2.J;(=XCG6V$.L.MM4T.C3AD,0!?S2(DJ6J\
M#%GD1CYH !;P#I"Q720A'UM*=&96@#IGX X X X X X X X X!'38#($G<^\
M68BT[(GY &VUL>R1-V!GQ:Q3I9>NZB0Q ZL?EZ]#QQM.)AWHRP2#M<DK+&(N
M4U9DOR@\EDV,#R[J]:1^>%?[P/MP]Y4M))>O.L2D[3-Y@&NNU;[MH.\5;7^K
M*7@PF1:%GI>XSPI:ZD+$LOR#)T2Z6PEIH4W'Q1G775%J+]LH84(!X@T=Y*E[
MT27*ZC=M[UD&Q>?+SSZ?/R\\^7G^7R\_N\_+[O/^/R_L\39-JM^-.D2_7G0&
M-8J^R$CLVRZ]=I-BCXZ @PI@>[%,K37IETOZ?ZHX!W(Z6E/M_.=2C*"WEN.1
M<JAQ@?XB5/'%'O2O'=7?+KB09)Y+UHINH<T41B4G?>P*<,7 B[-T8F;M.R*T
M\9M1H2 &U\#/F VN>71+TZQ5MDJ@Z]/,B:Y* 9D922+GWJ] M3\16\D3XQF0
M1#KI;=U'T_O?H"2'F@. . . . . . . . . <U7BH73M=ICM)8KAIW>]>J0M
MWTK#QM#J5X[>]<M14FOF_8O==%E[%^*?>LM"V1-X OMKUU>:YLW7LU% ,Q5/
MGHJ49EI<06)E)7A?/+EOS^P[1*OX:=?WI6>L0$;OC&R&I1=ZNQVO0MQ;1@=U
M;2 U.=(M$T]FZ;2K<O8(NXED.+E9&$D6IZ7<8J1U>CG3<J"]EFCOONIO]P!P
M!P" 7\(._,GT5_O>)AUG_4^RL?[> 3]< < < < < < < < < C^N$E)F[;VN
M,=LBFW86+G:^'$UBM18@,WJL)RF5XQRFWDL>S3CTM89 TDJZ"&'156);KUHA
MA$1)(C TH;E\,OO-*)M[UJFP>#B=I=9:BV=G5;2GU=1CB>UYF=V!3KYBUV6-
MQ4A9$;-: -RU S/SVGV\.R WY,K1E_\ ='[%SY2!@F\Y9^+A3BU^#KSJ\524
MTM2.(K-\JGVXJ$[4\34I7LS8B!L3,*][$D%ELE@GS97A2?4R1['Q#F/6W\L!
M\H7+C6'O<2M6U;M.JXR[[2W2MI@4;5FO<ZRJWV:5:+!;LYDSI/,I8R<D%M_-
MRU^XQL94Y[ ;7L^]EKW%^X:0:7YHR3EILY;:7]KC[I96ZF&,C\G2[CE$2LRL
M3"BF(!^X.1DH_9.H41VQZ;KYN1V!F.DP;;&"2)6R8UVG6]]W7--659JZN,N$
MD0.-80I(-BRELQ=9F&4ULH<@@Z.JV:M7E?T6%PRZP)#>: X X X X X X X
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MR-'" (D84Z/D![. [-3T"XNLEE,BGQM5;[O$=]JK4@D=Y0. . . . . . .
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M'1OW.X_*Y1D]YP?]H6X^I37[7E/ *WP!P!P" ;\(._,GT6_27]9_U/LK\O\
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M-203DP((N'V)Z"B8Q#V36!EX(']+[C"&U>^SY*SAU'J Z$. . . . . . .
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ML#8<1BJ%3S],C\M)I5:QD^-KXDDY].SEPM>2S<D@=27 ' ' ' ' ' ' ' '
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MRM.%9SC A>O ' ' (!OP@[\R?17[O_>8=9_YO^I]E??_ +/Y^ 3\\ < < <
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M \".4!G$>\E"6G"@FSUF+5Y.^^0,?.RKL31C!*Y(RPD3:K3,@3(CHH["SXB
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MEKLDR/B&"]F6L"W4-N+FY%OTF2JG&VUJ/>(RM"59RG%(7=P!P!P#GW_"(OS
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M%XLDAF6O,NJ70Y!0/ML?4&@SU?):]CR4*G#3V<FY']6$JO\ <(>)+_DO/?\
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M#;]M)0J7[<D*-,?1A"'WHH,%/M(PPPVPPMQI:N_M^_QCJ9A?<7BATWLI?HV
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MM1#\&F.&WG-,50D'7!4M(!18TVAB\E@U)<DZ^8W&0OUY]0*9D\!:A3G$MA$
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MUG$@(.RP3[C;:4X N_@#@&$W^MG7TG=8G9 C2VL7]^@Q"H$/<;M+@%[&%BE
M/1.16+8H',PWG$.01"I(25@I$*01#I?Q&/NBK S9P!P"S[EKZC[#'@1+W4J_
M;Q:M;*]?*X/8HH.69@[I4CDR57M46V8TZD*>K\@E)L1)L806 4G#P[K;F,*X
M^]RK5J2:3:6I?+J2;2U:96J'%U\VE.'24G=(O#@@X!A/=W6WK_V5A8:N=@]-
M:VW1 5V3=FH*%V7486XQ<1+O". NR<>#-B&#BGK">>$R4TVE[X[KK.%^VXM*
MG??JR_-J2>E-K2VF],N&],K2VK-I:M23=5\SB[+XUWKB@ZCI5?UQJZFUO7U
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MPB26U&!"$,@6W>?#"Z:['NX6PK=0+C)60>.U$'(+1NG= D9;)#0[\<YJ6V[
MAA+\S&;%OE,&C&(P"]7D:P6HF,<*$D98S!#B\A/?=C/6U>K6EMS[,U1M^^5Z
M7+V!IENS TN;A+E<*JV] 7/$3FU4^W1E9G(F*OE)GWH&%(E:?<@INO&NQK."
M(]QETIH@#'G7/H-U@ZJ6HVZ::I=BC+"Y3L:W@C+9LW9FR&J#K'$XFRIUCK(+
M85MLP>NM?_7VV9==5I[$1%OF"@K(9>1' (& W)X X X X X X X X X X X
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5 *\UAP5VT\ONSJ?X(. . . . ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g772024g10m87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g10m87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+2^8R0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "<   !S@
M 0                         !              <X   "<
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "<     !29VAT
M;&]N9P  !S@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M_:UFXDEWMKK]K&,GTZ_S]G\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #( D\# 1$
M A$! Q$!_\0 '@ !  (# 0$! 0$           <(!08)! ," 0K_Q !2$  !
M! (" 0($ @0*!0@&"P$% @,$!@$'  @1$A,)%!4A%C$8(E;7%R,R-D%187>8
MMR0X<7B!)3,W0E)RD;9#5V*6UO *-41G<W2"L;*S\<'_Q  < 0$!  (# 0$
M             04& @0' PC_Q !5$0 ! P(#!08$ P4#!0X#"0 !  (#!!$%
M!B$2,4%1\ <387&!D:&QP=$4(N$5%B,R\0@70C,T5'+3)"5#1$5256*"DI.4
MLM13<Z(F5X.$A97"P]+_V@ , P$  A$#$0 _ /\ ?QPBY6?%DT?LO?>D:Q3M
M/:>+;.V5%M$<Y3S,&'K7$&E&A)6NSX[A&U7C8U#L>L4GFXST?&SM8Q++=:R/
M'E8T"&PX799(0WMIU]?;]50;<_'QZ\;^159>T>MNPW;G>%-V;KC2%[:!@GJ_
MK+3^QC1ZGA(NB-D:8[J5XMM#L%!%&K6(M,:I;8TY4B@VIGZO7B5JN-8&XK!$
M-"KMQ9=GU3KKU5-0'0KMK!JM45=>K5LN-'$B==@>Q>D/Q_J6?/[*]@@6ENVE
M7M/:9'U+9,>LV&$3V?LS2!_)^ZF@E]?D5:%:U5SY^@B,IA'7#CJ1<7X<]PW;
MU;V%N.NO+=N._G[K_1MI^D[<J75O5.NC]T&XWG5]%4&FV#8!T=,O@I>SP=$$
M!C=I*C<':R0MT1ZS199*4UFQ!99I"UJ43A.R,O(J@ZX:+Q=7;[L"_P"NCS^T
M"=8.W2G;;W+K$F?J%9GTT$?9UMLJR4\:9C5<E:+G*"O3QHF*],AJLQ9M,O+R
MVGTMK2TW!Q\#] ?JBE+8EZSKT"V=Q4+K=?<(1Q_TBB!$GC+?S#4AWYUV$J5$
MPB S\O[;TCW<^AUZ.CT9]SRG"X_C7[!H!7#"L8QB\\<'X3!*,5M8.\;([OG0
MF6$"!G=[+Y"_1[XVV.UIGLN8%^\6(.H/VQ@F";-/)4?C,?KCA]$[NWQL[ALX
MBF+JA_>;4<>P-ID<CMH;%C3;:?>$M245]0W1^P17U.>XU)7LX2]4&Y;#&&<K
MA@<Q'"OSD]S#WE;KN<(A8PUGY.;\QGV/(,S]M-7@K: TV2LP4WXFI+)79BI'
MX6V2-FP714/=/J3-4.#SJZPBLW^%+M_D]IRIV%TF.'$14YZR[5_A8&.B;E>K
M9C#H9)-NTV("5M)W-.W8.RU@)F.W_&A[O^)-@'LFLZ7$",Z)[!"<EI\(?DF5
MU\W&$#<S7VV,S2,SZPK+ ^)[GO2Y/LJRU'0X[[:LI].=SH>T1U;64E(<CY]I
M/Q<\,'XFJP)D5)3]\]K.^J)?Q9<RGBVMN638):QKG;)M9:-7]F8H:.LK!GWL
M\JQ24\]0*:DS"Z2KJ>XC=((*:$T31)43;.Q#$7@/D<UNT+W52XG>;8=?R:&V
M>I#;/8=,9C:QW,-K@BQQ<%]V[%[$0M+Z16$;$0;H<!5FQU$)8=LFQ<*NW&PM
MUVXT6.'AD)\AB$4]&UZZ&G#=?=XKS%?3].39<"S'G;)J<E6Z>8$584-9+$F1
M]OUQL IJ'<>PGH4JK$ZW GV@%.E:I>;^I&956)P(YNOO?AA?OG88.]==<>*=
M==?%9U_NS9R54!7<=5H8FC"-GUJEV,XH] +WBR_2 @PKL6&SK9H*U]"B.K*8
M:K96-92$P@B,Q+=&AX9H([.$V5((WJSW6C?)?L#3B-L+:S/ZV3'F!\B&R^#Z
MX%E!GZJ"M(XT$F66HT<G+98P9=#$G&@2Q&2@R4Z"-GQ#T,H^45CN$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%2'9_9#:]
M$[D]?.O82C:]N%#W,+N1 ])%VRQ+V[KX#3JR6+D=I6*LXK'X3%ZS1:$5?7D*
M1-LGU0]9[5';%^'H#X]PG777STIKV ^*E>=*;$V$(B:8JECHHS;%ZZWZ^EOW
M4R+M9+=5*IFH+9]:N<9NM3A(35Y23M=07$@:^1L,%%;274S*38HHX:ZZ]=.*
MMAS\3[V]_/0WX<<*'^*QM)Z_E*"6TO0DR-);+IFLNR!,=<[#EJ?/V1W&M?3N
MI&-(PY5?PX0A1C=5D; L,2WOQGHPR2BIPY+Y-I1A<OST_K8>_P $MXC=?V%S
M]O,+KGMK<>OM'59-TV64*AJWF>@<J>)J-RN;C$A<*<0]<H=20%B)PX+<0=+=
M?)RH3(V-EM#<B6TZ_';=JBVG%O OT[%]&2G#]8>K/XO'S:[&D''30%P7]9B2
M@4,<W(E&'"(_+;PR- :>D$%/,-16W''D)41<2MN?'TZ\ZYUK=+N'ZV=U#!6M
M Y)$<-N'76Z:UJLV:A3;49FP7TY$FC*H)RZZE4TQ+@S?E64K]F#,DJ9BO2^F
M@^7WZOYIUS6D=:O_ *0OI+<^J!%WNW5_ME6[._/)C2HS4^G;;O.BMOCWTH2Z
M'V$ %!(T_+K3C>9<"4)@SQDK#L5YMYK#$R2OX>UO'F1R_JBOSGNV>LA&F0J5
M3)0G/8&FZ9M?6^!LZH6BFVLDJP[$FU7>PR\U C-A%(T_3E,^A[*?BQ5#%$ 9
MI+3+TAB.DE(7UM[*VTOXZ^&[Y_11_CXD!F\(U2>U%H?9):OW"_I9Q&LPJ!5O
MX0]8F>OW8#:P Y2+1:"@"N03L29J,<4L@IV48=& 2HB+CWI=EC.P*HICH'=5
M.QK?.JM(HM@NSA(L\;$/1F*Y3T5/5D?5?6R\2[)8G+%=Y"K.1B3^Q 1:X(..
M*GO#XA>"R&S,"CI=N(M>ZH]\&M^3=844AKR[OVDSJ_7A6^;%!U4BWK 7LVPZ
M,H.ZS@'$I69J0H58>\PXP8@1*.J=.)S7EM96\)(%I?X&WPNGUW+HORHG")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M*I_4#^9FWO\ >N[6?Y[7?D''S^@16PY47R=88?\ ;]]EI[#3B'FO=;0Y[;R,
M_P 6ZWZ\9]#B,YSZ%I\*3G/ZN<<XN8Q^SML:_9<'MVFAVR\;G-N#9PX.%B.!
M7)LCX]K8>YFVTL=LN+=ICOYF.L1M-=;5IN#;4+Z\Y+BHIC@M'[#C;)!Q0VJ;
MS$M!-$';X>./J-FC6$S 'PP+</9 ]MF:T6)PA0,>&1'L[4B7&'B(8]*$1X##
M+1%EX>I]6#AD$*/UK0((86U!CC1,.G5V,,'L"PY"O#&8,!D<B+$:' "Y4)!;
M8:;1$$$R V.EN'-DLN$6)EZZTC4BTK8$VB:LK1Z>]41$V[2*M4Q!>;(@3(5?
MH8R58W($>;(=@SI8X+4X;TQ:HLJ3#'B&VW7665$7YH@?1^M08N'K$3JNA5O8
M%DD20T:AP*E5P=TMI$?+(2I(UFO,P1]AL,\6!FS'WXR99&5!#R7W%K8@.*:(
MI7X1>!908V3CA7",!!F7!F%(@E<R.DG*&#Y$&)/(QX"G,2GH,&43&QIDMMI4
M>-((067G$.2V$N$7Y%&!)V$DD$)CS ]<B=$3.&3(\^&J4,G21A*,F3%<=94_
M )0Y8^:UA>7(TV+(C/)0\RXA)%XB]JK%?FA!IZQ@0A&RSLBZY +F!XV;8">$
MX7D<$BS)#+Y6=A"DKS$@-OR,)SA66_&<9X1?V;:*R.."*R0L0*!9+ W,> UZ
M:7'Q3AMD<UE\@Z($OR&YY)N"SC+TQR%'>3%:QEQ_*$8\\(L%C:.L\C4F<;$H
MN0Z[%^$$%<6ZO_35VSW,M?A=,[ZA\JJQ>[C+?T3#N27N8RCY;U8\<(MZX18*
MSV>O4NO&+7:S ^OUNOCY!0T:*2$1!XP?$1ER1*ER',X0VTVC'WS]U*5G"$84
MM24Y(O2%-AK(+AFZ\6&G0Q!M3L L(G1B0V:TAQ;*G(DV&X]&D(2ZVXTI;3BT
MX<0M&<X4G.,$7E(VFM!YV!A:P!1A'(,O9_DB!.'#DXK@!\;%.'E,R'FUH#AY
M!D2P2)*QB'"=(PD2'FU2&L*(L#G:FL," =ASL>AX 6>4J#6SF;A7L"+#-0XI
MI<,&2R1^2+2D.H6TJ/ ?D.I<0I&484G.,$6SCCH4O+.0!18<1G5DFT%L4.%,
MCR9(,N^(%GV!A9AEQ;@^>\#-AC#464EIYP:5'S4HS'EL.+(LKPB<(G")PB<(
MG")PB<(G")PB<(G")PB<(JN;0Z<:#VM;[3LLW59@?;-KH[FOY>TJN=,"+=#
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M=-IK3O *\LCKAH"4^ E2=+ZQ?DU4S#L5;?=I5?<="'!X:J5Z"4&.*@95$F1
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M= @+X;L^X)>6H,"6G8![,L9+B1AL=#I11; Z07P>NF0<6[7I 15]--ZTNCQ
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MASE;FW Y6C DA/V7L.)!&.- /FV1@JO(8BD8L]E8]F&5O\=]_7=Z<=_)=[
M )5006L5H2/ URN"1P( #$Q&8 H,%$1&8 L4-@QD-QX< ?"CL1(<5AM#,>.T
MVTVA*$)Q@HLMPB<(L/8;$ J0,K9[4<$5JM@H,@H;L!\E##A XV(WEV40*%2#
MT># A1FDJ<?E2GVF&48RMQ:4XSGA%5[6W??I=N"Z1-=ZS[-Z<N%V)/N1@M;%
M705DC8I#7N9<9JZ)+T=NT.)2TXO*:\X2SEM"G<>6\>KA%F=Q=3M=[AO$';,T
MYLJK;=K6O+OKF@7BJ[1V,'AT49?H.(E@GBJ! M</7D\E.?C!24]XS69^"\VK
MU99?$UNNB6XI%&A7X;O4:Q2#$RUT"PVR98*ZP$+O6'9^S9S<DLBG4V@S-CQH
M.+:T.$;>+U77E*%E]KA(8V^3<5Z'*4=3,>G/RRM_A][K)"OAX=3 Y^DVB)KL
MPX?I!!!E).=LC99%^[G&-E$]S03NVTSK:^SMXP*VV:*['#$-CM65\/;9[Y(8
MJ+^HTA;KW^^Y+GKK3Q5C]S8QG4&U?.,9\:WO.<><8SC&?PP4\9^_V_X\*==7
M6B];",(1U3T$6)2$1!POKWJLC/E.85EN-"A:X!294AS"$J7E#+#3CBL(2I64
MISZ4YSXQGDQCI'LC8"Y[W-8QHM=SG$-:. N20. 5 +B&@7)( ',DV ]U6VU?
M%8Z0UZNF#8O;GXQ(C8+TJ%5Z[5+>V;.R48QAD<-=. @X=J1(6K&,/$2D*(TC
MU..OI2G/G<:?L_S3-/%%)AWX9DCPUU1/44QBB;Q>\12R2$-'!D;W$V &JRC,
M$Q)[VM-.8PXV+WN9LM'-VRXFWD";Z+"ZZ^+5TQN=5A';-?YVKS3SLEB;3[=7
M+#.+051W,H0_\[5!1\-*ARV\I?BO,S\/>A6428T9]"VL?6M[/,STM0^&"C;7
MQ- +:FFFA;$\$7(V:B2&5KFG1P<RW%KG @KG-@>(Q2%C(>^: ")(W-#2#X/<
MUP(.A!'CJ""9XKG9J=MG84*MZ K53V!2(% UGLZW; LMU.4AK%7VI9+T! QJ
M0 :U_9I]@/08>N+2:*Q;$Y3![>?H0A@B[))DI5?T^KI*BAJ9J2KB,-13O,<T
M3G-<6/&]I+"YAT(-VN(/!8J2-\+WQR-+)&.+7--B0X;P;$CVN#P*KYKOO+M[
M:NJM%[2I6H].3(V[;G5:6V'([FV6*DT\E<Z,F\"63$J9UQ;8)R($>,3@&W *
M9XEM]L>\'+&6I<KY#KZV\[V]R-;'@18J%A;LWW.!<-0;@.<TG?IJQVAL=+VL
M03OM[[AWW6!_=X2WZLHT_.M@=/\ P2[3]K%B*[OL#8DZT/5'7!I-@UE6&*L9
M@4JM+V3L&4-D6QJF4>;&.88,1G&U+:]<^O;Q7%8%'>FU2%$'(VG8V,$=!-[;
MU2%?-[%S8-VVY>C4[E7K;6<V%IN;0[&4B.MDJU+AC[O)O'H"%ST6@RH<)V.D
MGWM^OEQ4PPNW^O@?6^U]BMGEZQ7@]#Q;X]P%U\E97'AIVI_.O.4S$39U-U/:
M85WF,1H[+=<LE5K\C,^=%;8=D#Y,4E(#Q(W[[&P\[7/M[+DQH<YK2YK YP:7
MNVBUH) +G!C7/V6[SLM<ZP_*TFP.6V3V$,07M#Q-'5^C;8>WR>M(VN%3FPR%
M-J2!M5U_:+V^19/@*-L.1,5/36E"8B&@^([;TK,EZ3Z&,M..O?<H6N:;.!:;
M-=8@@[+FAS38\'-(<T[BT@C0A0S4OB7]<[2W7(&%VEBXFM<Q[Y/HPZ -L5F"
M$$ZN7N,O1U!@Q:0<+V 1K^/-.8)AP\NH%OEFA >R3;*2& IA17$UUM&L[;U\
M/V;KM<FQ5.P,%9M/))0U"C7(5!FS80RP5Z3)=2Q*K-K3#04JAYQ;4$V GC3L
M5>1L^.^X^**E1[O+<P^N&[DWID \?KU7[?;%V76G=GS&QX&B=.-O*U3>$U*P
MMZ\>=MMNLKKL<M6!9$)5 ^4-38Q,[!],-Z6/5^M%?CN]^M%;6R[[UY4[7/IA
MB64;-C6]*NRD,"I#\9*-_7RTZXUWE$A'A*\RK-3C;15.$^H5#;CRW\*1(0GA
M15[!]WZCMVE#C.B!T\@<L^T=3:VIF;R,;A"+ WL<$%VE-LD",)/.$I$0%H"4
M7VJ\+G. S4:/"8"&80HTDD.@.NNO)%I5%^)1J,QH[4&U+()M#Y/8]="O31]*
M")FAF[6R.H4;8 RMDK 5#)/0*/>=A@*$1S!>FDE61Z>-B1)ZZU:W@DOUUYCQ
MU5MOZZYKI!RJ)PB<(G")PB<(G")PB<(G")PB_*U)0E2UJ2A"$Y4M:\X2E*4X
MSE2E*SG&$I3C&<YSG.,8QC.<Y\<(N!Y^3*^,GV0F405(DJ^&#U4OS*-AEH;S
MK0WNEV"J<IN9'H\"6R\E!;1VMIZ84XW*:0X/M9;#?R;DQ$L,6KDW^GM]CZ[E
M=W'7PX<=_ER];;CWKBQ8L&+&A0HS$.%#89BQ(D5EN/&BQ8[:68\:.PTE#3##
M#2$-,LMH2VVVE*$)2E.,8JB^_")PBX;ZSA*ZT=[;/H7JYJJB:XU(.@];:;L.
M;6.LO83;96R#"40Z:6Y<-QU;8U:UCJJSP(1V9E!VYU*Y8;$3AEC,DY[.9@,:
MZW=>/P];?G>^MM?7=:_C[^*[3V"W52IX&*M5GKU:2:)1PP;-@-#0V"QB7GQ%
M%#,D9,;$\E)SC.(\&+[LI[./#;2L\*+]EK55P) &(.60"&*V>8X/K0PL8'CB
M%AGLM>^]!!PIDAF26F-,_P <Y&@-2'FVOXQ2,(^_"+ R-IZQB#39F5L:AQA%
M:,XKEC*R+?7V1H"PY=;8P!-SG"*8HHSEYYEG N<ZQ.RZZVW['K6G&2+>TJ2M
M*5H5A258PI*DYPI*DJQYPI.<><9QG&<9QG&<XSC/G'"*J'4#^9FWO]Z[M9_G
MM=^$5KEK0A.5+4E"<>/*EJPE.//VQYSG.,??/Y<H!.@!)Y 74) U) ',FRT:
MX[/UYKY(M=UN5?K*34O,(7DL18C?.2$81EW#6%*SG#+&'6LR9*\(C1O=:]]Y
MOW4>K(T&#XIBAF&'T%56&G8))NXB<_NVF^S>P_F=8[#!=[]EVRT[)MT:S%,.
MP_NC6UM/3=^\QQ=[(UNVX6) UW-!&TXV:VXVB+B^ZHDQG/3AN0PO*_'IPAUM
M7J\_?'I]*L^?./OCQY\\QY8\7NUPMONTBWG<:+NAS3N<TWW6(-_BJS3.W>GX
MP\H8CM[%+@H-JB4@;8 FJ=A%:_;K7*OD766 M(-Q:\L9:Y+5VEH#9<$R7XTE
M+,TF/?F"!\V>QQ7)>F/VGH<JW'Z''IVZWK96:G7[N9#(TOL+,B+7;4^<B5^6
ME7T3V7WBDZL6*!'AL..2OG0A".XRA;./4&OAYIUU[KYA.WFCCJM3QV#QV"2W
M5<=BT2A!2].M(LS-L&IY%DA7S!0?+%(> BP9&JE!?UHOB(*GDECX8Z7+>)0T
MNOJBQPCN/J$]4-8W8./VE/#[F)-#]8,,ZEOWUBY1WZ6YL%DZ*"J!I(YK;E49
M>)(-R6&(65-+B>Y\XG+'"*?[791U$KDT^^&L).)$=;4H53JR4LIN2^1F)2M<
M8*#BR9;GJDR5RI\Q;;<:*W\Q.GR664.O8(H-J7</0E[-:\#U.TEC+>T8%1EU
M$\Q3K<S5GIM]H!':=-KA:PR@K VO6NP:]%3+3#KIQZ 3:@*',S6(L\X"ADB*
M4C\W3>:Y9 ]IEZSS4IK-M)VX4??JV:[+CAB<5N]$+'!(K^FR&11DG";MLHFT
MM$$F0BI,.-2I;6'"*(['V*T)INKZZ=J;8DY2+A@HS77=-1ZN6JXFLU1T9725
MB\A2,(3BLA;.9IU#>R%5.D0CUH!PLP&X31"2/(M^38NNLW9E?)).:6E[B-"I
MPJJD$DJ._LLL#@RC$4D-K\O#RK1/%0YHH_'FPQSCL1B2-,-/MH=AS4MD6G3>
MS&HJ^:L8R$(N!.Q.76Y 7AU'UX<MQRXS]8@J7'V#;8<&GP2Q*=7J,\?KM -6
M,TS ]JTPHM/'IFRG +!$B^ 7N+H*R& @H'93)0;9%ZYC";G$I-P=UV^1V\$&
MV#6H>;><!/PT')W. ;#,A8IN>.Q*,&15=RXFP$H0Q\BF+5=PJU^UW4;92X+H
MBLE ["1@.0/C"9==P.4X+EUF>)AN/0Q1&M3X4H"1&Q'GHT"<.D1&'7&F4+41
M2!PB<(G")PB<(G"*KN_+G8#1(-H'6TM<>^;!BN/V(XQ[F<4+7J%Y9,V&0XWX
M]J:03A8L0W[C3JWG5Y;=CRW!RW?-<\8Q75=31Y%R[*8\<QZ)SZ^M82?V%@+3
MLU=?(6D%D]0 ZFHVW:YSW.+7,D,!=ZGV?X+A]%2UO:#F:$28!EV5L>'4+]D?
MO!F)S0^BPZ-K[[<%,2VKK'!KVAC&AS)(6U(9/%(I@#7M3!TRL1,0@E?@MP8;
M6?3EUW*<J<D3)3B4HP]-G25O3)K^4IR_*?==SC&5^,;O@V$4. X7181AL0AH
MJ&!L,+-"YUKN?+(X ;<TTCGS3/L"^5[W$"]EH6.XUB&8L7K\;Q28SUV(U#IY
MWZAC;V;'#$TD[$$$360P1W(CBC8P$VNMJYDUB4X1:+LW9E"TU0+;M+:%I$TK
M7]&"S+#:K0<D8C#1 J"CUO/O+\*<==<5E$>)#C-O3)\QZ/"A,2)<AEEPBXJZ
M1U=??BP;AJ/<SLY52U0Z2:P,Y/=*NK=ICH:?VH692XS![.[T!K5(C2D3&'G5
MZVI\KUQXL!3<S*'!#LTAL&6^'77F>:M[7'OOOY=?9=Y,8QC'C&/&,?;&,?EC
M']7*HG")PB<(HKW9KB=MS6-HUR/MT^BOV= F*]9Q8P:7(P!T0\+)%HT*&7;>
M@)D%Q4*:%:G.-..BE$,%(B<S(<?''D;>(7)KG,<'-<6N&XM):1<6-B""+@D&
MQW%<^NB.\6]@&K/U_M(ZZ;.<U1<=GR!>WMS6[KK+NTDOK397X*E,/ZGJFS;/
MMVHNQ;3$+EJV6LU$J\00*R.@1&0$-=:%9+CUU^BN38NPRJYVEUEUHF:ZLF&]
MHZMV9LD%M%96N(JSC^KBE''V&IQPS)&3:72D9F_ 9TH@0%B0Z6IL9@7+,R$E
M6Q!6VA/+?ZJL.^OB8Z\T9MS8&J5:ZMMXS0-9E;/)M%?* XHDMM ?<=)5!O2D
M!LDZRM%A2KL1J0J8L4AY $)$M"8KJI1(88B#U^OOR]4MI?R^-_LH^$_%AK,Z
MXKI!#1MO&EZ%>ZYKKL4^W;JY.'Z?L5V[-V'JA2E@WD1V']G##FR:T0+ORQT6
MO/"J.J.8E0UEW%5Y$OU?QT]_T2Q^?P%_DKZ]FMBZ_P!:Z0V*6V+>:A0A9:GV
MVNBB=SL@>L0"1\C5#;L ) F&ID*/++36XLER(.8<<ER$1WULLK2TO*:@WCZ=
M%?OJUXSUCZYX^V<9T/J+^W&<9U]7O_'&>%%)-BH-'MP(K6+14:V>KQR$\.,!
MBH8?,'D8,A/I>C2HSS"FW6UX\9\9QY2O"5HRE:4JQV(*NJIIHYZ>HFAFB<'Q
MRQR/8]CAN<UP((/S%P="5]&RRL<U[)'M<T@M<'$$$;B#=8BAZBUAK"M0J=KZ
MA56I5D>M]V*'#AX<>*A^4[EZ5)<_BE.R)4EW.5ORI+CLAY7CW'5>E/CZ5>(U
MU?.ZIK*N>IG> '2RR.<ZS19K1K9K6C0-: T< N4D\TSS)++(][M[G.))MH..
M@'(:+"V31&L[3>@^RIXHX.N888&!X+52\7JCMFP%<,3;!7J]<1=,L@$1>J^"
M-$RQ .#N4 Z+&O&3B(D1I@X7:F],ZFY))-[DG??>3S/BOE<G?KK?U_7CS7O&
M:8UH'J.JZ(-K+<:J:3555ZQ$X)&'45=5)K\BK5C+<IX@Y.)_2P,N1 3]9DD<
M2<.>_-^9E)2\EU[J;UC2?7W2QX3=@5DUM5[4)V-<)M_N4*VCTVMHS<IU?@5-
M=@5FPJ)+@D(E7%C:\)<&JAI"!H,4<'1!BLH;P1:I$ZH:.'KK61U>LPV-2*U^
M%:$*&;/VD. Z^@?@]= R2UZ @W..%HEK53WI@/-VJ<$1<,1BAMU)S$L^;D$'
M,\3J;JN<YQ+G$N<XDN<XDDDZDDG4DG4DZE;O7M):RK5"L^LX-;5/I]W59W+O
M"LQH_;R5T?N;#D2T2K;8[44,V.QRS,)SZ?)E%RTM] UJ*,CK8@0H<9@HOYM#
M2FO=P_A55XA6-<FDE9YJKDJI?K_KDT)GE09&M%,LG==V>JF78I$"6(C)PZ3.
M>'RHTI:7HJU)0I!.O-:0KJ9H9$8J-&T\G7*\=J$.B&J=3[WL&F4,M6!U.B:]
M@P2-$JEI#U"6_%H@\;4&2;X595%?%"!N)OL!Q:89%M&OM%TW6)&TNTZ391-=
ML8J,(A42/9#+=+IT=-CO%M)R*0%3-]%7G&SVP#+DQ\.[$:A"QU7 @XXD/6A<
M1HBC=/2;KG]!A5J15;<2$0BVP"WLF=P[E.22*-L&A]DV?7SI(O?II*Q4G8=D
M%P;#=* =ED*39#K2RQ8!*GR9+[Q%Z-@]1]:;2VR8VU=9]SEDIM0U+6A(8'=K
MC4@X0GIZ[[#OM9MCD"L6$6+LIF.<OONPD6H68B"<!L(A->P9,1Y)+_7XZ*.>
MM/1:L]=I-)?QL2X7>)K<+/#T:L%'YR:< F3ZU7*A)NL00=-VPE$OI"O!28\P
M2$'1-8DMVRR?2Z<%3/6GA%A+O\.K4I%^@N:G,']&MT45.#0\4HI:?FHV)(76
M5;@VNOS&[<-6*V$$K^IZH)A6(PW:0AEAE<B[U*W$&!LR 2_1U70?A$X1.$3A
M$X1.$3A$X1.$3A$X1<3N[^Y=D=R-V2OA=]2;/-K>7QL$KWO[#5]>%HT3IPKE
M65ZJK!!MY+2MP;6AH<#IAXQ(4$K\V2N1&4TZ;G5B>7KU^NBMA8D^0'U/@NL.
MEM-:WZ]ZKH^E]1UF%4-=:[ 0Z[6 ,%.<ICPHB<Y<E3)"_+Y$L3E+?)F2TQ;L
MXL5ES",YYZ7*>=55%*'")PB<(N"VWJDN]_%DA%<:X025K$WUI7^-:UHB%:Y<
M9B:W)-IQ>=H6[?VOI5<R)6F2Z+EZ_P!5; $"1$G,A[!>TMG0<:<=_#=]>OAK
M>Z6\?/=NX?KY\%;SXF'7S8O9?7FNM8TK2%#VS6B=U8D;8,'[%5ZML*JZ]$3@
M=CE -1V&SARC%8L6QC0(.#.V^)ZYM>K,$BX.'2C<L.1#5 ;:\>"K#V0ZT]E>
MX&X!>T(.G@=' D8U8T\!/W:YL,W;2P[0_=>O[:QOVN I=8BDVW]T4"EI4" A
M'XQZ'*BTYFP3U I<F? AOPMZ[QKZW!Y:>?)UNO?0^5B+[]?)50J_PO.UE8#Z
MX,$=/:<MG\%%,UWJ:SZ>>V")37NPINGZ1[<ZO)]E#9&?6<AXAPK8^P]1/I'6
MR%,N2A5:L,AZ6@TP B3%NNN/T2^A%M3QT\/#PYV7?S3VI[?KKJ_JG1\O8,Z/
M>Z%HV@ZOF[/"Q!I6?BT5.C"*O,N0N%;AA<9/?<)CW2T1BQB2,=_*VTDX<CU/
M-JJGC;T^FGT47=%Q18'JK8H@[9R5T,#NS_:2(2M9B"#&%#\MK>EVP\3G#ZR+
M"@(<F4K]=R.($CX+><^&(S:?MQS\?L!]$5E-AZSI&U@35:OX--@",$8Y9J"H
M@5&X00BLR8[$C$@/.'R\Y;9F24>WE_+*L.YRMM2DHRG)85B^(X+4NK,,J32U
M#HG0.D$4,UXGN8]S-B>.5FKHV&^SM#9T(!-^AB.&4.+0"FQ" 5$#9&RAADEC
MM(T.:UVU"^-V@>X6VK&^HW*K]PZ!:!L:1F 4"P4-4*2MR:NNG9A#)>*Y[?JB
MR<6Q=B3&4W[><QI$%,=2,NN^^W*Q[6&=QH.TW,](9C42TN)"1FS&*JFCB[AX
MO9[#0BD+KWLYLA?< ;!9^;:U>L[/\OU(B[B.HH-AQ+S33O?WS3:['_B_Q&S:
MWY71[)%W;0=I:1@G4#KI72XD\(UTW%+@R$$J,F9L]TD*C$!TAJ7#DY8DV-V*
M\IF0RV[[3[#C"\I]+C2D9RG.)J,]9JJX)Z:?%2^"HBDAFC%'A[-N*5I9(S:9
M2->W::XC::X.%[AP.JR,&3\N4TT,\.&ADT$D<L3_ ,36N+9(W!['V=4%I(<T
M&SFEIX@C11*UTK?E:_@:.LNQ@]HZ_P!7O]6N=*UZ2UG'6;B"JWM@;M)JG7&W
M/6^3"MXF(F$_3Z_*AU*K2X &0S)L>;@:B8)/:EUUY=<ULW77G]5."M&9$6K9
M5PH-H:I)2XZ)U]I2I1XU<CSQFO<ZTF[9GUFRPH'U*"@NW%>V>VE%?<4-C(9K
M<=K!!22"_E&E[^5_(>_/DJTB[=H$M!!<&D-<1<7 <6N#20+ EK@#KLG<83G=
M!];L6?KY::=<;[3Y77R/KT0&&QRZB86R5S6U:V*#"C#D&5EM6)Q2;L@R6M1I
MF1F39/<F123+KTY$^$44;DOAV0BVN[Y0GCFAQC.R+*DR6CUSJ^/#TR@);HZ*
M(S9]%4E>TYS.K=S8@8<)/;6?,VW#Y7$-Q=1Q#'0X;;KKX=;N5Q8Z.VM-D[0L
M!KM C9N;W%K.%M;AU]+3VS5M_P!CZFNFNKF1U.5</6<FP)@7S6TW;-$>UP/.
M-?A</>JM+ME&EV\_+$CX9HN08. FAMEEI:B8)Q0Z)94N/76]0;K/HNK6Q[7B
MF]P&[-2:<=UOL$X L%<3+M5NVGJ[32M'UPZY>%6)2!-._"L6OD9--Q6"195@
MJXB0U=VA3Q@.4*WY7'KPY;NN2@G;?2'L+<A>QS878]28G/[#VV1HE!8KDH>0
M_ ^S^QFI=U&9:MEMV^/F+>DYT]7YM56BOB( M<TM6YI*+,GB]@5-KUU_7P4T
MTWZ>/F.7BMRU[TANEJU-9J3N\A7:K)*:T ZGJD?7Q2U%Y%?JC&V#&V+<?)DC
M1QPQ'V+LB6[485\("+<5B_7*9&/@S7M.Q8L:?#?NZW\_%%A-8]-MTZM[2ZRM
M+)"GW/3^N0H"O"31K,FOSQ=:J>I+MK6O$1U)J)(+66MPPXEDC568>?JA"K%J
M42N16&]5B)*OTVMU%. ?K#L\#:C%QI&QJY0+8%V#V+S439FFO[+!V'5O9>Y4
MS<=LAGJLS:-?S1%QK&S KD"IE8MHFC(X41EXL&-M'\P11%H.F>AMKH%9K-)M
M>V0A.C"RFA#]HK-9HDR"6N-EZRYJF-<%<W0U;B>0(:Q$M>TVY72JQ:M,((-I
M+@!EX<K\CUO$5P^O=#/ZWU-7:W;%#_Q9*)7.Z6QD3(=EB8%IV5>;)L>QB1,Q
MYF,[,%!S5KG"ALQR-'7*A0V)"H[.7,M)(IHX1.$3A$X1.$4<;7V4&U/2"MP+
MI7*7&PW##"&,_P"G'S\W.6A06 WC"W')$R1X]>6VW%1XK<F6I&6H[G->S1F*
MCRM@U5BU6'2F/9AI*2/6>OKICL4M' T7<Z2:3?LAQ9$V24@MC<MERCEBMS=C
MM)@U&1$)2Z:MK)!_ P_#X+/JZZH<2&MC@CW;3FB25T<(<'2-6AZ#UF8J@PS>
M[^IN;MK9DIL]=)GA*L"&<MIP)IX]6%.89&UZ)[<;VFW74*E8<2E]Z+'A>WA<
MC9<J\+IZO&\=(FS3F.1M=C$M@12,V0*3"*<W=L4V'P[,6RUS@Z4/.V]C8B,_
MV@9GH\6JJ+ ,O!T&4,L1.P_!(07#\8\./XS&:@$-+ZK$IMJ7;<QCA$6DL9+)
M/M6#YO:\[3A%K]KM=:HM9/W.YG157J=6$3SUCL1R:P.#A HN,Y,(DR4Z2MMB
M+#AQFG'GWG5I2A",Y\^?&,D7"2EUZV_&@VT'W#L<0<JOPN-.VE1#2.K#4>6'
M(]U-A5Z:ZPSMS8P>4TQ+;TH F,N8IE3GMH_$,EM<@JU_&%1\1U^O7)7EKK\N
MN%O&_!=]F668S+4>.RU'CQVFV6&&6T-,LLM(PVTRTTWA*&VFT)2AMM"4H0A.
M$IQC&,8X47UX1.$3A$X1.$7 ;X:!BI8[A]@ZS3+$$BB!A_LPI6NS-YZ@$=I@
M"R.P[N+*^=I>K-,5[?P4(Y8GR,@*N\;;M@>,"(5]DA'FRI %\:5-[<;::^EO
M+AYZ+J3NCJ55]O;&$;H8O^T:/MRG:VOVN-<V&MWBQQJQ3(NQ(3,<^810X90:
M%+D)DP;6R<Y4IUE9"54JUAY]*1;/@I??X[U%5I^%WTLNQ&-8[3J2&4ON->FZ
M 8V>W/E"]F6MT_BEJG;"M=W$*@GSNUVY=$$3X&Q)DQ5B@S)M@6Q*PV>)M/RU
M]_*W+S^27ZL#\U[!/PU.K BR4RVL@KS+/U8LQ83T\ELJX3L[:L<#;!;>X8_N
M=AXGF/L8I7]R'C&Q +IEKV1AR<MAAC 5F**8J7^OQWJU>ZXT>3I[::)##+Z4
M:YN[B$O-(=2AQ-7*X2XG"TJPE:?.?2O&,*QYSXS]^$&I YK3>LSDEGJQU]=A
MQT2Y;77_ %0Y$B+?Q%1*DHUT 4Q'7)RV[B.AYW"&E/Y:<PSA67,MKPGTYXO+
M@QQ8T/>&N+6%VP'N ):TNL[9#C8;5G;-[V-K*.)#7%HVG $M:3LAQ T!=8VN
M=+V-M]BHBN6V.Y$2K'90CK0#%DF!S[D4A&V:#N$J$M./*I$6L08<.4;DM-^M
M4> Q(PMU["/XF5A.8SVA5^,YZCHZE]/E6D9*R)[HWMQ>&L<P@?S-I61Q/G<T
M7+8VN:7$ :[CK\]=CS89"S"&1N#20\5D506VWD0L#72&U[-!N3;1W\IU_5&X
M.Z)2E#9I_KR.LTYUR3Z31>XB-9DYD=+N4M*FU,C!=?B.ISA:4R4LP&9;.&G6
MH2$_Q[_5P7&\_3X?#)5Y8IZB5Q?_ !IJ^'"Y7M#B&F2CDC>Z-V\7_('@!P8T
M&Y^5'7X^^G:Z3"FSDEUI9*B*C>X7TVH7MN"-P<&L#A8AO^)V)/;#M<KL?7 >
M[KAL710]6M].FM3TB@S7RM9ONTSM_OX_:5=-V(74"\2]20@@5K0=*JTOY>"!
MK%H+6UEC#CGXDKWH%')4RTT$E93MI:I\;3/3LF%0R&0C\S&S-:QL@!W.#1]3
ML,#I7PQOGB$$SF@R0AXE$;N+1(T .\P+<+G>H!UA5=]V?KQTOM>PMA[TK]RV
MI=-3N7^17-W7@N0-5F]ZC>L-CGV4;*IM23KN7^)1+*U5,8@L+J+STJ)!L4I)
M%YM'9!T'C8[O#UM[VW;]%V";;3=+7O\ RMVK@$ !UBZVNK0;'0D7 (VO9,O?
MX*5VIL&D"W8"UU]@C7]-!&W#T*T3JC8&AIK8NZ]P4$=?RX>$L>"$EZOI_7\<
M*Y+9#["'GB,\2="C%-177W7'SZ^>_P E&,+;&Y)SPUHCLVWCK7M;JLUA3DNV
MVP>1ZKV7]%Q)QS;FU]6B*>5J1  2V-%3+CW&':W3D.U6@0$@5\AF 6:$N /,
M7'QU(W\-V_TU5<TMV218.!<W4:M#G,X7M^9KAKRONL3>WJ'MV#;J0.JAB:35
M:D$]E.UZ:7O%EV4WLFETBR@A$_9E1NMHK-5,F*3()VX,*&O$@T%*97S$4&^>
M!PXQZ87%4.F;ZLY ?:@)/L5M*3K@1VCW&%L6V:TU#CW ?7<:(D633 !F=5*?
M%ABZL;VC#-1:^@0#8CV.QUX+0)+Q1NP3 QN7OK8#4Z<APWZ[K;]>:Y.U)(:&
MAQ)#1M6 .X-VBYQ W"[G'F2=5)G47:'8>W;AID/;5ANV=ES VVD=BM4$X"X-
M$UH)"Q-:_P #AFOCDC8X\+/L:YL^5!FP"<QZXJL%Z3*R1:I,5FJ53H;]?AU8
MJ/#/Q.[Z_2HI*I@:J4LD^FZM=;;#Z^M]HRUL,Y=]PB-GUX,!(["U\-MN:;6J
M9KTA($L["!203%W18B!DO%F@ !&:\OZ^WQ][(1KZD>7G:_KIY+U7C?6_;G7J
MYV$US);V83UM#Z^T+\&Z5+G6-<;)V9>*?$W/NR4)1%*FG++0,"RNH0-4=D3C
M)%*(EP#0Y;Y$P\T]5/GU^JG;KAW$V#NOL_:]4OD]<2-9UFGS2(L_ H=@JQ;8
MI6+6=.%8IJBD#NV2\UX6N5>+?+MM8(ZZ9F4.+$IX==KLLDE.,<=;NNO)+:#7
MXB_J.@NE_")PB<(G")PB<(G")PB<(G")PB<(O\]GQA/C(6SI)LBJ]2-%:WB6
M;>FX-?0B0S9)@RIP-JZ;>K 5IE2EQ*2-#ER5SLD>6,FFFQ,N0(A(2H&I+%@;
MFR1[:ZMOT]-_P\O@NIW1_IO2.E&E(FMJ^3G72]60K,OF[=O6#+C]OW'MRQ>F
M3;;W9)LEZ5,7F=.RXR''R)DO(H0U%BN2ILW,XC-*7NKB\(G")PB<(N,.P^I\
M8UV@&%K5VQZ:2]YBVJG::W9-B=.-)G>Z-?$,62)6Z ;"W_.S@%>9DQ+/,& J
M>?5HA4#!]<&!#%S)CZ&%.-_/XV^RM]"-=?9=DX$=Z)!A1),Z24D18D>.^3FH
MAM3"+S+*&W9TML=$@#VY,M:52'T0(,*&AUQ:8L2.QA#*"B]?")PB<(JG]0/Y
MF[>_WKNUG^>UWX13CLBZDJ%7VC8NB6_8<EPE'@9!TJ+"EEF6GV9+JB+S4Z;"
M1\BQF.EAU;2GGL/RH^/9]K+KK6-Q2OEPZE%1#AU;B;S*R/\ #4#(WS@.#B92
M)9(F]VW9 <02Z[F_EM<MZU74/IHA(RFGJB7AO=T[6N> 03MD%P_*+ &US=PT
MM<BD.XN[NP]?MUE4#KU<Z_\ 5R;L=YS9,1P>V20SAC/TT!]"E3,**/\ OYS[
MLE;F(Z4(]L;/]U>8_GV.]H.*X8*,Q95Q*#\1/W;CB;!&)&C9)BIOPTDMYWWT
M+S9NA$<ESLZ]79AJJ81%N&3Q;;R":MKF!P%OR1!AU>;[R3;2S'7-I] =B+::
M+AA<GK7O,,R5(0(+Y8B&"-#13<Q]IAPA.=490M$&$ES,B4YZ,.)8;<5AO*\8
M;SLM-F>NJ)X(7Y3S%3MFD9&Z>:"E$4(>X-,DA_$W$;+[3B!?9!L"=%DH\5FD
MDC8<)Q%@>]K2]T30Q@<0"]Q+A^5M[N.F@)WZ*GTSL]N@MI>#M"O["#S[[?-P
M5Z@-:!J-:UNY?M;0)/8\3J@F%'+O=Q#0I5T! )#@*XR]@36*XN\3F" S\+#$
M10L[;EF%,HRV;C3MC:E7M^\RU(I] ZXZ@W!/>/T35&#%4(7DKN@;;4V4@)8+
M5UUJKP]5Q)B\BY\\2B;+-*:)%!>!JF"* Q7<;>H"T],*5>(A:#G=5A6<O=BL
M&H;,QF74]IB]OG-*4%)>MAU4FMWBG5VI5LCNAYV5%R((2H*HT9D"Y8Y@F<>O
MA]5>'6F[?YWT6OY[8=BP&H%FKD>DINFE3+!GM2Y75];IBF:DO1_XXD/:.D2;
MNBFV<$U9W8<KZ4>)Q-H,@Y,9N2);05!S252Q() ) (!-M+F]@> )L;"^MC9=
M"NQ>SR]6ZV[IV7JZWU(-9Z%0+18QY>RB\6,4*+UT(HZX%+@VSU><CG9D9+8Z
M'$(SVU"RA$?+(!C##*PI H-XOX75">P7>/;FM'-A6VF$Z4:9H$H370FJ9 9!
M&3L2 6Z?W'L-*V9%)P"+-@Q$$7 /@,EH.I0%58H-^@OHDV$A")UF='X\?G^J
MH\=/Z]::?>QU-[-&ZG3=SEKS80&T VKNSVE-%@]B0%!ZE L0'=".N$.182DD
M7B=6E2:%8]Y&HDC EF%$(P*I#%2UPC+A(KF]</HHM0 ?$.%V_;M UC5*-7R<
M*V$+:\9M*]BS%0PU,J6S]^Z\G7(8Z(H!FMDHD>)HEVQRX5AMM-4\B[5\7795
MC=BD931.O50_5^\6Q*1LSSL2-//U+:^AF>R-* '7P%+BT6KD#':6[@J?#++
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MPE#;:$Y4M:LX2E.,JSG&,9SSB]S6-<][FL8QI<][B&M:UH)<YSC8!K0"22;
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M/7W'VREBE8B-(8RQ,'L%B#SLMIZ:?#>U5UK&R[]M!0_L?VTO=AB[#V_V9V6
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MS%@^.9BIJ;+53WN6L$PNDPS"H(HG4]# 6-+ZK\%"]D4G=OD+&R3S,[V9\?\
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M#;JEV$LW:&H&+W'@:_AKK^*WM^VER4*!K9VEPY%=Q"JY%J8/B^IPK?RZ 'Q
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M>XW=)+(Z[I99'.DD>2Y[B3=?G7&<8Q/'\1JL7QBKEK:^K>7S3S$7-K-;'&P
M,BAB;9D4,36Q11M#&-:T +5\=8_BB=TL(E]NNR0SI+IPFVI3W7/I=/\ FML3
MH#^?L,V#V+-,S_D""&LN12<?7T<A72D=S.$MQ7/NC(=?UZMYVNL9IP'J?IR^
M.G)7!T7U"Z)_#W!N3=9:]H6MC4Z.IHQL2PO.VC;=O<7G#DM9*Z'W2UV-*FOX
M5+D#!TA(Q,A:W(PR.CPE-34_I]@MTN>UMI;3K147H6@6R)'E-8]G8YYT?467
M([#J'W,5:&9=;ESG"C3:H,<@YF"J"I];JT1W$-R&R;CKKUS"_&MNOARSAQ!S
ML:6L5RL$-QS,"FF;%@A6@K#2O;B/3HHUS,0J9>;PMR6^].G1G&76F9&'WFEJ
MP45NH ^ *AQQPR%$'0(C268L&#&9B1(S*,>$-,1HZ&V66TX^R4-H2G&/RQPB
M]?")PB<(G")PB<(G")PB<(G")PBX'_#4O4:Y]R.R90O?!)W896P]A85I$YWS
MJ4C;'Q5'W[*JM/=L?7>C::"'JJD!68XP6-L1+=%XAHAOMR4LR5VMIT;/UZZO
MYJFW#P&[3=OOZ<;+OARJ*F=[[W:(U[8MR@C:[M,AZ#@0\;,M(*I2R]9$VXHS
M3I 768Z1'?P5/W\TUL&EI@#0@B<)3-L,$1--PS.) ]@EMWC_ $6AB?B:]8BQ
M^IU=+VQX)XW88=2N4 EK\K&5I2T%MP&.OX %N5]+CL6IS;)N< 8U^!<@OG84
M\C!<+8EHK"V3K@>WFK8^?CPW7^7#>K?[E\?P0;5\_P#JVO/_ )8*?_/Y<*+4
M>K7^K'US_N(U#_E]7N$4[\(G")PB<(G")PB<(G")PB<(G")PB<(OD^^Q%8>D
MR7FH\:.TX_(D/N(988891EQUYYUS*6VFFFTJ6XXM24(0G*E9PG&<\(O\WC/Q
M[KKO;M+M/IQT>Z@)WCLH%8;75]:;%/;EKX36=@8HT^9 M6R+(U'#H3#UY$1#
M64 +%6^42M8]T>U%4.)%8D+!6WRO_3GR\[\!=68&_"YW#VE)P;K\4[LP;WW'
M:GM%X'5'2$DUJCJ;6GVO#L:$4@P7!]YVBZ-?SER&:LY 7.4GU19Z2<164+==
M?K=+C@.._CQMY>BZ[ZXUCKG3U/$:_P!4T:IZYHX%C$</4Z4!&5L /:QC'J^7
M&"HT6*EUW./6^_EO+\AW*G7W''5*7DHMYX1.$3A$X1:?<+_3J"'?/6T_ #C6
M%J9PMYS+LB1)1CSF'"A1TO3)TSQ]_E8K#SV,>5*0E&%*P10+DEN/>7A )HCI
M;5\G"<J/3FT)V99X:_.?(B%A;C-7AR&\X],Q]69N,*:DQ7I;*WHJ2*:M?:PI
M>L1BAM2#M0UR/2LF6D*S+-FI./*E2BQ1[&9,MU;BENX;]2(K"W',18\=M7HP
M12!PB<(G"*/-E7V'0JY*(8<B/G9#>6*\'>4XMXJ1<4AMIMN-'\R7FF<KPZ_[
M?HQE*<->\TMUM7/-^U#M"HNSS+%9B7>4E1CU1&:?+F"S.E?48QB<CF10PPTM
M,'54\43I!+.8@QNPWNS-"^1CELV5<N3YCQ2&FV9H\/B=WF)US UL='2L:Y[W
MOFEM#&]X:61[9<=H[0C>UC@L;IZY6:\51PQ:0[8F<@G)B,99C2H;$Z(TU'<1
M+:CRW'GD82ZZ]&6K#BVG%L*4CTY]2$XKL5SMFG/N3WXWFW!(\%Q!F*55% (:
M:JHX,0HX8J:1E;#35DLT\;1-+-2N=WCXI)*9SHR/S-;V\[X'A.7\9;0X/7.K
MJ=U)%-)MRPSR4TSWR-= ^6!C(W$L9'*!L->ULH#@='&5>>NK3EP6C6*O]KNU
M=-V#9*7V\K:=?]H"E5&1Z'U0UX?TW)/=;]Y6S6X"SD>V#^HOX3H5+/R*9'*[
M"@C[U#&"(,VQT)Z6\$9(9F3QW>&E]#SUZY+E:PX7.N\[B/0>.^_@5WIY5Q3A
M$X1.$53^H'\S=O?[UW:S_/:[\@X^?T&_K=9%;#E1.$3A$X1.$3A$X1.$3A$X
M1.$3A%5'L9V_U1UU#DW;"="R#XZ(J7*'SCXJOA*]&RC*D$[K:C$F,%JHS&<M
MX]4^3\Z_EYGV(BF'%26M'S%GBCPBJ&#8523YBS/,TFGP/#B'/A%O\XQ*IUAP
M^E9=I>^8]Y9S2(Q&3(W?\L9!K,:I3CF,5E/EG*<+[5&/8F'-9.0;&GPFD%I\
M3JW6<&,@;W>TUS.\,P;"_BS%[Q;8[A6Y[/43K_8N[]Q%3U18&R+A')ZA^']I
MR:I26WW_ *[:$C+/N,^&PE>2,$2/8=(,.)="3K$RQ#DXQ.'Y(KL8K(<<[0*J
M+&*Z%_>T& 4^T,N8.7 6V:9Y_P!\*M@T?4U.VPWV0V41Q2C,XGG[#\$HIL [
M-J.;!,/F;W6(9CJBTYHQL-.NU51Z8;1N-G1T])W;_P H?M4YDFA=K>R?@0;0
M[<=BM8=DOB!]S*E>KFS)%-WK3FM-6M5BB/T*J2U%1>J];GR5I@FXU:;=DEF3
MMA+564=GPRDJ0I,8CG)#/IH :       !8  6  &@ X 6 &B\I+B2227.))+
MG&Y<2;DNO>Y)UU)UN=;Z=O:O<>M?7@# T_U_H0!A@3Y8%ZNT-3QK4&,]]D.O
MRL 8\,%'>]S"5$Y<N8\44K*Y$EN0YZU9O7NN/7LL_B'V/V5]R$T)HRL/JSG,
M(6IFU[#?C??]1XBKP"%>^C*5(>AX20B+]:'&LY3]W777IS+<Z?H'6]1G8..#
M)-NM:EX>?M]WF+LU@>D8Q]I")$Y.8L-U/WPAR!$BN83G*<K5]\Y6MN2_VZYJ
M:>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6H;!O->UA0KOLJW2)$2J:]J-DN]FE
M18KTZ5&K]4#S#IA^-"CI7(F2&AT"0XS%82IZ0XE+3>,K7C'"+E!TTR5M/;^[
M;" =AM26[7!:C[0F1M94[OAM3M!93*[5?Z0:J5RD:CMU?KM7TW%J8:*5$D(0
M&798HZ1;HE;@+CQ(29LJ>O6[Z?-7@!\;:G?QX^UO;7L=RJ+DYM_X1VFMP;9V
MKM@AL&YUHILD\4OL)JN *$P6JVS"@/5(;%CQ;I=;E62SU@5(T[5K&&UU9)DV
ML0+/-/E?;=^<',"7/Q5N=/#SW<>/'CY!>H-\*77XV[1[S+W+L<H1MEOKE^W]
M#=$4J+ W?;:5V3M7:VESI;<8&EZBP0&UK@49R/JKS?U&EL#J[,E*DQWC$IT>
MKZ)?R_J+=>/K>ZG:75VNML:-V$%V72J[>1(6J6JSB1ME&1BL0?81=4.M#S,5
MB4A;;1"&U,E-QY*<86VF0ZE.<86KA!O'F%[NK7VZQ]<_[B-0_P"7U>X44[\(
MG")PB<(G")PB<(G")PB<(G")PBJ;VW[L]=^D]&8NN];I@9+,O+'T;7U?BKL6
MS=F'\Y0W&KM I4%?U,X1E27H\54E6(@4<Y)8<,E1L9>'\$7-6-U][H_%'D-6
M/N>[9NGG2:8\B77^F%&/O#MV;E#8>9E0)/9F]C<H?K(,@TE"Y.LZ^Y#GH2XJ
M*68#&1D0U*F_X>!5T'(G7R_7CS%K<=W6[476GKSH-B,SI32.K-6N1JZ.J?U"
MD4:NU\W+K@G.%CQ!0^/'LFS$6.]C,GP6(37'IBW)KZW9;CCRJI>ZF[A$X1.$
M3A%IMSV%2M>#_J=SL@P#%5A664RWLJF2\HQY4W ',)>GSW<8^^6H<9]S&/OE
M.,??A%!CNS-N;4:<B:CHJZG6YC;S.=D;+P\,PY'<3EO$NMUB&XLK*6XWG+XX
MA)SF&I>$)E,Q5XSX=?=%K^BNJ4769XK9+H1#78IAYM5:=4.?4@4YAQQR696@
M@Z^G!B=GY=.%I2\N%["U-3GUOY4V5)OX<[:7\U<7A1.$3A$X10]9-ERI!5ZG
M:W@,VBVMY]!"8M><5NKIROVU2#<Y&<8<>;SZLI'Q5*?4MM;:L^^E,5[Q?,_:
MC55.+3Y*[,L.AS7G"/\ )B%8]Y&5\J-+MAU3CV(1D"2>(AVSAE(]U2]['1N(
MF#:>7=\*RI%%1QXYFJH?A&"N&U30M:#BN+FUVQT%,X$MC=<7J96B,-(</X9=
M*S(T[6D4'.79[)/=MMXE(_TFP$4XRB#A2585#!0_&&1D-&%K0CV4)>4A:T^I
MIES,=.2R7V74F X@_-69L1FSCGVK9:IS'B3&;% UP.U19?H@T0X30Q[;V,[E
MC9WL>\%\<4A@;UL<S7-B%.W"<+IF8+E^%Q[K#*4D&H(((GQ&>_>5D[K-<[O'
M&,.:TV<]O>&4.>K+44X1>:)"ACV<QX$2+"CJD2Y:F(D=J,RJ40EOSY\G+3*$
M(S(FSI,F;+>RGW),N0_)>4MYUQ:B+T\(G")PB<(JG]0/YF[>_P!Z[M9_GM=^
M.?7 =:(K8<(G")PB<(G")PB<(G")PB<(J[[:[;=8]%44ILO;6]]7TJDAR$P-
M,-DK>(D)6='^GYVO#X V1-*&+'&]2<.UX3!G&DY5C'R/G.,<(N35N[W=WN\\
M=X%\-G0\C6&CIOOLS^\':]HAK*D$1B5*2LIJJB9PY?[&-F,X7D98&Q#3B)6$
MLE(M=RA3ZL'B-'B.* T\.)/PK#WBTL^'[+L5J!?5D%5(U\&'QD M=)%%453V
MN#HIJ*1MSG\+KL-PAPJ9\+9B^(L(,-/B0<,(IC:[7STD;F3XC*+M<V*:6GI&
M.:6S05T3MD1OJKX:W3RL6B%>>W^V[[\2#?C+^9[58F"Y!+3X4TXYER4Y4]05
MUW-.D+]YQUJ0NZ'CS<WUYDN#(TI2E)N"Y=P7+T,D.$4$-)WSMNIG =+5U<FI
M[VKK)G2555(2XDOGEDL7.V=FY"F.9FQS,D\<^,XC45G<M+*:%Q;%24<=@!%1
MT<+8Z6DB#6M:&4\,8V6@&]@NQX<UN\B,@ -8:=J&GJ@-ALP0Z[O)8CX@#6$X
M;8BBJ/46T8#?*M82B/"E>F&C"?0G.$8QCF;6!ZZ^?6FA6/J-9-@7 %;=D[5_
M%#K/R[)^(S6&1"71<20Y):"A%0B"&X$-S#TAAZ2Y'7*_CW9>/4^OPF:];^/Z
M?%7KKK?8\%;ZKTZJTH>D54Z^)KT#'C*HXN$S%]Y>,>/=E.MIP]+?SC^5(E./
M/K_-;BL\JBV7A$X1.$3A$X1.$3A$X1.$3A$X1?Q2DIQY4I*<><8\JSC&/.<^
M,8\Y\8\YS]L8_IS]L<XN<U@N]S6BX%W$-%R; 7) N20 -Y)L%0"= "38FP%]
M!J3IP U/)?WG)1.$3A%JE[I5<V32+CKJX05DZE?:M8*9:!S<N7 <GUZT"980
MU"1.@/1YT-<H;.DL)E0Y#$J.I>'8[S;J$+P182EZ?U1KIYJ50]:T2GSFAB0_
MU.MU,$&*NC$YCJS"DE($"//E,..1(SSZ)$AW#[[#3[WK=0E>"*1N$52=J]X^
MM.EM@VK5^P[Y*$W*EZJ?W'8A\&IVP\S#J+5EK-19ALS@04C#(7(@>NE1B#*(
M/>E6Z<W9Z_,9#YAF1K\HK8VOPO;U6E"OB0=3RYRH5N/<;5'.VDXQ6"0V?K+8
M<%[6]DF[5*:,% ]O+DUM#&L2!O<00MKH&W;'AS1>P07E0'7Q7H)*)8_/X:E6
MCW)_T0;5_NWO/Y?G_-@IP@WCS&[?Z+4.K7^K'US_ +B-0_Y?5[A13OPB<(G"
M)PB<(G")PB<(G")PBC/<&Y=6: UY8-L;HO5>UOKFJM173UML\U,$5 S.FQQT
M!C*L)<?DS"!"5&@CX$-F1-G3)#,:)'>><2C)%REOGQ/K;V9L3^C/A.4T1V,V
M Y%'JNW9FWL%PO5704,PPE]F58S[L>(6OUU9AKQ)BT:KQ)#K;JL9DY)OC3(*
M/.OZ\OGX;U;<_*VE_4=;N%[J<^IGPT:#HZ\/=C=\78_VT[H'V$*L78G:S$>0
M[65.,K;>KVF*8GW .JZC$^8EQQT0&SDJW#E28>";(M](J/5%TSX1.$3A%K)N
MZTZMH4NPVJN THQY5]6-#A^<8_[LJ2TK/^S&,Y\_;A%7;87<+5-.CQ?P[.1L
M$B_*]IZ'7Y6&HT.,A/J<E/E'XZXCF<YSA$=B+\PIY?K]Q<=M&7,E0+[NNODO
M3#LF]MR0XLZH0QNFZ&5C1Y<*S',1K%>BXR6VA]B:)"L.+$"6Y4=>/&2+RI",
M+;DPI#J<I5PHMXIF@*!4R/XCGL3[Q<UKP\]<KS,5837OXQGTKA_-)^3'8:]2
MDQU0XK<AII7M9DN)QCA%-W")PB<(G"+5K%=ZE4E,(LA\:'=DM//QV9;^$OOM
M,8SEQ;3"<*=7C&<>A'I1GW7<X9;];JL(SJ69<]Y.R<ZG9FC,>%X))513STT-
M;4-9//%3M+I7Q0-#YGM!&PW983+*1#$'RN:PY?"\ QK&A(["L-JZYL3V1RO@
MB+HXWR'\K7R&S&FWYG7=^1EWOV6 N44YG7/<&<M!U3Z-K9SRETTM'R]JM<?/
MJ3E(IE7JR)%OI\9S+=3A]YM2?3[J5R(K7DGX_._;.3'@SL2R#V82G9EQQ[/P
MV;LX4Q+@X8/$\..#814,M_NV9HJ9XG-[L2,?44T6X_A\"R1^:N%+F'-++%E
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M'C,M1V&DX0TPPVAIEI"<>$H;;;PE"$IQ]L)2G&,8^V,<(OKYQG\L^?Z/^/\
M5R @[B#Y:HG*B<(G")PB<(L,0L=>$XRHJ=#C<)_/,\E#B>/S_/WWF_'Y9_\
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MV)^*/"#7$?;UD91V2).-(4K*?0_7M>WMC./4I"7DISZL;+F/+D)/>9CR^+$
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M'*\RMVW%@%HX]HMVC<C:)(=9K=;-))%V@U9O'Q(+1[;Z-0=:[7:E_=IB7>[
MNIX]S[8Q(0-JE<V"F8QG[J0RZ9%ON)_EYCJ^W,:[M'PF0EE)A^,22<'U%!-%
M3<;$R4K:^I T_P!#+A<?EO<#O-Q/ R+NQ>-P(N&PX;C4C]#NL_#867/"TA:=
MQ<%3NX]F_BA[-2_$K4B)I8?(QG#"]8=4R=WL\=*L9\HQ:]E;/M=>?<3G]7$E
M&LH_E.<K3';7XQC$U6>\RO:X8;EVAD.U9CG2YKJ'N;<_F[@Y/H&$VM^0UC=3
M;: (<NS'BV66G^++F2H\*/ 6 '76TE1B#+>&U&#<BX'&HE\ZD]L=O,RI_8.\
M=^-\5]M#I S1[_>RE(TF68CI^9=;M6I-::DJ <]7TI;4J>!R=',$8?N0')L=
MIU;O,%5X[VC5\,S99:K#*-T4G?C!L@5S,3= 8W=ZVCQK%<XR08;4[&U^'Q!V
M7\4%))LSG#JK8[A_<_>+*E*R2:'+V<*Z:)CI(6UT5#343Y6 N8VI;"9I#3[0
M F$;]LQ[0;J0L[I7KY5ZU-F;,I73^MD"693$%.R-2:B#5PD/R,81C(R"L%3I
M< 3+89?3B3/KY6N29T9V&R78F2(:)[^MX-B^>*&@=)E2JQ!U&Z:7O*7-V&9A
MSS2LJ UFU)39DCQNBQJCAD&RZ?#JBEQ6*&H[ZHI)H8JG\#33#\[9=QF)\^8\
MN8O2SLD,3:C*,-+%1.B #F_B*:J;(T5+2XM<Z*VU&(RX;2OQ4M\ZUJ$E#]PZ
MMV7!-O+>99F^#IQ5UUU./NZM)<[9<)>2O'KRIL3'\>?U&\9SSMR]I7:CA;3)
M6X%D7& '/_@X;5YTP2J<UH _,,<RVZCC<=76_&R- !!<" 3EAB'9?/OQ_,N#
M$WTQ3 'U89K_ (CA[=W*VM]X"MM7/B!:4^69B_2G0D=K"4)B0_$9EC'C'E#<
M><-"MHPG[8QA/A/C'\KQC'GKQ_VA,2IW[&+]EV88"/YG81C."8TTVOJP,EHR
M=HC\K39UB.-PJ*7)-1K1=HN"&^X8C08KAA!)T#S-3R!MN)U ^6<1W]TX_;P]
M>8Q-^EDFT8D&W7&5IA27?7[;2F87SL1Q&/2GU9R2;>_6SC+"7,--O]D?VA(W
M5E/4.R+F.BRRUEL4Q+$7TD&-44FNU+3Y>IGUDU=10?P^]FCJF3R-?(^"FD[A
MS7_,4>675$>%Q9TP6LQJJUH8J%M1/@\MS9D%1CLC(*6DJIK/V(Y(S$QPC9--
M&9F*P4/L'J*:VAQJV)0A>?U%/"#B&\_V^]@:IGT_VY<\<V&#^T3V036#\UOI
M'$VV:S LPT_J7OPKN@/$R!9C^[S-SAM0X9'4LM</I<1PR=I'AW=82?0%;!&V
M_K"5XPU>:ZC.<^,8DSVX><Y_V3/8S_\ /CF?I>VCLIK+=SG[+3238"IQ".B/
MJ*P0%OF;!=.7).;802_+V*$#>8J9\X]X.\63E['H4(?(*O6^O+@Q4I4\]%*1
M9RL84M*$X0Q!<D2'EJ6M*4MLM.+SG./"<\RM9VF=GM!AM3B\^=,M.P^D:'SS
MTF+T=>YH<]L;0RGH):FIF>Y[VM;'##(]Q(LTKIPY7S%4545''@F)BHF)#(YJ
M.:G!(:7$NDJ&111@-:272/:T :E9D/9 -@'Q2@<M"GP9C>7([[+R<>M.%90K
M"FG/0\TXA:5(<:=;0ZVM*D+0E6,XQF\$S1E[,>'4F+8)C%!B&'UL?>TU1#.T
M=XT.<QP=%)W<\3V/:YDD4T<<L;VN8]C7 @=&NPK$<-J9J.NHYZ:H@=L2QO83
MLD@.%GMVF/:YI#FO8YS'-(<UQ!!69PXC/Y+1G_8K&?\ ]L\S8DC=_*]A\G-/
MR*Z):X;P1Y@K]<Y7!W$%18]DN*D3Y(N.3'ODX2$NS!S,R.Y.BMK\>AR1$0XI
M]E"O*?2IQM*<^K'C/WQYQT.,X14XA5833XKAT^*4,;):W#8:VFEKZ2.0@1R5
M-(R1U1 QY(#72QM#KBQ-PNR^BK(J>*LDI*F.DG<YD%4^"5E/,YO\S8IG-$<C
MFV-PQQ(L;[BDHL*@X\S28^'C'WSF5-C1\>/Z_+SJ.6KQC"* $UV*8=1 :DU=
M=34P YDS2LMZI#1UE1I3TM3.>4,$LO\ Z&.6IS=HZY'YSB5=ZPA2?.,MMF(4
MAW&<?GCVHSKKGG^ST^?[.:?7=K'9GAQ<*O/F5&.9<.CCQN@J96EN\.BIIII
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M(<DY4@_DP*@-C?\ BQNGU_\ QW2+OLPG#&;J&E/^O$R3_P!8<I%%:MUD"PG
M37=%$83XRGZ94@$#.,X_+/F*/:SYQ_7G/G^WF6@P7!Z:WX?"<-@MN,5#31GW
M9$#YFZ[3*6EC_P G301_ZD,;/_2T+=68[$9&&X[#+#>/R0RVAI&/]B4)2G'_
M (<R+6,8 UC&L:-P:T- \@  %]P - +#D%_)$6-,;PU+CL2FL+0YAJ0RV^WA
MQI6%MN80ZE2<+;7C"D+\>I"L84G.,X\\.8QXV7M:]MP;.:'"X-P;$$7!U!X%
M0@$6(!&AL0"+C4'7D=R^_.2J<(G")^?Y\(M&=U?K5X7-!NZ]I"PQ&6]/GB55
M0%].FSY&,8?G2H7R'R[\UW"4^Y*<;5(5Z4^7,^E/C''",*=#)3G#,/,$KW22
MP_@Z?NI)'_SR/9W>RZ1W^)Y!<>)76_!TA8Z/\+3]V]Q<YG<Q[#G'>YS=FQ<;
M#\Q%]!JH(.=,=,2W7YM/:M6JRDC*LO3M;V@D$:?PK'C+4@1*62!KC9\8PN.V
M.90XC'H5Y3]N8%V2<&BF_$X4[$, JP=IM3@E?443@[@>Z#GP6&ZPB MHL;+@
M&'ON8FS4CG?S.II7,#AR<Q^W&6\P&"^XJO=HZ0W2*^[*!$]3[*8]7NMQ+]3Y
M5!L*%)_ZV+EJQ\5/GSE8Q^K+*,JPIS/J=QZ?OC/T>/\ :S@(#,*SLW&J5@LV
MCS)3]\[8XL%2P2AV@ N^(#RWK 563HGN+F0X=57U'?4[Z&8:WN:C#W1/>_\
MZS^-SX+1,"=UZI:5B<+[0:XBQ?4EN;1K(![!:^BMIS]I>*R33%*"AR/S6W,G
M2)*$8SE2%Y5S)?WKXBP__;/LOHJP?\-B&!1,D>_365\M!-'/&/%U.XCB-RQ_
M[+Q/#Q_"J<Q8>&?R=Q40XU1- X_AYPU[&::ATA=QU4;&NW.YHFQZ., [UJEG
M$>] 8DD3=-7KZN9?E$78TR+LB!/%H(#,Q6DH5/G!I&8D:"MN4.>1,2^OF7H^
MT_L(GIS253<3PVNKS*W9?'B$S\->R,=T!5U#((8>\EVF,%2U[1(":MT=,6/6
M.GQ?-+*^D%/C%%5P,,8=))3"A@D+WD/;71&,O9L-MMO@<&M80Z+^('*US'9'
M<CGC";UTAF9_JC[>,,JSGSXQC"7W<YQ_Q_\ \YC'.QU]MC-.*MONVIL!/P%4
M#X^2V$8OF;_XF3W[OY<2JFZ>&T#?]>2R2.PV\U?\U)ZCD/OGQ\ENM2/5^?Y8
M?5C[_P#'_P#[S[,Q'LGE_DS;B ONNW"7_".J/#W^?+]L9E&Z+*\G^IBT@X[O
MS@:]>"R#6_>P*O'IJ'7F?_\ D-YB4^KQ_P!GWLY_//\ 7^7G[_E]_N']F#OY
M<Y5;>6U1TKO_ $5.OZ%<AC.9_P#HW Y/%F-, _\ J!ZYK5=C=G.P]4I%AL&=
M::L%MCH;:\G8.V:[:\C<R)<>(F2BNQGXLLJXE3^$-1VGOLZI+JVI#3:V'.Q#
M_=; X55=G=XH8 Z6I[VC-,US&-)V?Q#'3]V7.V6M#8W22.<(XP)'M(ZU=C^:
M8*.>5N#8=&]K1LS1XI!5;&T]K0X4X+'2G71H=I<.(< 6EJ/M5OFUT,)8)&D!
M-[;EYG-9LH39U'J.2'R4Z1$6IRK&9;T\?)94RIE["U-,REMYEQF&([[3>+)!
MV:XF[\9@F?J2.@G:Q\#):"MJPP%H#F&H:V$W:_:#HY(FRPF\4MWL<5<-S%F:
M6CBDFR\RL=^<.J(,3HJ7O-E[F_YM(YSXW"UB;@.MMM:&D!2?CLSL9C_ZRZT7
M=K'V\_2[I1S>?O\ ]GY6<WA7]/CQG[_;Q^?.(P'+4G^1S[@3N7?05<%Q_P!I
MKEW_ -Y,5:?XF5<1'/N:NBG_ /0\>/']/ICMG+8\_/\ 7;?S><>?.1M7"ET>
M,?GE*H]A;]6/ZLXQ]\??E&5</?K%G;)[O_FXG) ?4.IS;U*#-DC;]YEK,;;;
M^[HX9@/5M0WCRX:K^?IF5!G[$M2=A!'C^4J?J]WT)_K\JBF)7G&/SSXQG/C^
MC\N<ADN5PO#F3)\_(1X]#<^0?$SXI^^-*W_*X-F.'6Q+\*?8>K97?#51^%^(
M7K,A>2U8)U.X!0<)#Z8)]<"21*R)<7*</QR-1@0G28I&<^[AM:9$]YO+:<3H
MT+*W/8Z4>!X55U<^"X;F[+F(9FHFB3$<#BKX8W4T)V 71ULLC::I?$9(A41Q
M[+HC( 23;:ZT>>*4U,C)\-Q&GHP#W54872RO>W>)*.)CI80;.V27/(L-MK-H
M[,FX[N==T_\ /V>PQ,_TXDZ_O:,I_HSY]->7C[?T^,YQ_;SM_N)F+_#%A[^6
MSC.$ZWW6O6#?P7=&=<O_ .*HJV?Z^&XA_P#QIG+])[P=8\Y]*]CNL*_J?IE\
M;S_QQ^&<^/\ C]^0Y#S0-104[Q_U,4PEWQ%<J,ZY;/\ QZ0>!H,0!^-*O:WW
M3ZQN?R=I0\?_ (E;N;7_ /97$<^9R/F@?\FL/EB&&.]=*TZ>*^@SCEP_\H^]
M'7CYTH6M7+OAUWJ@^).'V,I=GI4Q$;(VJ!Y'ST5G*%+<G2<V)5?B)C-^G#?I
M;E.RG'G&TMQU(PZZUB\2P<X#&RHS/B6$98I9I!!3U6,5\;8ZFH()%/ RB%9,
M]X:'22/[H0Q1-<^61@V=KY3YRP:-@=3.J<0>7 .BI*=X>QO&1QJOPT>R-  '
MEY)T;8.+;8UX\,M( )9@DC,H/81(XV*DY;<9S('%8C,Z$\IEU*'6E.1WVUJ:
M=0EQO.<H6E*L9QC%RQF*22(NC>8WN87Q2,EB?LN(VHI8RZ.6-UMIDC'.8]I#
MFDM(*V:":.I@AJ(B3%/%'-&2TM)9(T/:2UP!:2TBX(!!T.JS'/FOJG")PB<(
MG")PB@7879_0^JMDT?4.P-BC*YL38N16*K7GQQZ;[R3YW\+5QXV6&"IH.HQ;
M1:,*K%5EVXF#C6BR(< @'B)9MR&DBW'<O_1!M;^[:\_^6"G"+4>K7^K'US_N
M(U#_ )?5[A%(MIUW0[O+#3[A3ZY9IM>D*E@Y1P1")/BWU+:<6N&Y*9<4TE;C
M##KC>,^TMUAAU:%.,MJ3T:O#</KWT\E;14M7)2O[RF?401RN@?<':C+VDM-V
MM)MH2UI.H%OA-34\[HW3P12NB=M1F1C7ECK@W:7 VU /F =X%MRYWE]TX1.$
M7Y2A"$X2A*4)QYSA*4X2G&<YRK.<8QC&,><YSG/V^^<YSG[YY  !8  <AH$
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M5ZG*KMQ2L?TY[2]H_P!\?.;LL9:?_-E_!#_^E4(^4 7(X9AIWX?0_P#DZ?\
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M9VS:-(O"IURF4.6 1+BA10HRJ,X[9*_/GZ];R/NFECSN.>ZVOQZXG7]6=/\
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JOU[??R%@-K:<_:X%_2_GN&[CUUY5$X1.$3A$X1.$3A$X1.$3A$X1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g772024g11w74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g11w74.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2I:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *CZ^$(%#A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   F:T #
MA"24T$)0      $/=@K4H0T#=N&%EU]=/2>JDX0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M   0 " 2P    !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              +B   #N
M !                          $              [@   +B
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   +B     %)G:'
M1L;VYG   #N     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   "X@    !29VAT;&]N9P   [@    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-!
MP     ("     !    H    'P   '@  #H@   ( 0 &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A0(%H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,"TP-RTR.50R,CHT-3HQ-BLP
M-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#(P+3 W+3,Q5#$T.C4T.C,U*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,"TP-RTS,50Q-#HU-#HS
M-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z
M9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO
M=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*
M(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O
M;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-45!
M1C4W-S<P1D0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+WAM<$U-.DEN<W1A;F-E
M240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-49$.$)#
M1C0P-D0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HU
M1D0X0D-&-# V1#-%03$Q04%&04$R-3@Q034U-#4P.#PO>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F-R96%T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU1D0X0D-&-# V1#-%03$Q
M04%&04$R-3@Q034U-#4P.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-RTR.50R,CHT-3HQ-BLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^9G)O;2!I;6%G92]P;F<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-C!$.$)#1C0P-D0S14$Q,4%!1D%!,C4X,4$U
M-30U,#@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,#<M,S%4,3,Z-3,Z,C@K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HU1$%&-3<W-S!&1#-%03$Q04%&04$R-3@Q034U-#4P.#PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP
M-RTS,50Q-#HU-#HS-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E
M9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-45!1C4W-S<P1D0S14$Q,4%!1D%!,C4X,4$U
M-30U,#@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,#<M,S%4,30Z-30Z,S4K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-41!
M1C4W-S<P1D0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-49$
M.$)#1C0P-D0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP
M+F1I9#HU1D0X0D-&-# V1#-%03$Q04%&04$R-3@Q034U-#4P.#PO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_;
M $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .P!,0,!$0 "$0$#$0'_Q  >
M  $  04! 0$!            "00&!P@*!0,! O_$ #\0  $$ P$  00" 0$$
M!P0+  0" P4&  $'" D1$A,4%18A%Q@C)#$*(B4V47BX&3)!828T6%F!F)FQ
MUM?P_\0 &P$! 0 " P$               $" P0%!@?_Q  Z$0 " 0(#!08&
M @$"!@,      0(#$00A\ 42,4%187&!D:'!!A,4L='A(O$R(S,6)$)28J)3
MDK+_V@ , P$  A$#$0 _ ._C '_^_P#'_P#; .5J-\XR72*OZG>;\S>R//'.
M[WT_@HLARV"XS(]%LMXYGS+M5AO4GVCIK_7+:01W7L/2)Z1!*O8,='76=K')
M8VM4]Z.Z V++MB-:OJW#,N7H[WZY]/#QXY'Y1O,7MU[I7GR7+X//\T[#'5CS
M_P#Z;W^G105<YIP[CM1Y3Z;@NS<VF'XRQR$5SN;OEML_,K!9>:!.R LU9YV)
M) T>+0E.PDT\WK[7Y]":UKFS;7XW_/'K.F<BZA"T%,KXZ(D6_+PZANW\G=Z3
MJ?ZM2>! 5KU1<P*/KIE04\OH_4]1)S_3$S[C%YEJY-V=D>:1/ZF=TNM99\](
MD%\<=5[=9V?651[K:ZUU"V>=?1<CRN)L] YXYSAJT5UO@_$NK"I_ISUNNGX)
ME,KTF6BT*38B$%M#A;VEA6U(U+\5T5_._P"/Z(1!^VO^D%=)\S1/-C8'XY_3
M%,7;[.2 <;ZMJIG'H>4 C6A'B8.BDP3MNW,6DULK>]++4RS#M--D_P 3.I(6
MT(OU[.[/EKL,E&]\UP;Y\K=E^9+YY*]M3/J:=F8.3\?^N_."(>JB69%B]#\O
M&I%5G72C P]P5;EV9V2=E)=O1>SM,. A_?'#/D[TVI/X<NM:]B6[N?IKD;V8
M(1Y]B]-]&Y7W"?X_H9J=(F=U/MM*_BH%),J%Y[IE*M,MW>$8!V[K5CL8=MY6
MQ5Q);2F%Q,EZ6YD-MIS<8TH@#!ROD+ZR>Q#]* Y)71J-6^5]ZZ)=ZK_J<,4+
M9ZGSN&\NW(*XTZSIYNY-N6&&B>M6FLATV9AJG#V&23_-OV+^"<KTHL-:9[%[
M]T7=GG/H(&I(J,%;>9\Y[]:8^TW.]P0EQ>E:IT7U#3*2CG_,T\_7$= "AO\
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M1?A.,]7JH%$EK [=@X.,Y:B[VRNV:S5BQ4X@::M->K<NU,QR(YPMIK6F"TY
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M/D:8HU6/2N3O'2P:/$79F3L\%P%N3I_5+#YB[Q#7.KU;^.A(" ##A>J)YD)
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M&)%IH\Y9&8- T<Z''K8;G)#1+H;AVW&E%;&9G-]R]\M=02<90, 8 P!@# &
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M/E(^%T* \)';8&/)2^H/9JU(=)6VB<WW+[R(2<90, 8 P!@# & , 8 P!@#
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M''^9+MT [-QD>U-02;G3)F*<+ 4ZIE#D,>^TT!/PI)PK37%-$J&"# & , 8
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MI%.9?%8(:C6-0E5B&5!!#+):(/44:3.;[E[@DTR@8 P!@# & , 8 P!@# &
M, 8!;MKM]3HD$9:+Q:*[3:S';&3(6*US<;78(!1A3(0:3)>7)#CQ=E&D#B#:
M?(1M\I]D=K[G74(4!:(7;N-RG/;#UJ'ZKSN<Y?4XZ7EK-T*!N5>G*;!1L#&)
MFIHN3L<3(&1(C47$+;DC=NE)4.$ZT0YK33K:E 1.>)JK8_?'HDKY0>R0DC&\
MFK(D]S[XZ^6603;#E<YP4_N/M_I6;B"4_>'>NP$!N#5EQUD<J)HR&FM+DQ':
M]+-AK6O8DLX=_P!]O5'_ )AV/_3]P/ -A\ 8 P!@# & , 8 P!@# & , 8 P
M#G7]S2=/LGR-Q%'EDT^NLP]7\US-LCR4>W[Y'=O23T"XG5:(ZES[R\:WR 1-
M!D(;1%93WV,+:E6I<4TIXZFB/1X;B7/6O7\'11@ACZ=ZURJK@7.5LW3>?5V,
MYP_'"]#D9VYUR( H9,P("?$CW,R0DAQZN_* 2<:;'-3C@+AHD@"2,EUDL=;@
M']HZMRYVRUJF-=)H+EPND JUTZJ(N->79;95D-*?59:U!)D=RD[ )80MY4S%
MBE1R6D*<V3I"=[TNEQ=@?E;O=%ZS79TOE_2ZS: F"IBJE6KG5DJ]N16[*(S^
M P790BYZ%8L4$Z0R0[%2XI.AW],HDHYUAQ3+@&A_QU5F:IUM^0NLV*_VKJ,U
M$^Y'V3[]=Q*<!:K(X]Y,\HE-DS ?/ZI2*<P\*.^S&L)@ZK#L*#"'60R^<LHP
MF<WW+[L$E^4# & , 8 P!@# & , 8 P!@# +7N==&M=:E8(N1GXD<QE"EGUB
M?E:Q-,_JO-EIT)-0I(<B(AU;"62DL$(22*X\*]I;#SB%;J%5T:L*BA2J.+:W
M*U*%:F]Y.+WJ=2,H.R=TVKII-6:3#5_TVOL<[S4<7[YD^*_&_P NL5R)\K\9
MYWQ?I_R%]%?M=CF=V"5)I]9EJ)XWJMB-.=>"'G7 6;!T&-ABTCUR&"5%MO1L
MP%(1$GRMK23VABX1I4:4*.(KT*<*%*G1@J=*M4C"\:<8J4DK)SE><DEO2=D2
M.4;\;KF[V>5^/+C;MX6L=&D;"QD)" 5Z!CPH2&B(L6&A8N,&2!'1,8 (@&.
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M:N%E6_Y-\I&-DSC=&J]+JB7Q626XT?\ AZQ$L[!"%V0T^;LDPB<WW+W!)IE
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MWBFFY6:>?+N1L;G5&0P!@# & , 8 P!@# & , 8 P!@$77+?*OLNI3UJ./\
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MY\BJTJM"K4HUJ<Z56E.5.I3J1<)TYP;C*$XR2<91::::NF<A--76:9[&:RC
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M3T?G=-ZU1;3S?H-=BK73;C#EPD_ 3(VRH\\(MO[?HXA*VGFGAW=-E!EB/C'
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M>_V:;<'#&$04^4&DS1*8J,T).=M9WTO4K;?'7AP7@3192# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"QNH4U71>:=
M$Y\B2<AEWNBVVFHF&4*<>BE6> D(1,DTVE;2EN [.T4A"7&U*4UI.EHWO[M
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MV._2U,I]?K,E=9]2R7=S5J-AH\(F?D]NFFO;-E'"B/SFF/?D_*40MP#(^ ,
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MWY-R[I:M*Z)SJD7I2:U:::E5OJT+8MZJ-Y;C6;I5];E@B]ZK]M9AHAJR0_\
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526@,R8 P!@# & , 8 P!@# & ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g772024g12v69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g12v69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2-(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (RR^D 0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             $N0  !%H
M 0                         !              1:   $N0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $N0    !29VAT
M;&]N9P  !%H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M+VX[@; ^ZI_I_8*Z=S&;&_3M_0_S5?HV5+<Z+TMW2\4XQL8]I=N:VJOTF-D
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M#J"$Z*U220
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!@P%E P$1  (1 0,1 ?_$ !X  0 " @,! 0$
M           '" 8)! 4* P(!_\0 5A   00# 0  ! ($" @*!0H'!0(#! 8
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M&>([^TU&_L*K>?2<G$[.M@K;NGM7M%@V]W&HOLZ\FQM[EW.*D)4K_EM[A_\
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M'Y\\S=3.<'>UU/T)!H]R)\89ORM+YCR6U6ZFU8CT>QVN12F'W8X>1TGG(R.
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MS6OVF![RHP4\Q4'%PZ^2F?D\]5=@_4/%!+5.0W3AG5B *W7J68!0.?IS D[
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M,D+<>=^:E[SH]-XDMTW%3%32.'<L(SN+]1T3#S<MB[%MFR+E-C*N^R*3LB@
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MLV6]5EP?%Q;+2]._9,F392V33R<S@"FU!L]@(V=^;R44LK'?F4$#9F V/?N
M0IWV'>#,WS3GJ8M4J-2: /DB:)3ZM2A4T@^7F#*E7Q-<'RRLIIAB23DPP\2'
M'?(2&8L5E^:ZVN2ZU&8;<<4AEO2<5./1CJ4QZ:J$9B[+36E2LYV!<JBJ"Q
M+$;G8;GI-O,U#/U&Q+M0S<O/NKJ6E+<S)NRK$I0LR5(][NRU*SN5K!"J68@
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MG7M_^C/XA_M%ZHQ'GZ\!Z\?R&Q3$1B(Q$8B,1&(C$1B)AG1_^3R^?^QEH_\
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M[6.ET8HA*?Q JW4PFEHP,=CO*^Q^/;CR@\S>OO#",Z,IMY?!:QP]JFB.AS:
MV+?[V)J.,RY.G9M9WY;,7+J)IL#*.;LRRVIW65HP(&W5=7:#R'J/WD8<KJ?)
MD/4?/;8^!,ACPC:[#;:!U"58.3GN4/#>]=;"MP;%9W[+++K'6XBT]N \^PWM
MH+6$[8I4!YI>XT]RNRY$5AB/IO;MQQMBT8N=IJT:I1J@LT/2KB^/C+CI2+,2
MLJ'"D\UV2>;,<$<U8R$5F9M]O&,Q97)K:O:VP;,=^8AR"1_[HVY1YD$@;=3>
M'.,FQ&(C$1B(Q$8B,1&(D4]>X]6.U 0E=M<DC&@@+A7;P/<&1JY)?2>JDS9
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MPJK4*"06"<E,P[$W(,<GATN:8EL!G)<T,-)H4+D&F8R)3D)MU4V+CTKB[A;
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M"+@YB7<%7MF%JO9&/$.<^ZOS"\M<M-24]BJHU0]FO[5[&#E54;^35EFQ&&4
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M++CXN9)&S)@Y^3!<8?>@RI,1Q:H[[K:T3K M&I-;-V6S5VG58#8[G)BS+A8
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M%8ZU..,4"]&FE3K/,EW+H8 W*5/B0!]B09FQ!5B90+ANOW'I\>G\_*3Y_/\
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M(Q$8B,1&(C$1B(Q$8B=0"KX&KC&0M:""*Z'CO3)$<2"&PQ(QA\C-D$B#[,"
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MVKSZUV:S<;G<,N%2(49Z;29-Z"]'CRJ?U;EM,[)S*TQ;0"&B(FGC]'O MTL
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MBWI$F2^XVRPPTA;CSJT-MI4M6M;U=1UG2+-/ST35-/=VPLI55<S'9F9J'
ML)))(  ZDG:;.@\'<74Z[HMUO"_$%556K:;9999H^H(E=:9E+.[LV.%554%F
M8D  $D[24Q?IWS6@8.0OT)P]*T08B5)5U>AZ4E28[>E)5K9[YZWK>MZWK?[=
M;U\MYNKJ^DA5!U33@0H!!S<;<';N/[64]O"7%9ML(X9XA(-CD$:+J1!!8[$'
MV;J#(IIOI#SQ'[!VJ>_WGC#,$A%YEJ!,=ZA2&XLW<,$7:EZB2%G--2=Q7%H;
MD:96O;*UI2Y]*E:UO5IU;2AF9K'4M/"L,;E8YF,%;E1P>5NTV.Q.QV)VZ;[;
MRWS>%>*&T70ZUX<UYK*WU4V(ND:@7KY[Z"A=!CDH' )4L!S ';<#I].V^E/.
MLRK5=J%WKC4UU/8^%/*;A=.I4MQ#$3K],GRY#B(YMQ3<>)!ARYLI]>DLQXD:
M1(>6AII:T^=0U;2VII"ZE@,?;]._=S,=N@S:&).UAV 4$DGH "3TD\/\*\3U
MY>:UG#FNUK^H>(@#9I.?6"6T3.K107QU!9['1%4;LS.JJ"S &<FO0W 'UZ;8
M[EQYYS>M[TAKIE+<7O6M?/>])0;VK>M:_;O?R_9K^/+$:IIC'8:C@D^0R\<G
MIU/06> ZSGCPQQ*HW;A[7 /,Z3G@=>[J<?QD&^8NK4&%2;E'/]JYB7E*[AWR
M9%VP?K(93(^=V6\/QWEQ_P!(IVWV"[OXDW E_4TTN 0CL1_Q#,=$M_%B:AIC
M56=C;10/;=4+*^;5:6Y]5S71P2*RJFID4#8\W)V@/O["UXBT36_;<1CI&J$?
MJ/ARL']798'/3P]I=5J;]D06KL5EL'>C HP!$P_J1XC8/97E4O4+7R0GSP95
M^P?IF^[<B2K.PYL:&5!T,BABZ0#S;A!T+N(DM'>2^G1?[^MK8&;16YEKV:[H
MST7X38J4Y_;DWOVP/)7R\BUV"H@L4Y>=6_M[CHNUSH^-5C<#<949V%K56IVY
M6A^P*,&H8C 7W"PVO?0<E6%8N#FEE(_8\NP:W>WG2H8FW\TOH/\ -](B%J?8
M8;TP5(&OR6&G1DI"W8^YD<C!VXGY;UK\3#DL_/YZ6TK^++O+5+\3)KY_=>BU
M2R%2P!1NH)#+N/#=2/,&<3I;WX.JZ=D=AN].;C.M=Z6JC,MJ$*P5JK-CTZ*Z
MMY$3&_-P9D#P#C(UB5,G(3S6G3%S)ZX[DV5)*@X966_(<BQXK+CCLN:\O;FF
M$K<^>EO*=>4XZO%I=8JTW!K4LP&+0>9MBQ+UJ[%B H)+,23L-_'<[F;7%-[9
M/$FNVLB5DZKG(*Z@RUHM.0]**BLSE0J(H YB!W  ; 03SKE<P)[W]']-W82<
MJ'9^)\13L#(,%Y$""N<3N8:-N(*==_*X^HRN<D9*=H;6J.Z?FN0OPRRAC\57
M8N$:^(]5R^UL87:?IP[)K'**6?)K'+63R+M[*S;@$@VMR\O,_-T.IZPF1^CG
MA;2?9J4?#U_B$^TK12MM@2G3[V#W*O:N&&IU)U(YAC(+.854<DH^JPSASDS$
M1LV: J3U#B7SF I$2-,6B7V&D"EM+7,@SVMMH005+:UIG2DSHL-W:E--N,O;
MFKH;,,*++*_Z9IXYJRH8AL_'0CWE8;;,3W=X![MP:G@Z\8^M,YHHR-])U_W,
MA'= 4T3/N# (]9YMZ@I.Y!1G&VY!%CTI^E*4_/>_I3I/SW\OGOY:^7SW\M:U
M\]_Q[^6M:^?\6M?Q9:3ECU)\/@.Z07PK_P"JZY_/KTG_ /.0<K\#OS_]H7_]
MBJ=#Q#WZ)_\ M[3/PNGXZ>6O(_I_ AM;MR05;M-OLH:XA-UX446?A"Z/8+A$
M0T4G:5+#J2]6MP%K@:2M<<D^[M7WH\?:8RWR%S-.2J\5U6VW+?7V2.;5KI:U
M0'8[U]4Y25!)#'Q ,:33I]FD<1W96$<C*Q,/$NP;_:;J1C679^/A.6IKV2_W
M<GM +#L&J4;<K,#/&6,YZ,1&(C$1B(Q$8B,1( ZUY=X9W(X.LG4:4_93(H4@
M) F-6V[U_3 Q$N5.3&W%K%D#0WMZE39+OWWX[LG>G/M[>VTVVA%;F:3I^H6)
M;ET-;8B=FK"_(JV3F+;;4VUJ?>8G<@GKMOMM.ET7B_B'AW'MQ='SUQ*+KCD6
MHV#I^46N*)67Y\S$R+%]RM!RJRITWY>8DF!P7PRO&@"?9"$7F)B0[9R_YQ+;
ME=+Z;]J(]^&:C;CP=Q+=$>W&VIM<C>R#T^7IY]U.I6HR(\=BNJX3T*IKF7$L
M)OL[1P<S,V#<H&R[7@[';F]XL=R=B!L!T>1^EKCO)KQ:GU>A1B4=@A32=()=
M>=GYK.TP77G]X+^S6M.50>3G+,UUZI5@5(K(&GUB$H;7:R)@@P@]4N=/5"%C
M8Z(L*-N:3DS"$O;+#:$;D39<B2[\OK>><7O:MW]-5=%5=-2\M52+76O,S<J*
M-E',Y9FV [V8D]Y),X#-S,C4,O)SLNP6Y67=9D9%H2NH676L7=^SJ2NI.9B3
MRUHJ#N50.DU,TOX=MN*<W]#D+=<[X ['8.M_$"N/F\:1OS,OEW&;#Z(OG<(?
M->U5JNU%A+D:Z/T7HK1-P@>('3M559+#'%P0)61(CL^_/\^[UZ$U_'K\.[UW
M_G("L/B3LG1^>WD=4/*(#S2W$\0C?,)3G<2V\FTUW&_;Z5S2T0S\:7SVQSP>
MZ5S4'3+I$J=FZ#,KEX+.=0--[K05")VITR)+MU^'EN)T/TK<.9<#YG7Y![TC
M\/\ Z%P\K7Q]"KLP%4N)'^)/]?(5C<=R$[2G(@JHV9N=!CI$3;<S$1&8CE_Q
M,)MU\OA]/6^TG?N'7X_/KU^FTC,UY)]7W;M%^N)7C0:I+W3_ (@M*_'U'7FZ
MH<UMD#O8\^WQV;4551AON5C,7%,&J&^S&>X'X4=CILN06#5Y(Q+I06]>7W^$
MC?\ CY]WW>/C_&=H=\8>@HDF-9Y_(!_3*[5N@_#\O%AXXNTT%3G7P' O/=EY
MQT"M0V[*?@TUXM1>AG*[>J_!NY8'7;$2H\1<$MI2H4K'KUZ_&)^*+Y%[#SPG
MS7H9GQY7KCSBL]O]GW![R#7+9Q<@W4H_H=_GA#E'1 ,2X'*KQR:7Y\(K5YH9
ML.T>'R:W#Z<>W3%G0[#JR,?9X_3X^O ^8V,_;Z\OI_"=&W\-CIL_D-AJ=YY7
M0+G8(7PY_0''.7CIQ.LGQ7-.N=-ZCT6\<\Y?3"%B5%6+8YI5++6: #O<:()$
M01U>;;&$AX]>V-3(DI6/PIT$"7L,/D_*JG5JF<K/PFGYHVMSJ=78!2[>7O65
MLZ'W0R0@1YL/4LV YB]6Y*CLMI<NW-QX@@/,,D(.XC,;;=P\?#IZZ2>_O/G\
M?C]YF%T_QAW.#U#CT1WS]7:Y<N8>L/8/6+=[89L_,Y-AO%+] TWTS'H4\1!B
MD7.J$Y@V9TGF NZ@K7#!,5LG1:[$J3%KK$;1BNS\^LB5P#_"JO=XH?,:MTRI
M>UJ7=.2\_ <],V'C_=/#O(Z;>)(MIS\<3 F>;\[B=(Z#7'#.BUA"DN[#H5Z'
MJMA!Z5^).FK7)<>O7K\I)^0'U_,F?;W%6>VWWLE'[I;O+7H7D73+#QUJBE]\
MJ^+3P[S Q#"UCIW07QU6D,/M0)EQ2_!DAKU(*0Y+HB*Y;8@149LP$)/OI$W]
M^:FIS'GCAK)-BP12+7)>?-SXULZ5![+9V):*J+3(9L/6QCCH[IIIMW2DDKY
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M=B5#J2-P&4G<<94:A;6;EL>D6(;4JL6JUZ@P-BUVO7<E=C)N$L:FU48AFK<
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MS,;D/I;D.NMHY459E"ICZ@MBYV,B8V4EMU>18EV.BT.C74VWU6<AKY04M=0
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M,(GM#1Y/1.M&JX:L=6N=5E,D6VH5C &9$=R7'FPI3$*9$>CI1)S-2"L4.6E
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MP)! VW((&_=OMTW^$U]DZR<\P=<\F='L! 5.'W*G@_&79R8&+,&@I)%*'"G
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MOM:WKWVYE(!_S6'56'Q5@&'Q$U[>&T"^H^E>A^DBM_/)ZE:?/?.*ITSCDPO
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MM1('Y<(B1XC:88V/M3NW$B6&Q$_GRU\MZ^6OEOY_/7R_9OY_Q_/7^?Y_Y_\
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M3T?Y_-"G-.:VG5WK84/IW+=CW :3@5L<?(IR.SLJJY;*[#2[BNQ6W!5MCMU
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MFZ;5K3[#<R2A"];TEY>ODK;<^ &WAU(_*#T)'E);_7+\3O\ <4\S?[>%C_\
M"#CKY#Z_RB/UR_$[_<4\S?Y_^?A8_P#PA?Y\=?(?7^43^?KE^)W^XIYF_P!O
M"Q_]O\D+_P _M_T?-U\A]?'Z??\ =$?KE^)W^XIYF_Z_\/"Q_P#A"_\ ._\
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M)2E.M:1.1B)%?;.R4?S_ ,PM76^BR"S%4J46*[,:KX$Q:; 3G$R$0.$!@*Z
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MN[=CF<71?R]U#T7JL2N66@C& 71G781M%:*0ZI:+5HN9.K+5HT<9!,6,MN!
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MVER5MY:CIA6W7&EZBDCH"#)<LX",'3T L94X;/36#S@[3I29#$R2LMJ5#CQ
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FI*=:UK6L1/IB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g772024g13y87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g13y87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<04&AO=&]S:&]P(#,N,  X0DE-! 0
M    )O2^F7(X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "@P  !-P
M 0                         !              3<   "@P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "@P    !29VAT
M;&]N9P  !-P    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !S6     0   *    !3   !X   FZ   !RZ !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
MGP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3
M 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!
ML0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q
M GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#
M9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^
M!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/
M!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS
M"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-
M)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B
M0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@
M5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>3
M9^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO
M>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6
M=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_
MY8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AI
MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M74GTKE$NFL: F8M+2,RET!S+$71(/'W!ELL-1V8NF3]GO]/7R)Z\R;95WO\
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MJ-E,;([[:9 P)#A#BAM5[VDV_)?.:%1$9,WFK^MDJ<@*<,>S%HW59M)6Z :
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M^GY(IXU%R_MCY9S^>Y=OP@\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
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M1;N91) $;;NU=D&JY\P.#HN5M-/N;HMU2+EMHLKKI_?V33VVWUT_O9QC'\^
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MG"F>,^I-]QKNN\1)IN&0T7=&$,$<RTAC?02W6_2:X*839 ;#? / / / / /
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M:RDUE-93Z-9ZI]SZ,C_^UK1F+*-5-O(9,E,@4F(0=;56LK/2C!.>"X2VL=Y
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MQ4JH"DZ<0E 22;QTTCE3540<T#/GFPDDGLDKKNQ?80<Z[)*ZY3QE/?&H&;>
MC<O;]: +"C]4FIB(&V'*F[9U'HNZW63?E4WK26OV*;53[.6>79!A 9N^'L5'
M.CU^RB,D=M&ZS<,040 DCP$/$.A*(#OQHLW<=9 "9H_((N$&R&;1V/D#LABD
MAVB4D$@F1D@Q<FG@24Z;QPDF+2=X;'-=A:F</<91],KQ0)!9RV*D)&:AS"2@
M'TMC; 05D,79F!SF1 1D@W?Z 2)D*BXW)"V)K<44T$NWS9! CL-?X9J+9:./
MMTK36&TTFLIM8RLM97BLIK*[TUU3,6;W-4#N:F*V:6K6[FQ(\W<.S\";SB,K
M3,(U:,6I-TY+QA,GL;'(-1KYD0<K/&**:#%XU=J[:(.$E-Q#@Q.]Z5GV .\#
MMBO)PWE!@K'8\^ALO!2D:7D(0#^ZBH!D3!/GX]4XRC&-Y$L(PYP1_"(N"NC;
M9BV<+I@2OX!X#S6],5=T+9_1<T>\24[TY8\OAUM2EV3+=U1VHY-P?&)=F1J*
M24E32'0@@K?(\)J9;94'O>;7PB+:LFZ.L<SLQ2:Y3>O7]N_RR7X^'^/3[OD>
MCP!^=_!!/W1^*_<WX@;^XOP6'> GYW]&C^7_  ^'^=GV!7Y#]1^/P\VV=X:?
M9_49RM]>?"';> K4<ZRI\)>[;G%)2>2:SDV4?(RE*$5=8<TB-:,I;H04BJ]K
M6!&XV2A5;_N)$8\="T9:=%N%&&B)-9% 8[:/%W?CXOZ+/7I\%U;V67L91BY-
MI<JQ&4O>E&*Q&+D\.32<FDU&*;E.6(P4I-)UV"_%@XB/@9I)!]C2W\;$ T7D
M@W1Y4%LL"5I1N<3[-5PF0T<(>PU G<P:6V1]$, /Z[:'T7QE=MKC.C1RW=*#
M'H6YH:_*SZ2KUO9E4EB1*/;'9+%";(_'3\.E<7E\,-O(Y+8A,(?*APF2Q:3Q
MPVP=#RH8T-9O$-]-%]-%&KALX6 B/J#_ $I<%_[X)+_DZZZ\!<'P#P#P#P#P
M#P#P#P#P#P#P#P&MGXC'Q1^>/AJ1"%R&X&4KFLAGT@R&CU>USB./9?LP:MMG
MA:3D&T@/@6@^/CDL(MM7*SK*Q D\:,F2"NF'SEB>PZD;06*VQ\3R)1.V;I>E
M::X;GP(-,JVYGB$CPC8W0<+/LD"L=DW3U@1I[MH%@DE"/$'VG/L"(93=(.D$
MK)FIM/1U$$7K]@;4XS&(W"H\%B,.CX6*16.#6@:/1J."V04"#$L$=6[$8($C
M4&S <P:(::(MFC1!%!!/771-/77&,> [SP#P#P#P#P#P#P#P#P&'3"-&I*W9
M(A9W)8*HU6557<QMI%G:I#3?3&FB#K$GCT@2T31VQE1/+1-LIMMOMA7=77&F
MNFIU;3KS4:=&%GK>HZ)*G.4IU=/I:;5G7BXX5.HM2L+Z"C%^]%THTY9;4G)8
M2W.C:G9:94KSO= TS7HU81C3I:G6U6E"WE&3;J4GI>HZ=*4IIJ,E6E5BDER*
M+YFZD2SE>T#UP0^P6]]R11@ 1;:*D2+<4C*QV&RSA59H#9!P3&'K-2.BN$G/
MY(3]&<*+8(-32'TML_*-5]F'$M]Q=I&OT^.M2="PA3C.O<4[6&J4.SG.4Z5E
M1M+*AI,J5S&2C5_$VK34IJXI7D,4W]?TCVK\+:?P;K/#M3V?Z9&XU"I5E"VM
MJEW/2+GM84XPJW]:\O[C685;9PYZ2MKO.8P_#UK*>:BS*Z^>;!LNB[RJUC>,
MM(EK0J&>UZ$5EP^'-0(LQ*03D:Q)D5(;#P9_+)-17+0CHS>YWV%O'WVD%'6&
MVR?TS2]&U*PN95[OB?6-9I2HSIJTO[?1*5",Y2A)5E+3]*LJ[J0491BG6[-J
MI+FA)J+7RS5]<TS4K6-O9\)Z'HE6-:%5WFG7&OU;B4(QG&5!QU+6;^V[.;G&
M<FJ':J5.*A4BG-2CG6K+LMJT*2L"01!7EYG60&SX^7;5Y.:XFQTRB?0J7(47
MML3K<N!TASI>*G6*&K1HSDB8P<,<YWBZKY83KZ''?GRQ\>_Y8^_QQYSK%MR6
M4TE!IY:?,VT\.*46EE-IMR32>'COW-2W?&17<;ZN/VX.G5\VV$D%/''SY)1I
M&1S_ )^Y_IM[-C+;9#_]7"#<,ETK;QW7.RIY &/9(KHJ&4]D;A;;KHV]GLUG
M;XO"W6RRL]&7EC[O\R/O0G*7NS]R4744:;]W>4U&#C*.8+M(J4HN,^6O4RX0
MLP1>=$S&NY!6IRE*@"[5X!K(U#I&(FD-J43S5:%7YB8BR4K14$/WL]F4W<OC
MDBUK9D7;N",>*'%I.QKT>+(3'GTW^/=C[YWQT(DFI-R2:CF*:;<WS17*FDTF
MDW+,FEB+6>9I/%'7,_3>E6(C 02Q!\LA$R.;<F;O[_ABDPYX#NZ>CD!9K6=*
MOVH6!V-"',L2E1AQ%-F%DF1T8<#!OU&</<@XNPNO?]GYOS6%CYD]WE>[YLK"
MPN5QQ+F;ES933Y4DHM23DW*/*E+80^*3&>U19C$_3VQ\H*+'HC'HP?7"CD+0
MQ&5&#)&;M6$F1281D22E+<H0C")E5SE86'%24>_7:&!:_JOCC9^.^SVV_P"[
M^GPWWVR90;4FU4=-\E1<R<DVG3DG#W$W_-3=-Y]UJ>)M0YFM>0_C+J<T#X0-
MKRJNH>]YPA5&5W):WD<6)S)_%-($)?A+/F\-GT:MB.@"+FPVPN%8:C7T+=/Q
M36/!E$R*.V) '*QI>*VP^_+>VWAL\]V^^_0R:AB2YH945-3Q4YIRGV6:6&N5
M.G[[YN6*;4_YDTZ1DM2<^7M4U+6T1D4<:0^5P;X?5<<K0UE7DC4D)6=RZAHS
M<CK6T0&P-BR)BD)(2G(O$&$N=-9HT??F,D6C1PHPV=#B*L=2,^VG<4PN:B-E
MQ '9,I:2)NRADRMNRBP "/Y;&UN1CC9"F6XLQ%;34GH<G/ZUU-;/*Z4FAP*:
M/HEY2T?AA]:Z;KX+/@NN5YXV?5/NPWG*,4HN-2,V^J49IQ]R$MW**3]Z4J>S
M>].3_IE"4K$6;S/T'T#'VEH0;).I;)>])/#(%&</B$<ET)H:I><[[H:"Q-^8
M&+.9 R6L*<S>13!61QI[F31</=9.51I[DU'A[C>&!].4\7.Z[HM%]9$8M<+&
M&@:S!L/#$%K9>1B),=5Z<9#6DTD$G(:5/*6R#4"19TH\K)FLZ5'%[',R18R^
M*K$Q#'?L\;=?'P3P\;=<;;9QE9SE#'.XRC.$9J"DFHN>>?EE&$L5'%J+;?+B
M&8J?+*44^E$<^7Z^C*00=4$:G.3=,=><U3G>S9(G% 3>43KHPL>:6:?'/@)H
MQ*H;-12+F<)*QP61?E4S+1+YME':CQJQA]>J\F^]]=_'H^GD22:QGEW2DN64
M98364GRMX?C&6))[2299FOJ/MJ(="64_"@M89%Y#SG1-6-;W:NH(7/RN?5-(
M+&+GYM((2Y_5/7K^6"YX.#_D#VKU[JL">[N5,-]!"RS'GX;;^?EC;O\ BNO=
M6H\N>T4FN1*.)9Q)2E+#<<8A))-9W<\PRN9J,7G,=WG[&G84W!8DZA;CK)OT
MP-MUY-&+&3%A#&@(?6SN&Q2.!PKHA&I'/"X8W$9<4(/100974DD6S'4ZY=-P
MZKOWZ?5^>VWY_0QCRMQYFU'*YG%*32SNXQ;BFTND7**;V<EG*X%=TK>$1(<S
MPXN#F;"$PSJD;**RCLIEHVT)-2E+P?DJSH.=TEMB1\0S&;#Y/+R^(A%@KTU*
M3+8?.$,;'E6>[J/Q,3]OU7]MOGC;)MF\ \!IG[K[ZM[B[J.(AVY?F"25-9M0
M 6X"M[LZ.CW/DG"V8RG4G;&9TV+ZU989A6&%@3J.@';V4K"HDU+#<;#'[-]H
M93>!ZR;A@KI\^#B7I1FU'DW@UBZ(L&)#!9DQ?.&J2KMFS*X;,L$VK9QNHBW(
M89M,/4M-'.&R'W/M: =EX#1M<'PV[ZE_=\POB"R\!&:\M.Y.?;;E-BLK=M6-
MV%$8K4M:MJTLNCF=.!!BE:V %N@4$")KRZ12$6O'QSTPT<AC&S$1]4Q\?7[]
MY<^O7U_,K1'OA-=D)!J%.G2_/K>>\*UES+5W.X@7,YPYB]\(\Y='@;M6DMI$
MEZZ9OJIUF4;BXB+L084;8R@>1+$3;LJLPR@TQ2&X[ACGZ>T#6EE;6HXB^+,O
M3HJ[^DYP"A!,F=A\,,W'+UCK>$QV0F1$>)R-I&@J H>[/NH\"R7+Z$GJ(IHV
M51TR!'_1M3B1?47%-KI2VT79:0=6OQ3B)D[0FQ*KQR6G&?4:&'8&L'AE:% B
MF=0R*FY,8';O=W#TNXV6RJ6?[K ;$O / / / / / / / / 8[+)A$H& (RN<
MRB.PR+B$<N2TDE9L;'0(MOK_ .9<@8+N68]DCC_-5RX3TQ_^[P%!G/Q%8[9*
M[@/Q;2=K]FEDEMVW[SA#!"N.=&2Z>V^JBK[HVSM 4%.M$\ZXVW_I6C9Y/;3?
M7=N*7QG^ /CFA.Y[]SNMT3TX+YU@[SY;_P!&>)F3EA+<(9SJKHPE?4ME#7LN
M([XQONU?*U;6E0.=OM:[LC.,;9WV>O7K\MQE+7X7? &(T[C4@Y9JRP\E2C Y
M()9:X=6UK)E!P;KOHU,2BT+!<R.P3[[715=/?8G)'".Z#ETURC^D<+(;@7I%
M"A@(8-"!!S$.&#L&8H0)%M$& T6,'MTVC <.8M4TFK)BR:HI-FC1LDF@V;I)
MHHIZ)Z:ZX Y_@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@.M5,AT2
MC<(L6&I&G;;=XU$*OFJ91RT3VWTW=-Q^RN':S;39-37==-'9+7;3?7.V,Z[8
MP!V7@/@@Y;.L*Y;.$'&$%U6RV4%4U<(N4-OI6;JY3VV^VNCM_=52W^2B>W\;
MZXS_ !X5IKJFLK*RL93Z/X/Q/OX0X; B/*ML/!;YF29Y6=ML.V#I!XVRX8.U
MV#Y#"[?=1+*S-\V<,W:6-_K;NVZ[=;719)334#ZK.FS?=LFX<((*/5\M6::R
MR:6[MSA!=UENVUWVUV77PU:N7.44L;J80;KK?3]M)3;45)O+2;267A=%E++\
M%EI9?>TNK/OX0> \]OQ,1<QD75<E@7/K3IHQ9%J<@QF$=*Q^G:*YRM>/$N=2
M4_ML3$DQ<AZ M"LOV3.W9DW:([=_&]9H/PQ6#O34>3>CQ2RL?K&._P"(]=_T
MV\?31OBKP.RCL @T?'#BP<>"A\9#L!!]PV=G13(8%9,FHXTZ9N';1R68H()M
MB+AJZ<MEGB2RB#A9+;53:@S#P#P'\^>/Y_G'\?QG^<?QGY?/Y9_U?QG&?Y_R
MS\_ ?W&<9Q\\9^>,_P XSC_#./\ 7X"GW4'^E+@O_?!)?\G777@+@^ > > >
M > > > I]<_=W-5)2;2NBLU>V%<KG7/XZAZ1CARYKI?*9SC5+#BOZ^9'"T;9
MK;[8UP<F6(W'4?EONZ,-TDU%-&<?X;_(&G>%V=\>"\N_IC%-8>[Y&XXE(=^]
MCLBLFJ*=L=Q5T,1%ZO(T19+QR<O$9'=DC*-T!!>/D)K*8_$]CQ(B2B3H> 9-
M]IEYZ;;]?'R\?M^A=L>>?/IOY8^[-I44^&]0'YX?.;[?6#V19(USJ_'3#JR3
M(V:+CY#^=MG,(J=(:$I. ;:*[;[-E8A7 D@AIG73<@MMIA3-(7Z;MT&B"+5J
M@BV;-TM$6[=NGHB@@BEKC1-)%)/75-))/3&-=$]-===-<8UUQC&,8\!]? /
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M!CI?F$UX1 @[\3J_2F^/&7Q?<.P=R(%C5I[=E G?0.TV0?,TSTDF.M<:3/\
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M;)I-B65W+A;+U)?*JZN_U*;# RKP#P#P#P%/NH/]*7!?^^"2_P"3KKKP%P?
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M-6-G+R$U-:$$5K)=K?KRB87 'I28W]++5UL%8&*:)V(W;1&)AG<!&"Y"J28
M&#XO(LOE6,;Z>;QZ]?L/'UZ^6379'?BK=K*-*%"&UZ$>2GO.J.9+0H,N.K>5
M-0'.#GHSI>.TFXCL]9;V2Z<VZRB$0E+*1CR:3Z".RLN'O1KQMH(5TU2>OO\
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M#LZD<$2%>-N3C*F5GO.5,ZN,[?5^J85[&1+O&W^O5T)'LG&F?G_/SU5Q_/\
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M(UX;8-43Z15Q- 24B8M![,^P0/QIXN*,H,&&"0MPS=*,62RBK5$@6:\ \ \
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M+"^ > > > > > > > > > > > > > > > > > > > > > > > > > > > >
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MHPQH')MR(@"3W,1,N@X=-S <<ZD+($^=+ZCU=C"3K\>W?B]42BXQ+9^ > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
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0#P#P#P#P#P#P#P#P#P'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g772024g14s55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g14s55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &@B^9F0X0DE-! 0      #T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   F:T' (% !E0<F]T96EN($=R87!H:6-?,#<R.3(P7W8Q #A"24T$)0
M    $(MLVD3=+?3JW%@1^)N[K10X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^
M-0 "  (X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              /7   '.@         !
M                  $             !SH   /7
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   /7     %)G:'1L;VYG   '
M.@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #UP    !29VAT;&]N9P  !SH    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     #W0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M;Z[K-UV?[@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M! ,! 0             %!@<("0,$"@(!_\0 81   00! P(#! 4'!08/#0D
M P$"! 4&  <1"!(3%"$)%3%!%B)187$7(S*!D;'P"B2AP=$S0E)RA]48)31#
M5UAB@I*6E]+6X?$9-41%8V2&DZ*RML74)BA'2%-F=X/B_\0 '0$!   ' 0$
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MS 'D<CS\?LV^HZ>O13&-SNI' CVN 7>/FM:["JK%J^RW%NL)W.S"QFV=]98
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M1&HB*JJJHB(G*^FH$@ DD  9).P '4D^ %.G6K5V.^.TE5+2%-S['V&[NQQ
M27S88G<\*T]A"%(@1U:OH_QY(^SA>[CA>-:N>,^%;.;N+C7M.CDYBIQ.'1&&
MQ$DL8>*,@['O'7'C5@VJ:>C<INHB?$J2Z#'7,B!D7'CEACQK5/.W4/D60Y!E
M<V2UQ[ZSF6CGN>O:"*5RI"C-([U\M7US(L".KUY;&BB:KOJ\Z\H7W%4NJ:OJ
M6I2RY>[NYY%W)"PARMO$N23RQ0".),'X47(!S6FK?F226=R#WSM*2=PH(RJY
MP?<C0*BYW"*.8UT;&GR')HSIR"970BL1PC36O625KD54(V GAD:-?_.3Q#*O
MJT*C5KUMKK3[Z^A:9L01MN&D'-(1U^ $!1@]&8,/X=Q1XY[E>\"B-",JS]6&
M>HC&&QTW8H>F 0<G2^+<>-)]LUTZ-QQ7917]+M+D=WN+)JPM ^)(M,<O0WM:
M!SY9 %/#%D.+5:>+*$$=[82*R6H5CR%3T-V?*O93V,Z[Q3J_>2#BGB'2Q8VP
M0)+/8Q3P6QDAC9Q^U:VBU>\A#NJR16\+\QC<,;ZQ+:5;/<2 2GO%<H 4)0LB
M$*"S#O.[#LO,RJ6"AL*2U>R3;_<7$=S\>!DV&VH[.N(1T>0-6J&=6SAM:XU?
M:0B?GH<P+7L>HR(HS!(*5%+(B'!(+T#0M?TGB33XM4T>[CO+24E2RY62&5<<
M\$\38>&:,D<T;@'!#+S(RL=IL[RWOH1-;2!USRL#L\;C!*2*=U8 @CP92'0L
MC*QK?68JZII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*B,@O(&,T-UD=J115E#56%Q8$:B.>V'6Q2S)"L:JM1
MY/""]!LY17O5K4]535K>WD&GV=W?W+<EO96T]U.W7EAMXVED('B0B' \3M5.
M:5((99Y#A(8WE<CKRQJ6;'K@''K6J^XW(EYS93\DR4S#V$Q"-B1D*I(E+!>Y
M'"JJMK_044",&AGL8-]A(&Z;+1TDKW)Y7U/BJ77[JXOK]B><N+6#F)BM("<K
M#$#@;  R/A3*X[Q]\ :?[5W[-/.RM*V?E&AP1%'GX4&!N.7G(+OESD8S[BRX
MTA">7,)LJ,9LH#5*-KE<UKVN:J/<WU, AAL5RM:CB-<JHU%37,=>=)4D2-@K
MC=<;X8'F7.#G!Q@^."< [5A+YXVR05#(P=1S $X!!'O8W9"0,X&2"3@&I#;*
MV%"B)8D<TDJ<Y5\54X<.,$CA@"SE$5&.[727)PCU*7M?R@AHVXX<N?9;=&D(
M[]_?E)(/F0F<]%7KUW+$$# JII\JJ.\SS%R0#C<(K$*H'D<<QV!RV#D* -'W
MM NI3+^NS>O'^A;IOG-G8A7Y *5NMFT4AB45A94,CNGNFRH;U$?!\ =_.YA.
MYP\CS ==$JVDDUU*:T]D\!:1I_9SPS==JO&T;0W9LRN@:9)RK=A+N/$ B20<
MRZGJH_9Q  &STXSS7'*CW AV0,L4322Y7*@N1U5#G"*#U9NI&.NVQ!K9KA.W
MF+[.;;8=M7AHGBQ["Z.'1P'G[$ES7 1Q9UK.<%C!OL;BQ++M;(@V,82=,DO&
MQC7(U/#_ !WQ+?<4:WJNO:G('OM6O)+J4)GNXPY"PV\08DB&U@6."!221#$@
M+,02=4NYC<3L[?O'IY*,\HR/ ;#PWSMN:W5]#FX5EF.T\K'[B0^5,P&W;1PI
M!7.>9V/2H@IE,$KW*JKY!WGZR,U.&BKX,(2)R-57U3V&\2W7$'!JV]]*TUUH
M=TVF]\[%Y);01)-:&1CDEHT=H 222D*DDG)K<.&[AI;-[=R2;20)'GP@=0T2
M]>D;"2-!@!8T11TK-#79JV*FE*:4II2FE*:4II2FE*:4II2FE*:4J RM]2+%
MLE)?!+(HAT%R^Z %2(8]2RNDNL0A410E0I(:&8-1&"1'N16%&[AZ.E*G]*4T
MI6&F6;=]+F8YOD.+Y%D7O+*+ZZGU,K'"9I:'K\9R:78X/GUD*IJ#RS4V.7%W
M<P\1MYD9@&^_I\Q:\\:8R;+@+')_.,^(^9'4>GV4KI0]E=L-O;W,]S;?-XA]
MNL(93#KL,Q]V0DB83:XI:;:W/CW7.8Y..SR=T[;+!A/CU./XJ>8(<EMU!N9M
ML68Z.2<>9\=O'/3;QR<_RQ2N?_0^=+XQW=;'N+*K#ED2)*F6<3<6_K(MW2YR
MN9UP*&NR)MF*';U=_P"][])='$GS32R/K;*P$^5*AS)<,GT\? ?7;'W_ -*5
M+5N#=,F'[C9$*KDM@YE9W5UDEZ^KNKI(U!<976[@!M2RK:H*T&*2WQ)6X,QC
MY=A7RZ=IC/CGA1HM*&*R?I_3']!UI54P-I]CFX?CF"562%#%EY)9;@8S;5.X
MLN+EMGD-FEC57>04^05]J*REDL8E]:4E@6M>H'1[20%J"EE:9&3G_#'W=*5Q
MBQ/8/:B9;9 V^=1L@5TG$Y8%RVWGTN#LD8K#DVLD=0R;+KL,G6.-81!G65P:
M+ <5M6LEIQGLYRV(DGKX[].O7[?*E=>/LWT^645UC!L0K6U-/4V-NV!G,V-7
M.P8F&8/40J?)XT:S$$F VV-;;XC/E5-JQM3:CJY,J0TT2SN1363]OIX]=O7?
MP\Z54=)A&R6;8S24%580,NQU:7*\@K*SZ2GLB'QW=^+=CM; PDF>\W5UK5Y-
M<UM7*D]KXD&<>-&,TK7.:R<YZ?=TQMCIMMM2K18ALUT]VU#MAE>W>6K6XFZY
MIG%"3)9XXFX3")=Y!C>.7]6:UK .R.!>9"&\IQ3JT]K7A8^&&K$8D&96"3OG
M_(^/W;'SZG-*NIBW3'M9B-I3W->')YUG260K2'+O<MO+LCY,>JQ6EB-E+82S
M)*CPH&#XD*%'*BBC.H*\@FM<)5<R3_D/7^I^VE5GM;LWM_LU76M3M]3.IJ^X
MLO>4F.^7(F(-PPMCQ(<9\EY""@00-\*(!7O<QKGN(0I"/>Z!.>M*NCI2FE*:
M4II2FE*:4II2FE*P-ZCMV'2LO+MK%E.%24@(9,E -[A^]K6PC#G!KIO#D;(K
M(5;*A'6*]' DS9;EDC<^OC*G"^TCC!UU0\-VTK1V]M'$^I\C%6GFGC$L=L_+
MNT$=N\<KI\,CR#F'[(5K6J7HDN6LB?V,03OEZ"61U#A7\&C1&4\A!5G8\P)C
M6L0\UMZX@7O:X0DYX1RO:UO<J*J(B^B<N7A>.?7\-<8UBZ@D#,@5000-\'Q\
M]SMY[^.-JPUY+'@'*C?J3L,]/+.3GR)]<9K'W%R#;D?E3%8:#7*LL(T<PC"L
M:1K8(R*G/<@557/1>U5-$8KV*$G#]&TL&/4G>1LP)[\(SC]H2=CN![F[*1L<
MKT.2,);LG?"/(9(\MC(9652!$"1Y9).=^:,$CE8<UI>OCKYH^DS9TZ4\B#9[
MPYG#F5VVN-&\*2V+(<QP)&9WL3O:_P"CV/N>A$"]J>^[9(M.)6")83:_TEV6
M<&WO:#JJV[I)%P_I[1RZS?*2BE#@KI]N^"OMEV,CFS_JT'/<,"5BCEVNU/?J
M25)1=CT'.QW" X.WBQ&V-MB1C#3V<_3+D.T."9'O=NVLZ3O3OFY+RT==/,:]
MI<9G2GW8HUT63S*3(\HLY'TCR49W(<3VT\*:,-C FLUCOTA>T:QXBU*TX5X?
M:%>&>% UK#[*$6UN]1CC%L\MN$]QK.Q@3V.R8>ZP-U+$6AFB-8[5;H/B!2"L
M9)<CH7 Q@>&$&5\N8D@X K=%T;;AV&(;UU%*P[_<6?>-CUM$4CO 64@)$NCG
ML$BHQTN/8C;"&1WJR)9SFIRKV\<R[#^*+G2N-HM([QSIW$(EM9H"Q*+=Q123
M6EPJC82<T;0%@-XYFS\((IZ%</;7\*@_L[K]A,,[$L&:%_5TDPBD_NR2 ;M6
M[/7N"NATTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI5'
MYIGV'[>5;;C,KZ%1PB$4,9#J4TN<=$[ECUU=%&>?8':U>]XH48[QB12D1@FN
M>F*U?6]*T&U-[J]]!8V^>57E)+R/C/=PQ('EFDQOR1([8R<8!-6]S=V]H@DN
M)5C4G"C#,[GQ"1H&=R!N0JG W. ":M+7=4.V%F9&!3)AQ5<K4L"4)21U:GP(
MD:(>3:JU45%1J5WB^O"C1>434K;M.X5NI D<U\L9.!.]C,(L>#%5YK@ ^&8
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MLYBHDNY64'2K&55[@*VJWG<PVZ2)G+6VBM4%W<J%Y .[CP/V8_=)7&\A&.1
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MOB@(C?TV.5'C.$S%<*1'(TL69&(2-)$>*8@G[ O$,^GRV][8S&VNK5@\<B$
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M+,B6<-2*KBRPS#*CTY/QUV1:%QK(;P7-SH^I$EFGM56:UGD;=I;FQ=D1IFP
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MP"1DXW.!XX&YQTJZP=]NG7T^=?J*CD1S514<B*BI\%14Y14^Y4]= 00"#D$
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M*22)B0RQW,CCEPLD9.168L^';,+%+/)+<,54LAY8X"P^+W%7O"O,#[K2E67
M8$$YVHTF.8_C,8\+&Z*FQ^')EEL),2DK(55&D3Y#1L/-.""  C2SL"%AI)&N
M,1HAM>]R,:B=D "JB* $B18HT&RQQH.5(T4;(B* %10%4#  %;(JJH"JH50
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MH'CMGLWC2Y=0L;I-(MI%/)$KH1W0"SQH)8I<2H%=PK3,%-?4*^[/>!-<T/\
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M^MZN3M^*JGKW?/U3T7E/AZ>NKSE7?W1OUV&_S\^@Z^5=+ROO#D3#?$.4>]D
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M1NI,K)&L7,Q]]Q"(PLG* J(>0S"0= >;&Q.0"2//"@9Z$@#;R'2N-9R _/\
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M/3CLX_7ZZN.7/@3OXY/W=/NJMW:_OL\F<[22.5/CNG,$./[OSK\\,#47PF,
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MLS=/W<US<E%"00+DJBAG:260XBAC!"Y>5UZ>Z&.U9?3+9S%)(P**SJ 6!',
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MEREVB(2BA9()8EDE$4T9E<MZT=BMY,8W^VJQ#=G$!RXU-E<$QO=]@C$GU-E
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M)&/KT\<"K?7+Y=,T'6K]Y!$ECI6H7;RD@=T+:TFG+\QV!3ESD]",[5[K1"&
M8PA&P00L8(0AM:P8AC:C&#&QJ(UC&-1&L:U$:UJ(B(B(FN?5\AR2Q+,2S,26
M8DDDDY)).Y).Y)W)K[TJ%-*4TI32E-*4TI32E-*5^.^"_@O[M*@>GU7\170/
M\OU?UZG7I_O#Z^@]?$^E4#^?SD52&34D3)<?O\<GJY(.04MI1S58B*](EM /
M DJSGA%=X,A_;ROQX]=7MM,]O<6]Q'_M+>6.9,YP)(G[Q/IS*#M6*U*SAU&P
MO-/GR8+^UN;.<#&>YNH)()>7.V>[D;&=L]:T(Y!06V*W=OC5[&\K<4D\];9
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M<$#&,BL7K.G66N:5J&CZA"L]GJ5G/:7$;*K I-&5YE!&TD;$21N/>21$=2&
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MQX/TF=9I%>"'6M39(Q$""IN;?3T$C.^/>MS<S1\IY6FMVP8CZ"8T>/#C@B1
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M_#UV.#_+'YQ5JW0_(_A44_X)_"_Q_P!6IEZMOGIXYZ#KG\[U;-T/R/R\/O\
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M\IC%(K6#$-C7/(1[FL8U%<Y41%76ILRHK.[*B(I9W8A555!+,S$@*J@$DD@
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M/LU66[*'H[AWCA@1OW3/+&7&3&'P<8^[U.UM&[IRTDQ /<Q %P#T+LS)&F?
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ME1X+Q$^%+RV<Q3\HR>5)"HGC7)Y8Y4&21FMQTN\-[9Q3-CO1S1S8&!WD9P6
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M)(A:&22*1H)0L4B=X#)"3WJXC5G%M +H1%^21%EY3A@CDJ&&=B1*8QX;'J,
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MJ,.)RI]04IC/J.<[A>R2)HQ$(BC<&.]1,/H_$$$]@&>"0S0Y(/-L\0)(#-C
M93L.8 $$[C&XQ5PCQ/R\X>,G"OC!!ZA7 . 3N0WPD^Z0K%0^U_HAQZPI-BX4
MVP:]BY5D=WDD,9$5'M@$;"IXQ.'?WDM*9\T#D^J2/)"5JJC^5]<=B.G76G\
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MURW_ $@-%XDBB_\ I![,^$N*;A8TC%^MM;172JHQ[@U&SU61,^4%U;H"2$5
M<5A1JL4X'M-M%(?/ \/,,&P>G1A]F*HRRZ1>MYK7"KNMH$:*J+P0N+'D24:J
M\*O)VF(KD3UY67SRG"N^>DO'G8"097[&83+_  QW_=1YP2,".2- ,[86$ >
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MD6!(^E3+&,&Q@QL:,;&M8QC&HUC&-1$:UC6HC6M:B(C6HB(B(B(G&KD
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M32E-*4TI32E-*4TI32E-*4TI32E8L[A]'FS&X5G(NGUUIB5M,*\\Z5A\N)7
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MI2FE*:4II2FE*:4II2FE*:4II2FE*+\%].?N^W[M*5:WZ7[C?[$4[_CKB?\
M]3K#>W:M_P!1O_\ [&S_ *UB?;=3_P"II/\ OUG_ //7R[,-R$^&S\]W_IMB
M*?J]96IO;=4_ZE?_ +_9_P#S4%[J?CHSC_C[,_\ F'Y^P\+LTW-3]'9BQ?\
MAG6&IS_PIB:G%WJ1ZZ0X^=]:_P B?Q^[>J@NK\]=+=>G_MEJ?GT;PKK/SG=1
MOZ.QUF_\,_P=O[>Z<G]?QU.+J_\ '3&'_&6YJNL]T?BLF3_MX&_!OS^/7?G^
M[;?T=A+9_P"&XF M_P#>L4U$7-]XZ<P_XNW/\ZN4+-\2%/F5;'7^$_G-===P
M]X47TZ>[A?O_ "D[>I^^SU.+B[/6P8?\1 ?_ #5=)% WQ7*I\XI6Q_RJ?NKY
M7<3>/Y=/-PO^4K;Q/_F2_P!'/X:JK+.?BMF7_M8C^#5<K:V)^+4XT^=K=-^"
M5^)N)O(OQZ>;9/QW+V]7]U@NJH9O&-A_O(?_ #56%CI9ZZW$O_ 7Q_".N1-P
MMXE^/3[:)_E*P%?W3M3@@]0P^BG_ ,XJJNG:.?BX@A7_ .&Z@?PCK[3<#=]?
MCL#9I_E(P-?W3=3X3^)A_N?T8U573-#/7B6%?_A6I'\(_P ^5%W W?3X; 6;
MO\I&!I^^;J<)$>LQ'_9D_@W]*-IFA#IQ-$WRTG4A^*#\*XUW"WC3X=/EHOW_
M )2\ 3]\[]>IQ%;_ /UH#_L9*HMI^D#IK\3?_#;\?BE<:[B[S)\.G>U7_*;M
M\G[Y_P#'V:F[FU_^N#_N\M46L]-'PZPC?\#=C\5KX7<?>GY=.=LO^4_;O_.&
MIA;V?C?@?\-,?S]U4FMK$=-25O\ A;@?B*^%W(WJ^73C;K_E0VZ_SCJ<6UC_
M -9*/G:7'\@:H-%;C/+=!OE#(,_;^?E7XNY.]GRZ;[A?7_91VY^'V_\ ?'4P
MM=/\=40?\'<_T_K5%E0='YNO[I'RZ^=/RD[U_P"UON/^5';G_..H^R:?_P!:
MI_W.Z^[W?QQ_6F21T&?J!^-?J;D;U?/IQMT^'_XH;=+^/_C'Y?KU#V73_P#K
M1?\ N=S_ $JF7E'2$G_M$%??Y1]Z/]KG;?\ *?MY_G#3V73_ /K1?^YW/]*I
MF6X'2US_ -O&/Y5K>ZJ^L+K6VLZFMA\,VAV!FY0#-L3R&1D.STJ=1Y+])(T"
M_K@?22-EV,$(_ C5@9#X3[J\DOQP#9+36M;,:(3A;CH/#_#E_HNJW.HZJ+9K
M6> 0WX5X>Z+Q.3"8)A_K0<JK".("8X/(RY.=5UK6-<LM1TZ"PT[VH7"2][:\
MROSA'4<XF3 @Y03EWRG0L#C%;?\ &;"XM<>I+/(:!^*WL^LA2[?&B6<*Y)0V
M)P,)+JGVU:JU]DZ"9SXZS8:K&D*/Q0_4<FM F6-)9$BE[^)798Y@C1]Z@)"O
MW;^\G,,'E;=<X.];?$SO&C21]U(R@O%SA^[8C)3G7"MRG;F&Q\-JG-4ZJ4TI
M32E-*4TI32E1&02;.%07DREBMG7$2HLI-3">QY&3+,$(Q8$5XQD"1[9$I@@N
M8PHGN1ZM:1CE1R/G2I?2E-*4TI32E-*4TI32E-*4TI32E-*4TI5&9%?99631
MQZ+!).3Q'QF%)/#D-'4M%(<0K'Q5C61AG>Y@V"*IFM\)R&1C55S'\8^ZN;Z&
M15MM-:\0H&,HNK> *Y9@4Y)3S' "MS <IYL#<&K&YN+R)U6WL'NT*!C(MS;P
MA6RP*<LK!B0 &Y@,>]CJ#4 N7[C_ .Q#.7_TVQ+_ .IU;B^U4C?1''I^L+,_
M@U6WMNJ?]2R?]_L__FKA=F>Y:?H[-V#OPSG#T_?+3^/GJ87FIGKH[C_CK0_@
M:G6[U$]=)=?^-M3^#?G\.N_.-T4_1V1LW_\ I[A+?WSOX_=.+K43UTIA_P ;
M;'Z[566XO#\6GNG_ !-NWX-77=GN[*?H[#VK_P -P\$3_P!ZP34_M-]_U:P_
MXNW_ #^?I5PDDK8YH&3_ 'XVQ]C5UG;A;OISV]/MP[[_ ,H^WR<_9\;/G^C4
MPN+SQT]AY_ZS <??5TBHWQ2B/YHS?^$&OA=Q-X_ET\W"_P"4K;S_ #GJH)KD
M];-E_P"VA/X-5TMO:'XM01/G;W#8^Q/P_P OG\HN\GK_ /=XM_NYW+V\_JL5
MX_IU5#R'K"P\_?0_@:KK9Z:?BUB)?^"O#^$=?:;A[QK_ /E[M43[]RMO_P"J
M>O\ 'RU4!)ZJP_Y3_P":JHL-)/77H1_\.OS^$=?:;@[P+\>G^T3_ "DX$O[I
MNIP$/5F'S0?R<U5&FZ(>O$<(_P#A>HG_ /3KZ_*!N_QS^0&SY^S\I&!_O\[_
M &:G"Q'K*1_V9^_#'^=5#I>@XS_I/"3Y#2-3_$Q@5QKN#O$GPZ?K1?\ *5@*
M?OF_Q]VIQ' ?_:,?.%_Y$U1;3M&'P\0Q-_\ #-0'XI7&NXF\J?#IYM5_RF;?
MI^^=_5J80VWC=@?]A*:HM9:6/AUN-O\ @+P?7=?S]U?"[C;T)\.G2V7_ "G;
M>)^^?J<06GC?*/\ AYC]NWX9JBUK8#IJB-_PER/Q%?"[D;U)\.G&W7_*AMTG
M_P QU,+:R\=14?\ "SG^7\JHM#:CX;P-\K>4?CC\^5?GY2=Z_P#:X6__ "H[
M<_YQ_CY\:F%K8>.IJ/\ @[D_RJBR1#I-S?\ 9L/QK\_*3O9_M;[C_E1VY_SC
MJ/LNG_\ 6J_]SN?Z53./ Y^[^M?J;D[U_P"UPN$_RH;<_P"<?EI[+I__ %HO
M_<[G^E4BSCI&6_WU'X_GYU])N/O2OQZ<K=/QW/V[_JL%T]ET_P#ZT7_N=S_2
MJ9DG'2WS_P!J@_E6.O5QOUU"[==-6\><XSM%:X%D.+8;,N*C+W9IMYD;*&=$
MD1GAF$HD+.][#[OS)(/DY*2&%<SPW(NLQP_IFE7FM:=:SWJW,,]RD<D'L]S#
MWJ,&#+WON]WMN&YA@BL5K-[?6FEWMQ!;]W+#"7CD[V.3E8,N,IC+@].4 YSB
MJFZ$M\NI#??:6/E/4=L8_:&]0<3W/;^86M!GL$PW/6[#@EF4^3X:C40?<"Y,
M4%CXB3:MS(9&@%2XHTS1]+U P:/J?ZPB][O$P'-JX..Z-T@$-S_>C *XY7RV
MYAP_J&J:A9B;5-/]ADP.1N;E]H4C_:"!LR0^H<[YRH"[#-_6M5GJ:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*HG/L^H]N*,%]?!MY4>9=TF.P85#52KJUGW.1
M6(*JIA0Z^&UQS$DS9 A<HB,&BJ][FM15T_/V4J,QC=O <JK!6<:]%3J_)Y>%
M$JLL$7$[V-F,%6^9Q<]-?L@3_?7AD#*C1 A,L^!(BV->Z5 E1Y)6/ZTKDNMU
M<%H<MIL)GWU?](+AUIXD0,^N>M$*JHI61FE9(QTUDBFB2*R%()"D20(.2YGU
M5:-'$;'!Z^'Y'\Z55-ID^-4<:3,N\AHZ>)"F1J^9*M+:!7QHD^:P)8<&2>7(
M"($R6*3')&C%<PQV'"\3'M*Q70I7,E]1NMW8^VZJ77S*]+9](EC#6W;5N+X#
M;)U:AO.MKW&_,I,4*1U+^;0G?Z:4JE,;W0PK+;C*ZC'[J':-PZ#2V%Q<0YD"
M70>7N_?2!\K;1)9XY7PGT%D*T:_PDA%$@WN<[Q$&Q^?L_J*53F&;\[<9U,'"
MJI]S6NFX^W+J*3E6,Y!B,'*,2?-@US<FQJ;D=?6Q[>I\Y:U(7DCD\P)MO3R#
M1AQ;>L/+B01_F#^%*KMN<X2ZLK;IN8XLZFNIS*RGMFY!4K66UD0I([*ZMGI+
M6+/G/.(H61(I2R'%$0:#5['-2&#Y=.M*DA7]":WEX^&[J"WT"(*?.I!64,EO
M"@G7M!-EUK#+-C1#.^J*28+ D7T8]5TI44W/<%?3GR)F:8F_'XSQCDWK<CIW
M4\=Y91(0F'LTF+"$\DT18@VD.U7RADCM12L<Q&#TQOY4KO%RK&06<>D+D-&R
M[EC.2'2K;0$MYC(T44Z0Z)6K(29)0,,X)95"%Z#C'"=ZM$5CW*5T*3.,9O0X
MWX%I$@V>5X]#RBHQNTE0X63%J)D4,KS#Z1TETWB(TS137A88,8[7B>95;RK\
MY\*50EMOEC5/N!$VUE8WN&3(IX)D^$6+A5M(I9--63J*MMK\5RQODEI*F9DE
M,*RL'/:.-YM'.16C(K8XVS^?LZ^%*N"#-\,E2:Z%&R[&)$RXD3H=3$!?U1I-
MI+K'*VRBUP!RW%FR*]S7-G C,*6(YJH=HU1=0I0>;885EP466XP4>.QQ3,@(
M.^JGLHHAPND E7#VRU;61S1VN.(\U0"(%KBL<K$5R*5SKEN*M;1/=DV/HS*7
MM'C#EN:U&Y&]XD.QE$Y9/%N]X%0S6UZR%<)4(B*SUTI49^4#$G7#:4%W7RS,
MC6LB?,B3H,BMIB5):(1H-U,'*5E98R4R*N+!AR6L+)"IB(C6M9XBE1\C=G;<
M$BAACS/'I\S*H=W/Q>-5VD2R=D(,='XEO[I+#*:+*)%7D/8AVJ60TD<7>416
M,4J<K<QQNR?4Q66\");W5#'R6'CT^;"BY%[FD"&7SI:9TA9K01U(@91VC?'
M=KQ.-W-TI7;J+S&K\TT]#<45T>O(RNLC5%A LC02]C98X,TD(QGQB>&=LED4
M[F.[#-,UG:1'+')QC)QG.,[9Z9QTS@ 9J&!G.!G&,XWQUQGKC/A4YJ%1II2F
ME*:4II2FE*:4J'R$5L:@O T!F1[TM/9BI9!/#08+8D([:XQ%*,PD8*8H7O\
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HE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g772024g15i85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g15i85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[28B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )@:^ES0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "3@  !F,
M 0                         !              9C   "3@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "3@    !29VAT
M;&]N9P  !F,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !OH     0   *     Z   !X   ;,   !O, !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MB,Z),XF9B?Z*9(K*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@:&QP0@RT>$C\18D,T)2)35#4U56U1<T-D1%<I*3E);3=X*#Q=3_V@ , P$
M A$#$0 _ ._QXB>(GB)XB>(GB)XB>(GB*EWY=BC E+?C]J"VI22AG(=V=1/8
MATV5;RHC!0,B:#Z\/G:MK:;RX60$N!L-G4V9:HEFFY4>W([BFNBCA+=!-5(4
M58G;U=\B0[EBUJ-X;GI^SHPT^1SCB*S&B2EB3%Y0==3*8.&;9Y6M<6*D&(/
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M8F2$HEU[W7-;OL.4$VS=HX?')-@>(! V+1OLKJSC\'@X"+0L"VW<.%E&8/\
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M.ON#E&FM;L%SG_><T O=MQ',[;@WE8'<K6M&:\S?'3+D8C;R/6YUJWD5FG*
MV;B.8;JO&NQXH3SI0L?I"/$5Y_$W-13ATZF.S([)C45W3WCXU-X"'*N#[L(B
M4U>O7KP7%;T^+(L;-<(T>^D4ADDK*Z+VL-5/2Z0F99(WS0+=5C!A>"LCD+XD
M;++-!;!DQ3=$G[ISENV1TW6VQIK]('[G\B5+@ 2!W=/T5@GI4)XB>(GB)XB>
M(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XBUU/+;K2K]AFEA38!$-C.KK85J;
M>ZM,O]6.6^KO+?[L9_)AOL[;84^G_P G*R>/_G8]CKV6QN,,0R%V"H9N;LNV
M?R=IR%H=R^>B]H^9&EBLGG,/ANQ^U<C5H>\=IV'O,HC[7LN3M.3??R=HSF\N
M8>:S(*9%2,0,/@G[8H&,L6I,429J85:OQ[U'1PT=ME,?V41<(*:*I[X_^5IM
MC/\ W^]L,T5B*.>%[9(96-DCD:=M>QX#FN:?(@@A>^O8@MUX;5:5D]>S%'/!
M-&X.CEAE:'QR,<.CF/8X.:1W@@J.O175];<TJ1)K-6QTH3F2S[ L7'T!ZKK5
MF,U2V?/E<DR(U#;5/"V,(MD557*_XU]\)Z(-UEM*]Q#Q3C^'!6]\CLS.LEQ#
M*T;7F.)CFM?-*7OC:U@<]K&@$N<XAH'4;J_%/&>+X3]S%Z&Y9DN&1S(J<<;W
M1PPEC9)I72RPL:WFD8QC>?F>XG0#6N<)#@#@R3@@LD"N/VP\@$CC8IU]FZ7[
M(TJS1?,5_P :FNJB?YFRZ2GV*:Z[Z?=]NVN-L9Q[/UYXK4$%F!W/#8ACGA?H
MCGBE8V2-VB 1S,<#H@$;Z@%6>M8AN5J]NN[G@M016('Z(YX9XVRQNT0".9CF
MG1 (WHC:Y;W<N]/$3Q$\1/$6GNA\QG6@;PS-9$;B$.Q4-D_U9+(SHJI(XQ&_
MZ-,_SD@ )H)+KJ&@PS]HB+31065W?-T-4TM]LXUR1=<WB3E2SND+:K>7VE&[
M3J,/3PGGLU"#9'@VON:(78E94-8XVRHDR<E&%PV*:3N25R7$766,B1\?& :V
M;6+'A(I'$R?:H.AWL? ?/8Z^/30/3H=Z.^FCR'* X'F)+?NZ=RAK^9NRX%KN
M<<G,W32PAQ:[F(:6/[2?BXJO6V^-2,TZ=EEWQ,?58H)-^*N@>>9:P,#SS1_,
M+)MB5TT^ R.:)PO:-%SD::Q.L-XV?*-)N'F:0Y,,,!.FR3=%Z-?W]?CU4$=W
MP/[$?NJSDOBCZQ"@DI)!2'.D'/#I):0N'<YMK*NJ1T)7,'N3D7?FB=2.)SF4
M0LI.4I23E64K57B68J@#<HZ.(^I)-2I A)')3Z^:D_T3R]&^>8KPS*XM.[D2
ML& 7U\?W.SPD,O"Y D#D\*#SF!UJ90+4XPGB=5.L2@$U7T,Y=Q%RY>Y=JJ.W
M#AQ]5\E/F?G^?S[_ -?'P5SGBA/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\
M1/$3Q$\1/$3Q$\1::Z M72F*FED[19;%SS5NU"PJ/)8QLZE$^DSUO'X3&VB7
MW:[K*EY(1'-E<)YSLBTV<NMOHF@IMKY;MCW6M),!S/ #(F>+YI"&1, Z;YGN
M;OX;/@L=EK_V;0L6@WM)6AL5:$?S3VYWMAK0M'B9)GL:==S>9W<TE9!4<7DT
M+K&#1>:RDC-IB'C8UM+)85=*/'9Z2[H:KG7^%E==-\,U"BSK U#.FNK0=JT:
M::ZZ(ZXQSJQR15X8YI#+*V-HED<2XODUMY!/7EYB>4'J&Z'@NW'P3UJ56"S.
M^U9CA8VQ8D/,Z6;6Y7[Z?=+R[D&M-9RM'0+8ON]>Q=3;K&8"(YVK^U>I?CZ!
M7])TZ35L*/1[Y(>_8*70?MP(!F*&[UQ5=:-H)HV23RJM&1YU 4I(QSYN;-,6
MO]0.E5GKX]/\_P TUX[/Y:_1=LGQ$\1/$3Q%7;\4/_8*I/\ \VNK_C[:/_\
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M_P!G14V*1=#5!.Y)TT(JP_BPG=\O[#.UW9TYZQ/0Z(U FSB8#H6-\-"0P_8
M>B@1HJ+)\SRZ26.3.L!BFS%7>6X4 J-%W2Q!]N=R,PL17C>(GB)XB@#\AO\
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M&@2OABDDF?'&Y^RR-\TKF-(:Z1Y!<>3]V+N3Q$\1/$3Q$\1/$4*>^KCCM54
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M9I*L]*02AYL5(\97A@E<6@#[[(YN=C&NG=$0(968YVNK&,8SV[?N<XQC^_\
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M]?#?%/$'!^3;F>&<I8P^4;#)7;=J]GVS89BPR,:98Y&M#RQFR&AW30(!._9
M*ZA-6QU&)5_'6,7C;9PX=MQ [*_ZB+AUG79PHGAPLOOI^3.FN<Z8WQICZ?ZN
MNOUS]6-Q=#$56TL;5CIU&.<]D$7-R-<\@N(#G.(V0.@.O(+CQ'Q/GN+LG)F>
M),G8R^4EBBADNVNS[9\<((C:XQ,C:>0$@$MYCOJ2M$]IQJN)3SI8;&R?X7]5
MD#+&HE_,DD1FV9X&"%7\;T$*K.&^SHNJJBX11'(966(-5'C7]=5)137V$XTJ
MXVYPYDHLFV!T;:\TU9L[VL!NPPRR5Q'S.'/*7 AL8YB\<PY2%2L]G+G#6-LY
M[%9V[PWF\7#:M8/,8S*SX;)5<HRE9$#:5VM/7G[:>-TT#Z['N%JO)/!)')%(
M]IV!SO'*YB5-P:/U5L&WA[ 0GAON#*(&6>Y1QMLZ.[JD$'#K19]L87>Y?:96
M^YNYSNV_&AHCHBGD>'ZN.IX>C6Q78^YQ0M#.PD;*SM'??F)>TN!>97.+QOH[
M;=   >K'9!V6JLR<N6L9VUD'/MW\O<R4N7NY#(3N,EVQ<R,\UB:S:?8=()72
MRN<QP[(!C6-8W5'<%;2RVJ,*P:'!SITJ7?8PF/"#:^()[JHBBN[!8PK8"B&H
MH6W*?HJJ%XHNWES-QJW_ (Q;1NH]^N&X[Q-C-X&7'5HK,[II1S15XL;(7!L<
MO(9'9$%L+&R%CA-5+;;'AIB>UI?N\<'^TS->R;+_ .EW#G"T?%>=AK35<73G
MRE_%U:EF;ED;<NNH9?$/N4B(34LT9WVZ\\5HE].1S&/CVUSU'"<0IV$Q@NP-
MBW@-B['8'2$5! A1DU;DWNK%NJ,K7&(:V0T9_@_2_B_^E69Y07)YV*J/=LY?
MARI)0PM"G*R>-U>-T0CL0T()8V-E?V;'18QK*30UG*&=DT%S-.DW*7DX[B'B
MN?C?,W^*K6$EX=M9F;WFSB9\E<RTT%AC&P32R9"_D\Q:L&Y)$ZX.UR$W9MG$
M+&PQQM@CUKVY"(G-^:[)1E8)D;TCXG,D";.L*ZK"CK#;"+4FP<MU$7#9TF@[
M=-MMTE=<+-7+ALOJHW653VQG'&-HY/AK(QWJT=ED#&V80\'<4\;@ULL;FEKF
M/#7O82UPVQ[FG;7$''Q>T/C/V84LSQ7P)G;'#V>K8FU#'=@AJ6V.AD,;WPV*
M>0KVZ-N$R1Q2B*S6E8V6**5@;+&Q[9!QJ"0V)Q<-#8[&@XN+@1Z(T2%19);L
MF;-'3.NJ6FB^%=U-MOOWW667W57<*J*K.%5555-]K#5QU&E4@H5:D$-.M$(8
M*[6 QQQM[F@.YB=[)<7$N<XESB7$DY#)\19S,Y:[G,GE;US+Y&P^U=OR3O;/
M//(07/<8BQK --:R.-K(XF-9'$QC&-:-<61S)0=N-V+:P*MBYS0<YW>-%$&[
M@$Z3742_!OMN^CKD2]<:92_U?PN'"J./[;83QMC&WL9E.%>'<S&R+)8BG98Q
M_.S49@<':UOM*[HI#T\"XCJ>G4K,X#VB<=\+WX,E@>+N(,?:KQSPQ]GE+4M9
MT5D 31ST+$DU"RPEK'M;9K2B*5C)HN25C7C$&W%7+C!JU:"J@!!/TTL)(/0!
M*2 #'VXVVWQLL=#&V)IRMC;;.?V'+]9?^VN/R?333&OB' G"3&M;%A*U?E&A
M)5DLU)M;WLV*T\4[CU_F=(7:Z;UT5@K^VSVK01]C)QQFLE$2YQBSSZ_$<;B\
MDN#H\_!DF.;UT&.!:UOW6@- "K[^1BI7-559%O\ 1G<<QC @M)F[8O7\VNJ8
M%&AY%D[%KBWL92F!PFK^2+E=F1(F@F0TT;M?UBV-,;"\[^UG[4<-)B,/4^R,
M[=I0S6VMGQN0S]Z6.RUDD+HI*@O6)CNI,633-$H#6%LNM1=/IS^&+C*+C#B_
M+_Z5\#X++7:>)EEI\28'@+!4YL<^>&W';KY5^$Q]1G+EZ;;%6I(ZLYTLW:T^
M;5L-4PZB#=9(5= C@2]Z=N+^3C EXX5F$1,_INUE&VF5?X:Q8:;:K%V>%/O2
M3,%H<\>/L:?LKXRHIMGUYPL/&0Q&.L0<0X+-F6I"Y[KE&<1R.Y '=ADZ-EIF
M8""T3RT7ODUSN!)(6C^,;?L:_P!*^(L;>]GW'7!0J9B_%$W#YRDZS#'V[RP7
M^&L]0F92E#2'>X4\Y!!6!$$9$;&A:6ZO["ZIYYC<3<*4-"V+\T>5'NI8WDI:
MQ(2\U;IIJ)"V+4>TA,A$%B?W[[H?SC?5+=!!=,?@@XT<;LJ_QIQQQAPQ4I/_
M -'*+9+%ET3[C+4^3H/#&AS86,BCH68)YMDM]X:&EC']EVC@XQ7[V.^Q+V0>
MTS*9F-GM$SUBO0QS+,6&DQ5+AG/P&1[FOMV);,V?QEVE4#0V7[/E<]LLD;[1
MJQNB;8E-7O7U.R<5&FLUE ZJ;")AAC@Y K&2*P0B)..6:*A$0S6FHZ/HF4VC
MS95NW=CMW"3Q/5-9+.<*8QZXXSC7"6X:C;]N+#Y.:"%]C&Y038Z:"PY@,L##
M?BK"<1R<S&R1<S9  X=^EJ+B7V*<;XFYE9L#B+/&'#52];BQ_$7"[Z?$-6[C
MXYY&U;L\>!M9)]!TT#622P6A$^N\NC?HM)7XZ-N"?5J-@$@KTK3J@"7S&,0A
M=W/WQK&NQ"7FV8I@5%NPA-FR6$"FRSDD9SMNLOHT;[+(XPFFIG$\3YO(8N'&
MV<;-A#!=OT\>Y^1DFT7WK$4$<T#X)8V.B@8]\TX)+NS87-T 5/LPX)X<XJM<
M28WB6GQNW)83!Y;/QP<-UZ)(K86A/<L4[<-^I/.R[<E9#5HZ;'&9I0Q^W.8#
M)D/_ "W\0+_G]ANQS^.9?S.P?5SJ(V*_K)_R&1>KW;=YJ.R[_-EEAWOLYPV_
M'A?;*OW9]:8>V[&+WCLNW[-G;=CS=B9>4=H8N?[_ &?/ODY]NY=<Q)V5JF[[
MG[[;^SA:&/\ >K'N(NF(W13[5_NHMF -@-H0<GO!A B,O/V8#-!<E[M7E3Q$
M\1/$3Q%%GK?F2N>H:]C@"R9[957CZOGPJY@-@51/L5E+HE)(@!DPMN;0F?Z3
MS<.Q8B9(86>.$OU-TM==%MGB*2*NJA/WZ'Y>2A3\;D/X4KZ52"%\?]]S_IS(
M6$$_STZ;ZN%WC#X.!?2\<2)S )!1":+.//UY(^T:+R)!/&JF\A?M]\[JE=M]
MB:^'R5OGB)XB>(JYODS_ *DQ4E#9ANH3>7X[>XZS%=)-L_TC>TDQ=\9R"UD.
MXK10GH#V*_J8+[CDU'^@_+C9FGNYPEKGTT_<O>H?M$VA2YCV_N0A-KEY'<O8
MB<B$NY^7FYR!R<^OO:3KIW+K>NF]Z[QO?+U[MZ\-ZVLY_+\DO_ZCP_\ 7_S:
M^?\ ^O\ "_\ V>LFN!/^+BW_ .7A_P#\BZO\;RBU\W_IK]U F V#\R3_ + F
MT4-1.KTJZ;I&4T5)1&Y$/H%B*:-]M@!:(S@4'TFY<D3<)H)ILU"!4G]Y)WJ?
M##F['7</>K]#V5,X2IVH;5LY!QA);6M129Y\KW 6(K=*20TX8XFEQ+^SBBU&
MWW>:1SR)\9%)D3?D8]C^P^]HN8P5PT#[CF2 "1SCTVWF<=N/,T  MGVFZ^1[
M37Z*@N)%]OK_ &43E=[M-<XSC']OP[0Q[G&<9^N/N_/G&V/IG[=?\O40MX&.
MN67BQO3J#7P[^OP(LLZ'Y=/BLG_C>47U>/V*J&GOQA=M.;F/W'6XGFZ!&I3)
ME)"JE$[>L_32.''[AP],FP3XG6#$H)&DB"RK[(=HX?KL%'.[1MNJPT0;M<5[
M2:^*]H5;ABC-QMQ_BJ?#T!@BKXW&8GLII@]G89"\W_2"F)[56!D=9DK1(\,8
MY[(VR33.?NCV-^T[%^RRIQ3'-P'PIQ/;X@+72W,])9[?W)L)CDPU;DQ618RO
M8F?)9E;(:\4KW 32%L%=K9[Y-?,0%T11<P7D:4(-D44MW,>E<JP4>[::ZZ;+
M?ADK>+,?S;_3*B^=W39/;?.V4M,8SC37&' L<UK8/:*(R &[O^SR0]P YI)*
M?&DVW.()/)"!LCH "L(W/>RU[Y9)_9UQ5'SN>]L=/VD4FQ1E[RX1L;/P#(]L
M; 0UH=(]VAU<X]35#;?2?3W270PB&ICYOO.Z:5<H&1%)H 3K.++!SF-34GCH
M6'6E+24X-#%5]&1I0'KA9HFP9,%44DL.5L8'CC^'WVAY-N!XDB]H7#4%!O9"
MM):K9[A?L722=O'9;7D9DHA8FB.VNM6Z8E9%'&S8VX[M]D_M^]AO!6$XIX>G
M]FG$$TV6$KY_>[V"XK?DH_=17&+LWYZ/#KZF/CD;S,CAHWN26U8L/^\&1BX:
MLNG)':,@;P8)UC20&QE-<:_Z,K,YPL.K+,W6TTQLLBE";!M2,G"*R7]_S;AV
M+YK]=%-DE=D]-MM<C>X*]I>.@-N;)8>>BW7_ "A1P3LA1(/<YUJCQ#-#'S=^
MI#&>H!:-@+38S_L7>X@<"<<M)V0P^T'%M(V>X!_ O,0.X=2?B?'0MU6'VJ;O
MZ,0.DK.JFVW,4W8I39K6<>B2+.+%U2[AH_%6['RLJFLA!L6C71'/[3HH(9[X
M<KMV":!UINIC5?&.*]L>.R> L5*KI\3?$;H,C'@12QL\G:.,K+;[LUM[X&P<
MDC98K,;'L>>QU,T..\_9F/X3<MPEQ98XIH3XK-UNVC;0SW$<F6SC:C*K)*MC
MAR;&8W#UW6I;;I8_=WT;$[)H6FRY]&7LU8UB)]8?3'UNJF,9^G_=1,FSC&?_
M '?^VG']O_H]=?<N+_\ M_"__;MG_P =6C_MGV-[_P#0/CK7_P"H6)WK_P"Q
M57YT1V+U-0-[0ZE%2=<2S>5-(N[R?95#(F"GTDIMT(U1"!]K2>Y.K,\MLYSK
M_(L,+O=MF&,I93RXVUEQ3QSQ=PUQ)C\ 9<;=%UE1YLLPEF-W^M6'P!M:#[7?
M[PYG)U_Q8^9Y,?37,?I+V9^Q'V0^T?V>YOCQE3BC#-Q$V6A^SI^-<99;_P E
M4(;I??NCA& 8]DW:ZW[M9[. "R><.[(3_P!XQUUIM]J5P44KI_W;N*/F.BF<
MY_SQG5&Z/LQC&?[8^G]\X_OG^_ME&GQH">7.</N;X%_#]T.^.PW.Z[^Y?-XR
MWL6<-NX*]H4;O%L?'^"<WX$&3@0NV1W^'DH66SP5T/;%[1.\#%\P)J?CF0>[
M58/"Y:':!,Q=QAZ)1# U)B9570?/=EEBVN),'^[=RY51UWW6VQBA9KV<\3YK
MB.CQ#/Q)CH[-05^0P4+D#(/=']K"V"N;TY<V20N,_P#K4/5SBT$N*WMP9_$3
M[,^#?9[F> *7L\XCFQV3&0;*R]G<-=FR R\?N]U][(,PE!D<D%<1QTC]DW=-
MBB8\M:P%32R%[$TU^NMB\Y+;:X^N-%*DL='53./_ )NZFEPJ93QO_EMMHGOG
M7Z_777/TQCU^['C8#_G'A8D>)PV6&]>>LX0-^.@=> 6BO?\ V(..CPQ[3V G
MJ6\9\+O+0?%K7<$-#B/ %S=^)"A?8M3?(^6Z7@TS!V%$_P"CV"0I1QF.&3$:
MJD:U8[;9,!Y+7Q(Z5D1M<YC7?"[Q#0RLK^XW_5(!]6"&!]"RF%]J4W%N-OU\
MI2^SXA"7^ZRSU,/$QAW8@M8R6S-:L.L:T7M=.YW.WDEKB,"+>G#'&7\+U/V5
M<08/(<-9DYRR^VV/[4HTLIQC:FL "E=Q?$M7'4\70CQ^VF."0T8V=A+VU6\;
M,AM3-_/V8WS]<C>9"FFO_P W0S:8113&?I_EG<&>T2SCZY^N,Y5^[&GU^NN=
M_HG>^;CEI.XN%)F^&I\O7=^.Z]D>8UOPWL[T-&=G[#)!H6O:O3)\74>$,@UO
MS#<AC7.WKPY=<W<>7;X3S* _)$YZAC5HLMPZL#&["'*\%B%K_@KO^"8)H-SL
M5>,Y$,!/7Q>1Y3>/=##N)/\ #%P1:Y1)I:BF^K2@7\;[5'\7U,O$:_V;%V#G
MX^GF0W&&O$ +%.2.S%7EDFMD/>)W4I.S=+'J4" %F^<'Q'_"Y%[)<IPE8;=9
MQ%:%V*/B'-<'&3B?[0L.DEQ^7@GQ=O(UZ]+%AT$!HPYFM[Q%6E$E1QN2F::^
MUZ6L)SG^J>4K;12TSG&[J&2.JYRA],8_ONFV;S8075T_MMG7745^;;7[?^B_
M)OA/%_/$&8A_\[X/S36CO?1M8?(-\.H8W(0S.&M_]"'=-<O5:';[/N#[H_Y(
M]L/!;WD?=ASV+XPX>D)WT:Z63 7J3#W;)N<@._O\H#CJG;Y'.=&%DHU?*LSR
M G<8RB7>3N);QT7&B>4,N4A$ARX?*$6+I9#**B;O0<X$?:Z;;;DM=-]]T\+_
M .5'A>/+-P]PY''6=<LS\A2=5BJS<O,V"SS/,L;W-+7!XB=#I[290"2+@/X8
M/:=8X6?Q;AQP[Q'CR>>E!P]F6Y2WE:@>(GW<8(J[:MB%D@>UT+K4=W<4H%4N
M:&NF!#['KZPF>"$$F\3F++./KEQ&9 *-Z:?VQG.JO\<Z<;([ZXSC[DU<:;Z?
M7_6UQGUWHY3&9-G:8[(4KT?BZI9AL ?^]V3W<I\P=$>2TGF^%^).&IS6XAP&
M9P<X.A%EL;<H.=Y%GO4,0>TZ.G,+FGP)69_=K]WV_=C[OI]WV_7'W?;]?I]W
MT_S^GU_M]?I]/K_;WO6#T=;T=;UOPWY;\UY\4+5#*]:8(S3:N6%I0-Y/M"3X
M-O#F\G$JR34L,U<;$1NPC1UE[AZRU:.LNFV4?RHX;K94UU_'M],0SB#!R7SB
MX\OC7Y(2OA-%MR VQ-&'&2(P!_:=HP,?SLY>9O*[8&CJXS^SWCJM@AQ18X1X
MB@X<=4KWFYR7$W&8LTK9C%:T+KHA 8)S-$(I>?D?VC.4GF&]K^RZIR>(GB+K
M465)K>WZWFMK51 NU:X"W^4IF92J($_BTKRVVS8F&KV$0]RL3M"8VTWD0<@U
M"BAHJ3MA@ML(B;M@IEH.=E$R)@V/SWW>?EW=0.[N/AON)'52X '0<'=&DEO,
M "YH):0YK3MA)8XZ+2YKN1SFZ<>ROXH3Q$\1/$5=OQ0_]@JD_P#O_P#C:ZO^
M/MH^@=WXN_4KD[O_  'Z!6)>E<4\1/$3Q%'RX^8ZNO<S&SM@;S[=]$MVSF/:
M1>TK$A# 829[D-FAQN,B,E#,,2%MH5?MD)!EO_,),G.[+1[AKC5+&?Q'$F3P
M<-B"@* 9;#FV#9QF/NR2Q/$8? Z6W6FD-=QBC<ZOS=B7M#RSFV5YIZL-AS'2
M=IMFBSDFFC#2-Z<!&]HY@'$!VN;1(WKHM\L6:0]DS8(;.-T&+5NS1W=N7#UU
MNDV1T13V<O':BSIVXVTTQE9RY65<+J9V564W4WVVS@GO,CWR.#0Y[G/(8UK&
M@N)<0UC UC&@G[K6M#6C0:   O2!H:\NG4DG\2>I^9ZKZO<44"+GKF4\\S0W
MU9S\$>E6)%1(ATW1()'*B%K1QKJFF^M"""$\I(-;QAXY/+K;\.R*5D1]HY $
M]53R81[BXXN]7S52+AW-2M8^,%F R\SM.QT[MEF/N2'9=B+3SR]031F<V:,B
M$RL72YI83(P$^,C!_O#Q<T?\8'_Q <O?HJ9L'F\4LF'QJ?P8XQDL/EX9A((X
M=&J_E9$Q))#1PU<I9SC7?3;.F_VK-UM$W#5?55LY22<)*)Z5:W4L4+5BE;B?
M!:JRO@GAD&GQRQN+7-/@=$=""6N&G-):03VM<' .:=@C8(\0LJ]YU*XTH&$'
M&^K0T*&EVFBNJ^C4HQ:D&^J^FN^FBVJ+M)9/577113353&N-]=5-]<9QC?;&
M>N6&&=O)-%',P$.#)6-D:' $!W*\$; ) .M@$^:ZIH(+#.SL0Q3QAP<&31LE
M8' $!W*]KAS $@'6P"?,KV#A@T0UT8B1[$6R3VWV39CFC=DU3V5WRHIMHW;)
MI(Z;*;[;;[YUTQG??;.VV<YSG/ICBCA8(XHV1,&R&1L:Q@).R0UH &SU.AU/
M4J8H88&"*"*.&-I);'$QL; 7$N<0Q@:T$DDG0ZDDGJ5]WN:[$\1:CNNL25O0
MA]!6DU>PL::PHUD"S (),K%A2J6^NXW_ .-=<Y88RO\ A<?MLMTG6,HX2PIA
M-3?&<3FL9)EJ3Z++LE*.;;9W1PPS.EC/_1_XH/)]X!W,PAW36]$K!<18:;/8
MV7&,R$F/ALAT=MT5>"PZ>N]CFNA_QP>RVXM?VD9:\<O+O1*SV+C3(<".&R&1
M+2PPU35T>R%<8.#*DMMW"RJ2FXP4FD/:Y0;[I-<:MD]=5-4,+;_553?.??5C
MFA@CCL6'6YF A]AT<<+I27$@F.("-NFD-TT 'EV>I*R=.&Q!6BBMVW7K# X2
M6W0Q5W3$O<YI,, ;$SE:6LTP 'EYCU)7/^[UZD\1>I5N@OC7"Z"*V-<YSKA5
M/13&N<_YYUQOKM],Y^F/K]/\_I[BYK7?S-:[7=S '7U!7-DDD>^S>]F^_D<Y
MN]=V]$;7[TTT3UUT3TUTTUQ]-=--<:ZZX_\ #777&,8Q_P"[&,8](      Z
M  : 'D .Y<7.<XESB7./4EQ))/F2>I7G;77;'TVUUVQC.,XQMC&<?77/UUS]
M,_7^^,XQG&?\\9Q]<?W]* D'8)!ZC8.CHC1'X@D'S'1<49 @Y&R5&R ,*.CE
MM<ZK,# YH39*ZYQG&<*-7J*Z&^,XSG&<;:9_MGW3/7KV8S%9@AL1.&G1SQ,E
MC<#W@LD:YI!^(7KHY'(8RPVUC;US'VF$%EFC9GJ6&$=06S5WQR-(/4:<%35\
M@?*_-XW%6+A)5":$+&)N*#DP+?4>-#$XU)38D2<FB,=V)C&;/^BDU<$"#M@@
M@U78J*H$%$?QMW".C/:7P;PLQN(D@N4.&YYLA#!) P00PS5;=F""S>;5,T#&
M?9[7]M*^(-88]ME+-->W[D_AN]K_ +4;9XOCR&(S_M%IT<!<O5<C*;-J]5RN
M*H7+N/P3\H*MJ:;[><SW:M!9DDFCL-9)69)S21/MZKQ@&%P"#C(Z;WDL?'0^
M-,04C4>IDE#X=H&9-QAK<@CG*+[<HR31>[/$LY3<Y7RLGG[=\>W7C(X(<;CX
M:U@VZT5&I'7M&02FS R"-L5@RM^[(9HPV0R-Z/+N8="OBKB:Q>M\2<06LG0;
MBLE9S>5L9#&-@=5;CKTU^Q);H-K/T^NVG8=)7$#QS0B,1NZM*S'WN6$3Q$\1
M/$3Q%&_J\JR2I.90XC K*L!A;0"752\85C!%K$)!FTN@<LT7/GH^W.1Q;>-H
M),]QJRB9=DHY,%0HG1RTW)ZO&Q%6E\5Q*ZT)J<AE@YZ(4B40J5J#!*7+\>=9
M\B#</ IF,BVJ:-@0:>2=W)Y F-27U5B;D6Q:KM\/#>Z^K@4FBJ17>^(GB)XB
M@#\AO_4?F;_U]<1_\?XAXI'<[Y?N%/[Q0GB)XB>(GB*!U)?'90-"7[+.A83M
M+U93(_Y_(L 7*CW,6ANTI<97.[1MJV$,RF<KZ;KL6FI@L4U8#G3ALEKMOLFN
ME>,S[0,[G,%5P%T5!6K^[]K8BBD;:N"JWE@]X<Z9\70@2/[&*+M)&M<= %IQ
MU?&5JUF2U'VA?)S::YP+(^<[=R -#NO=]YSM D!2JLZGZMNB.+Q*UX#%I_'U
M_P#6P/DPAH1PU6USC*;P:Z53_=$D$=L:[MB(QPT?ME-=5&[A-37&V*KC\GD,
M5.VSCKEBG.W_ 'X)',YAXMD:#R2,/<YDC7,<.CFD+WN:UXTYH</(C?KYJF^N
M>"I3\<EX&^HJZ?RKH2HU&$K#2NN&2#A*W(#"I$_%D]I+']LOG;>X=XQ_';8+
M1UYL"-O6&N3 ;0F9;HC/;7R/',/'6$AX:O1UL+D&OJS5KTCFOQUNY69+&*\A
MY&/Q;;(D_P *8>\1QOU#*^.%Q>L7!CF4[#[3"9"X/:X-'*>1[FNYG-!(D>WE
MZ\H8';YN7F 5U4#G</L^'1VP(!(!TJALL&-S$?/B5OSL2+!SC/V*)[9QJHDJ
MDIJHW=-7":3ID[27:.T4'2"J6FH[E.S0M3TKD+Z]JM(Z*:&0:>Q[>\'O!!&G
M-<TEKVD.:2T@G*M<' .:00>H([BN9> PA!^.*OPXI\4$;*[B23P>T<OQ>ZVO
MV+;#GBR.[AELKK_JJ[-E$LJ:_P"KOG./[>\#Z\$DD4TD$,DL!)AE?&Q\D)<-
M.,3W-+HRX="6$;'0KVPY"_6K6:=>]<KU+H8+E6&S-%6MB,\S!9@C>V*<,/5@
ME:\-/4:*Y3W<O&GB)XB>(GB)XB>(M!/^7Z*)W$VOM]7XYQ:;7\&Z<BV>EM4=
MWC1G@<T*. FC_4"Z+-6.NC9N2<#57:>B2"F%?SMFRJ5<DX1X=ESC.(Y,9"[,
M,Y2+1?-KG8P1,F= )!7=,R,!C971%X :0[F:UPV-6]K7M"J<$2^SJOQ):BX1
MF[1KL8(*9D;!-.;,U2+(.K'(PTYK#G2R58K3(7.=(WD[.65C^0F/-U$SUW@G
M)JMB+DSKG;;20C1V([)DMMO\]T9-'-Q)]%3&?[Z[I$=-]=OIMKG&V,9]VWN%
M^'LB_M;>(I/G'=9BB]UMM\=MMU3#9:0>H+900>H(*\V#]J/M"X=A-3$\79J*
MB0 [&6K1R>)>!_NOQ.4;=QKVZZ%KZKFD="".B@#KP5? #JO_ $Q0&]=0D+'(
M[;1Q[+"DOL*7CV& ^S%*%E1A]]JG((ZFXWW1_*]ER:N!NVBR229-%/?&M?\
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MLN<3LDDDDDDDD[*_7I4)XB>(GB)XBB]VC:\!I?EN[YS95C%ZCBR5>2<#O90
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M6#T?=TE+BHZ^%RJQZX4K]43J&T$S)Y!F;05+I8*W(R**6,N$+E45F(Y@^B!
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M3Q$\1/$3Q$\1/$3Q$\1/$4,.^5>41/-DLFW9U6LK=I*N73.:OXL]K(I;'XY
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M1SD-.!F)QD$,1+KD-N*'*P79' -T([5=ONT0ZD")QG!( LZ:0[&4L5[F9/\
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ME6FY%BLK^+#@B:*250[SG#-MI9+9K-C/\9N4!Z['I_4#FC9'L/T#/V.H<7M
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M\@UVUV3K&THJ[$RMB^&Z[&XT01<"#:6FKV/G!8TDCH[23<,G!%B]N<><K6M
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M]@:RLAK/>C(<((3B0J9)YWC#8G&1T.?OA<?V';"X.$:M@_ZK%)Z]?V_53Y?
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MH'G0X\AN<5*-QV&+]Z^)MWPMP+(O!RSU].Y2YSG';B7'31LDDZ: UH&^X-:
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+8?XB>(GB)XB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g772024g15j64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g15j64.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "V E@# 1$
M A$! Q$!_\0 '@ !  $$ P$!              4$!@<( @,)"@'_Q !*$
M!@$"! (&" 4!!08& P ! @,$!08' !(($1,4%1<)&%97E]86(2)5E9;5UQDC
M)"4Q63(X04.40E%T=[;4)B<S1%*W*5B1_\0 '0$!  $% 0$!
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M;;9,QM=K%9B9">L,_,.T6$5#0T4U5>R4G(O7!R(-63)H@JX<KJG*1)),QS"
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M=H:%09F$OF!0'/MW?4.E6^K<"G;.HC5G-@W"UHEONH-I2I@]K3T]1B]7K:B
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M<L'8PL2]D+;7K^H1(R5A%^UDEY*21;E0?+O7C+^G4?BX3.#W:5,2N>H!TR&
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MIJ_2?K_Y;XYV*\2?%BN19-;T=.05DW"0H+D5SM@10BZ(@<HHK%/81*HD)5%
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M@,? 1V>J&/7X^D.B/7.#?BAXKY%HV=H>CQR(X:.T6SQLH;.^"0*HDH5-RV6
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M1$1\9F?HB,XI*I+I)KH*)K(K)D5162.51)5)0H'3434((D434((&(<HB4Q1
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MR; M,;J-:Q'9KGI63#'%(K]ME("?QZ"53E7<;.R\PR[TXF>/ICX\^O//P_\
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M!S'S1XQGK=<SQ>_7TC\=D-?WU4%XS1[^UC>5SXC(\1G!GR4=Y\3\XN;L  *
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M/$99/\'*8]_\;\-G7SOK;?=ZK_9AWYV#^C\U7W#;'VD3^:S_ %_'\'*8]_\
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M&F,\7LE^D1S-0[[:Z9"P6-)F)K,RZAXZ6EH&TDDY-HS,"2+]^1I<6;9-T[(
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M+,)NV6:F^M&N3)79EM&6HL%03LU5)7%K@V,K6:H$Q3#2NU8!1'*5OLJC'F8
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M%6<C("W(J=1J10I2JM3MGC=V;I).&+P@] ^IWK&(U&QL):A#J]-[4OLQRE3
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M@2F(CF./28]9B?6)B8GUB)CF/28B8XGUS);TVLO&3+5-3&F:V2V)-;N]2F(
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M);V0,MK1.G+J?>16M6&#KJ\5["?%02B.W7B0VDMH>$5U-=EP3JT84NS;H,M
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M#2X:/6+Q$[=VT=-U>(,R2[9R@HHBNBH4R:J1S$.42F$!F^Y=;]KNGOR;JO\
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MS^SQ/GY&GI;52KP)BSY:*_@17\P7A=\:GW'YKX>)YGW5^P^[Q/![?OG@^/\
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M9!03/3CO?%W'VO#\]SHN\_)<3AN-RYC\&=>_X:=4?Z;V'_>#SY_Z@_OYM?\
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M@X96,R4C R7= >L^SCK+?=6KW6WV:M*'3/FNSIS::VS!KN*!]A3H83+!LY5
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M3XTQC3&-,9]*'HDO]UZ9_P#-RU_^GJ;KZ[]AG^!EC_3M[_NNOSV+H+^\C?\
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M6,-1"(LXF.(F9^,D,1/$R0Q$S&BZGIVMATYO*-*M4NW+>KO5ZU2]_<EA[:[
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M28CH1.."J3#@7T775EUQECLUDEFC^5!;CL]+S'EQX4<Y1V.)J/K&8++;+@6
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M_"*S\WZ8RC)QRXD+(.E_ \FFZC-BEVYHRLBU2Z*\B?K(I_2[["[CN-CD_/\
MF)MFI?\ E?6QE9Z]6(_9W(WX16?F_3&/7JQ'[.Y&_"*S\WZ8QZ]6(_9W(WX1
M6?F_3&/7JQ'[.Y&_"*S\WZ8QZ]6(_9W(WX16?F_3&/7JQ'[.Y&_"*S\WZ8QZ
M]6(_9W(WX16?F_3&/7JQ'[.Y&_"*S\WZ8QZ]6(_9W(WX16?F_3&/7JQ'[.Y&
M_"*S\WZ8QZ]6(_9W(WX16?F_3&/7JQ'[.Y&_"*S\WZ8RI9<<&*'[QHQ1KV0R
EJO'*#1(RD36P3*HX5(B0R@EMIS 0#' 3B4AS 7F(%,/(!8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g772024g16p24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g16p24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2U24&AO=&]S:&]P(#,N,  X0DE-! 0
M    +3:^$5=#A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   F:T #
MA"24T$)0      $/=@K4H0T#=N&%EU]=/2>JDX0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M   0 " 2P    !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              1,   %E@
M !                          $             !98   1,
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   1,     %)G:'
M1L;VYG   %E@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   $3     !29VAT;&]N9P  !98    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-!
MP     (Q<    !    H    'L   '@  #FH   (OL &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
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M7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M(1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ7J#WM[D[)F5>BZSW90]CUJ\]E^M6I!':6+UZD1 <)O<'7W=5_W12(M.4?&
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MJMKZQ4*L6%R:16^CV::DEL>NJB1\L+;?BI(OK?9]D2AY2MIS9ZUB!&*YL(/
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M 0L/V3M#1U]%Z?!F16CMMU_3=QLI;7QF5+MDP=J<$,P?FD(^W6G'R[H!_O\
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M>+W:M>US2&XDF6[;-V#KH*)L4O4%XE/2Q8^58/@F\'"G(\U%7+:ZVF+]UUZ
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MZ&^L0!_-\4I^,;Z'?2WT-]8@#^;Y&1SR.._N^-3@^P\]O?3\8WT.^EOH;ZQ
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M(X))HR<2CU:4;XXV=%D12&1SBL15NK>V[E1M5:YV%ITE3PVH0'9.':K+#NM
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MK:.PBY';!W4ETUW/JVOM(5>IU&CVC3Q'9UHV!JV_LW"%L<JT9.R-421M:PE
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M%[#:OM:/3XWBMK=-PE>)#:6\DL4ACWR0++//)/(/PW;P1NUA'#%$,1(H(_\
M+;N8_%C@@''(&%SR,9)%ZHO5/TO^^9KY_<?=JH=7A%E3A)C7?7VOECDRNHB,
M/C_("-DS:90UPD[!@&U2!]WDN-J*SF,8@H80.SR)U7T4L56.TT:74WB_)<7[
M)&)2Q#$R(J$,$W-&%:'!V@Y/#5FPQ[G Y[=_=GN/TS4KT'T(_1T$HF8VG7KQ
MV&O-@1*=/W+;-[L4F0^1)/LD"DL2*KDX"/%H?+XFD8OM&"A*+[SFQGBTUIU6
M<ZEQZ9:U)M2VDAL(4(V0VL* ;5!55=I [/X<*?RJ=JG:#4A0/>3G/EW\L"K
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MADC59!$QD1D*R%-X0A@"&V>+!'Y3GL:!@<@$'(\B"< ]_P!ZFO6_2#0/7VS
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M;DO%812 //M865G"BI'#:6RL%#3=(1Q6]L)!)(2))2B=:=-P;(@$7Q.>P_\
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M !]$'4/T6^H-$NQ+G? E-O\ ?7Q,%M9%,>Q3HT4A%*2R#):*Y//IKSKLD:_
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M=_'?W$LB6X5Y+:22WM1^&[,@CTY(2X&XO>W%\Q8H4=L=EI\]L\)DE1T@A:)
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M11HB!41$#G"QHB DD*"23*(L8VJ!CN3CN<#).<DD^TDGY5LFS[+$J&S'I%=
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M_:?F<?Q4GW>P?(9_FLCMTKN^/?[G ISFS'*6^%U"YB37*Y7GUA&F[Q,:V?\
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MU K9"I1'@==FHM &:;E&&$5QV* M3C@B>L":4)5NP02:UJ<6DVX1;&.7J2B
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M+B^>^O)P%!#&25@L$,DCR22MZTT<<0E8*\L1FE6,&6MP (JJO)50JY]PP-Q
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M9GEF+!Y21XQM<@C&,;21(I)P"WMP![,<# '8=@/=5RAP_P!5ZN5(PK$KRO\
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MC+%$(HT."[@#<W_DY(QYGMDY ) '<XY-;WKK6%G@FMF;^[7@Q;<.%*EV"G5
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M=\9=02\N;?3)[*.2Y>XDN9%O+^8$QB65Y9;F_E4J[=/I*L3^$K&TS!ZR* .
M-P(P 0 JJ!V4 !>_/F<\9Q@5<VOZ5[A6HCVQJS432/6+6^QQ80-IPV#I=8V+
M?($)ZE3!3TDU&K3]("H+5<L\P['<LKMUC15*>$ \SAT%JPE:SK:':KILL45Q
M>W,+N]Z [VL,KK,&3EUF=D>/*C9T6XW.%+&,>_$>_'?OR<_H>WO[GV>=3_JK
MIGKBJP=*V3;'AO7>>F0T6.#W+=&9/MXTZH0@48)TBJXGOUG7XX@A.%X#UR#'
M:<>CPRA-\G8&,F%ZMUJ]Q*UW';?\*SNW)>T@P%9-VY5FDVB2=E/_ )2,>Y50
MJ'8&/,\GV_?;O]FKA\J:FG%*<4IQ2G%*<4IQ2G%*<4IQ2N#FX/RM;1_2+=OV
ME)\4J -J]F-RR+4,T'I?;=4TQIC5]LM3+^_PFF+)I?36*R2M^:+37MLUZPZ.
MM=1+U"D6JKW*ERK;KN0'Z];3(2(>+;LK2I+-6$6:.?Y_CS[?7'/\SCC[^_\
MKMCD?217JW7:D'B5^J 0M9 0,R500E>%P0H>%F9+?GS,Q!@UB-"C9ESI4F;)
MRRRC+\N0_)=RMYYQ:IJ*S7%*<4JE74K\IWI ?UU<?PB=2>*D^7P^IK2_26=G
M3'5'KU"V"%,Q0,D]>A]%60E5LK:,^4Y5[;,CQHL$/C$B),ESQ,-A@M(?ACQN
M5JD3YT./A<AN_P#1V/3)+]CJJ2R01P;XHX71&>YZ\"Q*V]E#1D,^]1DMP #R
M1CDW;? 0#GDGR&#G&.Q[8/MKYA]2WOTD^WJ@;):1TMNHKK_8\9J%+D$ )(C4
MK5D6+DY@PGCU?ASJH>:#F67ZD6]X70=@*XUZG+@4O'E-A>WN_2RRN7C6]L;:
MUN+4,]N[V4(>T:6(39 =K\3=28*,0VUOD$&4GJ,T>%;?8"48D$KG\0Y(!QP%
M*$8!/=C[L8&;Q:O]#SV[[#PVV^T^TVM.ZM?F1CPV@50G(?M^9XXN/*@)A8#K
M]^@T(7+DUJ7)JYIV2@A8AY40F>O,U?L,J/S]_P"ELSS.T,]S=E6V137), 6&
M*=WA6-;9XI<JNQ@[-$N6<>JH0K5[6%0H\(4G)8#Q9) !SOR/T /8>(Y(KMOU
MU]&_U ZQAQ _7FI@\\N*;@>:XW+&+3;2<H; P+B$21(@C++DY(Y+41UV/$C(
M?PUB0\TN6Z_(=Y.:]O+E0D]U<3(OY8Y)Y9(U\,:$JCNRKE8HU. .$4=E &;
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MZGM7()$#65NKW<\P(&\VD4\"*V]YPB.5\]<'.U')R0,C:&[<[B0H!\MQ!)X
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M88=4J+^E1C81SJMI*9M6D3=<7V-3609VE3ZJS1WP.*T0GUP5'146"AIJOPY
M44.FCAJ2DOU ^5%QE:59RVA2K1<4IQ2G%*<4IQ2G%*<4IQ2G%*YV;BN&Y8WI
M ^LE9!:PDG]2QZ>==/;%1K Z;Q4I=R![6;L;,?8K,?W!7V52]?ZLBF6)AP)*
M'(/"(^*YL!RY0)>NWW]_?TI]_?W\JZ)\4IQ2G%*^8?TJ-#C1^Y<F[S;M9ZD
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MLK))]M?3"Q_Y&Z]2%[ZM;B,@MM-RX8C.U5'_ !\%W?PA>!DCQ<UK_P"6O?\
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M8&-VW%7_ +.YU5.QA,JQ5>CCR43,EYP77XUSBAHSDN'7(:FV\C;77\3_ %2
MKSZ'I(]KPF2'Y"6TY(3/+;P^C7_J"ULG6].8;2X=M\T=MHUO=Q19Z>(8;B\8
MS2(F;@;W16;=&, *:L(],](Q&-VN1Q.W+JEJLX4]]JRRD.P&Z09VKG" @Y.-
MZ"_^SO\ 1"!EUDC5HDT>_)BONQV1#V9.4Q\DLK2T0/'+$\TZZJ:RKUN4.(2E
MEUA3+D=UIN-80^B?I"9%>\].]9G56R5M[+3[(LIR&4]..2,' B",(ALQ(<,T
MBO'G72-4+AIO2"\8 \B&&. E>00,2.BD )M/3(&')5BRE.VNM->UC4NO*/JZ
ME0U#ZAKNI@*76("UX<5# UH7&$"HREI2A*U,PHC+>5)0C&<ISG"4X^3'<01=
M"&*'J2S=*-$,LS!YI2J@&25@JAI'(W.0J@L3@ <5?QITXTCWO)L55WR$-(^T
M ;G8 !F.,L<#)R<56S7?S]NUGZLO2G]X/=CF3S/P'S:LGD/B?DM2-=>IG6/9
M)^R6G8.A-3W6QW#W'\*35HI $X1L&*W&DP@2"TDC"D.36Q<":0'16GLJ;2-)
ME1RDJA%"#$F:BMQJ.C=,T'X4_ K5>OZMB[V-^WVY(.I!!R+'9Y*Y3KYPNB-"
M0B81<>GD'\R'4J7B01(R$^#T^8MY2JY^CH;;9ZETMII"&FFMA]C&VVVTI0VV
MVCLIMU*$(0G&$H0A.,)2E.,)2G&,8QC&.0/J?F?OY5)^@^0^_G4@V/JX#*;G
MG[OJNS=L:PL5ICTZ'LP'0#E>B5?:42A/.YK3=LA'ZM8"$.3$@/.@7R=2*5HI
M) .+'*F)\V7^:C6:FX-PDLT+N(Q*L;*$F$6=F\,C'(!*DJ5)7PY\ZKWL$:Z-
MW'/<6[R"(3K"R!+@0D],2!XW8$ E"T;1L4)7.>:]>'U%UI!ZR6;JK')6I%#M
M=>NM:*G\2@B;JJ%>3AT^2>030!2*5*A2[!-9%KD!)#4>*W';?9DN)===+91+
M:O: MTW616;P[\2,SGG;C(+G&0>/WH-.@%C)IX,@AE29&?*=7$SN[$'9MRI<
M[<H1VR"<YWV?HNIEMN:WW$5(V B;U-1[-2Z*!E2H"JN&=MZA+-@N"(2!B""[
M?-#AX]=P0R4Q!8"/SH[ Q#\QZ3G(;=#-%.2Q:"-XXU)&Q=^T,^,9WE5"YSC:
M2,<UE:TC:Y@N6+E[>*2*)"5V*9=H>3&W/4*KL!W8"%@%\1-5]L'0FC7<E:K+
ML3;6ZK]>3(2K5VI7PX7HL&R:M%4K8([:-831TUG7X$*Y/@7<.)+/%+:'M$^>
M@>U"EON1'YK4K6?38I&=Y9IY)&1$21FC#Q+'()5Z>V-1GJ $EPY.,'C-:;Z1
M#*TDDUQ=33.B1QS,T2R6Z1SBYC$/3A1<K*JL6E61FV@$D9!]4_T I%EUS)U0
M5W'O%VCVHX>LVX1*2^O_ #;ML-EMR+F8-7><O73DX1/DDVH\!#FNI%(1' Q(
M8EEM"(D=YN'TR-XF@,]QTY'9YUW1_CN\G59G/3R"6P,ILPH ';-0^CQ20^KM
M<W?1D=Y+E=T7_+=Y.JSS-T=RL6 'X!B 0!0!@$7Q::;8::8:3Y&F6T--HQG.
M<);;3A"$^*LY5GRIQC'CG.<Y\/ESG/+(# P.PX%6X&!@=AP*\G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2O5G2LPH<J7B,_,S&8<?]EBYCXD/X:3E>6V<RY$6
M-AQ6,9\OKY++?C_TG$\\NVQ&8*S[03M7;N;'.!O95R?+<RCVD5XD?IH[[&?:
MI;8FW<V/)=[(N?\ ^3*/:16LR)CQ)=)(,K)BVB1)>7X"WHR%O17*^8)M,3D1
M'ID=></P8KG]1*7C"/.UES*7'$9P%S)ZJXZD0DDRR$IDJ897"OL9U/**?"Y\
MQG!(K4:1I3I\JF:%9926C)0%D-M/*JR!&D4^*-#X7.!D9Y(J*KC<:75:YODS
M**U:,H7C#1=4HL+'89<F5,5%BLDY2\K]DR\0=F)9S,2E"I>)7F4VK$AQ&C/+
M"D6JE.D\F=A160.SO;1A$/<AF<M@,/S;B<>(BJGN+:./T@,1MY)@RQM$LD:N
MTDME"B1OM#,&>4N%#+R^_./$1$]EW]1IYO1\H;3(EQ*$X[9<1(B(9F2Q[182
MEH9FOKR(D$IL,C,=CRHQ.%$B09:!N)\-V6S#==BX)=47?:"+3Y+AV0,25*FW
M+; @4-"9"&+<.JJK*A*%P&VZDWI#$CV,2:7+=W!@CD=41FEM6E:*.,1@VYF*
MR,QVRB.)'2)W1G2.1DJQNGM)<AE1W/6VW]?@K-8K=&#L@6)$$I;ACDB/7PTF
M*[$45E 'I ^##;;G/RWVI<F:@NZ*%*:'3Y8K6N;RY%M</?FRALP',Z1*TESL
M$L@, ,A,#/M5$DF*C:QD,:AQ'C2O-8O%LKB;5$T^VT[:_K4:!I+XJ+B=39HK
M"6T>78D<4T[,JI(TIA0R"(UTXTL7(6#3FICQ?.5%3>LZ&7)JS':B9R0)585,
MFYS$9;:9BYS)>=SF.TTTTQ_]DVVA"<)QT%JRO;6[HQ=&@A9'(12RM&I5BL8$
M8+ @D1@(,X4!<"NQLI$FLK26)S)'+:V\D<C+&C.CQ(R.4A"PH64ABL2B-2<(
M H KC1N#\K6T?TBW;]I2?,];57*LOHK^H]KV07OQ07M5 "R[!5MFWZ+'[MV@
M.ZWW+9SAQNS2+Q9]&Q;*W1"9:=8VF3I6)D:T",%4*FEA$UY^4I]C[_OV_K4Y
M_P"_/[_FNC/%13BE.*52KJ5^4[T@/ZZN/X1.I/%2>R_#ZFL=V5[F/]=MEUZF
MNZT:MU;<HXK8-UL35V2#L 4&:W'0M,0HM0J+M6)QKR?R=OXXE[ED6BJ/S(,2
M3#$.DC#T(=*5%4QJ?ID&MA0J>+U]U@N=PV:<$7B99]<"+G'?(U,JQKFQ;<TN
M&C26JB[*MDG=&N:V1LL%@&)45"(COBH FUFLP1\]]_.IQ_WY>7MQ[:G?4OI(
MA^VKIKX:!UX!(:]N6UZ9H&9>P&Q"LPK%V]<>MR.S+>0= LNM:>?*:U$U1UJM
ME;/8G:9=(5J;*,3=:0QX2?.PJ*Z>\4IQ2G%*<4IQ2G%*<4IQ2HGW)=G*+3I!
MA$2#)9]Y5\<4<*6>52X \18#XVM2BS]DC""^8# Q\Q%D37L-Q7(D#VD@Q+;?
MB--/8W(8B,,RL0'R ?RJP#>+&!WQC.>017DX)"[BI/BX![ C(SC'.<=^,@U\
MZ&@M/S>^.T!W8S:$*%?NO>I[>Y7^M.Y=9[ 26M ^89U *IVY+A?9&PS9*=;G
MR-RK=2KU:=@!K%"A1Q-PF"PS++E5-2?$\R6\3.YV*HP"02,X\(P 203QV[\5
M$LJ0QEW(4 8&02H).%&%[9/E@CD>WCZ&:I78^5J)E&66W<N06QN9&!JFIOC-
M5C!V5%B1H<3!=]R.[E:XL: VE"G<LPXJ'?(FK@0S2/=3JJLSH($9@\81IG*R
M[3VDR" 05(&3M!8U71)UG>>9<'*"%68.FPR$K(%.<-D-CD<9.T%LUF;!B))7
M*&LR'U,P!DS!:$X)9CPYD^$\&S">==FC<NRG&V".7\.09RFL>,5Q6<)<QAWQ
M=].4R0K))LAAD%Q"UNJ12RQO;=-F>:W+2%4FW PS8 Z9)P1N]S;6WQJ3A(WZ
MBF(!&=#%L)+QDL0LF[P.1^4_&-;U=V:J0$C!$5)2T$7<Q0(9E.%M8E/-[*&Q
M'">&G6W(0U$DI#4\]GR83&P\ZG*6V7'&Z/5M573YK>"WC%Q?SMT[.V497JNN
MNQ1&XVL&BMQ)-'O?C;'N8>%&(T+V\6V>.*)1)<R';!"!D;B+V-3( 04C#2+D
M\<9/ !(TX3JL1*?'VG;,OW^>>EJ?=AEB670 5MTG47G1(]A;B([\2'$(%$^"
M\*:5'RK*FUIC(>Q6VWH_;2/%J'I$XO+QI2S1W$^ZSM0TVFNUO F51XHDEF W
M @IDD,$5AIQ:9&[)<ZFW7G+DE)),P1 RVQ,:+G!5$ED7GC;S@[0U:KL;8]?U
M_6XT%A]@!#>P0CA@U;B0Y\RP25@#34E,2!"CLMPFT2B;<>>_[<RUA)14A;CK
MV$-\J]=UVRT6PCC#K:1OUX[6UL(HYYK^3U&]+K!!%&.F \HCE<2H-MP79BP
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M;S^?6OALK7Y$H2MYQ3C[BUK7E.5*RI3B_#^EG&)$2* )&FU0<*J*3R]L2<
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MJ*0[1@0VH73 S =.N[!6YJ:E'#BV<DX0#7)JQ##4<?[0@ /?E-RVXLV,WEG
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M8(JJH))9F(   )))  !)X%;$DL<*/+-(D42*SO)(ZQHB*"S,[L0JJJ@LS$@
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M,UPRJ4\.V-I6C7'(50"2V36Y<WJW:<4IQ2G%*<4K0-C7-NC@4EG@U@-M/$1
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M$NA]?[1W^V/9NX$CH34$.'+D#:A3S+@&[V C)PL1/8M[4&!"%H#$ARYLA,9
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M<QHSP/ ZNA)5U+/',N,CG9M<$8##D5!FQ+JU:M@W+3P=<@<]FK '+]8IBF&
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M7@]9ABEE,YN@]W>/UDC>UG2;J0V#0I'/;0PO<HY-Y"5MMJ#40QC;6PI[H8P
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M!(,2Q4.0.%RBB.QFV4D)(T?+G$Y4& _+P\[#AR21&1%C+;8>G2W6U2'('O\
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M*4(2E"$)2A"$)PE*$)QC"4I3C&,)2G&,82G&,8QC&,8QX<R=NU9@      ,
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MI3BE.*4XI3BE4([I:>['[1G4UWKO8I50+0=?]@*O/L[FU[52Q04UL/4MAJ5
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M9=1.<G[^_;452/5'3_N@S4^M==C]7&]97CIP1[PW]O:EDV[KT'/W7-W2(WK
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6BE.*4XI3BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g772024g17q11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g17q11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2C(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    **R^$$$CA"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   F:T #
MA"24T$)0      $/=@K4H0T#=N&%EU]=/2>JDX0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M   0 " 2P    !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              5T   %;@
M !                          $             !6X   5T
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   5T     %)G:'
M1L;VYG   %;@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   %=     !29VAT;&]N9P  !6X    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-!
MP     'HT    !    GP   *    '@  $L    'G$ &  !_]C_[0 ,061O8F
M5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/#
MP/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,#
MP!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,#/_  !$( *  GP,!(@ "$0$#$0'_W0 $
MK_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M        $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4
M%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$
M7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO
M8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A
M,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$
M55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V
M=WAY>GM\?_V@ , P$  A$#$0 _ /2; =[M#R5&#X'[E>23N+P6\+1@^!2@^!
M^Y7DDN/P5PM&#X%*#X%!SNG]8ORGV8O5/LN.]C6B@4->6EI<76-M>_Z5N_:_
MV?Z+_KDNG876<?)<_-ZB,VAS3^C]%M1#R6;2QS'/\ T;6ML]CO](EQ^"N'Q2
M >1^Y95?\ SM# 'MZ>7MT<X^N-T ?I/T?T-[_S-OZ-=&DD9)$7GPWZT"O7[
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MLB =PWM;[=415.G474U/%S=KWO+B?6?>7:-;N+[65;/H_S3&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!<7@B0Z3Q\&6$'"^8B@5EI"7IY""J&#^(YQC=?[6PCD)-BX7-QA  #>!UXK
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M(-)N4C;M[$%-Y2@A\W8E6S BP.Y?%];!IH1J>GJ<DDAM*+WCU]A!$0\,U/+
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M HY%P3PE.3S!L3(LBB?B72MW1MW6;)ZZJ%X>K2*]6I> 5KB[7TKJ1=KVX*-
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M%SQ)$L+FHU^:)GJG8N4HHWCYA\*%C452+LG[>/Q^2M@/R #% A:32DV(C<;
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M!,VM$Y+'9X\CY.473*Y)%&6VXUYH%:?5$JO*@'LX9D6P]>MM0E'4,'N+L&F
M0+M#</9Q&(9(198?*K.LIU-2$6$&$="&ZA0/5T@L-64QX3II\L1EH2&FGNR2
MH=)%P110AWA;0(&4A)P/VS+N,M".2#"/,& 5Y"6N]:FB,UJ^-5$)+2^0&J]@
M56RDB[DAR'C93(-3NKL@UV)1A@[UT;D6W(UT)V_N5I9UM(7^Q/4B0>1>T(5)
MFP75?</9(OLU,.T4L.$2&TI6(EJQ?G'$'B+2,O9Z1DR<8C4B?$K*7D$DV+#2
M+J)SX85#7)O1$9L&TW5K'NN]25]6J6;!91*PY7(Q<0/LS920RG8YL]?).)VP
M<;1R1^TCL@^ %MF3E5ZBZVT7(M.=<O"TMRI+N(&YG-JHDU4;6A3TQ(R)'$Q(
MWE:,8Z_-K%.5!%YLX>BQ,3CS*/6@5JVP'[9@XE;TL1KW#9Q(OHGZ #@B>/&?
M?^'):XI7PNV-(=L>M3.K[RI:WXKU?7>G9?#K5**K7Q##!2"0\4_-C([#$]G!
M@BH+)1%U$25AR$>PKJ''8#%QP601**UNQ8D6]#GA44"9#6&/['V'ON_LN.W-
M4U8N6DU(1QE&VLSL_NW<PJ:C8\7(,XC-+CC]9]H9XP<;RF+S!K'&$.D<BC^[
M4:;D^>$6]L]+A9:-R?Z8[&)%;]MCL75W;4;9S.*Q,>!<S^C8?64$AK<#438T
MJR,0)"!UB#&R=CB2NC#YZ7+R!C*0+S$?P")X\:J.<5\-%6!_6)P;[-QB6R2/
MGE;B)15U%@,!!R:SA%A]DK5JV46"2^DYF<@D0WG/8XZO+1$2%I-C*4?&(!UF
MH%<I$GY%:C0T:CU8U15M("I<,E)"H*?JR).5VY!FN4=A0\9TB@"4/F"+A9RT
M8RG>)EUACQ;7#9^L/)IM%U]V#KY(BW+PB<(G")PB<(G")PB<(G"*B;KQ/!-5
M^)]:_5*NI# ZKK&*OXW%X[1L3===HNYE !EUQ"VVD8(18P_*]B9:[83>P9H4
MWED5V#@U===V9<>LW!GB)$BN2MVOE+6K29UTC*SD%6EP5<0C,8RV!NI)&5E=
MTU$C4?UD8HT(;FV"B6K@40<#'"PM]H@2890(-&KE'"2,2-PDD#'&XX26N(9(
MUY:'-(>S$&X=Y&YDL=\<3V2-:]N;'X'8L+7=5[;. <WKL<RY:X%KPW%BP2-=
M&^V"1CXRYAKZ?>$]2I,:8"O++MQ$$=!/8R]CX96O@@!L#(1^/#7+8.(8P/5H
M(>Y.1**'_IAGIJ6<,XR#AI%X_AS/<,OL><<C)<A)%45]3"<+2(YJ][GDAEMV
M60.DD,4>$,>7N-0)[D'!O5PWZUF4,;KEUWLH6L8P.(=<F1L<8>XW<T, A,8R
M73UYUEK[KGW_ .MK.&%['-D3/3#M8/D1.<6=.Y8/(.([9O2QLD2!00L?7K.M
M5"*CIT[*CJIAD'"/G"J>5QF^K5GJ@)&&)C6X60P4]-$VY=AAI8(Z:%I<XESG
M"*)@<]Q+GNNXYE'.<Z261YQ/GFJ*F5UFM!EJ)GSRD-: UK3)*_"T"S6V:-%,
MS?JEU-4N'%K*4=3F]R_0FVF#^T3CV9!D9L:R2W,9&Y0^;[/\FML[YE61^3.%
M]MFWTK\GME'/+T=2X_._,XL6+!OMR,./[]KVP;W^:_\ $MG>RX>C=G><>=>9
MTWG&'#O=RS%;%BO:UL6+/';%PQ6R4,9COX;L8N.2F#ZMGFI>+['M3S^*1L-V
MVLJHU.TS^,NM2B42@,-#RFG#EKJ@';PE/(_# Y$P+76*FI8-'$WYYX\Z5W+N
M$+=\/3ZS-)3LSMI$A&.X;D\H2)T9W!91<'V[LT RHYKB0KDJW0B@TX186 +C
M$<9GU$(R(.2<03"IL3[H:0P1:6CD:\)LB<J^RV92UW4KN.5)SZ(3>3D.Z+&3
MVR3=/Z3&0>;RHM)4F)221763QBA1=%3"6[?5%W/A$1&U.6>S%9TW=D6[X!!^
ME,0Z]W?9T7L*[F7767M)U [8!$#_ &(;R!G8+JU98*MXV_BI-DC?#:Z);-CJ
M,'.[;#\R%,5'H]'XL-'"E'&A$BRJJU^ARLGF]-14P?VFI?K-&*TG3"R\W<+D
M N@J]B#60,((9E5JM!RD3D$/B'84/+)E$%S FS0(VQXW))N*9I.0KQ$BC+V$
MZ7>&M=T,P1 ]AJWJO:!R3,H.3\'>$:DHL8E*,G(+HTDB$HFKT /1=2\3HZCC
MAUNU3S/X$U%ND#@A"5Q(T1=V<ICP_;"E^_6V:6!*2M\5UO?4@C]\E3RD9/!Y
M_P!C)#3MFV22 3,(D$K@C-7.+WHL4/BSP.Y'D8!-1%;-0IF'F91'G)%T4@IG
MH56_3ZD8)8W8=*QNOD.FG99NQE$')(22,F(E+^LO9S-_UPL2K1P?.B85'J,.
MVQ)7Q1"2$9P),QT:[UDCHPNQ'N2+9CV1^%[/;,K \D4*#Y.@[IN',HO'Q78B
M 0$83KN_):(Z]1[L)78<3'J\AQ4#V12F(ZHQ_8$%'GQ:QTR ^/)%GB*3=,H"
M#HM:=DH'X69NT;*6MFQ[*BAD#*;*E=I 8X<OS>J#TZ)5,)$6P&C2#0'(*X1N
M3>NG\;D$J$T"\!WN/;-7A3=1FQ-V(B?*J2/5(!T[UO,@=Z_RN4D9:TIV5,W$
M>EN+!7/I;R._94]NZ1S0Q;".]GD;7?6E'0 6PPL]>Z2"&LP<+:8%#19H<GL1
M64<(G")PB<(G")PBU3>%T0/KS5,TN.RB#EA$(0*^D'N@YFJ3.&7[IR@, Q:+
MAF_F[/RZ7'WHR,Q*/,==WYZ1E1@EDGNZ>):Y(H\]!:MNJMJ5D)OL,>)%+;O"
MW[+O^21XL5VD#^K&-GF$B,2I=>1^WAL>S4D,:1^":D!C,8$3P%P.!,$PS%BL
MN13<X1.$3A$X1.$3A$X1.$3A%X7#=!V@NU=((N6KE%1NY;.$]%D'""VFR:R"
MZ*FNR:J*J>VR:B:FNVBFFVVNVN=<YQPBJSZ[]? =DT3>M3Q:=V;UZCX3O'V@
M="'_ %OD(NK38YB,M:4((QUDNV $QS2-K8>?*.1346CHHJV:;Z*)?)9QOS5-
M/YU%N]_44_6#MY32-CD-@1AQ%KQA-\Q8&X&EERUE+YY#N?.:JEZP=O:.40S9
M C#C+']0WZPMF0,Q9>AT;\+/3I>=7D*7;?L?8^N\TDLLV@R\B;QBJ#WU@#JA
MM5)S!\_6-:525OA;!->2IGPVKTJS%N=A*.&'L./.H-C^8OQBNJY/M'OW6,,@
M?B%KRQV>9'C4OQMN0#A%L_&V1Y/=%/+QM3:%1]K)(872AE._&TM^VBL\R2"^
M(R![,3@TX!:QQ@QX81>56,%(2>05"K#@/<VQ^UZTZ'5LV5[!3D;9 6]LHUI.
MY3)V\FC),37)BV@4;ASA42^04KV$ 639E&BHABKO[2^C6=I>&?",.8,SV#4^
MSCL6[>6_VI+)":T%CCQO!X[+)=35?-S;-!J^"A(--BL*EDA7&.F^Y9:LHX#9
M)H"73O5(BBE%/!^LT"5K)XXLFEG$=K[?*4;@CNOBQME5\8C!DE(8K7\'ECE<
M<=E06?NR+@%=4DG#/,ED,-7UCFNY5H.&X1(I&POHQ<H;HU>W1D^[I(W&)]7E
MK,X9)R88N]%C)YV MRZY]*T3 +5JE@L%JH7,($ZALE^8"#DKF[(V5?"8VS;#
M-<D6?*=&I@0<]A;&UE4$@%]6CTR'=5*VL*L0A6/OJY,.(B4S+[-=R9IN,EQH
M\<L/:"O6+KYXB0"1:HH(B+<LRVY17<B@SV)\.GO#'X^DUZ^]B[RG8N2V:Z(2
M^&:=I[CC$A0A30AV5-Q!@*L:R+'/NHJR'H6-4T..OXTB2):9AC><;1.;E(\(
M$J$68VCX>O;"3X4["5E;0NNNS*T9[='9]!0,LD(YO.IM>F0#&EHJ1LN/$P!1
MFVI&#5[3HV/D72N01N1U9%G4C%D KAXNV)X]_P"*[*1=".R%Q=,J5HB?&"S&
M=?0_<V!6#(K.LG:W#T7;W[7MU1B!6D\)O21A,LZ!IG@$:0KX&=D:,*BLX?1P
M;(9"+C+P@0(M@B?"C8P.THB1KF50W>N!D_HJT'DDG<.;$[ZA<CIF]9[V DD?
MJ21Q=O%83#(7>,OGQH9,H^!C,:CT4C)V: (W&7H>1C1T7(M:7OX7=T3^RS92
M+$NN[V+2>U+GL@I.9("D@RW33:U)_ [7&P"U%F@TV/LNM(<2KL?6P>/ZE@2J
M46U@)M)-':N%8]*BGN^8\=_XJ6O3OIU..MUORT^4)Q7:)$ZF7%(LH*+S%H9K
M+IWV:[#7L4AT/A*A,J[C4 IH59 N,07YZ[WR22E$@7:-!":*P[0JK)^$3A$X
M1.$3A$X1:L=/#K&Z(Z,UD9->.2*N9^6<1APU _1;$M%9#50\<1'NT J$AU65
M:RDSH\0>G'K!79PGNDT0V;HYT(MI\(G"*CF%&9)MXG,]N"2R60O: D,ICPVG
M[)<3BQ#M'KARG72$Q=(%&#XWMK%J)"JEK;4DP]I%B/56R)"3FA)=\PL#!.0A
MM8017C<(G"*OV8$I.MXGW7X6]C+5E$V/3#MDZ RO20(NW9XJ]MSIUJ=%.(WJ
M.17#) TVHM5 BH2>IE\E%$TV[/(]3+@IQ]A_2^7N_;CABWA(].U^S&>TZ@ZW
M\S_8?NAN(UO:U-8UN94DVTKVDF5]9-B::N/I'?*6(NG,=*YPT\M/J3\M^_\
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M;(1^/_2;QSH[%M7A BO4X10L(=!>NAT_N5E4>?3$$ZQ--RE>2C((I7QAS,+
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MA 8,>U%B1(H;:'2)JP',&+-)%LU9LVR>B#9NBGHFDEIC337&,>7*7%QN3<V
M[@T!K0!H UH#6@6      "@ &0MF7./,N)NYQYEQ)+B<RXW)))4^.15.$3A$
MX1.$3A$X1.$3A$X1.$3A$X18Y,)A%:^BDCG4YD0:(PR(!24DE,HD1!J)!1\
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MKP3UB&!I_E%B"NC9[-N4]%31RMV94/;&,;A-41.<7$DG$V&:,NSN2T!I-PT
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M,/"+Z2N$3A%7W+XD-8>)_P!?YFB^E"I21]+^V 9\.>S*6$8DT;1VW>G:K)R
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M(,5ACIND[:D4G;=1@Y:KIX51<H.]%,MUFZR6VJJ2R:FR:B>V-]-LZYQGA%K
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MIUHDI2"=>RSN.=7;^CKZ8S.2SX9AN^D\SZKE'(RUG=:5N9K\%9Y1S%%E1(B
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M;3Q-G.I,S8HVU#G._GWE4*B>-P)#:>:"$-BW6YCLEC-*YF3"^0MX-+3/,Z'
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M/Y3&/U?S\FXAN/L8KZVP-%NW2_#EGV9IOI?6R?&[YIDD0^#][Y?_ %I?S_\
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M^GBAP#A=JL41@Z0(N#)A>XL&\:W&QO5<7O%K 9/%\\K"V;2J?,@<]WB8T/.
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M.9).?/AE;A\SK9$Q]WV_=G\/3]?\WW<I[^'#+\;V]_;PNB>[X>6?C[_/[?\
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M?J_YS/ICX<#:='ZQ]\A]QQ/?F.W/\."='57JQ\;/J3ZD2+\U1^SU=H>[W_\
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M -O^KU_I=)TE_P"(ZV?]-^I]E\L^6M@G1]5ZL?&SZD^H\AQYYPU1QG/EG/\
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MCR'\U1_E3?\ UGIG_?QTG1ZXW7_R/]WW1?4ZIT?5^K'QL^I/J/(O7^"H^O\
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M*IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JZJT\/EO .P
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MVQL'I2/-F-'"[G6:V]KN(:+N(!H!.(C1K2YV>C6YN=;DT7+B!DT%QZH)&[;
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M+D=OE)<[,K:R P2-M3K):H8REH%/C$]H=L9+-]P<W#J:R$B[0VZ\2\>U/F
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#(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g772024g18m24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g18m24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1NB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &X:^<$8X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             "B   !(H
M 0                         !              2*   "B
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "B     !29VAT
M;&]N9P  !(H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   H@     4F=H=&QO;F<   2*     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M!CQ3I*4DDDDI22222G__T.R^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         /_A0(%H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB
M5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z
M>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N
M,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @
M(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q
M.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A
M=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,"TP-RTR
M.50R,CHT-3HR."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z36]D:69Y1&%T93XR,#(P+3 W+3,Q5#$U.C Y.C(Q*S U.C,P/"]X;7 Z
M36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,"TP
M-RTS,50Q-3HP.3HR,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA
M9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O
M<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO
M<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @
M("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$
M/GAM<"YI:60Z.30U-$0W-T4Q,40S14$Q,4%!1D%!,C4X,4$U-30U,#@\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM
M<"YD:60Z,#4V144R,T(P-T0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+WAM<$U-
M.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^>&UP+F1I9#HP-39%13(S0C W1#-%03$Q04%&04$R-3@Q034U-#4P.#PO
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-R96%T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP-39%
M13(S0C W1#-%03$Q04%&04$R-3@Q034U-#4P.#PO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-RTR.50R
M,CHT-3HR."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC
M;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]P;F<@=&\@87!P;&EC871I;VXO
M=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0D(R1C$P.3$P-T0S14$Q
M,4%!1D%!,C4X,4$U-30U,#@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,S%4,3,Z-38Z-#0K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HY,S4T1#<W13$Q1#-%03$Q04%&04$R-3@Q034U-#4P
M.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,"TP-RTS,50Q-3HP.3HR,2LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.30U-$0W-T4Q,40S14$Q
M,4%!1D%!,C4X,4$U-30U,#@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,S%4,34Z,#DZ,C$K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI
M<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$
M/GAM<"YI:60Z.3,U-$0W-T4Q,40S14$Q,4%!1D%!,C4X,4$U-30U,#@\+W-T
M4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$
M/GAM<"YD:60Z,#4V144R,T(P-T0S14$Q,4%!1D%!,C4X,4$U-30U,#@\+W-T
M4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^>&UP+F1I9#HP-39%13(S0C W1#-%03$Q04%&04$R-3@Q034U
M-#4P.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,\!= ,!
M$0 "$0$#$0'_Q  >  $  @(" P$             " D&!P4* @,$ ?_$ #X0
M  $$ @( ! ((!0,# @<   4" P0& 0< " D1$A,4%189(2(Q4YC7%R,V>+@8
M)$$R46$F@24X0F)Q=K3_Q  ; 0$!  (# 0               0(% P0&!__$
M $H1  (! P(#!08#!@$* @L    ! @,$$04A$C%!!E%A<? 3(H&1H;$4P=$'
M%2,RX?$6)"4S-$)28F-R@B:3-4155F1SDJ*STM7_V@ , P$  A$#$0 _ ._Q
MP#3_ &"D5*+HW;CM\4I-,5KRV,6=7RR[FFD!90:7%G+EB];*;OTT<AEY2B3%
M2=CG<C\2<P9,9U.)#8%#GAM;>$Z4U!VLU\%;BU^5N7MO?J;T_.:RIVR0'7F_
M[%MV@GKN)K/7ZCW@#BP4&GU"10BZ;40.SR-+F6W,R:)LSD,E$AM3XYSW?E_?
MXE>>O/Z_$K-I068FK:RGT>I[GC=:LZ,\/B!XL$7-5VS!=LVZ6.Q#TCLC(O\
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MDXE>CD2,5Z;Z)S\V^/V]?EX%W\=_J=D%!@77ZDV>L) ;7@P:O-E#10KAFLB
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M _$,_H3K7_?QT?\ \AZ5P5=?+Y;HGYP0< < < < < < < < < < < < < <
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M$:)#0Z^OS=D/^UE^2\I3S[CCJU+R!G/ ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M<_F1$>EA?WF\\$.3X X X X! /Q#/Z$ZU_W\='_\AZ5P"?G ' ' ' ' ' '
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MLNW!9D29JX#QN7#9D)AQXDA^4I#F<1V6E./>A'EG($5WNZ6QNP#J@G0C4/\
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M.2IPC3@GPI+W81C%87)([5&C2MZ:I481ITXMM0CR3DW*7//-MM^+,YYU#E'
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M^M=LN=8[[.=G7JM:;*<L(AS6=JZOA]&VX)BZ0M$U/#]W$6Z"U?A+$/6P.N6
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JUH9)2Y#"OR  5YT>S'6X*@+5F,T,3,. . . . . . . . . . . ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g772024g19z11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g19z11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2(<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (@"^AP0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   )FM  X
M0DE-!"4      !#W8*U*$- W;AA9=?73TGJI.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             #&P   ZD
M 0                         !              .I   #&P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #&P    !29VAT
M;&]N9P   ZD    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M/>X-W9 :W<0))9;#6S^<K:R>HY>3;U#$P^G"JRRB]EF<ZW=MKI<VP>FQU?\
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MQ>X,'M=&XGTVL<[;['.</;N4SU7IP<T'(9#FN<VR9K(:[TW@7_S.]C_\'O\
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M9D.?2_):,88P+A7?]"AU66_VMKV9-]%K[&6?SWI>]:G_ #HZ#@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM;:W,C=2<7:'D;'!)C,T-3A"8G.FL[3A\/_$ !L! 0$  P$! 0
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M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBP5H_5FQ?Y"E_\
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M$3A$X1.$3A$X1.$3A$X1.$6F;%S-IH5QS6\12IW%;F,QN)S):8G)& 7O&#E
M)49AGT>OSD=.5^KT_;QYYZ1"(R,$W6"(N ?U64R9?V,]FW\=%FP,+VA^;(39
MV2V:W=?2_BM.Z]?4_P"0[5'U?B!Q.?057]]BMJD%1/P?R8/Y9[O,HE)GQ.8W
MX7)^%8]U@[XC ^<L>[SRS]1UA]FZWJK,R]?DZS-D;GOU?9MGS9+:Y,M];I)U
M>8]5GR6%NLRYKV&:^72V:]NZU]5X\=\+QN;77;E^<9ZU;AW1J-(W5"SF6&E:
MAUOL"LQNOZ1;=TN]BJN_,7F2BW(R6L41.ZX2EEIYD1>!&<OS,&KW:R_$GQ\@
M3\BL=+<"+^>RUO?SL]".A7Y6!^DNLR+C5I&$VB1%[+EP:AL-**J4'\SV+>96
M@Q%E5! SJ((%==*KC+Y,1'37P48XDD(64RAMM\/M]-WN0VOIL5%K?[1OM96-
M?ZCD,Z.'7/6C0^R+Y>[QC56V9#7 -\@W;!F-8@78\C @57HT+6S;1>0;);!9
MN8%DX"(AB8\@@L]M?[//Y]_\;33GA\O>MVZT]]NS6U-HM52RZCB;2$G3TU<H
M^IT.L&TVVW<>*%UL15MQURR;+V#'TF)U]M4VW6F#K55GCF"03*D^\W=990\B
M*V'EY<=Z*SO1&<FK*;W,G+%2YS7DU(]RK0[(4NR2-6EIR!=1HKK\P@:0D:5/
MVFK%.O,M-&MKB)^282P2TV\ZT4@@=FHK\\(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JE]W=RV32?6_8<]
MKF/A++NFRPYM(T109K!K^-B[;L4>8U6*H)'QCPQYV5-L'S4HI!<;'1-?AIB?
ML4W7JU$S$]&T7N -22+#B;Z>^RR:"7- XCXZ>IT6.Z 3?8:P]/-$RG:>D5W7
M>[5TYL6S52KEM%Q@47''FQ]-+7D>7GQQ9.7I8L!+S (\R>T%*'%CX4,I"@!*
MYKF.<QXRN8XM<TVN'-)!!L2-""-"1P*CFEKG-.A:2TC@0;'WJF7<KV=^U^R/
M:4+:0QFGK5I"5J.HP=AT+8TA<F;-8Q=$V?86RXC2 8 $%-TQ[3>Z-FRNLIS:
MY<MXEQFM?,H:A;*PZ."S@>>>>^XT0&W&^MK6T)T/?L^>PV*O3TCT5:.M'5G4
M&D+I*5^5LU&AIAB4S4%RKE.AESEJGK.-4::Y.-#S+M.HX4T-3:F[)C"&N5Z!
MC5D!B.*4,T&G/N\!N0[=.?OX]ZM3RJ)PBI=U%_77O)_IHV3_ ' ==^$5T>$7
MYG/C&<Y\^,8SG[8SG/V_=C&,YSG]V,8SG/X8QYX11U7-N:TMK<6]7;G"23$U
M4Z;>(I]LG+#!M6V&_*C4B59>*0PUZ;,1!R[$4(M:3R'8XIO J5-*QQ\T7U ;
M9UY:(Z/EH&SB2,9)'3T:T<T-(-C"&UEL]Z;9F''Q&DP& V8TM[#LY\N9*:0R
MX&X0@H3+Y%DH+8=*LQ\O&0EDC3CX.P+JQXR75,+S.MUJ"N#@,?DI#")C"*U9
MH.665$*."2.<E.2,/,$M,D6A279#2L/;A*-*W@8"R'V,VIBCDQ%A;C7)Z/,J
MD44&NPYB<UX=O$]>*M5F#B95F/,N,JBGAE/V<8R)'(OJO=CM(VFMVVX0^PH=
M58HT"':[/-23$I!! 5"3%D#8>YL.3H$;F5ID\-$2KM=M\.D^MV'$9()A)0]8
M1*6B+!+[9=?&5Q39FQ1HUZ5.F8Y0TO7[9#E5\NODU0281>1)2!#)UVV$]>J5
ME1%\:K@SS%MKA0[SPLU'O$$4T5:UP-TATSU;.S(1:I*>AE/+$-!>9EJO/258
ML,<2'(CB&BF1$_#R<4:P0.TMHL)Y'C*<84HBV+A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$6@[0V=2].42P;'V!+?)JM6QF7C'VA2Y&0-
M+,*8CHB#@H>/9)E)^R6&7+!@ZY7H@4R7GIR0 B8L0HXQAA9%6[5VLKI;)><[
M-[]B<Q6SY:IST)JS5[Y8TD!UUUG,,I)(KJ7PW7XR1VU=DAQLAMZW1[I(R"0X
MZ@U@\JJ5G$M9,XOSD?[[?\06<?YR/]]O^(<\V5H-??J#2/\ HA6O]2A<]:S^
MEU7^\3[-GYURRG_/S?VLG^-RI?WRZX]C>PL=I,?06_3=.8HN\-47FWQK->J,
MBQ*Q%4V'6;&5:6I&?@)HXB9ID9%2)D-2LJ'JMW+*Q$6Y+T;G&$ZZ\P0+W%]#
MSW>*O/7@92+@(.-FYQZS34=#Q@,O9"  8LBP2@@3 \A./QD6TQ&1STL6VZ>Z
M!',L@AK(4.(TV.VVC!19CA$X14+Z+US%2DNZ-=3.6.R8C.YMJ;Q-VZ57.6(_
MWVBNOQ7O).5<:968XU[_ .'85EI'NQ66&<8\-8SDBFWL9J#:&XJ7)UW5W9/9
M'7&:*K-MAF9W7]=UC/?%2<]%? PTI*KO5)L=@"Q6R\*,%51;'2)ES!).43@Q
MK48?'$5?NAW4WL=UAUI3ZKOCNSM;LQ,005C'DHZT1%+(J[KLO,D2$6^/:Y^K
M2^\I)^"#<2(.J?VF;'+RX\RS#!QK$='A3GGN^]7RY^'N^:P%NZ3:'F )J&E-
MJ)2,5NFS6;,1-SXS45#1MNKMAB/R)# U^P5&1&KU=&N=MEJ7%+E4EPY%DD6G
MPY2"*?BGQ%^'F+J+A5TIT'-H#16=KQ8Y)DE&J%1$IHD@!8[A!VS:NQD.SL4S
MCW%L=E"=HDL6V%)4IZQ5>&8 ->:8.*)346WP_2;6T7M^ W&1>T2,T#:8A]R!
MP.S!51NQ5F"I,>")4Z_5IZ#BX"2'+UZP<3&'"6410"U1:HEO$4&<R3GGGYK/
MPO5'6UKLTC?KG,QMXJ\?.;L,IP<;.$N5Y<?MC8U:VU*RMFP&0Q&'6*B[$A)A
MBL>]7*Q\*.#!3S&0;/'-KCB+\@^L].DJA.5.;W6=;Y:]ZFUWK2D6B+138N6B
MZ/I64F+!1[!#1P3!\/9[%&66Q+F[--NQ[E:EWV(T%-9B(S! 1CGGG[RU4_HS
M-6FW;3LEYW4_*,;EC;M7-A,5V@1M>,FZ?LFGZ.H]QK(I!T[8Q81#E>T%4HJ(
MF8X'YH#'S%A6\LF?< L0I%9[6$5&ZE@AJ5:[36F;3<K]N*^1\<F4:%R>K8&V
MK#>GXR"'D?@SI5%>5?X2!))9#0I\QT1YQAER28:413!(R,?$1YTM+'!Q<7&!
MDR$E)2!+(0$> &RLDPXXPE;8X@@H[;CY)+[C;+#+:W75I0E2L$7019JV[@S+
M=@A',1Y9 !^42H"\ G"#OF%!&921G Q8P@I)1 SWH>9''??<0EIIQ22+Z!L=
M>DW0F8V>AI!Z3 +E(UH&3"+<D(R/)%"/D0D#ON*+!",."$++8PX.,28*P\XA
MTAE"R+DF)V$KPJ3I^9BH,);R!T&3$B)&"J(<2M:&$D&O,,J>6AIQ:&L+RM26
MUJPG.$*S@B[XQ(QH[!@9#!8A3+1 I0SK;XY([R$N,OL/M*6T\RZVI+C3K:E(
M<0I*D*RG.,\(N;A%UUEB-OLBN$CMDDJ=2..MYM+Y"F6\//)9:4K#CJFF5)==
MPVE66VU8<7X3G&>$L==-FWN\5U4S,.N3S")EHU4SAA\G,0DX7,G@87$?DHC(
M&'<EX8&Q+167W<M>[9Q)Q^7%)P:-[PBY#)2,CW@!SY$$$B4*^"C&#"QQGI$W
MW3C_ ,( T\XA9A7N&77OAQTN.^Z:<<]'H0I6"+\9E8LB0,B1Y(!^5CFAGY",
M9,'=D 6#,+R(\8$AQ1(S16&W,C./-H0_A"\M95A*O!%W^$6%^I*]\_75/GL/
MBT-Q@LTNN9D@\3B8<TB1%#E<Q67OCOEQ1,1*#L&>X^'=>CC6D.96*\E!%WCI
M&/C&4$R1P<>.X6" V^<2R(RX=)F,1T:&AU];:%%2$@4,"$.E67BC"&!F$./.
MMH418G%OJ>8[$QBT5W,0II]],IB;C<QRF!2APB7L'8)^&RT.86*(^YAWT,E$
MCCN92Z\VA1%DA):+/?>%!D@#"1Q@C2!Q3!R'V Y/#ZHXMUIEQ:VQI!(I*@GU
MIPT5@=_+"W,-.>DBR'")PB<(G")PBPEFLM>IE=G+=;9J,K=7K,3(3UAL$T:Q
M'1$+"Q0KILE*29Y2VQPP01&72"2'G$-M--J6M6,8SPBIYK"LV#LI>Z_V3VI"
MR4%K>I$O275K3]A#> / ^*$?C\]A]F01C:71-D6>**-'UE6#DI)U?0)AXJ6%
M"V';)Z-J9%<F=_\ 4<S_ )*D?_Q'N9Q_G(_WV_X@LX_SD?[[?\06%U]^H-(_
MZ(5K_4H7/:L_I=5_O,__ )7+*?\ /S?VLG^-R\I?;&6B.I^MM 3ECML%&TQC
M<YK%KH5A[$;IZX@[/&*US<6(J':M77^HVW9,F97IQ<?:6(T<=BOX3%N9FD/N
MO1RQ=4^'.[GSV@+S%];7V;1M N+GTTW;=H5O.DURKTITOU7>*377"*]]'6:7
M@ZS4MA[$W(_)-1]BLJDQ]<V)N^.I]^N94N0*XF+.N0<,E3Y;(0Q.(-@(]8;/
M?MOJ=OO0[3M\]OFJXS?M.B86E:[OSG7:>(AM@:CG-DYC!MF5(NTU20C):RUT
M6.M,)' GM1=+S:(FN5&7V.](I#:L]YA *C W@*+M4G M>'._=X<+^2G/=SY+
M8-+^TTJ&UKF16Y/5-QJD3$U6TD3\W%N2>R)438=! U]+7:FPM(H]5D;3::^%
M&;(@W:]=H<)Q^PDBR@SU2AD,B$FU%(G12VP][/[FVZOHFVX:;[E6@D!%CJUG
MI4VEIK1/7X1?S"KW.'@+/#NY>'<RAB7AP7W6?=%--K%?8><(I)[=Q7:27UC,
MB]79>I1MG7"RB"6)08AJY&G*>C<Q"*-8"K%"56 .;0F2R:5:!Y -UM;"&DLJ
M2OWGU/1.7HS#B<+^DT-7)2B:,M,3FFC8S+)UOMT#:>:JGC),>1M,Z-X(<77!
MTTZUM6Z%PHW,$F5WUAVR=,O5N+FL8=MR\.!TV;X5Z'UWOK P4DWVSFJ\^"J?
MFW!XZPOA639:VEQ->1$$@6BFVD^EC59);<JC,.9$KGDFX-)66@0D-..STYJ.
M@L\\9Z*0U#7B" .DIVOI\-N):@RM?35E+'6/JBPQ'KF2B#)D9D+VO*\,.;B+
M6N]M++9G6#K/EV,RD/C>8\E\W9+<][ZV(7)0.FEEBOR$Q-G)H,.#H@M_!%SH
MXP)UUW?AD$\=BP[*$N&O# HR8L)ICTQ;!@)>?E,S<Q996'NHC\KE"/SU=-:Q
M9NBUN(L^JIBF2^O*PS1MM[AV&:2&"^"XD/8/:B(WW LDP:*R>!<_D5<@H>&#
MAG9*CYA+?$Q$T-9YF !>KIY%B*QT$VK6#*"2YN*B64'7^]RMN,0<MKR>9&L2
MI9%639;%)R3]XF2V=FV1J%G1).R&LV%E:+A9"DXPY-2XY[3<+<>\WVZ6[N/R
M5):0VP((%G$N!!=F-BT!HR@-RMRDN.8%V8!P:VPVF-7;5HM)NM"L>N]3#%76
M,OMOL\K5[:6[0)[8=K1&Q$36H>K%:XC'JM3!( !V)D1B*]/?+8:.K)#YVQ[+
M-W$T0HH4U3TFV!2+OKBPS,M02 *W;&KI)23!LC*72NDQ]^[0W3%;K4HW1ZK&
MSHUP1V&%C[C8UQU&PIJ$L+;%1-;L8:H,BQ.TNK/:2,J]YL^L-T7B7OK\)=B(
MJOM;?V0EJ5E+%"=FP6P(8*T6@*G01*']@=>UP;^7(8.M/ZD**AB8MY3#DJ3G
MGGX76#BNJ?8?:NL4+MDW.:AVC5'J] Z^G+A?2-ESX$5'7ZQ;*N%E:L<)*E34
M:%?SI6G58>"Q81[E4*WK>(#CKB/+!QEI6]W/IXI[UF*OJ+M!,U;MY%[#J]H,
M-LLRP;K.)F-OL6BIW*K5_;^P[<)0*_#2M@/'K"[)0'JU39&RS+U8CY6O254A
MI>"B)&IV@PP.=_/=\D6F6#V=FTYZ2VX4W=:-'B7^T[AF 6"2)&5<>&V#"=U@
MJZ24L6E03\ ["/\ :J-%E819MX08W S,J'9!\.QT#E\/GK?GQ166U7UXOE*W
M-]<%QU7J<=:2=LVR8 UP8P35J.78*-U[US"U*'7,Q$"98)"U%:RD]HS\[FAP
ML*B>":CS8T@O*92>(MHENL-DF>N]WTO;-G2.W)RS76SVN*MFT8:I*S"C3FPR
M;:!$,C5"H0 J6HR*)>!2_F.(>2::>Q&KC*S\I@(@G.GO]5J-IZV[P<L52D*-
MM1^"C!-T2E[LC.=B;-!:'HK.QJC+UBA5ZK-JE:7]-,:RC+5292HCP]:"3*34
M;,@3Z11)J-L!%&XW3GL?$UV4#B>R-T7,R$?68]]\_<.VI#XP",@>LCMGC!)"
MSYN#%9+MERUOOPO-M KDE+PT1N!EED(T)@FO"E?+GFWHN>N=,=SP9<WZ=OSF
M&[/==9VRQV$O;FQI.[R\= ZJTOK.YU\N:BX.H,LRAC>L)\X:\UX6M2=F1<T-
M2L1 .U\5XI<V&NS2US8"]R/"Y)X7U61>\@-+WEK6Y6@N-FLSN?E#;V#2]SGV
M&F<EUKN).,5TU[#CV2(L+6XFY&0AS[3'0MA)V+M(.SU2KS,EI5V&+04RV^O8
MA\+$ZI+"D*C>Y+-;MY<N,;994EYHIYTL%,VU-"[,W;.Z5OLT'1ZS,P]:B0;O
M7I"7/F":#)HVYI;;I$KKZ7#@B!)FPC?DK(J3KCZJ^+DB1C9\:8*%A%P\V19,
M;0^S3]WW+<D@12JG(V+0MBUFQ],3\A+D)N-E;UX8FP".*UY3Y2"$@I.GF!O'
ME6*X25H!15S60J:N#7$E$57MK]7.V-1JT@_J?:.Q;P_*$B14C64;KV,_-9A7
MC-$'YD(^9O=[BVXQZ-E:?NLPLF*FAY<P#98<3AL^,8<CXHBD"/ZR;UG7:%MM
M^?*I&RH>T_,K+3)VZOV22DJ#68F@TRL:R/V57&V#3194"DS&RY>3"+CV#MA7
M:3#GPI*GRUKK,F^_W_P"=RP>D=+=E"M*:X V]$6[Z]K'8>NW&V1MWVF'?WK'
M5R-0-:_.G(HA^?G!Z_%5.YV!R]/U-VQRK\E.TF<M-<;:<M->KHA%H.MO9X;8
MHD#!(-F]86$V!)KY^*K)RTJ["2[]>N/0Z?>!D;4)K&,5F.L(?46R(7EW7YI,
M!]70$6\JUHC9&8>EM^\<E6^A'>#Z7^U7#ZV:(MNG;E;'I=$,Q!2% @ 0F:UA
M U8%FY3=O8S:TG4*O%NO8D :CK**VG U&IO& 1:3HSU_#QP#0GP(U45Q^$3A
M$X1.$7PXXAI"W75H;:;0IQQQQ6$(;0C&5+6M:LX2E"4XRI2E9QA.,9SG.,8X
M14+AD.]V[?'6\Y#GYG6OK +*4&)=PMMGM#L.M'MD@;'F6,KQ\7H2A38J7]=0
MYK.!]I76,:V(0R_18"BE6\G/@K[\(M,V-:*]2J%<K;;)<.!K=>K4Q*34Q(.>
MZ#CP!07EOD/KQA2LX2G'A*&T+==<4EIIM;JT(5L4D$U554]/3QNEGFFCCBC8
M+N>]S@&M'B=Y( &I( NO:GC?+/#'&TOD?(QK&-%RXEPL %JNA+[3]F:;US<J
M'/@V:LR=5BQPI>/R[[ATF)'3#R@RFWVF2&"8^4!,!+'(9:>8)'=:<0E2>;.+
M4E318E6TU7$Z"=E1(Y\;[7 D/6,<+$@M?&]KVD$@M<""O2M@EIZNHAGC='(V
M5^9CMH#B7-.EP0YI!!!((((*\O\ VU-RI&O]+:FL]UJ(TB+B^W2OXODS=;I1
M*W08RT:>OT-84&2](CSSB;-:HHA<;K8&4?@X1C8@E;G"I\8F%"CI;F[QSSY]
M_'76X\\^6OE=6]]F^\ 5TIT:;&QM@ &DHVX2KAEGL,Q:Y:W'RNQ;A(RNRL6*
M?@JQ,RT5M63*,V77RI&N0).8"V1C:XB.PC C5'A9#M^ZWNW=ZE>2ZA]5YB5$
MG);KGI.3F0*C)T *4D-9U PX2CS0\^)+U 8DB)<=9K<D-:K,P="MJ3'DMS\P
MET=6)$OWI2YX\\@+<*=H72.O)\"UT+46MZ99XNCQVM(VP5>EU^#F0=>Q#P[\
M92A)&-CQBV*P"\((Z-"MNI ;6(*I+'D9GT$4#]1?UU[R?Z:-D_W ==^$4J[_
M +QNW7U779-.ZMKFU5QD=+'3<#(VJP0=D?='2)\H J4/!4JU_4)\DXX6VZR:
M9 CB9:'<=,P.Z20'HUTM9#$9*2".H+6N+F/>]KR1;*V-K&.S$DF]W-M;S7*Q
M:JQ.D@,^'4,->8V2.EA?/-%.X@-ZMM/'%2U'7/>2X$/=$UM@2X-+G-AOJ!M3
MMILFN1;N_P#3D'0&XL<Z'G9V4E+!7[O.3H+03P<L-KHFDC08T)*LF90Z<!<'
MVF3A"FV &_"A1M7"ZC%)V--=2QP!N9KR2]LSG  M<(LF3(Z]B0_0@Z#8N=T?
MKL>K86.Q;#HJ,,#HY9'OGBJI96AA:\4;J5L38I XW>RI< X$!H((;$]%U%V(
MGW=)1]L1MVHV"LSSTMV+M]NV_:)^D[/L ,48T3(ZSA-;]B8*3K=7FYE91]:B
M3*Y7JU"1DG7@I_6,B[!D0\)V%]-R/OTU6FSNCNTT!8M2C40W=F(4;<6Z96Z2
M1&]9>UY9I)W9Z'(UDHC%ZVNOX=J+Z^1F3 !CXG8L/*0>;!09BF5R^6\6[0I.
M>>?%:G0=2=Y8F2B?JH_;DU"JNU5,H[P6RFX<NF0<)/:%:V0;M*"G]]WE^Q8V
M/6ZMN0VJ0K]SV7'PYUL('R)0GIH,:(<\\]RIMIX:^/IX?;O5J.O2]MU?5MLU
M'L2D[;EYZ*K=MD*G:I.=,)N5OK;$)78B)^I[+*[^M[5;VO;[61<LP,37=P@0
MXD%7!+29*ZM)F@8@4HH:T[KOMS&WK4;UR'VJB+BK Z:5-2FSV':K$4GZ_P"S
MLC982]T@G<%ZE)B3L-/LNC(VC@R$AMB6JHT; ,&W@8^HV(MPBY-HVKV@&MZQ
M>]AA/$V0"&@[S,CU5-<U<6W'H5 ]FLP34=B':18#,P1]/ZQDQZS29)*R=E7@
MFS8DX4-0>OR+0QG^W&\]?P.TZ,BSE;+UBY"U^NLW-J"I@5CE9G9$C<-D'K7$
MLUBDWN!AZ' :DK%,NL&"Q3[C(YL\BF.;C9"2"'(MGA=N;\V?2.Z$7:QMD@B4
MLS$' P**Y7@9IG7P&U=BP=U,KLE2HD29:O$QJ"!CGV*J9(R\XW*9#N]8+Q7[
M_5XN'<\5>'/Q^[YG09O5W?QZ3W4BOJV<S&S5UW/(4\E6U@8W'P,A6N[8VN%U
ME)FY;4H>+(>NW7)MK#4=J>.KA\!3<HI#QE5L%L!(;;N ];:^]66TU7]RPNZ8
MY4K';'K=5DQ=R&TRL[3N+NR)>J4)-/ZWQ;0MML<?<[R,2?+[FC;C::7#G7V>
MG(ZG2U@&&,A!%.5>N%%MELUQV3NG6N[5K85E1*;D^O;)*TF1TS/6O3+[573L
M O%7$(E87833[_HI!#RE"&SC8^0%Q8<P'(V>+?F3B#:+K7[%CN35IRC@4>-L
MEDK;^Y#XR2:+FM5$0U4TA![ JE?B,3Y-J;*V1;96PZP-M5O^HF+GFSBS]>"%
MEQ#RY/$9)$4>M+]I%%5J8+<(^I9Q^,KHK #L=I6/?CLFP/6:>N4Q *$0R&19
M(:>LO9^H50*>6?7G@*%3'I:/FS"&K%<B<^/P2MPG?AJ3EB)N3LY<K,W36AK,
MJ9G5 M7JM1E]2Z7KNP7:Q5@+%)81+1-XC]N2TG V-RS0[!WRB6J&2\S!JRFO
MO'#9?PTTX>JH-@X6&H V-)TUT)%VFX&K2"1<'0V.#S$=^0[O"6I^,M!DE'$V
M^LL& 2^K':K.1[\AH46!L&R*U*6ED*(KLU%U*^RED)U=!!W&)-*.^EX8!4QD
M8ISSSYA13=M]G>FS+'H6ZZUKVU*_5I*%BI8J(Q:(ZAF4BRD[5T[8%R.W*K]9
MQ>;#$YU/&;)AWZVEBX8')..AB81B6F "1YX<-_N^]%WXX'?IN_K]?HFJ;%JU
M+E>O\RS$UVY6B#(A&-NNL:^.J@S$"%NW958)DA$L6F&,,KE0U?!09H,_F5D=
MD(MT/9 *BK9MO87?K351E9Z0-DK5'F/!P0LFU#Z;C#X4PR0T28%+-'L1)=?A
MOB7;3ORO%25PAY&N,PNO*6(D8:V3 ]AO!%M  O:6PV:B=A*N#:#!)*6$J=RB
M9Z(8IUN3IRD@5&'?DDZTG"X^);NEDV,7N*[A,N /O-ZXG!XZ&RFQMUAMU]_W
M?/W)R/OY\N&,TUL[L+N;1FMK5?/K9,R[V7J(5YCU0L'#E0]:=U@'(5P")EJ5
M&0\=8*R)O:4IA$U(8'4756US]!NA\@32;%)E$//-@HNUOJOO:!2H,*_QV[I0
M -<0N>@@=T QMTEH]N]=!SK5&QDF]V"M4@&4?"4KM1F,DB]MLO%MS%L3'C4*
M)NM<J"G/)Y/!737QTOP%^[?HKL]88?;L)>KF#L9%N9"QK:HD@A7">^JI.%1(
M;K[)2-*K,K:!).<B+%?:MIXO7-?V+,A6"Q/'F1]??*L=A];4T<45U^$3A$X1
M.$5$+J:;W'N5@TW62R1>KU$F"H#L!=8]YX5>[+9&/J9E>NE*D&D)R]1(EU"A
M=_VR-(0@Q[/Y&H0M^0=V6JJ$5Y@@@XT,2.CA!@(\ 4<($$)AH4,(,5I# H@@
MS"4,CC#,-H98890AIEI"&VTI0G&,$7*\\T.TZ00ZVPPPVMYYYY:6FF6FDY6X
MZZXO*4-MMH2I:UK5A*$XRI6<8QG/* 20 "22  !<DG0  :DD[ @!)L!<G0 ;
M2>"H#*D27>F1,K4.\;$=-XB14):K.*X3'2_9F6BRLI)JE1+;RT7&Z7CCV%CV
MBUC*%D;R<+F%K)+4"W)2A7UD89T6:V>0-DZ1R,S00. ?'@C'B[:BH:06R8F]
MIO# [,RE8[K)VF8LC9V66P@"1UG8HX Q1FSFT+7"XED!!#JEP-XXS=L0.:0%
MQ:T7*UOK:BZAI<)KS6U:CZC3*ZT0S#P,9A_(H:3#") QS+I3Q!1!!9Q1)A11
M1#Y))+[KSSJUKRK/SE;6U6(U,M96SOJ*F8M,LTELSLK6L;HT!H#6-:UK6@ -
M   "YE14354KYZB1TLTA!?(\W<ZP &RP        L OYHO;06S$+VCA8ZDW#
MN6/LDC3]6>>JT5-[=A>DR8K-BM6(Z1LQ&AMAT/;*+Z20T2S/9JS-B7B&9A7E
M1^'6D^=0\.XKS;OO;=MM?RO[_<O=#V?YLG(].M$FS1T9)2Q%6/7(FPT[O&RQ
M3QF+-.I?^!G.R2$;O/8:<2IE*]@87),Y;R,"Z_",QCSE6*N+PB<(J$=% K='
MR'<\.^3\%:;:QW-M>)F?K59,IT)(NJT9U_<&< K1]FN)<4AD%8HKS;UEE,D$
ML/&(6.V2@,<BLYMW:$QJZ'!E(?46T-NO&NF-+B]8 U@XZ,P*+DA!,HBRVFLI
M0(4O^3LJCLR9>7L9Q\%G'I]71PZACKY'QRXC08<&!I$E>^=C'YG6+8S!3SW<
MT=HY\C;?I;;;--3MJ'.:ZIIZ8  YJASVAUS:S<C'ZC:;Y1;?PKIU8[@W7L0%
M#NV3JONK5&)62L(+EEF&(0N@1[<*T0\RLJ5ECZO<5/FN,8B\)%H1 3<PM(V)
M!QE!+XO8Q[HY2X,Z00X_AF(&-D+A!$96U;S*0"&QQLGI@&@]9=U6'&/7(#E#
MM_$\+AH'.$>(TE4&MC<&,+Q,[/8$!C6R1BWUM90<FM@; PQJ/M)V"=H-%F)J
MO,;(L4_+S,GLD0Y9,8908N,MVF:J]4X2&K6IJM\LL&1]ES<\/!6P^S$!"U,W
MXF[3++SZX?Y;GN^W^&Y<=;# ]V-IS"]?9SJ2*^(MRH B1KXZ-D(G "K!.U^(
ML.OQER%'"C\7O1D=,FVG;;ASK$2]#0SC,(@4Y<TW62<_'OY^.F7/MAV<LC86
MLZKKT>CWVU:XUE9R;G%1$W+1] E;_L/4(1D6'BTP+ZIQ^-H&R9E/STVD8KPE
MII5A5A4D3$V2L567X\\^@XJV].?+ROO"SL+W7W_+1MAD&^NB T50VWG2L;-3
MQ:[.F"HY,<W)UE^*JT;/?";#/%?4['(F&:Z 8X>T2)#KC8Y#TU>>?!1<NANV
MVSR=C3%<W#'/!U*4FH5J--GXB4B[-4!937>L,11A3L;0ZY59FM6'9T^=4!7&
M7U63ZRLX$:V U$QR_=M_=K\K?-%/3>UM@#]IMA4<0XFR:]@]-3EKS"-Q+#C=
M9O$*]0,P\41*#5:%DHCZIC9^?-CF#[!?V[:H4YV%^C4TN2C["15HG>]78"G5
MV9F+?H"%&?PQ  5UJ!-O$LLRR6!/6R9:&<#DZO7LFL!P?8DN)^"%/%,.LFG[
MHM#X@\@H"M#SSSY[$&O//.U9!CM/N67L.N-J0$>Q-ZDM<Q4=<3K58RU9]9QC
M@=1B)W8^X6K5$14E8CZE!72]FZY9<BTJ'(DM5KDI)R%J1=BM$419O5/;_8^[
MM45*\_((C7S]@[&ZQH!;$44F6E:]2[!2JGLEMBTQ\FV0N*D+=*RH^M(]UT41
M^9@;)!WB$8B/J*);!<^G/FAYYN>=%7O6?;#M;/Z]BS;I(3,.P0_7,SNP@-=@
M&.PT1,V#H^%:S6"BM?Q%>=EJ0C;78-E\5^A+!K[$ -'S+EOD*3,SYY%<71^Z
M-Q6*<N0L]%REV^6ZJ5:*M%X@0J')SXP.]-[TJA6HB/GDQ&(:1W)K>K5.RN"2
M+T;$M$0IAT/%P8DFJ/:(LY8;=O:WT'J[:&UW;1MJV!<*O#;7I,3!T*QD0L;/
MUB<EY)R0<LE9O/R3,=(P8382T&"/1XTV_'6!ER8;8Q'D4%3?>+>E>;U^P1U^
M9EYZ^:<E]GY@XMRVLC5HMRK;*M%7A)J8*@LR:WW7->B5NR-QM0-1#3-QATNG
M-D*A8RU/+GG^*OGSI]ON7);NZ78VCP\BJ5Z[0\Q,M6]-: ,AI^:C*JEB-LO8
MJH&G3DO<(RNC0X]IFM#0;M8)P:8D$#<E21D>S2($8'=RBZ[':_LV-.R<+C6U
M?L5AQ==KU%L-L.VPM.KT?2K!V!D:X9..M5:9L#]AFJ=K"EX9)%F?IV8'OM<E
M (X)R0;R6YY^:+F@>XVS(3:@[U]KI41JB:@R9:4'M$7-!RU(@J_LCM@S:KM'
MR\/K\"$,A*Q1]=:S,LP5EEARQ8 Z"(C'I.>F\%6@KN\S\OO4O[3WGL&E=D*K
M7VBY$;6;4569F<AV:09, R]&,I^]9W8E^?L04.9*@FT&9I&M(L2+CCF&VEV9
M,9+0LQ)WRG.Q;GGG<HNA"[VVR+-=G,18BMF 4>S:NC]:L' O1L2V?>+U8*?9
M:V;/P-&AI(5=-%"B)J8KI5?N,[78DH"QF7FQ1]RCHJKD4-6+OANNG-U*,MVG
MJ= 3EIF(!Q4L5-6D>FP-1<L]XIELF[!)SD+7LQC$ ;2&[8=)NO*#B:Y<ZN ^
M+(E+Q+'D6*G>XVYM<REOV<769BYZHO6LIK;&N19",>#KL&P$9MD+6-1B9."K
MQ\PBP;AIU%I-TPU:2VH&)/F+%&N2\?/3='KL\Y*+;]A]G]U2G7^G;&J:(RKW
M28U#V9O*HZLC#V45V]:L2Q6JM1"1SHZS.,2XOSB9M-AK[8A\I$V;7YL(7B0
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M5+<<6I*$(3E2E83C.>4 N(:T$N)   )))-@ !J23H -250"2  220  +DDZ
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MKVHPRJ[5*)3:S7UR[%@5!5^L0D-#JGABPCQIM49' C!9EQSHV.,8DLL9,9*
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M;0I:U)2G.<8M:Y[FL8USWN<&M:T%SG.<;-:UHN2XD@  $DFPU6 !<0UH)<2
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M)!O2IC^$AI#+(K;<(H5['72CZ\T/MFW;*1-.4&+HT\U;45W .)I4)*AKAC<
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MYDF(Q)"O$4&FUD3X4:>6['#6)^(%)%A)Z4CA4!-VJ-GHK&$$QA+3<O;CZ$_
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F%QJG///R7IOPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g772024g20c85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g20c85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3&X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,9R^$G #A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   F:T #
MA"24T$)0      $/=@K4H0T#=N&%EU]=/2>JDX0DE-!#H      .4    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M  "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8F
MIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M   0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #
MA"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M  %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M!#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F
M]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M$       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W
M5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'
M0               !";&0@56YT1B-2;'0               !2<VQT56YT1B
M-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M  4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"
M!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&
M-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M      #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;V
MYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L
M   0 " 2P    !  (X0DE-!"8       X             /X   #A"24T$#0
M      !    !XX0DE-!!D       0    >.$))30/S       )
M ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&
M9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M$ -0    $ +0    8       $X0DE- _@      '   /________________
M____________\#Z     #_____________________________ ^@     __
M___________________________P/H     /________________________
M____\#Z   .$))300(       0     0   D    )      #A"24T$'@
M  !      X0DE-!!H      S4    &              -"   $$0
M !                          $             !!$   -"
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   -"     %)G:'
M1L;VYG   $$0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   #0@    !29VAT;&]N9P  !!$    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-!
MP     )WT    !    H    (    '@  #P    )V$ &  !_]C_X@Q824-#7U
M!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M!A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4
MA0("
M       !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W
M!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !
M1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M   "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6
M=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M     2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.3
M8V+3(N,0
M              6%E:(        /-1  $    !%LQ865H@
M       %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-
MI865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                        !D97
M-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&
M%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(                             9&
M5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S
M8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$                                  '
M9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $
MP)5@!0    5Q_G;65A<P         !                         H\
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M]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)"
MP)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,#
MP,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,#
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M7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
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M7Z=]5/VC_35)8P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @(# 0             ("08'! H! @4#_\0 1A    8#  $!!0,*! 0% @<
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M<;%R<(7#?Z1K8N*( D1@# & , 8 P!@# & , ]1C 4 9A@PEEEA$,PP8M
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MI^M$R/,8L"TK'9+8229O!)Y)8#\[2.Z)^XV(PRUP;7.=.ZA ^&V(TN0W8UQ
MPJU^!E[E1O&U*P?</GS!RLT:BCBU6G*9Q 4<^C_Y!913&UJIZK%N<WE$N$H?
MB7]6S)BDS:O3@5-/QR0H99NIMW>SQ?5_C^H,'9."+YK_ %3D@CMEU_9,XJ&5
M<U2/:R?[D\303(5*\T7104AVXJV-IF"]G-=E=JI']DUHA[-^"93$+LO&M4[<
M-T;_ #_'O-KU5S/8$#O.GWJ1GIG]6B<>L[^MR=QYN-9(6.T+V>X.RQVN(DU.
M3FXO(61MC&WLWXA8>I/5;A#:].PDKC(0(R'GSY^8+'\ 8 P!@# & , 8 P!@
M%8'DYZ[A5-U*Z\VQUFDUM]4=80Z8550_/]8N!"6QY(LES"Z1U;-UCD,M0F@D
M%AQ*I6\/4Z?"RVU$!K5!3?$FI5FTA@ZL_A2\-M\5AY29@_VG/H*R?F]9)$U$
M^0PAV>GA;,Y=;U2.;S#X_'5BEE9R 1Y.S2 TR9N*[19AFT9T?;D"Y.Z">$0'
M?7P!@# (!>4>M6FW.#>@H.]SJHJS;%3-$'U3/+Y-5 J&,ZAECPZ9@<)T2EWL
M3@T[,8 )BF904K;WMP/1M#F@<&Y:J1'O/G8$!?$/8$)EUKVD@B]A>(Z9*4-<
M(#U*3QV4T^UG825/]I&\D*J?.#H+:=?#1&"T6F0$!",M[&D.]- !OU#S^?\
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M , JN[5[PFL3L1LXJXAB[-=/=L^:2W+;:XF&F5AS1!%FRRE%RW\\(]#+:FQ
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M_=1W$YO-D[J.P:%K2AH1/FF .$B2R69U!)9F[*E#9'F!0Y2\]DFYSZF:H*K
MP;5N"_W(GA QH5)2S0%L8>H_*-V;[*;D+EUGXJI]S +W71_<:<2NSG!M-] @
M<(!S%%EQSBW.6BQ:6-JBRG@+&O($'1R8@>M@V!F]>>'&CW25-5K]N63:/D/N
MANWI2D?.E'0E=4L67#V$:D-=<^,^D]9Q9I.,#[86MR0R8)(_^J4> W>QX!;:
MTM+4PMB%E8VQO96=K2DH6QI:429N;&Y$F!HI.C0H$91*5(E(+"$LE.G*+**
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M21TAU?YI)90^IV%IF+PU(T:5<S1)^B)4B+"U,C.<\F&HVU9LA(B5[=J#NE8
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MIDCV2 UTFLX=BP[]M]G<U=!JY)+'@XP9IOQ+PXJ"TOOAD-Q")'HM, "3V ,
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MM6TJA.KLUO[Z-7\N0&%D.5WW#6W>=T; & , 8 P!@# & , 8 P!@# & , 8
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MCDB=V_Y>IS)H;TKW-T=73,TQL4F=N=N4J(L?D>I%C1\S1-:EA=.A+(;%EF6
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M RJ<7&KK^CPHABW=JU=DS[&^"KKY'%RE6W+:,GR[[MRW#R4QL/KNL[:NZL0
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M# *XO+]_A>=Y?[8K5_MM7D?S7=[UY?L!*SF+]6OGK^!U3?V$P90;QP!@# &
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MO"-^/@62R<&WAS!S,/*MRKHJJ^><[Y*F<%1"J%795PDG%\S:+6<WXPHP!@#
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M6F7K$D?9G1[4I&M*8N<U2=J0GKSDS<A*_P"JL7GED"*2)2_^HH4"+)!^D/6
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MHJW?0VNX29FAEHU4GBK1MG3B1Q1$Z0]Q1L#V%U=TTO;3$[ZB^!2'$E&@618
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M%MD$X:<M*Q@& 04VTWOA!$$6@;T+6]@9U@# & , 8 P!@# & , 8 P!@# &
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FEYR@SVQB%[7M"WO8&6X P!@# & , 8 P!@# & , 8 P!@# /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g772024g45i96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g772024g45i96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %-"^4R@X0DE-! 0      %P< 5H  QLE1QP"   "RO0< E  "')R,C8W
M.#DT' (% #M-:6-R;W-O9G0@5V]R9" M($,T("T@4RTQ7T=0($1R869T(#<N
M,C@N,C R,%]?4')I;G1E<E\N9&]C>#A"24T$)0      $!_79E;]-,7:('E&
M'T3_]V<X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q <L            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              $W   %^@         !                          $
M            !?H   $W                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $W     %)G:'1L;VYG   %^@    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M-P    !29VAT;&]N9P  !?H    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!$       $!
M #A"24T$%       !     0X0DE-! P     "E8    !    H    "$   '@
M   ]X   "CH &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_
MVP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4
M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M! 4&!P<&!34!  (1 R$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU5!'=(9^0W$5AYE]8[CC95]<RKC2RI9.F)*W%>XRWV4]FDG'NH3S7QN+70;
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M^*_HK[6?W,]O5_\ @K&/\30]?+S5O]ZZG_[A>?\ R9:^OVA?[DTC_P!LL?\
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ME8]23+#:C/+63?1+:#%>>C8Y;V;KDBQHK4VQ,8?$LGI%>^ZH-28SJ-@2O,.
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MF^^?85)%]S_^Q_6IV-15+5.+K<3GOM;8<_']E3IQX_#W1W'E3_#_ -6IT/\
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M'[>V.V4+$=NHC9YI$R(K!T;#(<EKJ)REBK]EP?2D2Z=^Q-R0R^KL9HD410C
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MU#^W/^H='_E/3^_\/G5\?WU]_P!C44OW#MG?^N_RZUJ)^CQ_[3'-?^>W(_\
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M=YK_ !AKVH7;NS?[0N+6!"Q(AM;:1H8((QT"JJ%MANS%CDG-:Z_OX]_;^O\
MU:Z2O&;> ].N=_H]/:I'>UONE?X#U6X;CT"7(2DW&;FXK?5XF:QY(%$>FP)1
MLHJBKT*9&;-EQ!\@%UT/)!<)%]WV<ZC-8\3VD",>YU'FM9XQT8\K/$Q'@4=<
M\WED=":S-V%:[=Z5QW8V,<C_ &364FLKJ'/P.RQ/-!(5V^*)X]CX!B-@:C#Z
MO]V\CWLZD]WMP,CER9,FPS:_@U\>0X1#64=/8/UE-5QP)51EB# BLMHV(CRY
MZCAH3KCA%]R^"-%M>'^%=#TNT1%2'3[:25E S-<W$2SSSNP'Q/)(Y/,<D+RK
MG"@#!_'VO7G$W&/$>LWLDDDESJMY'"LA8BWM+:5K>UMHPP')'%#&H"C8L6?J
MQ)UI\E]U]^?^A%5/Q_+G\./Q_AKU5>0J4OM ;LY'MSUH8%0UTJ0E#N8Q;8?D
ME8!$L>8P=9+LJR2XTG(^M7V4%AUIU1\Q:)\!)$=+G$7;=HEKJW .IW,R)]IT
MA[>^LY2/CC;ODAF16Z\LD4C!EZ$A3U45FW^'[B"\T7M+T:UA=_LNNK<Z9?0
M_!*AMY+BWD=>A:&:%&5^H#.,X8UJ9UA;JY)O+U)[PYUDTM^7*F9M>0(#4@B)
M*ZFIY[U94UK#9>S+$2#%:;0!04\_4->3,E7V?!&C6N@<*:%IMHBHD6GVTLC*
M!F6XN(DFGE<]69Y&))).P !P!7@N/]=O.).,N(]7O9'>2;5+R&(,3B*UM9WM
MK6%!T58XHURHP.8N>I-:T<<_Q_'VXY^?;A?O?BG\R+KU5>0Z^I^CGU\>OA^4
MH7:%W<R7;;K5VXH*N;(2BW1.PP7):T358TZ/,@R)]=(<9Y4/7KK*%&DL/(B.
M-@K[2$C;SHEB/MNT6UU7@#5;B9$^T:/W6I6<I4\\;I(L<RAAT26*1U9=@S<A
M.2JE<T_P_P#$%YHG:;H=K;R.+77C/I-_"">ZEC>%YX'9?N\\%Q&CHP 95+J#
MRLP-VO6@=?2ZFE*:4K6OJCZ8L$ZIMMY>#9@W]%8QB<GXKD\9H3L<<N4:)MN4
MRBJ/U$-\25F?!<)&Y+!>RMO-LNM^>XDX<LN)=/:RN\HZGO+:X3'>6\P!"NN0
M<J02LB'9E/\ B"D>.XWX*TKCG1I-)U)>1U)EL;U%!GLKD#"RQYV96'PR1GX7
M0XV(4BK!O_T,=0O3Y;S6K_"K7(<89<=6%FF*P9=Q0RHHJ2B[)>B-.N5;OIIR
M['L0CF"JJ"K@\&NN&N<'Z[H4K+<V4MQ;9^"]M8WFMV7P+E S0MX%9 N^,$Y%
M:,\7=EO%_"5Q*+G3;B_L06,6J:?%)<VK1YR&D[L,]LV!ADE"XSLQ!%:LJYDY
ML_9_G=K'_9^B4YWHJO'"I].J^"K[_P# 54_A[>:YI<=WF4C/W/YF-S@#DZ>&
M,8\]L&O!\VH%.XS>]WT[GFFY">F.[/P^'3!VST K:_I]Z#^H7J$MX3=-AEIB
M^*NNM'89KED"73TC$0U'U'8:RVV7[A_P)5:8K0?4R%4<<:$2-/3:%P;KNNRQ
MB"REM;1B.>^NXWA@5,_>C#@-,<9Y5C!!ZD@5[[A#LIXOXMN(Q#IL^G:>2IEU
M/4H9;:W6,D9:%9%62Z?&>581C(^)P,XL_;1='VS^V&P;?3]-QZNS/$K)OZC-
M!OX3;P9A;N269CTZT8\E16VI$>.,&,AJ$2/&CM@2D)&>T'!UF_ \-F-#NI[2
M]M&:8:A$W)<M<R*RR3<XW4E6**HR$CP@V&:W<T'L]X<T7A->$);*+4],E4G4
M5O8UD&HSO(LKRW"]".\5>Z0'EB1$5>A)X;_0^^BS_P!FW:S^&.L)_P#MK)/_
M %F]H'_ZNUOYWCFN!_U/]F&,?]!N'L?_ ,!/ZUT'=;H,Z.ZC;#<6UJNG3;*+
M9UV"Y7-KI4?'6?J(TV+13GHK\=4)2%YEX <944\A<$5'@D378Z-VD<=S:OID
M4W%>LO%+J%FDJ/>/RO&UQ&'5L[<K*2&!V(ZUU6N]DO9K;Z)K%Q;\$\/Q3P:7
M?RPR)8H'CECM971T(.0RL 5(W!&U4>8]!:K8M"5/8JR4QL518$KP5OU4'A5]
M+A145X7W3\M?0=YX0C$3PY$;$'O4ZA20?O8SG?\ ;%?,=(I<HIAE/Q1JP[N0
MD9901\*Y'B"1X9/G5^?IHZ=]DMH\4QO*MM=L,3PC(\FP;&V,@M:&K"!.M&W*
M^%-=;FN"ODXAS.)!H2(JO)Y%[_'S;XKXIXBUV\NK/5]9OM1M+34;MK6"YG,L
M<)$LD:M&#LN(\KMM@XQ7U;X)X-X6X<L+._T/0=.TJ]O]+LEO;BSMUAEN 88Y
M6$I'WLR?&=MVW.];1:\C7NJC3[OC+TCMZ]0K,=IUYTZ2B0&F0)QPE_6>GY00
M!")>$Y5>$]D157V1=7Q_?7WJ*8X0G]?G6HWZ/7%E0^C7-&9<:1%=_LU9$2-R
M&7&345Q[&D0D%P151Y14Y1%3E%3Y1=73;OMY"J0#X2?,_I4M?5,*GTU[\@(D
M9'M)GXB HI$1+C-EXH(BBJJJOPB)RJ^WXZBJ5NA]C^E5X_T;V#-AR.J/ZR'*
MBJXUMTK?U,=UCS1',DY\/5 ?+CE.>.>.47VY34TV,K@Y^'!P-MO7IOGH.F/6
MH81U/UN!G]*M+:AJ>JA'?]KY\OK-Z>78D*7*;;VRH$-R/&>? %3<.\54(VP(
M45$X515>?=/;W3F>+'*P) ]\=,$5QYL\RXZX/Z^%2_\ =2[=KG6]LWC5YM^<
M&OWTVO@E)PR1-<&+$R:HEL-NV>(SY:J@Q3DOMM3*B:[Y-Q)[9-.^#$QYQN.-
M^0YQD'KY_7UD5?(G.!CJ.F?$>7XX]MZB?Z?^\#U+]$U#"Z?.LCI^S3(YF"1P
MI:+()@R<9S :>!Q&AQ9YV5>]591%C- +,&]B2@*1&!H7GYA#ZZR-&&^)6&Y)
M(SCQ\/Z$_.K!(R *P]L[=/,XW]",D=,$U\G43W?.I3KAQV?T[='W3_FN-OY\
MP=)D%U7I*R;,9%)8HL69 A.5D%FMQB#*!U69]W)E*;,4G "1#$R>0(@HYG8$
M#P&X/IX?A0RE_A4'?8[[[YZ8W&.I.#\O&7[M1]OF?T4;6V]YN/-:N-\-S0@/
MY<ZS+<FPL6IX2N.UV(ULDC()*L//',MIK:"$F<K;;*E'B,F5DC\Y&!A1T'[X
MZ#ZWJ2-.4$G&3Y> \O7W_ "H9>X97SWN]YLO*:@S'8P9ITS*4AN,\; H-S4^
M2DZ(*"(/"^2J7">*\\>)<2+_ &+?/Z_*HI!F0#S*8^1]?<>OCZU;^3_.O^%5
MUQZY-5J^[WVP]R\PW"'K+Z4*^QE[AQ"K[3/\0QHW6,FDVV/ML_9N<X>,<A>D
M7+#$2,%E71$29(.*U.B _)*0!S1R  J^X/Z8Z'SW&WEGTJ&2,D\RC)VV_<?C
MGQWWP3TPELO^D [H[98RQ@74UL3:Y;N#CC/V9-R&MF_J==SWHP"T"Y+C-G5^
M$*T7Q193\56 ?-5<^B9)5\JF$'X@PP2?;&=OZ'UJT2L  PR?#P.,[]>I\O$G
MP\3R]IN/UH]YBVB8N]M_<]/715CSSF19O9-#,^HS-NG9=E-5K-[80X'ZS6+K
MK2M1:VJC)3UCA_6V!OR&(XK3"1Y(;G?;  Z=-_'?RW],&F6E!_NK@D_I@GQ\
M^F-MM^F/?T=:KE5?4;U%MNPID:..U=<S&<DQWFT<!O-88@B.. *&7BGRB^_"
MKQ^5TV>5,GW'KX'WZ_GCQS2$Y<]/N^&?,>!/R^7XX'[D>V51O-WEI>T]]-F5
MU1N)DNSF(SK" @%-@,WF'X[ ^MC"ZJ-N.17'1?1L^!<5OTR(4)52L9*QLWED
MC^GX_K[U1QF3&>I S[D^HZ8V\_"MQ,5ZY>MSM3.!T^]4.SMOO7M'C+Q56V&Z
M<!^9#.5C3)FE9$AY3]!.K;1IF*(B%/;E%N:D4^D)UR,RRBV<BN 0P!(W7H ?
M0?(^/K5W.\?PL.8#H?,;^/O@?6^*NHGO:=1W5/0R=D^D_9')\(L\U8=I9US4
MK.S'<&7"G@L:3!Q^+4U3;%*;X.DV[:!]1*CMD1,.12Y>&Y8E&[,"!^!QUS5K
M3,VP&,^N?V&WUYBI&^SSVR+_ *4JZSWYWSBLAOCG%45=68\3HRWL QN:XW*F
M,3I0FXT[D=TXVR5EZ).#!8!(?K..N242R1^8X&RC\^G]/;85+&A&2W4]!Y9)
M)^>_[5BGNS]MS=O)MSZ;K<Z06)Y[MXV[56>98OCRHUD4^QQM *IS/%FD)$L+
M=B-'8A6E.($[8,LLO,-R'%D,.UC< %7^Z<XVZ9ZYQOO\_#PJV1#GG7KU/GMC
M?P'0'.XZUB/;;](*R[ J!G$.I?IIRDMR\?9&MN;&CDGC)V4V,'@<FSQJ_KFG
MZ::ZHH4IAEUUE'",F6VFU%H7=9^XRD8SU_IG;!'7>J"8C[RG8D$]-_PZ]<BM
M<=ZNJ'K8[QF58KLILCM#?;<;(0\DK[*_F@M@]4@]'>1H;W/,U.'!KQBU$>0]
M)AX[7JKLA_AP&9LAM@F+@J1@DD$D$#'CGTWQZYV'F>E4+/(0 #R[9VVSX[^1
MW_?;)JQ_M9T-[9[<=&<GHY<<D6^,7^#WV.9C?/(OVC?9!E,9Y;K)S1QQSPDC
M8NA(KFB,@B,0H4=%46>5A+$MS>.?'<5,$')R>&"/QW_6JL&"Y!UH=D??[*X5
ME@DW,=I<JEC#FD[$L$P#<6KBO.G3W-+D46+):H\IAQC=$X[JG*C^K)BS8DF-
MZ3JSGEE7; 8>?4 >V!@C/MC\(!SQ'H2.@\B2=M\?KZ[U(9)[]>Z6\D)K >F7
MI&RFXW>R)E:^H6582,H@U5A)1& L$J::H:=FL0W' =(I\FO@@B(<QT&4)-6=
MT!@E@1U./+Q_I]&K^]8Y 7XO#!SOTZ8\_/\ UB?A;+;R;0=T;86HWNM)66;J
MWF\FS&>[C7++#LB/&R3-+ZIOI];]<T"QI"U221B//,>E$!QEQJ*(QV6U6_(:
M,D'& 0!G .-^GKT_IX1 %9!S=<Y/S\>GKOM\JMD=T'IPRWJDZ.-RMM,!CK.S
M:.57EN,52. T5U98U)^M^QFC<(&TD6,97V(J.$(%))D2).=0HW*P/AG?VKDR
M LI SGJ,>8\/G5<KHD[I6[7;SVKE]-NZ'3)E=]^KN3W5G5+/*UPV^JBMWAD6
M5985]C121DMA-$WXTAHFE0'E$A<'P/4SQAVRK+N <>/O_3\*A5S&"""1GRQ@
M],>7AG;.<YJ3?N2[V2.I[M!5V],7$9V+N[@7V#VZ8LX\Y9RZM&LEGP?0<D!&
MCF_S],COG].VB(8HJ(G!+'& ),$C8G\0,]? _P"F^:N<\T:G!'Q#;RQG<]/V
M\\BLQ=D/'(5WVXJC%\FJTE5=YEVZ=1<5-C',6IM99SUAS8LAET1(F9,9YQHT
MX]Q)>%1=4E/\PX]-Q[#?Z\J0?=/EG'X=?KWJ)'<KIQZPNSKU*7>_'3?C=MN5
MT]Y"Y*:FMPZZ==5GZIR):6)8EG\*N;?FT\BG,$2HRE&T91&1>&0+CLJ(Y(&6
M0<K8#8V) _7\R-A[U:5>-LKD@G8;GJ>AVZGT_'-;3/\ Z1I2.8^ 0.EG+',S
M*.H%!=RR.M*-AXHB"+S5,5D<=7%3V6(#WCR/'EPJV]R?\2^N_3]?KIFJB?KE
M?P/ZG'U@UKEL#TE=6'=2ZJ:WJFZM,6L\"V4J9M7+BU=M63J*/=8]3OC+J<&P
MFHL$9LGJ:6:D=QD;X*W(%Z4\+[\F0VVW<62-2J;D[$^O0D^WETJBJTAYFV&Q
MS@;CR!\!@>O7?KBMO^]=V_-TMS9FW_4WTXT%C>Y)MICD#%\JPS%XSCMZ5'CL
MQ^RQG(<>KH_D]8/T9/.PI-?":<EK%"$[&9<]!P5LC91E6Q@YZ^&>OZ#]O(WR
M(?O+G. ,#TZ$]=O/_.L:;5_I!\K$L&K<6WXZ<\TF;HX] 9I[6PQ^:Q50[RRK
MVQBNS)U3<06IE+,D.-^<Z(VDMMN0KGHB *+0U,)SL5Q[_/'AZX_/'6K1,<#*
MY/B1L,>!W^7D-ZU9J\%ZH^\UUDX7O/DNUMGMAL)A#M#7_;$^'.8I:K"Z2Z<M
MY-/5W,V)"+*,HNY;TLGBKVE9A*^).?3QV&T=N)6)" 06;R/IU\>GY^^:M&96
M)(P.A._0;XZ^/7;I5R.+'")&CQ6N4;C,-1VT5>5\&6Q;#E?Q7Q%.5_'7'KE5
M[]*5X).45..>45.%^%Y3CA?WZ4JH=W#^EO*MA=\<JOVJF4_MOGMS.R3%;Z.P
MZY CN6C[DN=13'Q$FXUA7RW'Q!ITA61$)B0RBB1BWJYQSP[<:'K-U.(F.G7\
MSW-K< $QJTK,TEN[=%EC;.%..9<,/$#Y_P#;#P-J'"W$]_?I;R-HNK7,E[97
MB(3#')<-S36DK@8CFCDYL*Y >,JR=2!'RGO^'NOX?C^[7BJQ#XX8D ^)V]B<
M^W^=3.]I7I:RO)-THO4!D=5)K,(PIB<WC,J:PXS^L&2S(ZQ!.N%P05^'5QGG
MW9,L/)CZ@F6 (G$<]/*W9AP[<W.IKKL\31V5FKBV=U9?M%PZ\N8\XYHXE)+.
M,CGPHSOC9+L X&U"ZUI>+[Z"2#3=.CFCT]Y5*F\O)5[LO"&'Q0P1EB902I=E
M5<D-B/;NC]&69].F_P!F.;5U%-D[0[E7]AE.,9##BNNUU5.N9#DZSQFS?;!6
MH<V!/<D?1B\HI*@%'=;5PQ>$?K[V0\>6'%7#5A82W$::YI-M'9WMJ[*LLT=N
M@CAO(5.#(DD2IW@49CD#<W4$X>[;^SG4>"^+-3U*.UE;AS7+V;4+"^1"T%O-
M=MWL]A.Z@B*6*8R&(/CO(F4J3RD"+CQ+W5/=5Y^[Q_/_ #*B?">_Y_CK+OMD
M_B3^Y-84.PR=AC.^P_T]:G\[*G1AFEYNI&ZHLUHYU+@V%P[.-@CEG&=BGE&2
MV40ZYRPKV7@$GZFI@R9:%.$59<G.--,&1,.H&MO;WQY86VC2<':?<1W&HZA)
M"^IB%U<6=I#()1#*4)Y)YI40]V2&6,$L,-6U7\-?9SJ5[K\7'>I6LEMI.EQ7
M":0T\;H=0OKB(P-/ KA>:VMX7D_FKS(TI4 Y4XU'[H_1AF_3GOWEV;0J.9,V
MDW,O[#)\8R2'&=>KZV?;OG-LL:M'VP5J!/AS77SB-/$ RX)LNL*1 Z#?M.R#
MCO3^*>&[#3I+B--<TBUBL[NT=PLLT5N@CANX5)YI(I(U4.5R4D#!L9!/@.W#
ML[U'@OBS4=22VE?AW7+N:_L+Y49H()KEVDN+*XDQRQ3),7:-7($D;*4)Z5%T
M@DO JBKROMQ[JGQ_/^7/MQ_V9>K"A( R2 !U)(P /7/3\O*IZNRMT:YGE&[\
M'J<S"DG4^W^ 1K(<+E6,=V*64Y=.BE7MR*UMX -^KIX<F6^_/;Y9*?\ 31FB
M<5'_ $]<NWOCJPL]#DX1L;A)]4U)X3J"1,&%E8QN92DI7(6:XD2(",D,(PQ(
M',,[1_PV=G6HZCQ'%QQJ%J\&BZ.DXTN65&0ZAJ4J=T)+<,%Y[>UB>1FF&4:8
MHBDE6Q;"UII6^M-*4TI32E?DVP<$@< ' )." Q0A)/R(2145/YE14U0@'J ?
M>J$ C! (/4'<'Y5U[]3\2^J^N_5?'?K5+R67]BUOU/E\^7K_ $WJ>7/OY>7/
M/OSJ'[-;<W/]G@YO\7=1\W_-RY_.N/\ 8K/G[S[);=YU[SN(N?/GS<G-^==A
M  ;% ; 0$4X$0%!$43X1!%$1$3\D34X &P&!Y"N2  , 8 V '0#RK]:4II2O
M!")B0&(D!(HD)(A"0JG"B0KRBHJ>RHJ*BI[+H"0<@X(W!'4'SH0""",@[$'H
M1Y&N+^P:/_U-5?\ VZ'_ /QU-]HN/_/F_P#JO_\ =4'V6V__ "\'_P!&/_[:
MY01$101%!$41!$41!%$]D1$3A$1$]D1/9-0]>M3].E>=*5Z7X\>4T;$EAF0R
MXB(XR^T#S1HB\HAMN"0$B+[HBHOO[Z4K\18<.$VK4*+&B-*2FK<5AJ.VIJB(
MI*#0 *DJ(B*2IRJ(GO[:4P!T&*]Y@#H$VX N-F*B8&*&!B2<*)"2*)"J>RHJ
M*BI[*FE*^6)75\#S^A@0X7J<>I])%8C>IX_L^?H@'EX\KQY<\<^VE*^S2E?#
M*JZR:X+LVN@RW0%!!V5$CR' %%\D$3=;,A%"^\B(J(B^_P Z4K[N$^./9/A/
MW?']&E*Z_?8EBN5,)&R?&J#(HX_LL7M/7VS(_/[+<^.^"?*_")\KI5" >H!]
MZ4.)8MBK*Q\9QJ@QU@OVF:.GKZEHOCY;@1V!7X3Y1?A-*  = !CIBNP:56OA
M=JZQ^0,M^N@O2P4%"4[$CN2!5M>6U%XVU<%6U]P5"117]GC2F!Y5]VE*:4KI
M5UMMMWD<]NTR# \-O+-KCTK&WQBDLIS?"JJ*W+F0GGQ5"7R3ASV7W3W]]*8!
MZC-=MCQ(L2.$2)&CQ8K0>FW&CLMLQVV^./ &6Q%L X54\1%!X7XTI7IBU=9!
M(CA5T&&9H@F<6)'CD8HOD@D3+8*2(7NB*JIS[_.E,#RJG?UA<?Z/7@RK_P :
MG3[Q[>__ )BQ5.>?RY_#^*\>*JDX.(3Y;_J,#Y^?]:XY_M? [C'AX[_,;^_7
MS-7#K.HJKJ&[7W%97VT!X5%Z%90HTZ(Z*^RBY&E-NLFBI\H0*BZ@KD5PN/X)
MA&)DX>+8=BV-D\O+Q4-!55!.K[^[A5\2.I_*_M*OROYZ50 #H /88KM6E5II
M2NGWNWF 91("7DN$8CD,IOCTY-WC=/:OAPO**#TZ&^X*HONBH2<+ID^?K\_.
MJ8!W(&?/ KL%94U5+%;@T];7U4)I$1N)6PX\&,VB?" Q%;::'C\/$$TJM<AI
M2N.M*BINX;E?<UE?;P'D5'85G"C3XCJ+[*CD:4TZR:<?@0*B_"Z4KB,?PC#,
M3]3]5L2QG&_655=^P:*KJ/45555]3Z"+'\_E>?+GG2J8 Z "N:<JZQV0,QVN
M@.RQ4%&4Y$CG(%6_[6HODVKJ*'^X5"Y'_<\:56ONTI7'R:FKF'ZDNMKY3G_I
M),.,^?QQ^VZV1?'M\_'MI3 \J]A5U><881P(90QX\8A16"C#PODGBPH*TG"^
MZ< G"^Z>^E*]L:+%AM(S#C1XK**I(S&9;8:0B7DB1MH1!%)?=5XY5?==*5['
M&FW0-MUL'6S%1,' $P,53A1,211(53V5%145/94TI72V=L]N(]@5LQ@&%,VA
M.(\5DUBU&W/)U%\D=66$%'U<1??S]3RY]^>=*I@>0KNHB(H@B(B(HB"@HB(*
M)\(B(B(B)^")[:56OUI2NH66WV!7,P;&WPG$;6P%4(9UCCE/-F"2?!#)DPW7
MD)/P5#Y3\]*5VF/&CQ&0CQ6&8S#0H#;$=H&66P%.$$&VQ$ %$]D$11$3V1-*
M5[M*5T/<#<*CV[IUM+<R==>4FH%>RHI)FOH/*B'*\ T'LKKQ?=;14]B)1%51
M33)"O,Q]@.I^O.M.[+JGS9^49UE=3P8B*OIL.,.27.$\N/4>-T5-53CR\&VN
M"_9_#FN.F=O'?/[;_A76/J$I/P!5'D1D_K]9KO&/;O81O!%7 -VL3H+&%<^$
M?TK2!'L**<\XJ"#4F).!](CQD7BR\+A"AJ*>31*FN/=6MM>0O;W<$5S!(,-%
M,BR(PZ;JP(!]>H\#5LHL=6@>RU.TMKJWE!5X;F))H'_]22*R@[X!ZCSK$&[W
M3/T =->,V^]&=;1XQ!A51@L>&Z[:606MJZI+"JJG'YEDY729<@Q56V4C(TTT
MV;SR@PT9#X75.'>!>'K:75[[2;2..)ARJ1+*'E8_!%#;M(8V=L84<N ,D_#F
ML<:_P9V3\&V5QQ+JG#VFP16I#(K+),)KAO[*"WM))6A>:1AA%$8 &6.%!-1<
M9MWB-VFIHU>S.W^![?876\QJ>LFU96TI(+1*D=#&._7UL3D$^^Q#B*VWSX@\
M:\GK'5YVJ:MSB/2;&QL+./X88Y8S-((QT#!6CC3/^%!@5@[5?XBM>$O<\.:/
MI>E:;".6WCN(6N)>[79,K&\$$8;;X(T8*.CD],U;(=US&=V)4?:_JTV[P^3C
M&3&U6R<DC5HS<=:=D&@-E?XY;+/;"$AFGJ3HKYG&_MJL> J8^FX4[8;RVU"V
M.HDZ9,' BU739I83#(2 K2H#SQH>CNDC  [KC)'I>%^WC3^(730N/]&TXV=\
M5A:]2+OK#F<X47EE<B8+'G [U';D.Y78D2 9!T;]OC:JGM-Z[O9':FKHZ.!^
ML4BZD5OUU,W&01?C/UU6_(D5;KLDR:&"U%BJLAUUL&4533C9#4>U[C2#299+
M[C'4TTV& O)-]I"LT/*<#OXU$TG." BB0EB5 S64KGLS[(=!@GXDN>%>'[:V
MLXOMKW3P=[;(BX=)(H&=[<EB5[L)'\3,H4'(J,'=?O&9G'L7*+I\V_Q7$L+J
MB6%3R\AKEF3I,)CEMDVJB"_"K:AA1029B-I*1H.!,E+E$U7UKM=U2YNI6TNV
MB6-G8_:M0,EQ<SDD_P QT#J%+;'#.[9V8G<#"VO?Q%:@DS6G"&CV%EIMOF*W
MFO8R\CQ(<*R6D+116Z$8Y4S)@8SY5^]L.[2YG+J8'U6;783FF 7YI$M["OJ6
MO"$RXJ"DF9CUJ[.@6++**1."PY%DHG"QT,^&UYG#7;+JVG7\$U\AMV5UY-1T
MJ26UN+<].?NPQYU&W,%<'&=CC!NT+M]75F&D\>Z%IFH:5=D1SSP0CDC5ACGE
MLKHRQRJ-RW=LL@S\ )PIDOQ3HI[=DRCB;XX[LWM3*Q635EE4?)'0?D8NS7,-
ME)>L/L^;,.IBA%1IQ7VW(@?3NM.-N-B8$";0#MBXUO=(65>,[^33'MVE^U)<
M(G-;@$NSW*HLQ  //S/S @J<$$5F2P[+^QV2WBXFLN&>'WLF@-_'>\I>P2!%
M[QIQ%)*ULBH$)?,8Y"K<P!&VB^^G=UC8E/<POIBP;%#QNCXKX.3WZ,QJV0W'
MY;XI,6A2*WZ2O3A?0.2\#I"B%](V)<:UCXC[7)GNYET>$79,C-)J5^\CFX?/
MQ.D>1(RDYP\K@L-^4;9QMQ1V_P 6G2'3>"-+T^6SM@(HK^\DB@M65!C%I91R
MPE8AC"M(R%@,B, BL<[6]Y;=BMNXS6[F#X;DF.O/@$N3B\ANAN(3!$B./1VW
M[*=!FFV*JJ,.C%\_%!]<5X+74Z9VM:K',HU6QM;FW8@.UH'MYD'BRJ[21OC_
M  DKGS\:Z;0?XBM=BN4'$6E:7=V;.%DETZXCMKF)"1EU22YFCE*C<K\!8="#
MO4^6T>[V!;X8/4[@[=7D>]QZV!4%UI4&3!F-<)*KK".JJ<6=$-?!]D^?D3;(
MVC!PLW:7JEEK%G%?Z?,L]O*.HV9' '/%(O5)$)PRGIU&003M1H.O:7Q+IEOJ
MVCW27=E< \KH1S(Z[/#*N28Y8V^%T/0[@D$$Y,UV%=Q32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*57OZ@.V;
MU&;E=T3&>KS'7,(3:JISG:C(90S<@<8R'Z##:NEAVZ-U:07!)[UJ]_Z8/J!]
M82$E4>534JN!&RG.3T\CG],?AXXS4)1N\# #&WCN-^OOY^>2*L(:BJ:FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4J/#J?LY,K<0:
MTW#6/6U%>+#2K]P2D@<ETQ%?9",G."7\4 $7]E-5'UYX_;_/WKI=08F< G94
M&!Y9SG\:UO\ Y_V4]U_#\$7V15^/E/X\+^6F/K\/3?Q&WD:X/0_CX?6/K%>U
MIPFW < E @(#!47@D(53A47CV7V7^GGCVTQ^P.1T/T/#R/SKOU&V^V/ C\]M
MJTM[L^Z>1Y)8;$87*ER$J(^W+&626$-48F7EG,DUKDYT47Q<="+7H $O/IH\
M]PB(Z7.!.UV\F;4M-T[G_P"SPVIN^0?=:65V3G]T5.49_P 1(K63^)#5KF34
MN'=&YV^R1Z>^HL@)"27,SO"';?=DC3E&<XYV(^]O#DG"<_BO\.?YOA-8AK6,
MXSGE\\_%GTW\L?G7GGA45/E/C]_S_3[:=:IMCIC&/\]SG?88],^M2B[[;\9I
MDG;WZ9\,G3YQ1[#*\UJK243JJ=E6X _&C4,.4:_?>;CA< 0B?L10VO)"5M%U
MD'6=9N[G@3ANS=WY9+N\BF8G)ECT\A8$8_WE'># \0BYS6=^*^*M2O.Q[@BP
MDFEY;F^O[:YD+_%<0Z.0EM'(<995,R-@G<Q+G.*BZ3^O/MK'U8)SCH ,^N=O
M;WW]MCD=?"+^/\Z\?T^RZ50=0?:I-<%WLS2N[:VZ>"1Y\Y*\=X<?QB-(%QQ/
MI<?R2ND7=I5-N>RBQ(GU*NN-(7!),?0ONNDA>]M-7NXNS[4[%6?NAJ\%J#DX
M6WND-Q-$#@X5I$.0"/[0C<;5G+2N)M1A[$M=TU991$O$-KIR.&([NROHVN[B
MW0G<(TD394'82,.AP8RU7W7GGG]W]/X?S?T^WY)KP58.QO\ $=O?T\/;&-O+
M'E7C\5TJ@.^<CSWSU^7CO4\W9+SBY6^WAV\<>D.T'V/4Y5'84B-B+:!.&L?<
M 5^ZR4J*ZTA^*IZOTPDJ+X\ZS+V0WDOVC5[ EC!W,%VB_P!U)2YB?'D74 G'
M7ER1XG:S^&G5+DS\2:,6=K18K748U.2B3LY@E*C8*94Y2V-B5#8.35A/6<ZV
MSII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4K2OJ>P"R?G1<XKV')$3Z1F!:HT"D<0V%)&)+B"BE].Z!BT1K]UL
MP'RX0^=*ZN_@8D3*"1@!\>&.A_;\/EILHDG"<<*G*<+[+^*JBHOPJ+RG^;5<
M]=SGZSOG^M=7^WIUW\:[/B.)7&8WL.EJ(QO/27A0S\%]*.R))ZK[SG"HVRT/
MWC(E_(113(15DG_3]?QZ]:DBB:5PBC<]3X >9^ORS71>ZCTAWF8[:X1N?MY7
M2+FSVGHUQ_)*N(R3MA+Q(.9 6T=EI".2=7,5UR6T J:1))OBGC')%Q-VH<-W
M&HVMOK%E$TT^GJT5S"BY=[1CS=XBC=C$^[  GD)(Z-G#';[P)>:[I-EQ!I4#
M7-WH<3PWEO&"TLFG,><RQH,ES;OS,R#+=VQ*YY2#6X,2 E Q43%>%$D5%3CC
MGE%_'W_C_AUK^#GI]?7C6EAV.""""0P.QSX^'AY'?P]:[7@^#93N/E-+AN&T
MTZ^R&_GL5];6P&#>?>??)!15\45&VFA\G7WG.&V60-UTA ").1:6EQ?W,-G:
M1-/<SN$BB0<S$DXR0.BKU9C@ =378:7I5_K5_;Z9IEM+=WUU*L,,,2EV8L<9
M.!A8T7)=V(55!)/A5B3J&[?-R[T*[>;<X<P%QN7L]]3ETB-#1"/(9UTTY(R^
ML@JJ<FXCALG !/'ZDJYL$1">'6=-=X%F_P"AEAI]H!-J.D<UVP0?]Y>4,;R-
M#XD\V8]LMR*.IK</B_LDFE[+M(T+30+C6N',Z@JIM]LFG5VU&&,D9+/S\T0Q
M\;0J,988K<3(<JOE2(4Z.]$EQ7G&),:0T;+[#S1JVZTZTX(N-N-F) 8&(D!"
MHDB*BHF!""I965E96*LK JRLIPRLIP592""",@[&M+I8I()'AE1HY8V9)(W4
MJZ.I*LK*<,K*1@A@"#L17UT=%<9+;U]#05LRWM[62U"KZRNC/2YLR4^7@TQ'
M88$W7'")401 57Y]D1.4NBBEGDCAAC>::5@D<42EY)'8X"HBY+$^0%2VMK<7
MUQ!9V<$MS=7$B1000J7EED<[)&BJ6+$D] 0!DX(&19:V][=\]GH&R'9F[]"'
MNQFLH=QW">-$CU.7PV&DH:%]X4+AEFO9^S9SHH0MRITQT?(0$5S_ &' 4@X(
MN-'G*IJEXWV\\QRD-XF#;PL<$D*@[MSO\4CXR #6ZND=D,B=E-YPM=E(]=U1
MCK$CY^"WU-0IM;8O@?!%&@@E;ISO(XR,"JWF:X/E6W>26V(YE16&/9#23'H5
MC5V49V-(8>8)15?%P>#:-$1QE]M3:>:('6C,#$EP)=6MS8W$MI>0R6]S"Q62
M&52KJ1Z'JI&ZL,@C!%:9ZGI=_HU]<Z=J5K-97MK(T4T$R\K*RG[R\P'.AP"K
M+D,/B!QC/6H\:1+?:C1679,A\Q;989 G777#5! &VP0B(B)4$1%%525$1.5U
M  20 "68@*H!+$G8  9))/0 9K@JC2NJ1([N[85%!9V9C@!5&2220  ,GUJT
MOVK>E;(=B=LKK/L^K7JC-MSOHG6:66T3,^EQ>"I.U[,]D^#8FV#[QS78[@HX
MPRD8'$%SS%-C>S;AJ?1=/GOKZ-HKS4^[;N7!$D%M&/Y:2*<<KNQ,A7JH*@[Y
MK>GL-X$N^$]"N=2U6)H-4UQHI/LT@*RVMC$"8(Y5(!665F:9U(#("BG<&I6]
M9+K.=-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E>IYEF2TXP^VV\RZ!-NM.@+C;@$G! 8&A"8JGLHDBHOPJ*GM
MI3KUK$%GL)MA:2CEN4"Q3</S<;@3),2.1*7DO##;GIMHJ^RHT()Q[(B:5QFM
M+=FYC&,^0) /N 1]&N^8SA>,8?'6-CM/$K0-.'76@4Y+_P"7KRG%.0[PONB&
MXHHOPB>VE2QQ1Q#"*%!ZXZGW/4UV5QL'0-IT!<;<$@,#%# P)%0A(211(215
M145%147A4XU0@$$$ @C!!W!!Z@CQ!J\@$$$ @C!!W!!Z@CQ!K23<GMW=)6YU
MT_D5YM?$J[>8Z3LV1BD^9C;,QTU(C=?@5SC=>KIDJDXZW%;<<7W,BUY"_P"!
M.%]1G,\VF1QRN2SM;.]L&8$;E(BL>3G<A03XUCC6>R3@'7+E[N\T&"*XD;FD
MDLI)++O&SDL\<#+$68_>;D!;Q)K*^RW2KL+L !N[7[>4]%9OMJU(OWQ=L\A>
M:7V)I;BP.1,:9/CDV([C+!+[JVNNRTCAG1-#RVFV$,$C#E:8CO)V'B#-)S.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g88515dsp003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g88515dsp003.jpg
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M(3$2 T%1!&%Q(C(3\(&1H;'!0G(C,P71X?%2%&*"0Y*B4Q6RPM)C)',&_]H
M# ,!  (1 Q$ /P#ZIP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M, & *1C'ZRLG1>HMF7KU_+ Z@.BGXO'&Z?RXGCE[CSZ?SIA^7/AGEWEW&D]
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , 4I]GVEQ
M([6-NSM4LQB0DD^)RP!=P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & *94?K*MHEKZ=AU/\ )IK&7]_]V-L_E\,_?_0\\?G9/R^[/ZES&H]
M8 , 8V[[KN=MN=G9V44%P;D@O&[.)$C5OS93I5E"HI%*\6('CC96J:;9[NGZ
M?;MMVM=M:>Z)X+O?R6)GMW;N,=E;7\MI%Z3<8FEL LC&1:1F5!*--.:,$\OP
MG+/CC+TE,<CT+]OH[.BL]5'%L,,XP[GSSS)+GN;=(MMO-V2TA;;X5NNBIE83
M%K;6 6732CM&<ES \\\%MJ4N)C3H=M[E=MV>MZ9PP\4=O">YE>\[POK."W>>
M.%.L\P:5HKM51(8PY)1HA)X\=.GVXJVD_9&W;_;:7;2;PCC3BXSU1]I+'W1N
M_4MY;FT@@M)+)MPF4R,94CCT!U%0J5)?*I&7'$]-<^,&#Z':AJMF[*^A882Y
M]_ KV??LMU;QR1V:]29^A$AE4CK%K>,!F0R47J7)J>-%X9XKV8X^V)LW/VE4
MLT[8+'+AXWQC&*_,TWW7?%N(=N]/;?J,O5?J=1C#T81'5J:=88M,JZ?>:XPT
MJ)X'E73[6EWFVA1PQES[HPS]Q7M>Z[VXGM[86%)[PE;<A]48-O*8KS6],ND5
MJOXZCAG3)[:7'VX&S<_;Z53MJPKGS\2FD+MX_P!L,?8=Q;GN-)+6UA$,"P&[
MZLI5B9E#D1\M.1&!JW$Y9<<2VVEF3>Z+;V\+6<N8A<L,>]_#,=)W'>ML%IN5
MO::I+IJ2+2201)S5<I&K2..4"BKXUX X:%J:,5T5%O6V[6PKW*<L,<%[RA==
M\S1);%8X LRHSSAI9HU!BDD:G2C+D#I4S44\:8R6R>G;_:DV\;8<,$\TN+CC
MS[B3_>%^]GZE;:"!8+:&YO/42.!^>6T*A5#0%8]6IAE49<:/24F'_KJ*VF;.
M;.JA+A$SCVQ"_@6(>X]RGW22R2"&+7U!9&9I5Z@0:ED5PG3D5A7E1M2^(XTQ
M=$E)KMT6W7;5VV\M41AV1,KO:AF9+WSN<%E9W-S!;1"[MYKH$&XD55B:- K%
M(V(),GQ$4QGZ*;<'JK^U;=KVK5V>FRK]U9R^+[#1F[JW&)I()-M,=W' ;TH[
M\BVPBU$LP'\P2CIZ?^+AC%;:YGFKT%'#5YJ[:?\ =/TCQ3[LQD_?5I!N%]:R
M1JPL[1IP%D4R/+%&LTD6CP 21:,?[7E@MEM)F5?VJUJ5LGYK1EA#<)SWIX=W
M,M2[MOUO)!:3VUMZV\D5+5DE<QC\N21^H"H?D6(TI\5?#/$5:O$TUZ?9LG9.
MVFJQPQS248QC/N[1LV\;_'?;?;-;V@]695E/5=M)@J6*T4"C*,@:4\<%6L-F
M5>FV72UIMX8X+C[RGM?>\N[7)M[*V16:0QQO+(A%=$\BEA$TA^&%:_WO9C*V
MSI6)NW_VM;-=5WPG!=M5QCF_@5Y.]MS@L[6YNHK6!;E+F776XD5$MG2,ZNG&
MS#47K6E!B^BIP-B_:]NUK5J[/2ZK[J\R;XOL+O\ O5%W."PF@6&:2T$LL32@
MR1W+1&<0% *D"-&JWG3SQCZ6$FC_ -8WMNZ<I6C+!UG3J^+6'>00=[W=U:1F
M"P_UW026YM:M(T+LZ!N6-2\B"-^HND59?#%>RD\\#9?]KK2SFW@U-)Y3@^>"
M<K3CDRQ'W%O%P=L]-%9NE^\L+L9)>5X0[-D4!&4?PL 0<CPQ-"4S.!K?1[5=
M>IW\"3R63CM[<U@T17/>&X16L\AL5ADLY8K2\,K.46YFE1 (]"EG01N)*@<&
M4<:TJVE.9E3]MH[):I5D[5B)TI-XXX.5I]S[)CB[QW66YAMA9I&[H[F0I=.K
MJLO35T5(BZJW&K@?2,\'M+G]#.W[;MJKMJG+C7E.,VB>X3<.^+NVO)H([:-C
M$2J1GK%IG-S-;I&K(C(C/T1360*G"NRFAL_M=;53;>/=AX:V;Q<N-7#D7KWN
MJ6WV][H6RLR7=W:A"Y I:QS.&K3[W0I].,5MRX[C1M= K759^[6W_4ZK_P"Q
M2F^84,, DFM#'(BP"X@,B!XII'=98VUE ="1%E(^($'@<9+8-]?V=V<*TKQ0
MX>*24/CFW#Y$H[JWB>TMKBUM;<=:XAM6661LFGACE!!C#@@&0CCAZ:3Q,/\
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M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MM_Q?8<-+ >MM_P 7V'#2P'K;?\7V'#2P'K;?\7V'#2P'K;?\7V'#2P'K;?\
M%]APTL!ZVW_%]APTL!ZVW_%]APTL!ZVW_%]APTL!ZVW_ !?8<-+ >MM_Q?8<
M-+ >MM_Q?8<-+ >MM_Q?8<-+ >MM_P 7V'#2P'K;?\7V'#2P17>[65K:S7,S
M$10(TDA"DG2BEC0#V#%5&W!'9)2SF$^;O8SJ"+R3/A^1+_Y<>G_!W>1YO\S;
MYDDWS8[%@:-)K\QM( RAXI5R(9@351047&*Z/=>2,GU>VN(/\UNRDTA[J1=8
MU)6&2C#S4Z:$>T8O^'N<B?Y>WS&_]VNQ] ?UDFDF@;HRTKG_ &?9A_A;O(?Y
M>WS%7YL=DL'*WDC+&*ROT9 J#^TQ6@^G!]'N<@NKV^8L7S8['F$QAOFDZ )D
MT0RMD*#5DO#,9^W!]'N+-#_+V^9&_P WNQ45B;R3EX@02_\ EQ?\'=Y$_P S
M;YFYM?=>Q;IN=QMEE<]2_M(XYKF#2P*),H9"20!F&\#C1?9M5*S6#-U=VMG"
MS-?&LV!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , 4S(/UE
M8^LU?3LWIZ<AYP->KS\*8VQ^7,<<SSZOSHG[N7#/,N8U'H/G'O-4E[E[T2)'
M,QW"Q#$L"I)CDI1:!A]>._T_DI/]MCB;_FOWHRK*:[DM1;;60+^5M-S=:EC*
M*[E%19)7C^(*Y8@'P\*XVW23FWE-5):A9B7>X1(T>TV%M!>J&U.R(XEFG6,9
MQR2:V*B34=6E1XZ>!Q*T;\5G'\"VLEX4I)(;";4+9MRFBN5KHL-S@#OX$21R
MNQ$@+2LP9:5H*KX8CNLXPYIE5'E/N8\[/;VD99-W@AAHC27#HDS*Y%69"78C
M6E:*.84%<\/4=LZN2^FEQ*SRWNVR1WW3GN275H[_ '..D99N7D@;J:%E 5AJ
M/-^'+&22NHE+L1@VZN<^\L]5T1-QVT1OMDRGUNVUT*KH))&!BEFK41L2K([?
M >%*8PC[MO-P9FI\RRXHG[0$1[YVJ2VYK3U@6,M4$ @FC _>%16F1Q=^?2<Y
MP-F/4492>_2L-9'$Y9#W8X*.X,YSX >_/%((3GF_T"F #+S8X%%TL .5Z'A@
M0"K"N3BF9RP '6.)(]ZGQ^K  !(:T :G&GA@ J1Q4CQX?PP Y06%5%1[, +T
MY*TTFOE3$ @5C4@&@XX *-Y'+C@!, & # !@ P 8 , & # !@ P 8 , & #
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MNP  +6@)4^7_ (X 6K+\68\QQ^K !I'%#3]AP H.H$$9^(P @JI"G,'X3^[
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M>1)9S9)-JJK'PTTK7 %BSO;2]MUN;29)X'^&1#49<<0$V* P 8 , & # !@
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MBZM*@$+2M; :@<FUNC.:YEL^- ,;]SRH[77I+9K'9G&KZ)QW8<R/M9H?UV>
M*I6(RF#J"7KJHTH 2*P  5"BM0.'CB[GE,NO3]%/G$Y1Q?XN_P#H=GCSG#..
MW!-A_P!UK+-O,\-ZUS B[<FL6S2(J%5E0*59FZBT<D4Y1X8WUU:<CM[+WO\
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M"-=O*@B#ENF%+UTUU\M// I= I0> P B?#7SSP( ^)C[A^_]^  _&/8"?W8
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M<R@9 $^50/0B@!IEE@032,"E.X4C<(=.7Y4F?_$N,JF(\41BHS9LQYGP-<9
M*!7U/F2,O*OLP 4YB6R4BM/<?' "<68MDN67B< -8$I0CXB0J?3XX (EUN9"
M:J,E]M,&";$*& #WX KE0CF/@I%5/E[?XXI"3,Z6&3Y$CP.7' "\&4KF,ZKY
M8 "*,I7-<S0?5E]> !A33IS4D'2/9GE@ ?X"R>/AYURP M >9<B,C_ X@",U
M45%&XD>_!@I[S9W-[M-]:VS].XGB:.)JTYB.%?;PP!YKV[V;W))/?(G^@;TL
M]OU=:_'+&45>0G+4:UQ <_V/\O>[4[A<D#;O21S12W"RHQ#21M&J@1LQ/,0?
MZ\$"3L#L'NFS[UMI9XEMH]KD+W<HEC:J@$%%"L6.NM,Q[\ >YIDHRK0<,4'G
M_9FS;=W#)N>Y;Q'ZR\,^@QNS (I%1D"/</*F("WN5YLO8.PW]Y9W+W+2L$MK
M%Y%D47#5TY**J !S5\!YX \^[3GL+/O[8]QO-UBNKJ_BEN-SN=8*)<SB15A)
M'WJ%13S. .[^<=O =@VEVB0R'?\ :%9BH+$>K44)I7!E12[JVW<KKYQ[-9[3
M??H^O8;TSW<$4;RK%ZN(D0JX:-79J<S*:"N5< 8F\]_]V=K7.Z]JW6Z>OOEO
MMMM]L[@GMA)-%;;C'))(\UO;K2:2$0-HTKS5%1@4T-D[MW.U[LVFPLM[W+N?
M:MT:6"_&X;;);26<BQF2*X29;>W3ILRZ&1JTJ*8$,K9.Z/F-)V7V]NTN^K<;
MOW?=1[1ML<EM$+>S#2RE[Q](#2S=.$@*:+PR\X4WM]'?/:^Z]JQ+W--N^V;M
MO5K8[@+V"W2<"0.2L;PH@Z<@4ZE(U+04;CBLA#V;%\P>[]LW"]F[KFVJ.VW/
M<+/;A:6UL[,MO<LBM<F5&U*N2*BZ<A4DDX Q8OFMOFYR;9L%_N#;'=P^N7N#
M=MNM'NY)'L+GTJK:QB.<1"8\[,RG3P&$E@)_F#W39SOMEIN=UN=@+_:#9;]=
M6+6DQBNKP075E-U(8HW;205=5!H< =]WON>[VW<W9^V;?>/90[Q?7=K=O&J,
MVE;*22,CJ*X!20!A[L\L&0\MV:UW+;/D=?;C^IR7D3;@T46W74%K);QN-Y"/
M*%,52\F9.HD GEIEB%.^V]^Z^\MQWZ[M.X9^W]MVO<;C:MLM;*&WD9WM*+)/
M<M.DA<-(>5%T\N*0SM\W;OJRO=OL^Z-TN-BVM-O+7._;':&YAEW 2LI$QDAG
M:",1!7TZ "2>:@P8.W[*O+^][9L;F_O[3=;J6.K[EM__ $]P-1"R(*"A*@:A
MX-7%!L$DN OD06Q2 W* %&8()^GQ. !Q12!S.1@!?"OQ,W#^K ")DJDYN1D,
M -%1'YN5X^ RP $#E'A7F/B2!P& $@763*1[%_9E^S!@FQ"A@ (!!!S!XX$*
MU"A9#S4.L>T>)]^*"7+5S&JD<K>6> %'%@^=3DWMI^W  I(!U9J2<_LSP ("
MM2,U)X>-.&6 (YQJMYW4TJC"OG0' %JW'^GB_N+^P8UE)-.!0TX X#>>_-\V
M[O*3;7AMDV99%M8+DI)+U)WM3.(WFBD803:P L4D0#+S!\Q@"I!\YK2'MR/<
M-TVJ>._2WMKFYM(G@YHKBT]69H09&9E"*W+\0^]3C@"[?_-S:[-9'.TWTJ"[
MN+.W:/I$S&R0O<NBABP"*!0-0L30>)P$&QV]WSMV][]?[-%:SVMQ8J9%:YTH
M9HU<(9(XR=>BI'-2GG0Y8 Z73@0-. *VXBEA<'_Z-OV8+,/(^>=Y<V3DV=S*
M$E2L4L;R)K@J:*H)4@57@<?1;7BS.#N8/ ]*^7)G_P"YG<@D *FPL2LND R$
M0QZCJXM3+CCG]5^A7O9[NG_6MW(]4QS3H!@ P!7W)BNW73 T(AD-077@I^]%
M60>]<_+/%KF;=E>.O>N7VX?' Y+8-LW:YFM=P0AK02 LS;ANI:BM0_DW 4-P
MX,*'&^]DL/L1V.KW]NJM1^:/_'M?6OV':X\YP@P 8 , ([JBEW(55%68Y  >
M)P*E.".8[=L%3>[J],T3/.'TQQ-,H*EJ@E9!SGS;53R QNN\(.KUF[.U6D/#
MG'V9=Q?VO9+ZRGBD:_DEB5=+P$GI_#3E7@.;,?5C&UT^!Y]_JJ736E)\^)LX
MUGA/.=W>U'S"C1C;U:YMV8-ZC3K58P.H5Y.L-2Z/N_#7'KK/IGTW3JW^$WXO
M+;^WMRXZ<YXYP>C8\A\R& # $%_:1WEE/:2&B3QM&Q'$!A2N+5PY-FUN.EU9
M<')P^U[@NY=OS]JV6Y1-N]L[6T@<,E8%D*MI#"K43++'ILHMJ:P.]O[/I;RZ
MB]'Z=O%SQC^)V^VV26-A;V<9+);QK&&/$Z12N/-9RY.%O;KW+NSXLL8AJ# !
M@"H8S^KK+T!3TY7U.K,<X.C37AXUQMG\N)XY'GT_FS'W<_?E!;QJ/0?//>#P
M0=[]V2RTF0W>WB:( A@G3;('X37_ ,?(]W93>W2.5CC;S2W+]Z.B^4MH(NX;
MXFY:=Q'IBY2$-N_YT+@L:YB0B@ IPXX\G76FJP/3T58L\3UK3CFG0#2< <5O
M47RU[=O;+9KW9[2W'=4[H-%M&(9)[<"51,PII)9OR_[1\*X%)MOO?EON.RP7
M AL8+.[%I/Z6=(HV5X[<7-J)$%0KQV\>M?)5RRP!5F[G^4UK8W%W:R[;=?I\
M!N_36@B>7IV(:9>FN53&)6=<_O$C(X 6"W^34MK:110[*;>ZN)$M(@D(#7#:
M$D6E..:*:_V?[. -7;-K[ WB:3<MMM=OOIK>[>26[AC1RMYREV+@?S.52?:/
M/ AT>DX 32< 4+W4M_ 0/\J2OL&I<\95(.<! &XGQ\SYXH!AI D;BOV ^6 $
M;BLC9 'AY XH Y.&89D45?;@"-R0 !FQ8@GVYT& +"J%4*. %!B *8%"F "F
M &RQN0KJ,U(S]AR.$D&HE5C&H*<RA.=*5R-,) X!"Y8$U4490/XX  8]9=02
MO C]IP 53665:J.(KXGQ& %8H7!10?O,*G/R^G  [(P!11J;+B>'C7 "EXBN
MK30K[<P< 4-[6>;9;RVM&$-_+$ZP$N%JY_"3Y\, >7]O;%W-#->=+7M;O:W$
M*SSGHJTKQE8U!:E3KIF.''$!@=B]H]Y67<+S&*39Q%%/'/>7/Y49:2)E1=39
M.2Y!%*^> ']@]I=WV/>5I=7-M+M\%M(3?WLYT1-&0=2]1CIDZGA0GSP![XJE
ME#IS(<U93J!'L(PD'+[GV%:W%_+>V%[/MD\]3<" \K$\30%2*^_ $UCV#VQ;
MV!L[BT2_5W$LLER Q9U! .7"@8XH,]_E9VU_N2UWB"&."WM4 _3$B7HO(-6F
M0FM=0)!^C$!K]V]L1=QV%K9RW#6PM;^TW .BARS6<HE"$$C)Z4)P*.G[:AF[
MSM>Z#.RS6NWS;<+72-#+/,DQD+5K4:*4IB@Q]Z^6>V[ONV[;I->SP76XBP>T
MFMPJ2V5SMFOHSPN=6ICU#56%*9>.) DM[3VMO\>[1[GOW<MSO$EO$\-I:1Q)
M96J]04:26&$GK24X%C1? 80"E'\L-K'8-AVA+>3D;6RS6&[1:8KF&YCE:6.>
M/XE#*7I3@1A DA?Y:[ON6Y[+N'<'=%QN=SL=]#>V2+;0VT'Y5=0>.,\SR5%7
M)R'P@5.$ YCY;=K[_=]O[G=['W+<;(+S>=U6\A%O#=IJ2\D02P=7.&32 "14
M&@-*X%.I3Y6V&W6>T?[;W&XV?=MF2:.#==*7+W"73]2X6[CDHLPEDY_ AN&$
M$DDN/EK)NNS;G9[]OE]NE_N;PS?J TP+:R6K![=K.W2L46AQJ/$MXG 2-C^7
M>^2[]L>_;[W--NMYL$TDMK#Z:"VA998C$VI(S76=52]?"@ P@%8_*3_\'MR[
M;7N";] O;CU5I:&WB9[:0W@O'TS#2TBE@5 ;@#@)+USV)N4.Z;E?=M=QS[%'
MO$IGW.S%K!=1^I*A'N(.J089'4#5Q!.=,( Q>P+_ &V2RD[;[DOMMN+6U]'.
M]V!N,=RA<R&66.9EI/K8G6IX&E*80#8[3[:L.V=CM]GLY))XHFE>>ZF(#RS3
MR-+(]$"JNJ1SDHH.&+!#9=EII1 &7/QRP I:/3I5 2P\SX^)P*(CH%S2LAR.
M9S(P((AC4$%27K09\?+Z, "]-:C/634<*4/[A@ ")1HU?//4Q'@< 1R*[*O3
MH2RD( > -!7[< 3"/0 M* 9# !3 H4P 4P!'<*"FKQ7Q'D<C@B"*V>H_A&L>
M_P <4 "%CSS5JT^G@, *:QJ%\#RJ?;[<0"M6-0%^'@!Y?U8 CN0%M92O_+84
M\\L 3Q3LD<48@E?DA'4505_,Y>-?N4JWLQC!M5)4RN/R_CP*1[EL0NH1RFH)
M HOG11\7WAG^VAQGZ;/3_@7YH<>XK ,1HDH"XU46E$%:\?$Y?U8GILG^#?L*
MPVGMN^W)-Z?8DEW)E$8W!X(FETF)J_F5KD*QU]M.&(ZP:K[&G!M>S]GW#)>V
M>U;M(HKGMR)X],**LMM$51%A9$4Y_#''^61X5IPQ([2/:C[U>/U^W-=A++L7
M;MY;1VESL"/:M*MR(9;>,HLTP8O(PJ>84I(?;XX:>T/:B?%7C\OX\"6PV[9[
M6]DO[39?2WMZ$]3<I#&DAZK$L'(/W2NI_H.>&GM#VHGQ5X_+^/ O)>.VC_27
M"Z]'%5Y=;E>;F^[34WLQ8[0]J/O5X_3[<EVB"\<Z?])<#5IXJN6J31GS>'Q'
M^SA':'M?ZJ^RG^7>,OW,NTW+F)DY)!TY  >6HSH3DU*CV8B6)JW*QVGS]NT6
MW6TNYRVQ/Z>&Z=G:E2H2>4B1E 4D%(D;XEH:4XDTQW]MV:JGG]APMR$VUD>@
M_+E5_P"Z&_-K'4.U;?U(@&JOY,5.8@ _0,>+JOT*_BL>SI_UK?A1ZQCF'0#
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M!R"GW3@!R"9S1JZ1\-<JCSP E'8F,L-*\23Q'E_' !0JW3#BI^$UX# !I$5
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MVXR((O,.HO$^'L' 8 5<R9%SKD1[!E]> %HBQL[9J]3I\O $X BF9E8,V9C
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M$$%\BES&?B/W;LF;_%]&6,MS/V^PW]>YW7[O[7_\/":V,#QA@ P 8 , & #
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M.$@IW/=_S.FWS:MLW"7=K&];M^UO]RL=DL;.ZE6\DGDC=I%N0="E5&0;)LL
M=CL^_P#<#=V[KM%U>3R6]CVU97\*7<444XNI3,))95C  <Z%U*.4'A@#DTWO
MOZ[[1^7V]Q]TW5K-W1/8V%_%';6;1@SI(TDZZXF.LZ!E\/LP!:WWO?O+9MYW
MS8(-SZ\Z3]O;5M^XW$,-()=S5Q<73HBHK,=%0OPZO9@#;WNV^8^P[%OL-AW+
M#ONY!;5MJ%REM#N$1DDTSC_*@<N@/0#K\66>$@G^5G<FX[C>;SMNYWU]=W5B
M8)%L-XLDLMSMDE4U,I@ AFC=EY&0>_ &CWKON\;=W1V986-QT;7=KV[AOXM*
M_F)%922HI)!(HZ@Y8$/,NS/FUW;?VW:6U[U<]/>]QW6VD:<1Q@7^SW*S\R@+
MI#1RQ=-](!X>>$E@Z?L^_P"]^X]MVWO%NY8K*SO[Z16V">"$68LTG>%8%EHL
M_J6T5#:_BRI3%!ZDX<"@CH3D*@^/OP((RR("RJ!09C+.F $579:$"H-6X5!P
M((C2C-U'-P;2*$>&!1 :,QT J,M.8I3C3 @GY;OJ6JE1QXBI\\4!H$C@ T91
M6G U.66 !F<.$D\!4>6?[, '(7I)RT HX\Z_9@!LB,%8GB#DW@WC0X(HD$P5
MC"XJO%">(KG2N#1"<QUS4U'VC$*(KD9<5\0>& %* C4G#Q'B, 5RY,P(-$05
M/[*_PQ2#M($:,!G4:4\O:< *&*.H',QR8GA2F!19% *F//.C$^%1XX(#6Y:!
M<V!!)/MRSP(1W0'I9UXLT;5/CPXX M10R/'$ZW,B+HA/371IY,SQ!//6C>SA
M3&,FVMTE$+C\_P"' 5;684K>S-336O3STR%S]W[P.@^SVYXL]AD]U?VKY\HY
M^_O,M[;N8J:3_P#,R#J#0D4 .G*OW?P^.,YJ>M;G3\N7MG\>8_T_<G4KZA::
MR:ZA2FB@--/P^SSSQ)J8^IL1EP^WV]V!<LK:^$,37-W)U1I+Q@HR\H8:2VFI
MKJ!8^8QBVN!IW=RDO351[_X_#L9*EK,ICK>S/HZ>H'I\V@$-JHOWZU:GEE3"
M>PP>ZG/A7'GQ]_#@"6LZZ*WLS:!&#7I\V@DM6B_?K1J>65,)[ ]U.?"N//C[
M^' 1+6==%;V9M.BM>GS:'+&M%^^#I/LX9X3V![J_M7'G_'AF"VDXTUO9C336
MO3SI)K->7Q'(?9[<\)[ ]U?VKY\HY^_O&7Z,FT74;2-*QCDYWI7FJ0,@!E6@
MQ$\37=SDH/F?>HI+:ZN'D=)+^82'<&%-&MV+:$TLZY>=?&@Q]+M.4N7 ^<W,
M&^?$]6^78F'S.WPM&!$=KL-,NFA<]&&O-Q8#VXY?5?HU_%8Z/3_JV_"CU;'-
M.@& # %?<EU;==+2M89!0*[5Y3]V,AS[ES\L6N9MV7XZ]ZY?;A\<#DM@W+=[
M:6UL$4):&0!E;;=T5J,U6_.G9@O'BV0QOO5/'[4=CJ]C;LK7?FC_ ,FU]*_8
M=KCSG"# !@ P 8 , & # ',;AN'<5IW'"D0MXMCEFCBE:542:2232/R?S1K\
M=55!'W0U,;JUJZ]IUMG9V+[#G4]U)O"827]WAP[,6N<'3XTG)# !@#/[AGVR
MWV+<)]U77ML=O(UXE*ZH@IUK04K498RHF[*,ST]'3<MO56WYW91WGF$6Q64&
M[;#N$O:G^W;>2_MS:7T<XN6U.?RX;FWJO3ZI( 8$Z&ICV:VTUJU8'U=NJO;;
MW:+?]:RI::NNGO=;<8Y82CU_'A/BPP 8 , 4RX_653J25],S=*GY7Q@:J_B\
M/=C;'Y<PL_?D>>?SHE^7+AG]2YC4>@^=.^!;+WAW=([=5?66'5@ 93E"^74H
M1GQRX8[_ $\^G3NL<3J(UW[T=!\F2GZU>$"IZ0J]2:YM[!CR_N62/1T&;/7]
M6.4=,-6 #5@ U8 -6 #5@ U8 -6 #5@"C=$_J5L1G2.3+WE<5$)' (++D134
M#[_'&0)"!H-.6:AI[!^_$ R@>@^%R,O;_'% M/RPOPRE:$^'#AB%&4+ %1SY
M$H>!IQQ2#9 %8-$<_P 1]V:M[".!P!-"RS+5<J?$#X'VXC ]F500,E\6/C@4
MJLSRL F4?W3XM[?<,4A(M X5171^T^)/G@!8UU,Q^)JT\@/# "KH6I/,U3I\
MOH'\<0H*K/J+'EJ:C^)Q2"J!5@.%>/T>&(!GJ;>.<Q*R"0KJ*%AJRJ237V8%
M&->6G6827<(>).I*ID0:(R*AV%:A?[1P(,.X;:YAI>P?GT-O21"903IK'GS#
MW8%%;<-G]+),M[!T(SI>42QZ%<\%9M5 <)!-'>;>\W06XC-P!J,(=#(!0&ND
M'52AP(<:/EY\M#O0W!I565;G]3_33>L+'U(YQ=^CZG2U_?U::>.(4UH.WNPF
M[DL]ZM8[#]7@BFCLF@:% PF(ZC!$IK>L?Q<1GYG &COFT;-NS6$FYA3^DWB7
MUHPEZ82YA5M):AH:*Y.DX IS]M=HB^WL32*MYW1$EKN<1GTM*L41@58UK52(
MWIRC &#<_+WY>RW(O(MQN+1X+6WVQI++=I;4=&T4K!'(8I$JRK7XL^.!36;M
M'L6WDW"*\=))-^L[>POXKNYZK7%O;QF*+^8U2U&-7&9.?' A'MO9?8VP2//2
M*5Y[>VL^MN4ZW)]/;(RP1HUP31=+'A\7' $_;O8':?;MW!<;8DD4]G9';X%:
M=Y1':23M<Z-+$T'4)TGRRX8 @WWL/M7?=Y3>I;F[AW%H$LUN-OW":U+P@M*B
M'HNFKB6'UX K;A\MNQ][>!9+JZ-]8V@L);FTW&<74MHW,(KN1'URJU2>?/ I
MHW&Q=E/MVT6ZO;Q;=VY=0R;8L=PJ1PSVR,D:,=6>E6/*V!"+=^TNPK^[W<;N
M(9+K?X[9;^%[C2SK: ^G>-0RF-DXATH?' %#_MI\NK:PW#;;L&\DWIHEO+K<
M+V26]D:W(: +-(_54Q$@IIX' H'Y?=J[?!=6UONDUKN5S-9WFX[C=WTL]\T-
ME*'1&DDD#"+BE#RYFH. -S==N[5W6YVS=[J>*5MHEEN;&=;A4C1ID-N[-1M+
M"CZ<SQ]N!#)M.Q_EW7MNW@6%YNV29M@TW6N9 U2:D,6E0\:&HRP*1)\N?EO%
MO<FZZPK65WZ]MM:\?T,%XYKZ@V9?I)(7-02..8& -_;H-CVN!88KTF&ZEEN(
M7N+GJM))</K81/(Q)6IY57(#(8I"X+W;)9S;Q7,3S(VF2)9$9U(KD5!J#E@!
MTTEF ]9E1TJ&JRU7+4:Y_AYL_#/"2"B:U!"&:.I^$:AS475E_P .?NP!77=M
MNCMUE-];F G2',T175345#%J5IG3 I:0QN"PR))S'U9C "!0S,#QRI]7A@04
M,RL0XUK0<17S\,4 $!8],Z@0*(34_0?'$*,2JNX7-?%#]7CBD&E-:T6I=,J?
M>I@!T,Q!"N:/]QAP8>S]XP!.55@2,F\1Y^[$*5Y92IT(VEZ5+?A'GBD$6,=.
MB"C'+1^$4XGVTP \&C*$/M9_8!@!64$KTQ1,R3X\/Z9X%$!S54%%KF?/+P_C
M@0650!2/X21S?3]IP12*ZTBVF4"IT-J/_">)P(/B-[TXNFT0BT0T#!BU/\S@
M:?#33[>.,<#;71&,SC_+^8*=TH-305Y:T5_QG7X_\NE/[7LPP,GZ?^KY<L/G
M\BG>WV]0.4C@66D9?6D;LM>I0>.9"4JOB<^&,TJLW[6UM64MQCS7+^/$C;=-
M\#D"SR#R #0W!4JHK6G'[W \!GAIKS,EL;,>;E]?;#AF3;?>[Q<2$30I"BZ"
MQ='4L&4UTU/&M#3[O YXEDD8;VWM56#G/BO;^.9:0[G5.HT!'Y?5TJ_D>KIJ
M?.FFOMKC' TOT\8U<>7N_F"'<^36T'^7U-*OQJ>KIJ?*FFOMKA@'Z>,:N/+W
M?S!#NG)K:#[G4HK\=9ZFFI_!33[<, _3X:N/+W?//L '=.74\'AJHK_\SFIG
M_P OA_:]F+@'Z?\ J^7+^/R&WAF_2[CKE>IH?-*A:5.GXJYZ:5]N)Q-=XX9'
MS7N:>GENH;B!EE!=2C$@AZFC9K]W\./I:8I-'S=\'!ZI\NEC_P"Z&^,'!<[3
MM]8PK*0!#%S&O*:^S',ZI_D5_%8Z73_K6_"CUC',.@& # %?<EU;==+35JAD
M&G2[UJI^[&0[>Y37RQ:YFW9<7KWKVQP^)@]M[I;VMI;[<;2[60N1K6QO8H1K
M8G-I^H5&>99\;=RLN?M1T.MV'>SOJK'XZ-_]L?0Z;&DY08 , & # !@ P 8
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MP95S#^[^& !9/4-1B0!QA S]Y_KP!-PY?OG@B_O. '!="4)IY*O$DX 4L5C
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MYR%OK-IEB241=R[]0T_1+! PHP;<I&/U^D.! %[WY0G]"VT-XM^IR5__ &3
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M8E-ZK\-\/G(MM67BIB.N3\R^YYK>TNMD-G B(YFOK@],2,K#68P2SH6X "I
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MXY-^_&#NF\&>+<ZRMKO3=)81J2>7N7T-B(.JEALFN6V,*1]8H\S)F-6KFS0
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M2*FA/,.*G]V,E;M1NKU'_P"RF/\ I_D2FQ,NX(7V:[C60\[BX"(NJ@JP0BH
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M"@^7[\$!(QSCWC!@:>)Q2#U^!OHQ"C< .<?#[L )'\:^_%((>.(BBK\#>\8
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MO9T.G_5MW(]4QS3WA@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M' TJ?/  @R)/"F &$D^[P& 'OD1^*@^C "(*AJGWG !6M /AP K$*Q/C7ZL
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M9[]EMK2GD8[-7=ZGQ-S=U[:[AV:>][<6:X] L:776@!CJZ,&MR2@&I ]'6H
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M9M[NXK5CT8N-<A3V8Y?5?H5_%8Z73?K6[D>L8YAT P 8 , & # !@ P 8 ,
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MH)&18R=55X\?=C:Z66)U+]%U-:ZG;")\JRYQ,G3/M1%G%"FSK()6JZI-6>,
M\"Y4:1].-6K',Y*WYNWZD1V>%^Z1@VQ7<I^DWL*LX"22715%I51726*KXY##
M5VHS>_'_ "4?=7'^IT>W6_0$Q]/;V^K33TQKJRI5N5.'AC59G+WKS&-K=_\
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M4[3M^H$J5IT8J4H 3XYXYO5?H5_%;ZG1Z?\ 6M^%'K..8= , & # !@ P 8
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M*)&*\K^EZK+%>=.4AIP-1 30#0UR]X^C*?B8Q\!NE949A9S1P$46]O (HU8
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M6I0T!*'37R\*C$WX>W:."+L2KUGF?1X^!?[H_9CY\[R# !@ P 8 <V8!^@X
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M%;ZG1Z?]6WX4>L8YAT P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M_P#2B:X[?VB>,*ULD>D@@Q*(SE[5'#V8BNT:]OK-VKG4WWXE8]H;&=)$;Y9
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M"/#+  PY*>(X_3@!?\L#Q&=, !^Y[#B =3)_;P^K $(Q0& # !@ P 8 , &
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MJ:U\< /;X:CQXX :G&G@>. %8-7(9#A@!4J5K3APP T:@:_3@!SJ> 'M. !
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M QYJ7M9ZGA&'<>B]:U6E8_:8W<M]'#>VUM="6>?HFUW!:O06US2D# &CRQZ
MRZOA) ]V_9I*;66:[T:-V\-)YY,RMRL+FTVP02(S7.W1A9255-4$QUQ2*BA0
MJ(9-!KP%&X8V4NG:>%C7>K2CBCT7Y9.&^8_<-$%#MVW$3 -5P88^))T_5CP]
M7^C7O9[NF?YMNY'K&.8= , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MV!#0H!S>? 8H$7/(^/[< *<A3Q/' !34 /$?LQ (6H13@.&*!=(KJ^[Q_JP
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MI1(JV%@ FLMI(A2IH>&KCCG=5^C7O9[NF_6MW(]5QS3H!@ P 8 , & # !@
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MPP I(/+X>!Q  %*GR_;B@0\PK][QP M:4'U_3B  HK7[O' !\61X^!Q0&:@
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MN3IJRM^G[?4,P(T]%-.0 X>..?U4^A3O9[^F_6MW(]7QS#H!@ P 8 , & #
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M/.D<MU!! DB=0(*J("31%X^.9-(.C^7%VY,LLUJD[+3\N-BJ$FPR0D T_P!
M_P#B'MP V3Y>;NMM#:HVW!+=P&G$+"XND'6_,GF9)-,E9JG2IKS<PU9 4_\
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M_P Q!J0D4R(X8H+D?:VU#9'V9A++:2,9'E+E9>KKZHD1XPFAE<!ET !:"@Q
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MB,%I=2QO=$N9$5K=#J+&1 'C'Q#CI)''&4X9FWU&]IS:J>G@_$^S)_9R.?\
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MB1C]_3[,4%7;-@[S6\ECT2G<;#TZ'<)KR40LB[<JO;A0:L))66LBCC5JZE&
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MVT+K&_5BZD:.JR5)UJ"#1JFM1@!\=E817$EW#;PQW4O\VY5%#OP^)@-1X>.
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MBQ$!F&E\@I(U99Y>=,0"NE&R(U4J#YCVX%'QNCKID&7#VCV80!E561H@X9T
M8J"-04\"1QP _6K,-7$Y$_LQ (Z.HJO%<P<4#PT<@&K(GQQ -02(" =04TJ,
M_=B@>=+_ !*0WF,0"A73[W+[1E]N '!8=.HTIQU<!]> %+E1D %^S$ QI%Y>
M<*6-$UFE3QHH\<4!6IS4DC[QP A('$B2O 8 4FF;-H'X6I_X8  :Y)R^?B#@
M!0X05)IX_P!D?3@!]0XJX&GS\/K&(!NE!FM![3_2F*!K1DYLQ^K "?"*(AKY
MG #.FS25D- H\>-3@!)IT10H(0,0NHFG'W^)Q0*$ 4LV07B!Q]V $U472OCF
MQ\S@ CC#\['D4T ]HXX 227714R7CEGE_7@D 4(BZB,O >+' #6JU6D/[E&!
M 5Z#\L9G@?9YX C8FM&DSI\*TK]N* *Z11$SXEF(&?OP!'U &H[T/CI\/>1@
M!6EC%'Y4!.E79@I)\J\"< .BD20=1&ZR^#1D#/WCC]> $R8\%;S\7& 'ZB$(
MU%M7%6(4T_;@!@(K1>/X&J?VTP \NM50@ CPHN9]AK@)'*O-F* 9DE/ >[$
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M0$GC;J&<'/\ ) ^/5YCAXTQIIR2Q-M^;>!S4 FWN]NKF[$:;)("LZN)&AC2
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MX2-(9Y:=64*H=Z<-3 :FI[< 2$TS"A_[65?LP 9G/45'F>& "H^Z%<^?#[,
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M[;?879?C2[3WDD5%.%!3ZL<,[0U3\7]XXH$+@.1Q) H/KP A-&5GXYT'E[L
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MM';Q:*36/\2 K@"W8=V]KW\@BVW=[*>9LA"D\?5/_ 3J^S &H:_YHH3_ (L
M(&4? =)_M<?KQ0.I(?Y@R_$?ZL0#0\0/+4'P)SQ0._-85J&'F?Z\0",43BA)
M\3F!B@C9UUJVHBO+[O+AA %=C0$2?":^. ./[RO9(MYCCEOKZV@.VW#VGH#-
MSWHE01C3$K!VIP5\CB H6.Y=WWV]0/N<=W!M%VJ;7<M!)TECN4B61[A!&>JE
M;D20Z_ATZ?# IDQS[M:0=OB[O[Q5N=M:>]-U=;@A-T9(QFT"R-JT5HC4''%(
M;&U7MVW< 6.[OIKW]7NTO;27K&U3;0).F])%Z24I'TV4U)\\\ =R)*N=*Z01
M7S8T_9A ,O?4OI)+3TR7+P@RB<6LG2>O3/3YBR5H_M]^-E(XGKZ1T6K5IG"-
M2E9X\'P*&TQ]Q0W<1N1)+<CK>M:>6ENX++T^D%UZ:"IR0>1QE;3!ZNIMT[J]
M,1AIA>)<YR^K*!M>]V2WB::820K16UH3(QFBEU/G]U=47N!\\930]#W>CEN%
MCV/#PVKA[XMWQR"6U[W:6\D+2HUU&XCBZB?Z<RCJ*R9\8]/3'M-<$Z8"M^C6
ME8>%K@_%&&/?YO<:\T&ZW-Y;(96AMYU;UBP.331G$RN0K)JU$/0&M ,8)I(Y
MU=S:K1PILO+*YYRN,<.\9:[7ORPVK2WDHDEG>._(T@>G6NET /*[=-:L/QM[
M*':O(VVWMB;150E-?Q<4^:Q>'^E=LZ.U1;A%ZD7<SRJ)#':AB,X$S1VIQ=M1
M#,?(8QM' \_4[E+:="2PE_BX^[DNTO\ 261"'_EG(G^&,)/,5P6#&)LZBF?W
MO"I]I&*0>"#$&:O3!%3XJ:\, .E>ND-P!Y&']..$ 4@4'4^'4-+#*I_C@429
MR5(?,'('P]GNP0 MIJ&S7S_C@01*JB^*T&7B, *A!!(X$G "UYS[A^_ &?W(
MU.WMQ-*D6TY&0-"(FSH:@_3C+;\R[S#<\K/ [!1>EGN)DCTQ@S2:8HT6-2-)
M("@5) &69.6.[=Z<CB56HLVT#W$,YL[F)-LB1GFEN>FDDA0Z@8E#+(H+2IF#
MEX,N>,;62B5XNPSJIF'@.%[LT+!;OKV%T-3*TJO) [%26*2,7D9 *"K5-3C'
M1;ABOF7559D/5[>&F$7(ZZ-U#*7_ -.26-8U/X@ #\.?[=D7Y?Q,9IS)7O-H
ME9O0=:\G4F5YP'AM4:@KKD1HY I1ZKI*U\?'&"K99X?4R=D\A+J$VIB3<+J(
MV/3C:TN+41.57IO)^<@.KP*\W'C5L6MIG2L2-1$O J[DIV^1UBEC?\N@?3%*
MK0\=:55@:TX\<9T\2Q,+^$],^7+(?F?W,&!$XL+#J,&!4_DI\*@#33'.ZK]"
MG>SW]/\ K6[D>JXYIT P 8 , & # !@ P 8 , & # 'GW>4,5UWG817!DC6-
M(?3RI+.>:21U?0D;HD;@ <Y4GZL>K:PHSZ3]MLZ=+9UARW.%>"6;:;:[)^IW
MT,0BACB#,XC4*'<EF-!2K,<R?,X\K/G;6EM\S@>XS:MOMR)(+9[DN-$\ZN\!
M6&$O'&[*X"2]5JDFFE<\>JDZ3Z+HM2V5#MIY*-6+AO+&L?%X'H./*?-A@ P
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MJDCB,2'3$K.%,A\  >/NP BW5L97BCD5G4Z64.I*,?NL!P/D,"BFZM8093(
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MI"Q5,WJ@Y<F-*XW[<PCN=%6SK6=26&3KE/+"V+RQSR4G;CACSG!# !@ P 8
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M4Z'3?JV[D>LXYAT P 8 , & # !@ P 8 , & # 'FGS%M([_ +HLK6<:H-$
M].\,+]9I960&-677/TOB=-851G0X]>PXJSZG]FW'M]/:RS\6,M1"XXQ6<DX;
M;P/1K2#T]I#;U4]&-8ZHH1>4 9(N2CV#ACRMRSYG<OJL[<WW_,R]QC[2CN6G
MW!;,7+,BNTW3+:F(5*ZO$Y"N,ZZN$GKV7U+K%->G'*?>;.-9X0P 8 , & #
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MA@!6+%BV>@?&/.G\, #ZGII-0N?L/LP ,3)D#DN?T^7\< &IGS!H4.0_M>.
M&F1J=4$\W*/<<OVXH$BY9R ::05'N%#^_$!9#L1S58#Q\1].(4-.KX6K7B#Q
MP :I$/$CV' !J5OB%/:/X8 9./RG(:I X'CBAD:F:,5J1TN;+A1LZ?5@0=U2
MIUD M(<_#/PX8 -2H0JU&OB:\#XG "L$0C0Q%>.7 ?BP . M#&_/P SS'C7
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M@H=:AG;(@5&8\L *K(%YEU/6AH>)P (8T!#!BWOXCP P #IHQ+UYLQPR]F
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M8%&  !;HQ:J'BWTXY75/\FOXK'3Z?]6W<CU7'-.@& # !@ P 8 , & # !@
MP 8 YCN#MR_WC>8F2<V]G;^GE<L9RLACF,A542=(B>45UQ'CX^&ZFXJHZW1]
M;39VG*FSU+[N$J,]+M\+'3XTG)//NXF<;].BS7$<K,S+&I9))$6.,:8J-1\V
M)B73\08D^&/53RGT?1I>BG%6ODL7GR_U/E$'H(X8\I\X9/=)8;-)IU_''717
M336*]6E#TOQT\,9[>9[.@_567'Z<.WEVF=V@2!? &-5 CT^FU&S!HV<>LDZ_
MQ_\ #C/=X>S/3^X_=SX^;S<,^SE[S/[8B1=YBN%L9H;B<2>JW61F,5YE6L2E
M!3/FS6/+AK&,]QX9^[D>GKK-[3KJ32B*+.G?C[L[=NDC[@2S??KAYX9I[E&A
MZ%Q 5%K ,B!>U0K6N8Z@?+X=.%)T^WR,NC=ELI)I5QE/S6_!C_\ '3VR=WCS
M'SX8 , 4RX_653J25].QZ5/ROC U5_%X>[&V/R^&?OR///YT2_+EPS^I<QJ/
M0?.G?$,<G>/=T:2@3S7FW)SK323$U 'J=67AIQW^G<;=.ZQQ>H7COWHQMOAF
MW7;C9VY]/812*;VX96*2,SMIRC$BT2-"0#^*OEC;>RJY>? TU6I1P'ON&Z;E
M,+/:7D_3[52%$^GHC\K1U9@:(FK2S!<V\,1;=:XV\S]L"N]K.*Y($V[:;&1!
M-')MTLZ-T;JSN':UDC4!*45#)&PK)5#6GNH<37:V6,<UB7159X=V0LQ[72%]
M$UV8"%6:WA9T:1D!<C259=7Q!R32IR7PP7J<8#T<)&2;3NNVEVVVW6R-NR":
M.WE]3>1E*JK2N-!.E/B$>2_7BJ];>9S\D1TM7RX?4G@-QNSQ;SM\C#=+=&6Z
M@(9RU%DDJCQKS*X9T()'W:_$,8OP>&WE,EXO$O,2]FW$4W>VUW45((GO@@@-
M*AM).E34U&9TUSQ>H4;;3S@;#G<3[3Z!;.0?W:_73' .X(WW??@!)%Y6(-#3
M/R/OP 5!Y7%/V?0< (FI4'WA3Z<4"( =6@T-34?U8 *C6P;E;*A^CSP &H8A
MAJ!%01[,L 'WB/C1LQYU& &T!Y.(&:^## # 9$)*9D?''2E?;3PQ02>I31J
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M>)6-0H)]II4XH+. !A4$>>! 4U . $7*J_A_9X8 !DY'XLQ]& !LF!^@_3@
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MC% 8 , -/*:_=/'V>W "L#\0S/EYC  :,N1]Q\C@ !# J1GXC  #3)OH;SP
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M_+3NN>XM=W3N:,=Q+:7FWWUY/9(UO):WLG4*10(Z%#$?@9G8G[U<(+)DS?\
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M]2WA"RT8&0EF<AB"U68DFND?4/(8.S9CN=1>ZBSP&1[%M,<SS+;+U'8,222
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M(N@+.S.P".#\(IRKGX\,>G9\N!]%^TS_ ([=7963MDECX<,U]6>C6SPO;1/
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M /U!M6WZB2"M.C%I %,O''-ZK]"OXK'0Z?\ 5M^%'K&.8= , & # !@ P 8
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MZ6^%A35]UC7&3IMM>6%S(K73P<C+_N7:[.X$OI+HWY8-'97H,2Q<U TC'5U
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MJ#\0^L8 -8_$/K& #6/Q#ZQ@ UC\0^L8%#J#\0^L8 .H/Q#ZQ@0.H/Q#ZQ@
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M , & # !@ P 8 , & # !@ P 8 , & *A!_5U.F*GIR-=?SOC&0'X/WXV_\
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M-F4TIY8 7?\ NU-JFLK.';KK<MTOTDFAVZUZ75$4 4RN[2O'&H4NJ_%FQ &
M$N.[J;3M^YV&S[CN<.X()%BMXXUEB!4,.LD\D)4YTIYX@+?;'<,/<&TKN4%K
M<6D;221"*Z5%>L3F-F&AI%*EE-"&SQ0:N # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 IE#^L*_3CIZ<CK5_,^,'3IK\/C6F-L_EY\?<>>
M/S9A>7/CG]"YC4>@, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MUC2&",<%1%"J/J&!"<D 5/ 8 , & # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@#/,D7Z^L?2'5](S":IU:>HHTZ>%*YUQOA^E,X:OL/*[+UXC'
M1G[\C0QH/4& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
M P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , -7I:WTZ=>6NE*^
MRN *L?Z-UQT_3]>N6G1KU?1G7 #C^E_J(KT/U'IY?!U^G7_'IK@"Q)TJ#J::
M5%-5/BKEQ\< 07?Z;U;?UG1ZNO\ TO6TZNI_]'JSU>[ !?\ Z=T/_4.CZ?4O
M_4:=&JO+\>5:\, 32=&B]3334-&JGQ>%*^. 'X AEFD"..@Y%#F"G_FP!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g88515dsp004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g88515dsp004.jpg
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M9'1VT9$C9&BTBQJ=!35K1M:]W@>-!QL/8NIX-MQURL3*S&C4^,Q4RQ \TW+
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M2$JC%N+C5\%!UH]EZAAZ?W&'Q<T^XR2,F,[RV;PD,EHD5QZLDD([TG;J:Y^
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MS1^J@R-OP%:1QC1!IOZU@B@OV>L;<>P=M!#B[+M&)CQ8^/APQPP+HB0(O=!
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MB9D&#CA2T<.+)+"J,1$.4@T-IC7EN;^74>"T$"=']810M'#NJQ2.[R&5)L@
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M<_>IMRDP ,7'EBRN; 8FNI%^;&6#:&;NZ2VKR6!^"@OY/]JQ/Z;?^FU!9H%
MH%!6VW^PQ?$?\IH+- H% H% H/%CI#JA\_*R)=Y98I':7&BCDG"I)S"R.5U=
M@2RZ#<<*"SMO26YP8>=#D9I,N;DXLLL\<LVMXX.6);N6#J9EC;NJ;+>PH*V'
MT;OZ9&')F[GXH8<T4S,\DY,N@KZRDZ5,:Z@MO7OWJ!G=)]6SY^9DP[QRHYIT
MEQXA),$4(\A&I0?V'4%0>.GM7A8)MXZ1WS)WV;<,#<CB0SM$TB([J=4:JNHB
MS*=(4@+P!U&_9Q"M+T;U4#CIC;TR1Q68LTL[/K,4:2<69M0=U=N/JZJ#$G0W
M4$>:<C$W0KWH=+239#$1PM(VAKLVM;RDVN/CH.ME=.;I-OK[@FX-'!S8I8L=
M6D4#0<<2!E4A6U1PR+Q'RZ"IN'3'4<^3D/#N6A))7=&YV0ILX;EG2K:%\/J&
ME5%GMWJ#0=%[SS4=MXG8-*C90Y^0-<>LM*@ >R:QI'=M:U!&.C>IHXTCBWER
M1&@$KRY!:.01H)9%!8Z^:RM</ZH-UXT'H]BVS)V[$?'FR&R!S6>)G9Y&5& [
MI:0LQ[USVT'1H% H% H% H% H% H% H% H% H%!#FXJY>'/BLQ59XWB9AV@.
MI6X_70<:7HW FC$4F3D&)=06)60(%=M;(!H)TZ^/$D^2]J"?:.GMOV1IIH97
MY1C <RD< @[S,P OP [>R@FDZEZ?BFY$FX8ZRZ2^@R*"%"<RYX\.X+_%05X.
ML^F)HGE&X0HD?,+<Q@AM%(8V-C_.4V\]!/D]2;5C/*LTA40-CK*Y4Z1XHD1F
M_FX<3Y*"K-UOTU'+C(,M9%RB>7*A!0!0Y8L;]T#E$?";6H)I.K^F(R ^Z8ZD
MA2/I!\L77]8-!G,ZEP<<8,B1RY6/N!MCY..%:/U&DNS%EL-",WZ* >KNF1&)
M#N4 0HLJG6.*,0%*^>^H=GG'GH(\CK'IR">*$YD<C2NR%HR&1-,;2LSM?2%"
MK^OA031]4=.RSQP1[C \TI41QJX+$OQ46\]!LG4>R-G/@>+C7+CF\.87.EC)
MH5](O:_"1>/GX=M!2FZXV"&62)Y'$L69)@.N@CZ:* Y#&YL-&@>OV7X4%M.J
M>G' *[ECD&3D@\Q?7X</Y1Q[*"3!Z@V3/$AP\V&<1())"C A4(OJ)\UN/Q4%
M+^-^FEVJ/<YLL08\J22(DJLLNF(D/]';5<$6M:@[H((!'8>R@4"@4"@K9/\
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MK</:(OLC]Y0.5N'M$7V1^\H'*W#VB+[(_>4#E;A[1%]D?O*!RMP]HB^R/WE
MY6X>T1?9'[R@PL&<HLLT2@DD@0D<3Q)]>@SRMP]HB^R/WE Y6X>T1?9'[R@<
MK</:(OLC]Y0.5N'M$7V1^\H'*W#VB+[(_>4#E;A[1%]D?O*!RMP]HB^R/WE
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MCO/ZMO\ [I0/X,WG_&.\_JV_^Z4#^#-Y_P 8[S^K;_[I0/X,WG_&.\_JV_\
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M*A5[J4[2>[V7-@>PG@.-!9VWJ+9=SG:# RER)4C65@@:P5K6N;6OQ[.V@Z-
MH% H/-YW4,!W2+#Q-P=II\@8JX\4 ?0X#EW+OI!13"P8B]F[O;04X^K<,Y.3
MCR[T^.V(7$CS8FA"8WE1@K'@3>![#RCLO07CNJ#%QLKWXI@RR5QW7'#:BI(:
MX%RNBW>)]7RVH*K]4;>JH3U #K-E5<4LQ]6QTA2;-S%TGL:XM>] _BC;N88_
MXB2Z@L7./W+!2U]=M'8I\O;P[:"?$WF++RX\2#? ^3*#IB.-I((UW5M0&E_H
MG[K6/=/#A00?Q/A\T1KOA<-S0'3$++JA>.-D! [S%YE"A;W\E!B7JC"C,/\
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MX+=_^)?Z!/30/!;O_P 2_P! GIH'@MW_ .)?Z!/30/!;O_Q+_0)Z:!X+=_\
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MV"L+L#_+P#7&V?J3QV+-E92M!#/+-(B3R\5E"Z4L4 81D,!?MOY.R@QD]/\
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MO^U97^XS4'HJ!0*!0*!0*!0*!0*#COT?TV^;-FM@H<K(8O-+=[LQ>-SY;>M
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M H% H% H% H% H% H% H% H% H% H% H% H%!YV#_N)F?\HQ?]YR*#T5 H%
MH% H% H% H% H% H% H% H% H% H% H% H/.]1?]3]*_[5E?[C-0>BH% H%
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M]G$CN^6I6ZE:L1?ZCP^?GPI^<TV9Y_FAGS>EXLN:2/$E;(C=IIW1K!66>UG
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M&\J!3&+:4$C/;^L+]Y>6&.H"]^%JO+;O=/ ]/2)YYI^5-U,Z[.+5LKK%EU#
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MVUT=&DCQG9%Q^2TQF67(TAD9;\&7NFBT?1_%R^[?&>'?F\GG>%_SFK1JY?\
M2OPHBS0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05XK>.GOZ^E-
M/]'C_P#Y7H+%!SLW:3-,LD,AC+$F4ZCY;<0.(/ 6L:".# 6#*2,V+2DS2E!8
M?1VTBW&W>;50=6@4'@<K<=\RMKEQATV(5O)+%"T<H1WQPCP:DC"^4#@QLUK"
MO3%L1/\ )^BT]'1LU(N\:N45K&$75B[&?RQBM92961OYBEY/3L3SB1\I,AXE
M(=S(Z1DII#:[)J8]NDKQN:1%O]F=.S1K%=6:4Y:5V4B9QKEC\:K,6;/N6)N<
M[;+!+EX\V/CRL(U<SMK1I.#KJM'&RW#<58$?)J4I,8N5VE&E=9'B71;,73G_
M !PFF4[9KEG%)VM\G=<X;0F5N&QP'-R,F+#\*]N^,B-0A[ZW8(\FE^'JACY*
MD6Q6D3@S9Z>SQ.6S4GEMMFZO_3..4[8BL=LQ" [SO$<4J'I8,&8A42,Z6:/E
MHJMW/DQEN_ZITV6KR1_9T_QM*9B?&X[ZSOVS3#/'%OO+YD&/B0ITU%F-EP2R
M9HAC*K'(\1!"N%N"?5/82.REE)^IGTT6W3=,ZTV\MT<M9SB)W<=S4[INT&*(
MH.G$,>-H\-&(9%473675='=U/W /64]YN%.6*_R:\#3NNK.KC=GC'NIGLC'=
M.5N+:3<MVGECC'3"%<8F(&9+A$9S&RQ'1:QCL;CNFG+$?4S;HZ=L3/C3\V.$
M]E<<=_>AFEWV+#VZ4;+CR1G#!S<5<9@%R.9&H&D*SZ44&RJ/A[!5B+:SCM=+
M;=&;KX\2Z/G^6>;Z:3W8[_S;YJ[I[E\1C]/XL.49IH5Q>0)F2$Q/8G2H%WD1
M>SNV[:D4KFSI3I^+RW:MTVTB:\U,:Q^$5[5O!S=YR]T,&?L,2$0R:LYE)5G1
MG1 "R^JP\A-^/FJ3$1&$N.KI:5FG6S5G./E[)I7V['-PMTZJA@5X^G8N84#R
MD1-#WG@#R*BA;_UB:3J/:16IMM_L]6KH>GNFDZLT]]?JI%<=TU^*>3<LF'9Y
M,B;IR''FCS4QL3&:(MW2P"N%1"3I_F</-4Y<?Y;'.W0MNU8MC6F8FR9F:\,9
M_%K-N/4.8TK/TS'%*K.>9*HD>V@*0#H*LSBPO>UN'DI%ML?4MNCHV4IK3,=F
M'Y[/;-HN3NL^1C0_PS#CQ2S1PY$I@U@8XDB+QV*"V@,W>/=.FZWJTB/J:FS3
MMMF?&F9B)F(YOJI-)SVX89XXI<_?=S3-.V-TZDT/BW\*I0E)40AN8MTTACJN
M6/='GJ6V12M6-'TFG-GB>+2>7''+LSR[,YW-3NN_9>+#%-TVL14\R*-XS(%?
MF6) *:4*B]R?6O=:<ML3_)?\?1LNF8UJ[,Z84]^->&U#@;CU3BP+C3]/)DF0
M/DRLD8B0S<A9+!0I ;F$K=N)\]ZLVVSM;U='T]\\T:O+E&=9IS3&_=C@G3)W
MR!-MRDV:%ILB?(.4!CM%IT3B+&D+:=4=H&8ZG\EZE+<8JQ-FE=-]LZDTB+:?
M-7Z:W1V_-3+:EBW3)R-JVS=L7I^*23(R0@14#/%".[SE(7RE;@W TV-)MI,Q
M5B[0MMU+].[5FD6_&=V?M*E#O/4Z& KTW'S(\>*/(=8'CU+RB6@CN.ZO,TJ+
M\!Q^.K-EO]G>[TWIYKYTTFZ:?-7;_*>VF.])N9W#W%C-'TZA&5CY"YFWPQ,G
M>UK'&"R!)$#QO)<>8D>>EM.;^3.AR>--=7^-UM+IGLF9SK$TF(=;;.H-ZDW0
M869LSX.$!IBR[EE9N&E0H7AP;M/#@:Q=9%*Q-7CU_1Z4:?/;J<UVV/;VR>DK
MB^64"@X/5N_S;4NW0X>$F?NFY97A=NAFD$$0DY3RL\DI5RH6.-O54L>P#C0>
M%BZ@ZHDAW#J[-Z:V#*Q=FER(Y\J*=QG6P79)C$\T%KJ8VTAV6]O)>BOI_CX/
M=OO#O>'Y/B/5.O1IU^KVWMY*(LT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4$4^-%-;6+.OJ2+P9?B-!"8<Z$ZXY3D#Y44FE?FLJCC\=!A9<_(7
M5&JX\9)%Y 3)8&Q[O8/UT#&CRES)3,H9610)A:Q*D^3M' \:"Y0*#PN)#U;G
MX$,\&_11R.)6&HI=8VX8[,J!@Q>)0S<1I8DB_97IF;(G)^@U+O3:=\Q.E,QA
MOS^K/=.$;XB(7SC=3#;]VE]YQS9[1VQ8HI%$<!,COQ9E'R"!J8>3LK-;:QA@
M\_/H<]D<DQ97&L8W81V[]G:KR874D>*96ZAB5HV25V+KH2 )W6/<[_?-S>VO
MAV5:VUR=(U=";J>%..&6,S7WX8?^/:J86/U?-!"7ZB@BE;&,CP%T=D;(AM$Y
M;0-0,BLP%N[Y-5:F;/ZNVK?Z:)FFE=,<V=/ZW8QGNI';MHZ6U8N[X.\JLNZ\
M_:+3Y,CRS)(6UO:!;M9@-,AU?)[JV/$BL73$QEB\OJ+]/4TL+*:GRVX1,;/F
M[-F&W&:['.CP^J)<?*3$ZFAEGB)BG>1K".2(1:RMD'JR:[^2Q \E:K;MM>F=
M3T\3;-VC,1.,=L36FW=3X56WQ-]S-FR$FW1$RX\SG8SM,D97%@>R:WB#@,PX
ML>/;4K;$Y;'&-31LU8F+)Y9LI.%?FF.VF6Q%C1=2LZ2-U+CS+,%RHN*QW@?N
MI+HT'NW(&B]F/R@:L\O]6[[M"*QX-T4^7?CMC//MSC<T?#ZDCR8<*?J:*'.(
M'*QM8+$E92-5XP6U.%(X#@"OQJVY\N#4:FA-LWQHS-F^G_3V[J\)7VP.J!LD
ML9WN$YS9FN/+)"Q\L&W*-EN+M\D=G9>L<UM<L'G\;T_BQ/ASR<F6VN_/CWT4
M\K;.JY,E)_?$#R0-)'%'')9G!97*E"H5F*KIT,>';JK<76[G;3U_3Q;3P[J3
M3./?MSI7;P-MP.JHXX'R=\@Y"<AY,<2*NB,)I(UJC=C"UKV>U[BEUUNXU]7T
M\S,6Z<U^;&FVOO\ WC=+:7;-[6+#Q\?>T7+P\1<;+U3O9Y#*I#:BC=]PC"Y&
MH=GEO4BZW'#:ENOI3-UTZ?RW7<T?+E%/?E%?<L9V%ONYMCS8&^1-B#%A,W+?
M0))$D#M*IC!TK)H*]IX<+5(FV,X<]+5T=*L7Z<\W--*Q6D3%*8YT<P;?U4V0
M\@ZGQA*A',59;JD;_2* I4CSM<_)%NSLWS6_U>KQO3Q;3P;J>[;EO]IQS=K-
MQ.H-SSC)MF\11[7)RI!RF!D",J$A2%8 ,H+!K^6N<3;$8QB\.EJ:.E934TY\
M2*QCEM[=F5.Q6?I[K)R))-TC?(0-RY-3J+O%H-D5 %M^F_;P[*O/9N=8]9Z6
M,(LFG[USKCPW-(NF>M52[;V%EX,W+%E9^6P9F!3C>30?B!\]7Q+-RW>N]+7_
M ->'[^_=5)#T[U@V7B/F[LN1!#E<^2,$I=0P(%E0:K@'NDV7SFI-]E,(9N]9
MZ:+;HLTZ3-M/;'CM[&1LO6TTN5(=T\+&TN0<:*X<@:I1 39+*NEH^[Q[+]O"
MG/9N/\GTML6QR<TTMK_\>;;GGCV]Z!MD_,"1YT7=5A1458G+!M0)#%1:.X*C
MN\TBY_9J\^GN=(]5Z*(B>2N_VKW\N7:VRMAZTB<9&/NKSY4MHF[RB)%>;B_*
M(5>[ 2>''6!V@TB^S<SI^K]+,<MUD1;&/;/RY5SQN[J3+V0%@!>]O*>VO.^)
M)0*!0>?ZOR-I'N? W/;TW&'<]QCQHUD"D12K').DUF!XJ8>%N/&@\EOW_P /
MOO\ /E':CON]B0/EX^UX^1F@S+:S3QP7QM8L/ZSC17TK7]#S-#>KJT6[W9>U
MO/1&] H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!Y1O
MRTZ;=)$D.0ZR+$A!DXA8190" #8BX/QUW_R+GV(^]Z\3$QRX5V;UO!Z(V;!@
MSH,9IHTW")(9[.+V1=.H</7-^\QO>LSK3-*[''5^Z:NI-LW4GDFL8>V'8K+^
M6_3BXXA3G+86$FI"UK1KQNA4V$(L".'&KX]SK/WK7F:S3VKV]JUD]%;-D2)(
M_,#1XZ8R$%>"QQ20H]RI.L+.W'XJD:LPXV?<]6V)B*8W5^,Q-/=6V%.3\M.F
MGQACD36 TB34NL#@1QT^33P\U:_R+G>/O>O%U</;O3-^7O3K93Y++(SR@B0%
M@0UY#(2;KYR0?..VIX]U'./O&O%L6X8?I1J_Y=].M,)E62.0* I4I8$3&8-8
MJ03J/EX$=HIX]RQ]YUZ4PF._=R[TV7T+LN3!BPNTJKB8R8<1!0GEQ\%U:E8$
MV)_7Y[6D:TPQI_==6V;IBGS73=WSWM\[HK9,W*7(F634D,<"J&%@L08(UR"V
MH!SQO2-68AG2^YZMEO+%,YGX_E@B/0>Q^YCM :9<0S^):SC46TZ "=/$ 6^'
MX:>--:M_[;5\7Q<.;EI^:E%^6FU#(2:;)ED/TIE ")JUS+,EB!==!7M'>/E-
MN%:_R)=[OO>IRTB(C+?NI/Q^$;MJ3-_+?9,AHC')) (] TJ(R-"1+$0 5[66
M->VX': "32->89TOO6K;6L1-:[]\SO[9_---^7O3\D(B'.C34'8(X[Q$DDHU
M74ZN],>)X]E2->YBW[QK1-<)_P"(C_Z_BEP.AMCP6R3#S#XO';$E#E2.4P"D
M#N_LJ!YN'GO4NUKI8U?NNKJ4K3Y;N;O^*L/RWZ?T11E\@QQ-&V@NI#&+U=7=
MO\'Q=E7Q[G7_ '6M69I;6:[-_>O[)TCMFRY#SX3S!Y5190Y0AA&FD V4?'\?
MP<*S?JS=F\_JON.IKVQ%\1A7CWNW7-X"@4"@4"@4"@4"@Y74/3.T=008T&Z1
MO+%B3KDQ*DCQ?2*C)WBA4E2LC CL-!?P\+#P<:/%PH(\;&B&F*"%51%'F55
M H)J"AM^X81P<:^3$6,27^D4DG2/AH+] H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
EH%!AW1%+NP5%XEF-@/TF@H96XX//Q+945N:;_2+V<J3X:#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
